<SEC-DOCUMENT>0000950170-24-036396.txt : 20240326
<SEC-HEADER>0000950170-24-036396.hdr.sgml : 20240326
<ACCEPTANCE-DATETIME>20240326160240
ACCESSION NUMBER:		0000950170-24-036396
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240326
DATE AS OF CHANGE:		20240326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Korro Bio, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39062
		FILM NUMBER:		24783456

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE. BUILDING 600-700
		STREET 2:		SUITE 6-401
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-468-1900

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE. BUILDING 600-700
		STREET 2:		SUITE 6-401
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Frequency Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170412
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>krro-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-26T15:23:05.9530+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:krro="http://korrobio.com/20231231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c5a7063d-575f-47e9-882b-df9c31119919" name="dei:DocumentFiscalPeriodFocus" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb">FY</ix:nonNumeric><ix:nonNumeric id="F_05629f41-d8ed-40c8-ba46-c41c32dc44d1" name="dei:AmendmentFlag" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" format="ixt:fixed-false">False</ix:nonNumeric><ix:nonNumeric id="F_2398e112-547a-4b2f-8db5-cddcd0e4e2d4" name="dei:EntityCentralIndexKey" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb">0001703647</ix:nonNumeric><ix:nonFraction id="F_df40f193-0acd-4da6-a9cd-f7e3b8583f44" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_b3f0be16-92d6-4d75-b406-665cb27d9874" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_3c03b9d3-a541-4644-82ad-919fd697092d" name="krro:PurchasesOfInvestments" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_7f34c903-b265-46b4-91f2-c9b15429742b" name="krro:AdvancePaymentsForPropertyAndEquipmentNotYetReceived" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_81265546-519d-4e10-aa08-5ad84f64dad1" name="dei:EntityIncorporationDateOfIncorporation" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" format="ixt:date-day-month-year">30-11-2014</ix:nonNumeric><ix:nonNumeric id="F_5a1b49f3-7a54-4e43-9407-97170c711b48" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8">http://fasb.org/us-gaap/2023#Liabilities</ix:nonNumeric><ix:nonNumeric id="F_c39e9862-e9fa-4ff5-9da0-641cc2ce94c0" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8">http://fasb.org/us-gaap/2023#Assets</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="krro-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_3b33040c-7342-4627-9634-346fa6638cb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f43d2a6f-7e41-4811-95fc-4e6af0a5b263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bd7505c-82d1-468a-a930-ab481a0db383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e34d372c-ba61-4919-8176-79ae6cf200b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_597278ba-5ca6-4b61-aca3-d85a7999b364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:CummingsParkSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9aa93606-02db-46a9-9b63-7b4d0578cd82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27d10e7c-da56-48f5-a64c-6c1e8a2c5c32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ffd1385-3f0e-45b7-929e-195ba02c78b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d015c4-04ba-473c-982c-ee84943ae574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f43b4902-d2c6-4c47-bc7b-f3057b2dc2af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_952c1d35-4cc4-4d37-8f7f-0c70663501bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:OKSFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcc2b54b-9a21-4b66-92b5-e1bcfac05a39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf439977-ea99-4550-a754-3c1783080c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e61d9b0-a7a2-4826-b526-6cf674a82d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_074064b9-afc6-45bc-a7ef-5e7a10262640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55691ac6-0299-4103-8d80-a1f6d05b4a80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fac002bd-d841-4cb9-87ff-6726c92a87a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f821a1fb-8b0a-44e8-b18a-e92e693bb9d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06426193-e63d-4cf5-a2db-19dbf1197a90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e46527cb-cdd6-49b6-ae87-4f92d5ccf0b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21957e3e-4ce5-42c3-b40c-20cefc6c2eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae8c2fd3-de68-4508-b076-43b5d6c93aad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68f1cdf4-0429-4263-8211-79aaef7f7fd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93f80774-1bcb-4131-b2c9-93def7a01c20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9019f292-8abd-4d72-a541-b2e15e70e9e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:FrequencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3e74070-621c-4737-963d-07ce423a28f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab8f59ed-af83-49c1-80a2-d1a10ec53e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3870cdb7-60a5-4355-8d59-703d871350ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fefcff45-a321-42bf-a7e9-1a416bde8bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fd09c06-35f8-4ac3-827b-5890bfa49ef1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46cc1979-5c24-47f7-bf95-9aa5c051807b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a623cd32-caa5-4962-8d16-001ea4eb82ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86dca00a-98c3-49ec-b174-5d61f32beb4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2ac73cf-1c8b-4a06-aca0-5f30e10f6acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba766246-72fe-4458-8363-5e1fe9dfc13c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98b4de31-fa14-4fd9-bd5a-480f77633a40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_093060bb-522a-4d5c-aa04-574677a7cb5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e12df146-e11d-4351-90cd-40afa0abdd05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11f11e50-ea6c-40c6-950d-f8060c5107d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efa34611-a425-44a2-86e5-16976c9be1dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_513af823-8be3-442f-a9fe-1a2fe1b055f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_397c2e74-ff43-4295-9f70-85a5ca23db1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">krro:Phase2BClinicalTrial1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce4b9b25-ec19-4975-80b3-be6c42826a43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_876e06d8-58c8-4927-a39f-dc45358c0f14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09fab13f-bf4d-4e13-b1df-cb7d113cce21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:CummingsParkSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d16b2e0-26d9-46e2-9676-3b3691cb6871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1efc944-079f-4e9e-8fcb-7284de744653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_919f3e26-6567-4206-aa08-0ae94fcbc65a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bed67611-bf29-4fae-9416-b0c86cc2e8d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_783f0bb3-c296-483d-8672-851d68ba26f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7af3db31-6c33-4c0d-98ce-e0c17f536ee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a982d847-1fa7-4a2f-a886-60eca2f91051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45db7593-eb9b-4883-9384-b026cd2ff9bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fcf0a27-21b0-415b-8c89-231bbee07b61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73266731-93a7-48aa-8ed8-61bc2b4c90d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f10a3be4-4ec6-4c00-b69c-d83c843296d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abf5d9da-538d-418d-b41f-9269c757a637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f61fcdc5-7781-4d89-9c78-e405590b9203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae566dce-3b97-4369-8930-694f01849c54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36fd05f2-24c6-4d41-93ec-f56ca9af1f89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:OutstandingStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_072ef9d5-51f5-493b-a877-923f3cd50ab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_002cf6f3-a14a-42d9-8339-4c9a7464ddc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16286e85-fcb2-4aeb-8a74-8b8cb490439b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecda1a05-7107-41dc-a5fc-7124dc194f84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f3a1082-a9d3-4417-a0f7-4d1bdd1bcaa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbf5ca73-fbe0-4461-be55-abde5434880e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aa971ad-c939-4c21-a327-57534a1ce091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d4501f2-ba74-4579-94ab-e81941e63104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:KorrosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b649a5e7-5c6c-446c-9fb4-344b0a1da0a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:OutstandingStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41f08d6e-847a-47a4-b214-65d33ec4097d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f825e298-5e6d-4e4a-ab77-5640165e55ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ab0d269-b1a0-4ec5-8ce7-bb7b469c3284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc4d7e4b-8b44-4d70-bfd8-4175df616bb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7797a79c-4109-4291-85d7-9f1f44b8f9ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a2b3b81-fe26-47a3-b213-a4e83175b18c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecd8a380-935d-40bc-8d1e-6ed89fa53199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_682c0c46-757c-48ee-8cdd-a8c28faac6de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7042021a-f5f1-4b64-8355-bd3286bb3502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c63df81-1292-4b21-8598-c514db4b083e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0304c01-05f2-44fb-9a26-a65525c2254d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b451ece6-a0b3-4778-9557-3099f2fc289b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b267ce26-7f99-4922-a593-840ac7ce4bac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_744282a9-e212-4b62-bd6d-0bd21501afbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_745d62aa-8d61-427a-9115-a346c910fcb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea294f12-f168-4831-b0a1-38dd8c3da158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c10f8f23-79a1-42bb-8447-ddc5b11bb910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8f40235-5f27-48ad-ad53-52935a2bb13b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_728a4108-5170-4a8f-b001-b85c0cd9973b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23c62caa-1ebb-4380-b45d-f24627644a23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8847dfc8-679e-433b-8e63-9ebb42630fe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fb87aaa-7763-4db0-b2e3-0eae4ddb9138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a831aa61-46f2-4591-9e51-98d9e0781061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72eb9539-da9d-42ea-ade5-45879867b4dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_588ba34c-1cc3-4361-8113-4bfbca87310e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81b7cadd-72c3-48d7-91c7-d8614a9176e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbd86c0c-db69-4c76-b0b5-17ba9213ddff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd46bccb-a691-424a-a33d-f99566514d8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cfbcf8e-1721-4cf1-9208-7dd35da5b429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45c261a8-1fa5-407f-ace7-946cf709a7e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">krro:Phase3ClinicalTrailMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab8215de-6795-4f27-b53e-55d3375d2af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8eca1fa2-2518-420d-8403-4912df0dca2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c310c39a-f47b-42e4-b993-0dc1ab10d95c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba47ceb2-3907-4c75-93da-352aebf2bc11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84565942-6987-4c97-b8de-234ea6a6f1a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6e3c39b-8096-4f8f-97f0-daa59596a1a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:OKSFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a91b6de8-ece5-41ce-aead-f4c5480a52b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f7339a6-1078-443f-9a49-06210ba9d73d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be8ba35b-0380-4fb4-a4e6-89fb909ebcce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df66f09e-7513-4224-913e-a00329ea7267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3253f6cb-13ac-491b-a7c7-9edb74475ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_186c69fe-8d24-44a5-865b-ef7a19de3a07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krro:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85bbe7f5-08dc-4646-8679-f35a1d5e2c54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28de2dc3-2ca9-4bb6-8723-f572b9234796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52ef87ed-863c-43f2-b64f-793064742302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fab291c7-d953-4b7e-86e4-50c5ceed14ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11d68bec-be21-47b3-aed2-e43151eea3b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e96165e-bcee-45de-b858-7909fc620d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65a239e0-5ccd-49da-844a-2f067baf9930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:KorrosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbbfcc39-8343-47e0-a50c-2b474af31554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a51d59d-f39c-4dbc-88ab-1479e858825a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22794dbf-a4f9-4f21-8513-02ae3c6a8843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a9015d7-d3e2-497e-ae73-4ee485589e02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c6858e2-8133-456c-a5ca-5b7016177e3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e149e85-1d4b-4712-863c-cb986c6595d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_306fb8af-4fc4-4970-872c-b483d03fb9e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_096221e9-4b77-4f75-a7ca-adeffcec02e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eb4912e-e6b4-4f6f-b944-30b2ae5249b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e3928f9-e795-46c2-8b3b-47cb73bcf901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19000ad4-b68e-4b1a-a943-897eb59fe630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4c0a17b-b744-4c53-8416-6686a4fc0acf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36085e8f-16ab-4161-877d-07990acb5c48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6c273ee-ecf6-4069-ae3d-4c61b89c6153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_883bc534-e8f6-4895-bf52-bf10d4e2a415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c288594a-72d1-4f6b-8b50-f8d38cf9d937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd07e99c-bb55-45ba-8e28-c3c05197c876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c761095-cfe8-42cc-a37e-889e388af4b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22e502a6-3646-4014-b58b-4798f5344e84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d3840a1-75bb-41e9-bdf6-5978eb8662d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4331d39a-acce-4178-b456-7b04be2b6063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76ec386a-8db0-4d94-8796-51f3034d3694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24975ddf-6b2d-4418-a7fd-437c84c577ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eb2b595-9ba7-481a-b2e8-779deb094693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeed3PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a634502-8868-4319-974b-a0bdac21d6bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:FrequencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0eebafc0-fac7-4906-a525-f415a4144d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa7dd013-7306-42b5-8ed5-d73bf12a2654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36660a78-b341-4333-95b7-20b31fa422ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1497c1b1-c02c-4386-9a0b-01290e5e3553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dd132b6-7063-44e3-af52-d367d2ce82ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55c76954-1de4-47a3-95e3-7300d73d84fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86de2748-fce4-4bbf-9e70-716575029823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ef3d01f-e4f1-47e1-8d30-5ca772b0c60e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8544c9be-728b-4911-819c-b239ec0b27ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a190f767-c341-455b-9ad4-483737f0d73f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bec03e77-9bf0-4f52-9023-3b2c608d690f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_745aa97d-b654-4fe3-a288-63cea2f6c854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2a2b4a4-d405-4a52-87f7-0d7d1dabb2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1ffa510-b12a-4e8a-ae92-845d73bdc92d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab007b59-97df-45a4-a462-77226307ef64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1de4389e-f2f0-4d25-b59d-6d52f9adce3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f5dc272-fb80-43d7-a5fe-feed1975a355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Securities"><xbrli:measure>krro:Securities</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_634fd6d0-ad20-46a4-8d5b-0841462aa503" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8183349e-ae67-46c6-8488-1322a4e5ecd0" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a52c9a51-41ab-4cd2-ad0c-8a6146078943" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08c296d3-be88-4b30-8017-c62ee2e1201a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be903220-e9da-41f7-bdfd-9ddd33e22087" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7a22a284-b1dd-4503-8f32-30e6114624e6" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission file number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4920c7a-36f5-4a77-91de-a820b51b49b7" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39062</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51321057-8c99-4843-ab14-ed43e42f3b3d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_645fca40-bcc2-439e-b428-622872590fe8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8520bb99-f6fe-4042-8767-e7fc01142ee1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47-2324450</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5af50d38-9257-46d6-98ae-417cce26bef9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">One Kendall Square</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_6d375288-0e1f-44ce-ab94-0235d3db1532" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Building 600-700</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_7325958c-fb41-4319-9e8e-c854265f4eb5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressAddressLine3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 6-401</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_84d38b7e-5dfe-4717-8dca-3a7b8a74afd4" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_49b78a08-c8ee-46a6-b3ce-0a014d469da3" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a704ba1f-b153-4eb2-8a10-d8d38cbed3ca" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02139</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deaca5be-3ece-4fc1-84f4-4a89a22a4e10" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8911f8a-4eef-486d-9bfc-735e495adf74" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> 468-1999</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_252af18e-b4d7-4ce0-b8c9-05fcf0b1c952" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_04b31cfd-aaf6-408c-b723-4a288ec81a4e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">KRRO</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">The </span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_08505ad2-4314-4e88-b628-0930b2865a04" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9eb73b5d-2d42-4841-a757-52dcab761a32" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ef3d438-4613-4d24-9a75-7148e872a3c5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36f4f087-c237-4f6e-bdb9-585408ed5c04" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">     No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91a83348-bd2d-47d0-9a20-8c813f4feff4" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">     No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_6a571421-76b5-48f0-bb0e-489ecf346308" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ce3dc34f-8429-4091-8230-54c8fbae806f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7c00ff15-feb2-416a-a2fc-77b2af24a0b3" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6132a8d9-f781-4ca8-adab-0f4c006c016c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e36d64d6-4130-4f54-8ef7-f785353b5ae0" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_417f9a85-7d52-4352-a081-cbda2da5e0f0" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_95be36e2-3fde-4303-ad4b-eeabac660773" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">     No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Capital Market on June 30, 2023, was $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6e62bf9-3d57-43e7-b38d-d1bdc37a62ea" contextRef="C_9fd09c06-35f8-4ac3-827b-5890bfa49ef1" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">12,148,224</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of registrant&#8217;s Common Stock outstanding as of March 21, 2024 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_936f5b53-0fe4-4aed-8f2c-ff10edff69bb" contextRef="C_22e502a6-3646-4014-b58b-4798f5344e84" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,021,946</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.998%;"/>
    <td style="width:81.924%;"/>
    <td style="width:7.079%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7_managements_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="text-indent:6.85pt;vertical-align:bottom;text-align:center;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">162</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 3, 2023, or the Closing Date, we consummated the previously announced business combination, or the Merger, pursuant to that certain Agreement and Plan of Merger, or the Merger Agreement, dated July 14, 2023, by and among our company (formerly known as Frequency Therapeutics, Inc., or Frequency), Frequency Merger Sub, Inc., or Merger Sub, and Korro Bio Inc., or Legacy Korro.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination between Frequency and Legacy Korro was effected through the merger of Merger Sub with and into Legacy Korro, with Legacy Korro surviving as a wholly owned subsidiary of Frequency. On the Closing Date, Frequency changed its name to Korro Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the context otherwise indicates, references in this Annual Report on 10-K to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively, to Korro Bio, Inc., a Delaware corporation, and its consolidated subsidiaries (including Legacy Korro).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report on Form 10-K may be referred to without the &#174; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K includes statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report on Form 10-K may include, for example, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recognize the benefits of the Merger;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our cash runway and ability to reach data inflection points;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the therapeutic and commercial potential of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our research and development and other expenses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet such competition; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manage the growth of our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, including those set forth under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Should one or more of the risks or uncertainties described in this Annual Report on Form 10-K, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this annual report. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business involves significant risks. Below is a summary of the material risks that our business faces, which makes an investment in our securities speculative and risky. This summary does not address all these risks. These risks are more fully described below under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investment. Further, there are additional risks not described below that are either not currently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business, operations or market price of our securities.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since inception and expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expectations regarding our cash runway and ability to reach data inflection points are based on numerous assumptions that may prove to be untrue.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be required to raise capital sooner than anticipated and our exposure to certain contingent liabilities and contractual obligations may be greater than anticipated.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never generated revenue from product sales and may never become profitable.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and development programs or future commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gene editing field and RNA editing in particular is relatively new and is evolving rapidly. We are very early in our research and development efforts and may not be successful in identifying and developing product candidates. It will be many years before we or any potential future collaborators commercialize a product candidate or generate any revenues, if ever. Additionally, other gene editing technologies may be discovered that provide significant advantages over RNA editing, which could materially harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are very early in our research and development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to obtain or protect intellectual property rights related to any of our product candidates, development and commercialization of our product candidates may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock is expected to be volatile, the market price of the common stock may drop following the Merger and an active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult and may discourage any takeover attempts that stockholders may consider favorable, and may lead to entrenchment of management.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are generating a portfolio of differentiated programs that are designed to harness the body&#8217;s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, we expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. However, the scientific evidence to support the feasibility of developing product candidates using our RNA editing technology is both preliminary and limited. Moreover, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and no clinical data has been generated to date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The advent of large-scale genome sequencing has progressively revealed causal genetic variation underlying several human diseases, both rare and highly prevalent. Genetic mutations, including single nucleotide variants, or SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and their associated downstream biochemical pathways. Data correlating DNA to RNA to disease phenotype have demonstrated that SNVs lead to a loss-of-function or a gain-of-function of the gene. In addition, the majority of SNVs implicated in complex diseases are due to modulation of gene function. By editing SNVs on RNA, we believe we will be able to address unmet patient need by transiently modifying gene function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our understanding of genetic drivers of disease has increased, significant advances have been made in technologies designed to introduce specific yet permanent changes at the DNA level to treat diseases. While these DNA editing approaches offer great promise for the treatment of certain rare diseases, they present significant risks from potential permanent adverse &#8220;off-target&#8221; edits. Additionally, the complex nature of DNA editing drug products presents multiple challenges including lack of efficient delivery to target cells and scalable manufacturing, impeding their application to treat complex highly prevalent diseases of larger patient populations. These potential limitations have spurred exploration of alternative approaches to genetic medicine development, such as RNA editing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mammals and other lower species like cephalopods have an endogenous process of modifying single bases on RNA, referred to as RNA editing. RNA editing is a natural physiological process, similar to RNA interference, or RNAi, that occurs in cells, including a mechanism mediated by an enzyme called Adenosine Deaminase Acting on RNA, or ADAR. Our RNA editing approach involves co-opting this endogenous editing system via a proprietary engineered oligonucleotide to introduce precise edits to RNA. We iteratively optimize the editing efficiency of our product candidates using a combination of ADAR biology, chemistry and machine learning expertise. Using this approach, we can edit the transcriptome with high efficiency and specificity. The application of such an approach can provide the ability to alter a SNV and affect biology in meaningful ways.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have assembled a suite of technologies and capabilities to build our RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_0.jpg" alt="img83127175_0.jpg" style="width:530px;height:206px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OPERA integrates a deep understanding of ADAR biology with expertise in oligonucleotide chemistry, machine learning optimization of oligonucleotides and fit-for-purpose delivery, all of which are expected to enable rapid iteration of our product candidates across therapeutic targets. OPERA relies on the following key components that enable us to generate the proprietary RNA editing oligonucleotides that form the basis of our differentiated product candidates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deep understanding from ADAR biology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, supported by extensive preclinical research using </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> assays and proprietary mouse models as well as the fundamental work of our scientific advisors and founders to elucidate key insights and know-how of ADAR biology. This enables an understanding of ADAR activity in different species and disease states, allowing us to develop novel product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expertise in oligonucleotide chemistry</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, enabled by the ability to identify and incorporate chemical modifications to generate a fully modified synthetic oligonucleotide. This increases our ability to generate oligonucleotides with drug-like properties, thereby increasing the editing and translational efficiency of our product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Machine learning optimization of oligonucleotides</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, driven by data science and computational capabilities for rapid design and iteration resulting in optimal product candidates for each disease being pursued. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fit-for-purpose delivery</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, made possible by tissue-specific delivery technologies that can enhance biodistribution, specificity, durability and editing efficiency of product candidates for each given disease. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such product candidates include Customized High-fidelity Oligonucleotides for RNA Deamination, or CHORDs</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CHORDs are single stranded, anti-sense oligonucleotides designed to have high target efficiency and specificity by leveraging the pillars of OPERA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The versatility of RNA editing combined with our OPERA platform broadens the therapeutic target space significantly. While our approach can be used to repair pathogenic SNVs, as demonstrated by our most advanced program, our Alpha-1 Antitrypsin Deficiency, or AATD, product candidate, KRRO-110, we can also engineer </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities as exemplified by three of our other programs (sAH, ALS, Pain). In preclinical studies, we have demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling us to pursue a broad range of diseases with potentially large addressable patient populations traditionally out-of-scope for other genetic medicine approaches and current traditional drug modalities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our programs demonstrates the versatility of the oligonucleotide-based ADAR-mediated RNA editing approach to bring additional precision and tunability to address a broad range of rare and highly prevalent diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repairing pathogenic variants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A SNV that is a G to A mutation on DNA, leading to an aberrant amino acid on a protein can be repaired using RNA editing. Such an approach is relevant when the patient population has a spectrum of disease manifestations from mild-to-severe. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disrupting protein-protein interactions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A single SNV observed in human genetic association studies has the potential to inform how to transiently activate a protein pathway. We can generate this protein variant transiently using our RNA editing product candidates, thereby engineering a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> SNV. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other target classes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> There are multiple other target classes that can be addressed such as preventing protein aggregation selectively modulating ion channels and activating kinases that have been traditionally hard to leverage for developing medicines. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pipeline chart below demonstrates the breadth of indications and applications enabled by our OPERA platform, with an initial focus on four programs that are all wholly-owned. In addition, we have two other wholly-owned programs not reflected in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pipeline chart below: one for an undisclosed target for sAH, and one for a kinase target for cardiometabolic disease. All of our programs are still in the research or preclinical stage of development and their risk of failure is high.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_1.jpg" alt="img83127175_1.jpg" style="width:624px;height:196px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to submission of regulatory filing and authorization to proceed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to make meaningful advancements across our programs, including advancing KRRO-110 towards clinical development. Specifically, KRRO-110 is our first development candidate for the treatment for AATD that, using our proprietary RNA editing approach, repairs the amino acid codon. This repair of the endogenous protein has the potential to clear protein aggregates from within liver cells to create a potentially disease-modifying clinically differentiated benefit for liver function and to preserve lung function by providing an adequate amount of normal AAT protein. AATD is an inherited genetic disorder that can cause severe progressive lung and liver disease due to a lack of normal alpha-1 antitrypsin protein, or AAT, caused by SNV mutations in the SERPINA1 gene. There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. Despite being minimally effective and not fully addressing the needs of many AATD patients, augmentation therapy currently represents approximately $1.4 billion in annual sales worldwide. KRRO-110 has the potential to elevate the standard of care and expand the number of patients on treatment and potential to be a leader with a large market opportunity worldwide. However, we have yet to conduct any human clinical trials, our product candidate is in early stages of development and there is no guarantee we will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 is a proprietary oligonucleotide that utilizes a proven lipid nanoparticle, or LNP, based delivery system administered intravenously to transiently restore production of normal AAT in liver hepatocytes. By correcting the pathogenic G to A SNV in the SERPINA1 gene, we aim to bring individuals with the Z mutation to a phenotype where over 50% of RNA has been corrected to produce normal AAT protein, preserving lung and liver function and preventing further damage. However, this delivery system has not yet been finalized and, while LNPs have been validated clinically to deliver oligonucleotides, such as siRNA, they have not been clinically proven to deliver oligonucleotides for RNA editing, such as our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our approach for treating AATD has multiple potential advantages:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a disease modifying therapy for both lung and liver manifestations by transiently editing over 50% of RNA transcripts in hepatocytes to restore normal AAT protein </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a treatment option that can be tailored to address the broad spectrum of severity within the AATD population </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential to enable physiologic regulation of AAT using endogenous ADAR, thereby increasing normal AAT production during inflammation </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fit-for-purpose delivery using a proven LNP to maximize editing efficiency, leading to greater potential clinical benefit </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated compelling preclinical data demonstrating proof of concept across multiple RNA editing oligonucleotides targeting the SERPINA1 gene, including KRRO-110.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 has achieved high editing efficiency </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&gt;50% editing in hepatocytes)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 demonstrated high specificity with no bystander effects in MZ human primary hepatocytes.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intravenous administration of KRRO-110 at 2mg/kg in a human transgenic PiZ mouse model resulted in secretion of approximately 50uM total AAT protein as early as seven days post-single dose.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 increases the expression of normal AAT protein to &gt;70% of total AAT protein in circulation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase in functional AAT protein with the inhibition of elastase activity was sustained through week nine when KRRO-110 was dosed every two weeks, demonstrating durability in mice.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Engineered surrogate oligonucleotides that edit RNA at an adjacent site on the SERPINA1 gene relative to KRRO-110 have high translation of RNA editing efficiency from mice to non-human primates, or NHPs, demonstrating the potential applicability of our approach in humans. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we believe we can demonstrate many of the key advantages of RNA editing, we are very early in our development efforts and not yet certain of the results we may achieve. Such uncertainties include, but are not limited to, the level of editing efficiency needed in a target tissue type to achieve a clinical benefit, and associated safety of our edits in humans. Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024, and an anticipated interim clinical readout in the second half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Team</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were launched in 2018 and were co-founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal and Andrew Fraley. Our science was based on pioneering research from the laboratory of Joshua Rosenthal, Ph.D., at the Marine Biological Laboratory, or MBL in Woods Hole, Massachusetts. Dr. Rosenthal&#8217;s work includes landmark discoveries in RNA editing based on adenosine deamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are led by an experienced team with deep expertise in genetic medicines, development of oligonucleotide-based therapeutics, building novel therapeutic platforms, and bringing multiple therapeutics to market. In addition, our executive leadership team has a successful track record of company building and leading biotech companies, including Ram Aiyar, Ph.D., President and Chief Executive Officer, an experienced executive and company builder with 20 years of diverse industry experience including research, business and strategy; Steve Colletti, Ph.D., Chief Scientific Officer, who brings nearly 30 years of drug discovery and development experience covering a broad range of therapeutic areas and modalities; and Vineet Agarwal, Chief Financial Officer, who brings more than 14 years of financial and industry experience as a biotech investment banker with J.P. Morgan Chase &amp; Co. We also have an accomplished scientific advisory board comprised of leading experts in the fields of ADAR biology, chemistry, translation medicine, and nucleic acid therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a mission-driven organization and thrive through a strong culture of scientific innovation and behavior that embodies our core values and principles. We are actively working to rewrite the future of medicine by remaining on the cutting edge of science and research. We believe our success is enabled by working better together and embracing diversity, leading us to employ a dynamic team with varied expertise, enabled by kindness and integrity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have attracted a talented team of industry experts and experienced scientists as part of a high-performing, nimble organization. Our research and development organization is comprised of individuals with expertise in DNA editing technologies, liver biology, CNS biology, medicinal chemistry, biochemistry and drug delivery, translational medicine and conducting preclinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have raised $343 million in capital, including $117 million as part of the pre-closing financing that closed immediately prior to the Merger, or the Pre-Closing Financing, from premier venture capital funds, healthcare-dedicated funds, major mutual funds and other leading investors that share our vision of creating transformative genetic medicines for diseases with high prevalence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases. We do this by applying our proprietary RNA editing platform, OPERA, which combines our unique expertise in ADAR biology and oligonucleotide chemistry with machine learning-driven optimization and fit-for-purpose delivery. Our RNA editing product candidates are designed to harness the body&#8217;s natural RNA editing processes to make a precise single base edit. However, this has only been observed in preclinical studies as we have yet to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, or commence a clinical trial. Our goal is to develop a portfolio of RNA editing product candidates with best-in-class properties across a range of diseases by executing on the following key pillars of our strategy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop a novel class of RNA editing therapies using learnings from a combination of genetics and approved medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are leveraging significant advances in the understanding of the correlation between DNA, RNA and disease phenotypes to develop novel therapeutic approaches across a range of validated biological targets. This novel class of RNA editing therapeutics combines the precision of genomic therapies with the properties associated with traditional approved drugs, such as titratability and ability to re-dose. In addition, our RNA editing product </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates are structurally similar to other clinically and commercially validated drug modalities such as antisense oligonucleotides, or ASOs, and small-interfering siRNAs, conferring potential advantages in manufacturing, regulatory review and clinical adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop and advance into the clinic a differentiated disease-modifying therapy for patients with AATD. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first development candidate, KRRO-110, has the potential to provide a differentiated therapeutic option for AATD by addressing both the liver and lung pathologies. Our RNA editing oligonucleotide product candidates, including KRRO-110, have generated compelling preclinical data that demonstrates restoration of normal AAT protein while preventing the aggregation of dysfunctional AAT in the liver. Our preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> data has demonstrated durability and high editing efficiency in both mice and NHPs, illustrating the potential applicability in humans. Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024, and an anticipated interim clinical readout in the second half of 2025. Depending on the evidence of efficacy and tolerability, we intend to pursue expedited regulatory pathways. However, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and no clinical data has been generated to date. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deploy our versatile OPERA platform to develop a portfolio of programs that modify proteins transiently to expand into highly prevalent diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OPERA has the ability to generate unique RNA editing therapies that can modify protein function or endow proteins with engineered changes that will potentially result in desirable properties to treat disease. In preclinical studies, we have demonstrated that single RNA changes can disrupt a protein-protein interaction, prevent protein aggregation, selectively modulate an ion channel and selectively activate a kinase. These modification approaches can unlock validated target classes that have historically been deemed undruggable, enabling us to pursue a broad range of diseases, including those with high prevalence. We are evaluating potential applications of our OPERA platform for use in other highly prevalent indications including the central nervous system, or CNS, liver, and cardiometabolic therapeutic areas. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to optimize and enhance our OPERA platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We believe we have built a leading RNA editing company through a combination of our OPERA platform, intellectual property strategy and human capital. Our computationally driven approach enables rapid design and optimization of potential oligonucleotide product candidates. In development of our AATD program, we were able to go from &#8220;design-to-data&#8221; in 5-6 weeks. We intend to continue to incorporate new data into these machine learning models to improve their ability to predict editing efficiency and to more expeditiously optimize and nominate new product candidates, although there is no guarantee that this will result in an accelerated development or approval timeline, if at all. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maximize the potential of our OPERA platform through collaborations and strategic partnerships. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently retain worldwide development and commercialization rights to our programs and platform. We actively collaborate with clinical leaders, academic medical centers of excellence, and patient advocacy groups to continue to enhance our expertise in our focus therapeutic areas. Given the versatility and broad potential of our OPERA platform across therapeutic areas, especially in diseases with high prevalence, we may enter into strategic partnerships with external parties that have complementary capabilities to broaden and accelerate access to our RNA editing therapies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Invest in human capital and encourage innovation to maintain a leading position and advance the frontiers of genetic medicines. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a mission-driven organization, and we thrive through a strong culture that embodies our core values. We are actively working to rewrite the future of medicine and remain on the cutting edge of science and research by working better together and embracing diversity in employing a dynamic team with varied expertise, enabled by kindness and integrity. We have attracted a talented team of industry experts and experienced scientists as part of a high-performing and nimble organization. Our research and development organization is comprised of individuals with expertise in editing technologies, RNA biology, liver biology, CNS biology, medicinal chemistry, biochemistry and delivery, translational medicine, preclinical and clinical development. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expanding the Frontiers of Genetic Medicines: RNA Editing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The advent of large-scale genome sequencing has progressively revealed causal genetic variation underlying several human diseases, both rare and highly prevalent. Genetic mutations, including SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and their associated downstream biochemical pathways. Natural genetic variations, revealed by population-level genomic studies, have also been shown to protect against or to increase the risk of disease. Beyond these developments, groundbreaking advances in gene therapy, cell therapy and RNA therapeutics have resulted in several approvals that have transformed the treatment of certain genetic diseases and cancers as well as the prevention of infectious diseases, such as COVID-19. In addition, various DNA editing approaches have been developed that introduce specific genetic changes to DNA to treat diseases. First generation CRISPR-Cas9 DNA editing has demonstrated the potential to knockout</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pathogenic mutations at the single gene level with several programs in clinical development and the first </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> DNA editing therapeutic for a rare hematological condition on file at the FDA. Next generation DNA editing approaches have recently entered the clinic and hold the promise to edit DNA at the single nucleotide level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite these advances, significant risks exist with DNA editing approaches. A key concern is the introduction of unwanted DNA modifications (&#8220;off-target&#8221; edits) which could have permanent adverse effects such as chromosomal integration and non-specific insertions, deletions and substitutions. Additionally, due to the complexity of a multicomponent DNA editing product, delivery to target cells can be challenging and even more so if there is a need to edit multiple genetic loci. Furthermore, manufacturing is highly complex and expanding to commercial scale remains challenging, specifically for a highly prevalent indication. Given these challenges, DNA editing approaches will likely remain a focus for certain rare diseases, while its ability to treat diseases of high prevalence continues to be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADAR-mediated RNA editing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA editing involves altering a sequence of RNA which intrinsically has the potential to address some of the limitations of DNA editing. RNA editing mediated by adenosine deaminase acting on RNA, or &#8220;ADAR-mediated&#8221; RNA editing, has recently emerged as a differentiated approach that can generate product candidates having features that combine the precision of genomic therapies with the properties commonly associated with current approved drugs such as titratability and ability to re-dose. Importantly, these drug-like characteristics enable ADAR-mediated RNA editing candidates to be potentially safer and target diseases with high prevalence that would be difficult for DNA editing approaches to address.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADARs are a family of enzymes present inside a cell, that bind RNA. ADARs bind double-stranded RNA structures, and convert a single base of adenosine (A) on RNA, into an inosine (I) that is typically translated as a guanosine (G), using an enzymatic process. ADAR mediated editing is found at high levels in cephalopods both on the coding and non-coding regions of the RNA. In humans, there are fewer recoding events, and most of the endogenous editing events occur in non-coding regions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Humans have two known active endogenous ADAR enzymes, ADAR1 and ADAR2. ADAR1 is constitutively expressed and is present in most tissues within the body, whereas ADAR2 is more highly expressed in tissues such as the brain. The ADARs are essential enzymes for normal physiologic function. ADAR-driven RNA editing has been found to be critical for the function of a number of proteins, such as the glutamate ionotropic receptor, which has been found to be almost always RNA-edited in humans. Given ADARs&#8217; natural function to catalyze A-to-I edits, this endogenous editing system can be leveraged to make programmed edits to RNA. This ability to introduce programmed highly targeted edits into RNA has the potential to expand the reach of genetic medicines with an ability to modify proteins to achieve a desired function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Oligonucleotide-based ADAR-mediated RNA Editing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are multiple therapeutic approaches to utilize ADAR-mediated RNA editing, including synthetic oligonucleotides, engineered ADARs, and Cas-based editing approaches. Our therapeutic approach delivers oligonucleotides to target tissues and cells to introduce precise edits to RNA through recruitment of endogenous ADAR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Normally, ADARs are recruited to target RNA editing sites through recognition of specific double-stranded RNA structures such as naturally occurring hairpins or loops in endogenous transcripts. Importantly, one can mimic these double-stranded RNA structures by introducing complementary synthetic oligonucleotides into cells. An oligonucleotide can be engineered to mimic the double-stranded RNA structure such that endogenous ADAR is recruited. Using this targeted approach, a site directed specific A-to-I edit can be introduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_2.jpg" alt="img83127175_2.jpg" style="width:478px;height:196px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 1: Mechanism of RNA editing using our proprietary platform</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key Advantages of Oligonucleotide-Based ADAR-Mediated RNA Editing as a Therapeutic Modality</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that oligonucleotide-based ADAR-mediated RNA editing is a groundbreaking technology that is ideally suited to expand the application of genetic medicines for indications that DNA editing is unable to address. Over the last two decades, there has been significant research around and development of oligonucleotide-based therapeutics, including modalities such as siRNA and ASOs, that has led to the approval of multiple drugs. Specifically, developments in oligonucleotide chemistry, delivery technologies, tolerability, and manufacturing, combined with better defined regulatory pathways, have led to the approval of oligonucleotide-based therapeutics specific for multiple different tissue types. We differentiate our approach from DNA-editing by leveraging the know-how from approved oligonucleotide therapies in development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_3.jpg" alt="img83127175_3.jpg" style="width:562px;height:233px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">While we believe we can demonstrate many of the key advantages of RNA editing, we are very early in our development efforts and not yet certain of the results we may achieve. Such uncertainties include, but are not limited to the level of editing efficiency needed in a target tissue type to achieve a clinical benefit, and associated safety of our edits in humans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specificity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Oligonucleotide-based ADAR-mediated RNA editing enables highly precise edits at the target single nucleotide level on the RNA with low risk of off-target or bystander edits, addressing a key safety concern associated with other DNA editing approaches that carry the risk of permanent insertions and deletions as well as chromosomal integration. Using synthetic oligonucleotides, appropriate chemical modifications can be introduced to increase the overall specificity and targeting efficiency for the site directed RNA editing. The OPERA oligonucleotides are designed to be highly site selective with minimal to no bystander effects or halo effects. To assess global off-target editing, we use a bulk RNA-seq approach to detect base frequency changes at potential off target sites between control and treated samples. We sequence target amplicons via NGS and assess potential A to G editing at all sites across the transcript. In preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies, we have shown that off-target RNA editing using our technology is negligible and transient. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_4.jpg" alt="img83127175_4.jpg" style="width:411px;height:252px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 2. Overview of off-target editing observed in mice across multiple oligonucleotides</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delivery</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Oligonucleotide-based ADAR-mediated RNA leverages well established, clinically precedented delivery approaches used in other approved products, such as LNPs and ligand-based approaches. LNP-based delivery of oligonucleotides is a well established and clinically validated delivery approach that provides sustained targeted delivery and editing efficiency, resulting in infrequent dosing and an acceptable tolerability profile. Additionally, LNP delivery of RNA-editing oligonucleotides enhances optimal distribution to targeted cells. One example of a well-established and clinically validated ligand-based delivery approach is GalNAc delivery of oligonucleotides, which provides highly specific and effective delivery to hepatocytes with improved durability. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: ADAR-mediated RNA editing has a low risk of immunogenicity and can potentially lower off-target editing events resulting in an improved tolerability profile compared to DNA editing approaches. The lower risk of immunogenicity enables the ability to re-dose patients if required, a significant limitation of editing approaches that utilize viral vectors and bacterial Cas systems that carry a higher risk of immunogenicity. The transient and reversible nature of ADAR-based editing confers an ability to modify or cease dosing as needed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Reliance on endogenous ADAR enzymes and the simple drug constructs of oligonucleotide-based therapies has significant advantages over the complexities associated with the manufacturing and delivery of multi-component exogenous complexes used in DNA editing. Manufacturing processes for oligonucleotide-based therapies are well established, cost efficient and scalable to effectively address highly prevalent indications. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Precedence of marketed oligonucleotide drugs with similar size and types of chemical modifications that therapeutic RNA editing product candidates exhibit. Guidance for the development of oligonucleotide therapeutics by global agencies, including the FDA, provides for an established pathway for the approval of this class of therapeutics. However, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and on clinical data has been generated to date. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our OPERA &#8211; Oligonucleotide Promoted Editing of RNA &#8211; Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we are the leading RNA editing company and have assembled a suite of technologies and capabilities called OPERA, Oligonucleotide Promoted Editing of RNA, to generate differentiated RNA editing product candidates, or CHORDs. A key challenge in developing a therapeutic approach for site-directed RNA editing is to design and optimize oligonucleotides that can drive high-efficiency. This efficiency is facilitated both by the ability to repurpose and optimize oligonucleotide constructs based on existing methods as well as utilizing computational methods to innovate on chemistry and design of the constructs. Our RNA editing product candidates are oligonucleotides capable of forming Watson-Crick base pairing with the target RNA and efficiently inducing the deamination reaction by endogenously recruiting ADAR enzymes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have assembled a suite of technologies and capabilities to build our RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OPERA relies on the following key components that enable us to generate our differentiated RNA editing product candidates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deep understanding from ADAR biology:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our insights and know-how of ADAR biology allow us to design oligonucleotides that efficiently recruit ADARs and promote deamination while maintaining selectivity and stability. RNA editing is dependent on endogenous ADAR expression levels and requires a deep understanding of the physiological role of ADAR, its cell and tissue distribution, the factors that lead to efficient recruitment of ADAR to targeted sites and any consequences that may arise from co-opting ADAR from its normal function. We have developed a cell-free </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA editing assay with purified human ADAR1 and ADAR2 that predicts the RNA editing activity with our oligonucleotides. With our cell free assay capability, we are able to limit the number of components implicated in screening (target gene, RNA editing product candidates and ADAR), allowing us to measure the kinetics of RNA editing more accurately. Using only three components including the target RNA, oligonucleotide, and ADAR, we have shown that target editing efficiency is correlated with the chemical modification pattern of an oligonucleotide. Furthermore, we have found that this activity predicts the rank order of oligonucleotides in both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell-based systems and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in rodents. This assay capability supports our understanding of the key steps required to edit RNA at a level of detail that is not possible in cells. These platform biology assay capabilities have enabled detailed mechanistic studies into the tissue distribution and subcellular localization of ADAR proteins and our RNA editing product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have found no evidence that our RNA editing oligonucleotides interfere with endogenous RNA editing occurring naturally in a cell. ADAR naturally edits thousands of targets for a variety of reasons. We have looked at natural editing sites and chose AJUBA, COG and COPA as they have shown to be edited by ADAR to different degrees. In this experiment outlined in Figure 3, ZZ HLC cell lines were transfected with RNA editing product candidates targeting two different genes. The assays were evaluated for % editing for Target A and Target B sites as well as natural editing sites in COG, COPA and AJUBA. As shown below, natural editing sites remained unaffected </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compared to the control group, demonstrating that our RNA editing product candidates are not likely to have any effect on the degree of editing of native RNA molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_5.jpg" alt="img83127175_5.jpg" style="width:562px;height:203px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 3. Our RNA editing product candidates show no evidence of interference with endogenous ADAR editing as demonstrated at the above endogenous sites</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expertise in oligonucleotide chemistry:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have a differentiated ability to create oligonucleotide designs capable of efficiently recruiting endogenous ADAR with chemical modifications that direct high specificity editing. Our oligonucleotides increase the potency and durability of ADAR activation, thereby increasing the editing efficiency and translational efficacy of our product candidates. We have identified critical structural, sequence, and chemistry requirements for our product candidates that drive efficient recruitment of ADARs and subsequent A-to-I editing. Examples of differentiation include oligonucleotide length for efficient ADAR recruitment, use of precedented and proprietary chemistries within the oligonucleotide, as well as backbone chemistries that provide improved metabolic stability. Additionally, we combine this with 2&#8217; modification chemistries that, together, create oligonucleotides with improved editing efficiency and durability. As RNA editing is an emerging technology, there is a lack of guiding principles to design site-selective RNA editing oligonucleotide product candidates. To address this knowledge gap, we developed a robust in-house process using our high-throughput cell-based assay and machine learning capabilities to design and synthesize up to approximately 1,200 oligonucleotides per month and generate up to 6,000 assay data points for any given target. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Machine learning optimization of oligonucleotides:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have built data science capabilities and a dedicated team to extract lessons from existing and newly generated experimental data to expeditiously design and optimize RNA editing product candidates. Our proprietary machine learning models have been trained to accurately predict oligonucleotide structure and observed levels of editing. We have been able to demonstrate that these models are able to make accurate editing predictions even for previously unseen chemical modifications demonstrating their generalizability across targets. We have demonstrated the utility of our machine learning models through an increase in overall editing efficiency of new product candidates over the last several quarters. In some cases, we have been able to go from design-to-data in as little as five weeks. However, there is no guarantee that this will result in an accelerated development or approval timeline, if at all. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_6.jpg" alt="img83127175_6.jpg" style="width:401px;height:194px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 4. We have shown our ability to rapidly iterate product candidates to maximize editing efficiency</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Structural modeling is another tool that complements our ability to increase the efficiency of our RNA editing candidates. Detailed structural modeling includes shape, size and orientation requirements that can lead to successful deamination at the editing site. These aspects have an important impact on our ability to optimize RNA editing product candidates. As an example, a modification predicted by structural analyses led to a conformational change that was shown to improve editing efficiency in the coding region of the Target A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_7.jpg" alt="img83127175_7.jpg" style="width:268px;height:222px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 5. We have a demonstrated ability to improve editing in target coding regions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fit-for-purpose delivery:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our product candidates utilize short synthetic oligonucleotides, which we believe can be efficiently delivered using technologies such as LNP or GalNAc. These delivery technologies are well established and clinically validated and have been developed for precedented modalities such as siRNAs and ASOs. Each of these delivery vehicles has optimal characteristics suited for a given therapeutic application. Using CHORDs, we achieved greater than 50% editing in vivo utilizing both a ligand-based GalNAc conjugate and an LNP-based delivery approach (see Figure 6).</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, LNP mediated delivery of RNA editing product candidates provides sustained delivery and an acceptable tolerability profile that have been manufactured at a scale sufficient to serve the target population. In addition to LNP based delivery approach, ligand-based approaches (ex., GalNAc for liver hepatocytes) can also be used for effective delivery and to improve durability with OPERA&#8217;s RNA editing product candidates, which we have also evaluated in preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> models. In contrast to treatments targeting liver hepatocytes where there is a need for a delivery system, our RNA editing product candidates have been delivered intrathecally to the central nervous system without a need for any delivery system in preclinical mouse models. Thus, our choice of delivery system is a fit-for-purpose model that is dependent on the oligonucleotide design as well the suitability for the indication and tissue localization of the target. However, this delivery system has not yet been finalized and while LNPs have been validated clinically to deliver oligonucleotides, such as siRNA, they have not been clinically proven to deliver oligonucleotides for RNA editing, such as our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_8.jpg" alt="img83127175_8.jpg" style="width:562px;height:238px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 6. Demonstrated greater than 50% editing using GalNAc conjugates in the liver in a preclinical mouse model.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline Demonstrates the Versatility of the OPERA Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a broad pipeline of four programs that are wholly owned and demonstrate the versatility of our OPERA platform. In addition, we have two other wholly-owned programs not reflected in the pipeline chart below: one for an undisclosed target for sAH, and one for a kinase target for cardiometabolic disease. All of our programs are still in the research or preclinical stage of development and their risk of failure is high.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_9.jpg" alt="img83127175_9.jpg" style="width:624px;height:196px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Subject to submission of regulatory filing and authorization to proceed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our proprietary oligonucleotides co-opt endogenous ADAR to perform a single A-to-I base edit on RNA to modify protein function. Delivery of these proprietary oligonucleotides into a cell forms an oligonucleotide-RNA duplex which recruits endogenous ADAR, ultimately editing a target adenosine (A) to inosine (I) on RNA. The location of the edit can lead to a multitude of effects including changes in expression and regulation of mRNA. In the event an edit is made in the coding region of the gene, the mRNA is then translated to a protein with the (I) inosine read as a (G) guanosine, resulting in a modified protein. The resultant therapeutic protein can be applied to go beyond repairing pathogenic SNVs by changing amino acids on proteins implicated in disease biology. Single amino acid changes to non-mutated RNA can create </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> modified protein variants with desired altered properties while preserving their broader functional capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Repairing pathogenic variants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our OPERA platform enables the development of RNA editing therapies that can repair SNVs on mRNA to express normal proteins through the introduction of precise genetic changes without creating permanent changes to the genome. These normal proteins can be uniquely expressed at desired levels and duration to address both rare and highly prevalent diseases caused by a pathogenic SNV. This approach is especially relevant when the same underlying genetic SNV manifests in a broad disease phenotype from mild to severe forms of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_10.jpg" alt="img83127175_10.jpg" style="width:289px;height:130px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 7. RNA editing of a single nucleotide can restore normal protein expression</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead program for AATD addresses a single genetic SNV in the SERPINA1 gene that causes the development of AAT deficiency, which has a high unmet medical need and for which there are no disease modifying treatment options. The disease manifests with a heterogenous population having both liver and lung pathologies. By specifically editing a single nucleotide, the normal synthesis of AAT is restored, resulting in secretion of normal AAT to levels which are predicted to protect the lung from further decline in function. The correction of a subset of AAT produced also prevents aggregation of AAT protein in the liver, thereby potentially alleviating damage to the liver.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, we are developing a product candidate that addresses a LRRK2 mutation for PD patients. Mutations in LRRK2 that are associated with aberrantly enhanced kinase activity are the most common cause of genetic PD. The G2019S mutation in the LRRK2 protein is the most common pathogenic mutation, accounting for 1&#8211;6% of sporadic and 3&#8211;19% of familial PD cases. Repairing the G2019S mutated nucleotide can restore the normal LRRK2 protein and return its activity to a physiological state, which we believe may be disease modifying in these patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other protein modifications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately 85% of the human proteome has historically been considered undruggable through traditional therapeutic modalities as many proteins lack defined small molecule binding sites or are inaccessible by biologics. The versatility of RNA editing, combined with our OPERA platform, addresses a meaningful portion of the undruggable human proteome and broadens the target space. Our target identification and selection for programs is based on strong genetic evidence implicating each target in its disease pathology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our initial focus is to make edits to the coding region of a transcriptome. Making changes post-transcriptionally, after the mRNA has been created and prior to the protein being translated, provides an exquisite, selective approach for modifying proteins. In preclinical studies, we have demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate an ion channel and selectively activate a kinase. These modification approaches have the potential to unlock validated target classes that have historically been difficult to drug, enabling us to pursue a broad range of diseases, including those with high prevalence and large market opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_11.jpg" alt="img83127175_11.jpg" style="width:562px;height:192px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disrupting Protein-Protein Interaction: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Modulating protein-protein interactions provides a novel modality to target intracellular proteins specifically for increasing the activity of the protein. Single amino acid changes to non-mutated RNA can disrupt binding of inhibitors to target proteins, including transcription factors, promoting enhanced biological activity of the target protein. There are two ways this could provide increasing activation, either through a hyperactive protein, or through the presence of a longer half-life or both. Such an approach highlights the broad capabilities of what an RNA editing platform can accomplish in driving biological change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_12.jpg" alt="img83127175_12.jpg" style="width:544px;height:160px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 8. Our oligonucleotides have the ability to disrupt protein-protein interactions using precise edits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of our programs for disrupting protein-protein interactions is in development for the treatment of severe alcohol-associated hepatitis (sAH). We are selectively modulating a validated transcription factor protein implicated in the disease pathology for sAH. This oligonucleotide product candidate leads to the synthesis of a protein variant that disrupts interaction with its inhibitor and, as a result, increases expression of clinically beneficial downstream target genes. Other approaches have attempted to disrupt the interaction with non-selective small molecules, resulting in unacceptable side effects, or by knocking down the regulatory protein, which is also responsible for regulating other important proteins. In a retrospective analysis of a study looking at sAH patient liver samples, increased expression of these target genes has been shown to have better prognosis. In addition to sAH, this transcription factor is a validated target for other liver, cardiometabolic and inflammatory diseases, which may provide a &#8220;pipeline-in-a-product&#8221; opportunity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Target Classes: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to disrupting protein-protein interactions, we are also advancing product candidates to prevent protein aggregation, selectively modulate ion channels and activate kinases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intracellular protein aggregation is a cause of multiple diseases across the body. Specifically in neurodegenerative diseases, accumulation of specific proteins within neurons are pathogenic including Alzheimer&#8217;s disease, PD, and ALS. Creating a protein variant that can prevent the aggregation, while preserving its intrinsic function, is a therapeutic approach that has the potential to provide a differentiated therapeutic option over knocking down or silencing the protein through alternate mechanisms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_13.jpg" alt="img83127175_13.jpg" style="width:478px;height:173px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 9. Our product candidates can reduce pathogenic aggregation of undesirable proteins</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of our programs for disrupting protein aggregation is in early-stage discovery for the treatment of ALS. We are selectively modulating TDP-43, an RNA/DNA-binding protein, which carries out a variety of important functions in healthy neurons including initiation of transcription, pre-mRNA splicing, and miRNA processing. In pathological conditions, such as ALS, TDP-43 is depleted from the nucleus and accumulates as protein aggregates in the cytoplasm in hyperphosphorylated, ubiquitinated, and cleaved forms. These aggregates are observed in more than 90% of ALS patients. A single RNA edit to TDP-43 is predicted to lead to the synthesis of a protein variant that does not aggregate and preserves its normal function. Given TDP-43 is essential for neuronal health, knocking down the protein could be detrimental.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the elegance and versatility of our RNA editing approach will enable a robust pipeline of potentially disease modifying product candidates to treat diseases previously unattainable by genetic medicine approaches. While the above examples demonstrate the breadth of applications enabled by OPERA, we believe our RNA editing approach will bring the first genetic medicine to address the complex genetic underpinnings of highly prevalent diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our AATD Program: RNA Editing to Repair Pathogenic Missense Variant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency, or AATD, that has the potential to be disease-modifying and provide a differentiated therapeutic option. AATD is an inherited genetic disorder that can cause severe progressive lung and liver disease due to a lack of normal alpha-1 antitrypsin protein, or AAT, with varying intensity based on patient genotype and environmental factors. Patients often develop chronic obstructive pulmonary disorder, or COPD, in the lungs and cirrhosis of the liver, which can result in liver failure or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. There is a single approved modality, a once-a-week infusion of pooled human plasma derived AAT, that does not adequately address the lung or liver manifestations of AATD. Within the United States alone, the opportunity to improve the existing standard of care and expand the treated population represents a large market opportunity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 is a proprietary RNA editing oligonucleotide that is delivered to liver cells using an established LNP platform to restore production of normal AAT. KRRO-110 is expected to be delivered via intravenous infusion, where it co-opts endogenous ADAR to repair the pathogenic SNV and restore production of normal AAT, creating a clinically differentiated benefit for both liver and lung function in affected individuals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the inherent benefits of ADAR-based RNA editing described earlier, we believe our approach has additional potential advantages:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a disease modifying therapy for both lung and liver manifestations by transiently editing over 50% of RNA transcripts in hepatocytes to restore normal AAT protein </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a treatment option that can be tailored to address the broad spectrum of severity within the AATD population </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential to enable physiologic regulation of AAT using endogenous ADAR, thereby increasing normal AAT production during inflammation </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fit-for-purpose delivery using a proven LNP to maximize editing efficiency, leading to greater potential clinical benefit </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated compelling preclinical data demonstrating proof of concept across multiple RNA editing oligonucleotides targeting the SERPINA1 gene, including KRRO-110. KRRO-110 has achieved targeted durability, high editing efficiency (&gt;50% editing in hepatocytes) and increased expression of normal AAT protein (&gt;70% of total AAT protein in circulation) in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model. We have also shown that earlier generation oligonucleotides that target a different site on the SERPINA1 gene than KRRO-110 have high translation of RNA editing efficiency from mice to non-human primates, or NHPs, demonstrating the potential applicability of our approach in humans. With regard to KRRO-110, we have shown high specificity with no bystander effects in MZ human primary hepatocytes. Additionally, we have demonstrated that intravenous administration at 2mg/kg resulted in secretion of approximately 50uM functional AAT as early as seven days post-single dose in a human transgenic PiZ mouse model. An increase in AAT protein and the inhibition of elastase activity were sustained through week nine when dosed every two weeks, demonstrating durability in mice. Finally, we have shown greater than 40% editing in NHPs utilizing an earlier generation oligonucleotide designed to edit a surrogate SERPINA1 RNA target site.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we believe we can demonstrate many of the key advantages of RNA editing, we are very early in our development efforts and not yet certain of the results we may achieve. Such uncertainties include, but are not limited to, the level of editing efficiency needed in a target tissue type to achieve a clinical benefit, and associated safety of our edits in humans. Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024, and an anticipated interim clinical readout in the second half of 2025. Depending on the evidence of efficacy and tolerability for our candidate in our first clinical study, we plan to pursue expedited regulatory pathways, including potentially requesting Fast Track Designation and Breakthrough Therapy Designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AATD Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AAT function</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AAT is a protease inhibitor belonging to the Serpin family. It is produced in the liver and circulates in its native state in human blood at approximately 1.5 g/L, one of the highest concentrations observed for protease inhibitors. The main role of AAT is to protect tissue from proteases released by neutrophils, such as neutrophil elastase. Neutrophil elastase is an enzyme that fights infections in the lungs but can also attack normal lung tissue. If not sufficiently inhibited by AAT, neutrophil elastase destroys elastin in the lung, leading to degradation of lung function. Factors that increase lung inflammation, such as smoking or infections, increase the elastase burden in the lung, leading to severe and potentially life-threatening lung damage in AATD patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Genotypes of AATD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AATD is an inherited, autosomal recessive genetic disorder that is most frequently caused by a single nucleotide variant, or SNV, mutation in the SERPINA1 gene. The most common of these SNVs is the &#8220;Z&#8221; mutation, corresponding to a mutation of glutamate 342 to lysine, or E342K. A healthy individual typically exhibits an &#8220;MM&#8221; genotype, or PiMM, while an individual with a single Z allele would exhibit a heterozygous PiMZ, genotype and an individual with two Z alleles would exhibit a homozygous, or PiZZ, genotype.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_14.jpg" alt="img83127175_14.jpg" style="width:562px;height:120px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 10. PiMM genotype (normal liver and lung)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of Z mutations on liver and lung function</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The presence of a single Z allele can lead to insufficient production of normal AAT protein, as well as the production of dysfunctional AAT protein, causing manifestations of disease in both the lungs and liver. The severity of disease manifestation can vary according to each patient&#8217;s genotype, as well as environmental factors, such as exposure to inflammatory respiratory agents or other complications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PiZZ individuals experience greater manifestations of disease as a result of their very low levels of normal AAT (10%&#8212;15% of normal levels), which are insufficient to prevent lung damage post an influx of neutrophils. They are also at high risk of developing emphysema or COPD, which can present in individuals as early as in their thirties and forties. PiZZ individuals with additional environmental risk factors such as smoking or infection frequently develop COPD as early adults and develop very severe symptoms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to lung disease, PiZZ individuals can also manifest with liver disease as a result of dysfunctional AAT aggregating in the liver. In adults, this can cause liver inflammation and cirrhosis, ultimately leading to liver failure or cancer. In addition, as many as 10% of newborns with the PiZZ genotype develop cholestatic hepatitis. A quarter of impacted neonates suffer acute liver failure and require an emergency transplant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_15.jpg" alt="img83127175_15.jpg" style="width:562px;height:168px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 11. PiZZ genotype that results in fibrotic liver and decreased lung function</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data from the UK Biobank, or UKBB, as well as published literature, have allowed researchers to determine the threshold levels of circulating AAT that are directly linked to the PiMZ and PiZZ genotypes. In Figure 12 below, the range of AAT levels associated with normal individuals (PiMM) is compared with the range of AAT levels observed in mutated PiMZ and PiZZ patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_16.jpg" alt="img83127175_16.jpg" style="width:554px;height:189px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 12. Median Levels of AAT and link to outcomes in liver and lung</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Figure 13 below, the Odds Ratios, or OR, associated with developing COPD and cirrhosis of the liver are compared across the two genotypes, with key findings summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COPD:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> PiMZ individuals have minimal increased risk of developing COPD relative to healthy PiMM individuals, while PiZZ individuals are at very high risk with an OR of 8.8 </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cirrhosis of the liver:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> PiMZ individuals have mildly elevated risk of developing cirrhosis of the liver with an OR of 1.5, while PiZZ individuals have significantly elevated risk with an OR of 7.8 </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_17.jpg" alt="img83127175_17.jpg" style="width:430px;height:190px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 13. Risk of developing COPD and cirrhosis for different genotypes associated with AATD. Adapted from &#8220;The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.&#8221; By Nakanishi T, Forgetta V, Handa T, et al. Eur Respir J 2020; 56:2001441</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on these findings, we believe that achieving normal AAT protein levels between the ranges of the PiMZ and PiMM genotypes has the potential to alleviate the increased risk of COPD and cirrhosis of the liver, and to meaningfully improve clinical outcomes for PiZZ patients. We further believe that by achieving &gt;50% editing efficiency across cells, we can reach these target levels and modify disease progression.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prevalence of AATD and limitations of currently approved therapy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AATD is one of the three most common, potentially lethal, rare diseases affecting those of European descent. Worldwide, there are an estimated 3.4 million individuals with deficiency allele combinations. Studies suggest that clinical unawareness of AATD results in a significant number of patients that go undiagnosed or misdiagnosed. There are currently an estimated 100,000 patients in the United States with a PiZZ genotype, and 125,000 patients across the United Kingdom, Germany, France, Spain and Italy. Studies of PiMZ prevalence suggest as many as one in 49 individuals in the United States and one in 58 individuals across Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The only FDA-approved treatment for patients with lung manifestations of AATD (co-indicated with COPD) is augmentation therapy, which utilizes AAT protein purified from pooled human plasma. The purified AAT is administered weekly by intravenous infusion with the goal of maintaining a serum level of AAT above the 11 &#181;M threshold. Even when the serum level can be maintained at or above this threshold, augmentation therapy has not clearly demonstrated its ability to adequately address lung damage nor liver inflammation caused by AAT aggregation. Augmentation therapy is approved in only a few countries due to its limited efficacy. Lung and/or liver transplantation are the only other available treatment options, outside of standard management of the disease manifestations of AATD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite being minimally effective and not fully addressing the needs of many AATD patients, augmentation therapy currently represents approximately $1.4 billion in annual sales worldwide. KRRO-110 has the potential to elevate the standard of care and expand the number of patients on treatment and potential to be a leader with a large market opportunity worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations of Alternative Treatments in Development for AATD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a number of therapies in development to treat AATD. Certain DNA editing approaches attempt to add a normal copy of SERPINA1 gene or permanently correct the mutation within the SERPINA1 gene. DNA editing as a treatment would likely be evaluated on a risk-benefit trade-off relative to the severity of the manifestation of AATD, limiting the applicability of DNA editing approaches to the broader AATD patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional approaches outside of DNA editing are also in development. There are approaches which attempt to use siRNA to knock-out the production of dysfunctional AAT protein, which only alleviates the liver manifestation of AATD, while potentially worsening the lung manifestation. Replacing plasma derived protein for augmentation therapy with a fusion protein is another approach in development. This fusion protein aims to introduce AAT on an antibody scaffold to improve upon the existing dosing paradigm and activity levels achieved in augmentation therapy. Fusion proteins do not resolve the liver manifestation and are unable to physiologically regulate AAT levels. Lastly, small molecule correctors attempt to promote proper folding of the Z-AAT protein. To date, small molecule correctors have been unable to achieve normal AAT levels and clinical development is focused only on the liver manifestation of AATD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe many of these approaches have inherent limitations including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inability to adequately address the spectrum of clinical pathologies associated with AATD </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inability to achieve adequate expression of normal AAT to bring patients back to PiMM genotype </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Considerable safety and tolerability concerns </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential issues around manufacturability and scalability for the AATD population </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach to Overcome the Limitations: Transiently Correcting the SERPINA1 Variant on RNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing KRRO-110 to treat patients with AATD.  KRRO-110 is designed to leverage endogenous ADAR to make a single base edit in SERPINA1 mRNA, correcting the amino acid codon created by the pathogenic E342K SNV which stems from a single G-to-A mutation. Specifically, KRRO-110 edits the adenosine (A) to an inosine (I), thereby correcting the faulty amino acid and leading to the production of normal AAT protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to bring individuals with the Z mutation to a phenotype where over 50% of RNA has been corrected to produce normal AAT protein. This would result in levels of AAT consistent with individuals in the upper half of the PiMZ genotype and the fully healthy PiMM genotype. Through human transgenic mouse models, we have shown our ability to drive the required change in RNA sequence with high efficiency, leading to secretion of AAT at target levels.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our approach has multiple potential advantages, in addition to those conferred by the RNA editing modality:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a tailored disease modifying treatment option to address the heterogeneity of the AATD population: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We leverage a transient base editing approach leading to restoration of normal AAT. The transient nature of our approach allows us to address a broader AATD patient population, inclusive of PiMZ and PiZZ genotypes. As transient editing is not permanent in nature, we have the ability to adjust dosing and even cease dosing as needed, providing a meaningful benefit in potential safety profile. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides a disease modifying therapy for both lung and liver manifestations: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By transiently editing over 50% of RNA transcripts in hepatocytes, we believe we can restore levels of normal AAT protein consistent with a PiMZ to PiMM phenotype. These levels of normal AAT have the potential to prevent further lung damage and reduce the risk of dysfunctional AAT aggregating in the liver. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential to enable physiologic regulation of AAT using endogenous ADAR: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Augmentation therapy and other treatments targeting static thresholds for AAT expression do not address the underlying mechanism of AAT regulation, which is endogenously regulated by inflammation and can sometimes lead to as much as 90uM of AAT in humans. During an inflammatory response, there is a simultaneous increase in ADAR levels. Our ADAR-based therapy has the potential to restore natural physiologic regulation by increasing the prevalence of editing during periods of greater AAT production. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uniform distribution of drug to liver cells to maximize editing: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike other modalities that focus on DNA editing, our product candidates, including KRRO-110, have demonstrated a uniform distribution within the liver, including in NHPs. We believe this will allow our therapy to restore production of normal AAT protein in every cell, reducing reliance on the chance of a survival benefit for edited cells as in DNA editing. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efficient delivery using a proven LNP:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> AAT is the fifth most abundant protein in circulation, with a large number of transcripts that require editing to achieve expression of normal protein. LNPs provide a significant benefit to delivery of RNA-editing oligonucleotides by increasing the likelihood of sufficient distribution into liver cells. In March 2023, we entered into an agreement with Genevant Sciences GmbH, or Genevant, a well established leader in the LNP space, to provide access to clinically validated LNP technology to optimize delivery of KRRO-110. Preclinical studies of this LNP delivery technology have shown improved dose-dependent efficacy with reduced clinical chemistry and adverse events. We are pursuing development of KRRO-110 with an optimized LNP from Genevant (GVT-1) for delivery.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRRO-110</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of our preclinical studies and data generated to date leading to KRRO-110 nomination</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated highly compelling preclinical data that forms the basis for our proof of mechanism. We have affirmed that multiple disease modifying early generation product candidates have demonstrated proof-of-concept in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies leading to the nomination of KRRO-110 as a development candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Earlier generation product candidates have independently achieved clinically meaningful expression of normal AAT protein consistent with a PiMZ genotype within preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">animal models while using clinically relevant doses administered on a weekly or biweekly basis. Given that human protein half-life is much longer than other species, we believe our therapies will support a longer dose interval in the clinic. We have initiated preclinical dose-limiting toxicity safety studies and nominated our first development candidate, KRRO-110, in December 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> activity in human cells:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our initial design iterations for RNA-editing oligonucleotides were conducted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> human systems, specifically containing human ADAR and human SERPINA1 genes with a Z allele. By leveraging the capabilities of our OPERA platform, we have generated multiple product candidates that achieved increased editing activity in human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Figure 14 below, we were able to demonstrate greater than 50% editing efficiency at the E342K mutation within stem cell derived hepatocyte like cells, or HLCs, with KRRO-110. HLCs harbor both alleles, an important quality that has the potential to be predictive of function </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We also demonstrated editing in MZ primary human hepatocytes, or PHH, which harbor a single Z allele.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_18.jpg" alt="img83127175_18.jpg" style="width:543px;height:225px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1 HLCs derived from ZZ patient, transfected with RNAiMAX with 1U/uL of IFN, editing measured 48-hours post transfection via amplicon-seq</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2 Primary hepatocytes from MZ donor, free-uptake of LNP, editing measured 48-hours post uptake via amplicon-seq</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 14. KRRO-110 demonstrated &gt;50% editing in in vitro systems with the Z genotype</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_19.jpg" alt="img83127175_19.jpg" style="width:526px;height:234px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 15. Negligible in vitro&#8239;cis off-target editing observed for KRRO-110 in MZ hepatocytes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KRRO-110 demonstrates high selectivity for editing at the E342K RNA site, as shown in Figure 15.  No off-target editing was observed in MZ primary human hepatocytes assessed at 100 base sites above and below the E342K site, against background levels.  A concentration gradient is observed with a dose-response at the E342K edit site.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical in vivo activity in mice with KRRO-110: To assess and differentiate our development candidate, KRRO-110, in a mouse model used widely in the AATD field, we used a human transgenic NSG-PiZ mouse.  The NSG-PiZ transgenic mouse expresses the human SERPINA1 gene with the Z-mutation. As detailed in Figures 16 and 17 below, intravenous administration of KRRO-110 at 2 mg/kg resulted in &gt;50% editing and secretion of approximately 50&#181;M AAT as early as seven days post-single dose in the NSG-PiZ mouse model. Increase in AAT protein and the inhibition of elastase activity were sustained through week nine when dosed every two weeks, demonstrating durability in mice.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_20.jpg" alt="img83127175_20.jpg" style="width:386px;height:292px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 16. Achieved &gt;50% editing&#8239;in human transgenic&#8239;mouse model of Z genotype with a single dose</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_21.jpg" alt="img83127175_21.jpg" style="width:562px;height:246px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 17. Secretion of functional AAT (approximately 50uM) as early as 7 days post-single dose</span><span style="color:#d13438;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> activity in mice with earlier generation oligonucleotides:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our screening preclinical pharmacology studies have been conducted using a second C57BL/6-PiZ mouse model and licensed by us from Dr. Jeff Teckman&#8217;s laboratory at St. Louis University School of Medicine. Dr. Teckman is the preeminent expert on the study of AATD. The C57BL/6-PiZ transgenic mouse model also expresses the human SERPINA1 gene containing the Z mutation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our preclinical studies, we have evaluated multiple oligonucleotides in varying doses in PiZ mice. KB-0794, an earlier generation oligonucleotide, demonstrated editing efficiency as high as 63% on day four following the administration of a single 3mg/kg dose. Normal M-AAT protein was observed at an 18 &#181;M concentration on day four, demonstrating the potential relationship between editing efficiency and secretion of normal AAT.  Upon observing the high editing efficiency of KB-0794, we proceeded to conduct an additional preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> study where four groups of mice were given a lower dose of 2mg/kg and observed in a multi-dose study that lasted up to four weeks. Key takeaways from the multi-dose study included the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Achieved up to 54% editing efficiency with up to 20uM of normal AAT, constituting 72% of total protein in circulation </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liver polymers associated with the dysfunctional AAT protein were reduced at day 28, pointing to a potential to provide liver benefit through clearing of aggregates </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The half-life of AAT in mice and NHPs has been observed to be around 1-2 days and 2-4 days, respectively. Human AAT has a longer half-life of 4-6 days, and when coupled with the optimization of our oligonucleotide drug product and the accumulation of drug product observed in the multi-dose preclinical studies, we believe that we will be able to achieve greater durability and a longer dosing interval in the clinic than the current once weekly or biweekly interval conducted in our preclinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical screening studies to identify product candidates were originally conducted using an LNP delivery vehicle comprising lipids used in the approved product ONPATTRO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Over the past decade, the field of LNP delivery has made advancements as measured by safety profile and tolerability. Our product candidates, when combined with current generation LNP delivery technology from Genevant, have demonstrated optimized editing efficiency, safety and tolerability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a preclinical study to compare the editing efficiency of a previous generation LNP (the comparator LNP) and current generation Genevant LNPs (GVT-1 and GVT-2), we evaluated C57BL/6-PiZ mice after receiving a single 2mg/kg dose of KB-0794 via each of the three delivery vehicles. As detailed below in Figure 18, GVT-1 and GVT-2 achieved comparable or higher editing of 37% and 65%, respectively, as compared to 29% editing for the comparator LNP. Post a single LNP dose, the percentage of normal-AAT increased to 66% for GVT-1 and 85% for GVT-2, compared to 56% for the comparator LNP, showing potential for disease-modifying effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_22.jpg" alt="img83127175_22.jpg" style="width:562px;height:228px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 18. Comparison of editing efficiency and circulating normal protein in C57BL/6-PiZ mice between MC3 LNP and current generation Genevant LNPs (GVT-1 and GVT-2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nomination of KRRO-110</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The above data demonstrates the highly compelling preclinical data that forms the basis for our proof of mechanism and therapeutic approach. Additionally, we have generated non-GLP toxicology data and affirmed that multiple disease modifying early generation product candidates have demonstrated proof-of-concept in in vivo studies.  The complete data set has led to the nomination of KRRO-110 as a development candidate.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Translation to NHPs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to our preclinical in vivo studies conducted using the PiZ mouse models described above, we have also generated a translational model to validate the potential for delivery and ability to edit the SERPINA1 gene in NHPs with an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">earlier generation oligonucleotide. Because the human SERPINA1 gene in NHPs does not harbor the E342K mutation, we are demonstrating our oligonucleotide&#8217;s ability to edit within the coding region of the SERPINA1 gene and the ability to translate that preclinical in vivo editing from the PiZ mouse model to NHPs.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_23.jpg" alt="img83127175_23.jpg" style="width:458px;height:209px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 19. Editing de novo&#8239;adenosine on cyno SERPINA1 to elucidate editing in higher species</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated the potential editing efficiency of GVT-1 and GVT-2 for the SERPINA1 coding region in NHPs. As detailed in Figure 20 below, the observed editing rate of GVT-2 was meaningfully higher at 34%, relative to 13% in the historical MC3 study. ALT levels, a measure of safety and tolerability, were meaningfully lower in GVT-1 and on par between GVT-2 and the LNP comparator. These results show that our product candidates, when combined with current generation Genevant LNPs, can demonstrate a desirable safety profile while increasing the editing efficiency.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_24.jpg" alt="img83127175_24.jpg" style="width:558px;height:265px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 20. Comparison of editing translation in NHPs between MC3 LNP and current generation Genevant LNPs (GVT-1 and GVT-2)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Optimization of our NHP surrogate led to KB-1494 formulated in the current generation Genevant LNP (GVT-1). Upon receiving a 2mg/kg intravenous dose, liver editing was measured 4-5 days and 14-15 days after the initial dose, in mice and NHPs, respectively. As detailed in Figure 21, the observed editing rate of GVT-1 in NHPs was meaningfully higher at greater than 40%, relative to 26% observed in mice, and sustained for approximately two weeks. These results further illustrate the translation of RNA editing across mouse and NHP preclinical species.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_25.jpg" alt="img83127175_25.jpg" style="width:593px;height:255px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 21. Editing of SERPINA1 coding region in NHPs and C57BL/6-PiZ model showed correlation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Steps</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024 to enable the initiation of human clinical studies, with an anticipated interim clinical readout in the second half of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Parkinson&#8217;s Disease Program: Repairing Pathogenic Variants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing proprietary oligonucleotides that address the leucine-rich repeat kinase 2, or LRRK2. mutation for Parkinson&#8217;s Disease, or PD, patients. This is the second program that leverages our ability to generate product candidates to repair pathogenic variants, similar to the AATD program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Parkinson&#8217;s Disease:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PD is a complex, multifactorial progressive disease that is caused, in part, by the loss of dopaminergic neurons in a structure of the brain called the substantia nigra, which is essential for the proper control of the body&#8217;s movement. Approximately 10% of PD cases are attributed to inherited genetic mutations, while the remaining cases are considered idiopathic or sporadic. Mutations in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LRRK2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are the most common genetic cause of PD and increasing evidence also provides support for a role of LRRK2 in idiopathic PD. PD is the second most common neurodegenerative disease with approximately 1.0 million people in the United States diagnosed. Despite the large commercial market opportunity, there remains significant unmet need as there is no cure, and current available therapies only relieve the symptoms of PD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LRRK2 is linked to several cellular processes including mitochondrial function, endocytosis, vesicle trafficking, and the lysosomal autophagy pathway. Additionally, LRRK2 is implicated in regulating cytokine levels and neuroinflammation. There are various mutations in LRRK2 that can result in PD, the most common of which is the pathogenic G2019S mutation that accounts for 1-6% of sporadic and 3-19% of familial PD cases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Differentiated Approach and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach is to make a single base edit to repair the protein caused by the G2019S mutation in LRRK2, which is expected to result in returning activity to the normal physiological state. We believe this change may result in disease modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As shown in Figure 22 below, our preliminary screening process in heterozygous LRRK2 G2019S patient-derived fibroblasts identified several product candidates that achieved &gt;80% editing in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> LRRK2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> compared to only 47% in controls. The 47% represents half the transcripts having the mutation at baseline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_26.jpg" alt="img83127175_26.jpg" style="width:271px;height:238px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 22. Editing of the G2019S mutation LRRK2 using our product candidates (100 nM)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Steps</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently screening additional oligonucleotide designs and optimizing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> assays to correlate LRRK2 editing with downstream functional endpoints. Additionally, we plan to evaluate our product candidates in a LRRK2 G2019S humanized mouse model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Severe Alcohol-Associated Hepatitis Program: Disrupting Protein-Protein Interactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Another of our programs is focused on the treatment of severe alcohol-associated hepatitis, or sAH, and demonstrates the versatility of our platform to modulate proteins. This program leverages our RNA editing technology to modulate the activity of a naturally occurring protein by disrupting protein-protein interactions. We are selectively modulating a protein transcription factor implicated in the disease pathophysiology for sAH. We believe that this approach enables the synthesis of a protein variant that disrupts interaction with our inhibitor and as a result, will be free to express downstream target genes. sAH patients with higher levels of expression of these downstream target genes have been shown to have better prognosis in a prior study examining liver biopsies at the time of diagnosis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Severe Alcohol-Associated Hepatitis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The burden of alcohol use and alcohol use disorders contributes significantly to the health care costs for alcohol-related diseases. These patients incur direct costs to the health care system for medical care, and indirect costs to society due to a loss of workforce productivity, absenteeism, injury, early retirement and mortality. Alcohol overconsumption can lead to the development of liver damage that can manifest as fatty liver disease, alcohol-associated hepatitis and cirrhosis. The amount of alcohol intake that puts an individual at risk for alcohol-associated hepatitis is not known, but most patients have a history of heavy alcohol use for two or more decades. It is estimated that two million people die of liver disease each year, and up to half of these cases are due in part to alcohol overconsumption. There are around 300,000 hospitalizations per year for sAH in the United States. sAH is an acute condition with a mortality rate of 25%&#8212;45% within 90 days of hospitalization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no FDA-approved treatments for sAH. Prednisolone is used off-label in this setting and is the only treatment available. However, many patients fail to respond to prednisolone or are contraindicated, and studies have failed to show survival benefit at 90 days. Physicians may also prescribe pentoxifylline, an anti-inflammatory, or N-acetyl cysteine, an antioxidant, but the benefit of these drugs for sAH is not well established. Additionally, some sAH patients may be candidates for a liver transplant. It has been documented that survival for sAH patients is mainly driven by liver injury and not significantly impacted by alcohol-relapse. Current strategies to address harmful alcohol use and the development of pharmacotherapies remain largely ineffective, leading to substantial unmet need for advancement of policy efforts and development of novel therapies with effective mechanisms of action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Differentiated Approach and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a product candidate that increases expression of a transcription factor (TFX) implicated in sAH. By selectively modifying a single amino acid, we are able to disrupt interactions between the target protein and our inhibitor, as depicted in Figure 23 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_27.jpg" alt="img83127175_27.jpg" style="width:277px;height:250px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 23. Changing a single amino acid disrupts binding of a transcription factor to its inhibitor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated preclinical data for our sAH product candidates, demonstrating target editing and activation of target transcription factor activity in both preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our oligonucleotides dose-dependently edited the target gene mRNA in human liver cells reaching  &gt; 70% editing efficiency as shown in Figure 24 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_28.jpg" alt="img83127175_28.jpg" style="width:215px;height:259px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hep3B cells transfected with RNAiMAX at the indicated concentrations with two targeting oligos, editing measured 48-hours post transfection via amplicon-seq</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 24. Our product candidate edits transcription factor RNA at the validated target site in a dose-responsive manner</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our product candidates edited the target mRNA and induced expression of downstream target genes by up to 7x in mouse liver tissue as shown in Figure 25 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_29.jpg" alt="img83127175_29.jpg" style="width:226px;height:267px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Wild type mice dosed with LNP-targeting oligos at a concentration of 3 mg/kg, gene expression measured via quantitative PCR from liver harvested 1 day post dose</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 25. Hyperactive variant of transcription factor increased expression of downstream gene up to 7x in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The product candidate has also demonstrated activity in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> model of sAH, showing protection against cytotoxicity induced by alcohol and TNF-alpha in human liver cells overexpressing CYP2E1, the enzyme that metabolizes alcohol as shown in Figure 26 below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_30.jpg" alt="img83127175_30.jpg" style="width:254px;height:296px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hep3B-CYP2E1 cells transfected with RNAiMAX at the indicated concentrations with two targeting oligos, cell viability measured 48-hours post transfection via CellTiter-Fluor Cell Viability Assay from Promega</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 26. RNA editing demonstrates increased viability of liver cells in an in vitro model of sAH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, as seen in Figure 27 below, the product candidate demonstrated activation of a transcription factor by creating a de novo protein variant resulting in sustained downstream activity in NHPs lasting longer than 21 days, demonstrating potential to preserve transcription factor function, and increase durability of its related protein variant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_31.jpg" alt="img83127175_31.jpg" style="width:610px;height:224px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 27. Sustained downstream activity in NHPs lasting longer than 21 days</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Steps</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently evaluating additional oligonucleotide designs and conducting preclinical studies to confirm that our product candidates will ameliorate disease phenotype in models of alcohol-induced hepatitis. We also plan to evaluate our approach in NHP studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Amyotrophic Lateral Sclerosis Program: Disrupting Protein Aggregation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing proprietary oligonucleotides targeting the mRNA for TAR DNA binding protein 43, or TDP-43, a protein associated with the etiology of amyotrophic lateral sclerosis, or ALS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amyotrophic Lateral Sclerosis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALS is an adult-onset, progressive, and fatal neurodegenerative disorder that causes muscle weakness, paralysis, and ultimately death. The majority of ALS patients die from respiratory failure within three to five years after symptom appearance, with a small percentage of patients surviving beyond 10 years. Despite being classified as a rare disease by the FDA and the EMA, ALS is considered one of the more common neurodegenerative diseases worldwide. Prevalence estimates vary, but it is widely accepted that there are at least an estimated 25,000 ALS patients in the United States. There is currently no cure for ALS, and currently approved therapies either only provide symptomatic relief or slow the overall progression of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Differentiated Approach and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach is to selectively modulate TDP-43, an RNA/DNA-binding protein, which carries out a variety of important functions in healthy neurons, including initiation of transcription, pre-mRNA splicing and miRNA processing. Hyper-phosphorylated and ubiquitinated TDP-43 deposits form inclusion bodies in the brain and spinal cord of patients with ALS and frontotemporal dementia, or FTD. The majority of ALS and FTD cases are sporadic, and more than 90% and 45% of ALS and FTD patients, respectively, have TDP-43 aggregations in neurons. Less than 10% of ALS cases are familial, and mutations in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TARDBP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the gene encoding TDP-43, are responsible for approximately 4% of familial ALS. Given the importance of TDP-43&#8217;s role in maintaining healthy neurons, the generation of a protein variant with the desired non-aggregating property could potentially have therapeutic benefit for the majority of ALS and FTD patients. We believe that by leveraging the ability of RNA editing to affect a single base edit in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TARDBP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we can lead to the synthesis of a TDP-43 protein variant that does not aggregate, thereby restoring our normal function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have created a series of TDP-43 variants that contain single amino acid changes designed to alter post-translational modification by phosphorylation, ubiquitination, acetylation or cleavage with the intent of reducing the ability to aggregate while maintaining function in RNA metabolism. We believe that modulating TDP-43 through the introduction of specific amino acid changes into TDP-43 mRNA sequence is preferable to other approaches that try to address protein aggregates after they form, to non-specifically prevent stress granule formation, or to target a single TDP-43 downstream target. We have engineered mutations amenable to an RNA edit using our OPERA platform that limit the formation of TDP-43 inclusion bodies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additionally, we have demonstrated meaningful editing of TDP-43 targets sites with our product candidates in a human neuroblastoma-derived cell line (SK-N-AS) as demonstrated in Figure 28 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_32.jpg" alt="img83127175_32.jpg" style="width:276px;height:247px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 28. Editing of TDP-43 mRNA using our product candidates (100 nM)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to initially pursue ALS with this approach and has the opportunity to expand our pipeline to other neurodegenerative diseases, such as FTD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Steps</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are continuing to design and screen additional oligonucleotides in SK-N-AS cells to identify proprietary oligonucleotides for further evaluation in aggregation assays. Furthermore, we are identifying and characterizing ALS cell lines including genetic-induced models and patient cell lines, to test the efficacy of TDP-43 protein variants in disease models.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pain Program: Selective Modulation of Ion Channels</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing proprietary oligonucleotides that selectively modulate ion channels associated with pain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of Pain Indications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pain is a condition that millions of patients experience and is often a component of rare and highly prevalent diseases. Pain can be generally classified as either acute or chronic and can be further segmented into subcategories including nociceptive or neuropathic pain. There are several classes of therapeutics to target the numerous pathways that cause pain, including opioids, nerve growth factors and ion channel blockers. Many of these treatment methods involve non-specific targeting of pathways that lead to off-target effects. Despite a large commercial market opportunity, there remains significant unmet needs for safe and effective pain management, including non-opioid therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several classes of drugs, including local anesthetics, such as lidocaine, are ion channel blockers, although they do not show a high degree of specificity and thus inhibit many types of sodium channels rather than selectively blocking Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7. No highly selective small molecule product candidates have been FDA-approved as therapeutics. One of the challenges in developing a small molecule inhibitor of Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 is the high degree of homology with other voltage gated sodium channels, inhibition of which has been linked to safety concerns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Differentiated Approach and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The introduction of genetic changes into the mRNA encoding Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 demonstrates the potential of RNA editing to create highly differentiated and selective therapeutics for ion channels. Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 is a voltage-gated sodium channel that plays a critical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">role in the generation and conduction of action potentials and is thus important for electrical signaling in the nervous system. Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 is highly expressed in the pain sensing dorsal root ganglion neuron. Genetic inactivation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SCN9A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the gene encoding Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7, in mice results in the inability to sense pain from inflammatory stimuli. In humans, mutations that lead to inactivation of Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 function result in a genetic condition known as Channelopathy-associated insensitivity to pain, or CIP. Individuals with CIP have severely diminished ability to sense pain. By contrast, mutations that activate Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 result in intense pain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our RNA editing technology, we have generated a series of site-specific changes in Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 that modulate our ion channel function such that it mimics a small molecule sodium channel blocker. We believe that using RNA editing to introduce these changes in patients has the potential to deliver potent analgesic activity without the dose-limiting toxicities that have been observed by other sodium channel blockers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have demonstrated that rationally designed single amino acid changes to unique target sites are sufficient to decrease the activity of Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7. Electrophysiology studies performed in CHO cells transfected with plasmids expressing channel variants demonstrated biophysical properties that are associated with a decrease in Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 channel activity compared to fully functional Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7. Additionally, we have demonstrated meaningful editing for these target sites in SK-N-AS cells as shown in Figure 29 below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83127175_33.jpg" alt="img83127175_33.jpg" style="width:313px;height:265px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 29. Editing of Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1.7 using our product candidates (100nM)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Steps</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are optimizing and screening our proprietary oligonucleotides in electrophysiology assays. Furthermore, we will perform a high throughput screen of Na</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.7 variants to identify potential novel ion channel variants with enhanced crippling of electrophysiology activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Cardiometabolic Disease Program: Activating Kinases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing proprietary oligonucleotides that activate a kinase involved in cardiometabolic disease. Cardiometabolic disease encompasses a broad range of complex, multifactorial diseases including cardiovascular disease, diabetes, chronic renal failure and obesity, among others. A number of validated cardiometabolic disease targets such as kinases have been identified but have historically been difficult to drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated a site-specific change in a validated kinase that is a central regulator of energy homeostasis. In an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutagenesis study, a site-specific change led to activation of the kinase and an increase in the phosphorylation of its downstream target. We believe that using RNA editing to introduce these changes with an oligonucleotide in patients has the potential to deliver efficacy that has been unattainable when using other modalities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pioneering RNA Editing to Deliver the Future of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our programs demonstrate the versatility of the ADAR-mediated RNA editing approach. Importantly, we are able to not only address classes of diseases caused by deleterious effects of misfolded or misdirected proteins, but we can also potentially utilize genetics to identify highly prevalent diseases where therapeutic benefit can be generated through alteration of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">protein function or expression. We will continue to selectively identify and pursue additional targets and indications based on a range of technical, clinical, and commercial factors to build a robust and differentiated pipeline. However, RNA editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products. We are not aware of any clinical trials for safety or efficacy having been completed by any third party using RNA editing and nor are we aware of any RNA editing therapeutic product that has been approved in the United States or Europe. It will be many years before we commercialize a product candidate, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no commercial manufacturing capabilities. For our initial wave of clinical programs, we intend to use qualified third-party CMOs with relevant manufacturing experience in genetic medicines. we plan to partner with suppliers and CMOs to produce or process critical raw materials, bulk compounds, formulated compounds, viral vectors or engineered cells for IND-supporting activities and early-stage clinical trials. At the appropriate time in the product development process, we will determine whether to establish in-house GMP manufacturing capabilities for some core technologies or continue to rely on third parties to manufacture commercial quantities for any products that we may successfully develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also in license technology for our fit-for-purpose delivery systems, including LNP delivery systems. For example, in March 2023, we entered into a collaboration and license agreement with Genevant, a well established leader in the LNP space, to provide access to clinically validated LNP technology to optimize delivery of our AATD product candidate, KRRO-110. Preclinical studies of this LNP delivery technology have shown improved dose-dependent efficacy with reduced clinical chemistry and adverse events. For additional information relating to the financial terms of such agreement, see Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries, including the gene therapy and gene editing fields, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property. While we believe that our differentiated technology, scientific expertise, and intellectual property position provide us with competitive advantages, we face potential competition from a variety of companies in these fields. There are several companies using synthetic oligonucleotide or base editing technology, including Beam Therapeutics, Verve Therapeutics, Prime Medicine, ProQR, and Wave Life Sciences. Several additional companies utilize other editing technologies, including Edigene and Shape Therapeutics. In addition, we face competition from companies utilizing gene therapy, oligonucleotides, and DNA editing technologies such as base and prime editing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates. This may include other types of therapies, such as small molecule, antibody, and/or protein therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and approved products than we do today. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We also compete with these companies in recruiting, hiring and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for clinical trials, obtaining manufacturing slots at contract manufacturing organizations, and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, particularly if they represent cures, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, and availability of reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patent protection in the United States and internationally for our current and future product candidates. We also rely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on trademarks, copyrights, trade secrets, confidentiality procedures, employee disclosure, invention assignment agreements, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to obtain domestic and international patent protection, and endeavors to promptly file patent applications for new commercially valuable inventions. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to continue to expand our intellectual property estate by filing patent applications directed to platform technologies and improvements thereof, pharmaceutical compositions, methods of treatment, methods of manufacture or identified from our ongoing development of our product candidates. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce any patents that we may obtain, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent may be challenged in courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot guarantee that our pending patent applications, or any patent applications that we may in the future file or license from third parties, will result in the issuance of patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or at all, whether the claims of any patent applications, should they issue, will cover our product candidates, or whether the claims of any issued patents will provide sufficient protection from competitors or otherwise provide any competitive advantage. We cannot predict the scope of claims that may be allowed or enforced in our patents. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries and patent application filings, we cannot be certain of the priority of inventions covered by pending patent applications. Accordingly, we may not have been the first to invent the subject matter disclosed in some of our patent applications or the first to file patent applications covering such subject matter, and we may have to participate in interference proceedings or derivation proceedings declared by the USPTO to determine priority of invention. For more information regarding the risks related to our intellectual property, see Item 1A &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Portfolio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect our proprietary RNA editing platform OPERA and related technologies and our product candidates, including seeking and maintaining patent protection intended to cover various target-specific editing strategies, the composition of matter of our product candidates, their methods of use, related delivery technologies, and other inventions. The intellectual property that is available to us is critical to our business and we strive to protect it, including by obtaining, maintaining, defending, and enforcing patent protection in the United States and internationally. As of December 31, 2023, our patent portfolio in total consisted of 32 patent families, with two U.S. patents and one patent in foreign jurisdictions (e.g., Canada), including five pending Patent Cooperation Treaty, or PCT, applications, various pending non-provisional applications world-wide (e.g., United States, Australia, Canada, China, Europe, South Korea, and Japan), and nine families with pending provisional patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a patent portfolio that relates to our RNA editing platform OPERA, as well as numerous disease programs listed below, and includes 13 patent families. These families are directed to various oligonucleotide formats, nucleotide compositions, oligonucleotide chemistries, modifications, specific linkage chemistries, oligonucleotides having a specific structures, methods of deaminating an adenosine using such oligonucleotides, methods of oligonucleotide delivery, and methods of treating disease by administering such oligonucleotides. The first patent family is pending in Australia, Canada, China, Europe, Japan, South Korea, Taiwan and the United States, and includes a U.S. patent. The first three patent families are pending in Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, Taiwan and the United States, and include two U.S. patents. U.S. Patent No. 11,479,575 is directed to specific oligonucleotide structures and expires in 2040; U.S. Patent No. 11,453,878 is directed to methods of deamination of an adenosine in an mRNA using oligonucleotide with specific structures and also expires in 2040. Any other patents issuing from applications in these families will expire in 2040, absent any available additional term for patent term extension or patent term adjustment. The fourth patent family is pending in the United States and patents issuing from applications in this family will expire in 2042, absent any available additional term for patent term extension or patent term adjustment. The fifth, sixth, seventh and eighth patent families have been filed as PCT applications, and if issued, patents in these families would expire between 2042 and 2043, absent any available additional term for patent term extension or patent term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adjustment. The ninth, tenth, eleventh, twelfth and thirteenth patent families have been filed as provisional patent applications, and if re-filed as PCT or non-provisional applications, and issued, patents in this family would expire in 2044, absent any available additional term for patent term extension or patent term adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent families related to our OPERA platform technology described above, our patent portfolio that relates to our AAT program includes two patent families. These patent families are directed to specific oligonucleotides that target SERPINA1 for editing to treat AAT. The first patent family includes pending applications in Australia, Canada, China, Europe, Japan, South Korea and the United States. Patents issuing from applications in this family will expire in 2041, absent any available additional term for patent term extension or patent term adjustment. The second patent family has been filed as a provisional patent application, and if re-filed as PCT or non-provisional applications, and issued, patents in this family would expire in 2044, absent any available additional term for patent term extension or patent term adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent families related to our OPERA platform technology described above, our patent portfolio that relates to our PD program includes one patent family. This patent family is directed to specific oligonucleotides that target LRRK2 for editing to treat PD, and includes pending applications in Europe, and the United States. Patents issuing from applications in this family will expire in 2041, absent any available additional term for patent term extension or patent term adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent families related to our OPERA platform technology described above, our patent portfolio that relates to our sAH program includes two patent families. This patent family is directed to specific oligonucleotides that are capable of editing a specific target associated with sAH, and consists of a pending PCT application. Patents issuing from this family of patent applications will expire in 2042, absent any available additional term for patent term extension or patent term adjustment. The second patent family has been filed as a provisional patent application, and is directed to specific oligonucleotides that are capable of editing a specific target associated with sAH. If this application is re-filed as an PCT or non-provisional application, and issued, patents in this family will expire in 2043, absent any available additional term for patent term extension or patent term adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent families related to our OPERA platform technology described above, our patent portfolio that relates to our ALS includes one patent family, directed to oligonucleotides that edit TDP-43. This patent family consists of two provisional patent applications, and if re-filed as PCT or non-provisional applications, and issued, patents in this family would expire in 2044, absent any available additional term for patent term extension or patent term adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent families described above, we also have other patent families directed to additional target-specific editing strategies, oligonucleotide compositions and their methods of use, related delivery technologies, and other inventions related to early-stage research and development efforts not reflected in our pipeline. Patents issued from or issuing from applications in these families will expire between 2041 and 2044, absent any available additional term for patent term extension or patent term adjustment, and includes Canadian Patent No. 3,162,416, which will expire in 2042. We also have legacy patents related to our pre-Merger operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the base term is 20 years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the USPTO. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent. The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that complies with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved at least one claim covering the composition of matter of such an FDA-approved drug, an FDA-approved method of treatment using the drug and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug, and a patent cannot be extended more than once or for more than a single product. During the period of extension, if granted, the scope of exclusivity is limited to the approved product for approved uses. Some</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, if and when our product candidates receive FDA approval, we expect to apply, if appropriate, for patent term extension on patents directed to those product candidates, their methods of use and/or methods of manufacture. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to our intellectual property, see Item 1A &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Rights by the U.S. Government</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our in-licensed patent rights may be subject to a reservation of rights by one or more third parties, including the U.S. government. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. When new technologies are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of rights or the unenforceability of relevant patents or patent applications. In addition, the U.S. government has the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;).  Recent developments in regarding the Bayh-Dole Act of 1980 indicate that the march-in rights could be exercised to affect pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology, which may include our confidential information, to third parties and to exercise march-in rights to use or allow third parties to use the technology that was developed using U.S. government funding. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. For more information regarding the risks related to our intellectual property, see Item 1A &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Secrets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we not consider appropriate for, patent protection. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual or entities&#8217; relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see Item 1A &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governmental Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, clinical trial, testing, manufacture, quality control, import, export, safety, efficacy, labeling, packaging, storage, distribution, recordkeeping, approval, distribution, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, CROs, clinical investigators and CMOs will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of U.S. Drugs Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drug products under the FD&amp;C Act and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a NDA. The process generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees for FDA review of the NDA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an IRB or independent ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of potential FDA audit of the preclinical study clinical trial sites that generated the data in support of the NDA; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies and Clinical Trials for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes the results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a clinical trial may move forward at designated check points based on access that only the group maintains to available data from the trial and may recommend halting the clinical trial if it determines that the participants or patients are being exposed to an unacceptable health risk or other grounds, such as no demonstration of efficacy. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was well-designed and well-conducted in accordance with GCP requirements, including that the clinical trial was performed by a qualified investigator(s); the data are applicable to the U.S. population and U.S. medical practice; and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Phase 1 clinical trials involve initial introduction of the investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#8217;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of NDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. During the development of a new drug product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase 2 and before submission of an NDA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Review and Approval Process for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#8217;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug, to the satisfaction of the FDA. FDA must approve an NDA before a drug may be marketed in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews all submitted NDAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards, including cGMP requirements, designed to assure and preserve the product&#8217;s continued identity, strength, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require submission of a REMS if it believes that a REMS is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population of 200,000 or more individuals in the United States when there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and user-fee waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may further reevaluate its regulations and policies under the Orphan Drug Act. It is unclear as to how, if at all, the FDA may change the orphan drug regulations and policies in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA is submitted, if the product that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for a standard review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, adequate and well-controlled additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit, and under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Further, under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a product or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for Accelerated Approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Post-Approval Requirements for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although physicians may prescribe approved products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including not only by company employees but also by agents of the company or those speaking on the company&#8217;s behalf, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Promotional materials for approved drugs must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs and those supplying products, ingredients and components of them, are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that a sponsor may use. Additionally, manufacturers and other parties involved in the drug supply chain for prescription drugs must also comply with product tracking and tracing requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program user fee for any marketed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond a patent&#8217;s current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketing exclusivity provisions under the FDCA also can delay the submission or the approval of certain drug product applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Privacy and Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations entail the collection, use, disclosure, transfer, and processing of sensitive and personal information. These operations subject us to privacy and data security laws and regulations in the United States and internationally, including, for example and depending on the particular activity, the EU General Data Protection Regulation, or EU GDPR, as the GDPR as incorporated into the laws the United Kingdom, or UK GDPR, and together with EU GDPR, GDPR, and other laws, rules and regulations designed to regulate the processing of personal information and for example reduce risks of identity theft. The privacy, data protection and data security laws to which we are subject impose obligations with respect to the collection, processing, storage, disposal, use, transfer, retention and disclosure of personal information. In addition, under certain of these laws, we must provide notice to individuals of our policies and practices for sharing personal information with third parties, provide advance notice of any changes to our policies and in some cases give individuals the right to prevent processing of their personal information and disclosure of it to third parties. Our operations extend to commercial partnerships and third-party processors, each of which may be governed by their distinct privacy regulations and data security laws. These laws are constantly evolving and subject to varying interpretations, requiring us to periodically update our policies and measures to maintain compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR in the EU and the UK, which have been incorporated into their respective laws, impose stringent requirements on the processing of health and other sensitive data. These requirements encompass: (i) providing information to individuals regarding data processing activities; (ii) ensuring a legal basis or condition applies to the processing of personal data and, where applicable, obtaining consent from individuals to whom the data processing relates; (iii) responding to data subject requests; (iv) imposing requirements to notify the competent national data protection authorities and data subjects of personal data breaches; (v) implementing safeguards in connection with the security and confidentiality of the personal data; (vi) accountability requirements; and (vii) taking certain measures when engaging third-party processors. The GDPR is also the regulation that informs our obligations with respect to any clinical trials conducted in the EEA or UK. The GDPR&#8217;s definition of personal data includes coded data, and it requires changes to informed consent practices and detailed notices for clinical trial subjects and investigators. Failure to comply with the GDPR can result in significant practical, legal, and financial repercussions, including the destruction of improperly gathered or used personal data, substantial fines of up to &#8364;20 million (&#163;17.5 million) or 4% of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">company&#8217;s global annual turnover, mandatory audits, orders to cease or modify data use, and a private right of action enabling data subjects to seek damages. In addition, the GDPR provides that EU member states or the UK may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the UK has recently introduced a new Data Protection &amp; Digital Information (No. 2) Bill. This development could reshape the UK&#8217;s data protection landscape, distancing it from the EU&#8217;s data protection regime. This lack of clarity on future UK laws and regulations and their interaction with those of the EU could add legal risk, uncertainty, complexity, and cost; and any resulting divergence in laws could increase our risk profile and necessitate further compliance measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To enable the transfer of personal data outside of the EU or the UK, adequate safeguards must be implemented in compliance with the GDPR. The European Commission has issued standard contractual clauses, or SCCs, for data transfers from controllers or processors in the EU (or otherwise subject to the GDPR) to controllers or processors established outside the EU (and not subject to the GDPR). The UK is not subject to the European Commission&#8217;s new SCCs, and instead it has published the UK International Data Transfer Agreement, or IDTA, and the International Data Transfer Addendum to the new SCCs, or the Addendum, which enable transfers from the UK. Companies relying on SCCs or the IDTA to govern transfers of personal data to third countries will also need to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal data under GDPR, including an analysis of the laws in the recipient&#8217;s country. Further, the EU and United States have adopted its adequacy decision for the EU-U.S. Data Privacy Framework, or the Framework, which entered into force on July 11, 2023. The Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to the United States are carried out in line with EU GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. When conducting restricted data transfers under the EU and UK GDPR, we will need to implement these new safeguards, and doing so will require significant effort and cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to implement valid mechanisms for personal data transfers from Europe may result in increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to export personal data may also: (i) restrict our activities outside Europe; (ii) limit the ability to collaborate with partners as well as other service providers, contractors and other companies outside of Europe; and/or (iii) require us to increase our processing capabilities within Europe at significant expense or otherwise cause us to change the geographical location or segregation of our relevant systems and operations &#8211; any or all of which could adversely affect our operations or financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, privacy and security of personal information are regulated by various federal and state laws, such as health information privacy laws, security breach notification laws, and consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with these multifaceted privacy and data security laws can be time-consuming, and failure to comply with any of these regulations could lead to significant fines and penalties (potentially including criminal prosecution), adversely affecting our reputation, business, financial condition, and operational results. Changes in statutes, regulations, or interpretations of existing regulations could impose additional requirements on our operations, such as modifications to data processing arrangements, changes to privacy policies, recall or discontinuation of certain data processing methods, or additional recordkeeping requirements. These changes could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a further risk that we may not be able to adequately protect our information systems from cyberattacks. Such breaches could result in the disclosure of confidential, protected, or personal information, damage our reputation, and expose us to significant financial and legal exposure, including potential civil fines and penalties, litigation, and regulatory investigations or enforcement actions under laws such as HIPAA and the GDPR. Further, all 50 states in the United States have laws including obligations to provide notification of unauthorized acquisition of personal information to affected individuals, state officers and others. Some laws may also impose physical and electronic security requirements regarding the safeguarding of personal information. In order to comply with privacy and information security laws, we have confidentiality and information security standards and procedures in place for our business activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the risks outlined above, the legal or regulatory actions may also divert our management from their primary operations. Prohibitions, restrictions, or allegations of violations of these laws could materially and adversely affect our business. Hence, ensuring consistent compliance with privacy and data security laws and regulations remains a critical operational imperative for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing, labeling, packaging, distribution, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject. Additionally, the activities associated with the commercialization of product candidates are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of such pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defends against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in statutes, regulations, or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling or packaging; (iii) the recall or discontinuation of our products; or (iv) additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation Outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the EU, for example, an application must be submitted to the national competent authority and an independent ethics committee in each country in which we intend to conduct clinical trials, much like the FDA and IRB, respectively. Under the new CTR (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022, a single application is now made through the Clinical Trials Information System, or CTIS, for clinical trial authorization in up to 30 EU/EEA countries at the same time and with a single set of documentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assessment of applications for clinical trials is divided into two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or Member States concerned of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Member State concerned, however overall related timelines are defined by the CTR. The new CTR also provides for simplified reporting procedures for clinical trial sponsors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the United States before we can commence marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of nonclinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of our medicinal products under the EU&#8217;s regulatory system, we are required to submit a marketing authorization application, or MAA, to be assessed in the centralized procedure. The centralized procedure allows applicants to obtain a marketing authorization, or MA, that is valid throughout the EU, and the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway), or EEA. It is compulsory for medicinal products manufactured using biotechnological processes, orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-EU and which is intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes). The centralized procedure is optional for any other products containing new active substances not authorized in the EU or for products which constitute a significant therapeutic, scientific, or technical innovation or for which a centralized authorization is in the interests of patients at EU level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the European Medicines Agency, or EMA, to be assessed by the Committee for Medicinal Products for Human Use, or CHMP. The CHMP is responsible for conducting the assessment of whether a medicine meets the required quality, safety, and efficacy requirements, and whether the product has a positive risk/benefit profile. Once the CHMP has completed its assessment, the CHMP will give a favorable or unfavorable opinion as to whether to grant the authorization. The time limit for the evaluation procedure is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CHMP). The EMA then has fifteen days to forward its opinion to the European Commission, which will make a binding decision on the grant of an MA within 67 days of the receipt of the CHMP opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition that affects no more than five in 10,000 persons in the EU when the application is made. In addition, orphan designation can be granted if the product is intended for a life threatening, seriously debilitating, or serious and chronic condition in the EU and when, without incentives, it is unlikely that sales of the product in the EU would be sufficient to justify the necessary investment in its development. Orphan designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the applicable orphan condition, or if such a method exists, the proposed orphan medicinal product will be of significant benefit to patients affected by such condition, as defined in Regulation (EC) 847/2000.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan designation provides opportunities for fee reductions, protocol assistance, and access to the centralized procedure. In addition, if a product which has an orphan designation subsequently receives a centralized MA for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the EMA may not approve any other application to market a similar medicinal product for the same indication for a period of ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The exclusivity period may be reduced to six years if, at the end of the fifth year, it is shown that the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, an MA may be granted to a similar medicinal product for the same indication at any time if:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the MA holder of the authorized product consents to a second orphan medicinal product application; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the MA holder of the authorized product cannot supply enough orphan medicinal product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A pediatric investigation plan, or PIP, in the EU is aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for MAs for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when an MA holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the EU. Medicines authorized across the EU with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate, or SPC, by six months (provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires). This is the case even when the studies&#8217; results are negative. For orphan medicinal products, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the EMA are free of charge for questions relating to the development of pediatric medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, the EMA launched an initiative, the Priority Medicines scheme, or the PRIME scheme, to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage development of products in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact and rapporteur from the CHMP or from the Committee for Advanced Therapies, or CAT, are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. The aforementioned EU rules are generally applicable in the EEA. The United Kingdom left the EU on January 31, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of United Kingdom and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through the Human Medicines Regulations 2012 (as amended). Except in respect of the new EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore largely aligns with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of United Kingdom and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new framework which will be put in place by the Medicines and Healthcare products Regulatory Agency, or MHRA, the United Kingdom&#8217;s medicines regulator, from January 1, 2024, the MHRA will take into account decisions on the approval of MAs from the EMA (and certain other regulators) when considering an application for a Great Britain MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2023, the United Kingdom government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. In particular, the MHRA will be responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single United Kingdom-wide MA will be granted by the MHRA for all medicinal products to be sold in the United Kingdom, enabling products to be sold in a single pack and under a single authorization throughout the United Kingdom. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply after January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is now no pre-MA orphan designation in Great Britain. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MAA. The criteria are essentially the same, but have been tailored for the Great Britain market, i.e., the prevalence of the condition in Great Britain (rather than the EU) must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in Great Britain or the EU, wherever is earliest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow U.S. price structures and generally prices tend to be significantly lower.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patients Rely on Insurance Coverage by Third-Party Payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.) to Pay for Products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. Net prices for products may also be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Even if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Uniform Policy Exists for Coverage and Reimbursement in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, an agency within the U.S. Department of Health and Human Services that implements the Medicare program. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently expect that any drugs we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain drugs that are not usually self-administered (such as most injectable drugs) may be eligible for coverage under the Medicare Part B program if:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">they are incident to a physician&#8217;s services; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">they have been approved by the FDA and meet other requirements of the statute. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical companies whose products are reimbursed under Medicare Part B must calculate and report certain price reporting metrics to the government, such as average sales price, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for product candidates may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, during the COVID-19 pandemic, millions of individuals lost employer-based insurance coverage. It is unclear what effect, if any, the American Rescue Plan will have on the number of covered individuals, which may adversely affect our ability to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Affordable Care Act and Legislative Reform Measures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been numerous judicial, administrative, and executive, challenges to certain aspects of the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Further, the Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2031. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs without generic competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. Further, judicial challenges to the IRA may have an impact on the implementation of the IRA&#8217;s provisions; and the overall effects of the IRA on our business and the healthcare industry in general is not yet known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other U.S. Environmental, Health and Safety Laws and Regulations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees as well as insurance for environmental liability, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for toxic tort claims that may be asserted against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 101 full-time employees, including 34 who hold Ph.D. degrees, and one part-time employee; 74 employees are engaged in research and development and 27 employees are engaged in management or general and administrative activities. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good. We also employ consultants from time to time, including to assist with Merger integration efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission, or SEC. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face as described below and elsewhere in this Annual Report on Form 10-K.  See &#8220;Cautionary Statement Regarding Forward Looking Statements.&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net loss was $81.2 million and $58.0 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $183.0 million. We have financed our operations primarily through private placements of our preferred stock and more recently, common stock in the pre-closing financing that closed immediately prior to the Merger. Substantially all of our losses have resulted from expenses incurred in connection with our research and development and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses, increasing operating losses, and negative operating cash flows for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue current research programs and preclinical development of any product candidates we may identify;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek to identify additional research programs and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate preclinical studies and clinical trials for any product candidates we may identify;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">further develop Oligonucleotide Promoted Editing of RNA, or OPERA, our RNA editing platform;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ultimately establish a sales, marketing and distribution infrastructure to commercialize any therapies for which we may obtain marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional research and development personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire clinical and commercial personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license product candidates, intellectual property and technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and maintain collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">should we decide to do so, build and maintain commercial-scale current Good Manufacturing Practices, or cGMP, manufacturing facility;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience any delays or interruptions due to global pandemics, such as the recent COVID-19 endemic, or other events unrelated to our business such as the Russian invasion of Ukraine or Israeli-Hamas conflict that could result in delays in preclinical testing and clinical trials or interruptions in the supply chain; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operate as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not initiated clinical development of any potential product candidate and expect that it will be many years, if ever, before we have a RNA editing therapy ready for commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a therapy or therapies with market potential. This will require us to be successful in a range of challenging activities, including identifying product candidates, completing preclinical studies and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those therapies for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have transitioned from discovery, research and development to early preclinical development for our development candidate, KRRO-110. Because of the numerous risks and uncertainties associated with developing oligonucleotide product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand business or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for many years, if ever. Our ability to generate future revenues from product sales depends heavily on our, or our collaborators&#8217;, ability to successfully:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify product candidates and successfully complete research and development of such product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek and obtain regulatory and marketing approvals for any product candidates for which we complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">launch and commercialize any product candidates for which we may obtain regulatory and marketing approval by establishing a sales force, marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which we may obtain regulatory and marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory and marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">address competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary rights, including patents, trade secrets and know-how;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defend against third party intellectual property claims of infringement, misappropriation or other violation; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract top talent and retain qualified personnel.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if one or more of the product candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate preclinical studies and clinical trials of, and seek marketing approval for, product candidates. Because we have limited financial and managerial resources, we have prioritized our research programs and lead optimization efforts in specific indications among many potential options. Specifically, our initial development programs target liver and central nervous systems indications, amongst others. As a result of this prioritization, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater clinical or commercial potential and we may need to reprioritize our focus in the future. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a collaborator. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our cash and cash equivalents were $166.1 million, excluding restricted cash, or $173.1 million, including restricted cash. We believe our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through several value-creating milestones and into 2026. However, our operating plan may change as a result of factors currently unknown, and expectations regarding our cash runway and ability to reach data inflection points are based on numerous assumptions that may prove to be untrue. As a result, we may be required to raise capital sooner than anticipated and our exposure to certain contingent liabilities and contractual obligations may be greater than anticipated. Our future capital requirements will depend on many other factors, including those discussed in the risk factor entitled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize any product candidates we may develop. We cannot be certain that additional funding will be available on acceptable terms or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of any product candidates or other research and development initiatives. We could be required to seek collaborators for potential product candidates earlier than we would otherwise plan or on terms that are less favorable than might otherwise be available. We could also be required to relinquish or license our rights to product candidates on unfavorable terms in certain markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our capital needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends and possibly other restrictions. In addition, if we raise funds through additional license and collaboration agreements, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, research programs or product candidates we may develop, or we may have to grant licenses on terms that may not be favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business has now become that of Legacy Korro, an early-stage company founded in September 2018 and which commenced operations in October 2019. Prior to the Merger, Legacy Korro&#8217;s operations (which are now ours) were limited to organizing and staffing, business planning, raising capital, acquiring and developing our platform and technology and identifying and beginning to advance preclinical testing of potential product candidates. All of our current programs are still in the research or preclinical stage of development and their risk of failure is high. We have not yet demonstrated an ability to initiate or successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale therapy, arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes about 10 to 15 years to develop a new therapy from the time it is discovered to when it is available for treating patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro&#8217;s limited operating history, particularly in light of the rapidly evolving gene editing field, may make it difficult to evaluate our technology and industry and predict our future performance. Accordingly, any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by very early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as a new business, we may encounter other unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss, or NOL, carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have incurred losses and we may never achieve profitability. As of December 31, 2023, we had federal and state NOLs of $302.5 million and $266.3 million, respectively. Under current law, our federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of our taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation.We have federal NOLs of $22.4 million that are subject to expiration between 2036 and 2037 and have $280.1 million of federal NOLs that do not expire. Our state NOLs expire at various dates from 2035 through 2043. As of December 31, 2023, we had federal research and development tax credit carryforwards of $15.6 million that expire at various dates from 2036 through 2043. In addition, as of December 31, 2023, we had state research and development tax credit carryforwards of $8.7 million that expire at various dates from 2032 through 2038 and state investment tax credit carryforwards of $0.2 million that expire at various dates from 2024 through 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as one or more shareholders or groups of shareholders who own at least 5% of the corporation&#8217;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a rolling three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Our prior equity offerings and other changes in our stock ownership may have resulted in such ownership changes in the past. We have not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. In addition, we may experience ownership changes in the future as a result of future securities offering or subsequent shifts in our stock ownership, some of which are outside of our control. In particular, if the Merger or the Pre-Closing Financing constitutes an ownership change within the meaning of Section 382 of the Code, we could lose or otherwise be substantially limited in our ability to use our NOLs and tax credit carryforwards. As a result, if we earn net taxable income in the future, our ability to use our pre-change NOLs or other pre-change tax attributes to offset U.S. federal taxable income or income taxes may be subject to limitations, which could potentially result in increased future tax liability to us. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed by us. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our business and financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. We cannot predict whether, when, in what form or with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase our tax liability or require changes in the manner in which we operate in order to minimize increases in our tax liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Discovery, Development and Commercialization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The gene editing field and RNA editing in particular is relatively new and is evolving rapidly. We are very early in our development efforts and may not be successful in identifying and developing product candidates. It will be many years before we or our collaborators commercialize a product candidate or generate any revenues, if ever. Additionally, other gene editing technologies may be discovered that provide significant advantages over RNA editing, which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates. We are very early in our development efforts and have focused our research and development efforts to date on developing OPERA, our RNA editing platform, and identifying our initial targeted disease indications. Although we believe we can demonstrate many of the key advantages of RNA editing, because we are very early in our development efforts, we are not yet certain of the results we may achieve, which may be important for registration and commercialization of our products. Such uncertainties include, but are not limited to, the level of editing efficiency needed in a target tissue type to achieve a clinical benefit, and associated safety of our edits in humans. We have also not yet shown that preclinical editing activity can result in clinically important effects, nor that the data generated by our preclinical studies can translate into positive results in clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our product development programs are still in the research or preclinical stage of development. Our research methodology may be unsuccessful in identifying product candidates, our product candidates may be shown to have harmful side effects in preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmacological properties ascribed to the product candidates we are testing in preclinical studies may not be positively demonstrated in clinical trials in patients, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. If our product candidates prove to be ineffective, unsafe or commercially unviable, OPERA and our pipeline would have little, if any, value, which would substantially harm our business, financial condition, results of operations and prospects. In addition, our approach, which focuses on using oligonucleotides for drug development, as opposed to multiple or other, more advanced proven technologies, and new products and technologies that may enter the market, may expose us to additional financial risks and make it more difficult to raise additional capital if we are not successful in developing one or more product candidates that receive regulatory approval. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of any product candidates we may discover, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, although we believe OPERA, our RNA editing platform, will position us to expand our portfolio of product candidates beyond the initial product candidates we may develop, we have not yet successfully developed any product candidate and our ability to expand our portfolio may never materialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commencing clinical trials in the United States is also subject to acceptance by the FDA of any future investigational new drug applications, or INDs, and finalization of trial designs based on discussions with the FDA and other regulatory authorities. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial designs or any clinical endpoints selected, which may require us to complete additional studies or trials or impose stricter approval conditions than we expect. There are equivalent processes and risks applicable to clinical trial applications, or CTAs, in other countries, including in Europe, the UK and Australia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates in the United States or any other jurisdiction, and any such approval may be for a narrower indication than we seek. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. We may conduct one or more of our clinical trials with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA, and there can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates. Similarly, marketing approval by the FDA in the United States, if obtained, does not ensure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by regulatory authorities in other countries or jurisdictions. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization of any product candidates we may develop will also require obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. If we do not successfully commercialize any product candidates we may develop, we could experience a material harm to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RNA editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focused on developing therapies based on RNA editing. Although there have been significant advances in the field of gene editing in recent years, RNA editing technologies are new and largely unproven. The technologies that we have developed have not yet been clinically tested, nor are we aware of any clinical trials for safety or efficacy having been completed by third parties using RNA editing or similar technologies. The scientific evidence to support the feasibility of developing product candidates based on these technologies is both preliminary and limited. Successful development of product candidates by us will require solving a number of issues, including optimizing the efficiency and specificity of such product candidates, and ensuring the therapeutic selectivity of such product candidates. There can be no assurance we will be successful in solving any or all of these issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated our research efforts to date on preclinical work to bring therapeutics to the clinic for our initial indications, and our future success is highly dependent on the successful development of OPERA, our RNA editing platform, as well as cellular delivery methods and therapeutic applications of that technology. While some of the existing, non-RNA editing, gene editing technologies developed by third parties have progressed to clinical trials, they continue to suffer from various limitations, and such limitations may affect our future success. While a number of clinical trials for oligonucleotide products conducted by other companies have not been successful, some have received regulatory approval. The pharmacological properties ascribed to the product candidates we are testing or will test in the future may not be positively demonstrated in clinical trials in patients, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. If our product candidates prove to be ineffective, unsafe or commercially unviable, our OPERA platform and our pipeline would have little, if any, value, which would substantially harm our business, financial condition, results of operations and prospects. We may decide to alter or abandon our initial programs as new data becomes available and we gain experience in developing base editing therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in our initial indications or any other indication we pursue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development activities in the field of RNA editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent reexamination and inter partes proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to our and our licensors&#8217; intellectual property rights, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;&#8212;Risks Related to Intellectual Property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are very early in our development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our product candidates or experiences significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are very early in our development of product candidates and have focused our efforts to date on platform development, discovery, research, and preclinical development. Currently, all of our programs are still in the research or preclinical stage of development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. We have not yet generated revenue from product sales or otherwise, and we may never be able to develop or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed or we may be unsuccessful obtaining clearance to proceed into clinical development. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials, abandon our clinical development plans or meet stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to CTAs in other countries, including countries in the European Union, or EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of our product candidates will depend on many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current GCPs, current Good Laboratory Practices, or GLPs, and any additional regulatory requirements from foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of the benefits and use of the product candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective competition with other therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment and maintenance of healthcare coverage and adequate reimbursement by payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approval for the commercial distribution of any of our product candidates, we must conduct, at our own expense, extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Preclinical and clinical testing are expensive, difficult to design and implement, can take many years to complete, are uncertain as to outcome, and the historical failure rate for drugs in preclinical and clinical development is high. For example, we depend on the availability of non-human primates to conduct certain preclinical studies. Over the past several years there has been an increasing global shortage of non-human primates available for drug development that has matured into an acute global supply chain issue. The supply of these non-human primates is currently constrained due to factors such as their limited worldwide availability, domestic regulatory restrictions and trade relations. If we are unable to obtain access to a sufficient supply of these non-human primates in a timely manner or at all, our timelines and our ability to complete preclinical testing and submit IND or CTA applications may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development of one or more of our product candidates can fail at any stage of testing. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our preclinical studies or clinical trials may produce negative or inconclusive results, including results that may not meet the level of significance or clinical benefit required by the FDA or other regulators, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may abandon projects that we had expected to be promising;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in filing INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divergent views between FDA and other homologue regulatory authorities as to the objectives and/or design of the clinical trials required in support of marketing registration; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">problems in obtaining or maintaining IRB approval of trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrolling patients or volunteers into clinical trials, and variability in the number and types of patients eligible for clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to open study sites, or enroll, treat, and monitor patients due to local restrictions, including as a result of COVID-19 or any other pandemic or endemic or other events, such as the Russian invasion of Ukraine or Israeli-Hamas conflict; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in developing and receiving regulatory approval for companion diagnostic tests, to the extent such tests are needed, to identify patients for our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">high drop-out rates for patients in clinical trials and substantial missing data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of future clinical trials to confirm positive results, if any, from earlier preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to consistently manufacture, inadequate supply, or unacceptable quality of product candidate materials or other materials necessary for the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater than anticipated clinical trial costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected side effects that may or may not be related to the product candidate being tested that are experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">poor or disappointing effectiveness of our product candidates during clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable outcome of FDA or other regulatory agency inspection and review of a manufacturing or clinical trial site or other records relating to the clinical investigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of our third-party contractors, investigators, or collaboration partners to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around manufacturing, preclinical, or clinical testing generally or with respect to our product candidates class, in particular; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">varying interpretations of data by the FDA and similar foreign regulatory agencies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not successfully conduct clinical development, we will not be able to market and sell products derived from our product candidates or generate product revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before we can submit an application for regulatory approval to the FDA or foreign regulatory agencies. If the development of any of our product candidates fails or is delayed to a point where such product candidate is no longer commercially viable, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to conduct clinical trials successfully due to various process-related factors that could negatively impact our business plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful initiation and completion of any of our clinical trials, within timeframes consistent with our business plans, is dependent on various factors, which include, but are not limited to, our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retain and recruit employees, contractors or consultants with the required level of knowledge and experience; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retain and recruit, in a timely manner, a sufficient number of patients necessary to conduct a clinical trial, which is a function of many factors, including the impact of the COVID-19 endemic, the proximity of participants to clinical sites, the size of the relevant population, the eligibility criteria for the trial, possible adverse effects from treatments, the existence of competing clinical trials, the involvement of patient advocacy groups, the availability of new or alternative treatments, lack of efficacy, personnel issues and ease of participation in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage the impact of the COVID-19 endemic or other global health pandemics or endemics on our early-stage discovery efforts and clinical trials; open study sites, and enroll, treat, and monitor patients due to local restrictions implemented in response to remaining COVID-19 effects or other global health pandemics or endemics; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop companion diagnostic tests for use with certain of our product candidates or identify partners with such expertise; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacture and maintain a sufficient amount of clinical material, internally or through third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ensure adherence to trial designs and protocols agreed upon and approved by regulatory authorities and applicable regulatory and legal guidelines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">apply the appropriate pharmacovigilance measures in case of adverse effects emerging during a clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">execute clinical trial designs and protocols approved by regulatory authorities without deficiencies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely and effectively contract with (under reasonable terms), manage and work with investigators, institutions, hospitals and the CROs involved in the clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiate contracts and other related documents with clinical trial parties and IRBs, CRO agreements and site agreements, which can be subject to extensive negotiations that could cause significant delays in the clinical trial process, with terms possibly varying significantly among different trial sites and CROs and possibly subjecting us to various risks; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct clinical trials in a cost-effective manner, including management of foreign currency risk in clinical trials conducted in foreign jurisdictions and cost increases due to unforeseen or unexpected complications such as enrollment delays, or needing to outsource certain functions during the clinical trial. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to manage the clinical trial process successfully, our business plans could be delayed or be rendered unfeasible for us to execute within our planned or required time frames, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we cannot successfully manufacture our product candidates for our research and development and preclinical activities, or manufacture sufficient amounts of our product candidates to meet our clinical requirements and timelines, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to develop our product candidates, apply for regulatory approvals and commercialize our product candidates, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing and supply capabilities. In addition to the oligonucleotides that we manufacture internally, we may utilize CMOs to manufacture the oligonucleotides required for our preclinical studies and clinical trials. There are a limited number of manufacturers that supply oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect our ability or the ability of our CMOs to meet delivery time requirements or provide adequate amounts of material to meet our clinical trial demands on our projected timelines. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with our facility or the CMOs&#8217; facilities and ability to comply with the applicable manufacturing requirements and quality standards, which could result in unusable product and cause delays in our manufacturing timelines and ultimately delay our clinical trials, as well as result in additional expense. To manufacture our oligonucleotides, we rely on third parties to supply the required raw materials. We will likely need to secure alternative suppliers for these raw materials, and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. For example, we source certain materials used in the manufacture of our products from China and other countries outside of the United States; the coronavirus outbreak or other similar global disruptions has made access to our existing supply chain difficult and further supply chain disruptions could impact our business. Additionally, our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than expected and could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we license the LNP technology used to deliver KRRO-110 from a third party. Although our current partner, Genevant Sciences GmbH, or Genevant, is a well established leader in the LNP space, and our preclinical studies of this LNP delivery technology have shown improved dose-dependent efficacy with reduced clinical chemistry and adverse events, there is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no guarantee that this will be replicated in clinical trials. There is also no guarantee that we will continue to source the LNP delivery system for KRRO-110 from Genevant. The process of establishing and maintaining collaborative relationships and identifying and securing access to optimized delivery systems that are fit-for-purpose is difficult, time-consuming, and involves significant uncertainty. If the current arrangement with Genevant is terminated, our clinical development, manufacturing, or commercialization efforts for KRRO-110 could be delayed or terminated, while we secure an alternative delivery system, which could have a material adverse impact on our clinical development plans and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The process of manufacturing oligonucleotides is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of manufacturing oligonucleotides is complex, highly-regulated and subject to multiple risks. The complex processes associated with the manufacture of our product candidates expose us to various manufacturing challenges and risks, which may include delays in manufacturing adequate supply of our product candidates, limits on our ability to increase manufacturing capacity, and the potential for product failure and product variation in quality that may interfere with preclinical studies and clinical trials, along with additional costs. We may also make changes to our manufacturing process or the delivery system we use at various points during development, and even after commercialization, for various reasons, such as optimizing costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of current or future clinical trials, or the performance of the product, once commercialized. In some circumstances, changes in the manufacturing or delivery system may require us to perform ex vivo comparability studies, and/or conduct animal studies, and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our manufacturing process during the course of clinical development may require us to show the comparability of the product used in earlier clinical trials or at earlier portions of a trial to the product used in later clinical trials or later portions of the trial. We may also make further changes to our manufacturing or delivery system before or after commercialization, and such changes may require us to show the comparability of the resulting product to the product produced via earlier manufacturing processes and supplied or delivery system used in clinical studies. We may be required to collect additional preclinical and/or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If preclinical and/or clinical data are not ultimately comparable to those seen in the earlier trials, we may be required to make further changes to our process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we continue to build on our experience in manufacturing oligonucleotides, we have limited experience as a company manufacturing product candidates for commercial supply. We may never be successful in manufacturing product candidates in sufficient quantities or with sufficient quality for commercial use. Our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, operator error, natural disasters, unavailability of qualified personnel, difficulties with logistics and shipping, problems regarding yields or stability of product, contamination or other quality control issues, power failures, and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, compliance with cGMP requirements and other quality issues may arise during any internal efforts to scale-up manufacturing, and with our current or any future CMOs. If contaminants are discovered in our supply of our product candidates or in the manufacturing facilities of our CMOs, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our CMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our CMOs were to encounter any of these difficulties, our ability to provide our product candidate to patients in clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial resources, we intend to focus on developing product candidates for specific indications that we identify as most likely to succeed, in terms of both regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration, licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have not tested any of our proposed delivery methods or gene editing approaches in clinical trials and any favorable results we may have may not be predictive of results that may be observed in later preclinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scientific evidence to support the feasibility of developing product candidates using our RNA editing technology is both preliminary and limited. We have not tested any of our potential delivery modalities or gene editing approaches in clinical trials and any favorable results we may have may not be predictive of results that may be observed in later preclinical studies or clinical trials. For example, we may use LNPs or other delivery modalities to deliver our product candidates. While LNPs have been validated clinically to deliver oligonucleotides, such as siRNA, they have not been clinically proven to deliver oligonucleotides for RNA editing, such as our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our RNA editing technology itself may lead to other issues, such as inability to deliver the desired efficacy or safety-related consequences as it is tested in clinical trials. We have not generated any clinical trial results to date. The design of a clinical trial can determine whether its results will support approval of a product candidate and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Furthermore, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Many product candidates that initially showed promise in early stage testing for treating a variety of diseases have later been found to lack efficacy or to cause side effects that prevented further clinical development of the product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not evaluated any product candidates in human clinical trials. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and none involving RNA editing technology similar to our technology. It is impossible to predict when, or if, any product candidates we may develop will prove safe in humans. In the genetic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. There can be no assurance that RNA editing technologies will not cause undesirable side effects, such as lymphoma, leukemia, or other cancers, or other aberrantly functioning cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any such adverse events occur, our future clinical trials could be suspended or terminated. If we are unable to demonstrate that any adverse events were caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any future product candidates for any or all targeted indications. Even if we can demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete any future trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may adversely affect our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any of our future product candidates receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, for example, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners, or other elements to assure safe use of the product. Furthermore, if we or others later identify undesirable side effects caused by any of our future product candidates, several potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully identify patients who are likely to benefit from therapy with any product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success may depend, in part, on our ability to identify patients who are likely to benefit from therapy with any medicines we may develop, which may require those potential patients to have their DNA analyzed for the presence or absence of a particular sequence. If we, or any third parties that we engage to assist us, are unable to successfully identify such patients, or experience delays in doing so, then:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop any product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of these factors, we may be unable to successfully develop and realize the commercial potential of any product candidates we may identify and develop, and our business, financial condition, results of operations, and prospects would be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully develop or obtain regulatory approval for companion diagnostic tests for our product candidates, or experience significant delays in doing so, our clinical trials may be delayed and our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development programs for some of our product candidates contemplate the development of companion diagnostic tests, which are assays or tests to identify an appropriate patient population. If safe and effective use of any of our product candidates we may develop depends on a companion diagnostic, we may not receive marketing approval, or marketing approval may be delayed, if we are unable to or are delayed in developing, identifying, or obtaining regulatory approval or clearance for the companion diagnostic product for use with our product candidate. Identifying a manufacturer of the companion diagnostic and entering into an agreement with the manufacturer could also delay the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any future product candidates, we may be unable to generate any revenues.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not have an organization for the sales, marketing and distribution of any future product candidates and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. To market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. With respect to certain of our current programs as well as future programs, we may rely completely on an alliance partner for sales and marketing. In addition, although we intend to establish a sales organization if we are able to obtain approval to market any product candidates, we may enter into strategic alliances with third parties to develop and commercialize any future product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. This will reduce the revenue generated from the sales of these products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future strategic alliance partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which will prevent us from becoming profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are based upon new discoveries, technologies and therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not adopt a product intended to improve</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">therapeutic results that is based on the technology employed by oligonucleotides. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide favorable reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other factors that we believe will materially affect market acceptance of our product candidates include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of our receipt of any regulatory approvals, the terms of any approvals and the countries in which approvals are obtained; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to consistently manufacture our products within acceptable quality standards; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safety and efficacy of our product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the incidence, seriousness and severity of any side effects; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the relative convenience and ease of administration of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to accept potentially new routes of administration and their risk tolerance as it relates to potentially serious side effects; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our physician education programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of government and third-party payor coverage and adequate reimbursement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our estimates regarding the potential market size may be materially different from what we currently expect by the time we commence commercialization, which could result in significant changes in our business plan and may significantly harm our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The pharmaceutical industry is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical industry is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">more extensive experience in designing and conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing, marketing and selling pharmaceutical products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates that are based on previously tested or accepted technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products that have been approved or are in late stages of development; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborative arrangements in our target markets with leading companies and research institutions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop therapies. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs are currently under development, and may become commercially available in the future, for the treatment of conditions that our current or future product candidates are or may be designed to treat. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may develop or commercialize products with significant advantages over any products we are able to develop and commercialize based on many different factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safety and effectiveness of our products relative to alternative therapies, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and scope of regulatory approvals for these products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability and cost of manufacturing, marketing and sales capabilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">price; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">more extensive coverage and higher levels of reimbursement; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent position. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute on our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that coverage and reimbursement by third-party payors will be essential for most patients to be able to afford any gene therapies for which we are able to successfully complete clinical development. Accordingly, sales of any future products will depend substantially, both domestically and internationally, on the extent to which the costs of any such products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on is investment. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in both the United States and globally. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the United States, the EU, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as its product candidates. Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. For an overview and discussion of the regulatory framework for pricing and reimbursement, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Government Regulation&#8212;Patients Rely on Insurance Coverage by Third-Party Payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.) to Pay for Products.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for any product candidates we may develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product candidates we may develop, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. Additionally, our estimates regarding the potential market size may be materially different from what we currently expect by the time we commence commercialization. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product candidates, or may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">While we intend to seek designations for our product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations include fast track, or breakthrough therapy, among others, and may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for any product candidates. See Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs for Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; for more information regarding these designations. While such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our product candidates, there can be no assurance that we will realize their intended benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may also seek approval of product candidates under the FDA&#8217;s accelerated approval pathway or request priority review. There can be no assurance that FDA would allow any of the product candidates we may develop to proceed on an accelerated approval pathway or grant priority review, and even if FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the EU, we may seek to participate in The PRIority Medicines, or PRIME scheme for our product candidates. The PRIME scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure in the EU. There is no guarantee, however, that our product candidates would be deemed eligible for the PRIME scheme and even if we do participate in the PRIME scheme, where during the course of development a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. For more information regarding PRIME and the EU regulatory framework, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Government Regulation&#8212;Regulation Outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for any future product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in clinical or commercial supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank Signature Bank and Silvergate Capital Corp. were each swept into receivership by the Federal Deposit Insurance Corporation and then a syndicate of U.S. banks infused $30 billion in First Republic Bank; and later that same week, the Swiss Central Bank provided $54 billion in covered loan and short-term liquidity facilities to Credit Suisse Group AG, all in an attempt to reassure depositors and calm fears of a banking contagion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to effectively run our business could be adversely affected by general conditions in the global economy and in the financial services industry. Various macroeconomic factors could adversely affect our business, including fears concerning the banking sector, changes in inflation, interest rates and overall economic conditions and uncertainties. A severe or prolonged economic downturn could result in a variety of risks, including our ability to raise additional funding on a timely basis or on acceptable terms. A weak or declining economy could also impact third parties upon whom we depend to run our business. Increasing concerns over bank failures and bailouts and their potential broader effects and potential systemic risk on the banking sector generally and on the biotechnology industry and its participants may adversely affect our access to capital and our business and operations more generally. Although we assess our banking relationships as we believe necessary or appropriate, our access</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Regulatory, Legal, and Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we are developing oligonucleotides, which are considered a relatively new class of drugs, there is increased risk that the outcome of our clinical trials will not be sufficient to obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable ex-U.S. regulatory agencies have relatively limited experience with oligonucleotides, which may increase the complexity, uncertainty and length of the regulatory review process for any future product candidates. Even though the FDA issued two draft guidance documents in December 2021 relating to IND submissions for individualized antisense oligonucleotide drugs for severely debilitating or life-threatening genetic diseases, one with clinical focus, the other with chemistry manufacturing and controls focus, and in June 2022 a draft guidance on clinical pharmacology considerations for the development of oligonucleotide therapeutics, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to overall development considerations for RNA editing oligonucleotide therapies. The general lack of policies, practices or guidelines specific to oligonucleotides may hinder or slow review by the FDA or other foreign homologues of any regulatory filings that we may submit. Moreover, the FDA or other foreign homologues may respond to these submissions by defining requirements we may not have anticipated. Addressing such requirements could lead to significant delays in the development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs. As a result of the foregoing factors, we may never receive regulatory approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may be required to perform additional or unanticipated clinical trials to obtain regulatory approval or be subject to additional post-marketing studies or other requirements to maintain such approval. As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. For more information, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Governmental Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. In addition, other legislative changes have been proposed and adopted since the Patient Protection and Affordable Care Act, or the ACA was enacted. We may choose to seek an expanded access program for our product candidates, or to utilize comparable rules in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we are developing product candidates in the field of genetic medicines in which there is little clinical experience, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to proceed into clinical development of any product candidates we identify, we will need to submit INDs or comparable foreign applications to regulatory authorities and obtain regulatory clearance to commence clinical development. Because the product candidates we identify are based on novel gene-editing technology, we may be unsuccessful in obtaining clearance from regulatory authorities to proceed into clinical development. In order to commence clinical development, we will need to identify success criteria and endpoints such that the FDA, the EMA or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. As we are initially seeking to identify and develop product candidates to treat diseases in which there is little clinical experience using new technologies, and while we may have opportunities to discuss our clinical development plans with regulatory authorities prior to commencing clinical development, there is heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. Furthermore, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the EU and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe. Within the broader genome product field, only a limited number of gene therapy products, such as uniQure N.V.&#8217;s Glybera and Abecma from Bristol Myers Squibb and bluebird bio, have received marketing authorization or marketing approval from the European Commission or the FDA. Some of these products have taken years to register and have had to deal with significant issues in their post-marketing experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If preclinical studies or clinical trials of any product candidates we may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidates we may identify and develop, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our collaborators, if any, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates we may identify and develop, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulators on trial design; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators, IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective CROs and clinical trial sites; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of any product candidates we may develop may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development or research programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in designing well-controlled clinical trials due to ethical considerations that may render it inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of any product candidates we may develop may be larger than we anticipate; enrollment of suitable participants in these clinical trials, which may be particularly challenging for some of the rare genetically defined diseases we are targeting in our most advanced programs, may be delayed or slower than we anticipate; or patients may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators, IRBs, or independent ethics committees may require that we or our investigators suspend or terminate clinical research or clinical trials of any product candidates we may develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of any product candidates we may develop may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of any product candidates we may develop or other materials necessary to conduct clinical trials of any product candidates we may develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing, and delivery of any product candidates we may develop to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events associated with any product candidates we may develop that are viewed to outweigh their potential benefits; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we may develop beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of any product candidates we may develop, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for any such product candidates we may develop or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to changes in the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on our distribution in the form of a REMS or through modification to an existing REMS; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be sued; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product development costs will also increase if we or our collaborators experience delays in clinical trials or other testing or in obtaining marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we may develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we may develop, any of which may harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the COVID-19 global endemic or similar events, the stage and severity of disease, the nature and requirements of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to commercialization, any of our product candidates must be approved by the FDA pursuant to a new drug application, or NDA, in the United States and pursuant to similar marketing applications by the EMA and similar regulatory authorities outside the United States. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have no experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that we may submit such applications, we may be unable to do so as quickly and efficiently as desired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval of any of our product candidates may be delayed or refused for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that our product candidates are safe and effective for any of their proposed indications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the facilities of third-party manufacturers with which we contract or procure certain service or raw materials, may not be adequate to support approval of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or REMS. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize our product candidates and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, quality, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical studies and clinical trials, and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to a continuously evolving regulatory environment and unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating companies such as ours are not always applied predictably or uniformly and can change. Any analysis we perform of data from chemistry, manufacturing and controls, preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay or failure in obtaining required approvals could adversely affect our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as a condition of approval, which may impose further requirements or restrictions on the distribution or safe use of an approved drug, such as limiting prescribing rights to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients as specially defined by the indication statement or who meet certain safe-use criteria, and requiring treated patients to enroll in a registry, among other requirements. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and payment. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by comparable regulatory authorities outside of the United States and vice versa.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and the activities associated with their development and potential commercialization, including their testing, manufacturing, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other U.S. and international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, including cGMPs, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to providers and recordkeeping.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws and similar laws in international jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on such product candidates, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of any approved product from the market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we may submit; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. If we fail to comply with continuing U.S. and foreign requirements, our approvals, if obtained, could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following any initial regulatory approval of any drugs we may develop, we will also be subject to continuing regulatory oversight, including the review of adverse drug experiences and safety data that are reported after our drug products are made commercially available. This would include results from any post-marketing studies or surveillance to monitor the safety and efficacy of the drug product required as a condition of approval or agreed to by us. Any regulatory approvals that we receive for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may also be subject to limitations on the approved uses for which the product may be marketed. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued maintenance of our marketing application, compliance with cGMP requirements and quality oversight, compliance with post-marketing commitments, and compliance with GCP for any clinical trials that we conduct post-approval. Failure to comply with these requirements could result in warning or untitled letters, criminal or civil penalties, recalls, or product withdrawals. In addition, we intend to seek approval to market our product candidates in jurisdictions outside of the United States, and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials for a variety of reasons. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, our CMOs, and the manufacturing facilities we use to make our product candidates will also be subject to ongoing assessment of product quality, compliance with cGMP, and periodic inspection by the FDA and potentially other regulatory agencies. We or our CMOs may not be able to comply with applicable cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our CMOs, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. We may not have the ability or capacity to manufacture material at a broader commercial scale in the future. We and our CMOs currently manufacture a limited supply of clinical trial materials. Reliance on CMOs entails risks to which we would not be subject if we manufactured all of the material ourselves, including reliance on the CMO for regulatory compliance. Our product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, consent decree, civil penalties and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our product candidates represent new approaches to the treatment of genetic-based diseases, we cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are monitoring these regulations as several of our programs move into later stages of development; however, many of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that could delay our commercial launch of the product and negatively impact any potential revenues we may be able to generate from the sale of the product in that country and potentially in other countries due to reference pricing. For more information, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business &#8211; Government Regulation &#8211; No Uniform Policy Exists for Coverage and Reimbursement in the U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">"</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8211; Patients Rely on Insurance Coverage by Third-Party Payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.) to Pay for Products.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement/payment for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary and/or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. At this time, we are unable to determine their cost effectiveness or the likely level or method of reimbursement for our product candidates. Increasingly, third-party payors, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts paid for pharmaceutical products. If the price we are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">able to charge for any products we develop, or the payments provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to pay all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and payment is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate payment is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Moreover, eligibility for coverage does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could adversely affect our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the United States and other major healthcare markets have been proposed and/or adopted in recent years, and such efforts have expanded substantially in recent years. For more information on these changes, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Governmental Regulation&#8212;Affordable Care Act and Legislative Reform Measures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for another product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s standards for granting orphan drug exclusivity in the gene therapy context are unclear and evolving. In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product candidate for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research, development and manufacturing processes involve the use of hazardous materials. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Our procedures for storing, handling and disposing of these materials are reviewed against the relevant guidelines and laws of the jurisdictions in which our facilities are located on a regular basis. Although we believe that our safety procedures for handling and disposing of these materials sufficiently mitigate the risk of accidental contamination or injury from these materials, the risk cannot be completely eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may become applicable in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violates any of, these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our collaborators, manufacturers, service providers or other third parties fail to comply with applicable healthcare laws and regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently, or may in the future, be subject to federal, state, local, and comparable foreign healthcare laws and regulations relating to areas such as fraud and abuse and patients&#8217; rights. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our products for which we obtain marketing approval. For more information on these laws, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Governmental Regulation&#8212;Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, criminal prosecution, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in federal healthcare programs including Medicare and Medicaid, the imposition of a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services, disgorgement, individual imprisonment, contractual damages, reputational harm, and diminished profits and future earnings, any of which could adversely affect our financial results and adversely affect our ability to operate our business. We intend to develop and implement a comprehensive corporate compliance program prior to the commercialization of our product candidates. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses, could divert our management&#8217;s attention from the operation of our business, and could harm our reputation, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory inspection findings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning and/or untitled letters; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on, or prohibitions against, marketing our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on, or prohibitions against, importation or exportation of our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of review or refusal to approve pending applications or supplements to approved applications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exclusion from participation in government-funded healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exclusion from eligibility for the award of government contracts for our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of product approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consent decrees; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, manufacturers and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud and other misconduct by our employees, consultants and collaborators. Such misconduct could include intentional failures to comply with FDA and other foreign agency regulations, provide accurate information to the FDA, comply with manufacturing standards required by the FDA or us, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing in human clinical trials of any product candidates we may develop and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourself against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidates or medicines that we may develop; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant time and costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any medicines that we may develop. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer and information systems, or those used by our CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of appropriate security measures, our internal computer and information systems and those of our current and any future CROs, CMOs and other contractors or consultants may become vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, or accident, and are unaware of any security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of data from completed or future preclinical studies or clinical trials could result in significant delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be significantly delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to adequately protect our information systems from cybersecurity incidents, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity incidents are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cybersecurity incidents could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data confidentiality, integrity and availability. A cybersecurity incident could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. To date, we have not experienced a material compromise of our data or information systems. However, although we devote resources to protect our information systems, we realize that cybersecurity incidents are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To market and sell our future product candidates in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to obtain foreign regulatory approvals or non-compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We, our collaborators and our service providers may be subject to a variety of privacy and data security laws, regulations and contractual obligations, and our failure to comply with them could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical studies, and are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and new laws continue to be proposed.  Outside of the United States, many jurisdictions have enacted stringent privacy and data protection laws. The collection, use, disclosure, transfer or other processing of personal data originating from the European Economic Area, or EEA, and United Kingdom, or UK, is governed by the General Data Protection Regulation, or EU GDPR, and the UK General Data Protection Regulation, or UK GDPR, which, together with the EU GDPR, is referred to as the GDPR. For additional information on these regimes, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Government Regulation&#8212;Privacy and Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance, and despite those efforts, if we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our reputation, business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The use of new and evolving technologies, such as artificial intelligence, or AI, in our offerings may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm and liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use and integration of AI presents risks and challenges that could affect its adoption, and therefore our business. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#8217;s Artificial Intelligence Act, or AI Act, is anticipated to enter into force in 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes significant obligations on providers and deployers of high risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. If we develop or deploy AI systems that are governed by the AI Act, we may be required to adopt higher standards of data quality, transparency, and human oversight, and adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. The rapid evolution of AI will require the application of significant resources to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Third Party Relationships</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently, and expect to continue to, rely on third parties, such as CROs, clinical data management organizations, medical institutions, preclinical laboratories and clinical investigators, to conduct some aspects of our research. For example, we may rely on a third party to supply LNPs, or to conduct some of our preclinical animal experiments. Any of these third parties may terminate their engagements with us at any time under certain criteria. If we need to enter into alternative arrangements, we may delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, the EMA and other regulatory authorities require us and the study sites and investigators we work with to comply with standards, commonly referred to as GLPs and GCPs for conducting, recording and reporting the results of preclinical studies and clinical trials to assure, amongst other things, that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of certain of our future product candidates or successfully commercializing or competing in the market for certain indications.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may decide to collaborate with non-profit organizations, universities, pharmaceutical and biotechnology companies for the development and potential commercialization of existing and new product candidates. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for its product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of any potential collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management time and focus from operating our business to addressing acquisition integration challenges; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coordination of research and development efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees from the acquired company; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning resulting from the acquisition; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural challenges associated with integrating employees from the acquired company into ours; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities, and other known liabilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated write-offs or charges; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm our business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and anticipate that we will rely, on third parties to design, conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and anticipate that we will rely, on third party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials of our product candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on own, including our inability to control whether sufficient resources are applied to our programs. If any of our CROs are acquired or consolidated, these concerns are likely to be exacerbated and our preclinical studies or clinical trials may be further impacted due to potential integration, streamlining, staffing and logistical changes. These investigators,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. Further, these third parties may not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our preclinical and clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA and other health authorities require certain preclinical studies to be conducted in accordance with GLP, and clinical trials to be conducted in accordance with GCP, including conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. If we or our CROs fail to comply with these requirements, the data generated in our clinical trials may be deemed unreliable or uninterpretable and the FDA and other health authorities may require us to perform additional clinical trials. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. In the United States, we are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Any such event could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties in the supply and manufacture of our product candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet manufactured our product candidates on a commercial scale, and may not be able to do so for any of our product candidates. We currently rely on third parties in the supply and manufacture of materials for our research, preclinical and clinical activities and may continue to do so for the foreseeable future, including if we received regulatory approval for any product candidate. We may do the same for the commercial supply of our drug product. We use third parties to perform additional steps in the manufacturing process, such as the filling, finishing and labeling of vials and storage of our product candidates and we expect to do so for the foreseeable future. There can be no assurance that our supply of research, preclinical and clinical development drug candidates and other materials will not be limited, interrupted or restricted or will be of satisfactory quality or continue to be available at acceptable prices. Replacement of any of the third parties we may engage could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, raw materials, reagents, and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available, may not be suitable or acceptable for use due to material or component defects, or may introduce variability into the supply of our product candidates. Furthermore, with the increase of companies developing nucleic acid therapeutics, there may be increased competition for the supply of the raw materials that are necessary to make our oligonucleotides, which could severely impact the manufacturing of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and they must be acceptable to the FDA or approved by foreign regulatory authorities. Suppliers and manufacturers, including us, must meet applicable manufacturing requirements, including compliance with cGMP regulations, and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards. In the event that any of our suppliers or manufacturers fail to comply with such requirements or to perform their obligations to us in relation to quality, timing or otherwise, some of which may be out of their or our control, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to increase the manufacturing of the materials ourself, for which we currently have limited capabilities and resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. Any interruption of the development or operation of the manufacturing of our product candidates, such as order delays for equipment or materials, equipment malfunction, quality control and quality assurance issues, regulatory delays and possible negative effects of such delays on supply chains and expected timelines for product availability, production yield issues, shortages of qualified personnel, discontinuation of a facility or business or failure or damage to a facility resulting from natural disasters, could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in available product candidates or materials. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be required to enter into long-term manufacturing agreements that contain exclusivity provisions and/or substantial termination penalties which could have a material adverse effect on our business prior to or after commercialization of any of our product candidates. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Failure to execute on our manufacturing requirements, either by us or by one of our third-party vendors, could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we may develop for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations listed in the section above titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Regulatory, Legal, and Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;, including certain laws and regulations applicable only if we have marketed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Personnel, Operations and Growth</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to attract and retain qualified key management and scientists, staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent upon our senior management and our scientific, clinical and medical staff and advisors. The loss of the service of any of the members of our senior management or other key employees could delay our research and development programs and materially harm our business, financial condition, results of operations and prospects. In addition, we expect that we will continue to have an increased need to recruit and hire qualified personnel as we advance our programs and expand operations. Failure to successfully recruit and retain personnel could impact our anticipated development plans and timelines. For example, as a result of the COVID-19 endemic, we have faced challenges in retaining and attracting employees to support our research and development efforts, and our failure to do so could have an adverse effect on our ability to execute on our business plan. We are dependent on the continued service of our technical personnel because of the highly technical and novel nature of our product candidates, platform and technologies and the specialized nature of the regulatory approval process. Replacing such personnel may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully execute our business strategy, and we cannot assure you that we will be able to identify or employ qualified personnel for any such position on acceptable terms, if at all. Many of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">biotechnology and pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in preclinical and clinical testing, manufacturing, governmental regulation and commercialization. In order to do so, we may need to pay higher compensation or fees to our employees or consultants than we currently expect, and such higher compensation payments may have a negative effect on our operating results. We face increased competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. If we are unable to attract and retain qualified personnel, the rate and success at which we may be able to discover and develop our product candidates and implement our business plan will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 101 full-time employees, including 34 who hold Ph.D. degrees, and one part-time employee; 74 employees are engaged in research and development and 27 employees in management or general and administrative activities. In connection with the growth and advancement of our pipeline and becoming a public company through the Merger, we expect to increase the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, our current physical laboratory space may be insufficient for our near-term research and development hiring plans, and the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a growing biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our potential product candidates. If our management is unable to effectively manage the expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize any product candidates we may develop will depend in part on our ability to effectively manage our future development and expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to obtain or protect intellectual property rights related to any of our product candidates, development and commercialization of our product candidates may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our industry, the majority of an innovative product&#8217;s commercial value is usually realized during the period in which it has market exclusivity. Market exclusivity is comprised of both patent and other intellectual property protection, as well as regulatory exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product&#8217;s sales. Accordingly, our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including trademarks, trade secrets and, where necessary in-licenses of intellectual property rights of others, in the United States and in other countries for our product candidates and platform technologies, as well as for methods used to manufacture our product candidates, and methods for treating patients for approved indications using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Certain research and development activities involved in pharmaceutical development are exempt from patent infringement in the United States and other jurisdictions, for example, in the United States by the provisions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of 35 U.S.C. &#167; 271I(1), or the Safe Harbor. However, in the United States and certain other jurisdictions, the Safe Harbor exemption can terminate when the sponsor submits an application for marketing approval (e.g., a New Drug Application, or NDA, in the United States). Therefore, the risk that a third party might allege patent infringement may increase as our product candidates approach commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot offer any assurances about which of our patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found invalid and unenforceable or will be threatened by third parties. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing and commercializing a product. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us in the future after patent issuance could deprive us of rights necessary for the successful commercialization of any of our product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to apply for patents or obtain patent protection on certain aspects of our product candidates or our RNA editing platform OPERA in a timely fashion or at all. The patent prosecution process is expensive and time-consuming. We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents being in the public domain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable, or that any issued or granted patents will include claims that are sufficiently broad to cover our product candidates, platform technologies, or any methods relating to them, or to provide meaningful protection from competitors. Consequently, it is unknown whether our platform technology or product candidates will be protectable or remain protected by valid and enforceable patents. Any failure to obtain, maintain or defend our patents and other intellectual property could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if they are not, we may be subject to entitlement disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Because patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we were in the past or will be in the future the first to file any patent application related to our product candidates. For example, some patent applications in the United States may be maintained in secrecy until the patents are issued. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, we cannot be certain that others have not filed patent applications for technology covered by our owned and issued patents or pending applications, or that we or, if applicable, a licensor were the first to invent or first to file an application for the technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies can be highly uncertain and involves complex legal and factual questions. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, maintenance or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal issues related to the patentability of biopharmaceuticals, and methods of their manufacture and use, are complex and uncertain in some countries. In some countries, applicants are not able to protect methods of treating human beings or medical treatment processes. Intellectual property protection varies throughout the world and is subject to change over time. Certain jurisdictions have enacted various rules and laws precluding issuance of patents encompassing any methods a doctor may practice on a human being or any other animal to treat a disease or condition. Further, many countries have enacted laws and regulatory regimes that do not allow patent protection for methods of use of known compounds. Thus, in some countries and jurisdictions, it</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not be possible to patent some of our product candidates at all. In some countries and jurisdictions, only composition claims may be obtained, and only when those compositions are or contain compounds that are new and/or novel. Also, patents issued with composition claims (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">covering product candidates) cannot always be enforced to protect methods of using those compositions to treat or diagnose diseases or medical conditions. Legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Lack of intellectual property protection in such cases may have a materially adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates, their manufacture or their use might expire before or shortly after those candidates receive regulatory approval and are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available upon regulatory approval in those countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be possible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent prosecution process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, or loss of right to enforce patent claims, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not uniform, can vary substantially from country to country, and are not always applied predictably, requiring country-specific patent expertise in each jurisdiction in which patent protection is sought. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our product candidates and RNA editing technology. While we will endeavor to try to protect our product candidates and RNA editing technology with intellectual property rights such as patents, as appropriate, the process of filing and prosecuting patent applications, and obtaining, maintaining and defending patents is time-consuming, expensive, uncertain, and sometimes unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our pending patent applications may not issue as patents, and even issued patents may not provide sufficient protection of our RNA editing platform OPERA and our product candidates and issued patents may not provide.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to claims directed toward the technology underlying our OPERA platform, our patents and patent applications contain claims directed to compositions of matter on the active pharmaceutical ingredients, or APIs, in our product candidates, as well as methods-of-use directed to the use of an API for a specified treatment. Composition-of-matter patents on the active pharmaceutical ingredient in prescription drug products provide protection without regard to any particular method of use of the API used. Method-of-use patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, providers may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common and this type of infringement is difficult to prevent or prosecute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or may in-license in the future may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. For example, while our patent applications are pending, we may be subject to a third party preissuance submission of prior art to the USPTO or become involved derivation proceedings, or equivalent proceedings in foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if patents do successfully issue, third parties may challenge their inventorship, validity, enforceability or scope, including through opposition, revocation, reexamination, post-grant and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review proceedings. An adverse determination in any such submission, proceeding or litigation may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. Moreover, some of our patents and patent applications may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize our product candidates. Further, if we encounter delays in development, testing, and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other parties have developed technologies that may be related or competitive to our, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same methods or formulations or the same subject matter, in either case, that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first-to-file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to our own. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our programs in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. Moreover, we are also possible that prior art may exist that we are aware of but does not believe is relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe the patents for which we have applied. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, lack of written disclosure, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal allegations of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Further, a court or administrative body could construe certain patent claims narrowly or refuse to prevent the other party from using the technology at issue on the ground that our patents do not cover the technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an infringement proceeding, a court may decide that the patent claims we are asserting are invalid and/or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revocation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business. Such a loss of patent protection could negatively impact our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An unfavorable outcome could require us to cease using the related technology or force us to take a license under the patent rights of the prevailing party, if available. Furthermore, our business could be harmed if the prevailing party does not offer a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a &#8220;reasonable royalty&#8221; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we in-licenses patent rights in the future, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we or our future licensors, as the case may be, may not be able to detect infringement against our owned or in-licensed patents, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our future licensors detect infringement by a third party of owned or future in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we or our licensors later sue such third party for patent infringement, the third party may have certain legal defenses available to it that otherwise would not be available but for the delay between when the infringement was first detected and when the suit was brought. These legal defenses may make it impossible for us or our licensors to enforce owned or future in-licensed patents, as the case may be, against that third party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. We are aware of competitors in the oligonucleotide space whose patent application filings and/or issued patents may include claims directed to technologies and/or products related to some of our programs and product candidates. For example, we are aware of patents and patent applications owned by third parties that have generic claims that may relate to our technologies and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a third party claims that we infringe, misappropriate or otherwise violate our intellectual property rights, we may face a number of issues, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infringement and other intellectual property claims that, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages plus the patent owner&#8217;s attorneys&#8217; fees; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the requirement that we redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization, including by enforcing its patents against us by filing a patent infringement lawsuit against us. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of its product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able to block our ability to commercialize our product candidate unless we obtain a license under the applicable patents, or until those patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of that patent may be able to block our ability to develop and commercialize the product candidate unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, a license may not be available on commercially reasonable terms, or at all, particularly if such patent is owned or controlled by one of our primary competitors. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to it. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee time and resources from our business. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any license of this nature would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates and we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Likewise, our patents and patent applications, if issued as patents, directed to our proprietary technologies and our product candidates are expected to expire from 2040 through 2044, without taking into account any possible patent term adjustments or extensions. Our earliest in-licensed patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Additionally, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own or in-license currently or in the future. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our future licensors, collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We may be generally obligated under our future potential license or collaboration agreements to indemnify and hold harmless our licensors or collaborators for damages arising from intellectual property infringement by us. If we or our future licensors, collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our future licensors, collaborators or strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to it. If we fail to obtain a required license, we or our future collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future growth of our business may depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates and technologies. There has been extensive patenting activity in the field of gene editing. Pharmaceutical companies, biotechnology companies and academic institutions are competing with us or are expected to compete with us in the in the field of gene editing technology and filing patent applications potentially relevant to our business. In order to market our product candidates, we may find it necessary or prudent to obtain licenses from third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary to develop or commercialize our product candidates or other key technologies. We may also require licenses from third parties for certain additional technologies, including technologies relating to RNA editing, such as guide RNA modification, or target sequences as well as delivery technologies for product candidates we may develop. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or other third parties the chance to access technology that is important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may collaborate with academic institutions to accelerate our research or development under written agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, such institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that it may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that we may be unable to obtain required licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, we may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected programs, which could harm our business, financial condition, results of operations, and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation- related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Also, we have in the past and may in the future be subject to claims that these individuals are violating non-compete agreements with their former employers. We may then have to pursue litigation to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our technical and management personnel from their normal responsibilities. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications are due to be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations, however, in which non-compliance can result a partial or complete loss of patent rights in the relevant jurisdiction. Were a noncompliance event to occur, our competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of foreign countries do not protect intellectual property rights to the same extent as federal and state laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our patents and intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover, the initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, filing, prosecuting and defending patents on programs worldwide would be prohibitively expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our RNA editing platform technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents and pending patent applications. For example, in March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the United States transitioned from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; patent system. Under a &#8220;first-to-file&#8221; system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our technology or product candidates or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America Invents Act also includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, allowing third party submission of prior art and establishing a post-grant review system including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, recent U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, these rulings have created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, recently the European Unified Patent Court, or UPC, was created as a common patent court to hear patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Although we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for our technology and product candidates, we also rely on know-how and trade secret protection, as well as confidentiality agreements, non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we does not believe patent protection is appropriate or obtainable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed by or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regards as our intellectual property. Any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, some courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may consume our time and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. The terms of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions including PTE and PTA, may be available, but the life of a patent, and the protection it affords, is limited. For more information regarding PTA and PTE, see Item 1 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments PTE term of up to five years as compensation for patent term lost during the FDA regulatory review process. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a PTE, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain PTE or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make gene therapy products that are similar to any product candidates we may develop or utilize similar base editing technology but that are not covered by the claims of the patents that we may own in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our future license partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our future license partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our future license partners or collaborators, may fail to meet our obligations to the U.S. government regarding any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our owned or in-licensed patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid, unenforceable, or narrowed in scope, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of our issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of our future license partners or collaborators to the same extent as the laws of the United States; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventors of our patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors may conduct research and development activities in countries where we do not have patent rights or enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any product candidates we develops may be covered by third parties&#8217; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a third party may challenge, invalidate, circumvent or weaken our patents, and as a result, a court could hold that our patents are not valid, enforceable and infringed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our use of open source software could impose limitations on our ability to commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our use of open source software could impose limitations on our ability to commercialize our product candidates. Our technology utilizes open source software that contains modules licensed for use from third-party authors under open source licenses. In particular, some of the software that powers OPERA may be provided under license arrangements that allow use of the software for research or other non-commercial purposes. As a result, in the future, as we seek to use our platform in connection with commercially available products, we may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that permit our use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to re-engineer our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disease outbreaks, epidemics and pandemics in regions where we may have clinical trial sites or other business operations could adversely affect our business, including by causing significant disruptions in our operations and/or in the operations of CROs upon whom we may rely. Disease outbreaks, epidemics and pandemics have negative impacts on our ability to initiate new clinical trial sites, to enroll new patients and to maintain existing patients who are participating in our clinical trials, which may include increased clinical trial costs, longer timelines and delay in our ability to obtain regulatory approvals of product candidates, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General supply chain issues may be exacerbated during disease outbreaks, epidemics and pandemics and may also impact the ability of our clinical trial sites to obtain basic medical supplies used in our trials in a timely fashion, if at all. If any of our raw materials or components suppliers become subject to acts or orders of U.S. or foreign government entities to allocate or prioritize raw materials or components to the manufacture or distribution of vaccines or medical supplies needed to test or treat patients in a disease outbreak, epidemic or pandemic, this could delay our clinical trials, perhaps substantially, which could materially and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our facilities are located in Massachusetts. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other disasters and do not have a recovery plan for such events. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation costs and the outcome of litigation could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, employment matters, security of employee personal information, contractual relations with third parties and intellectual property rights. Litigation to defend ourself against claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Operations Following the Merger</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of the events described in &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; occur, those events could cause potential benefits of the Merger not to be realized. To the extent any of the events in the risks described in that section occurs, the potential benefits of the Merger may not be realized and our results of operations and financial condition could be adversely affected in a material way. This could cause the market price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been, and is likely to continue to be, volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of securities by us or our securityholders in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of technological innovations or new therapies that compete with our products and services; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period-to-period fluctuations in our financial results. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to successfully integrate Frequency&#8217;s and our businesses and realize the anticipated benefits of the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger involved the combination of two companies that operated as independent companies. We are required to devote significant management attention and resources to integrating our business practices and operations. We may fail to realize some or all of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly than expected. Potential difficulties we may encounter in the integration process include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to successfully combine our businesses in a manner that permits us to achieve the anticipated benefits from the Merger, which would result in the anticipated benefits of the Merger not being realized partly or wholly in the time frame currently anticipated or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creation of uniform standards, controls, procedures, policies and information systems; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, prior to the Merger, we operated independently. It is possible that the integration process also could result in the diversion of our management&#8217;s attention, the disruption or interruption of, or the loss of momentum in our ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect our ability to maintain our business relationships or the ability to achieve the anticipated benefits of the Merger, or could otherwise adversely affect our business and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will incur significant legal, accounting and other expenses operating Legacy Korro&#8217;s business as a public company that it did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our new post-Merger management team includes some individuals who have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we continue to comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with operating Legacy Korro&#8217;s business as a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Once we are no longer an emerging growth company, a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as an emerging growth company, we may take advantage of exemptions from various requirements such as an exemption from the requirement to have our independent auditors attest to our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 as well as an exemption from the &#8220;say on pay&#8221; voting requirements pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. We will no longer qualify as an emerging growth company after December 31, 2023. After we no longer qualify as an emerging growth company, we expect to still qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule 12b-2 under the Exchange Act, in at least the near term, which will allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Once we are no longer an emerging growth company or a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our auditor identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. This will require that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our restated certificate of incorporation, as amended, and bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors such that all members of the board are not elected at one time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from the board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call a special meeting of stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 66.67% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of Delaware, or the DGCL, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our charter or our bylaws, or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange Act. Our bylaws further provide that, unless we consent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in writing to an alternative forum, federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived its compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such claims, particularly if our stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not continue to develop or be sustained and our stockholders may not be able to resell their shares of common stock for a profit, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that an active trading market for our shares of common stock may continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not sustained, it may be difficult for our stockholders to sell their shares at an attractive price or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales of shares by existing stockholders could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our existing securityholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after applicable legal and/or contractual restrictions on resale lapse, the trading price of our common stock could decline. Certain shares of our common stock are subject to a 180-day resale lock-up pursuant to certain lock-up agreement entered into prior to the closing of the Merger, and will be available for resale in the public market beginning 180 days after the closing of the Merger as a result of the expiration of such lock-up agreements. All other outstanding shares of common stock, other than shares held by our affiliates and shares issued in exchange for shares of Legacy Korro&#8217;s common stock issued in the Pre-Closing Financing are freely tradable, without restriction, in the public market. In addition, shares of common stock that are subject to our outstanding options or warrants are eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers, directors and principal stockholders, in the aggregate, beneficially own approximately 77% of our outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our common stock following the Merger, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will have broad discretion in the use of our cash and cash equivalents and the proceeds from the Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will have broad discretion over the use of our cash and cash equivalents, including the proceeds from the Pre-Closing Financing. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply these resources effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our business and financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. We cannot predict whether, when, in what form or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase our tax liability or require changes in the manner in which we operate in order to minimize increases in our tax liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to utilize NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed below, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a more complete discussion of the risks related to the net operating loss carryforwards and certain of our other tax attributes, please see the discussion under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital&#8212;Our ability to utilize our net operating loss, or NOL, carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. U</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nresolved Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ecurity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards and is integrated into our enterprise risk management process.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments, as part of our risk management process, designed to identify, assess, and manage cybersecurity risks. We conduct employee cybersecurity training and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents. Further, we intend to evaluate and update our existing cybersecurity policies and procedures as appropriate to continue to align them to our risk profile.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a process to assess the security practices of certain third-party vendors, including through the use of vendor security questionnaires, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although risks from cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition, we have, from time to time, experienced threats to and breaches of our and our third party vendors&#8217; data and systems. For more information about these risks, see Item 1A &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance Related to Cybersecurity Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Vice President, Information Technology, or Vice President, who reports to the Chief Operating Officer, is responsible for the strategic leadership and direction of our cybersecurity program. With over 20 years of experience in information technology, the Vice President works alongside individuals across other functions, such as legal and engineering, to establish and implement our cybersecurity strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Vice President and our Chief Operating Officer and General Counsel participate in periodic discussions with other members of our management, including executive leadership, regarding implementation of our cybersecurity program, program enhancements, and relevant cybersecurity risks or threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee has oversight over cybersecurity risks. With the input of the executive team, the Vice President provides annual presentations to the audit committee on our cybersecurity program, including updates on cybersecurity testing and assessments, cybersecurity risks, and related cybersecurity strategy as applicable. The management team will also update the full board of directors on matters related to cybersecurity as needed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we have implemented an enterprise risk management process, which addresses cybersecurity risks. This process is led by our General Counsel and includes participation by the board of directors, as appropriate. Our General Counsel reports regularly on the enterprise risk management process to executive leadership and the audit committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal office is located at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139, where we lease approximately 22,500 square feet of office space. The lease term began in August 2020 and will end in September 2024. We also lease 18,148 square feet of laboratory and office space at 42 &amp; 45 Cummings Park in Woburn, Massachusetts. We have plans to relocate our headquarters and occupy 50,453 square feet of laboratory and office space at 60 First Street in Cambridge, Massachusetts upon completion of the buildout of the space in 2024. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or substitute space will be available in the future on commercially reasonable terms to accommodate any such expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Lega</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any material legal proceedings other than as disclosed below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 3, 2021 and June 22, 2021, purported stockholders of Frequency filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Frequency and the Frequency&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March 21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May 16, 2022, Frequency&#8217;s Chief Development Officer, Dr. Carl Le Bel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, due to allegedly false and misleading statements and omissions about Frequency&#8217;s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in Frequency&#8217;s public disclosures between October 29, 2020 and March 22, 2021. The lawsuit sought, among other things, damages in connection with Frequency&#8217;s allegedly artificially inflated stock price between October 29, 2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. On March 29, 2023, Frequency&#8217;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April 27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. On August 2, 2023, Plaintiff-Appellant submitted its opening brief to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">First Circuit. Frequency filed its response brief on October 27, 2023. The First Circuit heard oral argument on January 8, 2024, and has not yet issued a decision on plaintiff&#8217;s appeal. The Company intends to vigorously defend against the lawsuit.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. M</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Mar</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ket for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;KRRO&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, we had 8,020,788 shares of common stock issued and outstanding held of record by 96 holders. The actual number of holders of these securities is greater than this number of record holders, as the actual number includes holders who are beneficial owners whose securities are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose securities may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Compensation Plan Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 12 &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 6. [Reserved]</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7_managements_discussion_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Mana</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gement&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.  See also &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are generating a portfolio of differentiated programs that are designed to harness the body&#8217;s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, we expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. However, the scientific evidence to support the feasibility of developing product candidates using our RNA editing technology is both preliminary and limited. Moreover, regulators have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and no clinical data has been generated to date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The versatility of RNA editing combined with our OPERA platform broadens the therapeutic target space significantly. While our approach can be used to repair pathogenic single nucleotide variants, or SNVs, as demonstrated by our most advanced program, our Alpha-1 Antitrypsin Deficiency, or AATD, product candidate, we can also engineer de novo SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities, as exemplified by three of our other programs (severe Alcoholic Hepatitis, or SAH, amyotrophic lateral sclerosis, or ALS, Pain). In preclinical studies, we have demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling us to pursue a broad range of diseases traditionally out-of-scope for other genetic medicine approaches and current traditional drug modalities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our most advanced program is a development candidate, KRRO-110, for the treatment of AATD where, using our proprietary RNA editing approach, we are repairing a pathogenic variant on RNA. KRRO-110 has the potential to be disease-modifying and provide a differentiated therapeutic option. Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024 and an anticipated interim clinical readout in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have focused primarily on organizing and staffing our company, business planning, raising capital, securing related intellectual property, and conducting research and development activities for our potential programs and product candidates. Since inception, we have funded our operations primarily through the private placement of our equity securities. To date, we have raised approximately $223.6 million of aggregate gross proceeds from the sale of our convertible preferred stock, and $117.3 million from the sale of shares of common stock issued in a private placement that closed immediately prior to the Merger (as defined below), or the Pre-Closing Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since inception. Our net losses were $81.2 million and $58.0 million for the years ended December 31, 2023 and 2022, respectively. We had an accumulated deficit of $183.0 million as of December 31, 2023. We expect to continue to incur significant and increasing expenses and operating losses and negative operating cash flows for the foreseeable future as we continue our research and development efforts, advances product candidates through clinical stages, and seeks regulatory approvals for its pipeline candidates. As a result of the Merger (as defined below), we also expect to incur additional costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission, or SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of its preclinical studies, initiation and conduct of any clinical trials, and its expenditures on other research and development activities, including the expansion of its pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any product candidates approved for sale and have not generated any revenue from product sales. We will not generate revenue from product sales unless and until we successfully obtain regulatory approval for our product candidates, if ever, and as appropriate, move pipeline candidates into the clinic and complete clinical development. We have yet to commence clinical trials on any of our program candidates. If we obtain regulatory approval for our product candidates and do not enter into third-party commercialization partnerships, we expect to incur significant expenses related to developing commercialization capabilities to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our development and growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private offerings of securities, debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a negative effect on its business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Developments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Merger Agreement &amp; Pre-Closing Financing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, we entered into the Merger Agreement with the private company formerly known as Korro Bio, Inc., or Legacy Korro, and Frequency Merger Sub, Inc., our wholly-owned subsidiary, or Merger Sub. Pursuant to the Merger Agreement, on November 3, 2023, or the Closing Date, following approval by our stockholders and Legacy Korro's stockholders, Merger Sub merged with and into Legacy Korro, or the Merger, with Legacy Korro continuing as our wholly owned subsidiary and the surviving corporation of the Merger. The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended. The Merger Agreement was approved by the members of the board of directors of both our company and Legacy Korro. In connection with the completion of the Merger, we changed our name from Frequency Therapeutics, Inc. to Korro Bio, Inc.  The merger was accounted for as a reverse recapitalization and accordingly, the financial statements of Legacy Korro became our financial statements.  Except as otherwise indicated, references herein to &#8220;we&#8221;, &#8220;us&#8221; or the &#8220;Company&#8221;, refer to Korro Bio, Inc. on a post-merger basis; references to &#8220;Legacy Korro&#8221; refer to the business of privately held Korro Bio, Inc., prior to completion of the merger; and references to Frequency refer to Frequency Therapeutics, Inc. prior to completion of the merger.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the execution of the Merger Agreement, certain new and existing investors of Legacy Korro agreed to purchase shares of Legacy Korro's common stock at $2.78 per share for the aggregate amount of $117.3 million in the Pre-Closing Financing. The Pre-Closing Financing was contingent on and closed immediately prior to consummation of the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of the Merger Agreement, immediately prior to the Closing Date, each then outstanding share of Legacy Korro's common stock (including common stock issued upon the conversion of Legacy Korro's preferred stock but excluding the common stock issued in the Pre-Closing Financing) converted into the right to receive 5,161,114 shares of our common stock calculated in accordance with the Merger Agreement (which takes into account the 1-for-50 reverse stock split of our common stock effected immediately prior to the Merger).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Legacy Korro's common stock issued pursuant to the Pre-Closing Financing were converted into the right to receive 2,077,864 shares of our common stock calculated in accordance with Merger Agreement at the effective time of the Merger (which takes into account the 1-for-50 reverse stock split of our common stock effected immediately prior to the Merger).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery of novel genetic medicines and the development of our product candidates, salaries and benefits, and third-party license fees. We expense research and development costs as incurred, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related costs for those employees involved in research and development efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">external research and development expenses incurred under agreements with contract research organizations, or CROs as well as with consultants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies and research materials; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments made under third-party licensing agreements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">direct and allocated expenses for facilities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our external research and development expenses consist primarily of fees paid to CROs and outside consultants in connection with our preclinical development activities. Our external research and development expenses also include fees incurred under license agreements. As a pre-clinical company, we do not yet track these external research and development costs on a program-by-program basis. We plan to track program costs on our lead development candidate KRRO-110 upon filing of an Investigational New Drug, or IND, application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates, conducts discovery and research activities for our preclinical programs, and expands our pipeline. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. Our clinical development costs are expected to increase significantly as we commence clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing an appropriate safety profile with IND enabling studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether our product candidates show safety and efficacy in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">making arrangements with third-party manufacturers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continued acceptable safety profile of products following any regulatory approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or another regulatory authority were to delay the planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any planned clinical trial, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of employee related costs, including salaries, bonuses, benefits, stock-based compensation and other related costs for our executive and administrative functions. General and administrative expenses also include professional services, including legal, accounting, auditing, tax services and other consulting fees. General and administrative expenses also include facility costs not otherwise included in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net primarily consists of interest income earned on money market fund accounts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,049</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,284</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,797</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,487</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,534</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,536</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(84,534</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(58,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,536</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,389</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">976</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,389</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">976</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(81,145</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(58,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(81,172</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(58,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,683</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,868</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,815</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,960</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,338</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab supplies &amp; consumables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,447</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,676</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,252</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,588</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,664</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consulting</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,646</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,931</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sponsored research and license fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">376</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,728</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,820</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,355</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,049</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $15.0 million from $42.2 million for the year ended December 31, 2022 to $57.2 million for the year ended December 31, 2023. The increase in research and development expenses was primarily attributable to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$4.8 million of increased external research and development expenses primarily attributable to increased oligonucleotide synthesis costs, screening and sequencing expenses and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">studies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$5.3 million of increased personnel-related expenses driven by an increase in headcount to support the expansion of our research and development function; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.7 million of decreased lab supplies and consumables, primarily attributable to reduction consumables purchased for screening and sequencing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$4.7 million of increased facilities-related costs primarily due to the expansion of our mixed-use office spaces and depreciation of lab equipment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.3 million decrease in consulting costs attributed to the increase in internal resources which led to a reduction in our reliance on external consulting services.;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.7 million of increased sponsored research and license fees primarily attributable to an upfront cash payment made to Genevant in March 2023 upon execution of a collaboration and license agreement; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.5 million of increased other expense primarily attributable to increased research and development software licensing fees and lab maintenance services.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our general and administrative expenses for the years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,443</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,970</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,473</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,507</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,529</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,978</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,253</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,653</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,081</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,698</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,284</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,797</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,487</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses increased by $10.5 million from to $16.8 million for the year ended December 31, 2022 to $27.3 million for the year ended December 31, 2023. The increase in general and administrative expenses was primarily attributable to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$4.5 million of increased personnel-related expenses is primary driven by $2.5 million of severance cost to Frequency employees related to the Merger. The remaining increase of $2.0 million is driven by an increase in headcount to support growth in research and development and increased public company regulation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$4.0 million of increased professional service fees primarily attributable to recruiting efforts and increased intellectual property legal fees; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.7 million of increased facilities expenses primarily attributable to the expansion of our mixed-use office space; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.4 million of increased other general and administrative expense primarily attributable to increased software licensing fees and corporate expenses. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income, net increased by $2.4 million from $1.0 million for the year ended December 31, 2022 to $3.4 million for the year ended December 31, 2023. The increase in other income, net was primarily attributable to an increase of $2.4 million in interest income earned on money market fund accounts driven by rising interest rates and higher cash and cash equivalent balance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have generated recurring net losses. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since inception, we have funded our operations primarily through proceeds from the issuance of convertible preferred stock and common stock. To date, we have raised approximately $223.6 million of aggregate gross proceeds from the sale of convertible preferred stock and $117.3 million from the Pre-Closing Financing. As of December 31, 2023, we had cash and cash equivalents of $166.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses and, as of December 31, 2023, had an accumulated deficit of $183.0 million. We expect to continue to incur significant expenses, operating losses, and negative operating cash flows for the foreseeable future. In addition, we have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $166.1 million. We expect that our cash and cash equivalents outstanding as of December 31, 2023, will be sufficient to fund our operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. We may also pursue additional cash resources through public or private equity, collaborations or debt financings. There is no assurance that we will be successful in obtaining sufficient financing on acceptable terms to continue funding our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses, operating losses, and negative operating cash flows for the foreseeable future as we continue our novel genetic medicine discovery efforts, advance our pipeline candidates into the clinic and through clinical trials, seek regulatory approval of our product candidates and pursue commercialization of any approved product candidates. In addition, we expect to continue to incur costs associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amount of our working capital requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of continuing to build our OPERA platform and discover additional novel genetic medicines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, manufacturing and clinical trials for the product candidates we may develop; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we partner our programs, acquires or in-licenses other product candidates and technologies or enters into additional collaborations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under any future collaboration and license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headcount growth and associated costs as we expand our research and development efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common shares. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product research and development or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67,283</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(53,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,164</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,060</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187,761</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,642</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42,567</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023 was $67.3 million, compared to net cash used in operating activities of $53.6 million for the year ended December 31, 2022. The increase of $13.7 million in cash used in operating activities was primarily due to the overall increase in our operating expenses during that same period, including an increase in payments made for external research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Provided by Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2023 was $11.2 million, compared to net cash provided by investing activities of $11.0 million for the year ended December 31, 2022. Net cash provided by investing activities primarily consists of proceeds from maturities of investments partially offset by cash used to purchase property and equipment.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023 was $187.8 million, compared to less than $0.1 million for the year ended December 31, 2022. The increase of $187.8 million in cash provided by financing activities is primarily due to $117.3 million of gross proceeds from the Pre-Closing Financing, $45.5 million of net cash proceeds received from the sale of Legacy Korro's Series B-2 convertible preferred stock and $24.4 million net cash acquired from completion of the Merger, which was accounted for as a reverse recapitalization. No comparable proceeds were received from financing activities during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimate in light of changes in circumstances, facts, and experience. The effects of material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers require advance payments; however, some providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize expenses related to preclinical studies and other studies on our estimates of the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and other studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Other Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contractual obligations and commitments relate primarily to our operating leases and non-cancelable purchase obligations under agreements with various research and development organizations and suppliers in the ordinary course of business. See Note 14, "Commitments and Contingencies" to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A description of recently issued and recently adopted accounting pronouncements applicable to our financial position and results of operations is included in Note 2 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">           We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We may take advantage of these exemptions until we are no longer an emerging growth company under Section 107 of the JOBS Act, which provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to avail ourselves of the extended transition period and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies, unless we choose to early adopt a new or revised accounting standard. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the prior June 30, or (ii) our annual revenues exceed $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_7a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $166.1 million, which consist of bank deposits and money market funds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in market interest rates would not have a material effect on the fair market value of our cash or cash equivalents.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees and operations are primarily located in the United States. We have, from time to time, engaged in contracts with contractors or other vendors in a currency other than the U.S. dollar. To date, we have had minimal exposure to fluctuations in foreign currency exchange rates as the time period between the date that transactions are initiated, and the date of payment or receipt of payment is generally of short duration. Accordingly, we believe it does not have a material exposure to foreign currency risk.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92%;"/>
    <td style="width:8%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page(s)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(PCAOB ID: </span><span><ix:nonNumeric id="F_5e38fc3d-fb62-4ae0-8e40-4c680eb1d075" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stock_and_stockholders_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_flow"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_consolidated_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Korro Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Korro Bio, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38f727e8-d714-4cfb-acda-5e56503a9354" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eec1bcf2-b1b4-4911-9aa9-228b1d8b0e83" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 26, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share and par value amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:13.037%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:13.037%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b2061bf-69e9-4718-a0bc-39831222fd12" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1301a00e-1932-4d83-afb4-35ad5504d109" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86da18d6-c7fb-4a62-a02c-1048aa8729c3" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bcebbaf-0598-47e2-8d14-a106773730ba" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1a521a8-bcf5-44bb-a846-9603c4c0487a" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_053dc648-9f99-40b4-9a37-c1b09cd87076" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_623dfcbd-ce23-4dda-b627-755ced327778" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,015</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88b31d2d-939b-469d-b49e-1119955b9253" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80008493-5810-4345-8b86-e94084a0f7a1" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6ed4dcf-675f-4a84-b40c-81e81ac96f65" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d4a89b7-3901-4b60-85d9-3f5fa995c938" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd6803c6-8c85-4f91-b699-d8a65eacb611" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_141e2533-2df8-44d6-8e98-fec111ec5314" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8becb9f-d449-4982-8ac6-1e2ee2e5bd01" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted Cash, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a9b115a-5d6c-4257-9a94-b6e576d3a3fe" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,406</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf080b3-0e6f-4f67-9546-ad8d7d5a2f37" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,541</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_927ba28a-813b-4e35-8acf-1e00fa6730ee" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0364bcb-51f6-4718-a20b-d3837769afaf" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f59cf58-4df3-4bda-b44a-86228a477352" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,663</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_407d6070-8734-49b1-afed-cdb040b116ec" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,742</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bc36799-e9fb-47ef-a474-05a0d6c88440" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_119a50af-efb0-4d02-8a8d-bf68934807cb" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f552e8d-20a6-4d29-a8bb-828217b49ca2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3c3b598-22e5-44e4-aa84-e52f5a6908d3" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb7994d3-31d7-4eae-861f-b45a2087e8b7" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,991</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f435c5-2f20-48df-929e-963446c1b31c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9076f0c6-9bd3-4fde-806f-c42edf6f31f6" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,483</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fef0387d-aff3-4819-b2c5-347b4c3b7ed9" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_716710c6-350a-41fd-b33c-1304e5e53150" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c409e4b8-16d3-49f9-80c4-a9cb2407c04c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_231b5b78-6533-4f03-aa5e-5955a0b78574" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,053</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67f347dc-583c-4c32-a9c3-fdb4483cb7b1" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e940de89-0e07-41e9-8c4b-f70f14e42dfc" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25c8c80c-e0ae-48ba-90a4-983217aa9590" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_df40f193-0acd-4da6-a9cd-f7e3b8583f44;"><span style="-sec-ix-hidden:F_b3f0be16-92d6-4d75-b406-665cb27d9874;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series Seed convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa81c196-979a-4a9a-91b1-535f422fb0a0" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a5bb69d7-13e7-4b45-846d-a722e7c3a55c" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_602442a7-69ac-4b22-bf9c-f15c3762482c" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_207cbb85-f4ba-449f-abed-fdc696f81f9a" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d00a6ed4-3b3b-4a60-84cf-c109e60f9e81" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba850d27-84e1-40be-bc47-5399f529aa3a" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0da7704f-77ff-41e6-a106-f0e5e0be84f3" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9da22deb-3bd4-4555-80d2-4bf1a0f5dc1e" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, issued and outstanding at December 31, 2023 and 2022 (aggregate liquidation preference of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1645bd9f-87f9-445d-bb69-6e4211603574" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_877453d9-b3a0-482f-9b0a-ba366051e9b2" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,115</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;at December 31, 2023 and 2022)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c621fba-d8c4-4ec5-8f1f-1eb132a96dfc" contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94789e3e-2c28-47c5-9deb-cb964304c69b" contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,924</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series A convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ed1014a-ba7a-4e21-b4b4-165d15b839b5" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f65ba488-90fe-4623-98e4-80ce764b6a3d" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec9c4c4a-1eff-44cc-899e-742f8f6364cb" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c3805195-d28c-4ddb-a583-dd8bb165b29e" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7116dcd0-e008-47b9-aa8d-1c3efd878edd" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9559690-d650-4e3a-84ed-e10af2326782" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_37185a1b-639f-43fa-b95a-cd9f31d8a2e1" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f4ca0744-bd39-4cc6-8b12-893bc35ebae2" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, issued and outstanding at December 31, 2023 and 2022 (aggregate liquidation preference of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28a69fa5-7f4f-4fa8-819b-19d1be9a20ac" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5bcdc91-aee9-47eb-98de-883d00b5c2f3" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;at December 31, 2023 and 2022)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff8ef5a5-2bd4-42a9-97af-e82ddc725864" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_028acb62-05eb-4547-aa38-c7dd6dab8c95" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series B-1 convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0253c473-77e7-4a78-8342-dbd8cf4413c4" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fdd04145-9881-47eb-b7c8-0a2978052b0c" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f45b7d-68f2-485d-919e-7f23ee0566f4" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_926bfb7e-5d2a-476e-a520-b3061d691ed7" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bf2abccf-eb82-441f-909a-855950179965" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a0fcdc6-c93a-43d4-99d8-4a90831a696f" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9b7153ea-246f-46c3-be59-a5411898cfec" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_239aa23c-939b-4c89-83b5-56c091cb6c00" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, issued and outstanding at December 31, 2023 and 2022 (aggregate liquidation preference of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afa507de-7042-45d4-942f-52c24412cfed" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eed24f44-e011-4230-a307-dd22de103b04" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;at December 31, 2023 and 2022)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51e7d991-751a-41b8-a018-085158415bc3" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a928748b-957f-4a9c-a0cb-dcb452e0b68c" contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series B-2 convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fbfc390-1d46-4298-92b2-3bee478dce14" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7eef9427-b96b-4c6f-93a7-cd2418474675" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6343578-a2c5-475d-95d9-6b63ba746816" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac20ea40-d242-4a15-8857-8111d6519f71" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,036,656</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and 2022; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e4689b-211a-42df-b675-3f1f8dbf3338" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c18d0ba7-363b-40cb-818c-4d31a75b6dfa" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5056490-d3c0-433e-8741-2876a211bab4" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_92b86e73-99c8-4893-be7d-5a697a4a0763" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022 (aggregate liquidation preference of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a30e0a3-425f-4645-ad23-1ead47fba548" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4852263-a6aa-4538-92d0-6b8f90428079" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;at December 31, 2023 and 2022)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5708460d-55e7-47a4-8a27-160c20762db8" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf9b969a-8a78-4203-bc3a-563308b058ff" contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity (deficit)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd932b9-d98c-4917-904c-c3b37b588664" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c2c11d37-3b78-48f5-9272-5486c24df5ae" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3604f747-010e-466d-86de-ec6d6fca9df8" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1dead66-168b-479d-964b-697aa58a5e55" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and 2022; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a2f977a-f392-480e-a28b-03d1ba64d8dd" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e2a78281-8a0b-4dfd-b408-7885052a78c6" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42c3c929-286b-41ef-bf2d-8579d8e87cbb" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6bfdcd5f-eab7-4a73-ac8d-ea5633d6dbc9" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d841b0a-f257-40e8-bb8b-16b328071876" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5abcb9fe-507f-49dc-bd6c-bf141d303ec8" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Common stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ce2f0a8-ea55-496d-85f6-0f09b6fc672e" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d83b5ac5-4ffb-4498-940a-4906e6b2ebeb" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d63c296b-e194-4314-8e51-acb3e4b8dc43" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c453bbb1-784d-4ba4-a2d5-11a62fbd8803" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,755,759</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and 2022; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c26c9ff-f4dd-49e5-9583-a54a3f66fb9e" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,016,516</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a5b57b9-e5bf-411c-8421-c40b2d4b4ef1" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">271,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued at December 31, 2023 and 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ef7762b-8430-49de-be7e-38ac03c2ee5d" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,016,516</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b8b8e3-5d3d-4142-a00d-2201e82f15c4" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">268,468</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares outstanding at December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c41932d9-4ecd-4031-8d6d-5ec6a2c2d5eb" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f896e7ed-c7c2-4ad5-810e-796c14eaeea7" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_437d9b8f-34c1-45a7-8466-3d22192949f4" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8873938e-2981-4c5c-b5a5-b668c8c3a99f" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc1c3d5b-69e1-4a54-a32a-0fc9586392e1" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1744a23f-1aa0-48e3-93fb-acf16d174caf" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d8bb770-61f0-4509-ad72-41b98ae505a1" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26db4087-53e6-46dc-bcd1-66cd99c10734" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080e2c76-19bb-4aeb-b5ac-065c9b94becd" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9a30140-5cae-45c4-9956-1ee123c8359f" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,031</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18bd1d7f-3b51-426c-bc66-248c46c5a232" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,663</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc8d8fe7-d9fb-483e-8d29-8f56a0437429" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,742</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Oper</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e5edb7e-3b36-4716-843d-ef86f95e3dac" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_629a2356-f1b3-4645-92b6-3a5de06e4c51" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,201</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53c08b35-5db5-4846-9de5-33c35273471a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60b39879-52b8-4bdc-855a-58b461c77f1c" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6522a20e-84e3-4903-ab50-40a48a5365bb" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_500fe696-a885-46f1-bb4f-521db8dee5e6" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70d88743-48fe-46cb-9a9a-e07e11f83ec9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e05c6e0-a8b4-459f-90b0-761a81326339" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f45b240-ad3a-45b3-bbf0-3b6dc63954fd" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05b4d3d3-b0aa-4059-93ef-95bbf35e0307" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">976</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed636dd-1c16-4fb1-bad1-ea979e946965" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_410af4cf-fd91-423a-8ed1-169055e2f84b" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">976</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e70a84d5-6cdd-4a3d-90d3-bff1d517585d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae9396f5-5ebc-44a2-b40d-db71b554c508" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f0033d7-b51f-4552-83dc-2d1fd80a0e1b" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c00a228-38eb-4951-823d-bb788f31a835" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f92e3556-dddc-4a14-b113-e03ab4bbcc7b" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da7c1058-2b2d-4dc0-8666-7dc139f7b4a7" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5da394ea-7da7-4628-991c-d99c2413588d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0adeca04-40ae-440c-8606-e295681dc0e0" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bfe9b68-ac56-4d0f-8ab4-139fb16e25aa" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34d1450c-b7da-415c-9850-1504eb76820a" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5d857b4-5345-4a3a-bec9-7344a5aaa133" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c5ea7c88-8128-4a38-bcc5-f91214429215" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">53.08</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a212b035-0ecb-4aee-873f-1035b898c26c" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f7a8f6e5-00f3-4662-9c74-47ceed834d4d" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">227.42</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6697c27d-699a-4b36-adc8-2b125612edc1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_186a4006-1496-4cc7-9bc3-f04867db64b9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,529,321</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47d4b1a1-b5d2-471a-b420-b0af14dee7f0" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_70cd0c18-b608-450f-a331-04769b68f24c" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">255,175</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stock_and_stockholders_deficit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Convertible P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">referred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.724%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:4.289%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:2.312%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:4.529%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:2.312%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:4.529%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:2.232%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:4.529%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:2.572%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:3.45%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:0.994%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:0.994%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.111%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:2.871%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:3.331%;"/>
    <td style="width:1%;"/>
    <td style="width:0.998%;"/>
    <td style="width:1%;"/>
    <td style="width:4.228999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series Seed<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-1<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-2<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">In Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee2185f8-8cb1-464e-9016-30d42c45fa87" contextRef="C_ba766246-72fe-4458-8363-5e1fe9dfc13c" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f703f3b7-c4d9-4a23-b11b-8411e7211ee5" contextRef="C_ba766246-72fe-4458-8363-5e1fe9dfc13c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,924</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99ffa825-44e8-43d8-ba31-a07895fb0a2f" contextRef="C_744282a9-e212-4b62-bd6d-0bd21501afbc" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1261356b-e2a2-4a06-9203-91cae6ad12b7" contextRef="C_744282a9-e212-4b62-bd6d-0bd21501afbc" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aac2a2e1-0d5e-40f2-a2a6-71505c0004bd" contextRef="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c2aeb25-71b3-443c-846b-8bbc5cf1004a" contextRef="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16a1a01c-5e8d-45df-b855-208c19794c46" contextRef="C_cd46bccb-a691-424a-a33d-f99566514d8c" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83e63268-d3f7-44b0-abc8-b4d04a74d5a3" contextRef="C_cd46bccb-a691-424a-a33d-f99566514d8c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06930ee1-f920-4879-b9db-8cd9f7534377" contextRef="C_df66f09e-7513-4224-913e-a00329ea7267" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">237,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b4a8d93-cb8e-44eb-b891-6bee396691b1" contextRef="C_bd07e99c-bb55-45ba-8e28-c3c05197c876" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d84f1d8-319a-4f6e-85b3-509b4dad6638" contextRef="C_074064b9-afc6-45bc-a7ef-5e7a10262640" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45de1917-c50f-4366-b05b-87a38d54e5c4" contextRef="C_85bbe7f5-08dc-4646-8679-f35a1d5e2c54" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">43,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e8d0e3-b3d1-4063-a972-6ac0072350c0" contextRef="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,208</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for services rendered</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f51f4137-c548-46a7-9e1a-d773cbb4d23c" contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1591c274-e6d8-4494-9bb8-bec45e73a7f0" contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1c73c30-f85a-4b08-9716-c2776070705f" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercises of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ad5b6bd-5da4-42a8-b53f-d3e401075f32" contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f54840-ed66-44b0-80c2-ac675e4d82cf" contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d192e343-b58e-4c66-9800-1f441e4b9cf6" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0a6e713-1fce-45eb-874f-c260f0710c9e" contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20d83a97-78f0-44c4-b375-9b019dad8dc0" contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb74ccba-1250-47a2-bac5-920bee440b10" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb292612-a0af-441d-b7ec-ca283e60fd52" contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fb7bd98-4a98-4677-ac83-857e63ed9aa8" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad79b0c0-fd52-46fd-b1a3-18e3dd24ec10" contextRef="C_36660a78-b341-4333-95b7-20b31fa422ac" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d7cee34-4d1d-4c7e-8877-bfa46fb943f9" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90ca89de-0978-43c6-a905-bca2664bab71" contextRef="C_9e96165e-bcee-45de-b858-7909fc620d7b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72ee9cdb-3954-4d65-83dd-9b6d2f62fe66" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0745e484-3a17-4906-b8c7-8a7efdeca8e3" contextRef="C_fbf5ca73-fbe0-4461-be55-abde5434880e" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e738311-887c-474a-a282-08e89e925e6b" contextRef="C_fbf5ca73-fbe0-4461-be55-abde5434880e" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,924</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbbd7294-4559-4d1f-9732-08bda40a511f" contextRef="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebfe7171-a622-4d1f-9873-18f6182dc82e" contextRef="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b84ba3-62db-446b-a364-81b4eba6b164" contextRef="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_616291f0-8241-4633-a041-7618c3998cb5" contextRef="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4649cd61-4ccc-4acb-88fb-9f246faf6f71" contextRef="C_19000ad4-b68e-4b1a-a943-897eb59fe630" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e2eb6c4-00d8-4fa9-9151-6fe739320419" contextRef="C_19000ad4-b68e-4b1a-a943-897eb59fe630" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4865223c-cb82-477f-9a9d-7140a0824d11" contextRef="C_8847dfc8-679e-433b-8e63-9ebb42630fe9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">268,399</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98723c62-3c25-41d3-b729-1985d70ccaa6" contextRef="C_41f08d6e-847a-47a4-b214-65d33ec4097d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6098682-589c-4267-87ec-644f3b50034f" contextRef="C_3a51d59d-f39c-4dbc-88ab-1479e858825a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe26ed6e-d650-4f39-9f88-ea32f09f8ef6" contextRef="C_f43d2a6f-7e41-4811-95fc-4e6af0a5b263" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3008631-02df-4449-b2a8-df271c286cf6" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,031</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Series B-2 convertible preferred stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9fcd9ec-bd6a-46a5-9d14-a6c07988ac5e" contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7" name="krro:ProceedsFromIssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">813,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfdf5a18-785b-4f26-8bea-2bc6532b899a" contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for services rendered</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_475b1aac-efcc-453c-8034-deed4c28a11c" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3441b754-7c88-4372-b7ce-3668d8ac9d6d" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad27d48c-2f4a-4701-befa-44df4c1e2cf9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercises of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_018f999c-5038-45ea-8a04-cdf9369eac1f" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da500acb-a3d8-4cdd-beae-74ea17e42e54" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f653315-6c49-4516-958f-2a70e7b677ce" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acb3070e-bae2-494c-ae38-6ecc930c5599" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,902</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c7d21e9-754f-4471-a1ae-440abe086a79" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ed99a19-678e-4084-b9e5-0908abbde663" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for cash in PIPE financing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a70ac37a-de4f-49bb-9db6-be791079a933" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:IssuanceOfCommonStockForCashInPreClosingFinancingShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,077,864</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdc6cd81-fe8e-488f-b2da-d83d83f73f0b" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:IssuanceOfCommonStockForCashInPreClosingFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67bdc641-486f-4d60-97cf-5e9b9aa8f7ce" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="krro:IssuanceOfCommonStockForCashInPreClosingFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6440752-7b59-423b-8dc6-8c9ea2c5977e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IssuanceOfCommonStockForCashInPreClosingFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,252</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of preferred stock to common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f466c81-ffed-43db-b4a2-d72ea88af8d4" contextRef="C_c0304c01-05f2-44fb-9a26-a65525c2254d" name="krro:ConversionOfPreferredStockToCommonStockShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_944f04a8-df73-48b4-927f-0519dd178548" contextRef="C_c0304c01-05f2-44fb-9a26-a65525c2254d" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,924</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66840a7b-037e-4755-9eeb-38ab41b97180" contextRef="C_e34d372c-ba61-4919-8176-79ae6cf200b5" name="krro:ConversionOfPreferredStockToCommonStockShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cc8536e-78ed-469b-ba5e-fb62455dfd48" contextRef="C_e34d372c-ba61-4919-8176-79ae6cf200b5" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96bf1aee-3767-4e51-b057-c0249e9710af" contextRef="C_55691ac6-0299-4103-8d80-a1f6d05b4a80" name="krro:ConversionOfPreferredStockToCommonStockShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77447277-7345-4ecb-8717-f61f128521e0" contextRef="C_55691ac6-0299-4103-8d80-a1f6d05b4a80" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e0db67-3f3a-4d77-ba8e-b45f8ae3089a" contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7" name="krro:ConversionOfPreferredStockToCommonStockShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">1,036,656</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeae8926-cb50-48c4-90ee-3bf4979deec0" contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,958</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e89a49f-e49b-4539-8843-aa26154dbda3" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:ConversionOfPreferredStockToCommonStockShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,855,208</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a658bee-0345-4515-92f7-0f5e83ce4807" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_524584ef-6739-4e7a-a67d-f9c377e73b2d" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e72b415-7412-4966-b962-5c997281cf80" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:ConversionOfPreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209,320</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock to Frequency shareholders in reverse recapitalization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01cd7110-b4eb-453b-904a-6d7177e0b778" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">738,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1965e5cf-d255-467b-98fc-b437e6915ce5" contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de" name="krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a11d90a-6956-4c3e-9670-6149316b1702" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2f431f6-8ebf-4b11-aa88-3a82cc0dd6ac" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse recapitalization transaction costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45c0b381-8770-46c2-8948-cc8982206631" contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14" name="us-gaap:RecapitalizationCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10719ba7-ecc6-4d49-9f6b-c9682741c682" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:RecapitalizationCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9056229b-c6db-48b5-b06e-69c0a6e43d7f" contextRef="C_27d10e7c-da56-48f5-a64c-6c1e8a2c5c32" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5dffea7-4d95-42dd-b7fb-f8c70a4be52e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a60e52a-0583-49a8-b8d4-1b15eeb04fb9" contextRef="C_783f0bb3-c296-483d-8672-851d68ba26f5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc0def33-c2c3-49ea-9d76-ce8d8e3b5fb3" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ba4ea25-b140-4959-8d93-f4bf52acda90" contextRef="C_682c0c46-757c-48ee-8cdd-a8c28faac6de" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_befb1077-fe04-4b63-bdce-83b05b8dbe52" contextRef="C_682c0c46-757c-48ee-8cdd-a8c28faac6de" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d19fba39-02ef-4baf-b3d9-1b4a89633c2f" contextRef="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e60a6381-6e58-477d-b2c5-18a7c3854e4c" contextRef="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_815b0b55-aac7-4ad4-877c-6fb54269c021" contextRef="C_76ec386a-8db0-4d94-8796-51f3034d3694" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7f0775c-c312-4c38-89db-95b8897c2188" contextRef="C_76ec386a-8db0-4d94-8796-51f3034d3694" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b235cfde-335d-4129-a5b3-2d3700947d1e" contextRef="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c6c66b3-7fcb-4a28-b29d-7bbe8748ed1b" contextRef="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be250c40-5aca-4e67-98b7-81393ba00716" contextRef="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,016,516</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2e552d6-c2c5-43b2-8d4a-3faaeecf251e" contextRef="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b52ad85-a862-4a20-9808-134d6d01396a" contextRef="C_c310c39a-f47b-42e4-b993-0dc1ab10d95c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f344646d-a3ed-46dd-b1db-c9ce28f1912b" contextRef="C_3b33040c-7342-4627-9634-346fa6638cb9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dafd73b-815a-4828-a4a8-b40d558053d3" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_flow"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d8f7833-d5bb-4b0b-9575-59e1b9a4ab96" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4045f26-05af-430e-8851-cdef08452ae6" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_525fadd1-8f68-434f-9188-2a0d8de38c72" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:NonCashLeaseExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,610</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a9d7278-6f45-4461-a423-5118aa924102" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:NonCashLeaseExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,396</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26c69d3b-b749-4078-90c5-21dcc1c29b2c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:ShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cee20a5-0398-47f6-905f-33473454c726" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:ShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86c2a5e3-351c-49c7-b470-fb8839ca0423" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05d3ad8c-f567-4a20-b3c0-ea897a5d1ca7" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,511</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55ac82eb-8fdf-4f55-803b-8edad5d3eed6" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1e8e22-5069-4347-a4c6-1525965e3528" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net amortization of premiums and discounts on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2114646-1ded-4381-a1c8-506651e4cc6c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e2bfb66-61ca-4d2f-a2b0-8a95c8ae254b" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ec94e4a-2a46-4ae3-a839-a01334718996" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b97620d-f2f0-4c99-8834-cb7ef16b79da" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8688568a-8ec0-462e-9be5-22bb058d5cef" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_857720e0-2859-47bd-8ceb-fda81daf257d" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d32befe-580e-4658-83ed-2f75b26393fa" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98dae78f-c638-4b1a-99c3-2020d1951d3d" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f048584-3a08-4ab5-a189-b67f09b334b6" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,270</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f23da07f-e460-4c01-9229-6c04e2582a85" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33e088e1-4ea5-43cf-8baa-9d4936c6c0b8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e130a28e-1052-4878-a9ae-7395e2bcb7bf" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb8774ee-3373-4178-8b74-65af01dd9a25" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,987</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c3940d3-986d-441c-8579-922a772c227a" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_569aa99a-348f-4f1b-823c-f7fd6baaa09e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c370a68-745f-4340-969a-4c888cd7f54b" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_3c03b9d3-a541-4644-82ad-919fd697092d;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e4ac8b7-177b-4194-a124-9d450a74488e" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:PurchasesOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_910779c0-301b-44c8-ab7a-a9e5bca880d9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f9d1aa-6525-4889-b938-100f98be6150" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,485</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df4529e-3a99-40cc-bfe3-d0bf66154512" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2aebfd7-2139-4f2d-886a-104bbb606e75" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance payments for property and equipment not yet received</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_7f34c903-b265-46b4-91f2-c9b15429742b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1c0a072-e0f9-4daf-bde5-df82ee95eb3e" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:AdvancePaymentsForPropertyAndEquipmentNotYetReceived" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80e69d6a-611e-4d13-a047-2dcb0e17f7b2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_647fee4a-33e8-4b3a-aff1-be38aff1c741" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,060</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Series B-2 convertible preferred stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bce5dff-227b-4907-8ca8-d4b43e78a3c2" contextRef="C_16286e85-fcb2-4aeb-8a74-8b8cb490439b" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03f1f635-a10a-433d-bdc2-305ea8d59f69" contextRef="C_f8f40235-5f27-48ad-ad53-52935a2bb13b" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercises of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d6bbd2a-9080-4574-b921-3d814ba89dbc" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a087c28c-d7d9-458d-a7d9-c1ef71bdc4f4" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the issuance of common stock in pre-closing financing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bfd4025-a1b7-47c6-95a6-dd76bef28fb4" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e55ab47-22a0-4504-b287-63365fad8bef" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash acquired in connection with the reverse recapitalization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10c300e7-94a5-4cb1-bc6d-fafd87a22b29" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:CashAcquiredInConnectionWithTheReverseRecapitalization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad3c4c00-de73-4e64-a88b-1340fea63701" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:CashAcquiredInConnectionWithTheReverseRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of reverse recapitalization transaction costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d80f4cbb-ae2e-4c29-ae55-4f7eec165405" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:PaymentOfReverseRecapitalizationTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ac1896a-0ae5-4211-a6c1-c42ea0f4ded6" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:PaymentOfReverseRecapitalizationTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other financing activities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e65ed290-7fc4-456f-b99b-a5db75615c96" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5912cfa-19c7-47cd-bbcc-57b45a21eb96" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbe1fed2-ebce-4954-b4a1-9df007bad5f2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20e48a34-2f57-459a-8200-902f61caf445" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18cfa912-6c60-4782-ba42-64afced94f91" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,642</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac8ef301-d02a-4b01-ab8f-e190c22e8d44" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,567</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8853513-efa8-4885-9ad7-15f0971a17e9" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_895a975c-b2f2-45a1-9953-9fe7bfca744b" contextRef="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,044</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3a5d085-6f77-4c07-a715-6506c4182831" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12362f84-071e-4a62-a228-c551aa8e60b7" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment capitalized under tenant improvement allowance</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0007a18-7b9d-40e7-a47e-73725625ec71" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,271</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b3e69f4-d1c7-4878-a2fd-3770901da65a" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment in accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64d208e0-1c55-4f9d-87b2-2c1d85a4521e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,983</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a581a107-9ce6-4c20-af8d-b20c7e7e1413" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities arising from right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_959a92d2-d3fa-4d94-b211-c003f6987567" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aaa2e54-e29d-4475-9139-617cee48a45f" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities arising from lease modification</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4620346-e37a-4b24-a6c2-1357feff07cf" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:OperatingLeaseLiabilitiesArisingFromLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,959</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31c799eb-f203-44f6-a9ef-0076c985d8f2" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:OperatingLeaseLiabilitiesArisingFromLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f3e20a1-d8e5-43ed-a1d5-225d5e862d34" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2a673a-6568-4192-bb4d-c54a2ee719ef" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d4e0e3a-27b5-4839-878c-37e82ae0098f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_950c43a0-e65b-43c8-9399-4ca889c2c1d2" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_consolidated_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Fi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nancial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f01e0d21-261f-40f5-9003-53d4846c06e2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. The Company and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company was incorporated in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_81265546-519d-4e10-aa08-5ad84f64dad1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2014</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a Delaware corporation. The Company's principal offices are in Cambridge, Massachusetts.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Merger with Legacy Korro</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, Frequency Merger Sub, Inc.(&#8220;Merger Sub&#8221;) a Delaware corporation, a wholly-owned subsidiary of Frequency Therapeutics, Inc. (&#8220;Frequency&#8221;), a Delaware corporation and Korro Bio, Inc (&#8220;Legacy Korro&#8221;), a Delaware corporation, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  The merger was completed on November 3, 2023 (the &#8220;Merger&#8221; or the "Transaction").  In accordance with the Merger Agreement, the Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as a wholly-owned subsidiary of the Company.  In connection with the completion of the Merger, the Company changed its name from Frequency Therapeutics, Inc. to Korro Bio, Inc.  On November 6, 2023, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;KRRO&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise indicated, references herein to the &#8220;Company,&#8221; or the &#8220;combined company&#8221;, refer to Korro Bio, Inc. on a post-merger basis, and the term &#8220;Legacy Korro&#8221; refers to the business of privately held Korro Bio, Inc., prior to completion of the merger. References to Frequency refer to Frequency Therapeutics, Inc. prior to completion of the merger.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with the execution and delivery of the Merger Agreement, Legacy Korro entered into a subscription agreement with a number of accredited investors. Immediately prior to consummation of the Merger, Legacy Korro issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dce1ce74-13b8-4e62-8891-ae9bbb6b4dee" contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">42,176,255</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6de63771-9567-49b4-80ff-128b1e362114" contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14cbdb18-0c5a-49df-b2ad-a2a1e78ceb55" contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d" name="us-gaap:CommonStockSharesSubscriptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">117.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Shares of Legacy Korro common stock issued pursuant to the Pre-Closing Financing were converted into shares of the Company&#8217;s common stock based on an exchange ratio (as defined below).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Legacy Korro preferred stock was converted into a share of Legacy Korro common stock, and then exchanged in the Merger for shares of Frequency common stock using an exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdbd8535-c351-42d1-a728-2109a14eec13" contextRef="C_86dca00a-98c3-49ec-b174-5d61f32beb4f" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_Rate" scale="0" decimals="6" format="ixt:num-dot-decimal">0.049688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Exchange Ratio&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger, the Company issued (or reserved for issuance upon exercise of options assumed in the Merger) an aggregate of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e2dbbb-1f83-4f98-883e-ca4b2dca5c87" contextRef="C_6a634502-8868-4319-974b-a0bdac21d6bd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,848,776</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to Legacy Korro securityholders (before eliminating fractions), calculated as provided in the Merger Agreement, (the &#8220;Exchange&#8221;), resulting in approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13675383-eb60-446b-919d-3d0c327932a0" contextRef="C_9019f292-8abd-4d72-a541-b2e15e70e9e2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,623,645</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock being issued and outstanding on a fully diluted basis immediately following the effective time of the Merger. This number includes shares of the Company&#8217;s common stock that was issued upon vesting and settlement of certain outstanding equity awards at the effective time of the Merger.  Immediately following the completion of the Merger, Frequency securityholders prior to the Merger owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7dfc9f0-5bc2-4115-b0a8-b2af419a1753" contextRef="C_9019f292-8abd-4d72-a541-b2e15e70e9e2" name="krro:SharesOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of common stock on a fully diluted basis and Legacy Korro&#8217;s securityholders, including those securityholders who purchased shares in Legacy Korro&#8217;s pre-closing financing, owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e4792d3-588f-4814-81fe-2b02c32f59cb" contextRef="C_84565942-6987-4c97-b8de-234ea6a6f1a2" name="krro:SharesOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares on a fully diluted basis. The Merger was intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "IRC").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon closing of the Merger, the Company assumed the Legacy Korro 2019 Stock Incentive Plan, and each outstanding and unexercised option to purchase Legacy Korro shares at such time, each of which converted into an option to purchase shares of the Company&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. In addition, upon the closing of the Merger, the Company assumed each outstanding and unexercised warrant to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro shares at such time, each of which converted into a warrant to purchase shares of the Company&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger, the Company entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;) with Computershare Trust Company, N.A. and Computershare Inc., collectively as rights agent providing for the payment of certain contingent cash payments equal to the net amount (calculated in accordance with GAAP consistently applied) of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to Frequency&#8217;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein.  Concurrently, the Company entered into an asset purchase agreement with Progentos Therapeutics (&#8220;Progentos&#8221;), whereby Progentos acquired the rights, title and interest in certain assets related to Freqeuncy&#8217;s MS program ("MS APA").  The MS APA included initial consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa50c0c3-4b12-4f58-9b10-77dc3fe5cb25" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="krro:InitialConsiderationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eff0dd75-beac-4fa5-b820-7665050b1720" contextRef="C_8bd7505c-82d1-468a-a930-ab481a0db383" name="krro:FutureMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07a8c67f-8e86-4fba-8465-84e26ac27002" contextRef="C_98b4de31-fa14-4fd9-bd5a-480f77633a40" name="krro:FutureMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment in the event of Progentos closing of an equity financing at or above a specified amount.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. For accounting purposes, Legacy Korro was considered to be acquiring the assets and liabilities of Frequency in the Merger based on the terms of the Merger Agreement and other factors, including: (i) Legacy Korro controlling the majority of outstanding voting shares; (ii) Legacy Korro controlling the Board of Directors; (iii) Legacy Korro&#8217;s executive management team became the management of the combined company; and (iv) the pre-combination assets of Frequency were primarily cash and cash equivalents and other non-operating assets. Accordingly, the Merger was treated as the equivalent of Legacy Korro issuing stock to acquire the net assets of Frequency. As a result of Legacy Korro being treated as the accounting acquirer, Legacy Korro&#8217;s assets and liabilities were recorded at their pre-combination carrying amounts. Frequency&#8217;s assets and liabilities were measured and recognized at their fair values, which approximated their carrying values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Legacy Korro after the consummation of the Merger. As a result, upon consummation the historical financial statements of Legacy Korro became the historical consolidated financial statements of the combined company.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split and Exchange Ratio</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with, and prior to the completion of, the merger, Frequency effected a one-for-fifty reverse stock split of its then outstanding common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding Legacy Korro common stock, convertible preferred stock and options prior to the effective date of the merger have been retroactively adjusted to reflect the merger </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e649222-d194-4969-bd02-75207f73d101" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_Rate" scale="0" decimals="6" format="ixt:num-dot-decimal">0.049688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange Ratio, which reflects the impact of the reverse stock split, for all periods presented.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company expects that its existing cash and cash equivalents as of December 31, 2023 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c5f2685-6d14-48a8-84dc-a63abc71adb8" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">166.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these consolidated financial statements. The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2b9208-8442-429b-afe4-d5eb5b70d588" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">183.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that the revenues or profitability will be sustained on a continuing basis. In addition, the Company&#8217;s preclinical and clinical development activities, manufacturing and commercialization of the Company&#8217;s product candidates, if approved, will require significant additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable rights to its technology and product candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0d51b51-67b4-40a3-bbe9-97b3dc0a8fba" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fca7404-f94e-43ab-a2ca-dcedc1d76f43" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aa78488-50be-40b1-8d2a-fcb5b0924151" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment. The Company operates only in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b2d2111-2aee-40cb-b1e0-2e83bf308ab6" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the fair value of the common stock prior to the effective date of the merger; the fair value of the CVR liability and the incremental borrowing rate for determining lease liabilities and right-of-use assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3164e490-fa78-493e-95c4-bc2ea54a77bc" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, (&#8220;ASC 820&#8221;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_265cbe9d-c50a-4d7b-9b14-90cd71101878" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#8220;Fair Value Measurements&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1193f5d3-c2f7-4209-9999-4a0375f4ca5f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#8220;Other income, net&#8221;. Unrealized gains and losses on available-for-sale securities are included in &#8220;Accumulated other comprehensive loss&#8221; as a component of stockholders&#8217; deficit until realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a7fc957-e326-445a-91b1-9622de312632" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under finance leases, is calculated over the estimated useful lives of the assets using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d026db1a-6648-4d29-85ce-bc77199aed65" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71b70656-ac6b-4b3c-b2e2-996cc121ce24" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 842&#8221;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f117b832-182f-4a47-8d30-3e079af1ab5d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d8d4be4-546f-4799-8f7e-f95c36e81a61" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:PreferredStockPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
         <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity (deficit).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#8217;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.</span></p></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0b19603-fd8f-4a24-bb89-bde4668d93d4" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b304e861-c497-45ac-be7a-aa6136a6cdbd" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IntellectualPropertyExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d914083c-0b90-4c18-a2ce-43d3677d68de" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#8220;ASC 718&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, non-employees and members of the Company&#8217;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and non-employees, the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, due to the absence of an active market for Legacy Korro&#8217;s common stock, Legacy Korro and its Board were required to determine the fair value of Legacy Korro&#8217;s common stock at the time of each grant of a stock-based award. Legacy Korro estimated the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#8220;OPM&#8221;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each valuation methodology includes estimates and assumptions that required the Legacy Korro&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which Legacy Korro sold convertible preferred stock to third parties in arms&#8217; length transactions, the rights and preferences of securities senior to Legacy Korro&#8217;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the grant date fair value of the Company&#8217;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-based payment, (ii) the risk-free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Due to the lack of Company-specific historical and implied volatility data, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures of all stock-based payments when such forfeitures occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aef4e9d2-91ce-4961-a1e9-a6671ab1b3d0" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#8220;Provision for income taxes&#8221; in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c78a6c16-33dc-4fc1-a0d3-670fb4bb80d2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net income attributable to common stockholders and participating preferred shares are allocated to each share as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Net loss attributable to common stockholders is equal to the net loss for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per share is computed using the more dilutive of (a) the two-class method or (b) the treasury stock method and if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Preferred Stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6380407-6a7d-483b-9ad1-b3ba80c3b192" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#8217;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#8217;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_845994c9-5ee0-4065-9bf8-b7949ff61f78" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging growth company status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company qualifies as an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c96c3b1b-893e-489a-a5a9-5227cf26c7b1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-03, and ASU 2022-02 (&#8220;ASU 2016-13&#8221;). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The amendments in this standard should be applied on a modified retrospective basis to all periods presented. The Company adopted ASU 2016-13 on January 1, 2023 using the modified retrospective approach. The adoption of this standard did not have a material effect on the Company&#8217;s financial position, results of operations or disclosures.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8459fcc-2405-42a8-8092-3f466b1042df" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" escape="true" continuedAt="F_b8459fcc-2405-42a8-8092-3f466b1042df_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Yet to be Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b8459fcc-2405-42a8-8092-3f466b1042df_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf25396f-1702-455d-a649-95ee15b3ceb3" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Reverse Merger</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 1, Legacy Korro merged with Frequency on November 3, 2023. The merger was accounted for as a reverse recapitalization with Legacy Korro as the accounting acquirer. The primary pre-combination assets of Frequency were cash and cash equivalents. Under reverse recapitalization accounting, the assets and liabilities of Frequency were recorded at their fair value which approximated book value due to the short-term nature of the accounts. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b221144-9a4c-4e15-b20f-3204b75ab88a" contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the operations of Legacy Korro for accounting purposes, together with a deemed issuance of shares equivalent to the shares held by the former stockholders of Frequency, the legal acquirer, and a recapitalization of the equity of Legacy Korro, the accounting acquirer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the reverse recapitalization, the Company acquired $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_029eb2cd-2dc7-4a1a-a59a-aff6fd4b00fd" contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash and cash equivalents. The Company also obtained prepaids and other assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_149e1e54-24e9-4ec0-be57-d26ca5637424" contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f" name="us-gaap:PrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and assumed accounts payable and accrued expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93b839b3-04e4-4f5e-8e4b-a8f707e81179" contextRef="C_c10f8f23-79a1-42bb-8447-ddc5b11bb910" name="krro:AccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Frequency&#8217;s development programs had ceased prior to the merger and were deemed to be de minimis in value at the transaction date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50d4d91b-3f5a-4a37-92a4-36bcc199cca7" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in share-based compensation expense as a result of the acceleration of vesting of stock options, performance stock units and restricted stock units at the time of merger. This amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe414e5f-5b6c-427e-aee1-54b49bcd13da" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:SeverancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in personnel cost related to the severance payment to Frequency employees and this amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The Company also incurred transaction costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e4d2363-9180-4333-a392-92398135dc18" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:RecapitalizationCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million and this amount is recorded in additional paid-in capital in the accompanying consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit) for the year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_916e07c6-1fdc-499c-8838-78f8658a5360" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include commercial paper and government securities that are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e7cf111-46ed-4e0d-bfe0-9ea8fda577dc" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8923679-8b22-4682-8b79-6e9598f81118" contextRef="C_72eb9539-da9d-42ea-ade5-45879867b4dd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dea35144-52da-45a4-8185-e2b3f98a0649" contextRef="C_8eca1fa2-2518-420d-8403-4912df0dca2b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa0f26e8-84ab-46d0-bac7-54323876e807" contextRef="C_ae566dce-3b97-4369-8930-694f01849c54" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d996d4-d499-4e41-bb49-afa50d0ba7b2" contextRef="C_a7d015c4-04ba-473c-982c-ee84943ae574" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MS APA asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65f16c9f-1683-48df-9c86-abf2084575b0" contextRef="C_002cf6f3-a14a-42d9-8339-4c9a7464ddc4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ed9312-2fc5-4b6f-9e2c-7ceca1007ea9" contextRef="C_ce4b9b25-ec19-4975-80b3-be6c42826a43" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c837db7d-f174-413f-bca1-5947d2e925b6" contextRef="C_c288594a-72d1-4f6b-8b50-f8d38cf9d937" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_305385fe-f851-49aa-95e8-d6078a9f04af" contextRef="C_745aa97d-b654-4fe3-a288-63cea2f6c854" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da475345-1203-47ee-b65f-c49494acb3fd" contextRef="C_2d3840a1-75bb-41e9-bdf6-5978eb8662d0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ebf8ebb-fdc5-42c0-a9b5-222bb68b428d" contextRef="C_d6c273ee-ecf6-4069-ae3d-4c61b89c6153" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9a6b0a4-7550-4f39-a020-27c81ff3ac0d" contextRef="C_aa7dd013-7306-42b5-8ed5-d73bf12a2654" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aebf3eeb-34ee-49fd-8e89-d25426f7da06" contextRef="C_7af3db31-6c33-4c0d-98ce-e0c17f536ee6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.621%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:9.936%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:9.936%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:9.936%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:9.936%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64554640-48f5-4147-82ba-6af6b76e7d12" contextRef="C_7797a79c-4109-4291-85d7-9f1f44b8f9ab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,904</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b75aea-1aab-4c29-873f-6dd88d828970" contextRef="C_3d16b2e0-26d9-46e2-9676-3b3691cb6871" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,904</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f7a4146-07bc-4c9d-910a-77a69f84cbaf" contextRef="C_d3e74070-621c-4737-963d-07ce423a28f8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06af4979-8dc1-41f6-a8b3-0d17ae87c45c" contextRef="C_46cc1979-5c24-47f7-bf95-9aa5c051807b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276fbe2c-bdf2-4ce6-a91e-4a15ed55db89" contextRef="C_d2ac73cf-1c8b-4a06-aca0-5f30e10f6acc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34db245d-4247-4cdf-bc8e-a139fb5a8793" contextRef="C_efa34611-a425-44a2-86e5-16976c9be1dc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4593215-3831-4413-a4ba-101a7fba20ca" contextRef="C_68f1cdf4-0429-4263-8211-79aaef7f7fd4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04114192-4a5e-4a99-ab19-190f788c0de1" contextRef="C_1497c1b1-c02c-4386-9a0b-01290e5e3553" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39024415-d7a9-4dd2-a053-b49a8634c0c8" contextRef="C_e12df146-e11d-4351-90cd-40afa0abdd05" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e65e95bc-4a34-4243-a412-33ef02931b62" contextRef="C_28de2dc3-2ca9-4bb6-8723-f572b9234796" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d15abc08-bec6-4b92-b641-b275c1afadf2" contextRef="C_bc4d7e4b-8b44-4d70-bfd8-4175df616bb0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5838003b-2327-486f-8f93-6457f60acc5b" contextRef="C_ae8c2fd3-de68-4508-b076-43b5d6c93aad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70d856a7-90d1-4b9a-ba10-6dbfcd837180" contextRef="C_73266731-93a7-48aa-8ed8-61bc2b4c90d7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,819</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dcc5709-6650-486a-a060-7adf6b0cb78d" contextRef="C_22794dbf-a4f9-4f21-8513-02ae3c6a8843" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,904</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc42bcde-f675-4871-a352-73dabab28554" contextRef="C_bbbfcc39-8343-47e0-a50c-2b474af31554" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d00b215c-b501-47c5-bb39-4c085e5de828" contextRef="C_f821a1fb-8b0a-44e8-b18a-e92e693bb9d0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted previously in Note 1, at the effective time of the Transaction, the Company entered into the CVR Agreement providing for the payment of certain contingent cash payments equal to the net amount of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to the Company&#8217;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the CVR is a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5a1b49f3-7a54-4e43-9407-97170c711b48;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derivative liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is accounted for at fair value, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aef2565-5874-4831-a5fc-081e9726c44e" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2815e8e-9e70-42ce-84a5-9392c1046c2c" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in accrued expenses and other current liabilities and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f0fcccd-3604-4a2a-a1b0-1eec36726223" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other non-current liabilities in the consolidated balance sheet. Concurrently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into the MS APA with Progentos, whereby Progentos acquired the rights, title and interest in certain assets related to the Company&#8217;s MS program. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MS APA included initial consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89cf140d-4dce-42e9-b9b0-5d7e9ffa04cb" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="krro:InitialConsiderationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b415ffd-4a9d-4763-bbde-419515c93f6d" contextRef="C_8bd7505c-82d1-468a-a930-ab481a0db383" name="krro:FutureMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb2bf865-eab2-43ca-aac3-76b73d429abe" contextRef="C_98b4de31-fa14-4fd9-bd5a-480f77633a40" name="krro:FutureMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment in the event of Progentos closing of an equity financing at or above a specified amount.  The Company concluded that the MS APA is a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c39e9862-e9fa-4ff5-9da0-641cc2ce94c0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derivative asset</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is accounted for at fair value, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3ff4cf0-8e50-48cd-92c3-2e7c82284e36" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:DerivativeAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb62d813-1a3b-444a-84bf-7a0c3f03ea70" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in prepaid and other current assets and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372d591a-bed5-4bd2-9874-42e7a6e05d84" contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other long-term assets in the consolidated balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the CVR liability and the MS APA are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR liability and the MS APA asset, the Company used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of significant judgment, estimates and assumptions, including the probability of technical and regulatory success, and discount rates. For the year ended December 31, 2023, the aggregate change in fair value of the CVR liability and MS APA asset was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_879f9104-5d0c-4182-9f14-dd5f18ed2c75" contextRef="C_096221e9-4b77-4f75-a7ca-adeffcec02e8" name="krro:ChangeInFairValueOfPreferredStockTrancheLiability" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.08</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no liabilities measured at fair value on a recurring basis as of December 31, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in valuation techniques, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d2006d2-2521-4c89-a888-650a3fee14fe" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dec654db-a54d-421d-a406-46ff99881669" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r were there any transfers among the fair value hierarchy levels during the years ended December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8ef9364-f1c6-4a4f-9e77-6f5471894221" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:InvestmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did not have investments as of December 31, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_312bfc85-8a3c-4543-87a2-ef642ce1891f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:InvestmentTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments as of December 31, 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0b1e1f0-f327-4e31-9c35-1b0372ac3fe1" contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6428b37-f693-4037-bddc-1eea2f18ac25" contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7261f1f-9c78-4142-9829-5e7acb16f639" contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dfd7116-38a1-40c9-b2bd-8059370d593c" contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ca680d8-6cc5-4cd0-8940-651a27972df0" contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c2c1546-615e-450d-af58-6b8a95bb43ee" contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdee9745-473d-439d-9adf-1085127dd53a" contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e9ff4db-ad4e-40e2-843a-3304b465e832" contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b47a0cf2-671a-44ad-965a-8c74fb2eb32a" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,920</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f45805b6-3981-49b5-92d1-0229b3344c6c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e924fb-2aba-4aa1-be94-e1f5efd34a50" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d7e627-dc7c-482c-b6f1-046eaaa2016c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6758845b-0e55-4409-a32c-d4b201931c72" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2022, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b4b40b8-5f70-4d33-8477-307751185fa2" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> securities that were in an unrealized loss position for more than twelve months. As of December 31, 2022, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41092256-ca22-4d71-a378-a7ccf2cfc253" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company maintained current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56e13fb5-33dd-4005-991d-ab878d95e8f8" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and non-current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c357400-17e0-4394-aa7e-a258637d2849" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of De</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cember 31, 2022, the Company maintained current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_353ab1a5-9c4d-47a8-9d7b-5d23dd1cb424" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and non-current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_348aaaac-9986-4e96-bb23-b354911780bf" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company&#8217;s facility leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9fb56b4-5a15-4b84-b461-b0e33ddcbea5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December 31, 2023 and 2022 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_177811ee-6134-4941-94b4-e045ca1e1359" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48699b83-a3ae-4a33-b2a1-cb155a871321" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa7b2b7b-430e-4495-abc8-71e9f8162a99" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e6bdd6-abdb-4b13-a67b-f3b1d01518fa" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c74329b3-bbee-451d-b500-080c9a48d897" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a30cdb28-828c-4516-bc17-017c9944be1d" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fe9155a-990d-41c5-88da-0b16f22e901e" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e18d8e93-f8dd-47e6-bf21-e1fe24b8d717" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, as of December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.6%;"/>
        <td style="width:1.52%;"/>
        <td style="width:36.04%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:11.9%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:11.9%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_979da3b5-4d87-4a12-a2be-164f380aa155" contextRef="C_5a9015d7-d3e2-497e-ae73-4ee485589e02" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><ix:nonNumeric id="F_4354be5d-b53d-47f3-8b1c-8be16c6a9264" contextRef="C_072ef9d5-51f5-493b-a877-923f3cd50ab2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b4d6a89-e2db-4cdd-86fe-d56e173d008f" contextRef="C_5a9015d7-d3e2-497e-ae73-4ee485589e02" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_747811b7-90db-441e-98b2-205724ccfd3c" contextRef="C_072ef9d5-51f5-493b-a877-923f3cd50ab2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9f2a7523-4f3c-49ad-93cc-5c430f01e129" contextRef="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><ix:nonNumeric id="F_f9ac0491-9ebe-429d-bb33-1609edc2f63e" contextRef="C_a982d847-1fa7-4a2f-a886-60eca2f91051" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52ec93e-cd2a-4060-b51b-0fd6799f5404" contextRef="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_798d9d9e-7efd-488d-8033-fc0c932e67e7" contextRef="C_a982d847-1fa7-4a2f-a886-60eca2f91051" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_57166e94-c121-40e5-b00e-eb22ab2e2d7f" contextRef="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><ix:nonNumeric id="F_d6fe2aab-d19c-4c4b-ad3c-af65efd42354" contextRef="C_186c69fe-8d24-44a5-865b-ef7a19de3a07" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e599f11-ecb9-45ac-8d62-78903a63c484" contextRef="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a45126d0-93e8-42cc-94b8-286da0a530d8" contextRef="C_186c69fe-8d24-44a5-865b-ef7a19de3a07" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2fcc4375-f07d-4f52-aa34-cf00a9e1b3e8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PropertyPlantAndEquipmentDispositions"><ix:nonNumeric id="F_ca98cf62-5092-4171-8e33-8a0904e7e7c8" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:PropertyPlantAndEquipmentDispositions"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_566359b4-0b59-4e7c-8cb6-705fe2d61ebd" contextRef="C_588ba34c-1cc3-4361-8113-4bfbca87310e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd1837f-2902-411f-86d2-92f7df2191e1" contextRef="C_c2a2b4a4-d405-4a52-87f7-0d7d1dabb2c0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c2204bc-323c-4847-8e75-82f995b1b62a" contextRef="C_86de2748-fce4-4bbf-9e70-716575029823" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,242</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff323ffa-31fa-407f-9806-572db5446091" contextRef="C_11d68bec-be21-47b3-aed2-e43151eea3b8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,049</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f0efeab-b67b-4499-9fe4-a7e0bbe55bfa" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,507</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2414fd7-359c-492b-bab8-b08f407c689e" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,121</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0008ce3b-1399-47f8-baff-64d3812dd0c2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,842</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab44e922-e8a4-45c8-98b8-cb76937e7d4c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,255</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dc8a3c6-4722-47cf-9f2d-d9e0b1ba8ccf" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,665</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc186522-8cc4-457c-b297-bf20f5f61f1f" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,866</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had construction in progress of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d459d97-4a8f-4607-9720-d97c12248cd4" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ConstructionInProgressGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61adab69-ea85-4758-98a4-6676fcb01c3e" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:ConstructionInProgressGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, predominately related to laboratory equipment received but not yet installed and capitalizable costs related to the Company&#8217;s future corporate headquarters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_260e5692-4a7a-43cc-b524-0af76746f3dd" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17434b00-03cf-4486-b2ab-80bdfddecad5" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1bf9641-8b5e-4e85-b791-60c00667915d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aede3f16-5518-49a4-837d-6e204838593a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59e03674-b317-407f-b2dd-5b22ff8b0148" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,896</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6affe0b-9ec3-4bb9-9eb8-5a7b1b6bbaab" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31ca596a-e186-4155-a8a9-85ce7170e187" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="krro:AccruedExternalResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,255</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2610ae7d-0754-45f4-a952-dcf740f35759" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="krro:AccruedExternalResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b41f676-fb55-4f00-9a59-cc85c62492d5" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e99a68c-a89c-4f4d-beab-8f63ded63143" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_204aa1dc-f388-46be-9c69-e097bf4f9794" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="krro:CvrLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9aabb1b-937e-46e5-a9fb-076a60c2c240" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="krro:CvrLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a389544-a917-4f44-834b-aa8ab2cbbad3" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d5d26dd-fc96-4ed5-bf16-bf74f674ec60" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1735acc-92e5-4079-836d-3d28d8ac6277" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9a076c9-9afb-4356-bd2c-76e6a3c36e6f" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,175</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e94ff6f9-9dfe-40cf-ad4c-6470cac37b67" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the closing of the merger, the shares of Legacy Korro common stock were converted into shares of the Company's common stock based on the exchange ratio determined in the Merger Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company was authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f9786aa-09af-4d68-a9ba-998fb2b013f0" contextRef="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_389eb49c-2f2e-4024-ac24-22a6ed78d9bc" contextRef="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per value per share. Prior to the merger, the holders of Legacy Korro&#8217;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth in Note 10. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5eb450c-fc7d-4d74-976e-048fbead3140" contextRef="C_65a239e0-5ccd-49da-844a-2f067baf9930" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends had been declared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16dc94e0-ae76-4b8f-ae3a-a8adba747696" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfConversionsOfStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had reserved for future issuance the following number of shares of common stock:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_473583bc-606c-4cae-b731-d1cc8c0311d9" contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7dfaad4-8615-45b1-b95a-2aa55886117c" contextRef="C_7fb87aaa-7763-4db0-b2e3-0eae4ddb9138" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332bbc9f-8506-4e5e-af0f-f1ce7682696c" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34be4bad-1d50-4498-bc1b-7acded2250d8" contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3ed88b2-7719-48b6-ba08-2667de33aca3" contextRef="C_4e61d9b0-a7a2-4826-b526-6cf674a82d27" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ad56269-b602-4aa9-9e67-506765503202" contextRef="C_a831aa61-46f2-4591-9e51-98d9e0781061" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1077992-ad0f-49fe-b144-b7886b8c5548" contextRef="C_9e149e85-1d4b-4712-863c-cb986c6595d9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5c2b95c-8481-4628-b4a0-de0b2e066d25" contextRef="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances of Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9eea60-6365-4704-bcb6-71ae6cf08fca" contextRef="C_9e149e85-1d4b-4712-863c-cb986c6595d9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb55e104-a855-44a2-be47-513cc9dabf8f" contextRef="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">813,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7f830f3-7ab7-4404-81a4-276c166b5357" contextRef="C_093060bb-522a-4d5c-aa04-574677a7cb5b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f87b546f-e5b4-44cb-bf0f-7f20d600abc9" contextRef="C_bf439977-ea99-4550-a754-3c1783080c28" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6315f4c4-7d70-46c9-866a-0442415ab448" contextRef="C_9f3a1082-a9d3-4417-a0f7-4d1bdd1bcaa3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,323,151</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45f394e0-8c80-4c81-b1e8-15f35a37b3d8" contextRef="C_0eebafc0-fac7-4906-a525-f415a4144d4a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">461,128</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of outstanding warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21fd93c0-1d6d-4bfa-bc8d-ec37c32d89ea" contextRef="C_21957e3e-4ce5-42c3-b40c-20cefc6c2eeb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,049</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb276287-4f1e-4c16-bba2-b60aff87fa0f" contextRef="C_ecd8a380-935d-40bc-8d1e-6ed89fa53199" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,049</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cc3ba99-57be-4c8c-ac76-34a26ba5a3dc" contextRef="C_45db7593-eb9b-4883-9384-b026cd2ff9bc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45c2899-9032-4e00-b21b-bc0b4e23de36" contextRef="C_52ef87ed-863c-43f2-b64f-793064742302" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">159,890</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa892fdc-e86e-4da9-9f1a-d4846677958a" contextRef="C_bec03e77-9bf0-4f52-9023-3b2c608d690f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">255,694</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47b2f2c0-cacc-45e9-9788-81d992424060" contextRef="C_2ab0d269-b1a0-4ec5-8ce7-bb7b469c3284" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 ESPP Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89b7fc3a-2488-48c2-8bac-73ea2a5ee267" contextRef="C_4ffd1385-3f0e-45b7-929e-195ba02c78b1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">88,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c713a6f-aa1e-4374-b50e-107c88b8e842" contextRef="C_dcc2b54b-9a21-4b66-92b5-e1bcfac05a39" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3da48fc-37b6-49b2-9c72-8bf48c3e05fe" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,675,396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76a9cd78-f143-4a1d-8119-74e580ca9dd2" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,487,208</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_4fb13c04-529c-43dc-b0f1-4facc382e71d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c954a977-07fd-4543-8907-3e2cc92e7ceb" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c285651-5b6c-476d-948d-efebeb4b806e" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f12286ee-ec30-4048-93a7-1d20a64331b6" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_54dec796-9527-4e2a-960c-c77d094cbaa3" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock shares issued or outstanding.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, immediately prior to closing of the Merger, each share of Legacy Korro's Preferred Stock issued and outstanding immediately prior to the Closing of the Merger was converted into shares of the Legacy Korro&#8217;s common stock, and then exchanged in the Merger for shares of the Company's common stock using an exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23e407f8-2811-43f3-be79-c209fdcbe2f3" contextRef="C_7042021a-f5f1-4b64-8355-bd3286bb3502" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_Rate" scale="0" decimals="6" format="ixt:num-dot-decimal">0.049688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The conversion was approved by greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4699e12-846f-4eb6-9b2b-ff8c4f354426" contextRef="C_7042021a-f5f1-4b64-8355-bd3286bb3502" name="krro:PercentageOfOutstandingSharesOfPreferredStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the then-outstanding shares of Preferred Stock, voting as a single class on an as-converted to common stock basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, Legacy Korro was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ac83cfe-5224-4e68-b705-7b15c668c544" contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_001e9ab2-57d9-4917-8633-b021c9d5a96f" contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39be8a19-8156-44f7-813a-a97ea1aa6dc1" contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6a5836dd-ad29-437e-9c27-325580a63d90" contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock shares issued or outstanding. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef7efbae-8103-4ff3-b293-b0008465c7a0" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfPreferredUnitsTextBlock" escape="true" continuedAt="F_ef7efbae-8103-4ff3-b293-b0008465c7a0_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, Legacy Korro Preferred Stock authorized, issued and outstanding consisted of the following (in thousands, except share amounts):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ef7efbae-8103-4ff3-b293-b0008465c7a0_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.44%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.040000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.7%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred <br/>Stock <br/>Authorized</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred<br/>Stock Issued<br/>and<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liquidation<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce450d72-a76a-476e-988a-b2b57968f005" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435d89f6-053d-452f-81a3-e8819ed86843" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b87dcef3-47c8-4929-8ea7-6464990fc134" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b11c60b8-4a03-440d-ba34-d6cd2d9610d5" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13f7227d-b25d-4a1b-8e29-d0ee739664bf" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba05d62-1375-405f-a61a-21c5ab3e6b85" contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b" name="krro:CommonStockIssuableUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95de4ae7-b6c6-4195-a94c-ffc86a7e9527" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9b9d1d1-c976-4eba-b214-7ea0df9678fd" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d14fc963-9ca5-4ebf-97a7-0bb1a4ef355d" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a229a24-2883-4fd3-b3cf-1250c9d7af38" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40465eb-d3ec-485d-a10b-c74373b33720" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e193e590-5149-4a57-9c49-4949f7c3d099" contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158" name="krro:CommonStockIssuableUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_789b7016-7449-413c-ac68-0125aed2bc0f" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63f9550e-3fa7-4df9-85a5-161a47b274fb" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1eac5b2d-c5e6-4b57-9605-e3d7593f6798" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a782b599-dbaf-4f80-b68e-4ff69264c4dc" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa3998a4-629f-4aa7-b756-29139ad5238b" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d32d2149-5f7d-45e1-8fe4-f76fd00c9a3f" contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6" name="krro:CommonStockIssuableUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17c73938-6262-4cc2-bf7c-57028551728d" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,036,656</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec522c68-c995-4a03-9485-0e88285f3a2a" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4a4ff436-cb55-4028-ae4f-5567b9c17996" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f09e7ba5-d05a-479d-9417-7e53f20cfee7" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ac82e47-f6e1-4248-8369-a109423ac3f1" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4452af99-3b5e-446a-ad52-49afed3fc342" contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82" name="krro:CommonStockIssuableUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c1d9967-8e45-46bd-84a3-c189ed780dc8" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,855,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15a727b7-8ab8-4525-87e8-f08cc1fd3ecc" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a9d7d1e5-70bf-41d0-af8e-cb11b4f12db4" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,042,000</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1569972b-17fe-4341-a470-0594b3552f65" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,863</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1d96648-a919-47cb-8e07-54583ebfe1a0" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c626a0f-ac48-4bd2-9a12-13c8f3aa60a9" contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9" name="krro:CommonStockIssuableUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,042,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights, Preferences and Privileges of Legacy Korro Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock as of December 31, 2022 had the following rights and preferences. In the discussion below, the Legacy Korro Series Seed Preferred Stock and the Legacy Korro Series A Preferred Stock, the Legacy Korro Series B-1 Preferred Stock and the Legacy Korro Series B-2 Preferred Stock are collectively referred to as the &#8220; Legacy Korro Preferred Stock&#8221; unless specifically noted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Legacy Korro Preferred Stock were convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the original issuance price by the conversion price in effect at the time of conversion. The original conversion price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cc02e0c-85a1-45c4-8b0b-a8e605b1cf7f" contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series Seed 3 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_604a26a9-7228-40a3-96eb-d4d9c7048c97" contextRef="C_3eb2b595-9ba7-481a-b2e8-779deb094693" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series A Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1b6c629-bbb5-4bdc-bcc1-d93be1880cb9" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.08</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series B-1 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2535aea8-1c69-471c-90f6-11fd37adbb6a" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">52.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the original conversion price of the Legacy Korro Series B-2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f485ad84-25b6-4072-9787-2a39b3d0632d" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">55.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Legacy Korro preferred stock are subject to adjustments to reflect the issuance of common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warrants, or other rights to subscribe for or to purchase common stock for a consideration per share, less than the conversion price then in effect and subsequent stock dividends, stock splits, combinations, or recapitalizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock was subject to mandatory conversion upon the closing of a sale of common stock to the public at a price of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c3db24d-4f33-4d04-ac15-eb4162159680" contextRef="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">111.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination or other similar recapitalization) in a firm-commitment underwritten public offering resulting in at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3d5e3c6-61d3-42e8-a2f5-5121c4e10e39" contextRef="C_f825e298-5e6d-4e4a-ab77-5640165e55ed" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of gross proceeds to Legacy Korro. The Legacy Korro Preferred Stock was also subject to mandatory conversion upon the vote or written consent of the holders of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_514abdca-7345-4655-9381-19f97d6a08d5" contextRef="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7" name="krro:PercentageOfOutstandingSharesOfPreferredStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the then-outstanding shares of Legacy Korro Preferred Stock, voting as a single class on an as-converted to common stock basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Legacy Korro Preferred Stock, in preference to common stockholders, were entitled to receive, when, as and if declared by the Company&#8217;s Board of Directors, dividends at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73fbcf99-7a6c-485d-a4eb-7e97ad2bccf0" contextRef="C_9eb4912e-e6b4-4f6f-b944-30b2ae5249b1" name="us-gaap:PreferredStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% annually. Dividends on Legacy Korro Preferred Stock were non-cumulative and were payable only when and if declared by Legacy Korro&#8217;s Board of Directors. The holders of Legacy Korro Preferred Stock were entitled to participate in dividends on common stock on an as-converted basis when and if declared by Legacy Korro's Board of Directors. Since Legacy Korro&#8217;s inception, no dividends have been declared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation Preference</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the holders of shares of Legacy Korro Preferred Stock then outstanding were entitled to be paid out of the assets of Legacy Korro available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount equal to the original issue price per share plus any dividends declared but unpaid thereon. For clarity, the original issue price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60020eae-4ff4-4b5f-8a92-754ab2f85caa" contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series Seed 3 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4997bb2b-0f62-4c48-92ac-3d914bd5f014" contextRef="C_3eb2b595-9ba7-481a-b2e8-779deb094693" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series A Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35219748-f338-47d1-a399-040f53b5acc0" contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.08</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series B-1 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc0e49c6-5742-4844-bdf2-0c50141c79fc" contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">52.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the original issue price of the Legacy Korro Series B-2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbf389d2-bb75-4439-ae56-554d6a649c53" contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">55.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If upon any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the assets of Legacy Korro available for distribution were insufficient to pay the holders of Legacy Korro Preferred Stock the full amount to which they were entitled, the holders of shares of Legacy Korro Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redemption</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock was contingently redeemable upon the occurrence of a deemed liquidation event, which included a merger or a sale of substantially all of the assets of Legacy Korro. As of December 31, 2022, a deemed liquidation event was not considered to be probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Legacy Korro Preferred Stock were entitled to vote based on the number of common shares that their preferred shares converted into on as-converted basis at the time of such vote. Except in specific circumstances, holders of Legacy Korro Preferred Stock shall vote as a single class with the common stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of record of the shares of the Legacy Korro Series Seed Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to Legacy Korro&#8217;s Board of Directors. The holders of record of the shares of the Legacy Korro Series A Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#8217;s Board of Directors. The holders of record of the shares of the Legacy Korro Series B Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#8217;s Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dad9ab24-c175-4d70-a478-c7008196365d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Stock Option and Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2023, the Company&#8217;s board of directors adopted the Company&#8217;s 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan was approved by the Company&#8217;s stockholders in November 2023 and became effective in November 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">connection with completion of the Merger. The 2023 Plan initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f2113e8-314d-4600-a461-58dceeaeded0" contextRef="C_e46527cb-cdd6-49b6-ae87-4f92d5ccf0b0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">885,028</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for the issuance of stock awards. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a9da549-07e8-4168-ae7a-19caa6774c9f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the number of shares of common stock available for issuance under the 2023 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2023 Plan, beginning with January 1, 2024 and ending with January 1, 2033, by the amount equal to 5% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Awards granted under the 2023 Plan expire no later than ten years from the date of grant. For stock options, the option price shall generally not be less than 100% of the fair market value on the day of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were in aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_224b04c3-3157-44a8-9292-df76da7258bf" contextRef="C_883bc534-e8f6-4895-bf52-bf10d4e2a415" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">889,922</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eb16bc0-4fc5-4461-bb06-3727272febd9" contextRef="C_883bc534-e8f6-4895-bf52-bf10d4e2a415" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">255,694</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available to grant under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Legacy Korro's Board of Directors adopted the 2019 Stock Incentive Plan (as amended from time to time, the &#8220;Legacy Korro Plan&#8221;). The Legacy Korro Plan provides for the grant of stock options, stock awards and restricted stock units to employees, members of the Company&#8217;s Board of Directors and non-employee consultants and advisors. The Legacy Korro Plan initially provided for the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b25d2ba0-f2a0-484a-b46f-10e3d0190103" contextRef="C_45db7593-eb9b-4883-9384-b026cd2ff9bc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">110,285</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The Legacy Korro Plan was subsequently amended in May 2019, June 2020, October 2020, April 2021, November 2021 and March 2023 to modify the number of shares of common stock issuable under the Legacy Korro Plan. Subsequent to the March 2023 amendment to the Legacy Korro Plan, Legacy Korro could issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33884be3-99bb-43d8-8c09-eeab7f2f8a61" contextRef="C_b267ce26-7f99-4922-a593-840ac7ce4bac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">747,752</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the Legacy Korro Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the merger, each option to purchase shares of Legacy Korro common stock that was outstanding and unexercised under the Legacy Korro Plan immediately prior to the Effective Time, whether or not vested, was converted into an option to purchase shares of the Company&#8217;s common stock and became eligible to be registered on Form S-8. The Company assumed each outstanding option to purchase shares of Legacy Korro common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of the Legacy Korro Plan and the terms of the stock option agreement by which such option to purchase shares of Legacy Korro common stock is evidenced. The number of shares under the Legacy Korro Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of common stock reserved for issuance pursuant to outstanding awards under the Legacy Korro Plan as of December 31, 2023 and 2022 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42bdd783-ae49-4a1c-9a98-4adb2f4a9312" contextRef="C_7c761095-cfe8-42cc-a37e-889e388af4b1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">600,977</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e77e8160-4ab6-472e-adc9-500eecf2eb83" contextRef="C_fac002bd-d841-4cb9-87ff-6726c92a87a9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">683,156</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. The number of shares available for grant under the Legacy Korro Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03d2dc5b-644c-4497-85f8-bd86b5417646" contextRef="C_f43b4902-d2c6-4c47-bc7b-f3057b2dc2af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6212e06-0947-4f6d-ac21-45f19bea7ec4" contextRef="C_ba47ceb2-3907-4c75-93da-352aebf2bc11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">159,890</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2023 and 2022, respectively. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the Legacy Korro Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2014 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 13, 2014, Frequency adopted the 2014 Stock Incentive Plan (as amended from time to time,the "2014 Plan"). All of Frequency&#8217;s employees, officers, directors, and consultants were eligible to be granted options to purchase common shares, restricted stock units and restricted stock under the terms of the 2014 Pla</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n. Frequency, reserved an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04eaf671-d9d4-4f23-a5f2-f1f97a732f12" contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">424,853</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for issuance under the 2014 Plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d615fcf8-3911-4592-9962-ad92d4e895bb" contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock available for future grants under the 2014 Plan and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9d95ba-29f7-40a8-9e7b-df0e2519989e" contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">36,455</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to outstanding option awards under the 2014 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Incentive Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 17, 2019, Frequency&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (the "2019 Plan"). Under the 2019 Plan, Frequency may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12cf8631-5426-4741-9ab8-c2265f5aa64e" contextRef="C_0fcf0a27-21b0-415b-8c89-231bbee07b61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">154,032</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2019 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the 2019 Plan.  Accordingly, as of December 31, 2023, there were no shares of common stock available for future grants under the 2019 Plan and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76f5c15e-553b-4b6f-a8a4-825d1ef5cde6" contextRef="C_abf5d9da-538d-418d-b41f-9269c757a637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">51,491</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to outstanding option awards under the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the IRC. Incentive stock options may not be granted at less than the fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">value of the Company&#8217;s common stock on the date of grant. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5fe850e-1270-4481-9615-6983726e227c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are determined by the Board of Directors. Stock options generally become exercisable as they vest. Options granted under the Legacy Korro Plan, 2014 Plan and the 2019 Plan expire no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28416616-771e-4781-9539-2026f993e1ea" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ef1ef88-cbc2-4f54-ab00-77643d3b331b" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_943c0d76-2c3e-4260-9732-f7d9070e8618" contextRef="C_5aa971ad-c939-4c21-a327-57534a1ce091" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bca714ca-d00a-4e4e-bb84-3391d5416a19" contextRef="C_4331d39a-acce-4178-b456-7b04be2b6063" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7284427e-f701-448a-964c-93c4df4c8eec" contextRef="C_dbd86c0c-db69-4c76-b0b5-17ba9213ddff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b6e5c0b-d3e6-46b7-8cf3-aa436a807f85" contextRef="C_ab8f59ed-af83-49c1-80a2-d1a10ec53e1d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2578dffe-fb62-4f38-a8b5-1bd00877bf4d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61211b65-aac4-4138-8a22-552578f16dce" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,140</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Common Stock Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the adoption of the 2019 Plan, Legacy Korro issued shares of restricted common stock to its founders as well as to certain employees. The restrictions on the common stock generally lapse over two to four years. In the event that a recipient ceases to provide service to Legacy Korro, Legacy Korro has the right to repurchase any unvested shares of restricted common stock at their original purchase price. As a result of this repurchase right, Legacy Korro recorded the issuance of such restricted common stock as a liability in the consolidated balance sheets. Amounts are reclassified to common stock at par and additional paid-in capital as the restricted common stock vests and restrictions lapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd139dbd-b6dd-43e1-bba1-b77cd1bd274f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes Legacy Korro restricted common stock activity during the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2225cc16-6b86-4d7c-884a-92f5a770e61c" contextRef="C_7c6858e2-8133-456c-a5ca-5b7016177e3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbb64bc2-6bb9-474f-91e2-d06a8754a072" contextRef="C_7c6858e2-8133-456c-a5ca-5b7016177e3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f77660c-9c0f-44c7-8ac7-13f00784125f" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fc7a818-9e17-4eb0-8232-d20107715211" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16cf03c9-756c-4322-becb-5923b0ed70bc" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33faad5b-380b-470f-91be-bdc37c60a60a" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_518b3b93-803a-477d-b99c-eb200cea3c1b" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eefb9d27-b3fa-4987-9593-ac98c9947f81" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7cd552-b403-4066-ba8d-d651a8729e5c" contextRef="C_6f7339a6-1078-443f-9a49-06210ba9d73d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5e7c24c-d5d6-473a-9bfa-f5c953826f39" contextRef="C_6f7339a6-1078-443f-9a49-06210ba9d73d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate fair value of Legacy Korro restricted common stock that vested during the years ended December 31, 2023 and 2022, based upon the fair value of the underlying restricted common stock on the day of vesting, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ed4b263-2d75-497d-ac6b-a1db3636ab12" contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a236fd35-2da6-4ebd-8a77-1e61844c2678" contextRef="C_9a2b3b81-fe26-47a3-b213-a4e83175b18c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5ff5b72-42f0-4f33-8bbf-80a53448f1f2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended December 31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.231%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:19.104000000000003%;"/>
        <td style="width:1%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:19.104000000000003%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50f53b42-6b9b-4159-8f99-628c848adf0c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d2c2287-6d35-4bbb-8b55-90e4e3205d1c" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9854f968-31fc-4155-a0bb-1b000fe7edc5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dd38928-999c-4754-921b-b649155b9499" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_036cf9bc-a70f-4c9e-9ad2-c00305edc46a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f5cc2e85-a70b-4262-9f69-62b4b9032cd3" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_988919e5-b07f-471e-8ed5-4792d5afd653" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34cb1df3-f8e4-4f4a-a203-0a5fc9b50fa8" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dd27c4e-2ea8-41b8-941e-4e926435d006" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eabfe6f-e281-4246-99d0-499f52ddd85f" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb503998-7051-4b45-8c0f-9ad37c712723" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes changes in stock option activity during the year ended December 31, 2023 (in thousands, except per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.26%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.48%;"/>
        <td style="width:1%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:10.940000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.48%;"/>
        <td style="width:1%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:11%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02f8ebc3-bb95-4a2a-a9f5-25dfa1e23513" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">461,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b01213ae-bf89-4684-9c89-88c5f18e0b95" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_118bb1ea-2323-4874-999d-51509b6f50a2" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_534dfb9e-db05-40a6-8619-3fe08b9f3fb9" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,953</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in reverse recapitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a427aef-b716-4e80-8602-9095004b4a4c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:ReverseRecapitalization" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,153</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78c077f5-c94b-42c1-9c6c-26073cc5ccbe" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:WeightedAverageExercisePriceReverseRecapitalization" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">121.91</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d2eb555-190a-48b5-90d4-5417dcb01bd6" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">835,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55612b0a-3ff8-45c3-a94c-67822dc4ed45" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a288e0c3-a5e4-4d64-aca7-f51420291c18" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef487d70-9aa1-47e5-96cc-7b2646220169" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33ec6bd4-b385-4ca8-bb2a-8969c8dce164" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0496fcf5-5208-45ff-93f4-8b77996657d5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5e6e0b1-91b4-4dab-b3cf-2ef0943cb217" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,455</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7489bdb9-f8b7-4798-b9ea-982719575fcc" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:WeightedAverageExercisePriceCancelled" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d0998e6-d4a0-4a94-a992-b4de09dbcae2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,323,151</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d31c149d-0699-40fd-adce-d8f92cdac470" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8bab1acf-09fc-42c2-9f09-79711c912a73" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d648d31-0356-4a56-8d24-d9c70a2a0d37" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58bf96c-a40a-40f9-84a0-8e097dcc22fd" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">368,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b6abab4-9b10-4f7b-ad69-57f0f427119d" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a0b44212-569e-453a-ae60-9cb1642b4ab9" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90d265cc-8549-44aa-af01-4cff0be107a2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45dd7527-e8d6-4d43-9fe2-21406542673d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b17ca62a-e5a2-44db-a528-e8e6b8197e20" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57cb11c2-1779-4363-92be-64993694df72" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_389ac3bf-d91f-4b2b-bdaf-ab6ce82d64c1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84cf7904-4d58-41f3-a6cb-d9a13f641845" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12d52701-5147-45ca-88a7-71ad7cc4de4a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes for the years ended December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f5a3739-5b0a-4ec7-8348-712e0d9cea49" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f00fb8da-ba04-43fc-8ef9-d9d827bb37bb" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0295dce7-cd7f-4ffa-b127-1b4824bfd6c8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cb3889e-2563-428c-92a1-1d061730c96e" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67594fa4-44e1-4f72-ad01-f8bf4b098269" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_111334e7-8bdb-4da8-b9c8-b97e9404efae" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d0f2b5a-1b0b-4c24-99cd-fcd6b34b84b2" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ffddc20-0fa6-4890-b617-69ac53e704fb" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae0cf5f4-ef7c-446b-a21d-bd9cac3dd9a1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bd1aeee-7654-4a70-a7a6-2b12b5b5dc8d" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b0bec86-4a5b-49a1-be86-10e69f152676" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d75cbd83-81f3-4dda-a4d0-0bae6a3313ca" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4902abc1-98d8-4a66-8121-83c12ff9c054" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81f7aa65-6752-4f8a-ba22-2cc5ba3abbd8" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8890fae6-0511-4f1d-aa33-7ec95ccf2379" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.358%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.358%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d37ad14-5044-43bf-9cec-db6ab600e9e5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7adf8496-9b09-40ed-9fa1-b41c8b255a65" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99704c75-2a7f-4ed4-8677-d12d190842cc" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb06c163-7fb0-4735-9168-f906b335284e" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f418a060-bc7a-4fd6-8553-19e24359b61a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:EffectiveIncomeTaxCreditCarryforwards" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37dd7008-bab7-41f4-bc28-932bc1751b51" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:EffectiveIncomeTaxCreditCarryforwards" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_561c0233-0c2f-4058-85e6-088889384c78" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd339b2a-b0f6-425f-9316-5e59f566d467" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3158521-15f5-4bac-a8d7-92181d6552f8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">30.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_759c7053-2aa1-4ee7-a6d4-2f51f81f60cc" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b146e17-938f-4de8-989c-c344514b8f02" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a093eb09-da9c-4b40-8952-942d7889d22f" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f079b5-66bd-4d72-97e8-5c557059e6c1" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cbd09f3-ec2c-4185-a999-8510e25fb453" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2be0aad4-dcb0-4feb-8b65-fdd1cedf7554" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96e5e8c4-bdae-4b79-b4ec-1c5b429af8ac" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,385</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc65d1ab-37f1-43c2-8dc8-8d694874ef76" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_780692bf-51b1-47e9-bb0a-3fabb0a0ddd2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a63ad551-cbed-4b03-ae7d-f0e4288fced4" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffddb3e4-de5c-463e-9135-ae3e11f60c9d" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aa50f75-da68-40bc-8a06-1e2c1ff6b71c" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f45680f8-4597-4ff6-91f9-be2ad3d65591" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33bcb766-34dd-4ab7-939e-e0076b091486" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e22ac67-aed6-4974-97d5-f354c66b9c36" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="krro:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e9659da-41a4-4978-8e06-a4596256e1c8" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="krro:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07307f28-20bc-40a3-80fc-b60f6da80c65" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6eeed9b-73e8-46a0-ba25-ce09b647e729" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57364533-2ba0-4224-b402-cb49cc73c797" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_967fef86-7c61-48cd-b066-0dacc138b415" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3465b89f-d3ad-4b82-9134-88c2fd56f98d" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153,481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19166d7b-b5a1-4742-b613-7179b5a2351d" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddcf029a-02a3-4668-9b5e-faf577c10dcc" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,766</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c3037f7-c95b-47c2-a3b4-a3e184925e0b" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c62a495-dd41-48d0-9c7e-a9fbd3de32de" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,715</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7a6071d-3ca9-4d3c-abe0-3acf1d8a3183" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_befc4c31-bfa0-452e-a9f2-2993f552ef5d" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,401</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9acf938-06cf-44fa-8256-f3b1f70a8f09" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f2cf8b5-b2f8-4315-a9b4-61ce4455019c" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a74a521-dcfa-4b6d-b045-5677fed82102" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ace855a-81ef-4d69-83f6-dd6762bda562" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,715</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48dcb79b-2d7c-43f7-bab4-e843867ceaf9" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8279b2c8-b4b6-4565-81ba-75af827535e3" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68a387c6-c100-4f0b-8e22-b5f6ca52b29f" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278c298a-a691-429e-a05e-8f2e786395a4" contextRef="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">302.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd51676f-4d69-43e5-806a-b88a220cd813" contextRef="C_8544c9be-728b-4911-819c-b239ec0b27ad" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">266.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91162885-47c4-4921-a206-ae5af37914db" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under current law, the Company's federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of the Company's taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11d9cd90-7e21-4f58-8080-8947cc3c125f" contextRef="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5" name="krro:NetOperatingLossCarryforwardsExpirationWithLimitation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that are subject to expiration between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51d5631f-70b7-4311-b13f-996322d131a7" contextRef="C_ab007b59-97df-45a4-a462-77226307ef64" name="krro:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcb171f5-4122-4a09-86f8-57816568657d" contextRef="C_306fb8af-4fc4-4970-872c-b483d03fb9e4" name="krro:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4d06699-950d-4785-b297-4d2e7ccbc95b" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="krro:NetOperatingLossCarryforwardsExpirationWithoutLimitation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">280.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal NOLs that do not expire.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State NOLs expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69ffecad-5fa0-458b-8a9c-6def065d7608" contextRef="C_9aa93606-02db-46a9-9b63-7b4d0578cd82" name="krro:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a590398-64bb-4127-a1fa-5739f26191b4" contextRef="C_93f80774-1bcb-4131-b2c9-93def7a01c20" name="krro:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95618fd9-18fb-4a74-b9da-95a48e836468" contextRef="C_a1efc944-079f-4e9e-8fcb-7284de744653" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df9f9a3f-b2dd-4604-b2b8-79b896c8961b" contextRef="C_5e3928f9-e795-46c2-8b3b-47cb73bcf901" name="krro:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c887c31-2ccd-4ce8-92a8-12f1f3bf794b" contextRef="C_ecda1a05-7107-41dc-a5fc-7124dc194f84" name="krro:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, as of December 31, 2023, the Company had state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_145951bd-df5b-4aaf-9e74-096297b907b3" contextRef="C_11f11e50-ea6c-40c6-950d-f8060c5107d8" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb75c5d6-7727-4f20-b937-eed97b4c2f49" contextRef="C_a623cd32-caa5-4962-8d16-001ea4eb82ed" name="krro:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22755b4-62f0-439e-840b-6b27d8cd84f0" contextRef="C_3ef3d01f-e4f1-47e1-8d30-5ca772b0c60e" name="krro:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which primarily pertain to NOL carryforwards, tax credit carryforwards and capitalized research and development. The Company has determined that it is more likely than not that it will not realize the benefits of its deferred tax assets, and as a result, a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_982cd7a6-4d3f-4508-a806-b3958c6cf7b0" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">145.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been established at December 31, 2023. The increase in the valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed23e78e-db44-4292-8633-16a232e8ff4f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">109.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2023 was primarily due to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76e0ac53-1ed1-445b-b88f-267d3461948f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the additional operating loss generated by the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the combination of deferred tax assets as a result of the Merger</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a898a5e-6925-41bc-8865-6bf97b828322" contextRef="C_f4c0a17b-b744-4c53-8416-6686a4fc0acf" name="krro:PeriodOfCumulativeChangeInOwnership" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7a81c6-7181-4c78-9a07-237e89afcce9" contextRef="C_919f3e26-6567-4206-aa08-0ae94fcbc65a" name="krro:CumulativeChangeInOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as defined under Sections 382 and 383 in the IRC. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change. As a result of ownership changes in the Company from its inception through December 31, 2023, the Company&#8217;s NOL and tax credit carryforwards allocable to the periods preceding each such ownership change could be subject to limitations under IRC Section 382, however the Company has not yet completed an IRC Section 382 study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3c09149-a1e0-4c13-997a-0a9af2053cb6" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_276fa272-3e5b-414e-8fd5-08ea5eb6c202" contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits as of either December 31, 2023 or 2022. The Company has not conducted a study of its research and development credit carryforwards generated during any year. This study, once completed, may result in an adjustment to the Company&#8217;s research and development credit carryforwards.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credit carryforwards, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated statements of operations and comprehensive loss if an adjustment were required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal tax jurisdiction and the Connecticut and Massachusetts state tax jurisdictions. Because the Company is in a loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb96b1b-d2f2-4334-b933-c76785edf22a" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incurred any material interest or penalty charges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4512ba6-2c8f-4294-85a8-5c9993e0fddb" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Genevant Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, Legacy Korro entered into a collaboration and license agreement (the &#8220;Genevant Agreement&#8221;) with Genevant Sciences GmbH (&#8220;Genevant&#8221;). Key financial terms under the Genevant Agreement are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af83c3ec-5e8f-4bd8-a5db-c99101ca13bd" contextRef="C_23c62caa-1ebb-4380-b45d-f24627644a23" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment to Genevant in March 2023 upon execution of the Genevant Agreement and recorded the payment within research and development expense in the consolidated statement of operations for the year  ended December 31, 2023. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will reimburse Genevant for certain out-of-pocket and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genevant is entitled to receive payments from the Company upon the achievement of certain milestones, including potential clinical milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd952e99-269e-4e4f-a514-5ccb86fbab54" contextRef="C_45c261a8-1fa5-407f-ace7-946cf709a7e3" name="krro:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, potential regulatory and development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f342e26b-bc65-4602-a555-efe89247e65d" contextRef="C_397c2e74-ff43-4295-9f70-85a5ca23db1c" name="krro:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and potential commercial milestone payments up to an aggregate total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9350ca4f-1acd-4ad4-94f7-00e7372c0e4a" contextRef="C_23c62caa-1ebb-4380-b45d-f24627644a23" name="krro:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">57.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genevant is eligible to receive royalties at percentage rates in the mid-single-digits, based on future annual net sales of licensed products within the scope of the Genevant Agreement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, no milestones have been achieved and the Company has recorded payments to Genevant of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b115613-5737-49a0-9a57-565b7f36f8e0" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="krro:ReimbursementsWithInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within research and development expense in the consolidated statement of operations during the year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_402b31d9-8ded-401c-91a6-b8a1b34acf75" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease at One Kendall Square, Cambridge, Massachusetts and occupies </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62db0d61-427c-4f81-9cf0-a920c3484683" contextRef="C_b6e3c39b-8096-4f8f-97f0-daa59596a1a7" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">22,561</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory and office space (the &#8220;OKS Facility&#8221;). On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7592afb-281c-4198-b5ce-cedb53c55dd0" contextRef="C_952c1d35-4cc4-4d37-8f7f-0c70663501bf" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 20, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an amendment to the Lease Agreement that extended the lease expiration date from December 31, 2023 to September 30, 2024 and provided the Company with no option to further extend the lease expiration date. The Company is also party to an operating sublease agreement at Cummings Park in Woburn, Massachusetts</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and occupies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_991ae706-bca9-4f06-9558-99df47f7b430" contextRef="C_597278ba-5ca6-4b61-aca3-d85a7999b364" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">18,148</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory and office space (the &#8220;Cummings Park Sublease&#8221;) which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ec0b283-814b-4c2c-ae9f-199e4f29a434" contextRef="C_09fab13f-bf4d-4e13-b1df-cb7d113cce21" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 31, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_994efda5-5844-4920-a95b-afa9086a8ad9" contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">50,453</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts (the &#8220;60 First Street Lease&#8221;). In May 2023, the Company obtained control over the space and the Company recognized the operating lease right-of-use asset and the operating lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdaf539c-d2db-4082-b10e-bbe70b09952b" contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cb4969d5-203f-4b01-86a1-997167e39100" contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the commencement date of the lease. The total rental payments over the 11 year lease are expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aab2aee-6204-404b-81ef-b4ee271a150d" contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, including rent credits and other lease incentives per the terms of the lease. Specifically, the 60 First Street Lease provides the Company with a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d62cee1-5a6d-4181-a513-37fceb4e233d" contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company utilized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_cce5c2aa-5b00-4b63-98a4-06f2cf1f4fb4" contextRef="C_55c76954-1de4-47a3-95e3-7300d73d84fc" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41d80baf-b005-426a-a5c9-102890a9f724" contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million tenant improvement allowance as of December 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1, 2023. The lease has remaining term approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e819857b-96bc-4f8b-9b64-3473747f9972" contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has an option to extend the lease for an additional period of five years with the rent during the option period being the then fair market rent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_337c85f9-ee6e-4edb-b9e9-b0641a29a65c" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments for all three leases, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0bcbd05-fc99-4955-8c4f-7eee1fa71204" contextRef="C_ab8215de-6795-4f27-b53e-55d3375d2af5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expected to be received and intended to be used related to the remaining tenant improvement allowance and rent credits associated with the 60 First Street Lease, as of December 31, 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:16.3%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef540a62-cee8-46e8-b82e-43e87f2457d4" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5598323c-05f0-448a-81f4-5ac6a482b577" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,247</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f599c0c-e242-4581-b961-1cf73bd4a0d4" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,341</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f57492f5-e86d-4ade-8bcb-3c673462ff2e" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f14f52-074e-41c9-b101-c70e5d8334f2" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,498</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Future Minimum Leases Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e747d2b2-db97-46eb-8db9-586e03ba9d3f" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,416</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f9071d3-6d19-4284-8af8-dac8032c6937" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present Value of Operating Lease Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a11183d7-60b9-4de7-94f0-ba40a0bc38d1" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58607e68-3040-4891-b61a-263769c412ba" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted average incremental borrowing rate used to determine the operating lease liability was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f6f5d4e-67be-4756-aa35-96eedf349590" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities and maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30a653cf-d428-4043-9294-f01e84ed822b" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statement of operations and comprehensive loss of its operating leases (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.249%;"/>
        <td style="width:2.3%;"/>
        <td style="width:1%;"/>
        <td style="width:19.075999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.3%;"/>
        <td style="width:1%;"/>
        <td style="width:19.075999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ec25fcb-7190-4e55-82d3-2ebe579feefa" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,948</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29a7bd3b-467b-4c4f-a213-941e4bb6e230" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df78b6c3-2b92-4901-b187-f050a00252ed" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5afd2098-bf4f-4c6d-bee1-1f5bf675fb6b" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6193903f-df5d-4fa6-aa2b-059f92ce9a96" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78c981d4-6ccb-4a35-86e3-3bc0106bfd7e" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95eee584-4a8f-4d26-95d0-1bc29cdc965f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19d9ce22-a0b3-4d03-8fd9-168b8a88b3b3" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,033</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Frequency and the Frequency&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March 21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May 16, 2022, the Company&#8217;s Chief Development Officer, Dr. Carl Le Bel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company&#8217;s public disclosures between October 29, 2020 and March 22,2021. The lawsuit sought, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October 29,2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July 15, 2022. On March 29, 2023, the Company&#8217;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April 27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. On August 2, 2023, Plaintiff-Appellant submitted its opening brief to the First Circuit. The Company filed its response brief on October 27, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The First Circuit heard oral argument on January 8, 2024, and has not yet issued a decision on plaintiff&#8217;s appeal. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d86fc1f-4b54-4d1e-84a5-5b6bf7a010ad" contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accruals have been recorded as of December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with the Company&#8217;s amended and restated certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company&#8217;s exposure and may enable the Company to recover a portion of any future amounts paid. The Company believes that the fair value of these potential indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f2aa78b-25dc-452e-b37c-38c9b1762400" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. 401(k) Savings Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a defined-contribution savings plan under Section 401(k) of the IRC (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation, subject to statutory limitations. Beginning on April 1, 2022, the Company matches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84dd07f0-b10c-4dfb-8bf8-4b65581736fe" contextRef="C_f10a3be4-4ec6-4c00-b69c-d83c843296d7" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s 401(k) contributions up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0f54ddb-673d-41f7-a0be-174c7593972a" contextRef="C_728a4108-5170-4a8f-b001-b85c0cd9973b" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the participant&#8217;s salary, subject to employer match limitations under the IRC. As such, the Company made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c637bb-6914-4458-be5b-7703a698e392" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f5e3fbc-43a9-4d48-bb80-3a4c8843e698" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of matching contributions to the 401(k) Plan during the year ended December 31, 2023 and December 31, 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e14228e7-b0ec-4ff1-bce8-184c1d9d05d4" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of Atlas&#8217; ownership of the Legacy Korro&#8217;s Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock which was exchanged in the Merger for the Company's common stock, Atlas represents an affiliate of the Company. During the years ended December 31, 2023 and 2022, the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67be121a-1156-4a4b-8f40-fa8900fc95d8" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="krro:IncurredExpenses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_08cfe937-3529-462d-9d67-9630952cfcad" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="krro:IncurredExpenses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expense and expenses of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad25d863-d42f-4dae-a612-284f5c53c029" contextRef="C_306fb8af-4fc4-4970-872c-b483d03fb9e4" name="krro:IncurredExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, related to consulting services provided by an affiliate of Atlas. As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c88c9c-ad3a-4aa5-be06-b5b1943a29ad" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:AffiliateCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d880b54e-e504-4e1d-906d-0f48fcac6a8a" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:AffiliateCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts due to this affiliate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_925fad4e-bac2-4f4b-b29f-92dd25a01b4d" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb0a9dad-8e3f-407c-8fca-7108ae5f5145" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.968%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:16.257%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:16.257%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca56d908-4a31-44ec-9f40-e2c66e476390" contextRef="C_fefcff45-a321-42bf-a7e9-1a416bde8bee" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43937e14-0b70-4e6e-88cd-d71145b795f4" contextRef="C_3253f6cb-13ac-491b-a7c7-9edb74475ade" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">684,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bbc58ab-989b-497b-87f8-9e22cfa57115" contextRef="C_8cfbcf8e-1721-4cf1-9208-7dd35da5b429" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf805268-4dbf-4e00-88bb-e4121113dc8f" contextRef="C_e1ffa510-b12a-4e8a-ae92-845d73bdc92d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31a58040-4827-4ed5-8b00-9e2476c6af2a" contextRef="C_be8ba35b-0380-4fb4-a4e6-89fb909ebcce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6278e31-3ccd-4c87-a31f-ab083ad4682a" contextRef="C_81b7cadd-72c3-48d7-91c7-d8614a9176e6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,104,178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aace4e5-39e9-4977-98a1-095ed299327b" contextRef="C_36085e8f-16ab-4161-877d-07990acb5c48" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72e5065f-6e15-405d-a55d-f77f46b2427f" contextRef="C_24975ddf-6b2d-4418-a7fd-437c84c577ac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested Legacy Korro restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0339427c-6cd1-454a-b998-6a57efe22f2a" contextRef="C_8dd132b6-7063-44e3-af52-d367d2ce82ee" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d179d95-5d88-4b81-9517-f9c6ee94948f" contextRef="C_1de4389e-f2f0-4d25-b59d-6d52f9adce3f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14993045-2207-4893-ae6b-d8da644ba41f" contextRef="C_36fd05f2-24c6-4d41-93ec-f56ca9af1f89" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,323,151</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ae631f6-aa43-457b-83ee-32bbec4750ce" contextRef="C_b649a5e7-5c6c-446c-9fb4-344b0a1da0a9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">461,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d999c915-29ad-40a3-b91e-48c86d96cb5c" contextRef="C_a91b6de8-ece5-41ce-aead-f4c5480a52b6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,049</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9630f50c-7020-411a-bca2-9c8ffed1b490" contextRef="C_fab291c7-d953-4b7e-86e4-50c5ceed14ec" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,049</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9a0f0f-708d-42fc-b870-4a64e10a5b3f" contextRef="C_513af823-8be3-442f-a9fe-1a2fe1b055f9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,331,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ccff7d-adc0-46c9-ae0c-dca7b3d9930f" contextRef="C_bed67611-bf29-4fae-9416-b0c86cc2e8d6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,514,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99334947-02b1-445d-9994-ff16c6349dab" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The following table sets forth the computation of the Company's basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.88%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:15.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:15.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f2ebe3e-db56-437d-9d13-fea95335474f" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c134da88-94f8-4b94-b07b-acb11b76c9f7" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f4d9e14-3d2c-4a56-a09a-fa33bdea8097" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_412936e7-d044-4d26-a02b-1c36ed5b4845" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,529,321</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8bfcef8-03ed-4ac4-be64-f4662b0e1d64" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a7aaa5af-35d0-4d9a-ac51-9f34555ba44c" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">255,175</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cabd71c5-1e8a-48e5-b33d-a08a36826ef3" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4659c477-0fe6-467e-af72-6fd066a009c5" contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">53.08</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d752ec48-53d3-4199-9ed0-b3f6c2e4eeb9" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6e63ea17-f123-44df-a676-b8c5aee19efe" contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">227.42</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hanges in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ontrols and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. We maintain a system of internal control that is designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding that we do not qualify for the relief afforded by Instruction 1 to Item 308 of Regulation S-K to newly public companies, management has not assessed nor attested to our internal control over financial reporting as is set forth in Item 308 of Regulation S-K promulgated under the Exchange Act, and Section 404 of the Sarbanes-Oxley Act as of December 31, 2023, the end of our last fiscal year. We will do so initially as of December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were unable to conduct the required assessment primarily due to the Merger occurring on November 3, 2023 and the resulting substantial change in operational focus, management and the internal control environment. Following the Merger, Legacy Korro&#8217;s historical operations, and not that of our predecessor business, represent virtually the entirety of the combined business. In addition, following the Merger, our accounting and financial systems, as well as personnel, were replaced by those of Legacy Korro. Due to the extensive changes to our internal control environment, it was impractical for us to develop, implement, and assess our system of internal control over financial reporting, and conduct management&#8217;s assessment of internal control over financial reporting as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than changes due to the Merger, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) On March 21, 2024, our board of directors established that our 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024. The record date for the determination of stockholders entitled to receive notice of and to vote at our 2024 Annual Meeting will be the close of business on Wednesday, April 17, 2024. Because the date of our 2024 Annual Meeting differs by more than thirty (30) days from the anniversary date of our 2023 Special Meeting in lieu of an Annual Meeting of Stockholders, which was held on November 3, 2023, we ares hereby providing notice, pursuant to Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, of the deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Exchange Act and for any stockholder nomination or proposal outside of Rule 14a-8 via this Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To be considered for inclusion in this year&#8217;s proxy materials for our 2024 Annual Meeting, stockholder proposals must be submitted in writing by the close of business on Tuesday, April 9, 2024, to our Corporate Secretary at our principal executive offices at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the proxy materials for our 2024 Annual Meeting must also comply with our bylaws and all applicable rules and regulations promulgated by the Securities and Exchange Commission under the Exchange Act. Additionally, any stockholder who intends to submit a proposal regarding a director nomination or any other matter of business at our 2024 Annual Meeting not to be included in our proxy materials for our 2024 Annual Meeting, must also ensure that notice of any such proposal (including any additional information specified in our bylaws) is received by our Corporate Secretary at our principal executive offices by the close of business on April 9, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">isclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Officers and Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our directors and executive officers and their ages as of the date of this Annual Report are listed below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.193%;"/>
    <td style="width:1.54%;"/>
    <td style="width:4.099%;"/>
    <td style="width:1.54%;"/>
    <td style="width:58.628%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Executive Officers:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ram Aiyar</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vineet Agarwal</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Todd Chappell</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Operating Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steve Colletti</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Scientific Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shelby Walker</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General Counsel</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Non-Employee Directors:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ali Behbahani (2)(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nessan Bermingham (1)(2)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jean-Francois Formela (1)(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rachel Meyers(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Timothy Pearson (1)(2)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David L. Lucchino</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Audit Committee member </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee member </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nominating and Corporate Governance Committee member</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ram Aiyar, Ph.D., M.B.A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Dr. Aiyar has served as our Chief Executive Officer and a director since completion of the Merger. Dr. Aiyar previously served as Chief Executive Officer and as a director of Legacy Korro since November 2020, and has served as its President since November 2021. Prior to joining Legacy Korro, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson &amp; Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc. Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University. We believe Dr. Aiyar is qualified to serve on the Board because of his significant operational and senior management experience in the biopharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vineet Agarwal, M.B.A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Mr. Agarwal served as Chief Financial Officer since the Merger and previously served as Chief Financial Officer of Legacy Korro since May 2021. Prior to joining Korro Bio, Mr. Agarwal joined J.P. Morgan Chase &amp; Co. In 2007 and advised healthcare companies on merger &amp; acquisitions, capital raising and strategic initiatives. Mr. Agarwal served as Executive Director, Biotech Investment Banking at J.P. Morgan Chase &amp; Co. from January 2019 until May 2021 and as Vice President, Biotech Investment Banking from January 2016 until January 2019. Mr. Agarwal previously served in numerous leadership roles at J.P. Morgan Chase &amp; Co. across different countries. Mr. Agarwal holds an M.B.A. from the Institute of Management Technology, India, and a Bachelor&#8217;s degree in finance from Shri Ram College of Commerce, India.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Todd Chappell, M.B.A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Mr. Chappell has served as Chief Operating Officer since the Merger and previously served as Chief Operating Officer of Legacy Korro since August 2023 and previously served as Senior Vice President, Strategy and Portfolio Planning of Korro Bio from March 2021. Before joining Korro Bio, Mr. Chappell served as Chief Executive Officer of Rasio Therapeutics, Inc. from June 2019 until March 2021. Prior to this role, he served as Chief Executive Officer of Perceptive Navigation, LLC from June 2015 until May 2019. Mr. Chappell previously managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at BioHealth Innovation, Inc. Prior to that, Mr. Chappell was a Vice President of Operations at Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for cutaneous t-cell lymphoma. Prior to this role, Mr. Chappell was an Executive Director of New Products at CombinatoRx, Inc., where he led the advancement of three programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from assay stage into human clinical studies. Mr. Chappell holds an M.B.A. from Boston University and a B.S. in biology from the University of California, Los Angeles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Steve Colletti, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Dr. Colletti served as Chief Scientific Officer since the Merger and previously served as Chief Scientific Officer of Legacy Korro since February 2023. Dr. Colletti most recently served as Senior Vice President of Drug Discovery Research and Development at Zymergen, Inc. from May 2021 to January 2023. Prior to this role, he served as Chief Scientific Officer of Lodo Therapeutics from March 2020 to May 2021 and as Senior Vice President, Head of Research and Development from September 2018 to March 2020. He previously held multiple leadership roles at Merck (NYSE:MRK), including in small molecule, natural products, oligonucleotide, peptide and fusion protein bioconjugate drug discovery, targeting programs in cardiovascular and respiratory disease, diabetes and obesity, immunological disorders, infectious diseases, neuroscience and oncology. Also at Merck, Dr. Colletti built and led the RNA Therapeutics Medicinal Chemistry department and was a core member of multiple development teams responsible for discovering more than a dozen preclinical candidates and advancing them to clinical development. Dr. Colletti is an inventor and author of over 130 patents and publications. Dr. Colletti holds a Ph.D. in chemistry from Boston University and a B.S. in chemistry from Loyola University, and was a National Institutes of Health postdoctoral fellow in chemistry at the Scripps Research Institute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelby J. Walker, M.S., J.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ms. Walker has served as Senior Vice President, General Counsel and Corporate Secretary since the Merger and previously served as Senior Vice President, General Counsel and Corporate Secretary of Legacy Korro since May 2023. Ms. Walker most recently served as Senior Vice President and Head of Intellectual Property at CRISPR Therapeutics (Nasdaq:CRSP) from March 2018 to April 2023. She previously served as General Counsel at Ginkgo Bioworks, a synthetic biology company, from May 2016 to March 2018. Prior to this role, she served as Vice President, Associate General Counsel and Chief Intellectual Property Counsel at Dyax Corporation, and previously held intellectual property leadership roles at Novo Nordisk (NYSE:NVO) and ZymoGenetics. Ms. Walker holds a J.D. and L.L.M. in intellectual property law from the University of New Hampshire School of Law, master&#8217;s degrees in biotechnology and regulatory science from Johns Hopkins University, and a B.S. in biotechnology from Worcester Polytechnic Institute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nessan Bermingham, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Dr. Bermingham, one of Legacy Korro&#8217;s co-founders, has served as Chairperson of the Board since completion of the Merger, and previously served as Legacy Korro&#8217;s Chairman and on its board of directors since November 2021, and previously served as its President and Executive Chairman from November 2018 to November 2021. Dr. Bermingham has been an Operating Partner at Khosla Ventures since December 2021 and has served as Interim Chief Executive Officer of Everyone Medicines since October 2022. Previously, he co-founded and served as President and Chief Executive Officer of Triplet Therapeutics from November 2018 until July 2021. Dr. Bermingham was also a Venture Partner at Atlas Venture from February 2018 until July 2021. Dr. Bermingham also served as Interim Chief Executive Officer of Liberate Bio from October 2022 until February 2023. Prior to that role, Dr. Bermingham co-founded and served as President and Chief Executive Officer of Intellia Therapeutics (Nasdaq:NTLA) from 2014 to 2017. Dr. Bermingham currently serves on the boards of directors of a number of private companies and previously served on the board of Xilio Therapeutics (Nasdaq:XLO). He also previously served as the chair of the board of F-Star Therapeutics prior to its reverse merger and subsequent to its acquisition as a public company, and served on the boards of several private companies. Dr. Bermingham holds a bachelor&#8217;s degree in genetics from Queen&#8217;s University Belfast and a Ph.D. in molecular biology from Imperial College London, and was a Howard Hughes Associate Fellow at Baylor College of Medicine. We believe Dr. Bermingham is qualified to serve on the Board because of his significant leadership and investment experience in the biotech industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ali Behbahani, M.D., M.B.A. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Behbahani has served on the Board since completion of the Merger, and previously served as a member of Legacy Korro&#8217;s board of directors since August 2019. Dr. Behbahani joined New Enterprise Associates, Inc., or NEA, in 2007 and is a General Partner on the healthcare team. He previously held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. Dr. Behbahani has served as a member of the board of directors of Monte Rosa Therapeutics, Inc. (Nasdaq:GLUE) since April 2020, Black Diamond Therapeutics (Nasdaq:BDTX) since December 2018, Nkarta, Inc. (Nasdaq:NKTX) since August 2015, CRISPR Therapeutics AG (Nasdaq:CRSP) since April 2015, Arcellx, Inc. (Nasdaq:ACLX) since February 2015, Adaptimmune Therapeutics Plc (Nasdaq:ADAP) since September 2014, CVRx, Inc. (Nasdaq:CVRX) since July 2013, Minerva Surgical, Inc. (Nasdaq:UTRS) since May 2011, and was on the board of Nevro Corp. (NYSE:NVRO) from August 2014 to March 2019, Genocea Biosciences (Nasdaq:GNCA) from February 2018 to May 2022, and Oyster Point Pharma (Nasdaq:OYST) from July 2017 to January 2023. He also serves on a number of private company boards. Dr. Behbahani holds a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. We believe Dr. Behbahani is qualified to serve on the Board because of his extensive experience as a public company director and investor in the biotech industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Jean-Francois Formela, M.D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">M.B.A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Dr. Formela, one of Legacy Korro&#8217;s co-founders, has served as a member of the Board since completion of the Merger, and previously served on Legacy Korro&#8217;s board of directors since November 2018. Dr. Formela is currently a partner at Atlas Venture, a life sciences-focused venture capital firm, which he joined in 1993. Dr. Formela is a co-founder and director of IFM Therapeutics, and serves as a director of Ikena Oncology, Inc. (Nasdaq:IKNA), as well as a director of the following private companies: Scorpion Therapeutics, Inc., Sail Bio, Inc., Triveni Bio, Inc. and Travin Bio, Inc. Dr. Formela also previously served as a director of Intellia Therapeutics, Inc. (Nasdaq:NTLA), Spero Therapeutics (Nasdaq:SPRO) and several private companies. Dr. Formela is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. Dr. Formela began his career as a physician practicing emergency medicine at Necker University Hospital in Paris. He holds an M.D. from the Paris University School of Medicine and an M.B.A. from Columbia University. We believe Dr. Formela&#8217;s experience as an investor and board member in the life sciences industry, as well as his scientific and medical knowledge, provides him with the qualifications and skills to serve on the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">David L. Lucchino</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> previously served as our President and Chief Executive Officer through completion of the Merger and has also served on the Board, each since November 2014 and was a co-founder of Frequency with Dr. Robert S. Langer and Dr. Christopher R. Loose. From December 2014 until June 2016, Mr. Lucchino served as the President of Entrega Bio, a biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino cofounded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of Semprus&#8217; lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. He started his biotech career by Co-Founding LaunchCyte, an investment firm where he was also a Managing Director. Mr. Lucchino is the past chairman of the board of directors of MassBio, a nonprofit organization that represents over 1,500 life science firms and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Massachusetts&#8217; Governor Charlie Baker as a member of the Commonwealth&#8217;s STEM Advisory Council. Mr. Lucchino also served as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility for fifteen years, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of NOLS (The National Outdoor Leadership School). Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. We believe Mr. Lucchino is qualified to continue to serve on the Board because of his extensive management experience in the biotechnology and pharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rachel Meyers, Ph.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Meyers has served as a member of the Board since November 2023. Dr. Meyers previously served as the Founder and Chief Scientific Officer at Faze Medicines, Inc. from June 2020 to January 2023. Prior to Faze Medicines, Dr. Meyers served as Entrepreneur-in-Residence at Third Rock Ventures. She also spent over 13 years at Alynlam Pharmaceuticals, Inc. from April 2003 to November 2016 and remains an active member of the scientific advisory board. Dr. Meyers also serves on several scientific advisory boards, including the National Advisory Board on Innovation and Entrepreneurship through the Department of Commerce. Rachel is listed as an inventor on many patents and patent applications, and has numerous peer-reviewed publications. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction and received her Ph.D. at the Massachusetts Institute of Technology in the field of in vitro transcription. We believe Dr. Meyers&#8217; extensive experience in the biotech industry and her expertise in drug discovery and development, including in RNA-based medicines, provide her with the qualifications and skills to serve on the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Timothy R. Pearson. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Pearson has served on the Board since completion of the Merger, and has served as the Chief Executive Officer of Carrick Therapeutics, a privately held oncology company, since July 2019. Mr. Pearson served as an Executive Vice President and the Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, from 2014 until its acquisition by GlaxoSmithKline in February 2019. He served as an Executive Vice President, Chief Financial Officer and Treasurer of Catalyst Health Solutions, a publicly held pharmacy benefit management company, from 2011 until its acquisition by SXC Health Solutions in 2012. Prior to joining Catalyst Health Solutions, Mr. Pearson served as the Chief Financial Officer and Executive Vice President of MedImmune, Inc. Mr. Pearson has served on the board of directors of GlycoMimetics, Inc. (Nasdaq:GLYC) since 2014 and as its chairperson since 2019. He previously served on the board of directors of Ra Pharmaceuticals, Inc., a publicly held biopharmaceutical company until its acquisition by UCB in April 2020. Mr. Pearson is a Certified Public Accountant and holds dual B.S. degrees in business administration from the University of Delaware and in accounting from the University of Maryland, University College, as well as an M.S. degree in finance from Loyola College. We believe Mr. Pearson is qualified to serve on the Board because of his experience in the biopharmaceutical industry and his expertise in accounting and finance, strategic planning and leadership of complex organizations, and human capital management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Election of Officers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers are appointed by, and serve at the discretion of, our board of directors. There are no family relationships among any of our directors or executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors currently consists of seven directors divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no family relationships among any of our directors and officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committees of Our Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The standing committees of our board of directors of are the following: audit committee, compensation committee and a nominating and corporate governance committee, and each operate pursuant to a charter. Our board of directors may establish other committees from time to time to assist us and our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit Committee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit committee&#8217;s responsibilities will include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appointing, approving the compensation of, and assessing the independence of, our independent registered public accounting firm; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recommending, based upon the audit committee&#8217;s review and discussions with management and our independent registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form 10-K;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparing the audit committee report required by SEC rules to be included in our annual proxy statement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing quarterly earnings releases.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The audit committee consists of Timothy Pearson, Nessan Bermingham and Jean-Francois Formela. Timothy Pearson is the chair of the audit committee and is a financial expert under the rules of the SEC. To qualify as independent to serve on our audit committee, listing standards of Nasdaq and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from us, other than for service as a director, or be an affiliated person of us. We believe that the composition of the audit committee complies with the applicable requirements of the rules and regulations of Nasdaq and the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our compensation committee will oversee policies relating to compensation and benefits of our officers and employees. Among other matters, the compensation committee&#8217;s responsibilities include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and, based on such evaluation, recommending to the board of directors the cash compensation of our Chief Executive Officer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining the cash compensation of our other executive officers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overseeing and administering our compensation and similar plans; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retaining and approving the compensation of any compensation advisors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and approving the grant of equity-based awards; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and recommending to the board of directors the compensation of our directors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The compensation committee consists of Nessan Bermingham, Ali Behbahani and Timothy Pearson. Nessan Bermingham is the chair of the compensation committee. Each member of our compensation committee is a &#8220;non-employee&#8221; director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. We believe that the composition of the compensation committee complies with the applicable requirements of the rules and regulations of Nasdaq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nominating and Corporate Governance Committee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The nominating and corporate governance responsibilities include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing and recommending to the board of directors criteria for board and committee membership; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying individuals qualified to become members of the board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recommending to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and recommending to the board of directors appropriate corporate governance guidelines; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overseeing the evaluation of the board of directors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The nominating and corporate governance committee consists of Ali Behbahani, Jean-Francois Formela and Rachel Meyers. Ali Behbahani is the chair of the nominating and corporate governance committee. We believe that the composition of the nominating and corporate governance committee meets the requirements for independence under, and the functioning of such nominating and corporate governance committee complies with, any applicable requirements of the rules and regulations of Nasdaq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delinquent Section 16(a) Reports</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who beneficially own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than 10% beneficial owners are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To our knowledge, based solely on our review of Forms 3, 4 and 5, and any amendments thereto, filed by such reporting persons and/ or written representations that no Form 5 was required, we believe that during the fiscal year ended December 31, 2023, all filing requirements applicable to our executive officers, directors and persons who beneficially own more than 10%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">140</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">percent of a registered class of our equity securities under the Exchange Act were met in a timely manner except for (i) two late Form 4 filings for David L. Lucchino with respect to the vesting of his restricted stock units, or RSUs, and two sales to cover tax withholding obligations in connection with the vesting of the RSUs and (ii) one late Form 4 filing for Richard J. Mitrano with respect to one sale required to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code of Business Conduct and Ethics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted an amended and restated code of business conduct and ethics for directors, officers, and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at https://ir.korrobio.com/corporate-governance/governance-overview. We will promptly disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver. Stockholders may request a free copy of the Code of Business Conduct and Ethics from our Corporate Secretary, c/o Korro Bio, Inc., One Kendall Square, Building 600-700, Suite 6-401 Cambridge, MA 02139.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Recovery Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with the requirements of the SEC and Nasdaq listing rules, our board of directors adopted a compensation recovery policy on November 3, 2023, effective as of October 2, 2023. The compensation recovery policy provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officers would have received based on the restated financial statements.  We have filed this policy as an Exhibit to this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Execu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 3, 2023, Frequency completed the Merger with Legacy Korro. At the effective time of the Merger, the management of Frequency was replaced with the management of Legacy Korro. Unless otherwise indicated, the disclosures in this section regarding Frequency&#8217;s common stock or securities convertible into common stock for periods or as of a date that precedes the closing of the Merger have been adjusted to give effect to the Reverse Stock Split, and the disclosures in this section regarding Legacy Korro&#8217;s common stock or securities convertible into Legacy Korro&#8217;s common stock for periods or as of a date that precedes the closing of the Merger have been adjusted to give effect to the Exchange Ratio and the Reverse Stock Split.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt in the future could vary significantly from our historical practices and currently planned programs summarized in this discussion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Compensation Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This section discusses the material components of the executive compensation program for our named executive officers, which consists of (i) any person who served as our principal executive officer during any part of 2023, (ii) our two most highly compensated executive officers (other than our principal executive officers) who were serving as executive officers on December 31, 2023, and (iii) one additional individual who would have been under clause (ii) but for the fact that he was not serving as an executive officer on December 31, 2023. In 2023, our named executive officers were:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ram Aiyar, Ph.D., our Chief Executive Officer and President;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">David L. Lucchino, our former President and Chief Executive Officer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vineet Agarwal, our Chief Financial Officer;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Steven Colletti, Ph.D., our Chief Scientific Officer; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Christopher R. Loose, Ph.D., our former Chief Scientific Officer.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">141</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Summary Compensation Table</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information regarding the total compensation awarded to, earned by and paid to our named executive officers for services during 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.64%;"/>
    <td style="width:1%;"/>
    <td style="width:4.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.52%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.84%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.4%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.72%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.04%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Principal Position</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Salary<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Bonus<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock<br/>Awards<br/>($)(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option<br/>Awards<br/>($)(2)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nonequity<br/>Incentive Plan<br/>Compensation<br/>($)(3)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Other<br/>Compensation<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ram Aiyar</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">498,487</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,013,364</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">336,479</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,900(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,858,230</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer and President</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">472,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">546,835</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,110</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196,545</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David L. Lucchino</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">558,767(6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,338,400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,981,098(7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,878,265</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Former President and Chief Executive Officer (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">630,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,209,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">927,028</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,159,278</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vineet Agarwal</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">426,484</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000(8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">511,121</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,386</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,900(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,322,891</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">404,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,676</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,339</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,743</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">629,008</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steven Colletti<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Scientific Officer(9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">361,667(6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,087,385</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,047(10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,647,368</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Christopher R. Loose</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294,211(6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">533,358(12)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">752,905(13)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,580,474</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Former Chief Scientific Officer (11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">480,344</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">604,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226,580</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,138</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,518,812</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts represent the aggregate grant date value of the RSUs granted to our named executive officers during the applicable year, computed in accordance with FASB ASC Topic 718, rather than the amounts paid to or realized by the named executive officer. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair values of the RSUs reported in this column are set forth in Note 11 of our financial statements included elsewhere in this Annual Report on Form 10-K. These amounts reported in this column reflect the accounting cost for these RSUs and do not correspond to the economic value that may be received by our named executive officers upon vesting and settlement of such awards or any sale of the shares of our common stock received. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts represent the aggregate grant date fair value of the stock option awards granted to our named executive officers during the applicable fiscal year, computed in accordance with FASB ASC Topic 718, rather than the amounts paid to or realized by the named executive officer. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock option awards reported in this column are set forth in Note 11 of our financial statements included elsewhere in this Annual Report on Form 10-K. The amounts reported in this column reflect the accounting cost for these stock option awards and do not correspond to the actual economic value that may be received by our named executive officers upon the exercise of the stock option awards or any sale of the underlying shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts represent cash incentive compensation awarded in recognition of individual and/or company performance under our annual incentive compensation program. Refer to &#8220;&#8212;2023 Bonuses&#8221; below for additional information.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount reported represents matching contributions to the named executive officer&#8217;s 401(k) account. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Lucchino&#8217;s employment terminated in connection with the Merger but he continues to provide services to us as a non-employee member of our board.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount reported reflects the prorated base salary for the named executive officer&#8217;s partial year of service with us during the applicable year.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amount reported represents severance paid to Mr. Lucchino in connection with his termination of employment in the amount of $1,958,224, comprised of $992,250, which represents 18 months of Mr. Lucchino&#8217;s 2023 base salary, $333,833, which represents Mr. Lucchino&#8217;s prorated annual bonus for the 2023 fiscal year, $396,900, which </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">142</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">represents Mr. Lucchino&#8217;s target annual bonus for the 2023 fiscal year, $61,473 in company-paid COBRA premiums, and $173,768, which represents the value of the accelerated vesting of Mr. Lucchino&#8217;s equity awards in connection with his termination of employment as well as $16,500 in matching contributions made by us under the Frequency 401(k) plan and $6,374, the compensation earned by Mr. Lucchino for services on our board of directors after the Merger.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount represents a transaction bonus awarded in connection with the completion of the Merger.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Colletti was not a named executive officer for 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount represents $9,713 in matching contributions made by us under our 401(k) retirement plan and reimbursement of $37,334 for expenses incurred in connection with travel to work at our offices and housing in the greater Boston, Massachusetts area. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Loose departed our company in connection with the Merger.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount reported includes $31,458, which represents the incremental fair value, computed in accordance with FASB ASC Topic 718, related to the amendment of Dr. Loose&#8217;s RSUs in 2023 to accelerate the vesting of such RSUs in connection with termination of Dr. Loose&#8217;s employment.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amount reported represents severance paid to Dr. Loose in connection with his termination of employment in the amount of $736,405, comprised of $504,361 of continued base salary payments, $201,744, which represents Dr. Loose&#8217;s target annual bonus for the 2023 fiscal year, and $30,300 in company-paid COBRA premiums as well as $16,500 in matching contributions made by us under the Frequency 401(k) plan.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Narrative Disclosure to the 2023 Summary Compensation Table</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, our compensation committee reviewed compensation annually for all employees, including our executive officers. Following the Merger, our compensation committee anticipates annually reviewing the compensation of our employees, including our executive officers. In setting executive base salaries and bonuses and granting equity incentive awards, the compensation committee considers compensation for comparable positions in the market, the historical compensation levels of our executive officers, individual performance as compared to our expectations and objectives, internal equity, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to us. We target a general competitive position and consider independent third-party benchmark analytics to determine the mix of compensation of base salary, bonus and long-term incentives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our compensation committee is primarily responsible for determining the compensation for our executive officers. Our compensation committee typically reviews and discusses management&#8217;s proposed compensation with our Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, taking into account the factors noted above, the compensation committee then sets the compensation for each executive officer other than the Chief Executive Officer. For the Chief Executive Officer, our compensation committee determines and approves the compensation, or upon request of the board of directors, recommends our Chief Executive Officer&#8217;s compensation for approval by our board of directors. Our compensation committee may delegate certain authorities to an officer of our company and has delegated to our Chief Executive Officer the authority to make certain equity award grants to employees (other than our executive officers), within specified limits approved by the compensation committee. Our compensation committee has the authority to engage the services of a consulting firm or other outside advisor to assist it in designing our executive compensation programs and in making compensation decisions. During 2023, the compensation committee retained the services of Alpine Rewards LLC, or Alpine, as its external compensation consultant to advise on executive compensation matters including our overall compensation program design and collection of market data to inform our compensation programs for our executive officers and members of our board of directors. Alpine reports directly to our compensation committee. Our compensation committee annually assesses its independence consistent with Nasdaq listing standards and concluded that the engagement of such consultant did not raise any conflict of interest.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Base Salaries</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of the named executive officers&#8217; base salary is a fixed component of annual compensation for performing specific duties and functions. Base salaries are adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. For the fiscal year ended December 31, 2023, the annual base salaries for Dr. Aiyar, Mr. Lucchino (prior to termination of his employment), Mr. Agarwal, Dr. Colletti, and Dr. Loose (prior to termination of his employment) were $498,487, $661,500, $426,484, $420,000, and $504,361, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Annual Bonuses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, Dr. Aiyar, Mr. Lucchino (prior to termination of his employment), Mr. Agarwal, Dr. Colletti, and Dr. Loose (prior to termination of his employment), were each eligible to earn an annual bonus based on their individual performance and/or our performance as a company. For the year ended December 31, 2023, the target annual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">143</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bonuses for Dr. Aiyar, Mr. Lucchino (prior to termination of his employment), Mr. Agarwal, Dr. Colletti, and Dr. Loose (prior to termination of his employment) were equal to 45%, 60%, 35%, 35%, and 40%, respectively, of their applicable annual base salaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although neither Legacy Korro nor Frequency had a formal policy with respect to the grant of equity incentive awards to its executive officers, we believe that equity awards provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and stockholders. In addition, we believe that equity awards with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the applicable vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of our named executive officers and from time to time may grant equity incentive awards to them. In 2023, we granted options and RSUs to our named executive officers, as described in more detail in the &#8220;&#8212;Outstanding Equity Awards at Fiscal 2023 Year-End&#8221; table below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Perquisites</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generally do not provide perquisites to our employees, other than certain de minimis perquisites available to all of our employees, including our named executive officers.  However, pursuant to his employment agreement with us, Dr. Colletti is also entitled to reimbursement (i) for reasonable expenses incurred in connection with travel to work at our offices and (ii) up to $4,000 per month for housing in the greater Boston, Massachusetts area.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">401(k) Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain the Korro Bio 401K Retirement Plan, a tax-qualified retirement plan that provides eligible employees, including the named executive officers, with an opportunity to save for retirement on a tax-advantaged basis. Plan participants are able to defer eligible compensation subject to applicable annual limits under the Code. Participants&#8217; pre-tax or Roth contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Participants are immediately and fully vested in their contributions. We match each participant&#8217;s contribution up to a maximum of 3% of his or her eligible compensation with participants vesting immediately and fully in such matching contributions. Our 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan&#8217;s related trust intended to be tax exempt under Section 501(a) of the Code.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the consummation of the Merger, Frequency maintained a 401(k) retirement savings plan, or the Frequency 401(k) Plan, for Frequency employees. Prior to their respective terminations, Mr. Lucchino and Dr. Loose were eligible to participate in the Frequency 401(k) Plan on the same terms as other full-time Frequency employees. Under this plan, Frequency matched 100% of the first 5% of participants&#8217; contributions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior Offer Letters and Employment Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro previously entered into offer letters or employment agreements with Dr. Aiyar, Mr. Agarwal and Dr. Colletti and Frequency previously entered into employment agreements with Mr. Lucchino and Dr. Loose, which were in effect in 2023 prior to the Merger and are described below.  We entered new agreements with certain of our named executive officers following the Merger, as described further below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ram Aiyar</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 13, 2020, Legacy Korro entered into an offer letter with Dr. Aiyar, or the Aiyar Offer Letter. The Aiyar Offer Letter sets forth his initial annual base salary of $450,000, initial target bonus opportunity equal to 40% of Dr. Aiyar&#8217;s annual base salary, initial equity grant, and his eligibility to participate in our employee benefit plans generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Aiyar Offer Letter provided that in the event that Dr. Aiyar&#8217;s employment was terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (as such terms are defined in the Aiyar Offer Letter), in either case within three months before or 12 months following a change in control, or the Aiyar Change in Control Period, subject to Dr. Aiyar&#8217;s signing and complying with a separation agreement and release, Dr. Aiyar would be entitled to the following severance benefits: (i) a lump sum cash payment equal to sum of (x) 12 months of his then-current base salary (or the base salary in effect immediately prior to the change in control, if higher), plus (y) 100% of Dr. Aiyar&#8217;s target annual bonus for the year of termination, without regard to whether the metrics had been established or achieved for such year; (ii) if Dr. Aiyar elected COBRA health continuation, a monthly payment to the group health plan provider or the COBRA provider for up to 12 months, and (iii) 100% of all equity awards held by Dr. Aiyar would have immediately accelerated in vesting and become fully exercisable or non-forfeitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the event that Dr. Aiyar&#8217;s employment were terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221;, in either case outside the Aiyar Change in Control Period, subject to Dr. Aiyar&#8217;s signing and complying with a separation agreement and release, Dr. Aiyar would have been entitled to the severance benefits as described in the preceding paragraph, payable in substantially equal installments over a 12-month period, provided that Dr. Aiyar would not have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">144</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entitled to any acceleration of vesting of his equity awards and the target annual bonus described above would have been prorated based on the date of termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">David Lucchino</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Frequency entered into a second amended and restated executive employment agreement with Mr. Lucchino on September 20, 2019, pursuant to which Frequency employed Mr. Lucchino as its President and Chief Executive Officer. The employment agreement also provided for Mr. Lucchino to serve as a member of the Frequency&#8217;s board of directors for as long as he was employed as its Chief Executive Officer. The employment agreement had an indefinite term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The employment agreement provided for an initial annual base salary of $525,000, which was increased to $630,000 effective January 1, 2022, and for an initial target annual performance bonus equal to 55%, which was increased to 60% effective January 1, 2021, of Mr. Lucchino&#8217;s annual base salary based on the attainment of predetermined performance objectives agreed upon between Mr. Lucchino and Frequency&#8217;s board of directors. In the event of certain corporate transactions, including a spin-off of assets or a restructuring, Mr. Lucchino would have been entitled to the same relative ownership percentage in the resulting entity or entities as he had in the company immediately before the corporate transaction. If a &#8220;change in control&#8221; (as such term is defined in his employment agreement) occurred, all of Mr. Lucchino&#8217;s time-based equity awards would accelerate and vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023 and in connection with Mr. Lucchino&#8217;s departure from Frequency in connection with the Merger, Mr. Lucchino signed a separation agreement pursuant to which he was entitled to receive the following termination payments, subject to his non-revocation of a release in our favor: (i) eighteen months&#8217; base salary, (ii) 100% of his target annual bonus and (iii) a pro-rated portion of his annual target bonus based on the portion of the year he was employed. The payments under clauses (i)-(iii) were payable in a single lump sum on the first payroll date following the 60</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">day after his termination of employment. Mr. Lucchino also received up to twelve months&#8217; continued coverage, at our expense, under COBRA, if he elected such continued coverage. In addition to the termination payments, all equity awards granted to Mr. Lucchino accelerated in vesting (including any awards subject to performance-based vesting).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Lucchino was also party to restrictive covenant agreements, pursuant to which he agreed to refrain from competing with us or soliciting its customers or employees during his employment and for one year following termination of his employment and from disclosing our proprietary information during or at any time following his employment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vineet Agarwal</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2021, Legacy Korro entered into an employment agreement with Mr. Agarwal, or the Prior Agarwal Employment Agreement. The Prior Agarwal Employment Agreement set forth his initial annual base salary of $385,000, initial target bonus opportunity equal to 35% of Mr. Agarwal&#8217;s base salary, initial equity grant, and his eligibility to participate in our employee benefit plans generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prior Agarwal Employment Agreement provided that in the event that Mr. Agarwal&#8217;s employment were terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (as such terms are defined in the Prior Agarwal Employment Agreement), in either case within 12 months following a change in control, or the Agarwal Change in Control Period, subject to Mr. Agarwal&#8217;s signing and complying with a separation agreement and release, Mr. Agarwal would have been entitled to the following severance benefits: (i) a lump sum cash payment equal to sum of (x) nine months of his then-current base salary (or the base salary in effect immediately prior to the change in control, if higher), plus (y) 100% of Mr. Agarwal&#8217;s target annual bonus for the year of termination, without regard to whether the metrics had been established or achieved for such year; (ii) if Mr. Agarwal elected COBRA health continuation, a monthly payment to the group health plan provider or the COBRA provider for up to nine months, and (iii) 100% of all equity awards subject to time-based vesting held by Mr. Agarwal would have immediately accelerated in vesting and become fully exercisable or non-forfeitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the event that Mr. Agarwal&#8217;s employment were terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221;, in each case outside the Agarwal Change in Control Period, subject to Mr. Agarwal&#8217;s signing and complying with a separation agreement and release, Mr. Agarwal would have been entitled to the severance benefits as described in the preceding paragraph, payable in substantially equal installments over a nine-month period, provided that Mr. Agarwal would not have been entitled to any acceleration of vesting of his equity awards and the target annual bonus described above would have been prorated based on the date of termination.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Steven Colletti</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 20, 2023, Legacy Korro entered into an employment agreement with Dr. Colletti, or the Prior Colletti Employment Agreement. The Prior Colletti Employment Agreement set forth his initial annual base salary of $420,000, initial target bonus opportunity equal to 35% of Dr. Colletti&#8217;s base salary, initial equity grant, and his eligibility to participate in our employee benefit plans generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prior Colletti Employment Agreement provided that in the event that Dr. Colletti&#8217;s employment were terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (as such terms are defined in the Prior Colletti Employment Agreement), in either case within 12 months following a change in control, or the Colletti Change in Control Period, subject to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">145</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Colletti&#8217;s signing and complying with a separation agreement and release, Dr. Colletti would have been entitled to the following severance benefits: (i) a lump sum cash payment equal to sum of (x) nine months of his then-current base salary (or the base salary in effect immediately prior to the change in control, if higher), plus (y) 100% of Dr. Colletti&#8217;s target annual bonus for the year of termination, without regard to whether the metrics had been established or achieved for such year; (ii) if Dr. Colletti elected COBRA health continuation, a monthly payment to the group health plan provider or the COBRA provider for up to nine months, and (iii) 100% of all equity awards subject to time-based vesting held by Dr. Colletti would have immediately accelerated in vesting and become fully exercisable or non-forfeitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the event that Dr. Colletti&#8217;s employment were terminated by Legacy Korro without &#8220;cause&#8221; or by him for &#8220;good reason&#8221;, in each case outside the Colletti Change in Control Period, subject to Dr. Colletti&#8217;s signing and complying with a separation agreement and release, Dr. Colletti would have been entitled to the severance benefits as described in the preceding paragraph, payable in substantially equal installments over a nine-month period, provided that Dr. Colletti would not have been entitled to any acceleration of vesting of his equity awards and the target annual bonus described above would have been prorated based on the date of termination.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Christopher R. Loose</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Frequency entered into an amended and restated employment agreement with Dr. Loose on September 20, 2019, pursuant to which Frequency employed Dr. Loose as its Chief Scientific Officer. Dr. Loose&#8217;s employment agreement had an indefinite term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Loose&#8217;s employment agreement provided for an annual base salary of $425,000, which was increased to $480,344 effective January 1, 2022, and a target annual performance bonus equal to 40% of his base salary, and was based on the attainment of predetermined individual and company performance objectives agreed upon between Dr. Loose and Frequency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event Frequency terminated Dr. Loose&#8217;s employment without &#8220;cause&#8221; or he resigned for &#8220;good reason&#8221; (as such terms are defined in his employment agreement), subject to his execution and non-revocation of a release in our favor, he was entitled to receive the following termination payments: (i) 12 months&#8217; continued base salary in equal installments following his termination, (ii) 100% of his target annual bonus paid in a lump sum within 14 days following his execution of the release and (iii) if he made an election, up to twelve months continued coverage under COBRA, with us paying the same portion of the COBRA premiums as we pays for active employees. If such a qualifying termination occurs within twelve months following a &#8220;change in control&#8221; (as defined in his employment agreement), Dr. Loose&#8217;s equity awards would have accelerated and vested.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Loose was a party to restrictive covenant agreements, pursuant to which he has agreed to refrain from competing with us or soliciting our customers or employees during his employment and for one year following termination of his employment and from disclosing our proprietary information during or at any time following his employment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2023, Frequency entered into a separation agreement with Dr. Loose pursuant to which, in exchange for a general release of claims in our favor, he was entitled to receive (i) continued payment of his base salary for a period of 12 months from July 28, 2023, (ii) continued group health plan coverage under COBRA for up to 12 months, with Frequency paying the portion of the premium that it would pay for active and similarly situated employees, (iii) $201,744.35, which was equal to 100% of his 2023 target bonus opportunity, and (iv) accelerated vesting of all of his unvested stock options and RSUs, subject to the closing of the Merger prior to or on December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current Offer Letters and Employment Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered new employment agreements with certain of our executive officers following the closing of the Merger, the terms of which are described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ram Aiyar</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 10, 2023, we entered into a new employment agreement with Dr. Ram Aiyar, our President and Chief Executive Officer, or the Aiyar Employment Agreement. Under the Aiyar Employment Agreement, Dr. Aiyar has an initial annual base salary of $498,487 and an initial target bonus opportunity equal to 45% of his annual base salary, he continues to remain eligible for equity grants under our equity incentive plans, and he continues to be eligible to participate in our employee benefit plans generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Aiyar Employment Agreement provides that in the event Dr. Aiyar is terminated without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; (as such terms are defined therein) outside of the change in control period (which extends from three months prior to a change in control to 12 months following a change in control, as &#8220;change in control&#8221; is defined therein), subject to signing and complying with a separation agreement and release, which shall include, without limitation, a release of claims, a reaffirmation of restrictive covenants, and in our sole discretion, a one year post-employment noncompetition agreement, then Dr. Aiyar will be entitled to the following severance benefits: (i) 12 months of his then-current base salary, (ii) a pro rata target bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year, and (iii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">146</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">health coverage, up to 12 months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Aiyar Employment Agreement provides enhanced severance pay and benefits in the event Dr. Aiyar&#8217;s employment is terminated by us without cause or he resigns for good reason, in each case, within the change in control period. Such enhanced severance pay and benefits consist of (i) a lump sum cash payment equal to the sum of (A) 18 months of Dr. Aiyar&#8217;s then-current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus (B) 1.5 times Dr. Aiyar&#8217;s target annual bonus for the then-current year, without regard to whether the metrics have been established or achieved for such year, (ii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, up to 18 months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us, and (iii) accelerated vesting of the then-outstanding and unvested portion of Dr. Aiyar&#8217;s stock options and other stock-based awards that are subject solely to time-based vesting and any stock options and other stock-based awards that were granted to him prior to the effective date of the Aiyar Employment Agreement and that are subject to performance-based vesting. The severance pay and benefits described in this paragraph are subject to Dr. Aiyar&#8217;s delivery of and compliance with a fully effective release of claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The payments and benefits under the Aiyar Employment Agreement in connection with a change in control may not be eligible for federal income tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Aiyar in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Aiyar entered into an Employee Proprietary Information and Inventions Assignment Agreement that contains, among other provisions, nondisclosure of confidential information, invention assignment and nonsolicitation provisions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vineet Agarwal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 8, 2023, we entered into a new employment agreement with Vineet Agarwal, our Treasurer and Chief Financial Officer, or the Agarwal Employment Agreement. Under Mr. Agarwal&#8217;s new employment agreement, he has an initial annual base salary of $426,483, an initial target bonus opportunity equal to 35% of his annual base salary and continues to remain eligible for equity grants under our equity incentive plans, and continues to be eligible to participate in our employee benefit plans generally.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Agarwal Employment Agreement provides that in the event Mr. Agarwal is terminated without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; (as such terms are defined therein) outside of the change in control period (which extends from three months prior to a change in control to 12 months following a change in control, as &#8220;change in control&#8221; is  defined therein), subject to him signing and complying with a separation agreement and release, which shall include, without limitation, a release of claims, a reaffirmation of restrictive covenants, and in our sole discretion, a one year post-employment noncompetition agreement, then Mr. Agarwal will be entitled to the following severance benefits: (i) nine months of his then-current base salary, (ii) a pro rata target bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year, and (iii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, up to nine months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Agarwal Employment Agreement provides enhanced severance pay and benefits in the event Mr. Agarwal&#8217;s employment is terminated by us without cause or Mr. Agarwal resigns for good reason, in each case, within the change in control period. Such enhanced severance pay and benefits consist of (i) a lump sum cash payment equal to the sum of (A) 12 months of Mr. Agarwal&#8217;s then-current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus (B) 1.0 times Mr. Agarwal&#8217;s target annual bonus for the then current year, without regard to whether the metrics have been established or achieved for such year, (ii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, up to 12 months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us, and (iii) accelerated vesting of the then-outstanding and unvested portion of Mr. Agarwal&#8217;s stock options and other stock-based awards that are subject solely to time-based vesting. The severance pay and benefits described in this paragraph are subject to Mr. Agarwal&#8217;s delivery of and compliance with a fully effective release of claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The payments and benefits under the Agarwal Employment Agreement in connection with a change in control may not be eligible for federal income tax deduction by us pursuant to Section 280G of Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Mr. Agarwal in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Agarwal entered into an Employee Proprietary Information and Inventions Assignment Agreement that contains, among other provisions, nondisclosure of confidential information, invention assignment and nonsolicitation provisions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">147</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Steven Colletti</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 8, 2023, we entered into a new employment agreement with Steven Colletti, our Chief Scientific Officer, or the Colletti Employment Agreement.  Under Dr. Colletti&#8217;s new employment agreement, he has an initial annual base salary of $420,000, an initial target bonus opportunity equal to 35% of his annual base salary (with any incentive bonus for 2023 to be prorated based on Dr. Colletti&#8217;s days of employment with our company during 2023) and continues to remain eligible for equity grants under our equity incentive plans, and continues to be eligible to participate in our employee benefit plans generally.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Colletti Employment Agreement provides that in the event Dr. Colletti is terminated without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; (as such terms are defined therein) outside of the change in control period (which extends from three months prior to a change in control to 12 months following a change in control, as &#8220;change in control&#8221; is defined therein), subject to signing and complying with a separation agreement and release, which shall include, without limitation, a release of claims, a reaffirmation of restrictive covenants, and in our sole discretion, a one year post-employment noncompetition agreement, then Dr. Colletti will be entitled to the following severance benefits: (i) nine months of his then-current base salary, plus (ii) a pro rata target bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year, and (iii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, up to nine months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Colletti Employment Agreement provides enhanced severance pay and benefits in the event Dr. Colletti&#8217;s employment is terminated by us without cause or Dr. Colletti resigns for good reason, in each case, within the change in control period. Such enhanced severance pay and benefits consist of (i) a lump sum cash payment equal to the sum of (A) 12 months of Dr. Colletti&#8217;s then-current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus (B) 1.0 times Dr. Colletti&#8217;s target annual bonus for the then-current year, without regard to whether the metrics have been established or achieved for such year, (ii) subject to his copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, up to 12 months of payment of the portion of the premium equal to the amount we would have paid to provide health insurance had he remained employed by us, and (iii) accelerated vesting of the then-outstanding and unvested portion of Dr. Colletti&#8217;s stock options and other stock-based awards that are subject solely to time-based vesting. The severance pay and benefits described in this paragraph are subject to Dr. Colletti&#8217;s delivery of and compliance with a fully effective release of claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The payments and benefits under the Colletti Employment Agreement in connection with a change in control may not be eligible for federal income tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Colletti in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Colletti entered into an Employee Proprietary Information and Inventions Assignment Agreement that contains, among other provisions, nondisclosure of confidential information, invention assignment and nonsolicitation provisions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outstanding Equity Awards at 2023 Fiscal Year-End</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth information concerning outstanding equity awards held by each of the named executive officers as of December 31, 2023. For Messrs. Aiyar, Agarwal and Colletti, each equity award granted prior to the Merger were under the terms of the Legacy Korro Plan and each equity award granted following the Merger were under the terms of the 2023 Plan.  For Mr. Lucchino and Dr. Loose, each equity award granted prior to the Merger were under the terms of the 2019 Plan or the 2014 Plan and each equity award granted following the Merger were under the terms of the 2023 Plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">148</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.889%;"/>
    <td style="width:1.59%;"/>
    <td style="width:1%;"/>
    <td style="width:14.027999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:2.504%;"/>
    <td style="width:1.089%;"/>
    <td style="width:1%;"/>
    <td style="width:14.027999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.59%;"/>
    <td style="width:1%;"/>
    <td style="width:14.027999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.59%;"/>
    <td style="width:1%;"/>
    <td style="width:14.027999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.633%;"/>
    <td style="width:15.004%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option Awards</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vesting<br/>Commencement<br/>Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option<br/>Exercise<br/>Price<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option<br/>Expiration<br/>Date</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ram Aiyar</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/2/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,007</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,226</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/1/2030</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/27/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.75</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/26/2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/1/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,130</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/8/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/3/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,265</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153,495</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/2/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David L. Lucchino</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,887</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/16/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,927</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/16/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,927</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/16/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,287</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/1/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,849</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/11/2030</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/14/2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vineet Agarwal</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/11/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,385</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,484</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/29/2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/27/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,854</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,107</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.75</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/26/2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/1/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,590</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/23/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/3/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">969</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,578</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/2/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steven Colletti</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/21/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,895</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/10/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/3/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">718</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,760</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/2/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Christopher R. Loose</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,211</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,284</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,284</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,935</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,149</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107.00</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/3/2024 (4)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1/4 of the shares subject to the stock option vest on the first anniversary of the vesting commencement date, and 1/48 of the shares subject to the stock option vest each month thereafter, in each case, subject to the named executive officer&#8217;s continuous service relationship with us through each applicable vesting date. The stock option is also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer&#8217;s offer letter or employment agreement, as applicable. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1/48 of the shares subject to the stock option vest each month following the vesting commencement date, in each case, subject to the named executive officer&#8217;s continuous service relationship with us through each applicable vesting date. The stock option is also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer&#8217;s offer letter or employment agreement, as applicable. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the shares subject to the stock option were vested as of December 31, 2023.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Loose&#8217;s service relationship with Frequency terminated on November 3, 2023. The date reported represents the expiration of the post-termination exercise period of the stock option.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Director Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 3, 2023, Frequency completed the Merger with Legacy Korro. At the effective time of the Merger, a majority of the Frequency directors resigned, with the exception of David Lucchino, and the remaining director vacancies were replaced by new directors designated by Legacy Korro. Accordingly, we have provided the compensation disclosure with respect to all directors of Frequency and Legacy Korro that served during 2023 and for those non-employee directors of Legacy Korro that were appointed to our Board in connection with the Merger.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have designed and implemented our compensation program for our non-employee directors to attract, motivate and retain individuals who are committed to our values and goals and who have the expertise and experience that we need to achieve those goals.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">149</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Director Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the total compensation for each person who served as a non-employee director on our board of directors during 2023.  The non-employee directors included in the following table under the heading Current Non-Employee Directors were our non-employee directors as of December 31, 2023.  Dr. Aiyar, our Chief Executive Officer and President, did not receive any additional compensation from us for services on our board of directors.  Mr. Lucchino, the Chief Executive Officer and President of Frequency prior to the Merger, did not receive any additional compensation from Frequency for services on Frequency&#8217;s board of directors prior to the Merger or from us for services on our board of directors following the Merger. The compensation received by Dr. Aiyar and Mr. Lucchino, respectively, as our named executive officers is set forth above in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Summary Compensation Table.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.971%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.118%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.938%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:12.577%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.398%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fees Paid<br/>or Earned<br/>in Cash<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option Awards <br/>($) (1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Other Compensation<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current Non-Employee Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ali Behbahani (2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,445</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,034</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nessan Bermingham (3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,137</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332,390</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">534,527</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jean-Francois Formela (4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,206</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171,795</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rachel Meyers (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,231</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299,994</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">304,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Timothy R. Pearson (6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,560</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,149</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Former Non-Employee Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Timothy J. Barberich (7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jordan Baumhardt (8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hannah Chang (9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cynthia L. Feldmann (10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,120</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,120</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Huang (11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,383</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,383</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Omar Khwaja (12)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert S. Langer (13)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000 (14)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,065</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Joel S. Marcus (15)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,535</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,535</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alex Silverstein (16)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Colin Walsh (17)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amounts reported represent the aggregate grant date fair value of the stock option awards granted to our non-employee directors during fiscal year 2023, computed in accordance with FASB ASC Topic 718, rather than the amounts paid to or realized by the non-employee directors.  Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock option awards reported in this column are set forth in Note 11 of our financial statements included elsewhere in this Annual Report on Form 10-K. The amounts reported in this column reflect the accounting cost for these stock option awards and do not correspond to the actual economic value that may be received by our non-employee directors upon the exercise of the stock option awards or any sale of the underlying shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Behbahani held options to purchase an aggregate of 16,000 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Bermingham held options to purchase an aggregate of 91,773 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Formela held options to purchase an aggregate of 16,000 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Meyers held options to purchase an aggregate of 12,551 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Pearson held options to purchase an aggregate of 16,000 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Barberich held options to purchase an aggregate of 2,335 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Baumhardt did not hold any options to purchase shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Chang did not hold any outstanding equity awards.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Ms. Feldman held options to purchase an aggregate of 1,185 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Huang held options to purchase an aggregate of 888 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Khwaja held options to purchase an aggregate of 3,726 shares of our common stock.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Dr. Langer held options to purchase an aggregate of 7,737 shares of our Bio common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts represent consulting fees paid pursuant to a verbal consulting agreement with us prior to the termination of consulting services upon the closing of the Merger.  The agreement entitled Dr. Langer to $5,000 in consulting fees per month. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Marcus held options to purchase an aggregate of 888 shares of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Silverstein did not hold any outstanding equity awards.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Mr. Walsh did not hold any outstanding equity awards.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prior to the Merger</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, Legacy Korro did not have a formal policy to provide any cash or equity compensation to its non-employee directors for their service on the Legacy Korro board of directors or committees of its board of directors nor did any non-employee director receive any compensation for serving on Legacy Korro&#8217;s board of directors, except for Dr. Bermingham who received an annual payment of $187,500 for services on Legacy Korro&#8217;s board of directors prior to the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, Frequency maintained a compensation program for Frequency non-employee directors, or the Frequency Director Program under which each Frequency non-employee director received the following amounts for their services on our board of directors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:83.92%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.5%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Annual Retainer for Board Membership</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$35,000 for general availability and participation in meetings and conference calls of our Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Annual Retainer for Committee Membership</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Retainer for Chairperson of the Board, Vice Chairperson of the Board, or Lead Independent Director:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Frequency Director Plan, Frequency non-employee directors were granted an option to purchase 29,693 (prior to the Reverse Stock Split) shares of our common stock upon the director&#8217;s initial election or appointment to our board of directors and, if the director had served on our board of directors for at least six months as of the date of an annual meeting of stockholders, an option to purchase 14,846 (prior to the Reverse Stock Split) shares of our common stock on the date of the annual meeting. The stock options granted to Frequency non-employee directors under the program had an exercise price equal to the fair market value of our common stock on the date of grant and expired not later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vested in 36 substantially equal monthly installments following the date of grant. The stock options granted annually to directors vested in a single installment on the earlier of the day before the following annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vested in full upon the occurrence of a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Director fees under the Frequency Director Program were payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director was not serving as a non-employee member of our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Following the Merger</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Merger, we adopted a non-employee director compensation policy, or the Korro Director Policy.  Under the Korro Director Policy, our non-employee directors are eligible to receive cash retainers (which are be payable quarterly in arrears and prorated for partial years of service) and equity awards as set forth below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">151</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:83.92%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.5%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Annual Retainer for Board Membership</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$40,000 for general availability and participation in meetings and conference calls of our Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Annual Retainer for Committee Membership</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee Chairperson:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee member (other than Chairperson):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Retainer for Non-Executive Chairperson or Lead Director of the Board:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Korro Director Policy provides that, upon initial election or appointment to the board, each new non-employee director will be granted a non-statutory stock option with a value of $300,000 (as determined in accordance with the policy and subject to a 16,000 share maximum), or the Director Initial Grant. The Director Initial Grant will vest in substantially equal annual installments over three years, subject to continued service as a non-employee director through the applicable vesting date. On the date of each annual meeting of our stockholders, each non-employee director who has been serving as a non-employee director for at least six months as of such date and will continue as a non-employee director following such meeting will be granted an annual award of a non-statutory stock option with a value of $150,000 (subject to a 8,000 share maximum), or the Director Annual Grant. The Director Annual Grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. The Director Initial Grant and Director Annual Grants are subject to full accelerated vesting upon the sale of our company. All of the foregoing stock options will be granted with a per share exercise price equal to the fair market value of a share of our common stock on the date of grant and will have a 10 year term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any of our non-employee directors for services as a director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a non-employee director and $750,000 in any other calendar year.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of the board or any committee thereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee directors receive no additional compensation for their service as a director.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information regarding beneficial ownership of our common stock as of February 29, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the right to acquire within 60 days of February 29, 2024 the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to them, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table lists applicable percentage ownership based on 8,020,703 shares of common stock outstanding as of February 29, 2024. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days, including upon the exercise of stock options and the vesting of RSUs. These stock options and RSUs shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of our common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">152</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.54%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:14.64%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:14.62%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Beneficial Ownership</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of Beneficial Owner</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5% or Greater Stockholders:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Atlas Venture(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,119,292</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with New Enterprise Associates(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,074,273</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FMR LLC(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">727,205</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">546,325</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Point72 Asset Management(5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">542,657</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Platanus Investment LLC(6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Citadel(7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529,251</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Cormorant Asset Management LP(8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529,170</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Invus Public Equities, L.P.(9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419,226</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Directors and Named Executive Officers:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vineet Agarwal(10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,794</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ram Aiyar(11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,394</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ali Behbahani</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nessan Bermingham(12)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112,455</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jean-Fran&#231;ois Formela</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David L. Lucchino(13)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,026</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rachel Meyers</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Timothy R. Pearson.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steve Colletti (14)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,726</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Christopher R. Loose</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All directors and executive officers as a group (11 persons)(15)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419,816</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-5.337%;padding-left:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Represents beneficial ownership of less than 1%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 942,075 shares of our common stock held by Atlas Venture Fund XI, L.P., or AVF XI, and (ii) 177,217 shares of our common stock held by Atlas Venture Opportunity Fund II, L.P., or AVO II. Atlas Venture Associates XI, L.P. is the general partner of AVF XI and Atlas Venture Associates XI, LLC is the general partner of Atlas Venture Associates XI, L.P. The members of Atlas Venture Associates XI, LLC collectively make investment decisions on behalf of Atlas Venture Fund XI, LLC. Jean-Francois Formela is a member of Atlas Venture Associates XI, LLC and a member of Korro Bio&#8217;s board of directors. Each of AVF XI, Atlas Venture Associates XI, L.P., and Atlas Venture Associates XI, LLC may be deemed to beneficially own the shares held by AVF XI. Dr. Formela expressly disclaim beneficial ownership of the shares owned by AVF XI, except to the extent of his pecuniary interest therein, if any. Atlas Venture Associates Opportunity II, L.P. is the general partner of AVO II, and Atlas Venture Associates Opportunity II, LLC is the general partner of Atlas Venture Associates Opportunity II, L.P. The members of Atlas Venture Associates Opportunity II, LLC collectively make investment decisions on behalf of Atlas Venture Associates Opportunity II, LLC. Dr. Formela is a member of Atlas Venture Associates Opportunity II, LLC. Each of AVO II, Atlas Venture Associates Opportunity II, L.P., and Atlas Venture Associates Opportunity II, LLC may be deemed to beneficially own the shares held by AVO II. Dr. Formela expressly disclaim beneficial ownership of the shares owned by AVO II, except to the extent of his pecuniary interest therein, if any. The mailing address of Atlas is 300 Technology Square, 8th Floor, Cambridge, MA 02139. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 1,072,936 shares of our common stock held by New Enterprise Associates 17, L.P., or NEA 17, and 1,337 shares of our common stock held by NEA Ventures 2019, L.P. The general partner of NEA 17 is NEA Partners 17, L.P., or NEA Partners 17, and the general partner of NEA Partners 17 is NEA 17 GP, LLC, or NEA 17 LLC. The managers of NEA 17 LLC are Forest Baskett, Ali Behbahani, M.D., Carmen Chang, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Edward T. Mathers, Scott D. Sandell, Paul Walker and Rick Yang. Dr. Behbahani is a member of NEA 17 LLC and a member of Korro Bio&#8217;s board of directors. Each of NEA Partners 17 and NEA 17 LLC may be deemed to beneficially own the shares held by NEA 17. The general partner of NEA Ventures 2019, L.P., or Ven 2019, is Karen Welsh. The address of the principal business office of NEA 17, NEA Partners 17, NEA 17 LLC, Ven 2019, and Mr. Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Dr. Behbahani, Mr. Baskett, Ms. Chang, Mr. Makhzoumi, Mr. Walker and Mr. Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Mr. Florence and Mr. Mathers is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">153</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 180,884 shares of our common stock held by Fidelity Select Portfolios: Biotechnology Portfolio, (ii) 40,253 shares of our common stock held by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, (iii) 197,128 shares of our common stock held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, (iv) 250,912 shares of our common stock held by Fidelity Growth Company Commingled Pool and (v) 58,028 shares of our common stock held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. All of the foregoing securities are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 546,325 shares of our common stock held by Mutual Fund Series Trust, on behalf of Eventide. Eventide Asset Management, LLC is the investment advisor to Eventide. Robin C. John is the Chief Executive Officer of Eventide Asset Management, LLC and Finny Kuruvilla, M.D., Ph.D. is a Co-Chief Investment Officer and Managing Director of Eventide Asset Management, LLC. In their corporate capacity for Eventide Asset Management, LLC, Mr. John and Dr. Kuruvilla hold voting and/or dispositive power over the shares held by Eventide. Mr. John and Dr. Kuruvilla disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address for Eventide, Mr. John and Dr. Kuruvilla is U.S. Bank Trust Services, Physical Processing, MK-WI S302, 1555 N RiverCenter Drive, Suite 302, Milwaukee, WI 53212. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 276,831 shares of our common stock held by Point72 Biotech Private Investments, LLC, or Point72 Biotech, and 265,826 shares of our common stock held by Point72 Associates, LLC, or Point72 Associates. Differentiated Ventures Investments, LLC, or Differentiated Ventures, is the managing member of Point72 Biotech and may be deemed to share beneficial ownership of the shares held by Point72 Biotech. 72 Investment Holdings, LLC, or 72 Investment Holdings, is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of which Differentiated Ventures may be deemed to share beneficial ownership. Steven A. Cohen, or Mr. Cohen, is the sole member of 72 Investment Holdings and may be deemed to share beneficial ownership of the shares of which 72 Investment Holdings may be deemed to share beneficial ownership. Each of Differentiated Ventures, 72 Investment Holdings and Mr. Cohen disclaims beneficial ownership of the shares held by Point72 Biotech. Pursuant to an investment management agreement, Point72 Asset Management, L.P., or Point72 Asset Management, maintains investment and voting power with respect to the shares held by Point72 Associates and therefore may be deemed to share beneficial ownership of such shares. Point72 Capital Advisors, Inc., or Point72 Capital Advisors, is the general partner of Point72 Asset Management and may be deemed to share beneficial ownership of the shares of which Point72 Asset Management may be deemed to share beneficial ownership. Mr. Cohen is the sole member of Point72 Capital Advisors and may be deemed to share beneficial ownership of the shares of which Point72 Capital Advisors may be deemed to share beneficial ownership. Each of Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen disclaims beneficial ownership of the shares held by Point72 Associates. The address for Point72 Biotech and Point72 Associates is c/o Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 540,165 shares of our common stock held by Platanus Investment LLC, or Platanus. Xinyi Cai is the director of Platanus and holds voting and dispositive power over the securities owned by Platanus. The address for Platanus is 3 E 3rd Ave, Suite 200, San Mateo, CA 94401. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based solely on Schedule 13G jointly filed by Citadel Advisors LLC, or Citadel Advisors, Citadel Advisors Holdings LP, or CAH, Citadel GP LLC, or CGP, Citadel Securities LLC, or Citadel Securities, Citadel Securities Group LP, or CALC4, Citadel Securities GP LLC, or CSGP, and Mr. Kenneth Griffin, or collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the Citadel Reporting Persons, with respect to shares owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company, or CM, Citadel CEMF Investments Ltd., a Cayman Islands limited company, or CCIL, Citadel Securities and CRBU Holdings LLC, a Delaware limited liability company, or CRBH. Citadel Advisors is the portfolio manager for CM and CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities and CRBH. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The address of each of the Citadel Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 312,052 shares of our common stock held by Cormorant Global Healthcare Master Fund, LP, or Master Fund, and (ii) 217,118 shares of our common stock held by Cormorant Private Healthcare Fund II, LP, or Fund II. Cormorant Global Healthcare GP, LLC, or Global GP, and Cormorant Private Healthcare GP II, LLC, or Private GP II, serve as the general partner of Master Fund and Fund II, respectively. Cormorant Asset Management, LP serves as the investment manager to Master Fund and Fund II. Bihua Chen serves as the managing member of Global GP, Private GP II and Cormorant Asset Management, LP. Each of Global GP, Private GP II, Cormorant Asset Management, LP and Ms. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">154</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chen disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The principal address for the Cormorant Asset Management LP entities is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 419,226 shares of our common stock held by Invus Public Equities L.P., or Invus. Invus Public Equities Advisors, LLC, or Invus PE Advisors, controls Invus, as its general partner and accordingly, may be deemed to beneficially own the shares held by Invus. The Geneva branch of Artal International S.C.A., or Artal International, controls Invus PE Advisors, as its managing member and accordingly, may be deemed to beneficially own the shares held by Invus. Artal International Management S.A., or Artal International Management, as the managing partner of Artal International, controls Artal International and accordingly, may be deemed to beneficially own the shares that Artal International may be deemed to beneficially own. Artal Group S.A., or Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and accordingly, may be deemed to beneficially own the shares that Artal International Management may be deemed to beneficially own. Westend S.A., or Westend, as the parent company of Artal Group, controls Artal Group and accordingly, may be deemed to beneficially own the shares that Artal Group may be deemed to beneficially own. Stichting Administratiekantoor Westend, or the Stichting, as majority shareholder of Westend, controls Westend and accordingly, may be deemed to beneficially own the shares that Westend may be deemed to beneficially own. Mr. Amaury Wittouck, as the sole member of the board of the Stichting, controls the Stichting and accordingly, may be deemed to beneficially own the shares that the Stichting may be deemed to beneficially own. The address for Invus and Invus PE Advisors is 750 Lexington Avenue, 30th Floor, New York, NY 10022. The address for Artal International, Artal International Management, Artal Group, Westend and Mr. Wittouck is Valley Park, 44, Rue de la Vall&#233;e, L-2661, Luxembourg. The address for the Stichting is Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands. The address for Invus is 750 Lexington Avenue, New York, NY 10022. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 38,794 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(11)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 4,613 shares of our common stock held by The Ram Aiyar Irrevocable Trust, or the Trust, and (ii) 162,781 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024. The address of the Trust is c/o Steven M. Burke, P.O. Box 326, Manchester, NH 03105. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(12)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 35,114 shares of our common stock and (ii) 77,341 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(13)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 22,150 shares of our common stock and (ii) 35,876 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(14)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of 18,726 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">(15)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consists of (i) 61,877 shares of our common stock and (ii) 357,939 shares of our common stock underlying options that are exercisable or will become exercisable within 60 days of February 29, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides information as of December 31, 2023 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.02%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:13.76%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:8.14%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:16.82%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Plan Category</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Securities <br/>to be Issued Upon <br/>Exercise of Outstanding <br/>Options, Warrants and Rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price of<br/>Outstanding Options,<br/>Warrants and Rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities in First Column)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by stockholders </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,328,229</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$16.48</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344,169</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans not approved by stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,328,229</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.48</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344,169</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes the following plans: the 2023 Plan, the 2019 Plan, the Legacy Korro Plan, the 2014 Plan and the 2023 ESPP.   </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 1,328,229 shares issuable upon the exercise of outstanding options, of which 600,977 were assumed in connection with the Merger. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average exercise price is calculated based solely on outstanding stock options. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, a total of 255,694 shares were reserved for issuance pursuant to the 2023 Plan and a total of  88,502 shares were reserved for issuance pursuant to the 2023 ESPP. Following the Merger, we did not grant any awards under the 2019 Plan, the 2014 Plan, or the Legacy Korro Plan, but all outstanding awards under such plans continue to be governed by their existing terms.  The 2023 Plan has an evergreen provision that allows for an annual increase in the number of shares available for issuance under the 2023 Plan to be added on the first day of January, </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">155</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">starting with January 1, 2024, in an amount equal to the lesser of (i) 5% of the outstanding number of shares of our common stock on the immediately preceding December 31 or (ii) such number of shares as determined by the administrator of the 2023 Plan in each case subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The shares of common stock underlying any awards granted under the Legacy Korro Plan, the 2019 Plan or the 2014 Plan that are forfeited, canceled, reacquired by us prior to vesting, satisfied without the issuance of stock, or otherwise terminated (other than by exercise) and the shares of common stock that are withheld upon exercise of a stock option or settlement of such award to cover the exercise price or tax withholding will be added to the shares of common stock available for issuance under the 2023 Plan.  The 2023 ESPP has an evergreen provision that allows for an annual increase in the number of shares available for issuance under the 2023 ESPP to be added on the first day of each January, starting with January 1, 2024, by the lesser of (i) 88,502 shares of our common stock, (ii) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the 2023 ESPP. The number of shares reserved under the 2023 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The number in the table does not include the increases from January 1, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Rela</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tionships and Related Transactions, and Director Independence.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock Financing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, December 2021 and March 2023, Legacy Korro sold an aggregate of 43,085,531 shares of its Series B preferred stock at a purchase price of $2.61 and $2.78 per share for aggregate gross proceeds of $116.0 million. The following table summarizes purchases of Legacy Korro&#8217;s Series B preferred stock by related persons (share amounts have not been updated to reflect the exchange for our common stock in the Merger):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Legacy Korro <br/>Series B<br/>Preferred<br/>Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Purchase<br/>Price<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Atlas Venture Fund XI, L.P. (1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,064,273</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,250,001</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Enterprise Associates 17, L.P. (2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,971,416</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Platanus Investment LLC (3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,764,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,750,002</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Qiming U.S. Healthcare Fund II, L.P. (4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,114,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,428,540</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Invus Public Equities, L.P. (6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,571,405</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Point72 Biotech Private Investments, LLC (7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,571,405</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Ram Aiyar Irrevocable Trust (8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,857</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250,001</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FMR LLC (9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,285,675</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Citadel Multi-Strategy Equities Master Fund Ltd. (10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">835,710</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,249,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Cormorant Asset Management LP (11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">835,710</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,249,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atlas beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Jean-Fran&#231;ois Formela is a Partner at Atlas and a member of our board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NEA beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Ali Behbahani is a Partner at NEA and a member of our board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Platanus beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Hannah Chang is a Partner at Platanus and was a member of Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Qiming beneficially owned more than 5% of Legacy Korro's outstanding capital stock and had a designee on Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund, or Eventide, beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Invus Public Equities, L.P. beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Point72 Biotech Private Investments, LLC beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock and had a designee on Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ram Aiyar is the grantor of The Ram Aiyar Irrevocable Trust, is our chief executive officer and member of our board of directors and was chief executive officer of Legacy Korro and a member of its board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FMR LLC beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">156</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Citadel Multi-Strategy Equities Master Fund Ltd. beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(11)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entities affiliated with Cormorant Asset Management LP beneficially owned more than 5% of Legacy Korro's capital stock and beneficially own more than 5% of our outstanding capital stock.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pre-Closing Financing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro entered into a Subscription Agreement in July 2023 with certain investors to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase shares of Legacy Korro common stock, at a price of $2.78 per share, for aggregate gross proceeds of $117.3 million. Seven of the investors or their affiliates were beneficial holders of more than 5% of Legacy Korro's capital stock, and the table below sets forth the number of shares of Legacy Korro common stock purchased by such holders at the closing of the Pre-Closing Financing (share amounts have not been updated to reflect the exchange for our common stock in the Merger):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Legacy Korro<br/>Common<br/>Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Purchase<br/>Price<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Atlas Venture Fund XI, L.P. (1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,217</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Enterprise Associates 17, L.P. (2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,217</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FMR LLC (3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Citadel CEMF Investments Ltd.(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Platanus Investment LLC (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,860</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Qiming U.S. Healthcare Fund II, L.P. (6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,443</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund (7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,217</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Invus Public Equities, L.P (8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,774</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Point72 Associates, LLC (9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entities affiliated with Cormorant Asset Management LP (10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,999,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atlas beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Jean-Fran&#231;ois Formela is a Partner at Atlas and a member of our board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NEA beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Ali Behbahani is a Partner at NEA and a member of our board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FMR LLC beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Citadel beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Platanus beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. Hannah Chang is a Partner at Platanus and was a member of Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Qiming beneficially owned more than 5% of Legacy Korro's outstanding capital stock and had a designee on Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eventide beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Invus Public Equities, L.P. beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of our outstanding capital stock. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Point72 Biotech Private Investments, LLC, an affiliate of Point72 Associates, LLC, beneficially owned more than 5% of Legacy Korro's capital stock and beneficially owns more than 5% of Legacy Korro&#8217;s outstanding capital stock and had a designee on Legacy Korro&#8217;s board of directors. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entities affiliated with Cormorant Asset Management LP beneficially owned more than 5% of Legacy Korro's capital stock and beneficially own more than 5% of our outstanding capital stock.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Agreements with Our Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with Legacy Korro&#8217;s Series B convertible preferred stock financing, Legacy Korro entered into investors&#8217; rights, voting and right of first refusal and co-sale agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Legacy Korro preferred stock and certain holders of Legacy Korro common stock. These stockholder agreements terminated upon the closing of the Merger, except for the registration rights granted under Legacy Korro&#8217;s investors&#8217; rights agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">157</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on our behalf or that person&#8217;s status as a member of our board of directors to the maximum extent allowed under Delaware law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Rights under Frequency Investors' Rights Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Frequency entered into a second amended and restated investors&#8217; rights agreement, or the Investors&#8217; Rights Agreement, in July 2019 with each holder of Frequency preferred stock, which included certain holders of more than 5% of Frequency common stock at the time and certain of Frequency&#8217;s directors and executive officers. The Investors&#8217; Rights Agreement grants the parties thereto certain registration rights in respect of the &#8220;registrable securities&#8221; held by them, which securities include (1) the shares of Frequency common stock issuable or issued upon the conversion of shares of Frequency convertible preferred stock, (2) any shares of Frequency common stock, or any common stock issued or issuable upon conversion and/or exercise of any of Frequency&#8217;s securities acquired by the parties after the date of the Investors&#8217; Rights Agreement, and (3) any shares of Frequency common stock issued as a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares described in the foregoing clauses (1) and (2). The registration of shares of Frequency common stock pursuant to the exercise of these registration rights would enable the holders thereof to sell such shares under the Securities Act when the applicable registration statement is declared effective. Under the Investors&#8217; Rights Agreement, Frequency will pay all expenses relating to such registrations, including the reasonable fees of one special counsel for the participating stockholders, and the stockholders will pay all underwriting discounts and commissions relating to the sale of their shares. The Investors&#8217; Rights Agreement also includes customary indemnification and procedural terms.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form S-1 registration rights</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If at any time the holders of at least 40% of the registrable securities request in writing that Frequency effects a registration with respect to at least 25% of such registrable securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of selling expenses, would exceed $10.0 million), Frequency is obligated to register their shares. Frequency is obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Piggyback registration rights</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If at any time Frequency proposes to register any shares of Frequency common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their registrable securities in the registration. If Frequency&#8217;s proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form S-3 registration rights</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If, at any time after Frequency becomes entitled under the Securities Act to register Frequency&#8217;s shares on a registration statement on Form S-3, the holders of the registrable securities request in writing that Frequency effects a registration with respect to registrable securities at an aggregate price to the public in the offering of at least $1,000,000, net of expenses borne by the holders, Frequency is obligated to effect such registration. Frequency is not obligated to effect more than one S-3 registration in any 12 month period.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expenses and indemnification</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ordinarily, other than underwriting discounts and commissions, Frequency will be required to pay all expenses incurred by Frequency related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration, filing and qualification fees, printing and accounting fees, fees and disbursements of Frequency&#8217;s counsel, and reasonable fees and disbursements of a counsel for the selling securityholders. Additionally, Frequency has agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement or alleged untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact required to be stated in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of registration rights</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">158</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registration rights expire on the earlier of (1) the date that is five years after the closing of Frequency&#8217;s IPO and (2) with respect to each stockholder, at such time as such stockholder can sell all of its shares pursuant to Rule 144 of the Securities Act or another similar exemption under the Securities Act during any three month period without registration.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Rights under Legacy Korro Investors&#8217; Rights Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro entered into a third amended and restated investors&#8217; rights agreement, or the Legacy Korro Investors&#8217; Rights Agreement, in November 2021 with each holder of Legacy Korro&#8217;s preferred stock. The Legacy Korro Investors&#8217; Rights Agreement grants such holders certain registration rights in respect of the &#8220;registrable securities&#8221; held by them, which securities include (1) the shares of Legacy Korro&#8217;s common stock issuable or issued upon the conversion of shares of Legacy Korro&#8217;s preferred stock, (2) any shares of Legacy Korro&#8217;s common stock, or any common stock issued or issuable upon conversion and/or exercise of any of Legacy Korro&#8217;s securities acquired by such holders after the date of the Legacy Korro Investors&#8217; Rights Agreement, and (3) any shares of Legacy Korro common stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares described in the foregoing clauses (1) and (2). The registration of shares of Legacy Korro&#8217;s common stock pursuant to the exercise of these registration rights would enable the holders thereof to sell such shares under the Securities Act when the applicable registration statement is declared effective. Under the Legacy Korro Investors&#8217; Rights Agreement, Legacy Korro agreed to pay all expenses relating to such registrations, including the reasonable fees of one special counsel for the selling holders, and the selling holders agreed to pay all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of the registrable securities, and fees and disbursement of counsel for the selling holders (except as agreed to be paid by Legacy Korro). The Legacy Korro Investors&#8217; Rights Agreement also includes customary indemnification and procedural terms.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form S-1 registration rights</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If at any time the holders of a majority of the registrable securities request in writing that Legacy Korro effects a registration with respect to at least 50% of such registrable securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of selling expenses, would exceed $15.0 million), Legacy Korro is obligated to register their shares. Legacy Korro is obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Piggyback registration rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          If at any time Legacy Korro proposes to register any shares of Legacy Korro&#8217;s common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their registrable securities in the registration. If Legacy Korro&#8217;s proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form S-3 registration rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          If, at any time after Legacy Korro becomes entitled under the Securities Act to register Legacy Korro&#8217;s shares on a registration statement on Form S-3, the holders of at least 10% of the registrable securities then outstanding request in writing that Legacy Korro effects a registration with respect to registrable securities at an aggregate price, net of selling expenses, to the public in the offering of at least $5,000,000, Legacy Korro is obligated to effect such a registration. Legacy Korro is not obligated to effect more than two S-3 registrations in any 12 month period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of registration rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         The registration rights expire on the earlier of (1) the date that is five years after the closing of Legacy Korro&#8217;s IPO, (2) with respect to each stockholder, at such time as such stockholder can sell all of its shares pursuant to Rule 144 of the Securities Act or another similar exemption under the Securities Act during any three month period without limitation during a three-month period, and (3) the closing of a deemed liquidation event.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-Closing Financing Registration Rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         In connection with the Pre-Closing Financing, we entered into a registration rights agreement, or the Registration Rights Agreement, in July 2023 with Legacy Korro and each purchaser in the Pre-Closing Financing. Pursuant to the Registration Rights Agreement, we agreed to register the &#8220;registrable securities&#8221; held by the purchasers on a registration statement, or registration statements, if necessary, to permit resale of such securities on a continuous basis pursuant to Rule 415. The &#8220;registrable securities&#8221; include (a) all shares of our common stock issued to the purchasers at the closing of the Merger in respect of the shares of Legacy Korro&#8217;s common stock purchased by the purchasers in the Pre-Closing Financing, (b) all shares of our common stock issued at the closing of the Merger to the purchasers in respect of all other shares of Legacy Korro&#8217;s capital stock held by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">159</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchaser as of immediately prior to the closing of the Merger, and (c) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. Under the Registration Rights Agreement, we will pay all fees and expenses incident to the performance of our obligations, including the reasonable fees of one special counsel for Citadel CEMF Investments Ltd, excluding any underwriting, broker or similar fees or commissions, legal fees and other costs (except as agreed to be paid by us) of any purchaser.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Policies for Approval of Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors reviews and approves transactions with our directors, officers and holders of 5% or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#8217;s relationship or interest in the transaction are disclosed to our stockholders, who must approve the transaction in good faith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principa</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l Accountant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We incurred the following fees from Ernst &amp; Young LLP for the audit of the consolidated financial statements and for other services related to the years ended December 31, 2023 and December 31, 2022. The following table summarizes the fees for Ernst &amp; Young LLP services to the Company for the last two fiscal years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fee Category</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year<br/>2023 ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year<br/>2022 ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Fees (1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,341,206</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,007</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit-Related Fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax Fees (2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,060</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,390</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All Other Fees (3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,358,866</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) &#8220;Audit fees&#8221; consist of fees for the audit of our annual financial statements, review of the interim financial statements included in our quarterly reports on Form 10-Q, registration statements on Form S-4, registration statements on Form S-3, registration statements on Form S-1 and other professional services provided in connection with financings and other regulatory filings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) &#8220;Tax fees&#8221; consist of fees for professional services, including tax compliance, tax advice and tax planning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3) &#8220;All other fees&#8221; consist of fees paid to access Ernst &amp; Young LLP publications and on-line subscriptions/content.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Audit Committee Pre-approval Policy and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval details the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">160</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">xhibit and Financial Statement Schedules.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a list of the financial statements included herein, see the Index to the Consolidated Financial Statements in Item 8 on page </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936dex21.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated as of July 14, 2023, by and among the registrant, Frequency Merger Sub, Inc. and the entity formerly known as Korro Bio, Inc. (incorporated by reference to Exhibit 2.1 to the registrant&#8217;s Current Report on Form 8-K filed on July 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312519263787/d796545dex31.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed on October 7, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex31.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed on November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex32.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K filed on November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312520253994/d62983dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed on September 23, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523299978/d597314dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. 2023 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Registration Statement on Form S-1/A filed December 20, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523287451/d597314dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Registration Statement on Form S-1/A filed December 20, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex108.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. 2019 Stock Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.8 to the registrant&#8217;s Current Report on Form 8-K filed on November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex1011.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.11 to the Form 8-K, filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Frequency Therapeutics, Inc. 2014 Stock Incentive Plan, as amended, and form of option agreements thereunder (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Registration Statement on Form S-1 (333-233652) filed on September 6, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Frequency Therapeutics, Inc. 2019 Incentive Award Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Registration Statement on Form S-1/A (333-233652) filed on September 23, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex1013.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Frequency Therapeutics, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Registration Statement on Form S-1/A (333-233652) filed on September 23, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex1012.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.12 to the Form 8-K, filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523277147/d416540dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated as of November 10, 2023, by and between Korro Bio, Inc. and Ram Aiyar, Ph.D. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed November 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523277147/d416540dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated November 8, 2023, by and between Korro Bio, Inc. and Vineet Agarwal (incorporated by reference to Exhibit 10.2 to the Form 8-K filed November 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523287451/d597314dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated November 8, 2023, by and between Korro Bio, Inc. and Shelby Walker (incorporated by reference to Exhibit 10.11 to the registrant&#8217;s Registration Statement on Form S-1/A filed December 20, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523287451/d597314dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated November 8, 2023, by and between Korro Bio, Inc. and Steve Colletti (incorporated by reference to Exhibit 10.12 to the registrant&#8217;s Registration Statement on Form S-1/A filed December 20, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523287451/d597314dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated November 9, 2023, by and between Korro Bio, Inc. and Todd Chappell (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Registration Statement on Form S-1/A filed December 20, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex106.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement for Officers of Korro Bio, Inc. (incorporated by reference to Exhibit 10.6 to the Form 8-K filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex107.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement for Directors of Korro Bio, Inc. (incorporated by reference to Exhibit 10.7 to the Form 8-K filed November 6, 2023).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">161</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523226463/d451428dex1027.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Investors&#8217; Rights Agreement of Korro Bio, Inc., dated November 8, 2021 (incorporated by reference to Exhibit 10.27 to the Form S-4/A filed September 28, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex103.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex104.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Contingent Value Rights Agreement dated November 3, 2023 (incorporated by reference to Exhibit 10.4 to the Form 8-K filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523226463/d451428dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement, by and between Korro Bio, Inc. and ARE-MA Region No. 59, LLC, dated August 10, 2020, as amended on March 2, 2021 (incorporated by reference to Exhibit 10.21 to the Form S-4 filed September 28, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Lease Agreement, by and between Korro Bio, Inc. and ARE-MA Region No. 59, LLC, dated August 31, 2022.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex10_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Lease Agreement, by and between Korro Bio, Inc. and ARE-MA Region No. 59, LLC, dated October 20, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/freq-ex1013_758.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture of Lease, effective as of January 7, 2020 between HCP/KING 75 Hayden LLC and Frequency Therapeutics (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Annual Report on Form 10-K filed on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312522192035/d328479dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sublease Agreement, dated July 8, 2022, by and between Frequency Therapeutics, Inc., and SalioGen Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed on July 12, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subscription Agreement, dated as of July 14, 2023 (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed on November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated as of July 14, 2023 (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Current Report on Form 8-K filed on November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex1013.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant Agreement dated January 22, 2021 (incorporated by reference to Exhibit 10.13 to the Form 8-K, filed November 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Ernst &amp; Young LLP.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signature"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on the signature page attached hereto).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1&#165;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="krro-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Korro Bio, Inc. Compensation Recovery Policy.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We agree to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#165; These certifications will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent specifically incorporated by reference into such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">162</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signature"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"/>
    <td style="width:1.08%;"/>
    <td style="width:4%;"/>
    <td style="width:47.92%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Korro Bio, Inc.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ram Aiyar</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ram Aiyar</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ram Aiyar and Vineet Agarwal, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this annual report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ram Aiyar</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Executive Officer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ram Aiyar</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/Vineet Agarwal</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vineet Agarwal</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Financial Officer and Principal Accounting Officer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ali Behbahani</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ali Behbahani</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nessan Bermingham</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nessan Bermingham</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jean-Francois Formela</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jean-Francois Formela</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David L. Lucchino</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David L. Lucchino</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Rachel Meyers</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rachel Meyers</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Timothy Pearson</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Timothy Pearson</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">163</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>krro-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="rom597314_16"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF SECURITIES</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following description summarizes some of the terms our restated certificate of incorporation, as amended, or the Charter, our amended and restated bylaws, or the Bylaws, and of the General Corporation Law of Delaware, or the DGCL. This description is summarized from, and qualified in its entirety by reference to, the Charter and Bylaws, each of which has been filed as an Exhibit to our Annual Report on Form 10-K, as well as the relevant provisions of the DGCL.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capital stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matters. The Charter and Bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of the Charter. See below under &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover effects of Delaware law and Charter and Bylaws-Amendment of charter provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; Holders of common stock are entitled to receive proportionately any dividends as may be declared by its board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the stockholders of shares of any series of our preferred stock that we may designate and issue in the future.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Charter, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of our preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purpose of authorizing our board of directors to issue preferred stock and determine our rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-takeover effects of Delaware law and Charter and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some provisions of Delaware law, Charter and Bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with its board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Undesignated preferred stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stockholder meetings</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Requirements for advance notification of stockholder nominations and proposals</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Elimination of stockholder action by written consent</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter eliminates the right of stockholders to act by written consent without a meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Staggered board</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by its stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Removal of directors</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of our common stock entitled to vote in the election of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stockholders not entitled to cumulative voting</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware anti-takeover statute</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to Section 203 of the DGCL, which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Choice of forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL or the Charter or Bylaws; (4) any action to interpret, apply, enforce or determine the validity of the Charter or Bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. Under the Charter, this exclusive forum provision does not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. The Charter also provides that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock will be deemed to have notice of and to have consented to this choice of forum provision. The Charter further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. It is possible that a court of law could rule that the choice of forum provision contained in the Charter is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment of charter provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. The provisions of Delaware law, the Charter and Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of its common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>krro-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.93in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">                                                                                                                                                        Exhibit 10.20</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SECOND AMENDMENT TO LEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">        THIS SECOND AMENDMENT TO LEASE (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) is made as of August 2022, by and between ARE-MA REGION NO. 59, LLC, a Delaware limited liability company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and KORRO BIO, INC., a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">RECITALS</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:6.983%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Arial;justify-content:flex-start;min-width:1.3493707990094506%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant are now parties to that certain Lease Agreement dated as of August 10, 2020, as amended by that certain First Amendment to Lease dated as of March 2, 2021 (as amended, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Pursuant to the Lease, Tenant leases certain premises commonly known as Suite 6-401, containing approximately 12,165 rentable square feet (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in that certain building located at Building 600/700 at One Kendall Square, Cambridge, Massachusetts (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">600/700 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), as more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:7.225612069058946%;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;" id="b__the_term_of_the_lease_is_scheduled_to"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Term of the Lease is scheduled to expire on January 31, 2024.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:6.983%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Arial;justify-content:flex-start;min-width:1.3493707990094506%;">C.</font><div style="width:100%;display:inline;" id="c__landlord_and_tenant_desire__subject_t"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, (i) accelerate the expiration date of the Term of the Lease from January 31, 2024 to December 31, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Second Amendment Expiration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and (ii) provide for Tenant&#x2019;s lease of certain space consisting of approximately 10,396 rentable square feet, commonly known as Suite 14-201 located in that certain building located at Building 1400 at One Kendall Square, Cambridge, Massachusetts (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), as shown on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attached to this Second Amendment (the &#x201c;14</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">00 Building Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.975%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__term___as_of_the_1400_building_premis"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. As of the 1400 Building Premises Commencement Date (as defined below), the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Base Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on page 1 of the Lease is deleted in its entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Base Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: Beginning on (i) the Commencement Date with respect to the Original Premises only and (ii) the 1400 Building Premises Commencement Date with respect to the 1400 Building Premises only, and ending for the entire Premises on December 31, 2023.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__1400_building_premises___in_addition_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In addition to the Original Premises, commencing on the 1400 Building Premises Commencement Date (as defined below), Landlord leases to Tenant, and Tenant leases from Landlord, the 1400 Building Premises.</font></div></div>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.472%;text-align:justify;" id="delivery___the__1400_building_premises_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; shall be the date that is 1 business day after mutual execution by the parties of this Second Amendment. Except as otherwise expressly set forth in the Lease: (i) Tenant shall accept the 1400 Building Premises in their &#x201c;as-is&#x201d; condition as of the 1400 Building Premises Commencement Date; (ii) Landlord shall have no obligation for any defects in the 1400 Building Premises; and (iii) Tenant&#x2019;s taking possession of the 1400 Building Premises shall be conclusive evidence that Tenant accepts the 1400 Building Premises.</font></p>
  <p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant acknowledge that (a) Tenant occupied the 1400 Building Premises prior to the 1400 Building Premises Commencement Date pursuant to that certain sublease agreement</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.99in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">between Triplet Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Triplet</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), the current tenant of the 1400 Building Premises, and Tenant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sublease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and (b) Triplet is terminating its existing lease (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Triplet Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) with respect to the 1400 Building Premises and the Sublease is being terminated concurrently therewith. Landlord confirms that on or prior to the 1400 Building Premises Commencement Date, the Triplet Lease shall have been terminated.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__building___commencing_on_the_1400_bui"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Commencing on the 1400 Building Premises Commencement Date, the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on page 1 of the Lease is deleted in its entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.454%;text-align:justify;" id="xbuilding___building_600_700_one_kendall"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Building: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Building 600/700 One Kendall Square, Cambridge, MA 02139 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">600/700 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and Building 1400 One Kendall Square, Cambridge, MA 02139 (the &#x201c;14</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">00 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__rentable_area_of_building___commencin"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Rentable Area of Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Commencing on the 1400 Building Premises Commencement Date, the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rentable Area of Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on page 1 of the Lease is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.5%;text-align:justify;" id="xrentable_area_of_building___246_793_sq_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rentable Area of Building: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">246,793 sq. ft. with respect to the 600/700 Building and 134,304 sq. ft. with respect to the 1400 Building.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__premises_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:9.463%;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.569402564697305%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of the 1400 Building Premises Commencement Date, the definitions of &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rentable Area of Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on page 1 of the Lease are hereby deleted in their entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.481%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: That portion of (a) the 600/700 Building, containing approximately 12,165 rentable square feet on the 4</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">th </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">floor of the 600/700 Building commonly known as Suite 6- 401 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and (b) the 1400 Building, containing approximately 10,396 rentable square feet on the 2</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">nd </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">floor of the 1400 Building commonly known as Suite 14- 201 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), all as determined Landlord, as shown on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="xrentable_area_of_premises__22_561_sq__f"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rentable Area of Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: 22,561 sq. ft.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:9.463%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.569402564697305%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__as_of_the_1400_building_premises_comm"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of the 1400 Building Premises Commencement Date, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">to the Lease is hereby amended to include </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attached to this Second Amendment.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__operating_expenses_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating Expenses</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__as_of_the_1400_building_premises_comm"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of the 1400 Building Premises Commencement Date, the definitions of &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Building&#x2019;s Share of Project</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant&#x2019;s Share</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on page 1 of the Lease are hereby deleted in their entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:33.593%;text-align:left;" id="x1400_building_share_of_project___16_47_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">600/700 Building Share of Project</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: 30.27%.&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Share of Project</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: 16.47%.&#x201d; </font><font id="xtenant_s_share_of_600_700_building___4_"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant&#x2019;s Share of 600/700 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: 4.93%.&#x201d; </font><font id="xtenant_s_share_of_1400_building___7_74_"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant&#x2019;s Share of 1400 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: 7.74%.&#x201d;</font></p>
  <div style="margin-left:9.463%;margin-top:0.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.569402564697305%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__for_the_avoidance_of_doubt__in_additi"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the avoidance of doubt, in addition to Tenant&#x2019;s Share of 600/700 Building, Tenant shall commence paying Tenant&#x2019;s Share of 1400 Building Operating Expenses on the 1400 Building Premises Commencement Date.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:1.065%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__base_rent_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Base Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__original_premises___tenant_shall_cont"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Tenant shall continue paying Base Rent with respect to the Original Premises as provided in the Lease through the Second Amendment Expiration Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__1400_building_premises___commencing_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Commencing on the 1400 Building Premises Commencement Date, Tenant shall pay Base Rent for the 1400 Building Premises in the amount of $105.00 per rentable square foot of the 1400 Building Premises per year. On each annual anniversary of the 1400 Building Premises Commencement Date (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises Adjustment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), the Base Rent payable with respect to the 1400 Building Premises shall be increased by multiplying the Base Rent payable with respect to the 1400 Building Premises immediately before such 1400 Building Premises Adjustment Date by 3% and adding the resulting amount to the Base Rent payable with respect to the 1400 Building Premises immediately before such 1400 Building Premises Adjustment Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__security_deposit__commencing_on_the_1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Commencing on the 1400 Building Premises Commencement Date, the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; on Page 1 of the Lease is deleted in its entirety and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$602,567.75&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord currently holds a Security Deposit of $301,083.75 under the Lease. Concurrently with Tenant&#x2019;s delivery to Landlord of an executed copy of this Second Amendment, Tenant shall deliver to Landlord an amended Letter of Credit which increases the amount of the existing Letter of Credit being held by Landlord to $602,567.75 or an additional Letter of Credit in the amount of</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$301,484.00 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Additional Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__parking___subject_to_the_terms_and_co"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Parking</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Subject to the terms and conditions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the Lease, and in addition to the parking rights granted to Tenant thereunder, commencing on the 1400 Building Premises Commencement Date, Tenant shall have the right, in common with other tenants of the Project to use (and shall be required to pay Monthly Parking Charges for) 0.9 parking spaces per 1,000 rentable square feet of the 1400 Building Premises. As of the 1400 Building Premises Commencement Date, the Monthly Parking Charges are $450.00 per space per month.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__signage___subject_to_the_terms_and_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Signage</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Subject to the terms and conditions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 38</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the original Lease, signage on the floor on which the 1400 Building Premises is located and signage on the lobby directory tablet of the 1400 Building shall be inscribed, painted or affixed for Tenant by Landlord at Landlord&#x2019;s cost, and shall be of a size, color and type acceptable to Landlord.</font></div></div>
  <div style="margin-left:1.065%;display:flex;margin-top:11.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__storage_area___commencing_on_the_140"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Storage Area</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Commencing on the 1400 Building Premises Commencement Date, in connection with Tenant&#x2019;s use and occupancy of the 1400 Building Premises, Tenant shall have the right to use that certain Storage Area in the 1400 Building commonly known as Suite 14-010 consisting of approximately 153 rentable square feet in the basement of the 1400 Building as more particularly described on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit B </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attached hereto (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Storage Area</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) for the storage of Tenant&#x2019;s property and for no other use or purpose. Tenant may not store any Hazardous Materials in the Storage Area. Tenant shall have all of the obligations under the Lease with respect to the Storage Area as though the Storage Area were part of the Premises, except that (i) the Base Rent payable by Tenant with respect to the Storage Area shall be $8,032.50 per year, and (ii) Tenant shall not be required to pay Operating Expenses with respect to the Storage Area. Tenant acknowledges and agrees that (x) a representative of Landlord is required to accompany Tenant or any Tenant Parties to the Storage Area and (y) Tenant shall be required to provide Landlord with not less than 1 hours&#x2019; advance notice (which notice may be telephonic or via email) prior to any planned access to the Storage Area in order for a Landlord representative to be made available. For the avoidance of doubt, neither Tenant nor any Tenant Parties shall have access to the Storage Area without a Landlord representative being present. Landlord shall have no</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obligation to make any repairs or other improvements to the Storage Area and Tenant shall maintain the same, at Tenant&#x2019;s sole cost and expense, in substantially the same condition as received during the term as though the same were part of the Premises. Tenant shall not make any alterations, additions, or improvements to the Storage Area of any kind whatsoever. Tenant shall, at Tenant&#x2019;s sole cost and expense, surrender the Storage Area at the expiration nor earlier termination of the term of the Lease free of any debris and trash and free of any Hazardous Materials in accordance with the requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 28</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the Lease. The term of the Lease with respect to the Storage Area shall expire on the expiration or earlier termination of the term of the Lease.</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x2__lease_modification_fee___in_consider"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease Modification Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In consideration for Landlord entering into this Second Amendment and accelerating the expiration date of the Term of the Lease, Tenant shall be required to pay to Landlord, on or before December 1, 2023, an amount equal to $250,000.00 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Modification Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). For the avoidance of doubt, upon Landlord&#x2019;s receipt of the Modification Fee, (i) the Modification Fee shall belong to Landlord and (ii) Landlord shall have no obligation to apply the Modification Fee to any of Tenant&#x2019;s obligations under the Lease.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__ofac___tenant_and_all_beneficial_own"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x4__brokers___landlord_and_tenant_each_r"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Broker</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in connection with the transaction reflected in this Second Amendment and that no Broker brought about this transaction, other than Newmark. Landlord and Tenant each hereby agrees to indemnify and hold the other harmless from and against any claims by any Broker, other than Newmark, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Second Amendment.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.7387678778996305%;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x5__miscellaneous_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__this_second_amendment_is_the_entire_a"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__this_second_amendment_is_binding_upon"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Second Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;" id="c__this_second_amendment_may_be_executed"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Second Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Second Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div></div>
  <div style="margin-left:7.731%;margin-top:4.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;" id="d__except_as_amended_and_or_modified_by_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except as amended and/or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.731%;margin-top:4.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and unchanged by this Second Amendment. In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment shall prevail. Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;" id="e__tenant_acknowledges_that_landlord_s_b"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant acknowledges that Landlord&#x2019;s business operations are proprietary to Landlord and agrees that Tenant shall hold and require all Tenant Parties to hold in complete confidence and not disclose at any time information regarding any aspect of the business operations of Landlord to any third parties.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">[Signatures are on next page]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;text-indent:6.999%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.833%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, the parties hereto have executed this Second Amendment as of the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">TENANT:</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">KORRO BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Delaware corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ Ram Aiyar	</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Ram Aiyar</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Its: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.987%;text-indent:-0.242%;padding-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.833%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> I hereby certify that the signature, name, and title above are my signature, name and title.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">LANDLORD:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ARE-MA REGION NO. 59, LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Delaware limited liability company</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By:	ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></p>
  <p style="margin-left:47.787%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:11.648%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Delaware limited partnership, managing member</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.787%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By:	ARE-QRS CORP.,</font></p>
  <p style="margin-left:54.453%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:11.648%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Maryland corporation, general partner</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ Allison Grochola	</font></p>
  <p style="margin-left:47.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Allison Grochola	</font></p>
  <p style="margin-left:47.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Its: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">SVP &#x2013; Real Estate Legal Affairs</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.352%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:6.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.027%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">DESCRIPTION OF 1400 BUILDING PREMISES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img183574933_0.jpg" alt="img183574933_0.jpg" style="width:601px;height:200px;">&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:6.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">DESCRIPTION OF STORAGE AREA</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img183574933_1.jpg" alt="img183574933_1.jpg" style="width:593px;height:215px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img183574933_2.jpg" alt="img183574933_2.jpg" style="width:378px;height:35px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.85in;min-height:0.99in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>4
<FILENAME>krro-ex10_21.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html>
 <head>
  <title>EX-10.21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 10.21</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">THIRD AMENDMENT TO LEASE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">THIS THIRD AMENDMENT TO LEASE (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Third Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) is made as of October 20, 2023, by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ARE-MA REGION NO. 59, LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, a Delaware limited liability company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">KORRO BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">A.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">	Landlord and Tenant are now parties to that certain Lease Agreement dated as of August 10, 2020, as amended by that certain First Amendment to Lease dated as of March 2, 2021, and as further amended by that certain Second Amendment to Lease dated as of August 31, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) (as amended, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).  Pursuant to the Lease, Tenant leases certain premises commonly known as (i) Suite 6-401, containing approximately 12,165 rentable square feet (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in that certain building located at 600/700 One Kendall Square, Cambridge, Massachusetts (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">600/700 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and (ii) Suite 14-201, containing approximately 10,396 rentable square feet (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;; with the Original Premises, collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and that certain storage area commonly known as Suite 14-010, containing approximately 153 rentable square feet (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Storage Area</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), in that certain building located at 1400 One Kendall Square, Cambridge, Massachusetts (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1400 Building</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).  The Premises are more particularly described in the Lease.  Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Term of the Lease with respect to the entire Premises is scheduled to expire on December 31, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Existing Expiration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, extend the Term of the Lease through September 30, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Extended Expiration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Term of the Lease is hereby extended through the Extended Expiration Date. Tenant&#x2019;s occupancy of the Premises and the Storage Area through the Extended Expiration Date shall be on an &#x201c;as-is&#x201d; basis, and Landlord shall have no obligation to provide any tenant improvement allowance or to make any alterations to the Premises or the Storage Area.  Tenant shall have no right to extend the Term of the Lease beyond the Extended Expiration Date.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Base Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:8.398%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:0.7303333988340865%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant shall continue paying Base Rent with respect to the Premises as provided in the Lease through the Existing Expiration Date.  Commencing on January 1, 2024, Tenant shall pay Base Rent with respect to the Premises in the amount of $113.00 per rentable square foot of the Premises per year.</font></div></div>
  <div style="margin-left:8.398%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:0.7303333988340865%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Storage Area</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Notwithstanding anything to the contrary contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the Second Amendment, commencing on January 1, 2024, Tenant shall pay Base Rent with respect to the Storage Area in the amount of $56.50 per rentable square foot of the Storage Area per year.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> DOCVARIABLE #DNDocID \* MERGEFORMAT 756833903.1	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">	</font><img src="img184498454_0.jpg" alt="img184498454_0.jpg" style="width:282px;height:60px;"></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating Expenses and Other Charges</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.   For the avoidance of doubt, Tenant shall continue to pay Tenant&#x2019;s Share of 600/700 Building, Tenant&#x2019;s Share of 1400 Building, and all other amounts due and payable under the Lease as set forth in the Lease.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), (b) not listed on, and shall not during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Broker</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in connection with the transaction reflected in this Third Amendment and that no Broker brought about this transaction, other than CBRE and Newmark.  Landlord and Tenant each hereby agrees to indemnify and hold the other harmless from and against any claims by any Broker, other than CBRE and Newmark, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Third Amendment.  </font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:6.667%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Third Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.  This Third Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Third Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Third Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this Third Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except as amended and/or modified by this Third Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment.  In the event of any conflict between the provisions of this Third Amendment and the provisions of the Lease, the provisions of this Third Amendment shall prevail.  Whether or not specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Third Amendment.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:2.57143775513484%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Tenant acknowledges that Landlord&#x2019;s business operations are proprietary to Landlord. Absent prior written consent from Landlord, Tenant shall hold confidential and will not disclose to third parties, and shall require Tenant&#x2019;s agents, servants, employees, invitees and contractors to hold confidential and not disclose to third parties, information concerning Landlord&#x2019;s business operations, including but not limited to information regarding the systems, controls, equipment, programming, vendors, tenants, and specialized amenities of Landlord.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> DOCVARIABLE #DNDocID \* MERGEFORMAT 756833903.1	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">	</font><img src="img184498454_0.jpg" alt="img184498454_0.jpg" style="width:282px;height:60px;"></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, the parties hereto have executed this Third Amendment as of the day and year first above written.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">TENANT:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">KORRO BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,<br>a Delaware corporation</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ Ram Aiyar					</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Name: _</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;"> Ram Aiyar</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">____________________________</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Its: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">			 </font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x25a1; I hereby certify that the signature, name, and title <br>above are my signature, name and title.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">LANDLORD:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ARE-MA REGION NO. 59, LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Delaware limited liability company</font></p>
  <p style="margin-left:33.333%;text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By:	Alexandria Real Estate Equities, L.P.,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Delaware limited partnership,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">managing member</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">By:	ARE-QRS Corp.,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Maryland corporation,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">general partner</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">		By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ Scott A. Sherwood		<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">		Its: Vice President, Real Estate Legal Affair<br>		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> DOCVARIABLE #DNDocID \* MERGEFORMAT 756833903.1	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">	</font><img src="img184498454_0.jpg" alt="img184498454_0.jpg" style="width:282px;height:60px;"></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>krro-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jurisdiction of Incorporation</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or Organization</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Korro Bio Ops, Inc.</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Korro Mass Securities, Inc.</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Frequency Therapeutics Pty Ltd</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Australia</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Frequency Therapeutics Securities Corporation</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>krro-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-248474) of Frequency Therapeutics, Inc.,</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-275353) of Korro Bio, Inc., </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-275354) pertaining to the 2019 Stock Incentive Plan of Korro Bio Ops, Inc., 2023 Stock Option and Incentive Plan, and 2023 Employee Stock Purchase Plan of Korro Bio, Inc.,</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263643) pertaining to the 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan of Frequency Therapeutics, Inc., and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234128) pertaining to the 2014 Stock Incentive Plan, as amended, 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan of Frequency Therapeutics, Inc.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of our report dated March 26, 2024, with respect to the consolidated financial statements of Korro Bio, Inc., included in this Annual Report (Form 10-K) of Korro Bio, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">March 26, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>krro-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, Ram Aiyar, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Korro Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ram Aiyar</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ram Aiyar</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 26, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>krro-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, Vineet Agarwal, certify that:</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Korro Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Vineet Agarwal</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vineet Agarwal</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 26, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>krro-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Korro Bio, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:</font></p>
  <p style="text-indent:5.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:5.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ram Aiyar</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ram Aiyar</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 26, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Vineet Agarwal</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vineet Agarwal</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:  March 26, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Korro Bio, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>krro-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">korro bio, inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adopted as of November 3, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), has adopted a Compensation Recovery Policy (this &#x201c;Policy&#x201d;) as described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.	Overview</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and the Nasdaq Stock Market.    Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.	Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.	Definitions</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Recovery Period&#x201d; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Rules&#x201d; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Board&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Committee&#x201d; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Covered Person&#x201d; means any Executive Officer. A person&#x2019;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#x2019;s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Effective Date&#x201d; means October 2, 2023. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Erroneously Awarded Compensation&#x201d; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exchange&#x201d; means the Nasdaq Stock Market LLC.  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An &#x201c;Executive Officer&#x201d; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation and received Incentive-Based Compensation after beginning service in any such role (regardless of whether such Incentive-Based Compensation was received during or after such person&#x2019;s service in such role): the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy making function or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">j.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Financial Reporting Measures&#x201d; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">k.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Incentive-Based Compensation&#x201d; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure and any other equity-based compensation provided by the Company or any of its subsidiaries, including, without limitation, stock options, restricted stock awards, restricted stock units and stock appreciation rights. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">l.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;Financial Restatement&#x201d; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">m.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Restatement Date&#x201d; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.	Exception to Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company has made a reasonable attempt to recover such Erroneously Awarded Compensation or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.	Tax Considerations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.	Method of Compensation Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cancelling or offsetting against planned future grants of equity-based awards; and/or </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any other method permitted by applicable law or contract.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#x2019;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. 	Policy Interpretation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.	Policy Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee; provided, however, that the Board shall have exclusive authority to authorize the Company to prepare a Financial Restatement. In doing so, the Board may rely on a recommendation of the Audit Committee of the Board. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">this Policy.  The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.	Compensation Recovery Repayments not Subject to Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img83127175_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S G # 2(  A$! Q$!_\0
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M[,WXXP*S_C!?RS^,$L68^3:6Z[%[9;DG^7Y5Y_6\(*UV9RD[GI/_  NK7O\
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M(_NFGTR/O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4NKP_P#+:5G'T)X_2F1-&/FD&['\.<9KJ2LC*Y<:?9!',D<:2NS!G4>F.@Z
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MERL?2'_"R?!__0<@_P"^'_PH_P"%D^#_ /H.0?\ ?#_X5\W45?LD3SL^D?\
MA9/@_P#Z#D'_ 'P_^%'_  LGP?\ ]!R#_OA_\*^;J*/9(.=GTC_PLGP?_P!!
MR#_OA_\ "C_A9/@__H.0?]\/_A7S=11[)!SL^D?^%D^#_P#H.0?]\/\ X4?\
M+)\'_P#0<@_[X?\ PKYNHH]D@YV?2/\ PLGP?_T'(/\ OA_\*/\ A9/@_P#Z
M#D'_ 'P_^%?-U%'LD'.SZ1_X63X/_P"@Y!_WP_\ A1_PLGP?_P!!R#_OA_\
M"OFZBCV2#G9](_\ "R?!_P#T'(/^^'_PH_X63X/_ .@Y!_WP_P#A7S=11[)!
MSL^D?^%D^#_^@Y!_WP_^%'_"R?!__0<@_P"^'_PKYNHH]D@YV?2/_"R?!_\
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MZ\].*6TN==$]J;R-(RLK^?$)5.X,Y"[>Y"K@]CS4^U]V]NMB_8OFY;]+_P#
M]1VHIKIUEC:F;R<IY)5D\H)@^8'!Y+>F/;WK1T&"^M]'MTU*5I+PJ&E);=@D
M<BM*BM+F05R'C_74T[1_L"28N+T%>#RL?\1_'I^-=?7C'C[3=3M-?FO+YC-#
M<-_H\RC"A1T3'8C]>M72BG+4F;LCG5EV;@O*GCGO0&JN&&!@<]Z?)(NU1&AW
M'C [GTKJL87.X^&MD;C5;O467Y;=/*1O]INOY ?K7IO6L?PQI']BZ#;VK*%G
M8>9-C^^>H_#@?A6T@RPKGD[NY2U)E&% K.UZ98=&N"TFP%<9$@C)'< GOC-:
M5<YXHN$\RVM7N9H=^6Q%$)=QR -RX)V]><$9(K..K-GHB_H, BLW>.*6"&5]
M\=O)_P LA@<#D\$Y/7O6I5;3[<VFGV\#",,B ,(U"KGO@#H,YJS2>X(****0
MP)P,FN=O/'GA:PG:"XUNU$BG#!27P?\ @(-<+\8/%5S;RQ>'K*9HE>/S;ID.
M"P)PJ9]."3^%>0 8&!6L:=U=D.5CZ1_X63X/_P"@Y!_WP_\ A2'XD>$""/[<
M@_[X?_"OF^BJ]DA<[/H]/B/X05<?VY!_WP__ ,33O^%D^#_^@Y!_WP_^%?-U
M%'LD'.SZ1_X63X/_ .@Y!_WP_P#A1_PLGP?_ -!R#_OA_P#"OFZBCV2#G9](
M_P#"R?!__0<@_P"^'_PH_P"%D^#_ /H.0?\ ?#_X5\W44>R0<[/I'_A9/@__
M *#D'_?#_P"%'_"R?!__ $'(/^^'_P *^;J*/9(.=GTC_P +)\'_ /0<@_[X
M?_"C_A9/@_\ Z#D'_?#_ .%?-U%'LD'.SZ1_X63X/_Z#D'_?#_X4?\+)\'_]
M!R#_ +X?_"OFZBCV2#G9](_\+)\'_P#0<@_[X?\ PH_X63X/_P"@Y!_WP_\
MA7S=11[)!SL^D?\ A9/@_P#Z#D'_ 'P_^%'_  LGP?\ ]!R#_OA_\*^;J*/9
M(.=GTC_PLGP?_P!!R#_OA_\ "C_A9/@__H.0?]\/_A7S=11[)!SL^H-,\7^'
MM9G$&GZM;33'I'NVL?H#@FMNOD0$JP920P.00<$'VKZ"^%_BBX\1>'Y(;YS)
M>6+B-Y#UD4C*L??@@_2HG"RNBE*YR_QP_P!=HG^[-_[)7DM>M?'#_7Z'_NS?
M^R5Y+6M/X2);A1115B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "NU^$__)0;3_KA-_Z#7%5VOPG_ .2A6G_7";_T&IE\+&MSZ&HHHKE-
M0H(!!!&0:** .>\4*UDEEKL2DMILFZ8*.MNWRR#\!AO^ 5T".LB*Z,&5AD$'
M@BDDC26-HY%#(P*LI&00>HKG_#<CZ=/<>'+AB7LQOM'8\R6Q/R_4J?D/T![T
M]T(WY%RON*AJS4,B[3D=#3B^A$UU/)/B-X:-A?G6[5/]%N6Q< #_ %<G][Z-
M_/ZUB^%_"MUXFOMB9BLXR/.GQT]AZM_*O;Y[2&^MI;:XC62"52CHPX(--M+3
M3_#^DK#"L=M9VZ9))P .Y)/4^]4YVT+B[H+2TT_0-)$,*QVUG;H223@ =R3Z
M^]>6:_\ $G4)]9CDT>3R;*W;Y0ZY\_W8>GH/QJMXS\8R^(IC:6A:/3$/ Z&8
MC^)O;T%<CMJH1ZLOD9[/X>^(NDZNJ0WCK87AX*2M\C'_ &6_H:[ $,H92"#R
M".]?,Q3-:.GZ[J^E "QU&XA7^X'RO_?)XH=-/85F?1.*,5XG%\2?$L8 :>WE
M]W@&?TQ2R_$GQ+("%GMHO=(!G]<U/LF(]J)"@DD #J37(>(/B'I.D*\-HXOK
MP<!(F^13_M-_05Y/?Z]J^J<7NHW$R_W"^%_(<5GA:TC174EM]#O- ^(U_#JT
MLVL3"6SG;YD5<>3Z%1Z>H_&O3[FVL->THQ2A+FSN$R"#D$=B#Z^]?.NTCJ*Z
M_P %^,)M G^R73%],<Y8$\PG^\OMZBG.GUB3%O9E3Q'X4N?#M^RR,SV39,4X
M7.1_=/\ M5K?#_PW]OU(:Q<1,+.W/[@2#_62?WOH/Y_2O4;BWLM;TQHI-EQ:
M3KP5/4=B".A]Z6&UCLK>.W@0)#&H5%'8"I]JVK"<+:H=4T:X7/<TR-=QR>@J
M:LI/H."ZA7)Z>XU?Q$MV))4,0,FWYXV4?=VD<JXXYZ$'UQ6GXBOWL[#"6SSH
MQ EVN4"+Z[ARIY&#4^BV\T5GYL\T\KS?.OG@;T3'RH<=QW]R:%HKEO5FE111
M4C"BBB@#YZ^+'_)0;O\ ZX1?^@UQ-=K\6/\ DH5W_P!<(?\ T&N4TNU6^U>R
MLY"RI//'$Q7J S ''YUU1^%&3W*M%>@WGPYBLO\ A))I+F4VMA!YMDXQ^_\
MEW'/'..AQWK'_P"$!U>2UL+BTEM;Q;R98%\EVPC%=PR2 ,8!Y&>E',@LSEJ*
M[+3?!UG<VVMPOJVGRSVL<!ANXYV$$;-(58,<<G P!CN*7_A!+S[.M@885U(Z
MJUEYYN#L.(MX&W;TQSNZ\XQ1S(+'&45U7_" :HUS;1Q7-C-!/!).;F*0M'&J
M$*^<#)() X!S3M'\)A?'2:#K"[D\F20F%R X\HNK ]<<"CF0K')T5T;^"=5C
MT)=6D:W2,QI.868ATB9L!SQC'?&<@<XJTWP\U;[78P17-C*+U)&BE5V"9C&6
M!)4'IT/0T<R"S.2HKK;3X?WU^BO::II4JRO)' 5F;]^Z#)"?+SWY]J63P;)=
MVUE+;M:6*#3$O;F6YN25(+E2WW?E^G-',@L<C1771?#K5I-0GM'NK&$QSI;I
M([L5F=TWJ%PI/W><G%9>F^&I]3N+]4O;.*UL2!/>RN1",G:N#C)R>G%%T%C%
MHKK8?AYJSR217%S86DBW7V-5GE(,DNT,H7 YW \5<L_ L<:^'I;FXBGGU"YD
MAFL3,8R"I((# 'H1\WH<8HYD.S.&HKK+;P%J%[:+=Q7FG1++')/%#+.0_EHY
M5CTZ+U)ITO@]K'3=4:Z>UE,2VLD-ZEPPB6.5L!L;?F&/ICWHYD*QR-%=5+X%
MNX=1M+)]6TLO=0>?&RNY!3( .-N3G/''8U+)X&>RTC4KJ_O8([NPO4MC;[\"
M0$ \'&<L"-OXYHYD.S.0HKLKCP)=W6KW\=JUG8PI>-:6L5Q<$F:0+NV(V.>.
MYQ5.'P-J<VE?;1<V2N;>2Y6U:4B8I&Q5_EQC@CUHYD*S.9KUKX'_ .OUO_=A
M_P#9Z\E!R,UZU\#_ /7ZY_NP_P#L]*I\+''</CA_K]#_ -V;_P!DKR6O6OCA
M_K]#_P!V;_V2O):*?PA+<****L1W&D:!I;^ UUFXTX75R99U8OJ M]JH,@J#
M]X^PJQ=>$M*-AJMW=W,5D]GIUK/&L$3E<N/O,"3DGI['FN*FU*YGT>WTJ1D-
MI;RO+&NWD,W7FM1/&.K"6X>3[-,MQ:I:2Q2P!D9$^YQZCUJ+,=T:_AGPW#9#
M5+OQ)9K$;;3S=6\%U&S(XR!O.T\@9 Q[Y[4R7X?3+F)=3@:]A:W^VVPB;_1Q
M,0%(;H^,C(%<O::G=64%Y##(-EY ;>;>-Q*$@X'IR!6Q+XYUV6VAA:: &-HF
M:58%$DWEG*"1OX@,=*+2N&@W5/"=Q975U%8S'48K%ME[/%$42W?."IR>>.<B
MMB;X;NMZ]G;ZS!/-!>16MT! R^3Y@^1N3\WN!7'W-_/>ZE-?7#9EGF,TNWY0
MS$Y/%=1X@^(5_J6JM<:<B65N+B.Y0>4HD=T "F1A]['.*'S!H1V7@:2\%N3J
M<,2S27:%FC)"?9^I//0_I[U-9> X-1AM)+37X7^WM,EBK6SKYS1\G//R@CUJ
MA<^.=;NI$8FTC$8F5$BME10)1A^!Z^OK4]IXVGTSPMI^E:="D=U;&;=<RQJY
M42'_ )9GJIQD$T>\&@LO@::+3'E.HP?VA':)?2V10C9 QP&W],CJ15Q_AM<?
MVNEC%J!E46[7$LRVK;=HQ_J^<29+ #!^M8K^,=9?2%TUI83&(UA,QA4RO$IR
M(V?J5]JG_P"$ZUH20&,6<4,2.GV:*V587#XW[EZ'.!_2CW@T''P5<KXO;0&N
MXE"1?:&NBAPL6W<6*]<]L>M;MSX&M-3.DKI,ZBU&EBYN+M(&+3DN54B/.<GT
M[8KD+?Q%?VFO?VQ;"WAN<;=D<0$6TC:5V=,$5>/CC66NTG(L]BVYM?LPME$)
MBSNV%/0'I0U(-#J;3P3;V2:?97-O:7-Z=9>W::0,4EB\G>H(!!QWQZUSA\%R
MO;_;([V,VK6?VI'\L@&0R>6(>O7=QFJ]MXTUBT_U'V5 MW]LC @&(Y-NT[1V
M!':J9\1ZI_8?]C"X LO/^T;0N&#YW?>],\X]:$I!H=//\+[R"]LK8ZE%FXF:
MWD9H641N(R^1D_.ORD9&.:HP>"8KY8+C3];BN;$O,EQ<_9V40&--Y)!.2".G
M2J<GC;6)-0MM0Q9+>VY9O/6V4-(Q4H2_][@_UIFGZ_'I?A'4M+M_M!NM295F
M+$"*.-?[O<L0<'VH]X-# SGD=****L05IZ!KMWX;UB+4[)8FGC5E E!*D$8/
M2LRNF^'^C66O>,+;3]0B,MLT<CL@8KD@9'(I/;4$=I9?&]UP-1T53ZM;S8_1
MA_6NPT7XDZ-K;JD%MJ:.?6T=Q^:9%:UAX.\.:9@VFC6:,/XFC#M^;9-;2JJ*
M%10JCH ,"N=N/1&J3 '(!'0TM%%0,*QM?TR>[C@OM/VKJ=BQDMRQP) ?O1M_
MLL./8X/:MFB@"EI6IP:OI\=W!N4-E7C<8:-QPR,.Q!XJX0",&L#4;6?1]0DU
MK3HFEBDQ]OM$',@'_+1!_? ZC^(>X%;5K=07UK'=6TJRP2KN1U/!%*^MAN.E
MR4 */054O((+^VDM;F)9;>1=KQN,AA5L@$8-1,A7D<BK1G*_0\C\2?#Z[TQG
MNM)#W5GU,/62(?\ LP_6N-&&SZC@@]J^BZP=:\'Z/KA:2>#R;D_\O$'RM^/8
M_C5W-85^DCQ/92;*[;4/AMJUJ2UA/#>Q]E8^6_Z\'\ZY;R&M[HQW,+*\4FV2
M-NHP>13YCHBHS^%D*6J>4LDTWEA\[ $+$@=_84\_8T;9Y3R(.#+N(8^X'3\#
M5R6TDNI&E%PLBD\$AN!Z8QQ]*'TB:,@,T8) (X8]?PJN8ETS.GMFMY2C<@\J
MPZ,.Q%,().35Z=5C@C@5MY1F9F ( )QP,_2MS0/ U]KUK'>O<QVMFY.TXW.P
M!QD#H/QI\Q$HJ*NSDV('7DG@>]=GX=\!7FK&.ZU9&L[,<K$.)9!Z?[(^O-=U
MHG@_1]#*RP0>=<C_ )>)_F8?3L/PK>I.;Z'-*2Z#+.""PMH[6VB6*WC&U$08
M"BK9 8>HJ)4+<G@5*  ,"L9#C?J   P*6HYYXK6!YYY%CB099F/ %5-.FN[K
MS+J=?)@DQY$++\P7^\WN?3M2MI<J_0;<Z/;7&J07Y&V6,$-C(WC^'.#V/\S6
MC112N,*KWEY%8VYFF64H.T432'\E!-6** ."U/XLZ'IK,AL]3=P<8:V,8_-\
M5S5W\<)&R+#1$'^U//G]%']:]?DBCF39+&CKZ,,BL:\\&^&]0R;G1+)B>ZQ!
M3^8Q5IQZHEIGSIXAUZY\2ZS+JEY'%'-(JJ5B!"@*,#J:I65T]AJ%M>1JK/;R
MK*JMT)4@@'VXKH?B#I%CH7C&YL-.A\FV6*-E3<6P2,GD\UR]="V,WN=-)XZU
M>>&Y@F$+P317$2QD'$8F?>V.>2#P,]JOS_$S5I&BDBL[2"5)XYRZESN9%VXP
M3@*0<8&*XJBERH=V=!-XH_=W\-EI-E90WRQ"5(BYYCDWAAD]2>#[5H/\1=3>
M_6\-G9[UO_M^/FQO\KR\=>F.?K7'UM>'-%@UB6^EN[B2&SL+5KJ<PJ&D91QA
M0>,_6AI!=E^P\>ZCI\5E"D%N8;:*:$IEE,J2N'()!R""!@C%5+?Q3<VOBI=>
MCMXS( 5\B21W785VD;F);H3SGK76P:!I?AS0_$ETSM<R"UMY+266V1F2.;.W
M*G@-G()[  BL;1?!-KJ>DZ>\U_/%?ZHL[6:)$&B41 Y\QLY&<=J5XAJ5I/'M
M_+IUM:M;0E[8HL4IDDQL1@RJR;MK=,9(SBK-S\1M0GO8KE=/M(S$T[A=\C;C
M*NULDM^0' K9U31[=](N#$EM;!=%T]G/V=3\SR$%MW4'U(Y-077P\TR+4[;3
M4U.[2ZDEE#B5(S^ZC7<TBJISST4'WS2O$>ISFC^+[W18=+B@M[>0:=-+-$9-
MWS&1=I#8/0=L4LOC&]ETU[$V]N(WTX:<6&[/EAMV[K][)^E:L?@W2)8#J2ZG
M?+I3:<;]"8%\X!9 C*5SCZ&B_P# EM:7%VB7T[I%>6<$9,8R4G .3[C-.\1:
MFKHOCO3[F"]DUB86D]Q+$)$A$JAH4CV?*R'.[KP>*Y&P\10Z1=:G#:6,=UH]
MZV#:79)RJME"2ISD5I:YX2TWP]I\\][?7;RR7,]O9)#$I!\HXS(2>,GTKHM3
M\"V&I^(=7NYKM-.LTNHK6%(A&BHQA1BS;B!CGH.3S2]U#U,J/XAC^RWN+JS@
MN]8.I_;(UE1A%"!&%5EP>HQC![5E6OCF]MX]/,MG:W%S874ES!<2%@V9"2ZD
M X()-7%\$68TY5EU*;^TGL9=001Q!H#$A((W9SN(&1VK6O/#VCV]]JMMI)=2
MFA+.ZW,"N,MMPRDDE6.221T[4>Z&IS$7C.^BB@C%M;$0VEQ:+G=DK,<L>O49
MXI[^-KR73Q8RV-G)!Y%M RMN^9(&W+GGOT/Z5TTG@[3H-(U#0[6=YM2&HV=M
M-<SPA1&S\GRSU*X/Z52G\!Z+!JUO;-KI6.195,;O%YK2(1A00Q5=V>-V",8H
MO$6I1D^(5Q)J5S?G1M/6:Y@\B<QO*I=>-O(;(QMZ#'!-5KOQQ=7_ /:8O-/M
M)5OY8Y]N6 BD10JLO/H.AK#U:Q.FZO=612=/)D* 3J%?'^T 2,_0U3JN5!=G
M71?$&^2YN+B;3[&=VNS>V_F!L6TQ7:67GD8['O52#QGJ$'E$PV\CQV4UGN8'
M++*Q9F.#][)^E<Y11RH5V(!@ >E>M_ __7ZY_NP_^SUY+7K7P/\ ]?KG^[#_
M .STJGPL<=P^.'^OT/\ W9O_ &2O):]>^.$+XT6?!\L&5"?<[2/Y&O(:*?PA
M+<****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5VOP
MG_Y*%:?]<)O_ $&N*KN?A)"\GCZ%U7*Q6\K.?0$ ?S(J9?"QK<^@J***Y34*
M*** "BBB@ K"N-/N=(NI+_2(_,AE;?<V(. Y[O'V#^HZ-['FMVBIE&Y49<K*
MMAJ%MJ=L)[63<N<,",,C=U8'D$>AJU67>Z.);DWUE,;2_P 8,JC*R#T=?XA^
MH[&HXM;-M(MOK$(LIB<++G,$A_V7['V;!^M1[3ETG]_3_@&GLE/6GKY=?^":
MK1@].#491EZBIP01D'(-%;*1SN*96KR'Q?9/:>+;W</EN")D/J".?U!KV8JI
MZBL#Q/X8BU^R7RV$=Y#DPR'I[J?8TVS7#OV<[O8\XN+!46&**:==DJPDG@'<
M3SP:6XM/.G@_?W*J=R-D\X5<Y'/4U%?PZEITWDZC#)"ZMD,5&&([AAUJO]LD
MDD78Y9P3M5%'4^P'-3S'I>SNKID>L0I'+YRE_P!ZI<ANH.2/Z5ZQX7LGT_PQ
MI]M(,2+$&8>A8[L?K7+>&_!]W?W<6H:S&8K>+!BMV4 N>HR.P[X[UZ.% [57
M,<&):=HHA",W05(L8'7DT^JEQ?I!?VMF$+R3AF)!X1%'+'VR0/QJ93MN80IW
M=D6ZKWE[;V$!FN)-JYP !DL>P ZD^U4)-;^TR-;Z1$+R8'#2YQ#&?]I^Y]AD
M_2IK/2O*G%Y>3&ZO<8$C#"QCT1?X1^I]:49)[%R@X_%H10VD^I3I=ZBGEQ(=
MT%H3G:>S/ZMZ#H/K6M115-W(2L%%%%(84444 %%%% 'SS\6/^2A7?_7"'_T&
MN*KN?BY"\?CV:1E(66WB9#Z@ C^8KAJZH_"C)[A1115""K>FZI?:/>"[T^Y>
M"< KN7!R#U!!X(]C52BD!I7/B#5KP7HN+^:47Q0W(;'[S;]W/' '8#%.L_$>
MLZ?IDNG6FH316DN=T:XXSUP>HSWQ67119 :\?B;51%!;S7;RVL21Q&$X >)&
MW*A(&<9_&M[7_'YU,1R:?:/:7B7/VD7;F/S8S@_(I51E>3G=DFN*HI<J"YJW
M?B;6KZ:XEN=0E=KB'[/(,  QYSL  P!GTQ4L'B_Q!;7%Q/#JLZRW"HLKX7+!
M!A>W! XS6+13L@N; \5:X+6\MO[2E,-XS/.K!3N9OO$<<9[XQ4B^,?$"32S#
M4I"\J*DA9%8-M&%.",;@._6L.BBR"YJ+XDUE-&;2%U"86#9!A&.A.2N>H4GM
MG%/D\4:W-:K;/J$AB%N;7&U<F(X^0G&2.!^59%%%D!LW?BW7[ZUCMKG59WBC
M*,HX!W(<J<@9R/7-/;QAKSWJWC:@6G5#'N,289203D;<') .3Z5AT4607)KN
M[N+Z[ENKJ9YKB5MTDCG)8U#110 4444P"O6O@?\ Z_7/]V'_ -GKR6O7?@?$
M_P#Q.YL?NR84!]QN/]145/A''<]&\3^';7Q1H<NFW1*;B&CE49,;CHP_ST)K
MP?5/AQXITNY:(:9)>1Y^6:U^=6'TZC\17TA16,9N)HXIGS!_PAGB?_H7]1_[
M\&C_ (0SQ/\ ]"_J/_?@U]/T57M63R'S!_PAGB?_ *%_4?\ OP:/^$,\3_\
M0OZC_P!^#7T_11[5AR'S!_PAGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_
M11[5AR'S!_PAGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_11[5AR'S!_PA
MGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_11[5AR'S!_PAGB?_ *%_4?\
MOP:/^$,\3_\ 0OZC_P!^#7T_11[5AR'S!_PAGB?_ *%_4?\ OP:/^$,\3_\
M0OZC_P!^#7T_11[5AR'S!_PAGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_
M11[5AR'S!_PAGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_11[5AR'S!_PA
MGB?_ *%_4?\ OP:/^$,\3_\ 0OZC_P!^#7T_11[5AR'S-:^ O%5Y.(DT.ZC)
M_BF41J/J37L_@7P4G@ZQ=YG6?4+C'G2*/E4#HB^WOWKLJ",C!J93;T&HI #D
M9%%1\QGVJ0'(J"@HHHH **** "BBB@ IDD4<T;1RHKQL,,K#((]Q3Z* V,;^
MQ);([M(O7M1U^SR#S(3]%)ROX$?2M@9P,XSWQ2T5,8*.Q<ZDI_$1+=6[W+VZ
MS1F=!EHPPW ?2I:QYM$D:YFGBO61W=G0E =C,H4G/?"C@>OK5>/1+NTC@\ET
M>2VBE2(EV4$E@4W#N ":SYYK>)K[.FUI(WG1)%*NJLIZAAD5'%:V\#;HK>*,
M^J(!60UKJT>@BW$DCW<<F%=9.9%SD98D$>A[TX6VIF:8L9=YF1U<3?N_+#J=
MH7L=N0>.?QI^T?\ *Q>Q7\R-NJUQJ%I:A_.N$4IC<H.6&3@<#GFL)="U":S6
M*6Z:&5&E!D$A?>&&!D=^W!_2KHT'?#<03W):&XPTBJ@W;^.0Q[9&0*GVE1K2
M)7LJ47[T[^AL*P90PZ$9YKGM9\-S:AJ?V^*Y5_W8C:TG!\IP#GDJ0>OKD>U;
M\,8AA2,,S!1C+=33ZN=.-2-I&=.K*E+F@R"S1H[.)'@B@8+@Q1'*+[#@<?A4
M]%%6E96,V[NX4444Q!1110 4444 %!.!DT$X%1\R'_9H Y+QUX*3QC8(T+K!
MJ%MGR)&'RL#U1O;W[5XQ=^ O%5G.T3Z'=2$'[T*^8I^A%?3 &!@45<9M:$N*
M9\P?\(9XG_Z%_4?^_!H_X0SQ/_T+^H_]^#7T_15>U8N0^8/^$,\3_P#0OZC_
M -^#1_PAGB?_ *%_4?\ OP:^GZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_
M *%_4?\ OP:^GZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_ *%_4?\ OP:^
MGZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_ *%_4?\ OP:^GZ*/:L.0^8/^
M$,\3_P#0OZC_ -^#1_PAGB?_ *%_4?\ OP:^GZ*/:L.0^8/^$,\3_P#0OZC_
M -^#1_PAGB?_ *%_4?\ OP:^GZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_
M *%_4?\ OP:^GZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_ *%_4?\ OP:^
MGZ*/:L.0^8/^$,\3_P#0OZC_ -^#1_PAGB?_ *%_4?\ OP:^GZ*/:L.0^;]+
M^''BG4[E8CIDEG&3\TMU\BJ/7'4_@*]W\+^'+7PMHD6G6I+D'=+*1S(YZL?\
M/2MFBIE-R*4;!1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 0@$8-1QDYQVHHH EHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CD)R!VIX&!Q110 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img83127175_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ G # 2(  A$! Q$!_\0
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M&Q2N>V>]=ED>HHR/44<S"QQ5MX8UN&^L[A;Q(H8V3S+7SF95C$S2; <<E1M
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M.UO,DK"=@%D8;58 KV4+TQSFK3Z%K5S=6$TAAC>**&/>MTY,!1B7*C #>8,
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M'Q;_ -!VY_[Y3_XFC_A8/BW_ *#MS_WRG_Q-'LF'.CZ('?ZTM?.W_"P?%O\
MT';G_OE/_B:/^%@^+?\ H.W/_?*?_$T>R8^='T317SM_PL'Q;_T';G_OE/\
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MXDO+*$-<SQ1.A2=+N=M^07S@8.58,O4@X7FNVHHY@L<5)X>\13JT;W:+;+%
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M18M(Y(;*WBE;=+'$JNWJP !/YU-114#'^4_]W]:/*?\ N_K1YK_WJ/-?^]0
M>4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]
MW]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/
M*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\
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MLO[1NA;R7,CE%5=I."PZ;B,5Y7]@D\"V+7MZK1>(9FQ90*^#;HK<RO@\YQ@
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MK7_GG1]K7_GG56BESL?LXEK[6O\ SSH^UK_SSJK11SL/9Q+7VM?^>='VM?\
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M**!A1110 4444 %%%% !1110!S?C;Q'-X;T19K.#S[ZXD\JW3:6 ."2Q ZX
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M6CRK;_GI^M'*PYT5:*M>5;?\]/UH\JV_YZ?K1RL.=%6BK7E6W_/3]:/*MO\
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MN@N$$B'V/]:LU@S=;!1112&%%%% !1110 4@Z4M(.E A:***!A1110 4444
M%%%% "#I2T@Z4M @HHHH&%%%% !1110 4B]!2TB]!0(6BBB@84444 %%%% !
M1110 4444 %%4=7U>RT/39=0OY?+@CZD#)8GH .Y-<IHOQ1TO6-0:V-C>6\8
M&3.P#(@SC+X^Z,D#/2J4)-72)<DG9G<T445)04444 9&H>)+72M4%E<I.J?9
M7NGG"$HBJ<8/^?0=Z0^)]/&G_:S]I"BX%L8?(;S5E(R%*=<X_G4^HZ'8:K,L
MMW&[$1/ 0LA4.C=58#J,@'V(ID'A_3X+>.$+*^RY%WYDDK,[RCHS,>3QQ5^[
M8CWKE.+QKH\T7F1/=.QV;(Q;MOD# D%5ZD85N?\ 9-1W/C;3H[FV2VWW%N^6
MFG5&V1KY32\''+8 ^7WJ<^$-'**JQ3QLB(B21SLKH$W8P<\<.P/J#0/!^BB4
M.MO(J!=HA65A'_JS'G;G&=AQFG[@O?(9_$>GS:K9QK 9_+$DID*'=$1$'!4=
MR5?%)'XXTJ6<!?M'V<6SW#W!C.V/:VTJ??/ZX'>G_P#"%:*8/):.Y8'(9FN&
M+-E G)SZ ?D*>O@[1EC\OR9BA21'!F;]X'.6#>O(!'H:/<"TR=?$^G/8P7<;
M3R">8P1PQQ%I&D&=R[1Z $GVJ-_%VE1PM*\LP5?,)_=$GY)!&W'^\PJ5O#M@
MUA;VF;@"VD,D4R3%948Y!(8<\@D?2H1X1T<2S2&*8F4DD&=B!EU<X&>,LH/Y
MTO<'[PR3QCI4*2M*+M#%)Y3!K=@=^-Q7Z@<D=A4=SXUTF".X:/[1.T,3R#9"
MVV3:@<@-TSM8'Z5=N_#FFWL4J2Q/F2Y-T760AEE(VD@]N.,4C^&=*DW[X&;>
M9"P,AYWH(V_\= H]P/>'Z;K]GJET]M DZSQQK)(LD179N (!SWP16I679>'[
M*QODO4:XEN$A\A7GF+D)QQS]!6I4NW0:OU"BBBD48NHZ7>7-W,UJZ6ZS(5DD
M$K?O!L( 9,8R"1A@<X%5+C0[ZZ9I94M3(_F *96/DEEC4,#CD@H3VZUTM%4I
M,GE1S,^@7LGFJLD8B:;S"A?+2Y# DL5/<@@$'&#STIR^'YX9-T*0%Q<B82NY
M.00H.Y=OS'@\Y!YSQS7244<S#E1SVJ:#<W\]YM:';.&VRNQW!3&4\LC&-N[Y
ML_IFEU#2Y[C4+>*"%%CCM519BQ A8.#E0.K8'M7044<S#E1S<>AZAYD\C30Q
MF5MQ$;$ G;(,X &/OKZGCKTK4TK3CIPF0%?+?RRJJ3PP0!CSZD9K0HH<FP44
M%%%%24%>*_%FSGA\517C@^1<6ZK&W;*Y!'Z@_C7M54-5T>PURQ>RU&W6:$G(
M[%3Z@]C6E*?)*YG4AS*QX[X9\6Z9I6DV%A?022"">>X,B)\T4A $;*>X(W C
MW%0Z@?#>L:99VFGS0V5S;1F26:6W\OS%"+E,C[S;MQ'7/XUV;_!_1V<E-2OT
M4]%PAQ^.*;_PIW2O^@K??]\I_A73[:GO<YO93[' :GK<.KV.D-+=S0WNGV3(
M&2$ &4290#&,#;_%ZBH/$^MG6KZ )<7$]M:0+!%+<$F23NSMGN6)X[#%>C?\
M*=TK_H*WW_?*?X4?\*=TK_H*WW_?*?X4_;4P]E,\>HKV'_A3NE?]!6^_[Y3_
M  H_X4[I7_05OO\ OE/\*?MX![&9X]1T%>P_\*=TK_H*WW_?*?X5I:/\,-!T
MJ[2YE,]](AW(+@C8#Z[0.?QI/$0!49FEX%LY[#P5ID%RI67RRY5NJAF+ ?D1
M714@[_6EKBD[NYUQ5E8****104444 %%%% !2#I2T@Z4"%HHHH&%%%% !111
M0 4444 (.E+2#I2T""BBB@84444 %%%% !2+T%+2+T% A:***!A1110 4444
M %%%% !1110!Q?Q*L_/T6RNIK26\L;.Z$MW;Q,59HRI&X$>F<UYC?S6:VL?A
MGPE++>_;W#W-SMP\V?N18[*O?WKZ"JK;Z986<S36UC;02O\ >>.)5)_$"MH5
M>56,I4[NY):1/!96\,C;WCB5&;U( !-3445B:!1110,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0=_K110(6BBB
M@84444 %%%% !1110 @[_6EHHH$%%%% PHHHH **** "D'2BB@0M%%% PHHH
MH **** "BBB@!!TI:**!!1110,**** "BBB@ I%Z"BB@0M%%% PHHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img83127175_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Y@C624!#M0-T!;ID]<5=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9F97M&O9-\@C*PKMSC(^9_F'R\?6L6#QG<VS223[[CYYPBDJB*!<"-2V%+<
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M.36O4#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO:0Q3SG,LB( SGW/>K-%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH ***:TB)]Y@/J: '45 UY$.A+?05"U_\
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M2WQ_BC_(U*MY$>N5^HI68718HIBRH_W7!_&GTAA1110 4444 %%%% !1110
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M=>G7BIRC#^$_E0(80!Q@Y]Z0\T_:W7!J"2XABNX;620+<3!FBC/5PO4CZ9%
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M43V\4R_=D0.,$'@C/4<'\*DI )BC%+BDQ0 8I,4M&* $HQ3L<4E "8H(I:*
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M/9JJW,.FO:&83%?(E*C:X'<<$<>H/:M/POIU[IUM=K=QF".256@MC<&8Q *
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M(!"0H+'H.37*>(U9E34]J_9X)$:8-G&Q3G<?8'&?:NCOV(MPH_B;%,V+LV$
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MXPNPX  S]:[FDHYF%CC'\ ))<I=2WRRSO+))<AH2(Y [!B%4,-N-H[GWI9/
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MWU(D\::1);^>AN2@C:1L0GY &V8/H=W'XU%-XYTF*!G5+IY!;&Y\KR2#M )
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MB]HNQD:1=:K<7E\NH6Z0Q1OB$!2"1D]^C#&#QZUKT4525B&[L****8@HHHH
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G24 )12FDH 2DI:2@!*2EI*8A*2EI* $--I32&F AIM*332: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img83127175_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# G # 2(  A$! Q$!_\0
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M -!_Z ^J?^0__BJ/^%_Z#_T!]4_\A_\ Q5?/M%'*@NSZ"_X7_H/_ $!]4_\
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M</\ V)JW_0,O/^_+?X4?V)JW_0,O/^_+?X4<L0NSN/\ A='B'_GQT[_OE_\
MXJC_ (71XA_Y\=._[Y?_ .*KA_[$U;_H&7G_ 'Y;_"C^Q-6_Z!EY_P!^6_PH
MY8A=G<?\+H\0_P#/CIW_ 'R__P 51_PNCQ#_ ,^.G?\ ?+__ !5</_8FK?\
M0,O/^_+?X4?V)JW_ $#+S_ORW^%'+$+L[C_A='B'_GQT[_OE_P#XJC_A='B'
M_GQT[_OE_P#XJN'_ +$U;_H&7G_?EO\ "C^Q-6_Z!EY_WY;_  HY8A=G<?\
M"Z/$/_/CIW_?+_\ Q5'_  NCQ#_SXZ=_WR__ ,57#_V)JW_0,O/^_+?X4?V)
MJW_0,O/^_+?X4<L0NSN/^%T>(?\ GQT[_OE__BJ/^%T>(?\ GQT[_OE__BJX
M?^Q-6_Z!EY_WY;_"C^Q-6_Z!EY_WY;_"CEB%V=Q_PNCQ#_SXZ=_WR_\ \51_
MPNCQ#_SXZ=_WR_\ \57#_P!B:M_T#+S_ +\M_A1_8FK?] R\_P"_+?X4<L0N
MSLKGXQ>)9HBD45C;L?XTB+$?F2*X>_U"\U2\>[O[F2XN'^])(<GZ>P]J=-I>
MH6Z;YK"YC4?Q-$P'\JJ4TDMA-L*:_P!QOI3J:_W&^E4!].Z3%(=%T\A&/^BQ
M=O\ 8%7/*D_YYM^55M(N95T33P&X^RQ=O]@5<^U3?WOTKE9J,\J3_GFWY4>5
M)_SS;\J?]JF_O?I1]JF_O?I2 9Y4G_/-ORH\J3_GFWY4_P"U3?WOTH^U3?WO
MTH 9Y4G_ #S;\J/*D_YYM^5/^U3?WOTH^U3?WOTH 9Y4G_/-ORH\J3_GFWY4
M_P"U3?WOTH^U3?WOTH 9Y4G_ #S;\J/*D_YYM^5/^U3?WOTH^U3?WOTH 9Y4
MG_/-ORH\J3_GFWY4_P"U3?WOTH^U3?WOTH 9Y4G_ #S;\J/*E_N-^5/^U3?W
MOTH^U3?WOTH 9Y4G_/-ORH\J3_GFWY4_[5-_>_2C[5-_>_2@!GE2?\\V_*CR
MI/\ GFWY4_[5-_>_2C[5-_>_2@!GE2?\\V_*CRI/^>;?E3_M4W][]*/M4W][
M]* &"&4G'EM^5:$,9CB"GKWJD+J8'[P/X5>BD\R,-TS0QA-_J7_W3676I-_J
M7_W3670A"$@=2!]32URGCL6YL])-XF^T&HQF<%2PV8;.0.U<P+_5M.M EC-/
M8:+/=SM:3294H@ V+EE8JI.2!CGIQ5J-Q7/3&N[99!&UQ")"XC"EQG<1D+CU
MQSBIJ\U@DO3XC,4CJEW=:E;-+)'%D8-J1O7(X&X=?PI7U_Q))ITLOF3Q"R\F
MSO'V8_>;F\R4':>P49P0-Q.*.4+GI-%<)I<^O:MJ5M9-KDL<)LI)A/;J&\PB
M4JF6*CG!&< 9Q6GX2U'5-5FNI+YV5;-$LWC( #7"Y\Q__0:3B%SJ****0PHH
MHH **** "BBB@ HHHH *\S^,?_'AH_\ UVE_]!6O3*\S^,?_ !X:/_UVE_\
M05JH?$*6QY/4MK;2WEW%;0KF65@JCW-15TO@*..7QC:+)C&UL9]<?X9K=NRN
M9H]<\'> ['2K&.:6/=*X!+$?,WN?0>U=DMA:*,"WCQ_NU.H"J .@%<SK5_?>
M&;C[;&ANM+E;$L1/S0L>ZGT/H>_IFL(0=1V6X5JRH1YY+3KY>8>*M3MM%LUB
MMK:)[^X^6%-H..V['\O>K?A_P]!IFFJMPBRW<O[R>1ADECV^@KF?"L,OB3Q+
M<Z]>+F. XB4] W8#Z#]37H5:UDJ2]DM^O^7R./!R>)F\3+;:*\NK]7^1!]BM
M?^?>/_OD4?8K7_GWC_[Y%5=?65O#>J+;B0S&TE$8CSN+;#C&.<YKB]+TGQ%I
MEOIPBNY;8:A+$LT<0:;[.@B8LQ,F=K,V >P..M<Z5ST;G??8K7_GWC_[Y%'V
M*U_Y]X_^^17 )K'B[R]3:03(T;A61;4LT">;@O&-H#_N\G&6R>?:IQJWB4ZY
M'%://-:B -!]IMBGVD;"26PGRMNP.2OTYI\H7.W^Q6F<>1%G_=%+]BM?^?>/
M_OD5Y?;WOB*);S48A?M+<+:)<W$EF8VCP'WA%V'(5L#.T\'\:V8KSQ9+?VYD
MN)EB\RUB=8[3Y&$D9\Q\E<C! /L3S1RA<[?[%:_\^\?_ 'R*3[%:9QY$6?\
M=%>;:??^*+33](M4FO.KK/)<6S$^<) /+;Y"=NW)!XSG[W%:>@OJU]XS%SJ
MNUD2WN8G#VVR* ^:NQ4;&&RH!SDT<H7.V%I9MG$,1P<'"C@TOV*U_P"?>/\
M[Y%>7Z0WB31;&TA@2\5YV,RH;,'[1,TY#K*V,J-@# G'7KQBNF6Y\1Q^%]5O
MO,GEOO/=((3;@&*-9"-RKC+G9R,]<"AQ"YU#6EFHRT,0'N!3OL5K_P ^\?\
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M.E-?[C?2G4U_N-]#6Q!]-Z3_ ,@73_\ KUB_] %6ZATBUE;1-/( Q]EB[_[
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MNTG<5&3]./6J]YK5CI\[0W4DD;*8QN,3%27;:H!Q@G/Y46 TM[_WV_.C>_\
M?;\ZI6VI6MTZ)'(5D=I%2.12C,4.&(!Y('K5O!]* ';W_OM^=&]_[[?G3:*
M';W_ +[?G1O?^^WYTVB@!V]_[[?G1O?^^WYTVB@!V]_[[?G1O?\ OM^=-HH
M=O?^^WYUYE\9&)L-'R2?WTO4_P"RM>EUYG\8_P#CPT?_ *[2_P#H*U4/B%+8
M\GHHJWI=@^IZG;V49P96P3Z#J3^5;F86.F7NIR&.SMI)B.I4<#ZGI6XOP_\
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M*<U7_G]3_OU_]E1_PIS5?^?U/^_7_P!E1SQ[ARL\VVCT%&T>@KTG_A3FJ_\
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MJ=K+ 9][10\8DF78K@]"I/459=%DC:-QE6!4CU!K+.D7#6\$37L;?9AMAW0
MC;M*_,,\G!Z\=/>NH\,OO>VD3E)+J!'&,JT@!&>G\Q39+^VC8KYR.X=8V1&!
M*EC@9';FL]O#ENULT(E/*NN\H"WS1K'U]@N:9%H4CD/-,B%)7:-4CP<&7?\
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MB01.TI:17(4IMX^X<8HO,+(Y/_A3&G_\_4__ '\_^QH_X4QI_P#S]3_]_/\
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M%,:?_P _4_\ W\_^QH_X4QI__/U/_P!_/_L:['_A-]"^RB<7,I!?;Y8@<O\
M=W;MN,[=O.>F*KMXVLY;NXM[5"P@FMX_.D#".192.58 \\\>OTHO,+(Y;_A3
M&G_\_4__ '\_^QH_X4QI_P#S]3_]_/\ [&NIC\=:;)J-Q&N_[%#;K*+C8V9&
M,A0*BX^8$]".M7Y_%6E0:?:WIEE>*Z9EA$<+,S,H)8;0,@C:<_2B\PLCA_\
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MC,D0C#MQG=C(ZXK2TSP=:V4EK=37-S/?12+*TKN/F(C\L+P!\H!.._K7-?\
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M*VC^ZGN?4^]-0;>H.2MH<\,XYZTU_N-]*=37^XWTKH,SZ;TG_D"Z?_UZQ?\
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MM^5;WACPCJ?BC48H(+>5+4L/.N64A$7OR>I]!2O8#Z*T6&-M!TXE 3]EB_\
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M10 >6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110
M>6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G
M]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?
MRH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RH\
MM/[B_E110 >6G]Q?RH\M/[B_E110 >6G]Q?RIP  P!@444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img83127175_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %^ G # 2(  A$! Q$!_\0
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M/:.1$1WC95<95B,!A[>M')'L',ST[_A=NJ?] :S_ ._S?X4?\+MU3_H#6?\
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MNJ?] :S_ ._S?X4?\+MU3_H#6?\ W^;_  KR^BCDCV#F9ZA_PNW5/^@-9_\
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M&X>HKZW^S6__ #PB_P"^!1]FM_\ GA%_WP*/:^0<A\D;AZBC</45];_9K?\
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M /0$U+\HO_BZ/[7G_P"@)J7Y1?\ Q=%@-2BLO^UY_P#H":E^47_Q=']KS_\
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MBBB@ HHHH *.U%':@!%^Z/I2TB_='TI: "BBB@ HHHH *:WWE^M.IK?>7ZT
M.HHHH **** "BBB@ IJ_Q?6G4U?XOK0 ZBBB@ HHHH **** &O\ <-.IK_<-
M.H **** "BBB@ HHH)P,F@!/X_PI:X0?$,7GCRWT+2;(7]DPVW%Y"Q(B;GVQ
M@8KNZJ47'<2DGL%%%%2,**** "BBB@!$^X*6D3[@I: "BBB@#+\/?\@<?]=Y
M_P#T:]:E9?A[_D#C_KO/_P"C7K4IO< HHHI %1RV\,^/.ACDQTWJ#C\ZDHH
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M=O)-!)=);OL/*!L_-[XQTK&O/BSH2^$VUW2TGU _:DLUM%7RY3*W12#TXYH
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M_2@!:*3!_O?I1@_WOTH 6FKU;ZTN#_>_2FJ#EOF[^E #Z*3!_O?I1@_WOTH
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M'Y4 .HIN&]1^5&&]1^5 #J:O5OK1AO4?E2*&RW(Z^E #Z*;AO4?E1AO4?E0
MZBBB@#S+QQJFFZ+JES&OBN"WGO(L7.DW^Z6WD0C&?E^:'([CCVK)\-66F/?Z
M1::[K.N1I$Z2Z?8WLZ26<S#_ %9BF48D XP"0?:NGU;P1K?]O:AJ'A_6[.SC
MU)E:ZCN[%;@A@H7*$GI@#Y3Q71Z#X<M-$\-V.B\745HH >9 2S9SNQT').,=
M* -FBBB@ HHHH **** "BBB@ HHHH ;_ !GZ4ZF_QGZ4Z@ HHHH **** "CM
M11VH 1?NCZ4M(OW1]*6@ HHHH **** "FM]Y?K3JY+Q;XMO?#NJ:1:VNBS7Z
M7LNQY$S\G(&!@=><\TXQ<G9";25V=;1112&%%%% !1110 4U?XOK3J:O\7UH
M =1110 4444 %%%% #7^X:=37^X:=0 4444 %%%% !1110 G\?X4M)_'^%+0
M 4444 %%%% !7 Z_\4;/0?$EUI#Z9=7/V:#S7EA(.#C.,=AZGM7?5S.E>!M+
MTCQ+J6N0M/)/?@B2.1@44$@M@>^.]7#EUYB9<W0O>&->A\3>'[758()8$F!_
M=R]00<'ZCCK6Q3(D2.)41%1 ,!5& /PI]2[7T&O,****0PHHHH *:W5?K3J:
MW5?K0 ZBBB@ HHHH **** "FKU;ZTZFKU;ZT .HHHH **** "BBB@ HHHH *
M*** "BBB@!.?:CGVI:* $Y]J.?:EHH ;SO/TI>?:D_C/TIU "<^U'/M2T4 )
MS[4<^U+10 G/M1SCM2T=J &KG:.G2EY]J%^Z/I2T )S[4<^U+10 G/M1S[4M
M% "<^U(<Y7IUIU-;[R_6@!>?:CGVI:* $Y]J.?:EHH 3GVHY]J6B@!.?:D7/
MS?6G4U?XOK0 O/M1S[4M% "<^U'/M2T4 )S[4<^U+10 U\[3TI>?:D?[AIU
M"<^U'/M2T4 )S[4<^U+10 G/M1S[4M% #>=_;I2\^U'\?X4M "<^U'/M2T4
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M #J*;\WM1\WM0 ZCM3?F]J/F]J %7[H^E+3%W;1TZ4OS>U #J*;\WM1\WM0
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MY]J.?:EHH 3GVHY]J6B@!O.\].E+S[4G\9^E.H 3GVHY]J6B@!.?:CGVI:*
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MMN;8H&X^IJ2B@ HHHH **** $Q\V?:EHHH **** "BBB@ HHHH 0#"@4M%%
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MOO6Q0 4444 %%%<!X[\<3Z19Z<-*F@AM+ZX:WEUIQYL-F0<'('5B00,\<<T
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MY.3N/<]: ,?2M'7Q*OAKQ9JEO+8:U;VVYHX7V@AUY1QU*]\=JZZBB@ HHHH
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1J>]7:** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img83127175_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B G # 2(  A$! Q$!_\0
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M1CCCFF+87CI"ZVEPRSY$3")L28Z[>.?PI^SB',SVW_A='AS_ )]-3_[])_\
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M_P!^D_\ BJ\*H)P,T>SB',SW7_A='AS_ )]-3_[])_\ %4?\+H\.?\^FI_\
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M^D_^*H_X71X<_P"?34_^_2?_ !5>%5<TW2KS5[AX+*-'>.)IGWR*BJB]22Q
M &:/9Q#F9[3_ ,+H\.?\^FI_]^D_^*H_X71X<_Y]-3_[])_\57BLVF7L"RNU
MN[0Q'#S1C?$.<??&5//O5B3P_JL5K:3M93?Z6[I#$(V\QMH!)VXSC!&#2]G$
M.9GL7_"Z/#G_ #Z:G_WZ3_XJC_A='AS_ )]-3_[])_\ %5XFFGWTD$D\=E<M
M#$2))%B8JA'4$XXQ3AI6HM,81I]V90H8H(&W 'H<8Z&G[.(<S/:O^%T>'/\
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MC8ZE6/(QUX%:M96M?ZS2_P#K^3_T%JU: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y;6?")U/4+FZAFA@-QY0?]WDG:LB
M,3ZG;(,?[M:/AS1I-$T^2WDF25GEWY1=H "J@X]<*"?<FMBB@#*B::/Q/+";
MF5X)+42B-\$(V['R\9Z5JUE?\S;_ -N/_M2M6@ HHHH **** "BBB@ HHHH
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MI6>E6WVF^G6&'<%W-GJ?I18ZE9ZDLK6=PDPAD,;E>S#_ #UZ4 5I?^1HM?\
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M %_)_P"@M6K65K7^LTO_ *_D_P#06K5H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BLO7YI;?3#-'?/9!#EY8X!*Q&#P >!GU(
MQ5/PC>WFHZ8UW<SW,L;OB(7,*(X [[DP&!]<#H>M '0455OM0@T]83-O8S2B
M*-(U+,S')Z#T )^@IFEZM::Q;O/9NS1I(8R64KR,'//8@@@]P10!7_YFW_MQ
M_P#:E:M97_,V?]N/_M2M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Q!<ZC:V[VFGA)9DC8A'S@L!_>KSPZC=,22Z$GN8E_PIVD_\AO3_ /KZB_\
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M[;_]=4_]"%,1];4445R&Q\M^*_\ D<-:_P"OV7_T(UD5K^*_^1PUK_K]E_\
M0C6176MC$*Z_X7_\E"T[_=E_] -<A77_  O_ .2A:=_NR_\ H!I2V8UN?1E9
MWB#_ )%O5/\ KTE_] -:-9WB#_D6]4_Z])?_ $ US+<U/E1?NCZ4M(OW1]*6
MNLQ"O6?@?_Q\ZW_N0_S>O)J]9^!__'SK?^Y#_-ZBI\+''<]BHHHKF-0HHHH
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M^1VC_P"O-/\ T)J\^KO/BM<1ZCXOCGLBUS$+5%WPHSC.6XR!7#>1/_S[7/\
MWX?_  KI@URHR>XRI;7_ (_;?_KJG_H0IOD3_P#/M<_]^'_PJ6VAG6[@8VUP
M )4))A?@9'M570K'UG165_PDNB_]!.V_[[%'_"2Z+_T$[;_OL5R&Q\X>*_\
MD<-:_P"OV7_T(UD5L>)E>?Q5J\T,,TD4EY*R.D3$,"QP0<<BLKR)_P#GVN?^
M_#_X5U)JQC8977_"_P#Y*%IW^[+_ .@&N3\B?_GVN?\ OP_^%=5\.9!8^.K"
MXNUD@@19-TDL;*HRAQDD4I-68UN?1U9WB#_D6]4_Z])?_0#4?_"2Z+_T$[;_
M +[%4-<\0Z1-H&HQ1ZC;O(]K*JJK9))4X %<ZW-3YG7[H^E+3E@N-H_T6YZ?
M\\'_ ,*7R)_^?:Y_[\/_ (5U71C897K/P/\ ^/G6_P#<A_F]>4^1/_S[7/\
MWX?_  KT[X/7UMI=QK!OY/LHD6+9YZE-V"^<9'/45$VN4J.Y[5165_PDNB_]
M!.V_[[%7K2\MKZ'SK69)H\XW(<C-<YH3T444 %%%% !5:/3[2&_FOHX$6ZF
M620=6 Z?T_(>E6:* "BBB@ KSY/B8T)N!>Z1*IB; \MN&!:7:P)P.5BX'4L<
M5Z#2$ ]0* .,U[QX-+U&:P@L9#+$T6Z20?+M;9DX!R!AP 3P6!':JO\ PLZ"
M.W=Y-,G;RDB+L)$7+-'O(P3QQP/4D#J:[TJI.2 ?PJG!I&G6U]/?0V4*74_^
MME"#<W?K]0#^% %N-Q)&K@$!@#AA@CZTZBB@#+\1:K+HFA7&H06CW<L13; G
MWI"7"X'OS7,Z?X^N+K7K:QDL%:&6V$K&#<TBN4+%0O4X(*G@<CKVKNJ3 SG
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MI;:6TLY+J">**5(IB1\T6\J./OELJH[XK?\ #FN'6TOV+6SBVNW@62W<LK@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img83127175_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #7 ;X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH \Z@UB>/5!)#K<]S?'59()-,\U7'D!FYV8RN  <_XU
M8MO'.IW.F370L;12OE,I:>,!0^<J1YG+#'0E2?08K<N?$FC:<DUTT+!A=&U!
MCB&Z5P0&(_V03@DXZ?3.I<S:;9HR74EK"KJTK+(54,%QN8YZXXR:J^FPNIR'
M_":3/<1R0^1MFAMQYLA<11EY)%9B"1@#9^.1SBAO&VI-9O<1063"*UGN7Y8A
MA'+LPISW'.:Z+4)=!NHA:75Y;1[W5 $N!&Q(P0H((/<<>X]:B:]T#0M,NXHF
MAE%C$\DT".))<9RV<G)))[GJ:-.P&ZC;T5L8R,TZLX:U8FZMK=) YG=HE9""
MJR*NXHW/#8R<>QK1J1A1110 4444 %%%% !1110 4444 %%%% !1110 445B
M/XNT%(A*=2A:,SM;[TRPWKC=R!T&1EN@SUH VZ*H:?K6G:K-<PV5RLLELVV0
M $8Y(R,CD95AD9&5/I5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YJ+P[-+HE_I4K
MB%7O7FBEQORAD$G3/KD?A3-<@T3Q3>0Z3_:]K]MM9M\MO'(K2% ,.A7.0"",
MUU%>96.@^ 7^).KW,>K2S:Y.LHO+.23"*#C=_",8X_BIW UD^'<:P6T9U)G=
M$,<[O#GS5+[N!NP#CC)W#':II? <<AU("_PEVDZIF'+1F4Y8D[N0.P 7WS3?
M#7]F:9XK\06EG/%':A+5HT\[(R5?.,GZ5M:9XLT+6=5NM+T_4HKB^M=WGPJ#
ME-K;3G(['BCF8K&?!X8EL9-+L[>7?I]I>/=KG@Q#8P"9SELLY.?3BNIHHH;N
M,****0!1110 4444 %%%% !1110 4444 %%%% !7(WW@2&\,Y6_DA\^XF>0+
M&"/+E5 Z#T/[M<-V]*ZZB@#D(_A[IDEK?6>HRRWEI<A$6+<8C&BR/*HW(02=
MTAYXX XZYS/AAI]OI-YXMTZS5DM;;5S'$C.S[5\M.,L2:]"KA_ 7_(?\;?\
M8:/_ *+2@#1\67/BN#3KAM!M+5V!78XD+2X[X0KM_4_2KWA^;7Y;* ZW:VD4
MAA!<Q2DN7XZKMP._1C3M7\2Z9HRG[1-OD#!3%$07&1G)&>E3:7K=AK$*O:3J
M79=QB+#>HSCD \?_ %ZGVL&^2^IHZ-11Y[.Q!JUM=R:MH\]M).$CG<2HK?N\
M&)\%QW^;;U]:XK['JGV'#V>N&V\I1+&))/.:\\MLN#NSLW;>0=N>>G-=WJ&J
M/8ZCIUM]F+Q7<CH\VX 1[8V?IU).VLZQ\3NVEWU]J5HMNMK:+?[89#(3 RLP
MZ@?/\C9'3IS5&8FJG7UN+'[)-*JQP!YUBB1EED\R,%22"0-I<\$'CKQ61I$/
MB$7.CV]RMX(+6X,LSN3^]$D;D!CZ(VX8/JGI6FOC6V.IQ6TUI-:QE)O.:XPK
MQ/&%;:0,C!4YSGT'4ULZ+J#ZKI%O>R0?9WE!W1%MVP@D8S^% %^BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWL 2%16.2#\W3I4'PTN7O-2\8W$EK-:O)K!)@GV[T_=IP=I(S]": /0****
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MT15  ^4A21GO^-;E "  9P ,\FN(\!?\A_QM_P!AH_\ HM*[BN'\!?\ (?\
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MB, X1%[ ?7KDUD>'.?VH+[_KM<?^BC63K/A^QU#1O"MI#XN\,B32H&CG+:@
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M)IO_ (")_A0!G_\ "P?!W_0T:1_X&)_C1_PL'P=_T-&D?^!B?XUH?\(UH/\
MT!--_P# 1/\ "LOP[X'TG1]!MK"ZT_3[N:+=NF:U3+98D=03P#C\* )/^%@^
M#O\ H:-(_P# Q/\ &C_A8/@[_H:-(_\  Q/\:T/^$:T'_H":;_X")_A1_P (
MUH/_ $!--_\  1/\* ,__A8/@[_H:-(_\#$_QH_X6#X._P"AHTC_ ,#$_P :
MC\0^!])U?1WL[73]/M)6FAD$HM4R DJN1P.X4C\:U/\ A&M!_P"@)IO_ (")
M_A0!G_\ "P?!W_0T:1_X&)_C1_PL'P=_T-&D?^!B?XUH?\(UH/\ T!--_P#
M1/\ "C_A&M!_Z FF_P#@(G^% &?_ ,+!\'?]#1I'_@8G^-'_  L'P=_T-&D?
M^!B?XU&/ ^D_\)4VJ_V?I_V8V0MOLWV5,;]Y;?TQT..E:G_"-:#_ - 33?\
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MX._Z&C2/_ Q/\:OZ7XET/7)I(M*U>ROI(UW.EO.KE1TR<&E_X1K0?^@)IO\
MX")_A5FTTK3M/=GLK"UMF889H850D>AP* +=%%% !1110 4444 %%%% !111
M0!Q7Q:_Y)KJG^]#_ .C4JU!]O'C75#G4OLOV(>6!'^YWX3[A/!?KP>/3^*M[
M5](L==TN?3=2@$]I. )(RQ&<'(Y'(Y KFO\ A5WA7_GVO?\ P83_ /Q= ',>
M,WU%_ASKOV[^W=H-KM_M..U5?^/B/[OD\Y^M>LUQO_"K/"1*^98W,BA@VR2^
MF920<C(+X/(KLJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "FNZQHSNP5%!+$] *=7!^._$$CV,VFZ8)I&6=(+F6UF,<L4F ZI&PZ.0.
M,\9PI^]0!9\4>)Y64:;HPE>>5H0T\;*%Q(3M0-G<K,%(#A2 2,]\='HL-[;Z
M7%'?W#7$PZ/(@63;V#X)!8#@D<$BL7PQX3BTW%_J%O:R:B3N1EA \G.<E<Y*
M%LY8 [<DXZDGJJ "D9E12SL%4=23@"F7%Q#:V\EQ<2+'#&I9W8X"@=2:\R?4
MK_QMJ(LDBB-G]K,J+)&)XFC3*K(0<*R'D-&2'5L'VH OWFMZ]XCU.W/AQY+2
M*(RA3-'NCE(.PE^04*G^!ADA@0"1\OH7;FLS0=#M= TN&SMP&9459)MH#2E0
M "?P  ]  *TZ "L[6]7AT337NY0&(941"X4%F8*,D_=&2,D]!5?Q-KT7A_2)
M+HM";AOE@AEE$8E?^[N/"_4\#O7(Z)I=QXKU8:GJ<:O!;QI"?M%J-YP6)C.[
M!5QN*N0"CKC&.0 #7\*OXCNM7N[R_E==.D:3%O/%LDB?<-J#D@A0"-PP&X(S
MDUV%-CC2*)(XU"1HH5548  Z 4Z@ KE?%7B-[(/I>GK,;Z6W>3SHDWF!00"X
M7_EH5SDJN2!SCH#3\5>+Y+#5H-/TV2)I(PSW,F2_D' V!XU!9D8G!*\J2I/'
M5_A#P=%I@CU&\B3[4T:;8VA0/&PW?,[*2'DPY!?@D=>] &SX7AUF#2 FMS)+
M<!OW9 ^8)@8W<G)SD]3U&3FMJBFNZ11M)(P1%!9F8X  ZDT *2%!)( '4FN!
MUC7M8UW4%M/#AFM_LUPT9F*965U RK\@Q@9W#<"&'(!X!HW^NWGBR_GTJR56
MLIIEC1E'FI*B,&+C("@J0 \;D%E(*]L]KX>\/6OA^Q\F%(C,Q8R2QQ!,@NS!
M0.RKO(49.!0!J0"46\0G96F"#S&08!;'./;-245FZ[K%OH>D3WL\L2%5/EB5
MMH=\$@9_#D]@">@H FU34H-)TVXOKG=Y<*%RJ*68X&< #K7)Z->>)-6\4&^6
M0P:6<"2VD4,H38"IC<';)N)W;@.,D'H <BUL+[QW<H]\#!%;Q%2TL(D:%F96
M*AC@>8-H*RIE2IY[9])M;6WLK9+>UACAA3.V.-0JC)R< >YH FHHHH ****
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M( RQ"@L< <D@ G ]*N5QA?4=2U:;P[KL<$J7"&XAFLF9'M,8VY_'HV>2.F*
M,VYUR\\5^)+6RL("+&(K<1F3<([J-DSN?CA<,=I&<, "#D[>RT+0;+P]8?9+
M)6PQW/(^-\AP "2 .P _"GZ1I%KHUEY%LBAG;S)G5 OFR$#<Y X!.,X'%:%
M!6-K/B6PT9DAE?S+J4F.&%.2\FW*H2/NENV:LZY+?P:)=RZ7$);U(\Q)C)/K
M@'@G&< ]\5S&EV\?C>S2[U.RDMIK9A%)D';=1E59E=65>0?;*LO!H S]'L[C
MQU+>7NJ(\=G+LC\OYE:(H<A4W+]U@3O!&00.<\+Z'!!%;6\<$$:QQ1*$1%&
MJ@8 %+##';P1P0H$BC4(BCH . *?0 A(4$D@ #))[5Q7B+QW#!#/:Z0K7-Q'
M(D4[J& A$BDHX;:00<<-R,^IP#8\8ZYK>@W-C<V=M#-IQ)6<,#EFPQ"DC)7.
M  0#EB <9J_I?AK3X-0&K+ ZR./-ABE S:LX.\*>H!SRO0'.,9H H>&O"D4
ML=4U!#)J$,"HC-Z '$C \B4JQ#<D9S77456U"_M]+TZXO[MREO;QF21@I)"@
M9/ Y- #KJ[ALX3+.X5>P[L<$X [G@\"O/[[Q4_BW4K;2]&3_ $5V2XBFDW!+
MD+R5==N?+)#*2#D%1D'(!MPZW<ZWKC:1?017>DZ@7$#01L-L6TLDJR@D,"!@
M_=96QZBNIT;0[7187$/[RXFP9[AE >8CHS8P,^IQR>: &:'X?LM!2X^RJWF7
M,GF2R.06)[#.!D#M^O-:U%9.NZS%ID4-LMQ!#?WNZ*R^T9\MI<< D>^/KTH
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GH/RHHH FAB6"".)"Q5%"@LQ8X QR3R3[FGT44 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img83127175_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 4\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2)-.DMHK6VBGCEE8;I@[R(2%!.%S'QGD]<=* -ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M?TO_ )'3Q#_URM/_ $%ZZ"N?TO\ Y'3Q!_URM/\ T%Z .@HHHH \_P#'?P]N
M_%VL6]];WT-NL5N(2LBDDD,QSQ]:Y;_A26I?]!>T_P"_;5[315J;6@N5'FO@
MWX97GACQ'%J<VH6\Z(CKL1"#R,=Z]*HHJ6V]P2L<9;>$]5.DP:)=WMF-,CNO
MM$ABC8RRJ)C*$R3A1G )P<C(XSD5[?P/>6WBBRURXOHKEK*\NKG<4=II4E60
M!,EB%"!U "C!"]JVK;QKHUU)"H:[CCGF,$5Q+9RI"\FXKM$A7;DL"!SR< 9)
M%;QEC!8%U!4989Z#U-(9SO@C1YM(T647$;Q/-.S10OC,,"X2&,XSC$:)D ]2
MWK6A%I+Q^++O63*ICGL8+41XY!CDE8G/H?,'Y5J;EW;<C=C.,\XJD-8L&UUM
M%6<'4%M_M+1 'Y8RVT$GH,GMUH O4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUG_KW/\ ,5\SU]+^/_\ D0]9ST^SG^8KYHK>EL9SW"BBBM23U?X(?\?NL_\
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M]<K3_P!!>@#H**** "BBB@ HHHH **** "BBB@ HHHH ^1I/]:_^\:;3I/\
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M^D_P.E5*%M:?X_\  .5_X61X1S@ZU$#W!C?C]*<_Q&\((0/[>M7!Z&/<X_,
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MO8[8W=U:PK$[VL62 SD2;23M)"JS,0.E5=,\32ZM\1$M;.\$VBSZ!%J$*B,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img83127175_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) G # 2(  A$! Q$!_\0
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M /A=NJ_] >R_[^M1_P +MU7_ * ]E_W]:O,**.2/8.9GI_\ PNW5?^@/9?\
M?UJ/^%VZK_T![+_OZU>844<D>P<S/3_^%VZK_P! >R_[^M1_PNW5?^@/9?\
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M/XV*L[)I6D>9$#Q)<R;2W_ 0./SK/_X7;JO_ $![+_OZU>845OR1,^9GI_\
MPNW5?^@/9?\ ?UJ/^%VZK_T![+_OZU>844<D>P<S/3_^%VZK_P! >R_[^M1_
MPNW5?^@/9?\ ?UJ\PHHY(]@YF>G_ /"[=5_Z ]E_W]:C_A=NJ_\ 0'LO^_K5
MYA11R1[!S,]/_P"%VZK_ - >R_[^M1_PNW5?^@/9?]_6KS"BCDCV#F9Z?_PN
MW5?^@/9?]_6H_P"%VZK_ - >R_[^M7F%!.!FCDCV#F9Z?_PNW5?^@/9?]_6H
M_P"%VZK_ - >R_[^M6+>?#B^M%O7%VLD4%M%-$_EX\YW.-@YX([GZ53D\+Z<
MOB&/0X]8GEO5=H9UCLB0)!CA/F&X9SR<=*5H#O(Z;_A=NJ_] >R_[^M1_P +
MMU7_ * ]E_W]:N1@\)W,NN7FGM*5BMQ/B[$1,<AB4D@9QUQ^%6?#W@BX\0Z1
M:ZA#>)&LMV;>2,IDQJ /WG7D9(!'O1RP"[.E_P"%VZK_ - >R_[^M1_PNW5?
M^@/9?]_6KFKWP6;3PR-8^W.?]%BNBCVY6,AVV[%DS@N.N,=*L:?X&74%VBZN
M5FCM+:>:.*V\YLS,=H4 C@+@D_7THM +R-W_ (7;JO\ T![+_OZU'_"[=5_Z
M ]E_W]:N9G\$W$.DWU\+V*06MVT 6-"1*BNJ-(&] 6''UJ[JW@"/1KRUAN=4
MF"7%PULK"R)9G !&T!CE3NQG(Z=*+0"\C9_X7;JO_0'LO^_K4?\ "[=5_P"@
M/9?]_6KFY?!3?8]<N;745N$TQVCCQ"1]H* &3'/&T'WS6+K>FIIE]''$[O!-
M;Q7$3/C=M=0><=P<C\*%&+"[.^_X7;JO_0'LO^_K4?\ "[=5_P"@/9?]_6KS
M"BGR1["YF>G_ /"[=5_Z ]E_W]:C_A=NJ_\ 0'LO^_K5YA11R1[!S,]/_P"%
MVZK_ - >R_[^M1_PNW5?^@/9?]_6KS"BCDCV#F9Z>/C9JQ.!HUF3_P!=7_PJ
M67XRZU" 9-%L5SV\YL_E7FEJ3&D\R_?C0;?8DXS3F2&W)22-II<9?YB O^-6
MJ4;7.>5>2GRK_@_HENCT3_A=NJ_] >R_[^M1_P +MU7_ * ]E_W]:O/$6PD4
M F6-V;')!">_N*CEM@D'GQRAX]VW)4J<_CUI>Q6Z*6)5^5W3\U^NQZ5%\;M0
M$@,VBVK1]PDS _J*]%\*>-M+\6P/]D+0W48S+;2_>4>H]1[BOFBM3PYJLVB>
M(K#4(&(:.90P!^\A.&!^H-1*FK:&ZDSZGHHHKG- KF_'>A2>(O"-Y8P#-R )
M81ZNISC\>1^-=)133L[@?(KHT;LCJR.I*LK#!4CJ"*2OI+Q#\/O#_B2<W-U;
M/#=-]Z>W;8S?7L?Q%<]_PI70O^@CJ7_?2?\ Q-;JHC/E9X=17N/_  I70O\
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M2?\ Q-'_  I70O\ H(ZE_P!])_\ $T<\ Y6>-ZAJMYJ<=K'=2!DM8%MXE48
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MG\EKM]&T+3?#]D+33+5+>+JV.6<^K$\DU$JBMH;*/<T:***P- HHHH ****
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M44 %%%% !1110 AJO,S)&[JA=E!(4=SZ58-1-P:F14=SD=,D#:G9-Y<FXE\
MX[@Y/X<UUCAVAD6,A7*D*3V.*Y.8_P!GZEYAZ6]QO/\ N-U_0G\JZU".H.1V
M-<F&T3B_ZTM^AV8JS::7?\[_ *C(K?[#8K%;1JQ0 ;2<;O7GUJ$!=1>VN A
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M4?J*WV6N<U325@C>:-=UKU>+'*>Z_P"':N.I%PESQ_K_ ('Y;]SLIR4UR/\
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M_P#O'^=-J@"BBB@">R_X_P"V_P"NJ_S%>L5Y/9?\?]M_UU7^8KUBDP"BBBD
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M"_Y&R#_KF_\ *O7*\7,/XJ]#[3A__='ZO\D%%%%<)[A\[_%7_DH=]_URA_\
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M>-D:+@;1M4# ]*S%_P"1OD_Z\%_]&-0!K4'H:*#T- 'D4G^M?_>/\Z;3I/\
M6O\ [Q_G3:H HHHH GLO^/\ MO\ KJO\Q7K%>3V7_'_;?]=5_F*]8I, KB_'
M'_'U9_[C?S%=I7%^./\ CZL_]QOYBD@.4HHHJ@"BBB@#M? __'E=_P#74?RK
MJJY7P/\ \>5W_P!=1_*NJJ0(Y_\ CWD_W3_*O)*];G_X]Y/]T_RKR2F@"BBB
MF 5<TG_D,67_ %V7^=4ZN:3_ ,ABR_Z[+_.@#U.BBBI **** "BBB@ HHHH
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ME)*HH4;CDX [FGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %1=.A36)=3!?SY(%@(S\NU69AQZY8U;HHH
M ***I:S-<VVAZA/9J6NH[:1X5"[B7"DJ,=^<<4 7:*\[L_%WB&WM[)7L;B_%
MQ>K$L\MF\+-$5CWL0 -I5G?J!D(3[U<T[QCJ][>6"OI<:V\]Y)9RO&'D*M&
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M[.Q4@<$9D/Y"NAHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *C:")YDF:)&EC!".5!90>N#VSBI** &M&CLC.BL
MR'<A(R5.,9'IP2/QIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4R&&*WB6*")(HUX5$4*!] *?10 U(XX@1&BH"Q8A1C)/)/U-.HHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img83127175_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ G # 2(  A$! Q$!_\0
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M&Q2N>V>]=ED>HHR/44<S"QQ5MX8UN&^L[A;Q(H8V3S+7SF95C$S2; <<E1M
M/?D=,5VU)D>HHR/44-W&+129'J*,CU%(!:*3(]11D>HH 6F%%D1T=0R-D,K#
M((]#3LCU%(,#/(Y- %7^R=.^S"W^P6OD!2HC\E=H!.2,8]0#^%*=*T\L6-A:
MEC'Y))A7E/[O3I[5:R/449'J* *XTZQ6..,6=N$C0QHHB7"J>JCC@'N*2+3;
M&!56&RMHPA!4)$HP1DC&!VR?S-6<CU%&1ZB@!(XHX8UCB1411@*HP!^%.I,C
MU%&1ZB@!:*3(]11D>HH HZK:S7NB7]K;.$GFADCC8D@!B"!R.E<M'X3U)KVU
M:<QBT"S(84N6/V<.1@*2N6P,GMUQTKMA@9Y'6ER/44T[ <*GA;7#<0W-S/%-
M.UO,DK"=@%D8;58 KV4+TQSFK3Z%K5S=6$TAAC>**&/>MTY,!1B7*C #>8,
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M'Q;_ -!VY_[Y3_XFC_A8/BW_ *#MS_WRG_Q-'LF'.CZ('?ZTM?.W_"P?%O\
MT';G_OE/_B:/^%@^+?\ H.W/_?*?_$T>R8^='T317SM_PL'Q;_T';G_OE/\
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MXDO+*$-<SQ1.A2=+N=M^07S@8.58,O4@X7FNVHHY@L<5)X>\13JT;W:+;+%
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M18M(Y(;*WBE;=+'$JNWJP !/YU-114#'^4_]W]:/*?\ N_K1YK_WJ/-?^]0
M>4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]
MW]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/
M*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\ N_K1YK_WJ/-?^]0 >4_]W]:/*?\
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MLO[1NA;R7,CE%5=I."PZ;B,5Y7]@D\"V+7MZK1>(9FQ90*^#;HK<RO@\YQ@
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MK7_GG1]K7_GG56BESL?LXEK[6O\ SSH^UK_SSJK11SL/9Q+7VM?^>='VM?\
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M**!A1110 4444 %%%% !1110!S?C;Q'-X;T19K.#S[ZXD\JW3:6 ."2Q ZX
MZ5YYH'C;Q-%:76O:GJ*2:9 XC\J:(?Z1(?X(\ 8(&3GH.]>D^*]$NM9TV)M.
MNOLNIV<HN+6;/ 8#!!]B#BO/[SP=XJ\5ZM;0ZG8VVE:;;]4@==@).795'5F/
MY5T4^3EU,)\W-H>MQ2I/#'-&<QR*'4^H(R*?3(HD@ACBC&$C4(H] !@4^N<V
M"BK7E6W_ #T_6CRK;_GI^M5RLGG14(!() )'0XZ4;%V;-J[?[N./RJWY5M_S
MT_6CRK;_ )Z?K1RL.=%0JIQE5.#D9%!53C*@X.1D5;\JV_YZ?K1Y5M_ST_6C
ME8<Z,ZWLK:T\_P B%4\^1I9>^YCU)J4QHR[2BD8VXQV]*N>5;?\ /3]:/*MO
M^>GZT^5BYUV.8_X0[0=N/L1SC;N\U]VW&-N<_=P3Q6S'!##;I!'$BPHH54 X
M '08J]Y5M_ST_6CRK;_GI^M#4GNP4HKH8D6A:;#J+WZ6H^TL6;<S$@%OO$ G
M SCFM JI()5<CIQTJWY5M_ST_6CRK;_GI^M'*V',NQ4VC).T9)R>.II>E6O*
MMO\ GI^M'E6W_/3]:7*Q\Z*M%6O*MO\ GI^M'E6W_/3]:.5ASHJ%%)R54GKD
MBD,:'JBGD'D=_6KGE6W_ #T_6CRK;_GI^M'*PYT5"JD@E02.AQTI-B<?(O!R
M..A]:N>5;?\ /3]:/*MO^>GZT<K#G13"("2$4$G).._K2A%5=JJH7I@#BK?E
M6W_/3]:/*MO^>GZT<K#G13$: @A%&T8' X'H*4*JDD* 3U('6K?E6W_/3]:/
M*MO^>GZT<K#G15HJUY5M_P ]/UH\JV_YZ?K1RL.=%6D !# @$'@@]ZM^5;?\
M]/UI!%;?\]/UHY6'.C!?PQH,KEWT73V8\DFW7G]*;_PBOA[_ * >G_\ @.O^
M%=#Y5M_ST_6CRK;_ )Z?K5>]W)O'L<]_PBOA[_H!Z?\ ^ Z_X4?\(KX>_P"@
M'I__ (#K_A70^5;?\]/UH\JV_P">GZT>]W"\>QSW_"*^'O\ H!Z?_P" Z_X4
M?\(KX>_Z >G_ /@.O^%=#Y5M_P ]/UH\JV_YZ?K1[W<+Q['/?\(KX>_Z >G_
M /@.O^%7++2M.TW/V&PMK8MU,,04G\JU?*MO^>GZT>5;?\]/UI6D^H^:/8J#
MO]:6K(BMO^>G_CU+Y5M_ST_6ERL?.BK15KRK;_GI^M'E6W_/3]:.5ASHJT5:
M\JV_YZ?K1Y5M_P ]/UHY6'.BK15KRK;_ )Z?K1Y5M_ST_6CE8<Z*M(.E6_*M
MO^>GZT@BMO\ GI^M'*PYT5J*M>5;?\]/UH\JV_YZ?K1RL.=%6BK7E6W_ #T_
M6CRK;_GI^M'*PYT5:*M>5;?\]/UH\JV_YZ?K1RL.=%6BK7E6W_/3]:/*MO\
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MN@N$$B'V/]:LU@S=;!1112&%%%% !1110 4@Z4M(.E A:***!A1110 4444
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3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img83127175_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 4$# 2(  A$! Q$!_\0
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M:E24%T(****S.@]WTK_D'P_[@J[5+2O^0?#_ +@J[7TBV/AGN%%%% @HHHH
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MLR?]?#_R%>'5[C\'O^19D_Z^'_D*FIL5'<](HHHK T.4\?3M'HT,0.!++S^
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M7_GF*QFW%V-(JZ/ KG1?$U_9VMG<E9(+12L"DJ-@/;.,G\:J?\(;K'_/&/\
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M/^&:\LKT/X@RE=-M8NSRDG\!_P#7KSRNJDO=,I[A1116A 4444 %%%% '/\
MBDMY=J@Z%F/\O\:]<^&'A]='\-K<NF+B[^=B?[O85P2:0NLWUI;E27\T%<?U
M]J]OMH%MK:*!!A8U"C\*PK.VAI!$M%%%8&@4444 %%%% !1110 5R7CZW>32
M(9E&1%+\WXC%=;45S;17=M);SH&CD&&!JHNSN)JZL>(T5T^K^"[^R=I+,?:;
M?.1M^^H]QW_"N;DAEB8K)&Z,.H88KK4D]C%IH92$@#)( ]Z4[MIVJ6;' ]:I
MVG@SQ#X@E,LD<BQD\*O  ^IXH;L"1:#HQP'4_0TZKR_"/4%3*2JK^HFY_E6A
M9?#[7(5\J26-QGAY)!Q^0J>>/<?*S" +,%4$DG  KTGPAX>.F0&\NEQ=2CA3
M_ O^-2:#X0MM*83W#"XN1T./E7Z5TM95*E]$7&-M6%%%%8EA1110 4444 <)
M,\:>/-3,FHVMHN8?EGB5_,^1> 2>/PJ-KG2HK_Q,FHF(M(X\I",LQP?N]^N*
M[E[.VDD\Q[>%G/\ $R G\Z#9VK2>8;:$OG.XH,_G7*Z#[]7^-SO6+C973V2^
MZWEY'&:9#*-=T"*[3+_V<P97&?7@UI>$((@=6<1(&6_D"G:,@;5X%=(8XS()
M"BEP,!L<@?6E2-(]VQ%7<<G:,9/K50H<K3O_ %8SJ8KGBU;?_-L=11170<@4
M444 <CX_MVDTJWG49$4F&_$?_6KSJO;;JUAO;62WG0/%(,,#7G.K^"K^R=I+
M-3<V_;;]\#W'?\*Z*4U:S,YQ=[G,44^2&6)BLD;(PZAABF@$] 36QF(2 ,DX
MIHD0G =2?8U6@\(^(O$4Q?RI(K?.%4<#'U/%;"?"*_5,B10_KYW/\JES2'9E
M*@ DX%;=C\/-<MAY;RI(O8R2#C\AFNPT+P;;Z:XN+MEN+@<J,?*O^-)U(I#4
M6ROX,\.M9I_:-VF)G&(D(^Z/7ZFNPHHKEE)R=V:I604444AA1110 4444 %%
M%% !1110 4R2&*7_ %D2/_O*#3Z* (5L[93E;>$'V05-TX%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R2&*7_61(_\ O*#3
M%L[93E;>$'V05-10 =!Q1110 4444 %%%% !1110 4444 %%%% !1110!PL6
MO:A!>ZND]PS0L;B.W8C_ %;H"0!^'\JU(O$<\-CIL$=E-?WLME'/(%8+P5&3
MD]\YXJS-X7MI[&\MGFD_TF<S[P!E&/I39O"Z,MH;>_N+::WMUMO,CQET QS7
M&H5HGHRJ8:>Z_JWD0-XO61;3['ITUR]S"TJJ'"E=IP0<^F#6A9^(;&[T^WN3
M-%#)<*3'!+*JLQ!(P,]>1BHK;PU:VD]K)#)(!;V[0*I[AN23[YJQINA6>GV-
MO;&*.<P;MDLL8+#+%OPY-:05:_O?UM_P3*H\-;W5_6O_  #E]%UFZM[J[O;R
MWN'\^\-N-TX*(21\H7V]?>MJ\\51V@OLVCO]EG2#"ORY;N*?)X6@?3YK47,J
MF2Z-TLB@91CCI^51#PC";>>.2]GD:>=)WD8#.Y?\:SC&M%67Z&LIX:<N:7Z^
M7Z7!?%J+:WCW%A-#<6LB1FWW!BQ;[N"*@U'Q%JT*6)CT>6%Y;H0NDDB_-QD*
M#[^O08J[<^&+:ZDU!WFE#7C1OE<#RV3."/SHF\.-<6$<$NIW331W N%N#C<&
M P,#ICFJ:K-6O^7<F,L,FG;\^W^=RI_PD8LKG5'N$N',+1*L&X'YF'W5P*>_
MBTV]M?-=Z;-!<6@1F@9P=RLP ((X[U--X5M[@7IDN9B]T8V+C *,G0BF-X3B
MEL[R*XO9YY[L('G<#< I!  Z=J5JZV\_U_X ^;"O?R[^5_U\Q8?%!>*^\W3I
M89K6-9/*>1<NK=#GH*QM7\3G5/#E^(5:VN('CR8YPXP3V9>*W;WPO;WTEXTD
M\B_:H8X2 !\NP@@_I5-/!-LMI=0&\E/VG9N8(HQM.> .*4XUW[O37MYE4YX6
M+4NMUW\K_J=311178>:%%%% !1110 4444 %%%% !1110 5D^)+^XTW19;FU
M95F5E"EAD#)Q6M6=KFF-J^ER6:RB,NRG<1GH<U%2_(^7<THN*J1<]KF-9^)+
MBXNM,BDV1EQ(EVA'*N@Y^GK5ZT\5Z?>7D5NB7*B9BL,TD16.0C^Z:CG\,K+X
M@_M%)@D+JPDBV]6*[<@_2H+'PQ=02V27.H+-9V3%X(UCVMGMD_C7.O;IV_KI
M_P $ZY?59*^VG^?_  /D3)XQTY[22Z\J[$$9 +F+C)., YY-1GQOIBF0-;WR
MM'_K ;?E%_O'G@4+X7D'A@:1]J7<)O,\S9Q][.,5+=^')+F35F%PJ_;H$B7Y
M?N;1C/O3O7M_7F"6$N_7_+R]637WB:ST^Y\F:"[*C;NF2$F-=W3)IFCWT]UK
M^M0R2EX86B\I3T4$'./RK)U/P1+J%T9?ML8!CC0;XR2I4 <<\ XK>TO2&T_4
M=0NFF#BZ\O"@8V[01_6G%U7/WEI?_,4UAXTGR.\FOU7_  35HHHKI.$****
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MH'6Z88SN(.,^O:G&M4;7ND3P]%)VG^7G_7S.RHHHKJ.$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img83127175_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 G # 2(  A$! Q$!_\0
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MKQ?R8O\ GFOY4>3%_P \U_*CV*#VC/:/^%P^%?[U]_X#'_&C_A</A7^]??\
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M?GS?\]7_ #H\^;_GJ_YT<L0YF?2G_"X?"O\ >OO_  &/^-'_  N'PK_>OO\
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M?GS?\]7_ #H\^;_GJ_YT<L0YF?2G_"X?"O\ >OO_  &/^-'_  N'PK_>OO\
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MB0[1TKD*OZGK%[JPM5NFC\NUB\F".*,(B+G)P!W)Y)ZDU0JD(**** "BBB@
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MC[;)_P \A^M7J*+,"C]MD_YY#]:/MLG_ #R'ZU>HHLP*/VV3_GD/UH^VR?\
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M@MQSU_&N*N[9K.]N+5R&:"5HR1T)4D?TK0?Q-K#S&5KTES-'/G8OWXQA#T[
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M,"H/.T$8X..<FKUK\3=8M+.PMHK2Q"V?DE25?YC$"%R-V!P>< 9ZT]0T*?\
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MWN)Y$)<B.3S/+7YL;,A>>OO1J/0I#X<^(C<3P+%9O+ WEN$ND/[S!/E#'5\
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M8SQ_;A?_ &1+::18Q(/+W_*3U?/&VJ%WX6U:QL9KVXBC2VB@AG:3S1@K*2J
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M\+^U3_H V?\ X$-_A1_PO[5/^@#9_P#@0W^%'*PYD:?[0/\ QZ:!_P!=9O\
MT%:\/KH?%_C+4_&>I1W>H".-(5*PP19VQ@]>O4GUKGJTBK(A[G3^==_\\S_W
MS1YUW_SS/_?-7:*Z+&=REYUW_P \S_WS1YUW_P \S_WS5VBBP7*7G7?_ #S/
M_?-'G7?_ #S/_?-7:*+!<I>==_\ /,_]\T>==_\ /,_]\U=HSFBP7*7G7?\
MSS/_ 'S1YUW_ ,\S_P!\U=HHL%REYUW_ ,\S_P!\T>==_P#/,_\ ?-7:*+!<
MI>==_P#/,_\ ?-'G7?\ SS/_ 'S5V@'/2BP7*7G7?_/,_P#?-'G7?_/,_P#?
M-7:*+!<I>==_\\S_ -\T>==_\\S_ -\U=HHL%REYUW_SS/\ WS1YUW_SS/\
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M%M1DA#W F<*J-"78M\NQ3N^4 $\>]9</ACPQ?>#KO7((;^/_ %X54D:8VIC
MV!\+CYN22Q'!XZ4<P6/.Z*]9U#X?:-;ZO8V%MIM[(7:5Y)'N) LD21AA@B/F
M0DGY$SPO!YJTWA+0]-DGM+'3KB>6WUJRQ="8&2VBD0-N/!^4$D<]3C/2ES#L
M>.45ZA=>#-(N;'4+^8W)=FNYWU'SU$44J3E%@9 /O,.>QYX&*S?&_A31-'TJ
MXN=)2YC>TU5K!_.G$GFCRPX8<#&,XIW%8X&BBBF 4444 %%%% 'U3\,0%^&N
MA8 &;?/X[C76UR?PR_Y)MH/_ %[#^9KK*Q>YHCGU\9:2#>><\D2VUQY&=A;S
M#ACE0N3CY'_[Y-30^+-$G&8[WC( S&RYR5'&1_MK^!!Z4D7A'0X71XK((R+M
MRKL-W##+<_,?G;D\\TT^%; 7UG.BA8K5S*(B-VY_+$8))/0*HX[D T_=%J,_
MX3316GABCFED$H<[UA;"*J[MQX^Z5.0>AIY\8:&%W->%5\OS,M$XXQN].I7D
M#J1S3?\ A%-"MUCC\MDRQ5,W#9(*;-F2<E=O 7H,53U'0_#VH2SVHG$5RUK]
M]9"515'E[\9V[@/ER><4:!J61XSTIM06U#OATRLC(P ?>5V,,94Y'?'6IH?%
M%E/I=S>1!I'MK3[3+&@)5?DW[=^,;L$<=>::GA_08 00I;*L[/<$LS;RX+$G
MDECU/6DCTG0[!I;.(,B7<1MY8%E8H0$P2PS@-L4#<>>*- U%N?%^EVK"*1IF
MN,Q!H4B9F'F$ $<<C)[4^/Q;HDTPAAO?,D:7RE5(V8EL$\8'3@\].#4<7A+1
M&+W$4<C/+M;SEN')RI5@5.>#E0<BI[?POI%J^Z&V*_.[@;VPI=2K8YZ$$_G1
M[H:B6/B2QU/4H[2S)E#1R,SX*["A4%2#SGYP:V:Q],\,:5I$T<ME"\<D890Q
ME9LA@H.<GG[B_E6Q2=N@SQC]H!1]ET!L#/F3#/MA:\0KW#]H'_CTT#_KK-_Z
M"M>'UI'8B6YVE.C4/-&A*J&8#+=!D]3[4VBNHQ/4+CP]HC:EI,7V.S\SSY8Y
M4A.$D41%E8@.25R.Y!-+;:%ITNJ7*RZ##'Y,$!7,)VS$L?-94W=\8!SQ7FUA
M?7&F7:W5G((Y@"N=H(((P00>"#Z5I#Q9K0=C]J0HRJOE- AC4*25VIC P2>G
MK6;A+N7S(W[F#18+:S2\TJVLY+O49(+C<2)+6$,,8&>#COSU.*U9=#T.37X;
M>'384<6UPZ\ PMMQY;%0Y+=?49KS6YN)KRZEN;F1I9Y6W/(W)8U-IVHW6E3O
M-9R*C.AC<,@974]001@C@4^1]Q<R/1++1=*DU^^%UH]G;6:O%$L,R['V$',H
MRX 4G/(R> *2P2RDM?#$(AM/LMM>7$4\XEVNA!;;DYS\P )/L*\ZO[^YU2Y-
MQ>R^;)M"@D !5'0 #@ >@JMM!["ER/N',=X-,T4^&6F,%IY'V-Y&O3+^_6[W
MX$87/3';'2F^)[/1$TW55LK.R@ELKBW$,D#Y:170%\\G(!/;IBN%P,YQ1@#H
M!5<NNX7%HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHJ*XN([:$RRMA
M1^9/H* "XN([:$RRMA1^9/H*YB\O)+R;>_"C[J]@*+R\DO)M[\*/NKV JO64
MI7+2L%%%%04'/J:7<VW;N.TG.W/&?I244 *K,K!E9@PZ$'!I,GU/YT44 *68
M@ LQ & ">E:&D:W?:)/-+9M'^^C,4J31B1'3(."#[@&LZB@"YJ6J7NKZE+J%
M[.TEU+C<X 7@#   Z   8JH&92"K,".00>E)10 NYL,-S8;[PSU^OK2AW#!@
M[[AT.XY%-HH 4,P4J&(4G)&>#0&(! 8@$8.#U'O244 .WON#;VW#H=QR*0,P
M! 9@#P1GK]:2B@ R3W/YUMW?B[6;W1_[+FN(_LS1)#)LA57D1/N*S 9(&!6)
M10!;U#4[S5)8I;R8R-%"D*<  (@VJ,#V[]:J@D @$@-P<'K]:2B@!P=QMP[#
M:<KAC\I]O2FY/J?SHHH 4,P((8@CN#S6UI/BW6=$L?LEA<1I&':2-FA5GB=A
MM+(Q&02!6)10!N:AXOUK5-,.GW-RGD,(Q)Y<2HTNP83>0,G%8J2/&<H[*<@\
M'N.E-HH V]8\6ZSKL"P7MPGEB7SV$,2Q[Y<8WMMZMC(_&L4,P! 9@#P<'K24
M4 +D[2N3@G)&>,^M)D^IHHH **** "BBB@ HHHH ^J/A?(DGPUT/8P;;!M.#
MT(8@BNNKY(\/^-?$7A>*2'2-2:"%SN:)D5TSZ@,#@_2MK_A;_CC_ *"T7_@)
M%_\ $UFX,I2/IVBOF+_A;_CC_H+1?^ D7_Q-'_"W_''_ $%HO_ 2+_XFCD8<
MR/H37- &M3V,OVDV[6SL=R)ER" " 2<#..N#[8K%D\ B6QBMCJ 410B)3';A
M P5PRE@#R>.?7.>*\5_X6_XX_P"@M%_X"1?_ !-'_"W_ !Q_T%HO_ 2+_P")
MII2071[;-X M7LVACN0DC2[R[0A_E\D1;2"<G !8$G@FE_X02/SYW^W$Q2%R
M(FAR#NC*$L<Y).<GD=.@KQ'_ (6_XX_Z"T7_ ("1?_$T?\+?\<?]!:+_ ,!(
MO_B:+2"Z/I#2+!M+TFVLFG,YA3;YA4+N_ 5=KYB_X6_XX_Z"T7_@)%_\31_P
MM_QQ_P!!:+_P$B_^)I<C#F1].T5\Q?\ "W_''_06B_\  2+_ .)H_P"%O^./
M^@M%_P" D7_Q-'(PYD=I^T!(GDZ!%N'F;YFVYYQA1FO$JOZQK>I>(-0:^U6[
MDN;@C;N?@*/0 < >PJA5I61+U.G\B[_YZ?\ C]'D7?\ ST_\?J[1718SN4O(
MN_\ GI_X_1Y%W_ST_P#'ZO['R1L;(Y(P<BFT6"Y2\B[_ .>G_C]'D7?_ #T_
M\?K0\F40"<Q/Y);8)-IVENN,^M$<,LP<Q1NXC7>Y5<[5]3Z"BP7,_P B[_YZ
M?^/T>1=_\]/_ !^KM2&"86XN#%(("VP2;3M+=<9Z9]J+!<SO(N_^>G_C]'D7
M?_/3_P ?J[118+E+R+O_ )Z?^/T>1=_\]/\ Q^KM%%@N4O(N_P#GI_X_1Y%W
M_P ]/_'ZNT46"Y2\B[_YZ?\ C]'D7?\ ST_\?J[118+E+R+O_GI_X_1Y%W_S
MT_\ 'ZNT46"Y2\B[_P">G_C]'D7?_/3_ ,?J[118+E+R+O\ YZ?^/T>1=_\
M/3_Q^KM%%@N4O(N_^>G_ (_1Y%W_ ,]/_'ZNT46"Y2\B[_YZ?^/U4OE,*JUT
MI=>@/W@*V*:Z+*C(ZAE88(-#07.<^T6?_//_ ,<H^T6?_//_ ,<I-0T]K-]R
MY:%CPWI[&J-9-M%E_P"T6?\ SS_\<H^T6?\ SS_\<JA12N!?^T6?_//_ ,<H
M^T6?_//_ ,<JA11<"_\ :+/_ )Y_^.4?:+/_ )Y_^.50)P,FBBX%_P"T6?\
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M_P <H^T6?_//_P <JA11<"_]HL_^>?\ XY1]HL_^>?\ XY5"BBX%_P"T6?\
MSS_\<H^T6?\ SS_\<JA11<"_]HL_^>?_ (Y1]HL_^>?_ (Y5"BBX%_[19_\
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M ("M_P#%4<Z#E9Y;]HL_^>?_ (Y1]HL_^>?_ (Y7J7_"@-0_Z&&V_P# 5O\
MXJC_ (4!J'_0PVW_ ("M_P#%4<Z#E9Y;]HL_^>?_ (Y1]HL_^>?_ (Y7J7_"
M@-0_Z&&V_P# 5O\ XJD_X4!J'_0PVW_@*W_Q5'.@Y6>7?:+/_GG_ ..4?:+/
M_GG_ ..5I^,/!FI>"]2CM;\QRQS*6AGBSMD ZCGH1QQ[USM/F%8[2GP_\?$7
M^^O\Z92JNY@HQDG')P*W,SUO5+[2#J6NSP2Q&_N;*>VD 8?*(T)##_>R@_X#
M6%+HN@C1HGEBMH;,QVI@OTGS+-(S 2JRY[#/;C%<-=VC65W+:R&)GB.&,3!U
M_ CK4&!UQ6:A;9E.1ZQ/8Z8&TW3+JRL;>P.KR!88YMRR1^40CL=Q.20/2LBW
MTJ+3K.XM%6".^GT.Y$RK*IW.)1@$YQD*.GM7GV ,G'0<\5;U+3+C2+PVEVBI
M,%5SM.1AAD<_0T^3S#F/1VTK1M(N=$N?L]@L\>H11.\;X1T9"=_+DG!Z,<<]
ML55BT^QGOH(-1M+>%7UBX$EL)B$V>1N4_>XR<'/J?PKS? '48_"C:,X(YZ=*
M.3S#F/1=/TC2-3GLKF'3;1))M+:<P L\22B0*"5W9/!Z9KD?$T,=OXBNXH=/
M;3X58".!E*D+C@D$GD]:JZ=JEUI3S/:-&!*FR59(U=77.>01CK4^N1ZG]LAN
M=4<23W<"3HP(/[LCY>!TP!T[4)-,&[HS****LD**** "BBB@ HHHH **** "
MBBB@ HHHH **** &NBR(R.H96&"#7-ZAIS6;[ERT+'AO3V-=-56_N8;>V;S@
M'WC 3^]4R2:&F<K5W1XTFUS3HI$#QO=1*RL.&!< @U2[^E.CCDEE2.)&>1V"
MHJC))/0#WK$T/9];\+:!JNK6EFD-JD9U"\C,MA;BWVB),K:MC.YR>0V.0#@5
ME0^ _#FS4KEK?5IH;9P#"/,22(^1YFT#R]SY? RP7@YKB]/\'Z]?7<MLUI<V
MLZ6TEXB7$;H90F,A!C);D 5<TO5_&&@1FRMK.X21KLA/.M"\J7!49"DC.\KC
M@Y]:FWF,ZO2/!.G6.H:=JS03_9C+I;P-,X:*0S']\IX^8 X'M4;^!=,CT>\U
M?5+2YAECNS*0LVU&C^T^64(V;4X/3)/'0"N%M] U:Y*FZCN[6%H)9XI9XI-K
MA 6(7 _7H.IJ33/#6MZQ>V%JT5Q;QZ@6,$]TKB)\*6)!QSD+1\P/2;GPAI5W
MJ=YIAM+JPL)-?$7D*5&Y!;NP="5R%)' SCZUF:5X#\/:FUK>I%J L[C3X+K[
M.9\LFZ4HYW*A)(4 A0.3GD5YR;'56L(M0:UOC:2,(X[@HY1FZ !NF>U=)HD7
MB?PW;ZE*UJ]E$+<3LE_9.RR^6PVA>.""V<G ]:+ 6M TK1[K3_&0.C75Q-:*
MC6D1DQ-$GF8)P5SD8!;CID<=:ZW6O!7A_7?$LTV9;%DU)+2X".H2;-MY@$:@
M?(20!WZFO,[G2_%&H:K)<3:;J<E_>JUPQ%NX:52>6P!]WD>W2F2>'K^.ST>Y
MDF0#5;AX8D8L&C='"'>,<<GZT6 WV\)6$WQ @T:TM[MK9K;SY8)F>*12$)90
M63<PX&/DR<UIZUX$TG28=7GM;+4]4\B2-4MH)@CVL;0"4R2':21DD=!TYYKC
M;W0=;M;^^ M[NY-E=-;2W<*.R>8&V\/CN?YBJT6E:S),88;&_:5Y&MRB1OEG
M7ED([D=QVI@>F:GHN@VQU5Q87-EI#6FF/(T;J5F1W4,R$KP5SR0>2#GTJM:?
M#C3(_$*Z3=+<7,D$'G7C0W&W8KS%(MH",3\@W'H.<D@5P[>'-9;3;6<0SRO-
M<RV:6:JYE1HP&8%,<#FLJ5+FTN989A-#.A*2(^58>H(Z_A2L%SU[3O"VDV/]
MFQ6EG<-<V^H:C;3:@K*<>6C;0X*D?, , ].2.M96G_#[1;FPTMI#>J)Q8L;[
MSE\J[,[8>*,8X9![GH<BO,A+(%*B1PI.2 QP3Z_6C>^U5WMM4Y4;C@'U'I3L
MPN=SK/A/18[[PV+*:XL[74KN:TG:YE#E/+E$9?. !D<XZ"NHTWPYH_AK5+B_
M&GWD,\>FWTB6EW,CR1^2P59AE<?."<9&!@XS7CI)(P22/0FE:21VW-([-C&2
MQ)QZ?2BPKGH7AOP]::[X2TYKMYWW7E[,+6(JKW#I$K+&C;<[F_'IP*O6_@3P
MXFH"*ZBU B>^M+185N55[5IXB[*YV_,4(]J\N#LI!5F!4Y&#C!]12[W))WMD
MG).X\GU^M%@N=AX?\*:=?7U\CW;:G):VTLRZ=9;HYY75@H3<RXSR2=N>E;UQ
MX>TF^\)65O+87-IJ-MIFH7<1\Q1L\JX(V2C;EVYQGC&*\P5W1PZ.RN#D,IP1
M^-&]CU=OS-%@N>LW7PVT2T:T:XCO8@(;HW$*W&XLT40<%79!P>1P"/0U#%X&
M\,B]B:6'46M[N;3XX(UN@&B^THQ.YMOS;2,]J\M,LC'+2.>,<L3Q2;W_ +[?
MF:+,=SU/3_!>A:;;:5J$DUQ--]LC)F*LT&X7/EF)QLVK\HZELY[8JAXL\)6E
MOH>KZQ%9W4-Y#J$HE,Q,4:H9BJB)=N'&/1@1Z8KSSS)-A3S'V$[BNXXSZX]:
M5YI9!AY9'!.[#.2,^OUHL*YZC)X2T/4+;3KJUT2^<+HD=TL%M. ;Z7=AD4[?
MOKG+$<D$<#%<%XITNVT3Q1J.F6<YGM[>78CL03T!P2."020?I66LTJ[-LLB[
M,E,.1MSUQZ4RA( HHHI@%%%% !1110 4444 ?57PR_Y)KH/_ %[#^9KK*Y/X
M9?\ )-M!_P"O8?S-=96+W-$%%%<*-%\166H7]QI\*+'+<&3#W \R3(<??Q]P
M%E(##(Q@' H2N([D,#G!!P<'':EK@$T+Q3!)>M#<2(9X][-'<#]Y)LB7@$?*
M<H^3GD'\G3Z)XLNFF-S=N8P8'2&"XV@[60E0QY!&'YQSD9I\OF%SO:;O7?LW
M#?C.W/./6N36Q\2_V3?Q&:3S6NU>(FX'F/#D%E# 80XX!'Z51_L;7M/L-8U"
M266;4[BWM8T>!\N2N X'''7K]318+G=LP52S$!0,DGM2@@C(Y%<'/I/C":..
M$3CRC!,CB2X#9#"3:K\89AF/YL<X/X[.B:=K5IJKRWMT\EJZ2#RC(&5#O&S:
M,<?+NS18+G1T445(SQG]H'_CTT#_ *ZS?^@K7A]>X?M _P#'IH'_ %UF_P#0
M5KP^M8[$2W.TJ2W94N878X59%)^@(J.BNHQ/2XO$^B#4;R:._C@@-\\UPAMB
MWVV Q@!!QQ@YX./6LVT\2Z<FB+IKSJEL=*GC:$Q9Q.7)C!..H!Z]*X:BHY$5
MS,ZBQU*W7P5)80:FFG7@DD:Y5HBQNT*X50P!^F./6MS4/%&DZD+FWN-0;[,L
MEDUL5ARR;?\ 6D9'7Z]?>O.Z*;@@YCTN^\4:,+V&XBOHY;B*RNX?.\MF)8X,
M62R\_E@?2J[^+;"-)[J"] OYK:Q#R>2<F1&/F]1C.#U_*O/**7LT',STF'Q-
MH,2ZOY#VZF6\EEVRJZK<QLN .%.<'/RG'K3-.\1:4DMD[:E##'_9<-M/E7$T
M;(3G8P4C//0\-7G-%'LT',Q\Y0W$IC9F0NQ5F&"1G@GWIE%%62%%%% !1110
M 4444 %%%% !1110 4444 %%%5[R\CLH=[\L?NKW- !>7D=G#O?EC]U>Y-<Q
M<7$ES,996RQ_(#T%%Q<27,QEE;+'\@/05%6,I7+2L%:&@SQ6WB+2[B:01Q17
M<3N[=%4."2?PK/HJ2CTW5_B)807NI6VG17MQ#(;[;=/< GS)\ ,G'$8"Y Z\
MTEOX\@DBUS5':.*0VL"6-K*^Z;[6D1B\X8&-NUFR3Z"O,Z*7*@N=XWCS3Q8V
MD?V"\FNHK&:S:YFD0-M>+RU7Y0 P!YR1NQQ5Z'XH6D-S!<#3;IGDFAEO$:<%
M$\N$Q8@&/ER#GGZ5YK119!<]$L/'EB8=/M/+N;64):V,D\DH^SQ013!Q*$ R
M'('/;J:U/$_B_3-.GEDLKF.^:ZMY8$M(F5H[?,ZRAV89W;SG(ZCVKR>BCE"Y
MZ#%XZT.+Q1=ZX=.U22:Z'F%9;A'$$N\-B,$8V\8Y&1QCI6=KGC.WU=M.F2RE
MBELM4GO0I<%62242;?\ >!&/2N/HHL@N>AZG\1X+O2]0MK2VNK::62Y:"0"-
MLK.^]@Y(R"#G[IY 'I3_ /A9T#ZG',VE,EM+:S1WBJ59GGEV[Y5R,?P#@]LU
MYS119!<]"3XB6TDZ2W":@)([R6998Q#EXI(EC*NI7:?N#@=1[UQFM7MMJ6MW
ME[:6IM;>>4O' 7W;!Z9JA10E8+A1113 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /J3X5W4-S\-M'$,BN88C%( ?NL&.0?\]Z[*
MOCC3=<U;1BYTO4[JS\S[_D2E0WU K0_X3KQ;_P!#)J?_ ($&H<"N8^MZ*^2/
M^$Z\6_\ 0R:G_P"!!H_X3KQ;_P!#)J?_ ($&ER,.8^MZ*^2/^$Z\6_\ 0R:G
M_P"!!H_X3KQ;_P!#)J?_ ($&CD8<Q];T5\D?\)UXM_Z&34__  (-'_"=>+?^
MADU/_P "#1R,.8^MZ*^2/^$Z\6_]#)J?_@0:/^$Z\6_]#)J?_@0:.1AS'UO1
M7R1_PG7BW_H9-3_\"#1_PG7BW_H9-3_\"#1R,.8]+^/]U QT*T$BF=#+*R#J
M%(4 GZD'\J\5J:[O+F_NGNKRXEN+B0Y>65RS-]2:AJTK(ENY[U_PI!/^ABD_
M\!!_\71_PI!/^ABD_P# 0?\ Q=%%1[27<KE0?\*03_H8I/\ P$'_ ,71_P *
M03_H8I/_  $'_P 7111[27<.5!_PI!/^ABD_\!!_\71_PI!/^ABD_P# 0?\
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MRH/^%'1_]# __@&/_BZ/^%'1_P#0P/\ ^ 8_^+HHH]I(.5!_PHZ/_H8'_P#
M,?\ Q='_  HZ/_H8'_\  ,?_ !=%%'M)!RH/^%'1_P#0P/\ ^ 8_^+H_X4='
M_P!# _\ X!C_ .+HHH]I(.5!_P *.C_Z&!__  #'_P 71_PHZ/\ Z&!__ ,?
M_%T44>TD'*@_X4='_P!# _\ X!C_ .+H_P"%'1_]# __ (!C_P"+HHH]I(.5
M!_PHZ/\ Z&!__ ,?_%T?\*.C_P"A@?\ \ Q_\7111[20<J#_ (4='_T,#_\
M@&/_ (NC_A1T?_0P/_X!C_XNBBCVD@Y4'_"CH_\ H8'_ / ,?_%T?\*.C_Z&
M!_\ P#'_ ,7111[20<J#_A1T?_0P/_X!C_XNC_A1T?\ T,#_ /@&/_BZ**/:
M2#E0?\*.C_Z&!_\ P#'_ ,71_P *.C_Z&!__  #'_P 7111[20<J#_A1T?\
MT,#_ /@&/_BZ/^%'1_\ 0P/_ . 8_P#BZ**/:2#E0?\ "CH_^A@?_P  Q_\
M%T?\*.C_ .A@?_P#'_Q=%%'M)!RH/^%'1_\ 0P/_ . 8_P#BZ/\ A1T?_0P/
M_P" 8_\ BZ**/:2#E0?\*.C_ .A@?_P#'_Q='_"CH_\ H8'_ / ,?_%T44>T
MD'*@_P"%'1_]# __ (!C_P"+H_X4='_T,#_^ 8_^+HHH]I(.5!_PHZ/_ *&!
M_P#P#'_Q='_"CH_^A@?_ , Q_P#%T44>TD'*@_X4='_T,#_^ 8_^+H_X4='_
2 -# _P#X!C_XNBBCVD@Y4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img83127175_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "R ET# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W.YO! ^WD
MGT%4VUN)&VLR*WH9 #3+[_C\D_#^58%[8PRZ]82M:QN-DN]S&#SA<9-,1T_]
MIG_GF?\ OJC^TS_SS/\ WU7!?;]5D:Z$1N5!A)7<F2CB11_= Z$\#-2W5W<P
MZPMF+RY$<30@RG&WDG<&..IX _"G9@=Q_:9_YYG_ +ZIIU7;C<N,G RW4UP+
M-JUYIUZD\DH<P2;XE5MP;/ 'R 8QD<$YK9N&D-CIY@\R0><F6=,MCG).1Q18
M#I_[3/\ SS/_ 'U1_:9_YYG_ +ZK@9X]3FT:6.2:ZE>YTZ5V4H 5D!7:!@<9
M!/'?%6'N-1;4(T@GD6#;&8FD5OG&?FR-AY[<D8HL!VW]IG_GG_X]1_:9_P">
M9_[Z_P#K5Q4DVH16 E>:[:26X=>!@1J"V.BDX.!VYXI;.YO;B2!;Z:[A9H8R
MBQQ<.QSNW';QV],46 [3^TS_ ,\S_P!]4?VF?[A_[ZKA;26YM;*Q5);M]KLL
ML)1@Y.1T.W&!Z<9SUXJ]K<VI17$<=B7_ -(38K!<B-@0<G\,_E18#JCJN&"E
M<,>@W=:/[6&_9@;P,E=_./I7$%M0OX4ED29//$NU-F&C 3 &<<9(/YU%'%=B
MW%Q;37:O#IZXS'RSC^$Y'Z46 [PZKA@I7#'H-W6AM6"8W@+D@#+XR3VKE]8D
MNU:-[97#>1*053)#;>.U4IHK^0+;//<N/-MY%E*#*DM\V.,<8_"BP':2:RD0
M)DVH ,DLX'%*=6 QE0-W ^;K7!WWV^:RN(9%FEVQ3H',668#&WH/_P!=31O>
MRNL:O<RVXEC"R2P[6!VMN[#@<<^]%@.X_M,_\\S_ -]4?VF?^>9_[ZK@[>2Y
M@L;6$SWT4:J^]EB+-Y@/"_=/'^<UIZ7]OGNVDO)9E"0Q_N]H"EB#NSQUZ46
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MT!.21D8Q59/[1:8.T]P4DN)83'L "IAMI'&>PY]Z5V%D=9]OE_O'\Z/M\O\
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MHFGL,&WXVLF-[8(8Y.>?6I$TRT0#]V[80Q@R2LYVGJ,DFK=+0!EIX?TR-<)
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MWF[G045R'_"97$ 99M/663SY$412_P *8R3D=>?I]*ZY6W*&QC(S5F8M%%%
M@J]8_<;ZU1J]8_<;ZU,]BX?$2/\ >--IS?>--K,T"BBBF(**** "BBB@ HHH
MH ****!A112T"$HHHH *.",&BB@!%1$&$55^@Q2T44 %%+10 E%%% !1110
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M\J** #8O]T?E1L7^Z/RHHH -B_W1^5&Q?[H_*BB@ V+_ '1^5&Q?[H_*BB@
MV+_='Y4;%_NC\J** #8O]T?E1L7^Z/RHHH -B_W1^5&Q?[H_*BB@ V+_ '1^
M5&Q?[H_*BB@ V+_='Y4;%_NC\J** #8O]T?E1L7^Z/RHHH -B_W1^5&Q?[H_
4*BB@ V+_ '1^5  '0 444,$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img83127175_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "V ?<# 2(  A$! Q$!_\0
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M'UHN@./TS7=<OVC".A9F)>,VQ!50@8 YQC<<@'GBH)O$^NPZ>K2!(YI&./\
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MT]F7HM2N;?B=/,7^\.M:$%];W'". W]UN#7@L4-_XHO)9)[U&G4%P)BV/HN
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MMLQ$Y/E+"?,8 =V&!C\,T2:OI%OMEB0-*/E 6$A@#]1P/T-,CU729+A@]FJ
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M%4 F.*3%<SX^O+JQ\->;:7$D$GGJN^-RIQ@]Q7EO_"1ZW_T%[[_P(;_&FHW
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M9\$-PGI47C&:2W:TDA+)(A)613@_2M^PL$LHL=9#]YJP_$)AO;B&/>S+"22
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MO3<R]$L);"P\N8C>QW$ ]*T33Z3%:-N3NR(14(J*&4TT\TTTBAA'---/---
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M[J_C5BT7;;CWYJ.HR8TPU)3#3 8:8:D-,-,"]#_J5^E/ID/^I7Z4^H&07?\
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IP>M%% ">6/6D\H>IHHH 0P _Q&F_95_O&BBG<!%M55MVX\4444@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img83127175_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "% G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEM_.7=Y4HPR^Q%<)/_R7:U_[!Y_]!:O1JF5N@T%%%%2,**** "BBB@ HHHH
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MCK_H:=/_ /!:/_BJ/[(\=?\ 0TZ?_P""T?\ Q5%O,+G845Q_]D>.O^AIT_\
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M*'GZG'5S"M4\O0  !@<"BBBNHX0HHHH ***P_&)8>$=2VLR'RL;E.".1T-"
MW**X=]0N%DTBPO)6^UV-^J3-G'FQ^6Q5_?('/N#5N'Q'JAMK35YH+8:7=SK$
MD:D^:BLVU7)Z')QD>]5RBN=;17(-XCU9=,O]4^SVOV>WG:WCBR=TC"4)N)Z
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MSS7K.DJ_V"%Y$",4&5"[<'OQ7*:)X1U&'7[[4=5,,KW#!E93D+@\#'M7<@8
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M;X(*@@Y!'6AAQ2(NR-5] !2FMCGZF5K,;/IEP%_NY/TJ'PCJ G\ZW;B38K\
MX[C\^E)XBN/(L&3)W2D(JJ<$G_"JOA]HH-96WC#?*S+G/&,8_F*Y'*U=6.Z,
M.;"ROZ_<=I1117H'E!1110!%<PK<VLL#_=D0H?Q&*Y'0F:*P%I*P,]LQB=>X
MP>]=G7.ZYH=Q+=#4M**I> ;9$)PLR]L^XKFKP>DXJ]CKPU2-G3D[)_F<YXHM
M(FQ-@Y?E\#@!1R<UL^"=+$=H^JRQ@2W/^KR.5C[?GU_*H;;PSJ>IS*^N3JMJ
MIS]DB/WC_M$=J[%%5$5$ 55& !T K"A0;J^UDK=CJQ6*4:*H1E=]6OR%HHHK
MT#R@HHHH **** "BBB@ JGJNG1ZMID]C*[HDR[2R8R.<]_I5R@\"@#(O_#MI
MJ&JZ?J+M(D]D3C9C$BX^ZWJ.]58/"B1/#"=0N'TV";SH;,A=JMDD MC)4$Y
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M6KV<9*6K^X]*KF/&GA/_ (2K3HXX[@P7$+;HV/*\]0:9I?BW^T+5F2$M(?\
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M2&5TM;JV+!R"RHO4M].]='12Y@L<7/H]\WA?7;=;1OM$^HM-$HQEU\Q"&'X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img83127175_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "[ G # 2(  A$! Q$!_\0
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M<%H")!^7!I>UCW&\/470]3HKG+3Q[X6O88I(M:M0), *[[2">Q!Z5J3:WI4
MS-J=G'G^].H_K5W1FXR6Z+]%9B^(M$<@+J]@2?\ IX3_ !K1CD25 \;JZ'HR
MG(-.XFFAU%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %%%% !1110 445%<W,-G;2W-Q(L4,2EW=C@*!U-
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M_P#0OV7_ 'R?\:/^%<^#_P#H7[+_ +Y/^-=112YGW"R.7_X5SX/_ .A?LO\
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M_&NHJEJ>IQ:7;1SRHSK)-'" OJ[!0?UHNPLC$_X5SX/_ .A?LO\ OD_XT?\
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MNILNJJTA@5)%3 CR,E5.U>>_'/-6-ES%<V>G7T\<.CW-ZP*P7;.$Q'D1%^"
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M0-2G=^)[ADD?3;..9(;);R4SR[/E8$A1QU^4\]*M7>NS67ANWU22T#RRF/\
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M6]BL&DF4[D\^0NJGU /%==54Z;B[LRQ.)55*,=@HHHK8XPKA/'R!-6T*X?\
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M2X?),A9$#E_+7 ^7<>3SG\ZOUM!MQ39SS24FH[!1115$!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !45Q!'=6TMO*NZ.12C#U!%2T
M4-7T&FT[H\T\.R'P]KMWI%Q$IG1CY$C#!9/3/ZUT-YKGV"\2W8,9ID+H%'R_
MG1XR\.R:I;I?V.5U"UY3;U=?3Z^E8FG:_P#VG;KLMMVI1*5:,CDFO-@W1?L7
M\O3MZH]B:CB8K$)7>TEV??T9GVFDZI=>('U349S#%&V]&5N6^GM71:1?I_9N
MK36Y+/$S=>3D=ZJ6OA[6I"UQJ;QMN.5AB/W%_NU/ITUK9ZS+:PD#*@2QL,'Z
MFKA%Q?:_<56:J)K>UMMM#GO#C7NN)/\ VJ3)&TF8BPVE?4K6?K.BR6VK.UOY
MGV=VZKR3]?6I?%FN-;:P+6UD"J.9&7@ ]AQ6=?:E=HT;S!HR6^4AB<X%<TY1
MMRO5KJ=U.-1R4UHGT.OTX6^F^'52Y81S YC7O7&ZM;VMWJCRP7*@XWB-QCGN
M#6R^E7EQ;VE_=3+Y;L%'SC&#TR#TK %DTWBL6LC*SB8)NDX'%%5MI1L&'BE*
M4^;74ZOP?$UCX-NKD@K/=S&-,]NU)?"03V_EJ&\D$*,?>P/3ZU/KXDTW1--T
MY7$3/(78D\*,U5U:\:ZFM-.T[,MZZ!/W?;/6KG)4X<KZ6^\QIJ56HYKJW\D1
M^&K:?Q/K]I)=1*$LT#7!48#,"=H/^>U>M5D>'-"BT#2DME(:9OFFD_O-_A6O
M77A*+IPO+XGJSS,?B(UJEH?"M$5#J5F+P6AG G)P%(.,XSC/3/M21ZK8RW?V
M5+A6FR5V@'J.HSTR/2LN?3-1N-5620JT4=TLR-YQ "#^'9C&?>IETF<):*3&
M/*NY9G(/\+%\8XZ_,*I3J-[$.G127O:V)7URW;4[:SMG64R.R2'GY<#/!Z'F
MK5QJ=G:SK!-.$D;& 0<#/ R>@_&LJRTR^BET^*6.!8;)G/F*^3("#CC''7GF
MC6=,U&_N)D0JUNZKLS,4"$')RH'S>U+GJ*+=M?\ @%>SHN:C?2W?S_RZ&G+J
MUC!<_9Y+@"7<%VA2>3T' ZT@UBP-U]F%PIER1M /;KSC'%8#W @U6=F_>1+>
MJ1 D@#E]H7=MQD^O6F6$O^D11G$OF2SI"B2@F+<6R63&0/J3C-3]8E>Q?U6/
M+?7;]#H?[:T[R3,+D&,-MR%)R>O''/X4LVLZ?;Q1RR72!)%WJ0"?E]>.@K-D
MT:Y2QTP1X::S5E9(YC'NW#!PP'M6??P"TG$/R0)]B_?1M< %P6)*AF4Y[],=
M:<JM2*U0H4*,W9-_@=(VJV*3QPM.%DDQM!4CKTR<8&?>H;;6[.X:\^<HMHY2
M1G! ^M9=U8ZCJK+*%VV\OE31AY2OE@8)4H!RWO4D^C7<JZC"-H2:X%S$_F$9
M(Q\IP..G6CVE5O1:"5&BE9O7UVV-/^V=/^SB?[0-A;9]ULYZXVXS^E33W7EP
MPRQF,K)(BY<XR&../?FL=]+N&M=XLB+DR;]QO6+J<!0P?'IV]*OS6=U/IUE%
M+(CSQ20O*_0,58%L?D:M3J-.Z,Y0I)JSZ^7Z$R:M8R70MDN5,Q)4+@]1U&>F
M?:H+W4Y+:\D@5(MJ6QFW.V!G=C!]JK1Z1<((!F/Y+YKAL$_=.?;KS3M5TRYO
M+F9HMFR6S:$%FQAMV1^%)RJ<NVI4845-*^AI"^MC&7,R8$@B//\ &>,?K4::
MK8R7#P)<*9$!+#!QQUP>AQ[52.D3'6$FWI]C^65TSSYH7:"/;&#]156TT2XA
M1H)(]WEI((IC<L1E@1]S''7FASJ7V$J=&U^8VH-0M+FW>XBG5H4ZR<A?KD]J
MC75[%[5[E;@>4A"DE2.3TP,9/X5#-IKS>'1IP95D$"ID?=R /TXJO=VE_?VL
M)DMXX9+>99$2.<C?A2#\P'R]>*;G473I_7]=11A2;WZ]UM_P?P)WU=&GMEMM
MLL4T<C;N005'3%+::S;S06GG.J7$\:OY:@G&??''XU5CTF=9K658A'Q-YH:8
MR$,XX.2.>E01:5J$2V/DQ)%-'&B2SK,<$*>5*X^8>GUJ.>JG>W]:&GLZ+5K_
M (^O_ V.DHHHKJ.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N1\1>$GGN_[7T63[-J2'<0.%D/^/\ .NNHK.K2C5CRR-J%
M>=&7-#_A_4X.P\<2)<+9:U;FTNDX<D8!/]*Q/&NJK#KL<EJ$+,B[G7^(=1S7
MH^J:)IVLP^7?6RR8^Z_1E^AKB;_X;3Q-OTR^5U'2.X7I[ UPU88B,>7XEWZG
MJ8:KA)3YW[C[=/OZ&18>%(-:N9+B\N&0S#=L YR>^:6Y^'^I064B0RK.\3>9
M$&Z./3ZU+<Z1XL@N(Y38EVC! -NXV_7'K5Z#5?&21>5)HTTKCHY&TU@G2VG%
MI^C.INMO3J1:[71SUCH_B""-(GMV,<I&Y'3<#M/ /I7:MHFGVVI#6[[R8@(E
MRKG^,=ZK*_CJ_4(EK;V2GJ[8W5/;> 9+J83Z]J<UX^<^6I(6M*:>U.#?KHC&
MM43=ZM1+_#JW^ASVKW,OB_5?LVEVK7 0X$I&%4>IKN/#/A6V\/PF1B)KUQ^\
MF(Z>R^@K8LK"UTZW$%G D,0_A08__75BNJEA>67M*CO+\%Z'!B,:YP]C27+#
M\7Z_Y!11176< 4444 %%%% #=B;]^U=V,;L<T!$#%@JACU(')IU% 7"FLBN0
M64'!R,CI3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img83127175_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ E0# 2(  A$! Q$!_\0
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M<^<%E>8%L9WOC<2>^<"J9*$<E:7*PN;WBA5^U:;-M"S7&F6TLP Q\Y7&<>I
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M1_PCNB?] ?3_ /P&3_"M*BB[ S?^$=T3_H#Z?_X#)_A1_P ([HG_ $!]/_\
M 9/\*TJ*+L#-_P"$=T3_ * ^G_\ @,G^%'_".Z)_T!]/_P# 9/\ "M*BB[ S
M?^$=T3_H#Z?_ . R?X4?\([HG_0'T_\ \!D_PK2HHNP,W_A'=$_Z ^G_ /@,
MG^%'_".Z)_T!]/\ _ 9/\*TJ*+L#-_X1W1/^@/I__@,G^%'_  CNB?\ 0'T_
M_P !D_PK2HHNP,W_ (1W1/\ H#Z?_P" R?X4?\([HG_0'T__ ,!D_P *TJ*+
ML#-_X1W1/^@/I_\ X#)_A1_PCNB?] ?3_P#P&3_"M*BB[ S?^$=T3_H#Z?\
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MR5!)R<+G Y/:K-2QD5S_ ,>TG^Z:EJ*Y_P"/:3_=-2T %%%% !1110 4444
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M)#SQ*0P4AG P3T'U-2T %%%% !69XD_Y%?5_^O*;_P! -:=9GB3_ )%?5_\
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M7$KXRO38S3^3:._DQSH$8XCW2;-C_P"U_G%;&K:GJ6GII\"?9&NKDR!V96V
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MO_0#6G69XD_Y%?5_^O*;_P! --;@?*R_='TI:1?NCZ4M=9B%%%% 'M7P2_Y
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M3)JY2*H50J@  8 ':EI15DD.3O)L****9(4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,&\=A>2@,P^;UJK(Z(1/(1N08#D98 ]@>O/I5J\5
MC>2_*?O>E5GA\Q"CHQ!]C^= #O(OQ#]I);WML_,%]<_WO;\.M(DQD0.DC%3T
M.32FYOS#]FPP/>Y[E?I_>]^G>FI%Y:!$C(4=!@T 7=.9C>H"S$8/4UM5B:<I
M%ZF5(X/:MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img83127175_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K A,# 2(  A$! Q$!_\0
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M/D\)76MW4%G_ &AIJSV3(D:;99)&'EN !M.T,_\ WR*.8+'G.U?[H_*C:O\
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M1^5+13 JR\2$#BBB7_6M12&>EK\&_$H4#S]/X&/]:W_Q-+_PISQ+_P ]]/\
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MK?\ Q-'_  ISQ+_SWT__ +^M_P#$U[Q11[1ARH\'_P"%.>)?^>^G_P#?UO\
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M ,]]/_[^M_\ $U[Q11[1ARH\'_X4YXE_Y[Z?_P!_6_\ B:/^%.>)?^>^G_\
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M^G_]_6_^)H_X4YXE_P">^G_]_6_^)KWBBCVC#E1X/_PISQ+_ ,]]/_[^M_\
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MM6JAM?.^S)Y\<<<@&"D3%E'I@D#M[5-4C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!"JL02H)'0D=*6BB@ HHHH **** $*JV-R@X.1D=*6BB@ HHHH **** "B
MFET4@,R@GH">M*""2 02.OM0 M%(&5L[2#@X.#T-+0 44Q)$D+!'5BIPV#G!
MI=Z;BNY=PQD9]: '4444 %%%% !1110 44$@#). *3(SC(SUQ0 M%,\Z+./,
M3/\ O"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 445SOC-]6B\/74^E74=MY$$DTLC+EL*I("^YQUH0'145A^#K
MN>^\(:7=74K2SRP!G=NK&M>>XAMH_,GD6-,XRQ[T 2T51_MC3O\ G\B_[ZH_
MMC3O^?R+_OJ@#F_%UM<W&H2>1$K[--D8DYW)\XR4Q_&!G'2B\U2>V%_/#/MA
M2[4DJ ))H_LT;?+G@G)_I72?VOIW_/W#^=)_:VF$?\?4/7/6JN*QB:1=7"^)
M[ZWD#16LMP[Q';_K7V)E2>V!S[\^E+/JEX-8EB6Y*RI?10):;/OPL%W/Z\ L
M<]/EQ6W_ &OIO_/W#^=']KZ;NW?:X<],YI7 P=,%SI?@O4+J F6[#W,H+(,D
MB1^2!UZ9JI:SM_:\\D=S]LC:[M5\YD'3:^>GIZUU/]L:=_S^1?G2#5M- P+N
M$?C1<+'+C7-0%E%&;@NYN5CN+E2NP QLPV'H 2 .>1GWI]UKM_!]@3SRUQB
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M2/\ LADP<-*$)WX]Y/+&:[?^U].[7D7YT?VOIO\ S]P^O6BX6,4Z):6VN:+
M8%D$=I*KNPSN*"(*3[]:ZBJ/]L:=G_C\B_.C^V-._P"?R+_OJ@9>HJC_ &QI
MW_/Y%_WU3X]4L9I%CCNHV=C@ 'K2 MT45Y7XOUZ]L_$NK6]YJUSIT4-LLFFI
M @(F;'.3_O<4TKB;L>J45F>'I;Z;P[82ZGC[:\*F7'K_ (UITAA1110 4444
M %%%% !1110 4444 %%%(3@$T +17G]IKNKMI>D:^]\KIJ%ZD+6(C&U4=RN
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MHQ!!(';J?SHNA#-!N9;O1+:6=MTP!C=O[S*2I/XD9K2JKIMDNG:;;V:L7\I
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M+C;YRB0A)-HP,COP*=T%B]HE])J6@Z??2ILDN+>.5E]"R@FK]-1%C1410J*
M% ' %.J!A1110 4R4@0R$KN 4Y'K3ZX3_A+KBVT2)5W2WC.P:21> ,G'UK.I
M5C3^(3:6YW$1!B0A=H*C ]*?7*Z9XOCGT\F[CD6=21F.,D'CK6MX=N)KO0;6
M>>0R2N&W,>I^8BE"K&;M$%),U****U&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !29&
M<9&1UI:YO3[FSM/$>N'SR(Q%%(Y8DX(\S?\ EQT]J8'1[EW;=PW$9QGFD+J'
M"%@&() SR0.I_4?G7'2D/JTI^?\ M'^UHO+ZY\C"9QVV[-_XYJ;Q TIO]5QO
M_=Z?;[=O78TS^=C_ ("J_I185SK%977<K!AZ@YI/,3#'>N%.#STKGM*DMX[S
M4X[:4QVDTJ1VY&<>9Y66V_@ ?J#6%;63R1W%J;B**W2RACFN$+%7D$@()SW(
M#9^O-%@N=^K*PRI!'J#2UB:'<32:1/Y%O$&AF>.+;D)*!CYAGG')_*M"SDOW
M=A=P11J!\I1\Y-%AEK()(!Z=:"RC.2!@9//:N;T:ZL[34== G/E+<(^6)/'E
MH"?^^LU)&]LGC>5%D)>6SPZDDC=NZ>G2BP'0*P90RD%2,@@]:6LCPPQ/ARS!
M.54,B'U0,0O_ (Z!6O2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *R1H-BFD?895\R)"S!G'()R<_K6M2,H=2K#((P:3BGN%BK9V-K:V
M2P6\:K'M[#KGO2Z=8QZ=816D3%DCS@MUY)/]:LJH50HZ 8%+0HI;!8****8!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4SRH\D^6F3U.T<T^B@!NQ=^_:-V,9QS3#;1
M-=+<E!YJQF,-_LD@D?H*EHH :(T4 *B@#D #I2"*,(4$:A3U7'!I]% " !5"
MJ  .@%+110 P0Q DB-!GKA1S0T,;$ML7<1]X#G\Z?10!';P1VMO%;PH$BB0(
MBCL ,"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M ILC%8V8#) ) ]:=39-WE.$.&VG!]Z !"6C5B,$@$CTIU-CW>6NXY; R?>G4
M %%%% !1110 4444 %%%% !1110 45R>F:K=6T^IQI83W2_;I<.K# Y''/\
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M.]M9?*,5Q%()21&4<$,1R<$4 )86<>GV$%G$24A0("W4X[GW-6*** "BBB@
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M?A1<5A]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !15'6KV33="U"_B56DMK:29%;H2JDC/MQ7
M*:+X\EN/">IZGJD$,5Y8(LABBR%=9$#1=23\V<4TFQ7.YHKS<>.M?_X1>2[-
ME9#5%UC^S?*VMLSM'^UG.>.M7]1\=S)X,T[5=/@ADU"]! ADR50H"920"#A=
MI_2GRL+H[FBLG2]96X\*VFLWQCA5[1;B8KG:GRY..^*I6OC?1KF66,FZ@\J
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img83127175_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z EL# 2(  A$! Q$!_\0
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MUJQU"SL9;4-<WC%(4C<-E@<,I/8C/-'+ +L[+_A=FL_] FP_[[>C_A=FL_\
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M$+,#SLP2P_'&/Q--*[L)NQ5USXQ:1IUT]OIUK)J+(<-*KA(\^QP2?KC%8_\
MPO"3_H7U_P# O_["O)**W]G$SYF>M_\ "\)/^A?7_P "_P#["C_A>$G_ $+Z
M_P#@7_\ 85Y)13]G$.9GK?\ PO"3_H7U_P# O_["C_A>$G_0OK_X%_\ V%>2
M44>SB',SUO\ X7A)_P!"^O\ X%__ &%'_"\)/^A?7_P+_P#L*\DK=\->&I/$
M;7HCG>/[)$LA5(?-9\MMP!D4G"*'S,[[_A>$G_0OK_X%_P#V%'_"\)/^A?7_
M ,"__L*X[3_!4]U9/>3S^7"SQ"W1=OFRH\PBW%"?E')QGN*=<^");6!IWNDD
M4VMQ<)'&REU\M]OSC/3U(Z'BERP"\CK_ /A>$G_0OK_X%_\ V%'_  O"3_H7
MU_\  O\ ^PKB9/ >NQ7*P/':@G?N<7*E(RA4$,1T/S+Q[BHK;PE>W,M_9KAK
M^UNXK0(CJ8R[[L@M_P !_P :?+ +R.[_ .%X2?\ 0OK_ .!?_P!A1_PO"3_H
M7U_\"_\ ["N'L_"%U)XAATF]FBA:>U>YCFCD61&4(S#YLXQE2">U,?P7K<<@
MC:&#)E\I2LP*L?*\W(/<%!G-'+ +R.[_ .%X2?\ 0OK_ .!?_P!A1_PO"3_H
M7U_\"_\ ["N*'@+7F@$JQVA!7<$%TF_[GF ;>N2O('M5>'P=K$\%E/%';M%>
M*[1/YZ[1M3>0QZ*=O-'+ +R.]_X7A)_T+Z_^!?\ ]A1_PO"3_H7U_P# O_["
MN&L?!U_=ZU>Z2\D45W;6AN5"G>LHPI4*1_>W#!JZO@7R]0M;&\U5;>:>Q%ZQ
M^S%EA7G<'.X8VXZ^IQ2Y8!>1UG_"\)/^A?7_ ,"__L*/^%X2?]"^O_@7_P#8
M5PNF^%)]7T"?4;&='EBN7B$+L$WHL>\LN3DMC^'TH'@C7-D#/#!&LL;29DG5
M1& N\[S_  G:<T^6 79W7_"\)/\ H7U_\"__ +"C_A>$G_0OK_X%_P#V%<&W
M@S6E%Z3';_Z%@S#SU^Z0"''JN&!SZ59O/ 6KVU]>6T#VMR+4[=Z3*/,;9O**
M"<E@H)(]/K1RP"\CL_\ A>$G_0OK_P"!?_V%'_"\)/\ H7U_\"__ +"N /A+
M5A%NV0&7R5G-L)E,RH2H!*=1]Y3]#5V;P%JT7V1%ELY9I_.+HDX/DB-L,S'T
MSW]>*.6 7D=E_P +PD_Z%]?_  +_ /L*/^%X2?\ 0OK_ .!?_P!A7$1^"M5C
MG@%]$(8Y;HVVU94\PL."0"<8'KGIS6%>P+:W]Q;JY=8I6C#E<;@#C..U')$.
M9GJG_"\)/^A?7_P+_P#L*/\ A>$G_0OK_P"!?_V%>244_9Q%S,];_P"%X2?]
M"^O_ (%__84?\+PD_P"A?7_P+_\ L*\DHH]G$.9GK?\ PO"3_H7U_P# O_["
ME7XX-N&[0!M[XNN?_0:\CHH]G$.9GTCX4\?:1XL8P6Y>WO57<;:;&XCU4CAA
M755\EV5[/IM]!?6LACGMW$B,/4?YQ7U98W0O=/MKL# GB60#TW '^M93CR[%
MQ=RQ7S;\0/#L_A[Q5=!HR+2ZD::WDQP03DKGU!/\J^DJIZGI-AK-DUIJ-K'<
MP-SM<9P?4'J#[BIA+E8VKGRA17O4GP<\+O(65]0C!_A6<8'YJ33?^%,^&?\
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M3L/KBNIK.<[Z(J,;!1116904444 %<9\3?#T^O\ A-Q:1F2ZM)!/&@ZN "&
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M2_[_ *__ !-/VD0Y6>#T5[Q_PIGPS_SWU+_O^O\ \31_PIGPS_SWU+_O^O\
M\31[2(<K/!Z*]X_X4SX9_P">^I?]_P!?_B:4?!KPP""9M2/L9U_^)H]I$.5G
MBNB:-=>(-7M],LT+23-ACCA%[L?8"OJ>VMTM+2&VC^Y$BQK] ,"L[0O#.D>&
M[=H=+LTAW_??[SO]6/)K6K*<^8J*L%%%%04%%%% !1110 4444 %%%% !111
M0!S7BOQ%=:%+8I;P)(MQYGF.P)$*J%_>''\*@DFL:Y\:ZG#<:O&D-NRVHD\A
MC&WS;71!@[OGSO.0,8X]:[QD5OO*#U'(I/)BQCRD_P"^15)KL*QPS^-M06U@
ME,=G&XCDD9)0RM<%9?+\M!GY7QR0<X) K?O?$'V;5M-MAY<4=S<26\@N 4?*
MHS!DSU7( S[\5LF"%BI,2$JVY25'!]1[TKPQ2,K/&C,O0LH)%*Z XN/QK=.E
MD56QD,D\D<GEN2'VS+&%CY^]AM_/:M#4M<U'2]7O_,^SRV-K9_:_*1")6!)7
M;N+8ZKG..]=$MM FW;#&-IW+A1P>F1[T\HC9W*IR,'(ZBG=!8Y6X\;):W]U8
MR6!-Q;P"1E28$;LH"A..#\XYJ&_\;R06<OE6"I=?9+B9!),"HDB+@KQU^X3G
MC(KKO(B+L_E)O;[S;1DT&WA+[S#'NP5SM&<'J*+KL&IR:>-G@6ZAN+"1I;3R
MXY)BZHC2,54YS]U<MG<>,"G2>+YH[NY66W18K>X5<0.)6D0V[2GCCTX(ZUU3
M6\#%RT,9+KM<E1\P]#ZB@01*^]8D#8 R%&<#I1==@U.47QVCQ1.NG,P+,)"D
MZLJ@-&,JW1O]8.G<$5>UWQ#<Z6;Y(;!V$%A)=+</CRRR]%/.?\_C6ZL$*($6
M*-5'10H '>GLH92K $'@@]Z5T!Q4_BG6(AJ,T=K#)%;WT=I"GED>9EU!^;=R
MV">,#G'6NA\-ZLVMZ'#J#JJ^:\@ 4$<!V Z]\ 9]ZT_+3'W%Z[NG?UI555&%
M  ] *&T M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <SK7B.ZTWQ+9:8D,?V:>-&DN'!(AS)M^;GOPH
M]SS6#'XYU>2SF?[- )!/$B8@8G:[NO"[LOPG4$<Y':O0FC1SED4Y&.1VI/)B
M!!$:9'3Y1Q5)KL*QQD'C*^FN;$-%9J)5MBT ):27S<Y:/GHO?@]#R*TKCQ,R
M:L+5&MHHY+"6Y07.8Y%=& ^93T4@D^O%= ((0Z.(D#("%.T94'KCTH>WAD?>
M\,;,1C)4$XHN@LSD]/\ %]Q>WND1B.U*7D$+R!&)8LZN24Y^ZI3!S_>[=Y)/
M',"M<1K:YD@;8ZM.JA3YYB&XG[O3=SV-=0L$*%2L2*5!"D*!@'KBH;C3;.[0
MI/;1NI=9""O5E.03Z\@=:+H-3EO^$[(BN+E[)$@2U@GA5IP'D:1F&WITR.#_
M (TV+Q\GFWK/:2/#';)=1 #!*M&C;<_Q-E^<=!S78-;0/]Z&-OEV\J#QZ?2G
M>3%C'EIC_='IC^5%UV#4JZ3?G4]+@O&@: R@DQL02.2.HZCBKM-1$C0)&JHB
MC 51@"G5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL'Q=I
MUYJ&D1K82W2SQ7,,@2"7R_,42+N#>J[<G&><4 ;U%>4W^A^*'O-3<VFI36S7
M):YCBO@IO$\R0IY/SC8%0Q CY<[<<UVL4NM:9I&FFZ>VE94MH;G?N,C.Q5'.
MX'!Y)/2@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "LS7O^0:G_7S;_P#HU*TZS->_Y!J?]?-O
M_P"C4H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y&[\8W<&I7]@-+5
M9H;F*WMS).,2AT=][8!VC$9P.3R,XKKJH76B:9>FX-S90R&X*&4LO+%?N\^V
M3^= '/Z/XZCU:^A4V9AM)HG99"^65DCBD;(QTQ* "/[I]:Z2RU.RU$R"TG64
MQXW@ @KG..#]#^5-@TC3K6]-Y!90QW!01^8B ': !C\E4?@/2H;?_D9+[_KU
M@_\ 0I: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K-J5B@G+WMNHMR!,3*H\
MHGINYX_&JNN$-IB$$$&YMR"/^NJ5P;?#K5EU/5[U3I4PN+M;B*WFW>7,!([E
M9!M^48?_ &LLN>!Q72R:-/I?AS2K9]1G?[)]CA:-0OEN5= 3R-W/UH ZJBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,M_\ D9;_ /Z]H/\ T*2M
M.LRW_P"1EO\ _KV@_P#0I* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S->_
MY!J?]?-O_P"C4K3K,U[_ )!J?]?-O_Z-2@#3HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HKBZM[2+S;F>*&/.-\KA1GZFI:\\^,ZAO BA@"/ML
M/!'UII7=@9V7]O:-_P!!>P_\"4_QK/\ M&A_]#'_ .5$?XU\Q>3%_P \D_[Y
M%6/[/B_YZ6?_ 'T/\**E*&G.RJ4ZFO(?1=G=Z6[W0G\0LH6<K%G4 ,I@8/7G
MG/-:-KJ6BVK,1KT,FX8Q+?*X'TR:^:;BTAE6 "6T.R((<GOD^WO566SBB /^
MCOG^Y@X_2L:%*G9=S?$3J7?;0^K(];TJ:18XM3LGD<A55;A22?0#-7J^5?#$
M48\7:&1&@(U"WY"C_GHM?55;RCRLY4[A1114C"BBB@ HHHH **** "BBB@ H
MHHH **** "LRW_Y&6_\ ^O:#_P!"DK3K,M_^1EO_ /KV@_\ 0I* -.BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHIKNL2,[L%51DDT 0:A<BTL)Y]KL
M40E53[S'' 'O6'X/UNXUJTN9+B*16C? 9CE2#G@<#D=_PK;CB:=C-.I&00B9
MP4![_4_I4EM:0VBE8%*J3DC<3S^-:J45!Q:U.9PJ2K1J*5HJ^G<FHHHK(Z0H
MHHH **** "BBB@ HHHH **** *MQJ5A:2K%<WMM#(_W4EE52WT!-6@<C(Z5Y
MSXHG27Q(=.TZVL%N)'W74QLQ,S#8#AP4.< @X7G![5Z#;016MM'!!&L<,:A4
M1!@*/0#M0!+1110!@S^,M"MQ>F2\?%G((I=L$C9<DKM3"_.<@@[<X(.:FU2X
MAO-#M[JVD66"::VDC=>C*94((_"N?'PXB@N]0NK+5[BVFN+E;J K&K""0,S$
MD'AS\[#G& <5HWGA^PTW1M/CB5V>S>TACD:1LX61%!(!QG\* .GHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O/?C-_R(J?]?L/]:]"KSWXS?\
M(BI_U^P_UIQW0GL>#4445UF04444 :GAG_D;M$_["%O_ .C%KZGKY8\,_P#(
MW:)_V$+?_P!&+7U/6%7<N&P4445D6%%%% !1110 4444 %%%% !36=4&78*"
M<<G%.K@?'CV:7T,2:?8W6I3!%5KA?.*)D]$((7..#@YP>.* .^K \7:W=:'I
M4,]E%'+<37"PJK\]0Q.!D G"]R/Z&_H=K%9Z+:11+$J^6&(A+&,$C)V[N=N3
MP/2KD]O!=1&*XACFC/5)%# _@: .-T3QK=:GJL44MO%]GEB=@L*LT@*10R;A
MZJWFD 8!X'K6YIEVMYX@U"1(IXP+> 8FA:,GYI.@8"M5+6WCG,Z01+,5"&0(
M Q4=!GTJC;_\C+?_ /7M!_Z%)0!IT444 %%%% !1110 4444 %%%% !1110
M444R6:*!0TLJ1@]"[ 4";2U9SGC2^U&QTV&33PP8R8=E8Y ^G?-:6EM/?V-K
M/=)LPBG9NW9?N<^@[?\ ZJGD*7[^2FUX1S(XY!_V0?Y^WUJXJA5"J  . !VK
M9S2@HVU.6-%NO*IS7B[:=-!:***Q.L**** "BBB@ HHHH **** "BBB@ HHH
MH XGQ#+IFE:\\D^NW]C=7$#2D16Z291?X5<QL5)QPN>3T%=1HUU!>:-:7%M)
M/)"\8VM<9\SC@[\\[L@@^]<'\09;>YU_38)8[":W5'20O'!+(K[E^4B25,#!
MSQD]*]#LK*VTZRBL[.%8;>)=J1KT H GHHHH *S->_Y!J?\ 7S;_ /HU*TZS
M->_Y!J?]?-O_ .C4H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KSWXS?\B*G_7[#_6O0J\]^,W_(BI_U^P_UIQW0GL>#4445UF04444 :GAG
M_D;M$_["%O\ ^C%KZGKY8\,_\C=HG_80M_\ T8M?4]85=RX;!1116184444
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M*P^RW%UM,DUK(T3AE9FW*5/#$L<D=:N:GIUG9:-:P6]O&B6\MM%%\N2JK*@
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M% !1110 4444 %9EO_R,M_\ ]>T'_H4E:=9EO_R,M_\ ]>T'_H4E &G1110
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M** "LS7O^0:G_7S;_P#HU*TZS->_Y!J?]?-O_P"C4H TZ*** / ?C#_R/O\
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M\,_\C=HG_80M_P#T8M?4]85=RX;!1116184444 %%%% !1110 4444 %%%%
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M].^R6(6&X2*9HMP67?,L8,8SP1NR<YZ=NM '6?:M9_Z!5M_X&'_XBC[5K/\
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MVB>5E>..6W$I=_EY ((R.X([5!:_$B]U._@BM+>SBMO[3CMI+B9W"O$Z.5[
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ME% "!$&,*HP,#CH*4JI() ..G%%% !M&2<#)X/%&U< ;1@=..E%%  55E*D
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, %HI** %HI** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img83127175_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ DD# 2(  A$! Q$!_\0
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ME('_ -<?A6E-)O4F3T.7EFEGD,DTCR.>2SG)-,HHKH,PHHHH **** "BBB@
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M"]/\76J+<%H;J+/E7"#)7V([BNEHIIVV \.E^"NN"0B+4=/9.Q8N#^6VF_\
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M]/\ _$T?\*6\0?\ /_IO_?3_ /Q->YT4>TD'*CPO_A2WB#_G_P!-_P"^G_\
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MF_\ ?3__ !->Y9I:/:2#E1X9_P *6\0?\_\ IO\ WT__ ,31_P *6\0?\_\
MIO\ WT__ ,37N=%'M)!RH\,_X4MX@_Y_]-_[Z?\ ^)K0TGX*W'VI6U?4H?(!
MR8[4$EO;) Q7L=%+VD@Y4065E;Z=90V=I$L4$*A41>@%3T45!04444 %%%%
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MH Z*$,L$8;[P4 _7%/K&TO6VU+49;=8T$<48W,"<^8#AU^@)QGZULT %%%%
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M)J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M11PQ)%$@2-!M50. *L1I54:7LX6W?7U)Q%;VT^9*RV2[(GB6K"BF(O%2"M3
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ML8..#Z_X4N+G^]'T]#Z_X5-10! !=?+EXO?@^O\ A0!<_+EXO]K /K_A4]%
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MR,A6B _A^4\<_P"%&+GGYXO;@^O^%3T51!!BYR/GBZ#L>N?\*%%S\NYXNV[
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M\@FR_P"N"?\ H(JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4A(52Q. !DDTM5)_\ 2I_L
MR_ZM<&4C]%I-V*BKL+8&XE-VX(&,1 ]E]?QJW0!@8%%"5A2=V%%%%,04444
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M6X&.>#5ZZT;Q\)[>*#Q-9/!(S+/)_9ZJT2XX*C=R<U35MB.IV@NK<XQ-&<D
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MD9.D:!#H]Q<31W$TC3*JL'"@?+WP .3ZUK444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img83127175_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" && @,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>,?^@Q_Y+0__ !%<A11RKL%V=?\ \+0\8_\ 08_\EH?_ (BC_A:'C'_H,?\
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MA2.$)L8$!2Q)// Z<<^W--\/^-]"TN\O[U[C64:XNYIY+15C:&978[003\I
MQDY_$\47D&AAZ-X&.I:?#>W6LV=C#=3&"R,@8FX8'&0."!GCGGV%<UJ%A/I>
MHW%C=*%GMY#&X'3(/;VKT/1OB'I\.B'3IGU'2A#/++ =.6-@R.Y?RR&'&-Q
MX[5Y_JUZ=1U>[O#+++YTK,'FQO(SQNQQG&.E-7OJ)V*=%%%6(**** "BBB@
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M4?\ "CO^IB_\DO\ [92YX#]\\AHKU[_A1W_4Q?\ DE_]LH_X4=_U,7_DE_\
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MPL8EE(R(R_3<?2G^']2GODOX+HJUS97DEN[*-NY>&1L=OE8?D:+,=S8HHHI
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M]&W-=!7)Z(VIMX[U4ZI#:13?V9:;1:RM(NWS;CJ653G.>U=90 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5C:EX3\/:QJ,6H:EHUE=7<0 2::$,P
M Y .>N/>MFB@#*UCPQH?B!X'UC2;2^: YB,\08KZCGM[=*U%544*H 4#  '
M%+10!S]M_P E#U/_ +!5I_Z-N:Z"N?MO^2AZG_V"K3_T;<UT% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <_;?\E#U/\ [!5I_P"C
M;FN@KG[;_DH>I_\ 8*M/_1MS704 %%%% !1110 4444 %%%% !1110 4444
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MG6Y';E;]$:TZ/.K\R7JR"R_X_P"W_P"NJ_S%+?\ _(1NO^NK?S-68GTN&9)
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MD20SR1"/"*BI&NT<<*HR>YR<"NDJ.!M]O&Q<.2H.X#&[CK4E !1110 4444
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M \<^-_\ Q]Z-_N2_S6O)Z]8^-_\ Q]Z-_N2_S6O)ZZ:?PF4MPHHHJQ!1110
M4444 %>L?!#_ (_-9_ZYQ?S:O)Z]8^"'_'YK/_7.+^;5%3X1QW/8Z***YC4*
M*** "BBB@ HHHH **** "BBB@ HHHH **** *FIF==-G>UMH;FY5=T,,S[5=
MQ]T%L''..<5Y39S?$^\TG4;/_A&+&*[FN)DBU"YN(U, +'!";/F51T;'/6O0
M?&EJ+OPZR_V)+K31S12I9Q7'DLS*X(.[(Z8SCOBO%+RT\/7UOJ6OW/PDO)(8
MYYC>7(UM@HD5CYAP&Z!LY(&* /H:W22*UBCE</(J!6<#&X@<G%2U%;%3:PE
M FQ=H#;@!CU[_6I: "BBN'^(7Q$@\$)8V\5N+O4+R1=L)) CBW!3(Q'09( ]
M2?:@#N**X3Q9XZU72=:N=,T/0TU)]/L?[0OGEN/*"1Y.%7@Y8@$_XUUNBZK!
MKFB6.JVP807D"3H&Z@, <'W&<4 9MM_R4/4_^P5:?^C;FN@KG[;_ )*'J?\
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MG]]_UTB_]#%?/%?0_P 5O^2?WW_72+_T,5\\5O2V,Y[A1116I(4444 %%%%
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MG>J_VI]D\[^S+3;]EW;=OFW'7=SG.:ZRN?MO^2AZG_V"K3_T;<UT% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <7\5O\ DG]]_P!=(O\ T,5\
M\5]#_%;_ ))_??\ 72+_ -#%?/%;TMC.>X4445J2%%%% !1110 5U/PX_P"2
M@:1_UT?_ - :N6KJ?AQ_R4#2/^NC_P#H#5,MF-;GTE1117*:A1110!XY\;_^
M/O1O]R7^:UY/7K'QO_X^]&_W)?YK7D]=-/X3*6X44458@HHHH **** "O6/@
MA_Q^:S_USB_FU>3UZQ\$/^/S6?\ KG%_-JBI\(X[GL=%%%<QJ%%%% !1110
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M_P#!%>__ !FN@HH Y_\ X3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\
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M%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"BLRCG_ /A,M+_Y]=<_\$5[_P#&:/\
MA,M+_P"?77/_  17O_QFN@HH \5^*=Q-XDN-,;2=(URX6%)!(?[&NDVY*X^]
M&/0UY[_8.O?]"[KG_@KN/_B*^K**M5&E8EQ3/E/^P=>_Z%W7/_!7<?\ Q%']
M@Z]_T+NN?^"NX_\ B*^K**?M6'(CY3_L'7O^A=US_P %=Q_\11_8.O?]"[KG
M_@KN/_B*^K**/:L.1'RG_8.O?]"[KG_@KN/_ (BC^P=>_P"A=US_ ,%=Q_\
M$5]644>U8<B/E/\ L'7O^A=US_P5W'_Q%>A?"RXF\.7.IOJVD:Y;K,D8C/\
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MV_4D@=ZXCP3\+M2\%C0KVSFLAJ49EAUD++)Y5U"SDJ5)7[Z )C@ \\^OIM_
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MT44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
,&:,T44 &:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img83127175_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 G # 2(  A$! Q$!_\0
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MW^&_A:XU_P 1V]XT3#3K*02RRD?*S#D(/4YQGVKZ(KEJO4[8!1116184444
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MBXD((_[ZI!\,_!C.R#2D++C<HN),C/3/S5#=>'_$%G82R6^HR2R+:K"L,4K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 9?AW_D"0_P"_+_Z,:M2LOP[_ ,@2'_?E_P#1C5J4 %%%% !1110
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MK67Q'H"(JKK.FJO10+E,?0<U\UR1(\C2"XBQN.R3/(/H:@95 <%!@??0=O\
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MT#IF\C^;[ZB(X)]1Z&I1I%P #_:62IR#Y;<CT-=\Z59*\8GG0S'!2=I5/Z_
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M "!KO_KX_P#917:5Q?PV_P"0-=_]?'_LHKM*^?Q?\:1^@95_N=/T"BBBN<]
M*X/XG7.D?8=.L=473Y1-.S"&\N'ARH1@61U5L,,CJ.]=Y7#_ !0NQ9:%93-?
MFT'VQ03OD0-E6&"T;H5'?[W;'- '5:,(AH>GB! D(MHPBABV%VC R0">.^!5
MZJ.C2"70["0.7#6T;!CNR<J.?F);\R3ZFKU !65XC_Y DG_76'_T:M:M97B/
M_D"2?]=8?_1JT :M%%% !1110 4444 %0WG_ !Y3_P#7-OY5-4-Y_P >4_\
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M>BRDD&C0>=M^U1H;O"FV\IY<D[>)-L9&WIDCG&:]#@E$]O',H(610P!]",T
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M^]1:_)'-H!EB=7C>2!E=3D,#(F"#W% &Q1110 4444 %%%% !4-Y_P >4_\
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MG_CZU?\ Z_?_ &E'6G4&YB-X.\.-:R6S:+9&"6X^TNGE#!E_O?S'XFML  8
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M.I,N1D?A4SQ])Q:5S2CD6*A4C)M:-=?^ =)13-C?\]6_3_"C8W_/1OTKQS[
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M\ J#N_E]:XQ?%?B1;?PZ9+@F>Y^^HM.+Q_M*QLG3Y,1DM^O0&N]TG_CZU?\
MZ_?_ &E'6G4&YX])XV\2KI,\WV]AMDYG_L__ %<_DR-]EVXY^=47=UYQG)%>
MNP.\EO$\J;)&0%E]#CD5)10!R'Q$GM(M!19M1N+"Y9R;6:!W4API)!V$$@@$
M8SWJWX&G%UX;24S-+()9$=G:1F4AB"I+LQ./J1Z59\706DWAF\-Y9PW<<:[Q
M'*6 STR"JL0>>H4UF_#V1I] :9%6&V\UXX[=4 "%6()#".,G/NH- '6T444
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M]><O_H)KY='05]1>+O\ D3M9_P"O.7_T$U\NCH*VI;&<Q:***U)"OI3X=_\
M)/\ 1O\ KA_4U\UU]*?#O_DG^C?]</ZFLJNQ4-SIZ***Q- HHHH **** "BB
MB@ K \0>#M(\1RB>[2:*[6(PK=6\A214)SM]",\X(-;]% $<$;101QO*TKJH
M4R, "Y ZG'&3[5)110 5E>(_^0))_P!=8?\ T:M:M97B/_D"2?\ 76'_ -&K
M0!JU%=<VDW&[]VW'KQ4M176/LDV20/+;D=N* /E7YM_\.\_]\R#T^M)QM!#$
M*#\K=XSZ'VH.,,-IV Y9.Z'^\*7YBW8N1U[2C_&NTYP/\0*>[QCO_M+1SE2&
M!8C".>CCT/O2<;1\Q" _*W>,^A]J"/O I[O&._\ M+0!] _## \ :?A2OS2_
M*>W[QJZF\_X\I_\ KFW\JY;X8\^ -/PVX9D^;U_>-74WG_'E/_US;^5<K^,U
M?P'@G:BCM17TI^9!1110![)X-_Y%+3_]QO\ T(UNUA>#?^12T_\ W&_]"-;M
M?-UOXDO5GZ/@_P#=J?\ A7Y!11169TA1110 53U?_D"W_P#U[R?^@FKE4]7_
M .0+?_\ 7O)_Z":J'Q(SJ_PY>C/"NU%':BOIC\S"BBB@#VKPO_R*^G?]<%K7
MK(\+_P#(KZ=_UP6M>OFJOQR]3])PO\"'HOR,S2?^/K5_^OW_ -I1UIUR\D&H
MW%OXHAM73$K2)"(_EE$AA0 AB=OT_G7%Z?X8\3V]OHL:VEVBP3DP.UR%:W_?
M(QDG4.0Q:(.N%W#D# R34&YZY17&> =+U?3?[2_M."XA61H^)[GS?-F /FRK
MR<*Q*X''3H*[.@#GO&URD'A>YC:>"!YRL2/.Y5 2PSDAEQ@9/4=*J>!XK:UM
M;FTL]:L-2MXV# 6<)4(S$DEG+ON)]SGBNK95=2K %3P01P:2.-(D"1HJ*.BJ
M, 4 .HHHH **** "BBB@!LL4<T3Q2HKQN"K(PR&!Z@BH[:TM[.!(+:".&),[
M410 ,\FIJ* .,G\,:F_B5M3CMM))\\3+*\UP &"[0YA!V%PO&[(KLQTYZT44
M %%<CXLU*^CN]-M-.2^AN9;M5\X+_HZQ@JSN^ <\955.,EO;(?X?NM92/4(V
M1]0:.<&.XN"]N'#9)4*P.-G X&#^= &OX=_Y D/^_+_Z,:M2LGPT6.@6Y=0C
MEI-RALX/F-QGO6M0 4444 %%%% !1110 4444 %%%% !1110!B^+O^1.UG_K
MSE_]!-?+HZ"OJ+Q?_P B=K/_ %YR_P#H)KY=5EP.1^=;4MB)[BT5.LELSJOD
MGD@?ZRB1[9)73R2=K$?ZSTH]H[VY7^'^9?LE:_,OQ_R(*^E/AW_R3_1O^N']
M37S664DXP!Z9KZ4^'?/P_P!%_P"N']314V,X[G3T445B:!1110 4444 %%%%
M !1110 4444 %97B/_D"2?\ 76'_ -&K5^ZN[:QMGN;NXBMX(QEY9G"*H]R>
M!6=X@=9-!9T8,C20%64Y!'FIR* ->HKG/V6;&,[&QGZ5+45U@VDV02/+;@=^
M* /E3/(._N0DG_LIH.,,"I"@_.@ZH?4>U*0=S#:-Q^\G9QZCWI ?ND/QTCD/
M;_9:NTP%Y+=BY'![2C_&DXV@AB$!^5N\9]#[4<88%2%!^=!U0^H]J7YBW8N1
MP>TH_P :!'T#\,L_\(%8;@ =TN0.G^L:NHO/^/*?_KFW\JY;X88_X0#3]H(&
M9>#U'[QJZF\_X\I_^N;?RKE?QFK^#Y'@G:BCM17TI^9!1110![)X-_Y%+3_]
MQO\ T(UK7MQ]DL+BYV[O)B:3;G&< G%9/@W_ )%+3_\ <;_T(UH:Q_R!+_!Q
M_HTG/_ 37SE;^++U9^CX/_=J?^%?D>7K\:IV"D:'%AQE&^U'!/H?EXJ'_A<V
MH;<G2K88.&&6ROZUYB@.S!3)V@O&.C?[2TX$Y4A@2>$<]&']UJN5",C:%64>
MB9Z;_P +DU'<5&EVI;&5&YOF'MS4B_&F?"DZ)$5(QO\ M) W>A&WBO+>-I&"
M$!Y'>,^H]J7G<<@%R.5[2#U'O2C0C$<ZSET2^1].Z!J;ZUH%EJ3PB!KF(2&,
M-NVY[9[U-J__ "!;_P#Z]Y/_ $$UD^ \?\()HNW./LRXSUK6U?\ Y M__P!>
M\G_H)K-?'\R:G\-^AX5VHH[45]*?F84444 >U>%_^17T[_K@M:]9'A?_ )%?
M3O\ K@M:]?-5?CEZGZ3A?X$/1?D9FD_\?6K_ /7[_P"THZTZRM-D2*;69)'5
M(TO"S,QP% BCR2?2KME?6FI6B7=C<Q7-O)]R6)PRMVX(J#<L4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &7X=_Y D/^_+_Z,:M2LOP[_P @2'_?
ME_\ 1C5J4 %%%% !1110 4444 %%%% !1110 4444 ,EBCGB>*5%DC<%61AD
M,/0BLUO#FA*I8Z+I^ ,\6J'^E:M% '*W%KX<:UE$6@()"AVXTP@YQQ_#3+*T
M\/)86ZSZ"IF6)1(3IA)W8YYV\\UUM%9\L[WO^'_!-N>GR\O+^/\ P#*3P]H4
MD:N-%L &&1FU0'\L5HP00VL"06\211(,*D:A54>P%245H8A1110 4444 %%%
M% !1110 4444 %%%% &%XKT:YUO2X8K0VYGM[F.Y2.YSY4I0YVO@$X/T/(%0
MVGA4)X?T_2[C4;H"UMXHF%NP1&9,'(!!(Y'Y"NCHH RO[%?_ *"^I?\ ?U?_
M (FD;1&92IU?4L$8/[U?_B:UJ* ."_X5!X7P!_Q,.#D?Z4>#0?A#X7.[_C_^
M;[W^DGFH7TKQ#%KVIW-O873ZFSW+VNHO?8MO+9"(8S%GG!VC&T8(W9/>I+:^
M/9=(_P!'N-2ADC%Q) )G@,SL(T\M)2HVD&3?C';&33YGW%9&E_PJ'PP"ISJ&
M5& ?M1Z4G_"H/"VW;_I^,YQ]J/6JT6E^,8=8U'[-=WRQ"2^G@,\L;122,(_L
MZ]R$'[SCCD5;\.6?B9M8T^XU07OV2+[0%^UR1F4*R18\SR_E/SB3;Z"GS2[A
M9&YIWA2#2K*.SLM2U**WCSM03 XR<GDKZFK+:&SHR-JVI%6&"/-7I_WS6M14
MC.._X5IH?_/?4/\ P(_^M1_PK30_^>^H?^!'_P!:FZ)8ZA%XVUZ\DL]1M[>1
M"L+S7'F1SG(.[&X[<?=50HPH))R>,6RM?'UCLN+C4+J4) KNLXB9 [6\A?(4
M9(658@,>IZYK7VU3^9_><WU+#?\ /N/W(W/^%::'_P ]]0_\"/\ ZU'_  K3
M0_\ GOJ'_@1_]:N1T>X\0>+?"VHFVGU"Y5(Y3;R7+HKF4VR*$RFT8WNY]L<\
MU)=:SXHTW7M"TJ_O+Q;N62$,L 0QSG[21*Q^7.PQ[=H'*C=GUH]M4_F?WA]2
MPW_/N/W(] M/#4=C:QVUMJ>I1PQC"J)E..<]UI\V@>?#)#+JNI-'(I1AYJ\@
MC!_AK8HK-MMW9T)**LMC@A\(/"ZJ@']H83[O^E'B@_"#PN0P_P!/PW)'VDU3
M.D^(X+S5)[2POAK!6Z*:B]^#!,&;,2K$21D+@ %0%(Y)SRW[+X\DAMWCN;^)
M(?/DB25H3+(/-A\M)L#:3M\[[N.,9.:?-+N%D7_^%1>&-P;-_D#&?M1Z4G_"
MH/"^T+_I^ <C_2CQ5&WTKQM;G4EMKR_5HA?26WVB:-TFD:8^3UR<",Y . &Z
M\#%:?ABR\2#Q!;7>JB[^R):W4<?VJ1#( TL)C$@3Y2V%DY';KS1S/N%D;EGX
M9CT^SBM+74]2C@A7:B"93@?BM2RZ#Y\+Q2:MJ3(ZE6'FKR#P?X:UZ*FX635C
MCO\ A6FA_P#/?4/_  (_^M1_PK30_P#GOJ'_ ($?_6JMH=AJMOJ7BBX6SU.V
M>97%K]IN!(LS N1(/F.TDL %P %5<Y-9(A\>Z5ITUU+J-W,8K*1F\]8F"O\
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MMH^;)X= 00?NC'L =9::1H%_&TEHQG16VLT=W(0#@''WO0@_C5C_ (1K2O\
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MJ"'1;Z:>X@$ CFMX&N)(Y6"-Y8&XD ]>.<>E'LUW#F9]*?\ "6^'/^@[IO\
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MB"%O[QZD_F36E116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3S$#8_.H?[)TW_H'VO\ WY7_  K7VOD1R'SF?'VK%[AFD@S/!'"Q7*D; P#
M@YS\S$YX.>E2M\1-8:>28M:DRPB&56!977.6X+8&[H<8_"OH?^R=-_Z!]K_W
MY7_"C^R=-_Z!]K_WY7_"E[1=@Y7W/F*+Q#<0>'Y]%B\I+:=]TC;F+$9!VC)P
M!D#MGCK67O4]&'YU]8_V3IO_ $#[7_ORO^%*NEZ>K!EL+4$="(5_PI^U78.0
M\B^$GA*].K#Q!>0/#;0HRVX<8,C,,%@/0#//O7M%%%9RES.Y25@HHHJ1A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img83127175_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] G # 2(  A$! Q$!_\0
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M)XJTZ[%Q=>7Y5PNG3Q$2(JF224(FQ=OW@"'?)Y^8U+_PI[Q3_>T__O\ M_\
M$T?\*>\4_P![3_\ O^W_ ,31>/<-3@!P,45W_P#PI[Q3_>T__O\ M_\ $T?\
M*>\4_P![3_\ O^W_ ,35<\>XK,X"I(93!.DH&2ISCUKN_P#A3WBG^]I__?\
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M #@ X!P<$\XYZUO_ /"<Z.U_YLMI>ND3VMPDB!$,LT(8#<@.U%.[HO3%9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!56ZTZTOIK6:Y@622TE\V!C_  /M*Y'X,1^-6J* .>7P-X;6W\A=+C5 P*[7
M8,N%90%.<JNUF&!QACZUNP016MO';P1K'#$H1$48"J!@ #TJ2B@#+TG_ (_M
M8_Z_!_Z*CK4K*TG_ (_M8_Z_!_Z*CK5H ^??&H'_  FNK\?\M_\ V45@X'H*
MW_&O_(ZZM_UW_P#916#0 F!Z"E &1P.M% ZCZT ?3L?^K7Z"G4V/_5K]!3J
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MZ]!0!4T9TDO-79&5E-X,%3D?ZJ.M:L?0H(;:YU>*")(HQ><)&H4#]U'V%;%
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MH *VM&_X]I/]_P#I6+6UHW_'M)_O_P!* -&BBB@ HHHH *3:-V[ SC&:6B@
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MRHHHKYD_2PHHHH **** "BBB@ HHHH **** "BBB@ I'#%&"$!L<$C(!I:*
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M,_EW=Q##<%0#/$DK*C\<'( Y'!Z]Z;J4^IRZG8O#H=S)%:7#N7\^$;U,;H"
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MVARR/-/YBF&YA(QM YRPJ)R36@XIW/2*CG_X]Y?]P_RK,_M74_\ H7KO_O\
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M_>K/_P"$-\4?] 8_^!47_P 57NTL324$G+H?"XG+<7*O.4:;LV_S,6K^A_\
M(?T[_KYC_P#0A5O_ (0WQ1_T!C_X%1?_ !56M-\*^);/4[6YDT5BD4JNP%U%
MD@'/]ZJGB:+BUS$4<LQ:J1;IO='KM%9']JZE_P!"]=_]_P"#_P"+IRZIJ)8!
MM O%'KYT!_\ 9Z\ ^]-6BL[^T;S_ * M[_W\A_\ CE']HWG_ $!;W_OY#_\
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M_H!W'_?R/_XJ@#(L?^0C:_\ 79/_ $(5],5X%;>#/%$-U#*VA7)5)%8X>/.
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M\ 8 S@#@4 :]%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T
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MB:R:?2] NYG@B$MS"945H\NRJJYX9B$8XX X&<FM?3/%7V_Q-<:'-IL]I/'
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9VD&U%4L6P,9/4T .HHS1F@ HHS1F@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img83127175_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $= G # 2(  A$! Q$!_\0
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M9)9%C1>K,< ?C0 ^BL_^W-,_Y_(_UH_MS3/^?R/]:=@-"BL_^W-,_P"?R/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S5C6\U>=IAN
M2TVK&AZ!B-Q;'K@@#TY]:TJH67_(2U/_ *ZI_P"BUI@7Z***0!1110!FW?B#
M1M/NOLUYJMG;S\?NY9E5N>G!-6%U*P:^-BM[;F[ R8!*N\#_ '<YKS36+JWM
M/B?JC7.HV%DC16O%W:>=YH .0I_A/O[CTJ76[K39O'FE-IPM9Y8K_,MI;VYB
MN?-VD&1W(Y3IZ ^IJ^4FYZ2U[:K<-;M<PB=4WF,R#<%]<=<>]0+K.EO9RWB:
MC:-;0\23+,I1/J<X%>6Z?'>67CEKGQ+IFU[K3[F6_=Y5=/*+#H!GY54!0O4Y
MS52:]TK5/#?C+4+#R;?[1:QK%I\2;2D4; !W &-S$].PQ1R!S'L:WUH]V;1+
MF)KD()#$'!8*>C8]*E26.4N(Y$<HVUMISM/H?0UPW@;S]+UK4=,U@(^KW2I>
M+=@'%Q%M VC/38>,?C7-VUW;Z#;^*EEU#5/MO]I%&B2Y*%8V9<3,=IP#T+@'
MBCE'<]@HKQS3]3UB]ATRP&LWJQR:Y+:>?#,S,8?*# !V&6')P2/>K-W<71\8
MRZ3)XBN;9+:\@C$DFH^3_HX093:>7<G^+O1R"YCUJF12QSQB2*19$;HR'(/X
MUY3I%[KFJ>)9H+G5VM[EI[B*XLS=,LGE -M\N+9M4C@AL\UH^")(8/AE=BWU
M>:&[BBD$QE)<64GS=$QD#O@4.-AW.^O=2M-/:V6ZF$9N9A!"""=[G.!Q]#4\
M<L<P)BD5P&*DJ<X(ZCZUY+IVL7DMII5O'?WKL-<AMY[E;MIHYU:-B?+<@';W
M(/0U1M+JYTGPY?06FHW:7 U=HM15YV4V\)=\/D*2FXXRX!HY!<Q[1++'!"\T
MKJD:*6=F. H'))JKI>K6.M60O-.G$]N6*API )'U KBXQ=WGPKUD76IB[41S
MF">WG:0^6!D(7*@MT()QR*YRXN[G3+"SM;G6M3LK>/1([C3C&YS/<L,["0/F
M ^4!#V-"B%SV2BO/= ?5M8\9S)J=_>P"TLK.Y>TBDV1F5D^8,/3(Y7U^E>A5
M+5AIW"BBBD,*HZI;++:/,ORW$"F2*4=58#/Y'H1W%7J@O?\ CPN/^N3?R- #
M[>7S[:*8#'F(&QZ9&:9>7'V2QN+G;N\F-I-N<9P,XING?\@RT_ZXI_Z"*?=V
MXN[*>V9BHFC:,D=LC% &>^N)%'I<CPD)?*6)SGRP(R_ISTQ5'_A*X[G2(]0L
MA%M>WFE\N;<K[D3=@#&".>3GZ9HL=,U62?2TOH[:&+3(V4212%C.Q38"!@;1
M@D\YYQ5-/#NIRZ796<RP1M9VMQ:AA(6$@= JMTX]QVJK(6I?G\40V,0EO/+V
MM]G 6+<SJ9>[#' [C&<X-:B:O826_GK<J8_-$&<$'S"0 N.N<D5S\F@:D8I)
MT6'SPMDZ1&0X+0DEE+8XSG@TZ&#[9XQ(C9#;Q*MU=QJ=PCN@NQ5SZ[3G_@(/
M>BR V9M8M[2ZNEO+BWBAA\H ESN!?.-PQ@9(XY-/AU>TN]/GO+203)"&W#!4
MAE&2"",@_P"-9FH:%=76J7%PC1>7)/9R ,3G$3$MV]^*N1Z9.DNMME,7S Q<
M]/W2IS^(-+0#/7Q/=+;027=E;VWVJT>YMW-P60;5#$/\H*\'J :M:GK&HV$L
M BT^WN%N)$BA N2'<GJ=NSH!DGGH*JCPI##X7EL[>"%=1DL?LS3%B>=N" 3R
M%SZ4_P"R:Q'KLEZ;*UN(XXUAM=UT4\M,#><;#\Q/Z #UIZ!J:NH:SI^ELJWM
MRL3,I=5P22HQD@ $\9%1V^OZ5=22I!?0OY4?FN<X79_>!Z$>XZ4EUI\TVMQ7
MJE/+2SE@.3SN9D(_#Y36--X6NKC2K&S,L,9ATIK-F&2/,/E$<8Y7]V<T)(-3
M:@\0:5<Q-)%>(55D1LJ5(+G"\$9P3T/0U)<ZSI]IYHGN55HI%C=0I9MS#<
M!DG'/%85[HVK:I)-?30VT%RD<20P+,6#E)1(2S;1@'&!QQDFEDT?4)S?75S9
M0O+<7$<T<<5VT;P[8PF5<#[W7VP319 ;$NOZ7 T(DO$4S*'3(/"DX!/'R@GN
M<5I5Q@\-ZGYC-? 7_P!LACCNMMX\."H(.0HPXP1V'.>.:[( * !T'%)V!"T4
M44AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %4++_D):G_ -=4_P#1:U?JA9?\
MA+4_^NJ?^BUH OT444 %%%% "%03R!^5)L7?OVC<1C=CG%.HH 3 /44;5]!^
M5+10!"US;*)&:>("+AR7'R?7TIAN;%IS"9[<S-@%-Z[C[8ZUY%J!EC\8:W=7
MD2R^';75H7U! >=Q0!&8=T4X)%5?$L*S:WXHE%G9M;M>6T3ZFYS)9!D7#KCM
M[YK10)YCVDW=HL_D&X@$V?\ 5EQN_+K7-ZAX1T*6^F:]O9DCO9Q/):/.H260
M8]1N[#@'%>>^*X-^N>*9#96DT(>SBDU&7F2S#1J!*N.<=R<^E:5XGA\ZGXK'
MBB2&2Z2%!8R7)^9H?+^5HO<MZ<YH4;!<]9"*&W!1NQC..<4BF(!F0IC)W$8Z
M]\UR&@W>HCPIIUMKMD5LFT]3=WTUT$V?*>&'W@<8YSWKD=-N=#E^$VLV<U[;
M_NI[EHD^T8.[<QC[Y.<< ]:GE'<];+P0Q*2T:1D_*<@#)]*?L3+':N6^]QU^
MM>3W5SH^H1^'?[4N;>72$T215+2 QBY5$!'^^!T'6N]\%M=OX*T9KXN;DVJ;
MR_WNG&??&*'&R!,W JJH4 !1Q@#B@HK8RH.TY&1TI:*D88&<T444 %%%% !4
M%[_QX7'_ %R;^1J>H+W_ (\+C_KDW\C0 W3O^09:?]<4_P#015FJVG?\@RT_
MZXI_Z"*;JLCQ:/>R1L4=+>1E8=00IP: +=%<?IU]-8:%%>_9]2>ZF6"&-;ZZ
MW)))(0 1\S8&3D\ XJ%;J\@UV[6^5'F:]LXP()75!E6YQ_,'@U7**YVU  '0
M5QEKXDU.#3;<W7V9[B[N9TA<*Y5%1FSN"C)Q@ 8_$U937]2U)#;VEG#%,ENT
MMP9RZC&YD78,9^;:3DC@8I<K"YU5%<M'([^$/#UN6;%V+6*1LG)7:&//N%Q^
M-4/[6U",ZW8_:G,]U<R)8.3DQ_-L<#_= W?C18+G<45SEEXBMK7PU;2W4TDE
MS'IR7,FY&._]V#][&,GZ]ZR=,\22VGA[5O/NY+FZM51XY)%;),HX4 C) DW#
MZ 4<K"YW-%<5;7+7WA'4D_M&\>YTL2A;A97C>3";D9NA/!'7N*T(H38?V'<K
M<7,K3R".4S3-(6#QD]S_ 'E!_.BP7.EHKG]2UC4X;Z_ALK:U>.QMTN',SL"^
M=_RC X/R=3^55G\47;+>7,-I$;2 0J@=R'D>5$*#T4 N,GFBS"YU-%<CJFM:
MU!NL<6D5\DULPD0L8WCDDVXQU!R"#['(J9_$UTNIO;I;1R)!.EO,J)(7=CMW
M,I V@#=W/(!Z4<K"YU%%<E8ZS?R0VMIIUM;[Y()Y]US,[!=DNW&>2<Y_"M"3
M79Y=%TJZM+=#=:D8UB25OD0LA<EB.2 %/3KQ18+F[17$V^N7FFRWEO*L)O+C
M491N^=XT58HR3@ MW''OUJ>W\0:G+J2W$L<<-E'I[W$\#!MWRNP)7('7;QGL
M:?*PN=?17(1>+KUHE+6,;O<+']G""155W95".S*/[P.1Z'BK5S>:[#K.D6TC
MV*B7SFF";]K*H'KR#@_G2LPN=+17'1>-93;M>R66^U>%YHUC5PR8Y4.Q&WYO
M;H?7K5W3GU$^+W741 K_ -G*0MNS%1^\/KW]^]'*%SI****0PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
MHW6TUBXCE(47>UXF/1F"[2OUP <>Y]*T:CF@BN8C%/&DD9ZJXR* )**H?V+I
M_P#SP/\ W\;_ !H_L6P_YXM_W\;_ !I@7Z*H?V+8?\\6_P"_C?XT?V+8?\\6
M_P"_C?XT 7Z*H?V+8?\ /%O^_C?XT?V+8?\ /%O^_C?XT 7Z*H?V+8?\\6_[
M^-_C1_8MA_SQ;_OXW^- %DVMN1*#!$1-_K04'S_7U_&D^Q6GER1_98=D@ =?
M+&& X&1WJO\ V+8?\\6_[^-_C1_8MA_SQ;_OXW^- %G[':E9%^S0[90%D&P8
M< 8 /KQ3)=/LIVB:6SMY##_JR\2G9]..*A_L6P_YXM_W\;_&C^Q;#_GBW_?Q
MO\: +LD:31M'*BNC##*PR"/<55&E:<$*#3[4*2"5\E<$CIVIG]BV'_/%O^_C
M?XT?V+8?\\6_[^-_C0!*=,L&@6!K&V,*MO$9B7:&]<8Z^]6JH?V+8?\ /%O^
M_C?XT?V+8?\ /%O^_C?XT 7Z*R[>VCLM;\N$,L4EN6*ER1N5ASR?]JH[2PM[
MY[JXN$9V-PZ@^8PP%.W'!]J -BBJ']BV'_/%O^_C?XT?V+8?\\6_[^-_C0!?
MHJA_8MA_SQ;_ +^-_C1_8MA_SQ;_ +^-_C0!?JEJEPL-E)'UFF4QQ1CJ[$8'
M_P!?T%-_L6P_YXM_W\;_ !J:VT^TM'+P0*KD8+]6QZ9/- $EM%Y%K%#G/EH%
MSZX&*6>%+FWD@E&8Y$*,,XR",&I**0&,GAFQ6S:T>6\E@**BI+<NP3:05*\\
M$$#!%/A\.6$3F1O/EE,L<S22S,S,Z9"D_GTZ5K44[L+&.?#5CMD"O<QYF,\9
M28@PN<[BG]T'<<CH<TZ?P[9W!B9YKOS8XS"TJW#!Y4)SM<]QG\NU:U%%V%C-
MNM)1M*M[.T(B-H8VMRV2%*$8!]1@8_&I$T>Q23S/(4R>9)*';DJTGW\'MFKU
M%*X%%M)LVTN#3BC&UA$81-QZ(05!/?H/K276C65[J-O?31L9X,;"'(!P<C(Z
M'!Y&>E7Z*+@4IM*M)Y+N1T;-W ()L,0&0;L?C\QYILFG;[K3R& MK,%E3J2V
MW:O/H 6_,5?HHN!@W7AQ=0UJ]N;J646T\$47EPS,F\*7W*X'4'</UJ\^BV$D
M5Y$\ ,=YM\U<G!VJ%&/3 4=/2M"BG=A8Q_\ A&K$VMQ#(]S(\Y0O/),3+E#E
M,-VVGD?_ %ZE30[>.]6ZCGNTD^4R!9R%F*@ ,X[G &3W[UIT478&?::)8V4D
M;P1LK1Q/$N7)PK-N8?G39=#LI-*MM.VR)#;;?(9)"'C*C (;KG'\ZTJ*+@8X
M\,V"P;$:Y27SC.+A9V\T.0%)W>X&".GM4K:':O/;S.]PTD,9B+-*3YJ'JKY^
M\,^M:=%%V!D)X;L5M);1Y+J6V< +%).S"(*<KLYRI! P>HQ3O[ MBML6N;QY
MK>4R),TY+Y(P03_=( XZ5JT4786,F+P[8Q1SP9G:TF1D-J\S&)0W4*O;^G;%
M2:?HEKIURURDES-.T8B,D\S2'8#D#GZUI4478!1112 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *%R=FL6#?WEEC_,*W_LM
M&C$MI<;GJ[._YN3_ %INJ.(9+*?^Y,<_0QM_]:I=*3R](LU](4_D*?01<HHH
MI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU['WI+C5]1M["^MX-2EE6VOXHH;O@LRL#E2>AQ3^JR[D_P!J4[7Y7^':]O\
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MW4RQ36\[;@0Q(RO<=*EU+7YHO%9F6^V6=K<1VTEOOQOW [FQWP<5:H3O9/\
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MR^*-<29YEU*82//]I+87_6[=N_IP=O'%4K2_NK!)EM9VB6<*) H'S ,&'Y$
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M1C59%*,&;:LRJ,X/OV!]ZQK+2Y#I2E+F@[-:_=J8'AW4$\-3P_94;[*HV2Q
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M4(Q?0O!X7V$+/?J%%%%,[ HHHH **** "BBB@#RWQ;H[>&=6?4[=<:1?29F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH9+NVA;;+<1(WHS
M@&DVEN-)O8FHJM_:%E_S^6__ ']'^-']H67_ #^6_P#W]'^-+FCW'R2[%FBJ
MW]H67_/Y;_\ ?T?XT?VA9?\ /Y;_ /?T?XT<T>X<DNQ9HJM_:%E_S^6__?T?
MXT?VA9?\_EO_ -_1_C1S1[AR2[%FBJW]H67_ #^6_P#W]'^-']H67_/Y;_\
M?T?XT<T>X<DNQ9JIIIW60?\ ON[?FQ-..HV04G[7;\?]-!_C1IR[=-MO4QJ3
M^(S2NG+0JS4'?^MQNF<:?&I_A++^3$5;K.M+NV@$\4MQ%&RSO\K. <$Y_K5C
M^T++_G\M_P#OZ/\ &B$ERI7"<9.3=BS15;^T++_G\M_^_H_QH_M"R_Y_+?\
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MTK0WVH?"?5T?4#?-MF:WDMI7D)C'(0LR@OW!XY%>AH8Y$$B;660 [A_$*>
M  , =J'(+'D$VHV\=EH\1U[4X=$_LYWCN897W-=@C]V6 S\O9>E;FIZCK0\!
M^&;F[DG@U&:]M%N=F58@MR& ]1C(KT'8N -HP#D#%.I<P['DT5WJJ7L.H_VG
MJ+./$\EB(&E/E>06/&W^O;M5/3[N6_\ $>AR7M]>S:N-6F%U:REO+MP X3:N
M,+QC'K7LM(  20!D]33YQ6/)-)\1ZG<1>'+6VO+R?4H$OUNXI-_S2A',:N3P
M3D# IJ:O,/!,ESIVM:E<ZLY@_M032/FV4MARHQ\GI\H) YQ7KH &< #/)H"@
M9P ,]?>CF78+'+> I+J72+EIM1BOK?[01;O',\Q1<#Y2[J"V#GGWKJJ0 *
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M( 8?K6K!J=C<W<MK!=PR7$7WXU8$KZUDV_AV*;4]2N;^)G26[6:)/.;8P"(
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M77+:T2X$D<S>7(A)&X *^#[5Z])&DT;1RHKHPPRL,@CW%1)96D:JJ6L*JI!
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MYG16W.QR3C&!] .*?,@LRYHLMW/HEC+?-$UT\"-*T+!D9L<E2.H/6KU( %
M  '  [4UIHTD2-I%5Y,[%)Y;')QZUF4/HHHH **:SHFW>RKN.T9.,GTIU !1
M136EC618V=0[Y*J3R<=<4 .HHHH IZ9_QXK_ +[_ /H9JY5/3/\ CQ7_ 'W_
M /0S2ZG*\&DWDT3;9$@=E;T(4D&IA\*+J?&_4MT5R&F:I)::*E_(=6N;B1(8
MTBO,(LDDA &TXX&3R>PIB:C>QZY=I?!T<WEI$L=O<DH-RGN0,@]Q@9K3E,[G
M94Q(HXV=DC12YW,5&-Q]3ZUR=MXJO8M-ADOHK43W5S-% 3,50*C-DN=O&  !
M@$GVJPGB6YU*'RM/L4:80/+.9)MBH S( IVG=DJ2#@#'UI<K"YT]%<Y;:M/9
M>%M!E6$W5Q=I!#\\FW+,F=Q.#Z4G_"1WWVA+ :;&=0-P]NR>?^[!$8D#;MN2
MI4CMFBS"YTE%<['XCN',-Q]@3[!/<&UBE\[YB^2H8KCA2PQUST.*HV?BJ\CT
M;3Y+Z.U%W>M)Y;-,5C"KU+$+P>@  .:.5A<["BN2_P"$IX:_2TG9OLD;>09L
M(6:<Q\ CKG^+N,5K66L2.^HQ7]NEO+8[7?RY#(I0KN!!P#G@@C':BS"YKT5Q
MTNO7@O\ 3=2O+;[-8FSN+D(DV]F0*I&]< ;L>YZTVX\77LMHRVD%J+G= RE9
MRZ!7D"E6.WAN<?0Y!XI\K"YV=%<S<>+1;Z@]LT$)$$D<4X$QWEVVYV+M^8+N
M&2<=Z9>>(-4D\.WVJV=G!';K#(]O*\WSG:<!BNW'/) S]:5F%SJ:*YC4/%4N
MG3-;S6UM]H@@$]PGV@@$$G"Q_+\S84GG Z>M5]2UN\OH8Y+2W\JQ748(//,Q
M61R)%#?+C[N<KR<]>*.5A<Z^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH JW?^OLO^NY_] >K55;O_7V7_7<_
M^@/5JI6[+ELOZZA7':9=7<T6E6,%X+0W%M+>SS[%9I'WC*C=QU8D]\ =*[&L
MQ="L&M_L]Q!'<1+,TT2RH#Y98Y('MDG\\5:9F<#YKOX2>V5XP/['WF58UW']
M^01G^Z?3I6I-/?:/JVKR17332R2VEMN,48V[E W=AD<@ D#)KLQIE@(_+%E;
MA-GE[?*&-F<[<>F><4^2QM)EG66VA<3@"4,@/F <#=ZT^8+',I=Z\U_9:?+<
M/;">68":2.,RO&J*PR%RH.21].U5[;6]<N+234E5Q 4N"Z,L82'8&VXYWELJ
M 01W/ Q756VF6-FL:VUI#$(BQ3:@RI/7'UIHT?31=RW7V&W\^4%9'\L98'@Y
M^O>BZ"QR&I7^K#1[N.;4=YN-'-X&2%5,3 J&"X[$-WR1CK6]J=U>6&FZ=;Q7
MF9KJX2W:\D1?E!!.<#Y<\8';)'6M<V5J1@VT1Q$8>4'W#U7Z<#BHQIEBNG?V
M>+2'['C'DE 5QG/3ZT706,.>YU$7\NG)K*Q&UL_M+7#PH3*2S#!'0*H49Q@\
M]JSWUS6+RPO;Z&Z2U%KIT%Z(1"&W,R,S*2>=IV_7GK73OH6DR6\,#Z=:M%"2
M8T,0(7/7\^_K5EK.V?SMUO$?.0)+E!\ZC( /J.3Q[T706.9N]0U%;N[BN;J6
M&.Y25;+RHT:,XCW8)^\'&&)SQQQ3-*FU1UT6QCU-BCZ;]JDD,2%VP4 4<8Q\
MQ&>OX\UTB:5I\5ZUXEG MRP(,@09YZTMIIEC88^R6D,. 0-B 8!.2![9 _*B
MZ"QS#^)[V'2-+N]\4LLNFW%U+'@?.R*I'3H,DYQ3M4BU$6FEEM>>1IKV#,D<
M48"[@>F!RN>F<_C71V^D:;:3-+;V-O%(Q)+I& >>O/O4:Z#I*6TULNG6RPS$
M&1!& &(Y'Y=O2BZ"QGZ[J=[I=S!'%*"+J!X8=R#_ (^<KL/X@MQ[5EC6[N^2
M$2>4PAN+2VF#1*0+@R$2$9Z$ #'IFNO>TMI%A62"-Q P>(,H.QAP"/0BFBPL
MU# 6L(#R^<V$',G]\_[7 YHN@.)2*\>PTW=J3R2MK<JJSQJ?*PTP.!W)'KT^
ME;EI>ZI-H.II'/%+J%K/+;PS2J$#D$;20.,\X],UKII=A'</<)9P+,\@E9P@
MR7 QN^O)Y]ZD:RM7@FA:VB:*8EI4*##D]21W-#86.2;6)Q-""[O<V\=V)#=6
MZ"6)UC1@,KQT8'(X((HCO==F98_[753+I8OMPMD^1_[H_P!DYYSD\<$5U$.D
MZ?;Q+'%90*B[L (/XOO?GW]:F%G;*01;Q B/R@0@X3^[]/:BZ"QQ,VH2:BR2
MR1Q*TDNER_(@!)=LD$]2/3/2K,OB"]6_62WN9);.X6Z$9DB15!C5B"F/F(!4
M@EN#74-IE@\1B-G!L(0%=@Z)]S\NWI3$T;3(YY)DL+82R$EW\L9)(P?SR<^N
M:+H+&0^HZC9>#5U*:ZCFNYDB8.\86.'S"HS@=57<3R>U0:A:WHUG1(/[6:2<
MR3D7!A3<@\KH !C/N1W[UU'D0FW^SF)#!MV>65&W;C&,=,8JO:Z5I]D$%K90
M1;&++L0#!(P2/PXI7"QRD6MZU>&"SBD<SI#,[2PQ1YE9)6C&0Y  ^7)QS\PZ
M4^\U?7%COY_M45L]FUJIM_*5U+2*F\%NI +'&"/K737&CZ;=Q)%/8V\D:,75
M6C& 2<DCZGKZU,;&T99%-M"5D*EQL'S;<;<^N,#'TIW06.7EO[V'4OL%U/'=
M^1J5LJ2R0J&"NA/0# ((.".<&J=]?:F^G3VM]J$T%]YD$N$CC\ORS.J[HV'5
M>1PW/KP:[5K*U>4RM;Q&0LKEB@R648!SZ@=*KQZ'I44<\::?;*EP-LJB,8<>
MA]O:BZ"QASW6M_:M6%O?>8-,$3+%Y*YG^0,X8XXSSC&.322:B^I/!J,4H:U7
M4H8K,A?O*1MD.>^=S#_@-;[6"P6DD6FB&TE90HD\K<!C@9&1G XZU!:Z%;6E
MMIUM&S>38Y9$XP[X(W'WY8_4T70&I1114C*>F?\ 'BO^^_\ Z&:GN8$NK66W
MDSLE0HV#S@C!J#3/^/%?]]__ $,U<J8?"BZGQOU,1?#,/V'['+?W\T(55C#R
M+F(J0592%!!&!3HO#5JDIFEN+J>=IHIVDD<9+1@A>   .>@K9HJ[LBQB?\(S
M;J#Y5W=Q%9VG@9&7,#-DL%X^Z=QR#FGS^'HYWCE-_>I.(C!),D@#3)DG#<8X
M)." ",FMBBB["Q@ZGH;RZ;I-A9/)'%9W$1WAP'5$4C()')Z58M?#]K:S03^9
M/+<12O,99'RTCLNPEN,?=P !C&!6M11<+&/'X<M(KM)1-<&".8W$=J7'E)(<
MDL!C/4DXS@$]*C3PQ;Q0QI#>7D302,]NZLNZ$-]Y1QRI]#GMZ5N44786,F;P
M]:W)+7$UQ+(8HXF=G&6"2>8"<#KG]*MIIMNEW>7&&9KM5656.5(4$#CZ$U;H
MHN!A0>%;*,QK+/=W,,4+V\4,T@*I&X *\ $\ #)Y]ZE/AY'T^2RFU"^FC;9Y
M;2.I:(J05*G;U! Y.>E;%%%V%C*30UBO/M,5]=QL^TSJK+MG90!N8;>"0 #C
M&<5$GAJU2WN+07-T;&9'3[)O'EH'Z[>,]^.>*VJ*+L+&/_8 $D<R:E?)<!!'
M+,KKNF4$D;OEQD9." #S39/#-K)=-+]INUA:X6Z-NL@$?F@@[NF>2,D9QFMJ
MBB["P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *UZDC1))$NZ2%Q(%'\74$?D32Q7MM,@9)D]PQP1[$'D&K%
M126T$K;I(8W/JR U+3O=%IIJS%^T0_\ /:/_ +Z%'VB'_GM'_P!]"F?8;3_G
MU@_[]BC[#:?\^L'_ '[%'O![GF/^T0_\]H_^^A1]HA_Y[1_]]"F?8;3_ )]8
M/^_8H^PVG_/K!_W[%'O![GF/^T0_\]H_^^A1]HA_Y[1_]]"F?8;3_GU@_P"_
M8H^PVG_/K!_W[%'O![GF/^T0_P#/:/\ [Z%'VB'_ )[1_P#?0IGV&T_Y]8/^
M_8H^PVG_ #ZP?]^Q1[P>YYC_ +1#_P ]H_\ OH4?:(?^>T?_ 'T*9]AM/^?6
M#_OV*/L-I_SZP?\ ?L4>\'N>8_[1#_SVC_[Z%'VB'_GM'_WT*9]AM/\ GU@_
M[]BC[#:?\^L'_?L4>\'N>8_[1#_SVC_[Z%'VB'_GM'_WT*9]AM/^?6#_ +]B
MC[#:?\^L'_?L4>\'N>8_[1#_ ,]H_P#OH4?:(?\ GM'_ -]"F?8;3_GU@_[]
MBC[#:?\ /K!_W[%'O![GF/\ M$/_ #VC_P"^A1]HA_Y[1_\ ?0IGV&T_Y]8/
M^_8H^PVG_/K!_P!^Q1[P>YYC_M$/_/:/_OH4?:(?^>T?_?0IGV&T_P"?6#_O
MV*/L-I_SZP?]^Q1[P>YYC_M$/_/:/_OH4?:(?^>T?_?0IGV&T_Y]8/\ OV*/
ML-I_SZP?]^Q1[P>YYC_M$/\ SVC_ .^A1]HA_P">T?\ WT*9]AM/^?6#_OV*
M/L-I_P ^L'_?L4>\'N>8_P"T0_\ /:/_ +Z%'VB'_GM'_P!]"F?8;3_GU@_[
M]BC[#:?\^L'_ '[%'O![GF/^T0_\]H_^^A1]HA_Y[1_]]"F?8;3_ )]8/^_8
MH^PVG_/K!_W[%'O![GF/^T0_\]H_^^A1]HA_Y[1_]]"F?8;3_GU@_P"_8H^P
MVG_/K!_W[%'O![GF/^T0_P#/:/\ [Z%0SW\,2X1A+,W"1(<EC_0>]/\ L-I_
MSZP?]^Q3XX(H<^5$B9Z[5 H]X/<0RTA-O:1Q,<L!\Q'<GD_K4]%%-*RL2W=W
M84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img83127175_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_24.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $7 DL# 2(  A$! Q$!_\0
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M2NB3M%]](OD^;[E"? >\D\)Z;XCB\1Z->:?=7UOI\ZVDLKRVLLOW-^Y$5O\
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M)6:65$B39][Y]]5-8^#GBBWO-573-%U+6]/TV=K>74+33KCRMR_?^\GR[/\
M;KV:V_:B\+VUU:1?V5JSZ?9W6EQ1/-Y3RRV=FCNF_P"?_6O+\U=?<?%K0?\
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M;G0M#L;?1;&X3_EK% FW?_P-][?\#JX\W,/4\WHHHK<R"BBB@ HHHH ****
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M.RO6<>]1[2?\Q?+ ^3O^';/PN_Z"/B;_ ,#(/_C5'_#MGX7?]!+Q-_X&0?\
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M_%__ +"EA_Z;;>@#U2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^Q;LVZ@#ZNM;A+RUBGC^Y(JLM6JHZ:RMIUHRKM5HUVKM_V:O4 %>6?L^_\
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MBB@ HHHH **** *%C_KK[_KX_P#9%J_5"Q_X^+__ *[_ /LB5?H *\J\!_\
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M=)E^U:E+OE_Y>OE_W:]TKRKP'_R7CXF_]>>D_P#MU0!ZK1110 4444 %%%%
M!1124 ,X/--;Y?N\FE PH%?,W[2?QG\5^ /&%EINB7T-M:2VOFNLMLLIW?\
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MX&U*>"19HGUJ]99$;<K?O:A\)_LX>%?"NN37<7GWMK) T*Z?=?/$F_[[_P#
MMM2?LX6<&G^ ]0MK:)8;>+6KU$B3[JKYM 'KE)2TE $?>O#_ -L;_DW_ %__
M 'HO_0Z]P[UX?^V-_P F_P"O_P"]%_Z'6E#^)$X,;_NT_1GR1^Q#_P G!:9_
MV#+C_P!DKZZU3Q/XJ;5K>:VNU2T\J=]_D)^ZV?P5\B_L0_\ )P.G?]@RX_\
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M<K4W"C&?+V/B<#553'U*7-\-_P T>KZ]_P @SQ!_UYO_ .BGKU#5O^0-<_\
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MNH>7]G\B7_7-\GW*YS^*L8THRJ2AVL=,O=HQG_-<_9+_ (:N^$G_ $/>F_\
MC_\ \37>^%_%&E>-M!M-:T:]BU+2[HMY%U%]QMK[>/\ @2FOPPK]=?V'_P#D
MUOP)_P!<KK_TKGJZE+V1S0ES'O-%%%<YL4;#_77O_7?_ -D2J/BCPW9>*O#^
MH:-J2,^GW\#6\ZHVUMC?>^:KVG_\?%__ -=__9%J]0!Y7HO[/?@C0;K0IK?3
M)))=#_X\WEF=]OSJZ?[VQE&W^[2> _\ DO'Q._Z\])_]NJ]5KRKP'_R7CXF_
M]>>D_P#MU0!Z@WWJYOXAZ]-X5\$ZUJ]LJ/<V-G+<1+)]W<JUT_>N&^-1_P"+
M6^*/^P9<?^@&M*:O-(Y,1+V=&<D?,'_#9'C?_GQT?_OV_P#\73?^&P?&;-N_
MLK1?^_#_ /Q=>%T5^AO*<-*/NQ/P%<4YA3K^].1[E#^UAXJANKBY_LK1?-E5
M5^6!_P"'_@=2K^V)XS7YETS1$_W(G_\ BZ\(HKGP^14*7\34[L;QCC<4[4?<
M^?YGT!I/[7/B^^U:RMI;'2?*EG5'V1O_ '_]^OL;^'>*_,GPW_R,&F_]?47_
M *'7Z;I]Q<&OG\XP]+#58QIH^YX2S+$9A0J2Q$N;E9)ZU\8?MD?\E$T[_KP_
M]GK[.]:^,?VR/^2B:=_UX?\ L]9Y/_O43NXM_P"174^1X'1117Z4?SI=A111
M0!]7?L0?\@OQ;_U\P?\ H#5].5\Q_L0?\@OQ;_U\P?\ H#5].5^59C_O=0_I
MOA[_ )%='T)J***\\^D"BBB@ HHHH *\L_9]_P"1/U7_ +#5_P#^C:]3KRS]
MGW_D3]5_[#5__P"C: /4Z2EI,B@"/O7A_P"V-_R;_K_^]%_Z'7N'>O#_ -L;
M_DW_ %__ 'HO_0ZTH?Q(G#C/]VGZ,^2/V(/^3@M-_P"P9<?^R5]@O_R#_P#M
ME=5\>_L0?\G!:7_V#+C_ -DK["?_ )!__;*ZKU<7_%^X\#)?]T_[>9\^?MYO
M+_9OPZ\IFV^0V[9_P"NQ_P"">5K+;^"_%OFSK-NU-778V[;^Z2N4_;POY;/2
M? $2R[(I;9O-_P#'*Z/_ ()Q_P#(E^,]K;_^)LO_ **2O ?M/:'VW[OV/]X^
MQ:H7'_(4M/\ <D_]EJ_5";_D+VG^Y+_[)6QS%^BBB@ KROX9_P#)7?B__P!A
M2P_]-MO7JE>5_#/_ )*[\7_^PI8?^FVWH ]4HHI* #^&FT;OEK!U3Q=IFD:Q
MIVE7-PL-[?;_ +-#_?VU$I1C\0*+E\)L^8/+RW%1VMY#<[O)E63;][:VZN5^
M)D,%YX<%C/!)<QWTRV_EPW/V=OXG^_\ \ KD+'4-076-*NW@FL;*UNFMY;>*
M^W)+YK[4W)L^;9NJ)>TYO=7NEQC#E]Y^\>PM2U4U+4K32;1[F]N([:W3[TLK
M;5JU&WRUL1R_:)**** "DI:2@#\K_P!KG_DXWQG_ -=K?_TGBKZ:_9)_Y-IF
M_P"PXG_I1;U\S?M=?\G'>-/^NUO_ .D\5?3/[)/_ ";3-_V'$_\ 2BWKZC%?
M[I3^1^<97_R-ZWS_ #/7O$W_ "+NJ_\ 7G+_ .@5\S_\%#(?.^('@>+<J;K-
MOF;_ *ZU],>)O^1=U7_KSE_] KYG_P""AGE?\+ \"^?N\K[(V[9_UUKYS%;'
MZ#@?B$_X)SP^3XX\>1[E?9:VZ[U_B_>RU]X-UKX/_P""=7E?\)QX\\C=Y7V:
MWV[_ .[YLM?>#=:YH_"CKJ?$.HHHK0R"N7\-^//#_CJSO9?#^KVVK16K-!.U
MK)OV-6_=0_:;66+=LW+MW5\S_!K]FG6M#\,WECXEU6YT5TM=+T^!O"NI2V[S
MK8V\L7FNR;?];YN[9_L+0!Z3^RM_R;;\,/\ L7;+_P!%)7K%>':1^RWH?AW1
M[32],\7^.+#3K.)8(+6W\272)$B?=55WUH_\,WV/_0]^//\ PIKK_P"+H ^2
M/^"H'_([>!_^O&X_]#2OBM)FA;=$S)7ZO>,OV'_ ?Q F@G\2:IXJU^:!=D+7
MVNW$K1+_ +.YJP/^';OP>_Y]];_\&UQ_\579&M&,>4QE'WN8_,7^T+G_ )[M
M_P!]4?;[K_GNU?HMX\_X)R_#O_A'7_X1B+4AJOVBW8?:-8EV>5YJ>;_%_P \
MM]=)_P .W?@VW*P:S\WW?^)Q<?\ Q='MZ?\ */W_ .8_+VOUS_8?_P"36_ G
M_7*Z_P#2N>N0_P"';GP<_P"?76O_  ;7'_Q5=IX?_94\/>$=&M]*T;Q5XVTK
M3;;<(+2U\27211;FW_*N_P#O-6=2KSQ",>4]VHKQ_P#X9OL?^A[\>?\ A377
M_P 76QX1^#MKX.UA-2B\2^*M6=59?LVKZU/=1?-_L,^VN<U.YL-WG7N[=_K_
M /V1*OU1T_\ X^+_ /Z[_P#LBU>H 3=7E?@/_DO'Q-_Z\])_]NJX/XN>#?%&
ML_'7P?J>GZ;>36D#6OD:A$R^58;;M7NM_P W\<7R_P"U6I8_!WXG:7XJUO7[
M;XD:>M[JT5O%/NT)-FV+?L_C_P"FKT >]5PWQJ7/PK\4?]@V?_T US/_  A/
MQ?\ ^BEZ;_X($_\ BZS?$GPK^*?B;0;_ $B]^)6G_9+R)X)"F@)OVM_P.M(2
MY9IG+B*?M:4X(^(Z*^@?^&#O$?\ T4>/_P $Z?\ Q='_  P;XB_Z*3%_X)T_
M^+K[R.=X6*ZGX=5X,S&52ZM]Y\_45[#I?[%_C"\\8:UI4_C;[/I]A!:RV^H-
MHZ;+IY=^]/O_ ,&Q?^^ZZ'_A@WQ'_P!%)B_\$Z?_ !=5_;F%\R/]2\Q\OO/#
M?#?_ ",&F_\ 7U%_Z'7Z9P_ZO_@ KY#L_P!AGQ'9W44\?Q*C$L3*Z_\ $G3_
M .+KVC_A!?B[C_DI6FX_[ "?_%U\UFV,IXR<9TS]%X8R>ME-&<:WVCUG;YG\
MZ^-/VR/^2B:=_P!>'_L]>XCP3\7,X_X65IO_ (($_P#BZ\Z^(7[*OC?XE:S#
MJ6L_$FW\^*+RE\G147Y?^^ZY,OQ$<+B(U)GKY[@:F/P$J%+XI6/E:BOH'_A@
MWQ'_ -%(C_\ !.G_ ,76+XR_8I\7>'_"]_J6G>.%U6]MHM\5DFCINE;^[]^O
ML/[<POF?D?\ J7F/E]YXQ17OEO\ L*^)9K>*1_B-&CLJLR?V.GR_^/U+_P ,
M&^(_^BD1?^"=/_BZ/[<POF'^I>8^7WG4_L1M_P 2[Q9_U\P?^@M7U!Y>[/O7
MS?\ #G]F_P ??"VWOX=&^)5FJWCK+)YVA(_W?^!UVO\ PA/Q=_Z*7IO_ (($
M_P#BZ^(Q5:->O.K$_9<GPM3!X*G1J?%$]AHKR"'P3\75D5F^)6FNF[YE_L!/
M_BZ]6A22.%%D??*J_,VW[U<A[)9HHHH **** "O+/V??^1/U7_L-7_\ Z-J'
M_AH'P_;^.=6\/WR2:=;Z<DN[5;AE$+/%M\U/^ [UKB/@C\;O >C^%=3@OO%.
MGV<K:Q>2JDK[?E:7Y6H ^BE^HIDGR]\5YK=?M#_#R&UEDB\8:6\JHSJOF_>K
MY:;]L#6YO&$-VNM6UOI[3K$UJL3^5Y6[[_S5Y]?$K#<MXN7,>AA,%+&<UI*/
M+W/N:2\@6Z6%I%6Y9=RQ%OFKQO\ ;'^;X :_Z[HO_0Z\H^-_Q^T5/&FFWF@Z
MYI=RL=GM^T+'YNU]_P!RL?XC_';2/''[,^L:?J'B.RO/$LL^V.SB7;*ZJ_\
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M1V^;)=WDMQM1?NHFYOE6NVH H_V78_\ /G;_ /?I:3^R[)6W+9P?]^UJ_10
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MC_\ 093_ ,!8/_B*?-^TO\2[7RO/U7R?-7>N^PB7<O\ ?^[1_8N)_FB/_73
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M\15_V+B?YHD_ZZ8#^67W?\$^[O-_VA^5+Y@_OK_WS7PA_P -/_$?_H,I_P"
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M.:ZGE6**);2#YF;[G\-3')Z\OM1'+C'!1^*$_N_X)]SY3T3_ +YI-L?]U/\
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M[RXH?]4_W8FW_P!_^]1'\:M2:;3KIK'2[FZMD98;F6*7>\+[]RM\_P!SYO\
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<#WI'/T445J>8%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img83127175_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $, G # 2(  A$! Q$!_\0
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M;9UL[*;<RR(@9 S9;&WKC.>>:B_X5;XQ_P"@6G_@3'_\51_PJWQC_P! M/\
MP)C_ /BJ7N]PU(M+\5OHA:T:5[^UAN0L0XV>2&))!(R2<\9X )]:37]=LM1T
M65;;(FNKU)71@-X6.+9O;'&YR2>/2IO^%6^,?^@6G_@3'_\ %4?\*M\8_P#0
M+3_P)C_^*IWCW#4X^BNP_P"%6^,?^@6G_@3'_P#%4?\ "K?&/_0+3_P)C_\
MBJ?,NXK,X^I+>7R+A),9"GD>H[UUG_"K?&/_ $"T_P# F/\ ^*H_X5;XQ_Z!
M:?\ @3'_ /%4U-)WN*4.9.+6C.?FMV>&W%LIFB4L3M]SW]#BDGTZ5;HK"I\M
MN0W)VCT/&:Z(?"[QB#D:8H^EU'_\52_\*O\ &?\ T#5_\"H__BJMU(/<YE0K
M1^&7?IW=^^YSTA_LYXQN:6=5!4DD*@^G4_C6>268D]2<FNP_X5;XQ/72T_\
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MY[9J#0O&]EIFA6>F7$$TB16UPK$(/DF<ML9>>FUR#]:QO^$#\5_] "\_)?\
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M5)'>@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/+7C H W**** "L/4?&/AS2;Z2RU#6K.VNH\%XI) &7(R,CZ$5N5\Y?$\_\
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M>?\ ]&M4SARHJ,KG<T445F4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M5C9HK+_X1^Q_O7G_ (&S?_%4?\(_8_WKS_P-F_\ BJS*-2BLO_A'['^]>?\
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M +X-'DO_ ,\G_P"^#7US11[7R#D/E2YU75KRQBL;BXN9+6+;LC*\?*,+GCG
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%BLBS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img83127175_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_26.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &< =0# 2(  A$! Q$!_\0
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MGNO_  NCPY_SY:K_ -^H_P#XNC_A='AS_GRU7_OU'_\ %UX511[.(<S/=?\
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MWP/X56XEN'BNM;6"2(S-L"LS X7H#CN/4^M'-I<+'G=3PV5W<6\\\%K-+#
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MP:^<:[#X9ZRVD>-;-68B"\/V:0>N[[O_ (]M_6HG&Z'%V9]%T445S&H4444
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MK.UK=PW"'#Q2*ZGW!S456+&V:\U"VM5&6FE6, >I(']:0'UG1117(;!1110
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M (5?X._Z _\ Y,S?_%T>U0<C/G.BOHS_ (5?X._Z _\ Y,S?_%T?\*O\'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45Q'Q/\3Z[X1\*SZQI,5@R0F,.;G>S99PN HP._4G\*P=8\?^
M((?^$NU6P^PC3O#EU%;_ &66(EKGD"7+@_*>?EP"/44 >JT5Y]J/B_5M3\80
M:%X?FMK:/^Q3J[7%Q"9-^2%1,!A@<@D]>>,5N^"?%<?BOP5I^ORHELUPI$J%
ML*KJQ5L$]B1D>Q% '245%%<P3,5BGCD8#)"N#4M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYX(KF)HIHUDC;JK#(-)WZ#5KZDE>:MXEUX>*S '?_CX\L6VWC;G&/R[UW?\
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M>#O^@Q_Y+3?_ !%?.TBJC860./4 C^=,KV%3BU='B.33LSZ[HH[45B6%%%%
M!1110 4444 %%%% !1110 4444 %>%^.KC4+SQ5XSDT^XOKV+3=/MV,D%V\
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M]AHKR+_A>/\ U+O_ ).__:Z/^%X_]2[_ .3O_P!KK7V<C'F1Z[17D7_"\?\
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MVU_]%/3ELQ+<^C:***Y34*^7/%G_ "..M_\ 7_/_ .C&KZCKY<\6?\CCK?\
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M4 %%%% !1110 4444 <=\1[_ ,*Z=H$$WBRR2]MS.%MH&3.Z4@XY)"KQGEB
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MA!__ $7'6=3X2H[GHU%%%<YH<C\4/^2=:K_VR_\ 1J5\Y5]&_%#_ ))UJO\
MVR_]&I7SE6]+8SGN%%%%:DA1110 5UWPO_Y*+I7_ &U_]%/7(UUWPO\ ^2BZ
M5_VU_P#13U,MF-;GT;1117*:A7RYXL_Y''6_^O\ G_\ 1C5]1U\N>+/^1QUO
M_K_G_P#1C5K2W(F8]%%%;D!1110 4444 ?7?:BCM17&;!1110 4444 %%%%
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M#T_]&25YS73#X492W"BBBK$%%%% !7NOP7_Y$Z[_ .P@_P#Z+CKPJO=?@O\
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M%?&C_D<;3_L'I_Z,DKSFO1OC1_R.-I_V#T_]&25YS73#X492W"BBBK$%%%%
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MZF6S&MSZ-HHHKE-0KY<\6?\ (XZW_P!?\_\ Z,:OJ.OESQ9_R..M_P#7_/\
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M]A!__1<=9U/A*CN>C4445SFAR/Q0_P"2=:K_ -LO_1J5\Y5]&_%#_DG6J_\
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MG_8/3_T9)7G->C?&C_D<;3_L'I_Z,DKSFNF'PHREN%%%%6(**** "O=?@O\
M\B==_P#80?\ ]%QUX57NOP7_ .1.N_\ L(/_ .BXZSJ?"5'<]&HHHKG-#D?B
MA_R3K5?^V7_HU*^<J^C?BA_R3K5?^V7_ *-2OG*MZ6QG/<****U)"BBB@ KK
MOA?_ ,E%TK_MK_Z*>N1KKOA?_P E%TK_ +:_^BGJ9;,:W/HVBBBN4U"OESQ9
M_P CCK?_ %_S_P#HQJ^HZ^7/%G_(XZW_ -?\_P#Z,:M:6Y$S'HHHK<@****
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M\4/^2=:K_P!LO_1J5\Y5]&_%#_DG6J_]LO\ T:E?.5;TMC.>X4445J2%%%%
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M5>TW4+^\D=;S1;BP51E7EFB<,?3Y&)H TJ*** "BBB@ HHHH **** "BBB@
MHHHH QM;\*:+XAFBFU.S,LL2-&LD<SQ-L;[R$HP)4]U.0?2M.UM;>QM(K6UA
MCAMX4"1Q1KM5%'   Z"IJ* "BBB@ HHJGJS,FC7SHQ5EMY""#@@[30!<HKPC
MP7KE_P")[?PCH&KW^HZ?8R6\EREP9F635I4=@8Q(&W!5!Y'5L=A@U"9M7N='
M^(=Q:V^LW5S8ZM>):W5OJC1"T1#D +Y@)"C)P%.1Q0![[17+^%?$L6H:'HZ%
M[Z^FEM8M]\+*012OL&YMV-HYSGT/%<WXDCNH?C%X2LSJNHO9:C'?":U-P5C
M$)P %QTSP3DC YXH ],HKRV*R.H_%Q]-T6\OK:RT.R,EV_VR657N91B-65F(
M(4?-CU!!JGIT5Y;?$/1=*\/ZYJFK260F/B&]GN7DMSN&45E)*!P<@!<$#Z'
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D K,/+C#'DA<?>.2,YZ5LT4 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img83127175_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_27.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( ;,# 2(  A$! Q$!_\0
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M]^H__BZ\*HH]G$.9GNO_  NCPY_SY:K_ -^H_P#XNC_A='AS_GRU7_OU'_\
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M\*ZCIMY<PS:G)>"<)>WTEOYR[% _>*<DC:>/I6M8^(M.U'5?$5C=OIB7ETD
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MDSV5U_9,DPCEN8\# Z$C/7'K@BHY/!NJWFN:K9Z-87-U;V5W+ )#CHK$ %N
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M45U__"K_ !C_ - ?_P F8?\ XNC_ (5?XQ_Z _\ Y,P__%T^9=PLSD**Z_\
MX5?XQ_Z _P#Y,P__ !='_"K_ !C_ - ?_P F8?\ XNCF7<+,Y"BNO_X5?XQ_
MZ __ ),P_P#Q='_"K_&/_0'_ /)F'_XNCF7<+,Y"BNO_ .%7^,?^@/\ ^3,/
M_P 71_PJ_P 8_P#0'_\ )F'_ .+HYEW"S.0HKK_^%7^,?^@/_P"3,/\ \71_
MPJ_QC_T!_P#R9A_^+HYEW"S.0HKK_P#A5_C'_H#_ /DS#_\ %T?\*O\ &/\
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M  J_QC_T!_\ R9A_^+H_X5?XQ_Z _P#Y,P__ !=',NX69R%%=?\ \*O\8_\
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M<ZQ D'V#3;:[9E/F^9=F'8>.GR-GO^51OX7T*35_[6?2;1K_ 'B3SS$-Q<#
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M7!5W%A_R#K;_ *Y)_(5H9%BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C>X@BFBADFC268D1HS
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ML+#U(]^M='0!R6E7UQ?>/;E[G2KS3F72XP$NFA8L/-?D>7(XQ]2#76USZ?\
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M3^0KAZ[BP_Y!UM_UR3^0H L4444 %%%% !1110 4444 %%%% !1110 4444
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M2?R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8WU--H **** "BBB@ KN+#_D'6W_ %R3^0KAZ[BP_P"0=;?]<D_D* +%%%%
M!15+5=7L-$L_M>HW*V]ON";V!/)Z#@5A_P#"Q_"/_0:B_P"_;_\ Q-.S87-N
M]NK^"55M=.^TH5R6\]4P?3!K!\1:QK=MHLSKIIM,D*9UG5R@/L/RS[T__A8_
MA'_H-1?]^W_^)IK_ !#\'RQM')J\#HPPRM$Y!'N-M<];#U)Q:C-J_I_E?\3I
MH8BG3E%R@G;U_P [?@<QX3UG5UU<0P^;>K(&+PO)QTSG)Z?UZ5W?]H:Q_P!
M+_R;3_"N7T+QCX.TQ+K_ (F%M"\EQ(5*QMDQ[OEY Z8[5K?\+'\(_P#0:B_[
M]O\ _$US8'"5J=%*4W^'ZIG7F&,HU:[<::_']&CJ1G R,&BN6_X6/X1_Z#47
M_?M__B:M:?XV\.:K?Q65CJD<US+D)&$<$X!)ZCT!KT>5GE71OT444AA1110
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M%];7:)I<:LT$JR 'S7X)!KJJYRWABA^(,XBB2,'2HR0B@?\ +5ZZ.@ HHHH
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M/M=M_P _$7_?8KKO^$3\-_\ 0OZ5_P" 4?\ A1_PB?AO_H7]*_\  */_  H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img83127175_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_28.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '! 74# 2(  A$! Q$!_\0
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MO_?J/_XY7A=%'LXAS,]T_P"%T^'/^?'5?^_4?_QRC_A=/AS_ )\=5_[]1_\
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M_P#/[I7_ ']D_P#B*.>/<.5GGL$\UK.D]O-)#,ARDD;%64^H(Y%2KJ5\M_\
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MI7_?V3_XBCGCW#E9YS17HW_"E_$?_/[I7_?V3_XBC_A2_B/_ )_=*_[^R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'FE[?\ B.P^)>K++J?G0CP[=7=E9PH1%&5E4(2N?G?U
M/O@<5APZQJ4-LEC#K%]-:7D6B27-P]T[R1&YD*S%9,YCWJ!TP!GY0N:]@^QV
MIOA?&VA^UB,PB?RQY@0G)7=UVY ..F15>+0](@L[FSBTNRCM;HLUQ"EN@24G
MJ77&&SWS0!S?A75M0C\-73?9;_5S;:I=VD'ERQF5H4F=48O*ZAL  9W$GWYK
M7L/$4EWK*:7=:)J.G3R6[W$9NF@975&16QY4KX.9%ZXK7M;6WLK6.VM((H+>
M)=L<42!40>@ X K#N?\ DHFE_P#8)O/_ $;;4 =#1163XB\0V7AG2_[0OUE:
M'>(\1*&;)SC@D>E &M17GW_"Y/#/_/+4?^_*_P#Q5'_"Y/#/_/+4?^_*_P#Q
M55R2["NCT&BH[>9;FVBG3.R1 ZYZX(S7,^(/&4>@>((-.F2-_M%KO@3=M:28
MRI&JY/"J2W)/3]*D9U5%<#KWC'5M$U:>QE:Q4VNEQWTI%G/*)'9Y05#(?D4"
M,?,P/4G'&*[!KF\GT5+FSB@%W+$C*LLF8U+8SEEZ@9)XZX]\T 7J*XFR\6ZK
MJEE:Q6$%FU]->3VYDD5T15B4MN,9PZEOE&UNF[=R,9@A^(?V^339+8V-M!/;
M6EQ*MV[[B9SP@91A,8X9N&8A1CK0!WM%<GHWBYM7\0R6BR62VYEN(HXLN)LP
MN4+;L;&R03M'*@J3UP.LH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGKG_DH
MFF?]@F\_]&VU=#7/7/\ R432_P#L$WG_ *-MJ .AK,U[0;'Q'IOV#4%=H-X?
M"-M.1TY_&M.H+N\MK&'SKJ=(8\XW.<#--7OH*325WL<9_P *C\*_\\;K_O\
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M";S_ -&VU '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %<]<_\ )1-,&?\ F$WG_HVVKH:YZY_Y*)I@S_S";S_T;;4
M=#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<]XH%_:V,NH6FI
M2PB/8ODJBD$EP,Y(SW_2M>PMI[6 QSWDETY;/F2* 0/3C_/-8QJMU'3Y7IUT
M_P _(WE12I*IS+72VO2WEYEJBBBMC **** /&O&'_(V:A_OC_P!!%8=;GC#_
M )&S4/\ ?'_H(K#KZ2C_  X^B/SC&?[S4_Q/\SUOP#_R*L/_ %T?^==-7,^
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M^E>6V'BW6CI45K<:GJ*:E?R:7G[3!;@PQW,FUY(2F1@\@*XRN!US7KI 92K
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M))R:R;D_\7$TL?\ 4)O/_1MM70USUS_R433!G_F$WG_HVVH Z&BBB@ HHHH
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M8LS,3R222:R[G_DHFE_]@F\_]&VU '0T444 %>"7?_'[/_UT;^=>]UX)=_\
M'[/_ -=&_G7IY;O+Y'S/$GPT_G^A#7N.@_\ (NZ9_P!>D7_H KPZO<=!_P"1
M=TS_ *](O_0!5YC\,3#AS^+/T-"BBBO)/K0KSCXF?\?NG_\ 7-_YBO1Z\X^)
MG_'[I_\ US?^8KKP7\9'DYW_ +E+Y?FCA:[SX9_\?.H_[B?S-<'7>?#/_CYU
M'_<3^9KU,9_ E_74^8R?_?:?S_)GHM%%>:_$GQZ-!GN-"FTH7MM=6),NV<HY
M5]RE1@9S@=?>O!2;V/O6['I59/B?_D6-1_ZX-7R[HVNZ/I_B>34!X6OVA62"
M2RB>\FQ Z\L6/\0)P>>F*]VTSQC+XP\%Z[<2626OD)L 60ONR,^@K2G%\Z?F
MCGQ+7L9^C_(X"KFD_P#(9L?^OB/_ -"%4ZN:3_R&;'_KXC_]"%?0R^%GYW2_
MB1]4>ZT451UC6+/0M,EU&_D,=M$5#L%+$9( X'/4BOF3],+U%>*>(/VAK72M
M:GL]/\//J%K&%V7)NC#ORH)^4QG&"2.O:NL\'?%C1_%5M8K+$]EJ-V[(+3YI
M I!('S[0.0,_C3LP.9\8?\C9J'^^/_016'6YXP_Y&S4/]\?^@BL.OHZ/\./H
MC\XQG^\U/\3_ #/6_ /_ "*L/_71_P"==-7,^ ?^15A_ZZ/_ #KIJ\'$?Q9>
MI]WE_P#NE/T7Y'$>+OB;I'AJUD-L]O?WL4_DR6INE@*]<G<XQP1TKG_"WQQT
M_7]2%O?:?#I=OL8^?)?I(<CML W<^O2O-/&2*_C+6PZAA]NFX//\9K#6*-#E
M(T4^JJ!0J1T\Y]">/+VVU'PM8W=G,LUO+< I(O1AM:O.*ZB;_DD?A[_?_P#B
MZY>O6P*M2^;/BL]_WQ^B.H\ ?\C1'_UR>O6:\F\ ?\C1'_UR>O6:X<P_B_(]
MSA__ '1^K_0****X3W HHHH **** "BBB@ HHHH **** "BBB@ KGKG_ )*+
MI?\ V";S_P!&VU=#7/7)_P"+B:6,_P#,)O/_ $;;4 =#117&7GQ8\#V%[<6=
MUK\4=Q;R-%*AAE.UE.",A<=10!V=>"7?_'[/_P!=&_G7NMG=P7]E;WEK)YEO
M<1K+$X!&Y6&0<'GH:\*N_P#C]G_ZZ-_.O3RW>7R/F>)/AI_/]"&O<=!_Y%W3
M/^O2+_T 5X=7N.@_\B[IG_7I%_Z *O,?AB8<.?Q9^A=EE6&%Y7SM12QQZ"O'
MO&'QN%@+9O#:6L^5<S)?02AB1C:$V<<\]<=J];U#_D&77_7%_P"1KY-KS81Y
MCZN3L>L^#_C:E^ETWB1+:$J(S"MA!*2,[MP??Q_=QC/?VK9^)#B2YTUU^ZT3
M$9^HKPT]*]O^(/72/^O<_P!*Z\)#EK1^9Y.<N^"G\OS.*KO/AG_Q\ZC_ +B?
MS-<'7>?#/_CYU'_<3^9KT,9_ E_74^:R?_?:?S_)GHM>#_&7_D=(/^O&/_T-
MZ]XKP?XR_P#(Z0?]>,?_ *&]>)3^(^[EL>>5ZE\.?^1 \3?4?^@UY;7J7PY_
MY$#Q-]1_Z#70OB7JCFK_ ,&?H_R,>KFD_P#(9L?^OB/_ -"%4ZN:3_R&;'_K
MXC_]"%>U+X6?GU+^)'U1[K7&_%/_ ))YJ/\ O1?^C%KLJXWXJ?\ )/-1_P!Z
M'_T:M?-1W1^EO8^=JZ/P%_R/>C?]? _D:YRNC\!?\CWHW_7P/Y&NF6QDMSL_
M&/\ R-FH?[Z_^@BL.MSQC_R-FH?[Z_\ H(K#KVJ/\./HC\^QG^\U/\3_ #/6
M_ /_ "*L/_71_P"==-7,^ ?^15A_ZZ/_ #KIJ\'$?Q9>I]WE_P#NE/T7Y'R]
MXP_Y'36_^OZ;_P!#-8M;7C#_ )'36_\ K^F_]#-8M:K8V9[%-_R2/P]_OC_V
M>N7KJ)O^21^'O]\?^SUR]>E@OX7S9\;GG^^/T1U'@#_D:(_^N3UZS7DW@#_D
M:(_^N3UZS7!F'\7Y'N</_P"Z/U?Z!1117">X%%%% !1110 4444 %%%% !11
M10 4444 %<]<_P#)1=,_[!-Y_P"C;:NAKGKG_DHFF#/_ #";S_T;;4 <K\9K
MB>WT/36@FDB8W)!,;E2?E/I7A,T=U/=)<OJVI^;&6,;?:FS'NZA3V!Z<5[E\
M;/\ D :9_P!?1_\ 0#7B=;P2<=3.3U/1?A!=W<OC Q3W=Q,JV;_ZV5GR05Y.
M>]17?_'[/_UT;^='P=_Y'=_^O.3_ -"6B[_X_9_^NC?SKT,#\<OD?-\0_!3^
M?Z$->XZ#_P B[IG_ %Z1?^@"O#J]QT'_ )%W3/\ KTB_] %+,?AB9<.?Q9^A
M/J'_ "#;K_KB_P#(U\F]J^LM0_Y!EU_UQ?\ D:^3>U>?2ZGU4P/0U[?\0>ND
M?]>Y_I7B!Z&O;_B#UTC_ *]S_2NO#_QH_,\G./\ <I_+\SBJ[SX9_P#'SJ/^
MXG\S7!UWGPS_ ./G4?\ <3^9KNQG\"7]=3YO)_\ ?:?S_)GHM>#_ !E_Y'2#
M_KQC_P#0WKWBO!_C+_R.D'_7C'_Z&]>)3^(^[EL>>5ZE\.?^1 \3?4?^@UY;
M7J7PY_Y$#Q-]1_Z#70OB7JCFK_P9^C_(QZN:3_R&;'_KXC_]"%4ZN:3_ ,AF
MQ_Z^(_\ T(5[4OA9^?4OXD?5'NM<;\4_^2>:C_O1?^C%KLJXWXJ?\D\U'_>A
M_P#1BU\U'='Z6]CYVKH_ 7_(]Z-_U\#^1KG*Z/P%_P CWHW_ %\#^1KJ>QDM
MSL_&/_(V:A_OK_Z"*PZW/&/_ "-FH?[Z_P#H(K#KV:/\./HC\^QG^\U/\3_,
M];\ _P#(JP_]='_G735S/@'_ )%6'_KH_P#.NFKP<1_%EZGW>7_[I3]%^1\O
M>,/^1TUO_K^F_P#0S6+6UXP_Y'36_P#K^F_]#-8M:K8V9[%-_P DC\/?[X_]
MGKEZZB;_ ))'X>_WQ_[/7+UZ6"_A?-GQN>?[X_1'4> /^1HC_P"N3UZS7DW@
M#_D:(_\ KD]>LUP9A_%^1[G#_P#NC]7^@4445PGN!1110 4444 %%%% !111
M0 4444 %%%8'B[5[K1]+M6LC&MS=W]M9))(NX1^;*J%L9&2 3@>N* -^N>N?
M^2B:8,_\PF\_]&VU5M"\5*V@W-WK<T<;VFHW%@TL<38D,<K(&VC)&0HSVSGZ
M5FS^+]#;QSI]TMZQ@33;J-F\F3 9I;<@=.X4_E0!F?&S_D :9_U]'_T UXG7
MK7Q7U[3]<T:PATR66YDCN"S+'!)P-I&?N^]>4>1<?\^EU_X#O_A713:Y3.2U
M.]^#O_([O_UYR?\ H2T7?_'[/_UT;^=5OA??0Z/XL>ZU%9[>#[*Z;WMWQDE2
M!]WV-%S?P/=3,HF*EV(/D/Z_2NW!SBI2N^Q\_GU*I4C3Y(M[[+T'U[CH/_(N
MZ9_UZ1?^@"O!OML7]V?_ +\/_A7K>C^,] M]$T^&6^*21VT:,I@DR"%&1]VE
MF$XRC&SN9</T:E.I-SBUIU1TNH?\@RZ_ZXO_ "-?)O:OI.]\;>'I;"X1+\LS
M1,% @DY./]VOF_R;C_GTNO\ P'?_  KAI.USZ:8P]#7M_P 0>ND?]>Y_I7B?
MD7)'%I=_^ [_ .%>L^-=>T[4#IOV2627RH2K[8)/E/''W:Z</**K1;?<\O-H
M2G@YQBKO3\SG:[SX9_\ 'SJ/^XG\S7G?VV+^[/\ ]^'_ ,*[#P#XATS3+B^-
M[/)")%0+N@DYP3_LUVXNI!T9)-'SV4X>M#&0E*#2UZ/LSUFO!_C+_P CI!_U
MXQ_^AO7J_P#PG/AS_H(G_OQ)_P#$UX]\4M0@UGQ5#<Z<)[B!;1$+I!)@,&?(
MZ>XKQJ?Q'VTMCAJ]2^'/_(@>)OJ/_0:\P\BX_P"?2Z_\!W_PKT/P/JMIIO@S
M7[2\,T-Q<$>5&UO)E_E[?+70FKKU1SUTW2FEV?Y%.KFD_P#(9L?^OB/_ -"%
M9?VV+^[/_P!^'_PJSINHV\.J6DDGG*B3(S$P/P PSVKV)58<K]Y?>?"4L+74
MU[CW[,^@*XWXJ?\ )/-1_P!Z'_T8M:/_  G/AS_H(_\ D"3_ .)KE_B'XHTC
M5?!-]9V%S)/<2-&5C2"3)Q(I/\/H#^5?.QW1^B/8\-KH_ 7_ "/>C?\ 7P/Y
M&N?\FX_Y]+K_ ,!W_P *W/!TOV#QAI=W=PW$4$4X9Y&MWPHP>>E=+:L9I';^
M,?\ D;-0_P!]?_016'5[Q/JUG>>)+VXMVEDB=AM80/@_*!_=K)^VQ?W9_P#O
MP_\ A7K4:L%3BFULCX3%X:N\1-J#W?1]SV/P#_R*L/\ UT?^==-7G_@WQ9HM
MAX=BM[J[:*4.Y*M!)GD_[M;_ /PG'AW_ *"!_P"_$G_Q->)7:=637<^UP"<<
M+33WLCY_\8?\CIK?_7]-_P"AFL6MCQ,S7GBK5KFWM[F2&:[E>-Q;OAE+$@CC
MWK*\BX_Y]+K_ ,!W_P *U35C9H]?F_Y)'X>_WQ_[/7+UL2ZU8GX:Z)IP>7[9
M"V9(O(DRH^?_ &?<5S_VV+^[/_WX?_"O0P=2"IV;ZL^1SJA5GBFXQ;5ET9V'
M@#_D:(_^N3UZS7BW@S6K'3_$*3W<DL47EL-S028S_P!\UZA9>*]%U&\CM+2\
M,D\F=J^2XS@9ZE<=*XL=)2JW3Z'M9%3G#"M35G=[_(V:***XCV0HHHH ****
M "BBB@ HHHH **** "J6JZ5::S8FSO$9H]ZR*4<JR.K!E92.00P!'TJ[10!2
MTK2K31K$6EFC+'O>5B[%F=W8LS,3R222:NT44 %%%<-\6-1\0:3X)O+[0KJ&
MT$";YYRNZ4#<H"QCH"<G)/0#CD\ '<T5S?C.YO\ ^Q3:Z-,PU"2ZMHSY,R)(
MD;2KO(W< E P'_UJX34?%]]-%%#92ZU;6UG8W]S>E9(6N$EMY51LL^5D5,L0
M%/S97/? !Z_14%G<)=V-O<Q,S1S1K(K,N"01D$CM4] !114=P<6TI\[R?D/[
MWCY./O<\<=>: )**XSPEJ%Y;:UKVDZIJDEP+.2V^S-<LA9TDCP'W* /G=7(7
MJ,>A%4K&_P#$$OCOQ%INJZM#:P+IB2VIME&RU5I)%5R7&"^%!)/&>,$#- 'H
M%%<GX*N[][C7]-U&ZGGET^_$<2SE6=(FB1TRZ@!LY+>HS@YQ764 %%%% !17
MFNN>)-0MO'-VDUQJ-OI>GSV$0-H(BA,Y()D5OF<,2%.WE0,CFM#XB:S)8Z;"
M^EZO=KJ<YDMM/L; ([7%UQ@MD'Y4QE@<#!.><"@#NJ*\]GU?5+#QEOUC[:NG
M-<V=A ]K.@A\]TR2R9W%2[!?; /3->A4 %%%% !16-XI?5H_#MV^BRV\-X$)
M$UPI98U RS #JP'0'C.,\5P6H^(-27X:^&KY-9OSKM_8JEG:VJ(TEY=LBE7?
M(/R+R6Z#!.><4 >K45R?BBYU=M,TVSTQS)J#WL"7BVMPD;JFTN^"W3.W'3.#
MTK2\)ZI;ZSX8LKZV:Y,;AE/VI@T@9796#$<'#*1D<''% &U1110 445@^,+Z
MWTSPY-?WFK2Z9:6[+)--"%WNH/\ JUST+' XYYXH WJ*\GGU;Q3::'HU[K":
MFL-GIMU>:DMM/%%/M$B^5O!QEEC#$@  MD>U>IV\J3VL4T98HZ!E+=2",C-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img83127175_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_29.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L 6H# 2(  A$! Q$!_\0
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MRBOG/_A:'C'_ *#'_DM#_P#$4?\ "T/&/_08_P#):'_XBCV3#G1]&45\Y_\
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MW5FCM\\*5P>BD<GGWHYV'*>-45Z'\+%;;K[PY@NEM (;T1>9Y!)(^Z,DYX/
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MS9F&,8<Y^8?6MN+P/?W.K-8VM]IMQ$EO]IEO8KC-O$F2,L^.#P>,?IFJ.O\
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MOMXV\/'XESZO_:'^@-I?V<2^3)S)N!QC;GIWQBLZPUOPWK.F>&9=3U9M.NM
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M(I9F. H&23Z5Z1X-^%5[J4J7FO126ED,$0'Y99?J.JCZ\_SJ6TMP2N:/P?\
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M_P *O\'?] ?_ ,F9O_BZ/^%7^#O^@/\ ^3,W_P 777T4<S[A9'(?\*O\'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT- !1110 4444 %%%% !1110 4444 %5KO4+2P56N[F* .<*9&QFK-,EABF
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MIW_7S'_Z$*Z.2/8YN9GU;1117,:F%XU_Y$G6O^O.3^5?,-?3WC7_ )$G6O\
MKSD_E7S#6]+8SF%7M-_Y?/\ KV?^E1P+9&/,\DZOGHB C^=6K>73;?S<2W!\
MR,QG*#C/?K7-BJO-!P46WZ,[,+2Y9QFY)+U78RZ*O>7IG_/>Y_[]C_&JDHC$
MK"(L4[%A@UT4ZJF[)->J:.:I1<%=M/T:9V_PC_Y'N+_KWD_E7T#7S]\(_P#D
M>XO^O>3^5?0-35^(4=@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#GK'_ )*#KG_8-L?_ $9=5T-<]8?\E US_L'6/?\ V[FNAH ****
M"BBB@ HHHH **** "BBB@#Y2UK_D.ZC_ -?,G_H1JC5[6O\ D.ZC_P!?,G_H
M1JO;VD]V6$$9<KR<$<5TRG&$>:3LC.,)3ERQ5V+9?\?]O_UU7^8HO?\ C_N/
M^NK?S-7;72;Z.[A=K=@JR*2<C@9HNM)OI+N9UMV*M(Q!R.1FN'ZW0]O?G5K=
MUW._ZIB/J]O9N]^S[&75[1?^0[IW_7S'_P"A"J]Q:3VA43QE"W(R1S5C1?\
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MSSO ^\2C++U(YZ<UJ6'_  D'VH?VA_9GV?!S]G\S?GMUXJOX9Z:O_P!A.?\
MF*W:Y\-3<H*;D_O.C%55&<H1@DO0****[3A"BBB@#Y2UK_D.ZC_U\R?^A&J-
M7M:_Y#NH_P#7S)_Z$:HUUHQ"BBBF 5>T7_D.Z=_U\Q_^A"J-7M%_Y#NG?]?,
M?_H0I,#ZMHHHKD-C"\:_\B3K7_7G)_*OF&OI[QK_ ,B3K7_7G)_*OF&MZ6QG
M,****U)"BBB@#NOA'_R/<7_7O)_*OH&OG[X1_P#(]Q?]>\G\J^@:YZOQ&D=@
MHHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GK#_DH&N?\
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M0?J:E!#*&4@@C(([T <_8?\ )0-<_P"P=8]_]NYKH:YZP_Y*!KG_ &#K'O\
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M"2?_ !RC_A%?$G_04TK_ , Y/_CE=5I6L6&MVK7.GS^;&DABD#(R/&XZJRL
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)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img83127175_30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_30.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '0 8X# 2(  A$! Q$!_\0
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M%T>(_P#GRTK_ +]2?_%T?\+H\1_\^6E?]^I/_BZ\YHHY(]@YF>C?\+H\1_\
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ML;%71Q@J1U!'8T<L6%V>A_\ "Z/$?_/EI7_?J3_XNC_A='B/_GRTK_OU)_\
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M_O['_P#$4>TB'*SPJBO=?^%+^'/^?W5?^_L?_P 11_PI?PY_S^ZK_P!_8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$B"(^3MX7+2?-GWQC_@(]::6Y,G9K^NA:HHHI%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 5[_ (T^YQU\IOY&L[PCQX+T
M(?\ 4.M__1:UHWW_ "#[G_KDW\C6=X1_Y$O0O^P=;_\ HM: -FBBB@ HHHH
M**** "BBB@ HHHH *K7S,MNI698CYT0W,,@@R*"OU/0>YJS5:^R8%VB$GSHO
M]=TQO7I_M>GOBG'=$5/@99HHHI%A1110 4444 %%%% !1110 561F.I3KYRE
M1#&1$!\RG+_,3Z' '_ 35FJR9_M*<XAV^3'@C_6$Y?K_ +/I[[J:V9$MU_71
MEFBBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_/\ ^H_/@4A[^O/^?TH Z[0?^01&1_>;^9K3K-T'_D$Q_P"\W\S6E0 4444
M%%%% !1110 4444 %%%% !1110 452UC45T?1+_4WB>5+.VDN&C3[SA%+8'N
M<5PWAKXI/XB\366FIHZ+97:F-;R*\64"X2%995V@ E%W;-XX)QZ\ 'HU%%%
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M^UK@@2[C!$"3]PC=)C'OUS_P&J6S(EO'U_1F!XC_ .0DO_7-?PY-9'MC\/\
M/^>*U_$?.I #_GDO\S_G_/.1W'H>@_S]*DL3U';_ #_];\O:E//([_\ UO\
M/^>4!]\]^#_G_/TI>H_+MG_/I_A0!UV@G.DQG_:;^9K2K-T'_D$Q_P"\W?/<
MUI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2O='TO4G5[_3;
M.Z=1M#3P*Y ].13TTVQCE@E2RMEDMX_*A=8E!C3&-JG' QV%6J* *]]_R#[G
M_KDW\C6=X1_Y$O0L?] ZW_\ 1:UHW^/[.NL]/*?^1K/\)9_X0S0L]?[/M_\
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M055C8'5KA?.8D01'RB/E7+2?,/<XQ_P$5:JLCL=2G3SE*B&,B+'*DE_FS[X
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M6:UHW_\ R#[GG'[IN?P-9WA''_"%Z%CI_9UO_P"BUH V:*** "BBB@ HHHH
M*BN)7AMWDCA>9U&1&A +?3/%2T4GJAIV9A3^(9[7R_.T6\3S9!$F6CY8]!]Z
MKEIJ-U<7"QRZ5=6Z'.9)&0@?D<U7\0_=TO\ [",/\S6S7-!3=1IR=E;M_D=5
M1TU34E!7=^K_ ,PJM?9^SICR?]=%_KON_P"L7I_M>GOBK-5KY&>!0L*RGSHC
MM8XP ZDM^'7\*ZX[HX:GP,I>(CC2^W^L'7\:Y7UQ_D__ *_\BNJ\0G&F=?\
MEHO>N4([?4=/\]Z18HZ\>OKU_P _X4G0#G'H?\_A2Y]_\_G]?S]Z.AST_P#U
MB@#:\-?\?<Q X\L8^F:Z:N9\-?\ 'W*?^F0_G_G_ #TZ:@"G?ZMINE>7_:.H
M6EGYF=GVB98]V.N-Q&<9'YU2_P"$N\-?]##I/_@;'_\ %5Y[\<#B'1/3,_\
M[)7C_-:QIW5R'*S/HN'Q/H \6W4YUS3!"UI&HD-W'M)W$XSFMC_A+?#?_0PZ
M3_X&Q_XU\N4<]_SJ88=035]VW]Y=2LYM-K9)?<?6-CJ=AJ<;2:??6UVB':S6
M\JR!3Z$@FE3/]IS_ .IQY,?3_6?>?[W^SZ>^ZO.?@G_R =3X_P"7H?\ H KT
M9$8:E._DJ%,,8$N>6(+_ "X]L@_\"/I0U:Z(>KB_ZV9S_B,_\3).3Q$._N?_
M *U9&.WY?Y_S_2M?Q&?^)DN.T2_S-8_0>V/Y?Y__ %FH+#&0..P_E_\ 7'^>
M@>G'3&?Y_P"?PI2.>0.O/'^?6DYQ[]?QQ_C_ )] #K]"_P"05'_O-_,UI5FZ
M#_R"8_3<W\S6E0!Y]K_Q6LM UR[TN72[B9[=@"ZR* V0#_6LW_A=NG\_\2:Z
M_P"_JUP'Q&_Y*!J__71?_0%KENOH>>*W5.-C-R9ZWI7Q>T_3-.2U_LJ[DVL[
M;MZC.YBW3\:N_P#"[=/_ .@-=_\ ?U:\7H'Z4H480BHK9%3JRG)RENSZPTN^
M74])LM01"BW4"3!&ZJ&4-@_G5NL?PE_R)FA?]@^W_P#1:UL5BR@HHHH ****
M "BBB@ HHHH **** "FEU#A"P#'H,\FG5Y#K=I(WCC4R]M(VLR:UIKZ;*L1+
MBV54\PHV.(P!+NYQR<]>0#U:_P ?V==9Z>4_\C6?X2S_ ,(9H6>O]GV__HM:
MAU+_ (2B62YALK72#;."L;S74JO@CJ0(R!WZ&J&DVWC'2]%L=/%IH3_9;>.#
M=]KF&[:H7/\ JO:@#K:*Y[SO&7_/CH/_ (&3?_&JCGG\:BWD,5AH1D"':!>2
MGG''6*DW9#2N['2T5Y%IWB3QUIL>I7]W:V\]O:PM+,EQ/(H!'8?)P?:K%WJ7
MQ"7Q6(EMK4'S $A2:0PLOUV<C'4]O;%<7UY>S53E>KL=[R^7M94^9:*_4]5H
MKGO.\9?\^.@_^!DW_P :H\[QE_SXZ#_X&3?_ !JNX\\N>)=2GT?PWJ&HVRQM
M/;0M(BR E21Z@$?SKQ[_ (71XD_Y\])_[\R?_'*]&UJR\8:UHMYIKVVAQ+<Q
M&,N+N8[<]\>57F__  I;Q1_S_P"D?7S)/_B*TARVU)=^A!>?%K7K[R!+:Z8/
M(G69=D3CYEY .7Z59_X71XD_Y\])_P"_,G_QRJ&I?"GQ'IB6S2W>E,+BYCME
MVR2<,YP"?DZ5=_X4MXH_Y_M'_P"_DO\ \132I)W[@Y3:2?0Z'P7\3=;\1>*K
M32[RVT]()@Y9H8G#?*A88)<CJ/2O3=04/;(#"TW[^$[5.",2*=WT'4^PKRCP
MQ\,_%7AO7[?54FT:=H0P$9FE4'<I7KY?O7=W \8W$80VFB+AT?*7LP/RL&Q_
MJNAQ@^Q-)N/,FB9)N#1H>(?^09_VT _G7*'OQC\/K6M?P>,+ZV\EK30T^8-D
M7DW;_MG67_PCWBW_ )YZ)_X$RC_VG69H'?\ S_GO31]>>,9^E5;FQ\4V^JV6
MGM!HQDNUE96%S+A0F"<_N_\ :J[_ ,(_XMS_ *O1/7_CZF_^-T ;'AK_ (^Y
MCC_EF/YUTU<;IVG>+]/E:06^AN67;@W4O_QJM'SO&7_/CH/_ (&3?_&J .%^
M./\ J=$Y[S]/^ 5X_7N'C3P?XM\9)9++_8MJ;4N1LN)7W;MOK&/[M<E_PI;Q
M1_S_ &C_ /?R7_XBMH325F9R3;//**[:/X4>))-:N-+%UI0E@MHKAG\R3:1(
MTB@#Y.N8S^8J[_PI;Q1_S_:/_P!_)?\ XBKYXBY6=3\$_P#D ZGQC_2A_P"@
MBO18U U:X;R6!,$0\TGY6PTGRCW&<_\  A7!^#?"WBWP?8W-M&NB7(GE$A9K
MF5<<8Q_JS70*/&*W4D_V31"714*F]FVC:6.0/*Z_-S]!6+:NRN5Z?UT8SQ&?
M^)DO3_5+_,UD<CH/P_2KFH:;XOU"X$S6^AH0@7 NYC_[3]ZJ?\(]XM_YY:)_
MX$R__&Z@L;_+@9_S^/\ GFE^OZU4L;'Q3J%SJ,,<&CJUC<?9I";J7YB8TDR/
MW?I(!]0:N_\ "/\ BT]8]$Z_\_,O_P ;H ZS0?\ D$Q_[S?S-:5<M91>,+*U
M6 6FAO@GYC=RC.?^V56/.\9?\^.@_P#@9-_\:H \.^(W_)0-7_ZZ+_Z M<L.
M@KU;Q#\+_%6OZ]=:H]QHT+7#!C&)I2%PH'7R_:LS_A2WBCM?:/\ ]_9?_B*Z
M%.-C-Q9YY17;:5\*?$FK6 NX;O2D0R21X>23.4D9#_!TRI-7?^%+>*/^?[1_
M^_DO_P 13YXBY6>P>$O^1,T+_L'V_P#Z+6MBN3TJV\8:7I%EIZVFA2+:P1P!
MS=R@L%4+G'E<=*M^=XR_Y\=!_P# R;_XU7.S4Z&BHK4W#6L1NTB2XVCS%B<L
M@;O@D D?A4M( HHHH **** "BBB@ HHHH **** "BBB@ K"U+Q*+'4Y+"VTN
M^U&:"!+BY^R!#Y,;,P4X9@6)V.=J@G"GU .[6#J'AZXGU:?4=.U673YKJW2V
MN2L*2;D0N49-WW7'F-R<CGIQ0!2\7^(?#\?A[7+.\O%F:WM&>ZM+69?M"I@9
M(4G@_,O7^\/45=M/%^D3S3Q3W*6<D=])8HEPZJ9G3;DISR/F'YUAZG\,K/49
M=:8WTB+J:RXW*SM T@4.5^;:0=@XVY]\ "GR>![:_:66SU?9+_:D]T;F!?WL
M+,R[XT=6&WE "#D'&"O% ';T444 <]X@\8Z=X;O8;2]65I9[=YH$C +3.KQH
M(D!(R[-*N!TX)) %5;[QQ'IVHR6EQI-W^X%O]H=9(B(C,VU1C?N;!Z[0?;-3
M^(O!EAXFODN+YB0EC/:H HW1M(T;"5&_A=?+X/O69??#TZE?/=7FHP32S0V\
M<\S6*F7,7.^-RW[LDG/0XH U/%U]:V-O8R7EE?3P1W4<QDM0N(BKKM+[B,@E
M@-HRQYP*K-X_TU+B_B:TO<6HE\M@J'[4T4HA=8QNSD2,J_-M!W YQS4^M>$(
M]5M&M8-0N;2"61GG7/F[BQ!#(7),;J5RI4@+D\'C%*;X=V5Q+J)GNY'BN1/Y
M,9C&(3-,L\F?[X,B+@'& ".<YH OIXM#WEC:?V-J0N;@!IH\1DVRF0QAF^?Y
ME)!(*;OE!;@5T=<*GPRL4?3Y/M?[RUE\QF$"C'^D&X"Q?\\EW$K@9^0X]Z[J
M@ K!T[Q3%J,GF+IUY#IK+(\6HR>7Y#A#@DX8LH."06 ! ^F=ZN4'@QVT>ZT2
M76;DZ/-;S6Z6Z1(KHLF>KX.[;D[>!_M;J *>N^,/#UI=V&KI*^H""SOKB*2R
MD1X]L0C\P'G[W*X_'-=3:ZSIMY>O907MN]Y&@>2W60&1 0#\R@Y'#+^8]:XJ
M]^&UDUBL%QJRPRS0W=JTNPYF>X2)-WSN26"PKQGGVQ70V7A867BE]9CO61'A
M\M[:)2BRMA1OD^8JS +@':#[F@#HJ*** .,M/B3I=_H5WK%I:W4UI9:>+VY9
M=G[LE=PA^]S)CD@<#C)R0*V]$U]=8N+VV:RGM+BS*>8DCHX(<9!#(S#L>.H_
M$5S,'POM++0Y-+L;\VT5QI!TR[\N!0)VYVS$ _?!9\]<[N>E6+30M!T&]NDU
M/5[&">]\EQ;6[BP0>7O"L$5\DG)!.<'8HQ\M !_PD]E#K>H7@TC5!JI^S6"V
MC^4IF4O,8V7YL+G]Z3N(. O R,W[3QQ8W\MJ;2RO9;2:T2[DNPB^7 CHSKO&
M[=G"\X! )4$\UG7OA:"UEN-3O/$B0W;3PO#<SI&B*\9?:77(#N5D*D\'"KC&
M*@7X?:#97=A,-16.+3[*)7,FSS3%'&\8?S.JH5=MV!@X'3G(!U6@ZT==L3=_
MV=>629&Q;H*#(I4,&&UB,<X(SD$$$<5JUSOA'PG;^%+.XAMIQ*L[(?DA6)0$
M144X7@L0H+-W/8=*Z*@"EJ^J0:-IDM_<*[)&54)& 6=V8*JKD@9+, ,D#)ZB
MJ*^)K6VL9;K6XGT18Y1$?[0DC56)7<"KJQ5AC/0Y&#D#%6];TB'7-*EL)I)(
M@S1R+)'C<CHZNC#/!PRJ<'KBL'5_!4^NVUO_ &EK,DUW;W#3QNL7EQJ&C,;(
M%1@VT@D\N3D]<<4 1Z=XGT>U\5ZAID4=P);N^D::9V3RE:.UA8L#G(79L]><
M]L5U%AJ-EJMHMU874-S;MP)(G#*?Q%<C:^ M.@U^2:+4$9D+R&S*!@J26Z6X
M# G)7$1//7D=JWO#&@-X<TR2S:]EN@\S2KNW;8@0!L0,S%4&,XR>2<8&  #:
MK+UW7K/P[917E^VRW>=(6D+ +'N.-S$D84=36I67KNAP:_:VUM<E3##=17+(
MR!@^QMVT@]C0!D?\)Q')::9<6VDWDRZF))+4%XHR\2 $2'>XP&# @'G'4"M.
M#Q!'>>%K37;.QN[B.[ABFBMU51(1)C&<D*,;LDYP "<UST_P_A@L[.);^U-G
MILER]O%?V8GBBAE(/ED%APF" >PP.U6=,TC2'T.*ST;Q DMQ:P1VWVA)UF3;
MNR%:('9AL%>@.#@&@"#0O%VCP1Z;86-K?M;W@CN3-)L(@:ZDE9%;YLG+*XRH
M8?=Y(.:N0>.H+K1UU&'1]2,<\D:62L(U-V'!*NI+X4;06.\J0.HY K/T_P (
MZ3;ZG (=>60V"0?:[8,A.8&D>,GG,:@RGY>F%4< '->Q^&VC064EC;7]O(&^
MSS6\301O&$BWA&=/^6I82$,YQNPO3% '>VEQ]JLX+@PRP^;&K^5,NUTR,[6'
M8CH:FJCHVF1Z+HECI<4LDL=I D"R2G+,% &3[\5>H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "L3Q7'J<NC!=+%PT@N(C.EM(J2O"''F!&) #%<]P?
M0@XK;HH \OGT[QV\:3++J DAM-\$7VE 2_VO*)+M.&808#'H>>2>:A@MM<TG
M7X-+BG>V.LZQ>R21+,-Z0"Y\X3*!T#1AXR?61.XP?5J3:N[=@;L8SCG% "T4
M44 %%%% !1110 4444 %<3J%MXJ?Q?*]M]L%I]HC,,JSQBV6V\G#HR$[C(9,
MD''=?FP"*["[FEM[626"V>YD4?+#&RJS?0L0/S->9+XG\1:O#X3>:*_L9+ZP
MN)[B*SDMXS*RB#:X,I(5?WC#:<-ZT 5[;P_XNFCT>+5#>S11MIMU<23W*LT,
MJB43D'/& 8SQ]1DYKJ_AY=:GJ.D7%_J5Y]J'G?9;>1'W)*D \LS#'&9)!(V1
MV*^E8]]XCUN/79M*DO8[.Q-_:60O%96FB1X&D+'<NS<[!4SR,L !G%%GXDU>
M'4[2RMI)M6MX=6N;)6C\E6N8DMPXR?E0E'++\N/N<\YH ](HK!\%W]UJ?@[2
M[V^=GN9H=TC-C.<GKCC\JWJ ,'QGH]_KWA/4--TV\-K=3PNB-QA\J1M8D$@$
MD<CGBN?OM*UBV\<B\']IW5NVG6\#7,$-LQD=9IF(</C;@.O*@=:[ZB@#S#2?
M#^IZ-JXO+C0[S4;6&[U0>2TT4C?OYD>*9/,?&"BE3R&!<Y'+&J]SX+\0'0;R
MUA,ENY\.2VJPPF)E>1GE9;?+#@*K*N1@>AKU>B@"*V5DM(488944$>^*EHHH
M BN1,;646Y43E#Y9;H&QQG\:\VM--\:306D4KZM! ;FR%T)KN,RD@2?:75D8
MXC.8\#U!("C%=7JFN:I9^+M)TRWTJ2:RNEE,LX9.-H7!&6!&,G(QSVKBX?$'
MB./P?JNL1W5V]U$D_EO=30&W&)]@(1 7!"]-W''- %9D\3>';.[\1ZIYB7EM
M962CS9U!O'CGFW0G!.YFC<8]69>I%>HZ);7=GH=C;W]PUQ>) @N)F.2\F/F/
MTSFN(GUW4C)/?R:N%NH-;@L%TA!&8VC:2-3U7S"Q1VE# C@ XP#E^@^)=:O=
M5T:WN4G%O-J&I0O<,8]LZQO*$4 '<-H4#) SMZGN >AT444 <5J_AG69]8U^
M_CU*66VN](-M#:XC&Z3]]A3\HP!YBD'.2<Y. *R4T75;G3-&6:TUHO87UM+(
MC&" [ CJVWRF&X X)W<X/'>NHU37-4L_%NDZ9;Z5)-972RF6<,G&T+C&6!&,
MG(QSVKD;J]\06NG>,VM?$%X]S87D5G9&X6(K'O$#;CA!DY=A]#TSS0!)I_AK
M5DL=$T\Z.UO<:5#<K=7N^/;>%X73Y2K%FWNRR'<!RO/.*UO"'A_5M)U6UFOY
MYYXUT2WMLRK&/*D5B6C&P#.,]>?J:YJ#Q?X@UN^2*,WUO(^L_8I;.V,2R1%+
M#?)&K2#&!,K')Z@<=1751^,OL_C+3?"YC$[3(8I9G=C+'*L/FX?$?EDE1R%;
MN#@ B@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JI?:5IVI[/M]A:W?EYV>?"LFW.,XR.,X'Y5;H
MH J'2M.82 V%J1)&(GS"OS(.BGCD#TZ5)%96L*0)%;0QK ,0JD8 C&,?+Z<>
ME3T4 ,AABMXEBAC2.-?NHB@ ?0"GT44 %%%% !1110 4444 96M>)-*\/?9?
M[3O(H#=3+#&'=5)+$#/)'RC(R>V:YLWUE!XHU#3D\+:9L2P-Y+=QNF9H'+@
MCR^2QCY!..<Y-=;J&E6>JK MY")1!,L\>>SJ<@_GVJG-X=M9];O-4:642W6G
MKI[*,;50,[9''7+GVX% ''0_$+0Y=*AUVTT6W$Z6<!W2E8F@,DXMS$S;<JJG
M)STP.G-=-::WI$5KILMVEC;R7,[);&U/GQ"1W*\2JH 9F.#G&22.35!/AKHT
M<TTD<MRAFBLXY0"N'-LZ.K'C[S>6H;U JYKO@FSU[4[*\FOKV!;1HW2WA91$
M6202!MI4X)(P2,$C'I0!TU%%% !4!LK1A,&M82)F#R@QC]XPQ@MZG@<GT%3T
M4 0"RM!.9A:PB4OYGF",;M^W;NSZ[>,^G%-.G61O1>FSMS=C&)_*7?P"!\V,
M]"1]"?6K-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img83127175_31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_31.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L H(# 2(  A$! Q$!_\0
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MXU*VVZ<QCD,D;1[I K$J-V./EX;H2:+0"\C>_P"%U:__ - [3?RD_P#BJ/\
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MQ*J3USMQ[5>D\$P7%C9264MW'/*MN9#,@>-O-B,A*8P?EVG/L<YHM +LU/\
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M*_EPN^Y5VJ3ES@#Z^U<?HGC*[U+6K;3YK>U ?>KO$Y(<@R8=.Q3$8SUY<<T
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M8[.>TABW0%VV,20P"Y8=BA+$ ^JGDUTM_?Q:;;&XG24Q+DL8XR^T 9)..@H
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MO^0+%_OR_P#HQJU* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *]]_P @^Y_ZY-_(U'I/_(&L?^O>/_T$5)??\@^Y
M_P"N3?R-1Z3_ ,@:Q_Z]X_\ T$4 7**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *SM?_Y%W4O^O63_ -!-:-9VO_\
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M6C6=K_\ R+NI?]>LG_H)H T:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH R_$4YM_#][)ND4!,%X@2Z D LN%8Y .1P
M>E<M\,Y?,M;L/=7-Q(D<"AYY78F/:VP@-%'P>3D!L]SQ77ZS]O\ ['NO[+2-
M[[9^Y20@*Q]#GCFN;\!Z7=Z<=1-SI-GIRL441V\XERP+YYR=H * +T'. ,T
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M1110 4444 %%%% &7X>_Y L7^_+_ .C&K4K+\/?\@6+_ 'Y?_1C5J4 %%%%
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M7*,5%-.[>Z[!1115D!1110 4444 %%%% !6=K_\ R+NI?]>LG_H)K1K.U_\
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M>)_^>>G_ /?EO_BJ]%^&_BO4?%>G7T^HK '@F$:>2A48*YYR37SU7M/P1_Y
MNJ_]?2_^@"G.*4="(MW/4J***P- HHHH **** "BBB@# UW5=1L-7TJWM(0T
M%P^)6,9;/SHNT$?=^5G?)_N5N32-%"SI$TK 9")C+?3) I]% &!I-Q?66G1P
M2Z-=[U9R=KQ$<N2/X_0U=.I7>#C1KS/;YXO_ (NM*B@#@CK'Q'D)0^%[")6X
M\Q;Q691Z@$X)JO=77Q&F@%H-(C5%(_TN*ZC65\>HS@5Z%+-%!&9)I$C0<%G8
M ?F:?6=2DIMMM[6W_K4UIUG3222T=]5^'IY'GZZA\1I%1I-#MH6AY")<1L)_
M9B3\OX>M7M+UGQP^H1KJOABVBL\'>]O=J[@XXP"V.M=B"",@YIJ2QR%PDBL4
M;:P4YVGK@^AY'YU48J+;[_UH3.;DDK+3^M2A_:5U_P! :]_[ZB_^+J*YOKR:
MUFB71KS<Z,HR\74C_?K7HJB#YS7X6^,@H']E1\#_ )^H_P#&C_A5WC+_ *!4
M?_@5'_C7T0\\,>=\L:XZ[F QQG^7-*LT3QK(LB,CXVL&!!SZ&M/:2)Y4?.W_
M  J[QE_T"H__  *C_P :Z;P'X,\3>&O%*:E?Z23 L+QGRKB-FR<8XW>U>P_:
MK?<%\^+<3MQO&<^E/CD25 \;JZ'HRG(-)U&U8.5&?_:5U_T!KW_OJ+_XNJVH
MW5[=Z7=VT>CW>^6%XUR\0&2I _CK;HJ"CYS7X6^,@H']E1]/^?J/_&C_ (5=
MXR_Z!4?_ (%1_P"-?1$EQ!%GS)HTV]=S 8XS_*E$L;(KAU*OC:P/!STQ6GM)
M$\J/G;_A5WC+_H%1_P#@5'_C75_#[PAXD\+^(WO]0TAC"UNT0\J>-CDD'IN]
MJ]=6>%F"K+&225 ##DCJ*>K*PRI!&<<&DZC:L'*C._M*Z_Z U[_WU%_\75FU
MNIK@L);*>VQC!E*'=]-K&K-%04%%%% !1110 5@3:KJ*>,X--6$?87B#%O+)
M)R');=T&"J+C_;K?HH J:DTHT^80V[SR,A4(A4'D>Y JA87E[;:=;0/HUYOC
MB1&P\6,@ '^.MJB@#G]:GU"_T._LX-'NQ-/;R1H3)$ &*D#G?QUKQ8?#3QQC
M'V!O_ U/_BJ^B:9)-%"%,LB)N8*NY@,D] />JC)QV$U<\%NOA_XSGMK>*/2/
M+>(89Q?)\W_CU5Y?ASX[F??)8DMC'%Y&/Y&OH6@$$ @Y![BHA&,-EW\]]S2I
M4G/XGV\MMM$>2_#SPQXF\,:Y<WFIZ9,\,EN8E$=S&YW;@>A;VKTC^TKK_H#7
MO_?47_Q=:$<L<JEHW5P&*DJ<X(."/J#3JIN[NS-*QS?B%]0U7PYJ-A;Z/=>=
M<6[QIODB R1@9.^O%_\ A5OC+'_(*C_\"H_\:^C*BDN8(@QDGC0+UW.!C_.1
M^=.,W'8&DSP*U^'GCBS25(M*AQ*,-FYC/]:J_P#"K?&7_0)C_P# J/\ QKZ*
M\Q"JL'7#_=.>OTJ,75N2 +B(DYP-XYQUI1:C)R2U>Y4I2E%1;T6WD>6?#GPM
MXB\*:O>76HZ0YCF@$:^3/&QSNSS\PKT?^TKK_H#7O_?47_Q=:".LB!T8,K#(
M93D$4ZAMMW9*5CF/$_\ :.L>&-2TZVT>Z$]S T:;Y(@,D=SOKQK_ (5;XR_Z
M!,?_ (%1_P"-?1E127,$08R31H%SG<P&,=?YC\Z<9N.P-)GS_-\.?'-P(Q+I
MRL(QA?\ 2H^/UJ)_ACXTD8L^F*S'J6NXR?YU]$"1"JL'4J_W3G[WTIJW$+E0
MDL;%LX 8'..OY4HM05HI(J3E-WDVSRSX<>&/$/A/4KZXU'2'*3PJB>3/&QR"
M3S\PKT7^TKK_ * U[_WU%_\ %UHJRNNY2"/4&EH;N[LE*Q7M;B6X5C+:36Q!
MP!*5.[Z;2:L444AA1110 4444 8$.JZB_C.XTUX0+)(LJ?+.?NH0^[IR69<?
M[%7=>%Q)HMW!;6LEQ+/$\:JC*,$J0"=Q'%:5% &;_:5U_P! :]_[ZB_^+K%\
M6IJ>N>%-1TRTT>Y%Q<1;$\R2(+G(/)W^U=910M /G/\ X5;XR_Z!4?\ X%1_
MXU--\-_'%P4,NG!R@PN;N/C]:^@VFB658FD02."50L,L!UP*<2 ,D@#U-4Y7
M:;6J!72:3T9\ZGX7^,V)+:6A)ZDW<?\ C7<_#;P[K_A*?4GU+2)"+E8PGDS1
M-]W=G/S#U%>HLP12S$!0,DD\ 4B.LB*Z,&1@"K*<@CU%-S;5A<NMS/\ [2NO
M^@->_P#?47_Q=8/C2#5/$'A.]TRRT>Y%Q-LV^9)$J\,"<G=Z"NPHJ$[:C/G/
M_A5WC+_H%1_^!4?^-6X?AWXSAL9K7^Q(&$I^^;J/(_6O>VN[9,;KB)<D 9<#
M)/3^1J1I$3.YU7 W')QQZTZEJBM)>?W#IRE3=X.W3[SYU_X5=XR_Z!4?_@5'
M_C7H'PVT+7?"4&I)J6D2DW+QLGDS1-PH.<_,/6O1OMEL 3]IAP "?G' />IJ
MIS;5F0HI&;_:5U_T!KW_ +ZB_P#BZYOQW9ZMXD\+3:;8Z/<"=Y$8>;+$JX!R
M>=U=M14IVU*/G/\ X5=XR_Z!4?\ X%1_XU:3X>>.([![,:3#Y3G)_P!)CS_.
MO?&N[9,;KB)=Q &7 R3T_D?RJ1I$3.YU7 R<G''K1-J=E)7MK\QPE*#;B[7T
M^3/G7_A5WC+_ *!4?_@5'_C7HOPXT;7/">G7T&HZ1,7GF$B>3-$PP%QS\PKT
M,3Q,"5E0X4,<,. >_P!*D!R,CI5.;:LR5%(S?[2NO^@->_\ ?47_ ,75RVF>
M>'?);R0-DC9(5)_0D5-14#"BBB@ HHHH **** "BBB@ HHHH Q?$.B2:Q]AD
MBDM]]I.91%=1>;%)E&7#+D<C=D'L16#+X'U2:2=F\1W #SM,@4N,-AMK'Y^H
M+*,#"X1>*[BB@#AHO 5S;VEQ#!JS("6\I09 N&G:5MP#C.Y6"$C!P..N*W_#
M>AS:%;744]Z;QYYEE,SKAF/EHAW<\DE,_C6U10 4444 <9K?@635=7U/48]1
M$;7UH;0Q/'N1%*;=P&1\V<<^F10O@J[AT&ST^+4HB]O>I=CS(,QH5F,N% (;
M))VY+'CM79T4 <=8^!Q;>3YLEI)'#?O>1Q>02%RA  8DM]_#G)ZC'2MCPQHT
MVA:/]CGE@EE,TDKO;Q&-"78L<+D[1ST'%;-% !1110!Q.N> 9-5U;5M0BU(1
MOJ$ @,<D6Y(U"KR.1\V4&3W'':I1X,NXM#TRPAU&)FL[R*Z'FP91=DA?" $$
M$YQDD\5V-% '!1?#J5)+1EU%8!;W+S(8$(:-3M(52Q/5EW$MGJ1TKH_"V@?\
M(SH@TS[6]TJS22+(ZA3AF+8..IYY/<UM44 %%%% !1110 4444 %%%% !111
M0 5B:SH<NHZKIM_#+;[K3>ICN8?,7#%267D8<;>#SU-;=% '#V_@74D,'G^(
MKF012%\!I!NYCR3\_)8(^>V9#@"HHOA_?0:*EE!K31/&D42%#*$"HK*>-^<D
ML'Z_>4=1Q7>T4 9FA:7)H]A);27'GL]S-/YFW!.]R_/O\U:=%% !7$:QX!EU
M'4]6OHM2"MJ.P-%+$66,)Y1&WD8),9R>X(_NBNWHH X\>#;N'2M$LX=2B<Z;
M<1S@S094;0PP@!!&0W))/2H]/\"M96]FK36<C6;SO C6VY$+IM1<D[BHRQ.3
MD[NO KM** ,KPWI4NB:#;Z?-+%+)%N+/%'L5BS%B0N3CDG@<#M6K110 5Q&K
M> 9=0U+6+V+4@K:D%5HY8MRQA?+(V\C!)C.[U!']T5V]% ''+X,NX=,T2TAU
M*)CIMRD^9H,J-H8;4P01D/R23T%4K;X=2PFPVZG]G^R-(4:V0AHU((5$+$],
MDDG)/3IC'?44 8_A?0CX;\/6^D_:C<B!GVR% IVLY8# ] <5L444 %%%% !1
M110 4444 %%%% !1110!RVK^%KJ^U6^O;:]BA-W;+#O>(M+"5W?ZMPPVJV[#
M <]<'GC*N_AY>WUC)!/KTS[[4P%3O*="0,;^@;;UYPO6N^HH XR7P5?27,<H
MUN95,LTDRY=AAVR%4%\8"_)R",=,'FNHTJS;3M'LK)W5VMX$A+*,!MJ@9 [=
M*MT4 %%%% 'F\OPNE;3/L*:LC(URURS2P%F#,CH0"&'R@,I [$'UXV]6\(7.
MI7QF>\@GA:PFLY%N(CN<2,K8W(5PHV# QGD\UUM% '$S^!9I=-FC%W9/>R:?
M%8_:)K(' #$NV 1DD; /38#S786<'V6R@M^/W4:IQG' QWR?SJ:B@ HHHH \
MWN/A=-)8-:)JR,DET]T[2P%F#.LBD*0P^4!U('8@_P![C;UGPA<ZI?),UY!-
M%]BFM)%N8COD$C*V-R%<*-@P,9Y/-=;10!Y[/\-)KN&YCFUJ2-I[$6LCPQ >
M:<("7!XV_NU&T8XSSR<]W96[6EA;VSR&1HHEC+D8W$ #..V:GHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>img83127175_32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_32.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &T >@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***Y;Q!\0/#_AUGAN+HSW2\&WMQO8'W/0?B::3>P'4T5XW>_&VY9B+#1H
M47LT\I8G\!C^=9Y^-/B+M8Z7_P!^I/\ XNJ]G(GF1[I17A7_  NCQ'_SY:5_
MWZD_^+H_X71XC_Y\M*_[]2?_ !=/V<@YD>ZT5X5_PNCQ'_SY:5_WZD_^+H_X
M71XC_P"?+2O^_4G_ ,71[.0<R/=:*\*_X71XC_Y\M*_[]2?_ !='_"Z/$?\
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M1%SC))P!S3 CHJWJ>F7>CZC+87\/DW4) =-P;&0".02.A%5*0!1113 ****
M);:YGL[B.XMIGAFC.Y)(V*LI]B*]N^'_ ,21KCQZ3K!5-0QB*<<+/[$=F_0^
MW0^&4Z.1XI%DC=D="&5E."".A!J914D-.Q]<T5RW@#Q1_P )1X;CFF(^VVY\
MFX'JP'#?B.?KFNIKF:L[&H4444@"BBB@!&8*I9C@ 9)/:OE?Q!JCZUX@OM1<
MD^?,S+GLN?E'X# KZ6\12M!X8U:9?O1V<S#ZA":^5ZVI+=D3"BBBMB HHHH
M**** "O2_AA)!%X=\6R7,]Q;P+#"7EMSB1!^\Y7WKS2M?0_%&L^&_/\ [)O/
ML_VC;YO[I'W;<X^\#C[QZ5,E=6&G9G9:!8Z/KWBG4;QI]0UFSTZP,T45\^Z2
M5ASM^F2>/4UI:A/:ZOX1\'2)IL-G;7&L!6M8\E,;V!QGL>3^-<._CSQ+)J\&
MJR:D6NX$,:.(D4%"<E2  "/K3-1\;>(-5>V:[OP_V:<7$"B% (W'0C [>AR*
MGE8[H].2YTW25\=11Z+;21V;Q.Z$G$ZL"=K>@!!/XFN;M-,TZY\+^#KAK&$-
M=ZUY<HQG<AE(*GVP /PKEK+QOK]AJ]WJ<5Z#<W@ N"T2E9,# RN,<>U5CXIU
MEH;2(W@\NSN3=P*(D&R4L6W=.>2>#Q[4<K"Z._UK3= NM(\76EKH<%G+HKHT
M5Q&Y+N69LYST'!&.1@^U7YM/\.Z%IC32:3I#V*:6)[=[L_Z3/<$9"LI.<'Z<
M?R\P?Q/K#C5 UYG^U"IO/W2?O<9QVXZGIBO2F^(7A\*DLET]S9+;+%_9DM@&
MD)"XPTS'!]:330)HY3X:V=IJGB^=+JUC>(VLKB,CY5/'3\"16[H%KH=IX:\(
MSW>@VM[<ZG=26CRR'&T&8KN(Z,0,8SZ>]>>Z;KE]HNHR7NERBUE=63A%<!2>
MGS ^U/3Q%JL=KIMLEUB'39O/M%\M?W;[MV<XR>>><U3BVQ)FQ+86^E_%2*QM
M5*P0ZK&L:DYVCS!QFNZ\2V^D:S_PF<3Z1#%>:8B3+>*V9)&*YYXX'&,5Y--J
M]]/K/]KR3[K[SA/YNQ1\X.0<8QU'I5Q_%6M22:F[7N6U-0MX?*3]Z ,#MQP>
MV*'%A<]!M_#NE2:UX#C&FP-'=Z>9+I1'D2'R@=S>O)JG9V^AZ3X9U;5KS0[>
M^:UUV2"-6.-J848]P,G /&:Y>S^('B:PTVWL+74C'#;\1_ND+!1T7)'(]C67
M+K^IS:;<:=)<YM;FY-U+'Y:_-*>K9QD=.@XI<K'='K5]X<\.2:AXBT.#1((&
M@L?M:708EU<C@*#]T# X'%4?!OAW3)]+TNSUG2-+1]2B=HV,KO<S#!;>!C"
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M !T JI5I65B6%%%%, HHHH **** .]^$>K/8>,5LBW[F_C:-AVW*"RG]"/\
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MTKZ8KQOX,:$SWEWKLJD1QK]GA)[L<%C^ P/Q->R5SU'=FD5H%%%%9E!1110
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M\'?] ?\ \F9O_BZZ^BCF?<+(Y#_A5_@[_H#_ /DS-_\ %T?\*O\ !W_0'_\
M)F;_ .+KKZ*.9]PLCD/^%7^#O^@/_P"3,W_Q='_"K_!W_0'_ /)F;_XNNOHH
MYGW"R.0_X5?X._Z _P#Y,S?_ !='_"K_  =_T!__ "9F_P#BZZ^BCF?<+(Y#
M_A5_@[_H#_\ DS-_\71_PJ_P=_T!_P#R9F_^+KKZ*.9]PLCD/^%7^#O^@/\
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M?_%T?\*O\'?] ?\ \F9O_BZZ^BCF?<+(Y#_A5_@[_H#_ /DS-_\ %T?\*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!A>--/NM6\$ZWIUC%YMU<V4L4,>X+N8J0!DD ?C
M7G=IX9\3^'+NVO8-$DU#[1X5ATN2&&>)6AND50 Q9@-G7+#/?VS[#10!Y/-X
M!U?1/!G@BWL(5OKS0+]+JZ@C<#S%9F:786(!(+'&2,_I70>!O#M]:ZIXHU[4
M[1[&;7+M62U,H,D<* A"Q0D!CN)P"<<<UW%% '$^)_#MKI7AN]OK.]UM+B!
M\;-K5XX!R.JM*0?H17;5S_CC_D2]4_ZY?^S"N@H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>!O#][;:SXJUZ_MI+-M;NU:*W=QYB0Q@A6;:?E8[B<9XXH V?''_ ")>J?\
M7+_V85T%<+XN\,V]IX5U"==1U>1HXPP6749G0_,.JEL$?6NZH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Y_QQ_R)>J?]<O_ &85T%<_XX_Y$O5/
M^N7_ +,*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Y_QQ_R)>J?]<O\ V85T% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO?O8[\=B*5:<7)6LEM;M<L131SQB2&1)$/1D8$'\13Z9%%'!&(XHUC0=%08
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M &V_]&O6578J&YU]%%%8&AR/Q0_Y)UJO_;+_ -&I7SE7T;\4/^2=:K_VR_\
M1J5\Y5O2V,Y[A1116I(4444 %%%% 'U'X3_Y$[1/^O"#_P!%K6Q6/X3_ .1.
MT3_KP@_]%K6Q7(]S9!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M.?\ ''_(EZI_UR_]F%=!7/\ CC_D2]4_ZY?^S"N@H **** /"OC1_P CC:?]
M@]/_ $9)7G->C?&C_D<;3_L'I_Z,DKSFNF'PHREN%%%%6(**** "NO\ A?\
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MHHI %%%% !1110 4444 %%%% !1110 445A:YXD?2=2T_3;72KS4+V^+E%A
M6.-5&2SNW"^WK0!NT5PH^)^G3:!8ZA;6%T]Y>ZC_ &9%8N55Q<9P0S D!1UW
M#/!%;OAOQ-#XA.H0&VDM+[3KDVUW;2,&*-C(((ZJ1T/'?B@!GCC_ )$O5/\
MKE_[,*Z"N?\ ''_(EZI_UR_]F%=!0 4444 >%?&C_D<;3_L'I_Z,DKSFO1OC
M1_R.-I_V#T_]&25YS73#X492W"BBBK$%%%% !77_  O_ .2BZ5_VV_\ 1+UR
M%=?\+_\ DHNE?]MO_1+U,MF-;GT91117*:A7SG\4/^2BZK_VQ_\ 1*5]&5\Y
M_%#_ )*+JO\ VQ_]$I6E+<F>QR%%%%=!F%%%% !1110!Z[\#NNO?]N__ +4K
MUZO(?@=UU[_MW_\ :E>O5S5/B-([!1114%'R)WHH[T5V&(4444 %%%% !7T9
M\+_^2=:5_P!MO_1KU\YU]&?"_P#Y)UI7_;;_ -&O6578J&YU]%%%8&AR/Q0_
MY)UJO_;+_P!&I7SE7T;\4/\ DG6J_P#;+_T:E?.5;TMC.>X4445J2%%%% !1
M110!]1^$_P#D3M$_Z\(/_1:UL5C^$_\ D3M$_P"O"#_T6M;%<CW-D%%%%( H
MHHH **** "BBB@ HHHH **** "N*\>ZAXH5[/2O#EE.D=WG[7JD<?F&U3T1,
M\N>>>W'KD=K10!Y-J'A/^S="\)MX=TC4#;:'JZ3W,$Z?Z1*A_P!9+C^(\]!]
M  !6]X$T*]@USQ;X@O+>>S76KM#;PRX$@BC5@KD?PDECP>1BN[HH X7Q=X<^
MR^%=0G_MG6)=D8/ERW6Y&^8<$8Y%=U7/^./^1+U3_KE_[,*Z"@ HHHH \*^-
M'_(XVG_8/3_T9)7G->C?&C_D<;3_ +!Z?^C)*\YKIA\*,I;A1115B"BBB@ K
MK_A?_P E%TK_ +;?^B7KD*Z_X7_\E%TK_MM_Z)>IELQK<^C****Y34*^<_BA
M_P E%U7_ +8_^B4KZ,KYS^*'_)1=5_[8_P#HE*TI;DSV.0HHHKH,PHHHH **
M** /7?@=UU[_ +=__:E>O5Y#\#NNO?\ ;O\ ^U*]>KFJ?$:1V"BBBH*/D3O1
M1WHKL,0HHHH **** "OHSX7_ /).M*_[;?\ HUZ^<Z^C/A?_ ,DZTK_MM_Z-
M>LJNQ4-SKZ***P-#D?BA_P DZU7_ +9?^C4KYRKZ-^*'_).M5_[9?^C4KYRK
M>EL9SW"BBBM20HHHH **** /J/PG_P B=HG_ %X0?^BUK8K'\)_\B=HG_7A!
M_P"BUK8KD>YL@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% '/^./
M^1+U3_KE_P"S"N@KG_''_(EZI_UR_P#9A704 %%%% 'A7QH_Y'&T_P"P>G_H
MR2O.:]&^-'_(XVG_ &#T_P#1DE><UTP^%&4MPHHHJQ!1110 5U_PO_Y*+I7_
M &V_]$O7(5U_PO\ ^2BZ5_VV_P#1+U,MF-;GT91117*:A7SG\4/^2BZK_P!L
M?_1*5]&5\Y_%#_DHNJ_]L?\ T2E:4MR9['(4445T&84444 %%%% 'KOP.ZZ]
M_P!N_P#[4KUZO(?@=UU[_MW_ /:E>O5S5/B-([!1114%'R)WHH[T5V&(4444
M %%%% !7T9\+_P#DG6E?]MO_ $:]?.=?1GPO_P"2=:5_VV_]&O6578J&YU]%
M%%8&AR/Q0_Y)UJO_ &R_]&I7SE7T;\4/^2=:K_VR_P#1J5\Y5O2V,Y[A1116
MI(4444 %%%% 'U'X3_Y$[1/^O"#_ -%K6Q6/X3_Y$[1/^O"#_P!%K6Q7(]S9
M!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** .?\<?\B7JG_7+_P!F
M%=!7/^./^1+U3_KE_P"S"N@H **** /"OC1_R.-I_P!@]/\ T9)7G->C?&C_
M )'&T_[!Z?\ HR2O.:Z8?"C*6X44458@HHHH *Z_X7_\E%TK_MM_Z)>N0KK_
M (7_ /)1=*_[;?\ HEZF6S&MSZ,HHHKE-0KYS^*'_)1=5_[8_P#HE*^C*^<_
MBA_R475?^V/_ *)2M*6Y,]CD****Z#,**** "BBB@#UWX'==>_[=_P#VI7KU
M>0_ [KKW_;O_ .U*]>KFJ?$:1V"BBBH*/D3O11WHKL,0HHHH **** "OHSX7
M_P#).M*_[;?^C7KYSKZ,^%__ "3K2O\ MM_Z->LJNQ4-SKZ***P-#D?BA_R3
MK5?^V7_HU*^<J^C?BA_R3K5?^V7_ *-2OG*MZ6QG/<****U)"BBB@ HHHH ^
MH_"?_(G:)_UX0?\ HM:V*Q_"?_(G:)_UX0?^BUK8KD>YL@HHHI %%%% !111
M0 4444 %%%% !1110 4444 87B?Q1:^&+>R:6"6YN;ZZ2SM;>'&Z21^G). /
M4T[P[XFMO$2WT:036MY87!MKNUFQNC<=#D$@J1R".M<_\1].OIKCPQJUG9S7
M<>E:M'/<Q0(7D$1X9E4<MCT S3/ .CWBZ[XN\07%O=6<6LWB?98ITV2>7&I
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M2?AO_G^U?_O^G_Q%'_"D_#?_ #_:O_W_ $_^(J_:HGD9X;17N7_"D_#?_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>img83127175_33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83127175_33.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E ?(# 2(  A$! Q$!_\0
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M )\M5_[]1_\ Q=>%44>SB',SW7_A='AS_GRU7_OU'_\ %T?\+H\.?\^6J_\
M?J/_ .+KPJBCV<0YF>Z_\+H\.?\ /EJO_?J/_P"+H_X71X<_Y\M5_P"_4?\
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M8M#N/%%S87S:=+=+:VEFLWS+A069FSUR&QSCIZ\'.@L<';V-W=Q32VUK/-'
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M\'?] ?\ \F9O_BZT]JB>1GSG17T9_P *O\'?] ?_ ,F9O_BZ/^%7^#O^@/\
M^3,W_P 71[5!R,^<Z*^C/^%7^#O^@/\ ^3,W_P 71_PJ_P '?] ?_P F9O\
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M#\Z]T\+^$M-\*6/D62%YG \ZX?[\A_H/:MZBLY3<BU%(****@84444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <_<_\E#TS_L%7?\ Z-MJZ"N?N?\ DH>F?]@J[_\ 1MM7
M04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445X-XHUO6TU?Q/>6FN:D(
MK+5+:WAU*WG?[%IZ$XD26$<.5R 3M?DKR#P0#WFBO)M>NKS6_&_BJ#^U;ZWM
MM'T-9[-;.Y>)1,R[Q*=I&XC '.1CM75^%/%?VKX=Z+KFL&;SKF!5D:.W>0L_
M(+;4!(!VD],<T 7KG_DH>F?]@J[_ /1MM705R%KK-EJ_Q"L39M.?*TJZW>;;
M21=9;?&-ZC/3M77T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QMY\--&
MO/[4A^U:A#8:K<BZOK&&51%-)G).=I=<G!(5AT%=E10!R6L_#_3]5U.:_AO;
MW3I;FQ_L^Y6S9 LT&1\I#*<''&X8(!KI-.T^UTK3;;3[*(16MM$L42#^%5&!
M5FB@#G[G_DH>F?\ 8*N__1MM705S]S_R4/3/^P5=_P#HVVKH* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEIT%F5TJZV>5=>=N_>V^<_(N.WKUKKZY^Y_Y*'IG_8*N_P#T;;5T% !1110
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M^Y_Y*'IG_8*N_P#T;;5T% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% &%XB\3V_AE[.74+6X_LZ8LLU]&F^.U;C;Y@'(5LGYN@(&>M<MX?\
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MZ@=ZW? .@:SI?PNT32WO&L-0C0R2%X1(R!W9PA5NA 8#VQ0!LW/_ "4/3/\
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ME>;&5>A)1J1YI.R;1ZDZ5#$1<J4N2*NTG^1[_17SG_PM#QC_ -!C_P EH?\
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M.:]&^-'_ ".-I_V#T_\ 1DE><UTP^%&4MPHHHJQ!1110 5[K\%_^1/O/^O\
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M1110 5]=U\B5]=UC5Z%P"BBBL2SPKXT?\CC:?]@]/_1DE><UZ-\:/^1QM/\
ML'I_Z,DKSFNF'PHREN%%%%6(**** "O=?@O_ ,B?>?\ 7^__ *+CKPJO=?@O
M_P B?>?]?[_^BXZSJ?"5'<]&HHHKG-#(\5_\B?K?_7A/_P"BVKY;KZD\5_\
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M>Y]Z .0N/&/AQO'.GW(UFS,*:;=1M)Y@P&,L! ^I"G\JV_\ A.?"W_0>L?\
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M +^BO"?B)J-GJ/CK4;JSG6>W?RMLD?*MB) <'Z@U]+4549<KN)JY\@^8OO\
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M:XU"S@@EC,LB*KQK@L/D.03V_6@#5\!^*+CQ-X-T[5]4A@L[NZ5B8D;"D!B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>img183574933_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183574933_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #9 HT# 2(  A$! Q$!_\0
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MLPP'V9998IX[FYCU?3C9:E_:[R:Z5NKK3KF90(I98@-MYX@N5 \BUYCLHVA
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M'R]1M6T[4I-1EBM MS<Z7>7 ('F9!74/$EUD@1D&*S$F=H"(9@#G]0T3Q?I
MU&U/Q;^)>BV]MJ=G8M'<>(_[3U"P21=T=DRHA-WJUUG(MXR8[>-D>1VX63.\
M&>&_B-XW_:>/@>Q^,GCW33_9UWJEW%J6JSW5K8BWG2W^Q*T3QI<3K]H5II(V
M,:2HT0+F,L.MTV%M%FL$@C6QO+$W.GP6?AB8WVH6]S<$F72],N')%QJ4F=]_
MJC'$()4,G[R1&_L\0D_MJZ%91VN^SL?A[=VL,<,F[1H/+U*T+0Z<Q&^=(#\K
M73C=/.DK9  " 'JEQ^RW\4+RRE6#XZ^)(99X2]N6%Y&4.T?*[?;&V-D_W6Z'
M@XQ7,?"CX/?$WXL?#;0/&T7QD\1:3%XDLUU*VT^6:[N&M#,7D$;R+<QAD52B
MAEC7/]T<"OK=84N;=U6*"\^UP;E6<!1?#8@W3_NOE/08 /!Z=AY+^R=;K-^R
M[\,C]GMY_M'A:PMPTV ;HB%_W$O[LXB&3@\_>;C^^ >/>+/@G\3?#_Q#\(>'
MU^-7BF>'7[B:$W"S7:"#R(FD8^4;EC(K;U&1)'MV$D/T'8C]E[XF^62_QT\0
M[HL^<%2].[Y,_N_]-^;D@<X[UZ'\2IT3XW?"+-S(FV]U-#M0'839J @^7E3D
M#/\ M'D8X])B@2*",&"WA%IG<(P"+']U_P L/W0W<'N!]X_[M 'R/\*_@U\0
MOBAX4@\1V/QH\6Z=8W$\T*P7]S<W4@2V9[4L'CN(EW.]N9"NWCS3EF/)UY_V
M:_B?/KD5C;?'G76F>U\V6'[3=PO;Q--"5D9#<2%F(BF0*#'G+?/U%=#^S!?>
M,/\ A3NE)8>'_#]_:6U[JDMM+?:U-#*F=1O%,@06,@5N77AVX],FO2/#.E:R
M_C?4=9UZQT"S%UI5JJ6EIJ+W/G>5.\CW,Q>TBV,!(NW Y(.<8! !Y4?V7_B=
M)&6B^.?B%3+%N@$J7HVOM)Q)_IORC.!QGO7!:E\!_BW8VVO7+_&OQ/Y&D:O9
M:=\MS>2%XWG1YKEP+A/+B2&Y5B"7^6%B7QC'V1);I=6\NV"VO1>6H1?M "_;
M_P!VWRS_ +KY5Y[ _>;Y>Q\F\7#Q+<P_%6'1](T2[M+NY:T?4+[4Y+>X;_B7
MP#RVC6RD!12S ?/SD\C)) /.=?\ V8OBD[06EI\>O$*7I$JM$);R%G#0^5YJ
M?Z4^Y(WN(W/ .4 #*<,)]"_9\\>>)M%M-6TK]H+6-4TV=3,EW8M>2PSQ$-M,
M+"^PQR%'IUKV?P=?:_K^MZ;K6K6>E:'IT=@T5O!IVI/=R@SM9NL>QK2(!-J
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M>?0_LZ_$"SU32KRY^)FI:S;V-Y&]S9R/>H)/D^]&9;F=&VE\X:/^$\C%8?\
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MXN+M)684444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD_>7YNY^1? 6O_&3QC\:=>\7VMKX3=7CG\.Z7_:$M[;[A9:@\=Z (1-N7[0
M5+%<Q$$+_K G1W?[1WQ5TGXC6OA2;PAHWBRZU2WNKF.V\+WL\8^SVR 7,T=Q
M.%Y626WC55C*N[2#S%*$4 ?3A:&X,CL;>Z-P&MWDCVXNE7SOW"9DX=?FR3Q]
M[ISM5[F*.=Y!=6<3Q31VPF<#$ 9HO]';]YGS'W#:>/O)P> WC-Y^U!9^&Q=R
M>-_"GBGP7##"3?7]]: 6-NG[T*JSB3;YF["ETWH3M.[:5:M'1?VJ? >L:9#J
MO]L76GP2!S$UWIMR\'E1_--^]B#PR,%BF82([+L!<%E!) /4I9888&(EM8!9
M8V&0*1I_[G_EK^\YX/;'##M\U3)% DWEB!$\J1IQ"=NZ%F:7,[?/]U_FQQGD
MY[A<[2?$VG>((+0Z1K5KJ/F(LMFUO(9LH8N&FVMR#DG)QR5'7KIQ-EHR'NO+
M-PXC#I)N\S=)NW_],_[N<#A<$@K0!# T+S0Q;K=Q< W!A0+NNF#1?Z1'^\.$
M7(R,$_,O/0-S>O\ @/PEXQDMKW5]$T+7+VYM?*%Y]DB\^]C"LP2WD+[D'S,<
M;B,,>>2:ZJ(R[B6DE,8D F CD#&7='M\O_IE][/4<]1AJ;=>>MM-Y\LF5MR;
MHVL4NX_*W,&,G=GL,GIWQ0!X7KO[&GPRU012VL=_I%Q#,3%J5EJ3O/YGFL-D
M<\TCRI)QM.&"L200<E1S/AGX'>*/!?Q]\-0VGQA\5^*M,\B:\FTSQ'?>?)I\
M<#6ADAS"41S+]HC!#J<*01G[U?3\OF"6X!DD\T("^V-]GE[GQLQQYF.N.>G&
M"*\W\)ZH?$7[1'BI%:5[;PWX?T^S1I5?B2[>2:13N^[(%A@9\<L'BW8V#.,H
MQNG;6YZ%&M5<)Q<GRJ+T;NNB5D[VU?2QZK=S/;VDTL<#W,B(S+#&0&D(&0H)
M(&3TY('O7'?"OQ'XK\2:=J,GBO1X=&NH+A8HHXHY$#?ND9_OD[@KLR!U.UMA
M(&.O;T5L>><OXL^(NE>#M1L;&]$\MU=KYBQVZABB>9'%N.2.KRQJ ,L2> :Z
MBLK6/"NB^(;FQN=4TFQU&XL95GM9KJW21[>165E9"P)4AE4Y'=0>U:A&01TS
MZ4 )'(DJ[D977)&5.1QP:=7(_#7X9:5\+-'N=.TJ6YGBN)A/))=>7N+"-(\_
MNT0$D1@DD;F8L2237!?M$>(_B+9:MX0T'X:7<%OK>JFZDF%Q:I.BP1>27E8.
M5 "B3:/F7+R("1G(EOE5S6G3=27*FEZ[:??^1[717QVW[07[0/@.;;XG^'<6
MMVBRM&O]F:5<"X95+X,CI(\ W!#EU;@D;8GW*#I^$/\ @H'I&L6R2ZQX$UNT
MB959[S1IX=0M("R"3$LA,31D(RLQ=  25R65@)]I'KH;_5*K^"TO1I_A=/\
M ^L:*\D\+_M8?"?Q;9M=VOC.SL;=3M>36(Y-.6-N2$<W"H%8@$A6PQ ) P#7
MJ-AJEEJL;265W!>(IVLT$JN ?0D&K33U1S3A.F^6::?FFOSL6J***9 4444
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MD >TOV_3VO+J4:W:SZ8-:GDUR(Z9I.H01DK%=WZ$[K30K<!OLUC]^Z82.RL
M\K)>WK:2]ZS7JV,]HMKJ<]SK&GF\N4N)R!#JNIP@'S+Y]VW3](7/E;HV9%VH
ML,VHRM,][J=\US9PM/#XFN]7\9 L+:%3LAUC5;90N^=R@33]*0*J&,2,@<;8
MU@O6T*8;YM3TF73;]K^X@L+=;V]TV[O%Q&LFX$7OB*\$@&"&BLXI6^55"-,
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M$O\ ,H";<#/..!C(EQB]T;PKU:>D)M?/]-OP/G6+]GKX[>$;Y8?#'Q:GO(1
MIMY-4DN)8\@Y,GV9R4C(W(H3S3'A3^YP0$OZ-X__ &H?!MI!=ZUX5T?QGI0A
MWA[>(07TVV(N 4B<X>5AMSY0$>02C<@?3LQWRA,23[WCD\F*15:4AHOWRGS!
MB-?XE[X/#9 :(,)K"1CYMYYZ*3)!*JB__=9S!^]^3UZCH>3]ZIY$MFU_7S-?
MK,G\<8R]4K_>N5GS?=?MW3^%?-M_%_PNUS2M46)F2RT^]@N)'8#.=DQ@=8\
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MVT37KQ_[.TZ6WC:UC TZV6*;[/80IY@MV9)#,_F.=R,KM[[X8\<W&D:KXP\
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M[AI]K96NEV]M:1V9M9[4*([!5BBO%V$XMU$F$')/<8(Y[UY[\$G6!OB,^Z.
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MW-MY:7KVACFD@_=';,Y4,&!'"$CZ<'&<$DY-'9B9RE"E&;N[7^]MK\$CY_\
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MGB&>;$KJZN^V;>NYO,8E@ V>_)RFE_\ !-SX/:59V,$3^+";.)XHY!XFNXR
M^#*0L;JJ[R-S!54$]J^IJ* /EF/_ ()K_!6&(1QVWB>.,6?]GA%\37H MO\
MGACS/]7_ +'W?:G7?_!-SX,7XN!<P^*+@7,4<$XE\3WK>;'&2T:-F3E5)) /
M ).*^I** /E<_P#!.#X5W,DAU#5/&6J1O(DQCN/$$J9D0J8Y&:,(\CIL0*SL
MQ 4<YYJ9/^"<'P;CF65$\5)*MTU\KKXHO@PN&4JTP/F?ZPJ2"W4@D9KZBHH
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M_P#:$L.L7@C-X(@)G0)(BC+ER-J*.> !Q7%:_P#L.Z==?M"Z#=V.AV8^$R6
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MP^'-+\0ZS<B[37+^[MK:[N;V1+BZ8QVX9K1Y2&<PQO(_EEF9MGE@NP&*ZO\
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MF&(JUJEQXSU+]IKX3^#?%.D:#I,NE1SZK#%X5F>2S>!I0PWI)$C1N6MBZX+
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M//8?2=9T_A3[Z_?J=F+TKRC_ "^[_P" I1_-,****T.,**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_C&SCL9)]*T8:?96B1V"V<;I:B5P9"J[W;>-S' "@"N-\._\$][?X=V+1^
M/&T?@R[U'PC!X;UVXL] AE74;F )Y=^$>3$;.5831G>LJN02'_>5I5251^S?
MNV_&TO\ [7[]GNE2UI)U/BOKZ>[_ /;?=Z7Z2Y_;FTRQ\%Z?K=S\//%$=UJ&
MOVOAZRLUFL'@O9;B%YHI;>^%S]DEBQ&RLRR_(W# =:]Z\ ^*;KQIX4L=8O-#
MN_#EQ<[R=.O;BWGEC <J"7MY)(B& ##:YX(S@Y ^4M#_ ."<FGB=I=>U[0;J
MTN?%FF>)+SPYI7A6.ST.2.SMIH#;I9&=U1IO/+22$L#M4;.,U]>>'/#6D>#]
M$M=&T'2K+1-(M%*6^GZ=;I;V\*DDD)&@"J,DG '<U;4%&ZW_ . O^#_P.N:Y
MKVZ?U^1I4445D6%%%% !1110 4444 %?#_\ P42\1SZ-XC\%J?&Z>&K*/3-2
MN7TO4=:U#0K6_=1$5>"^M#C[;'C]W%,KH?,)V]C]P5FZ[_QZP_\ 7Q'_ .A"
MLJD'.UG:S_S7ZW^7S5PDHWNK_P!)_I;Y_)_G]HG[<_Q.LOB)X.\*Z=X7DN[!
MM*T4IH_B-X/[;U:.YL#/-<^<9XG>2-T*GRK1T8J^]HRRK6KHO[</C2]^%=GK
M?_":>!M1O]3O="AU34+;0[Q+3P0E\9A/]O)G,<IB:-8P#+&P9LR *5S]XR_\
MA:V_ZY2?S6JL7_(/U;_KI+_*MW*\G)KO_P"E7_X&GRTNC.*LE'T_*WYZ_G?0
M^ [[]M[XQ:CHNJW>D3^$H8-!\):QXF;4Y=&N);?7XK'4C;12VR_:E,,4\>&R
M3)C!QD$$:'CO]IGQAXP_:(\&^&9O$NF>&+:Q^)6G::G@^TCFBU6\L&L3+]ME
MF$V)+:1YBNSRMN5C^;((/W]:_P#'M#_N#^5-3_C]E_ZYI_-J(-PK1F]4K:=V
MMW\^VRUL*:]I3<5HVK7_ *^[OIZGQ??>%_%WQ)_;J^(=I;2R:CX;\.Q>'IY;
M:Y\8ZKI*V*2QR-(]O;V@,5PS>624F*J2JC.&8CR'PE^V)\0OAS\'_#%LNOZ3
M9RKHFNZ];ZAXOM[C4)O$M[#K-Q!'I%LXF0K)LV="[ /'A0H)K]-:I:E]^S_Z
M^%_D:47RQ4%_3NW?\=GIIK=;=,ZD9\SY=7;\(I?C9OY]]3X.UO\ ;I^)%EXL
M\11+:>'[*_LM0U/3C\/KBPF;6+"UM],>[CU6:;S0&A:14! B"E7 5RV37UG^
MSAXC\5^-/@OX4\3^,M0TR_UC7]/M]6QI-B]I#;QSPI(L.UI9"Q7<07R-W]T5
MWP_Y#+_]>X_]"-7:OFCRM*.K_!=M?SWZ;6.>W2_]62_/4****S&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>img183574933_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183574933_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #> F,# 2(  A$! Q$!_\0
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MGB.^W,TFHZCJ^G6\TF22 8[2YA@4 8 V1KP,G)))D_X5W\3_ /HKO_EM6O\
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MG>77Q2DOK9]0LK26"'0+2%V2:YBA)5SN ($A(RIZ4 <__P (K\2?^AR^,O\
MWY\%?_(U'_"*_$G_ *'+XR_]^?!7_P C5VWPO^*;ZQX&TJXU6WU6^NH+*T6_
MU6.S61);B2VAF8^7!EAQ,I)$:J,G' KTFQOK;4[.&[L[B*ZM9D$D4\+AT=3R
M"K#@@^HH \9\+Z#XITZ[FGUV;XH^+ 4V10ZI?:#9I#SDLO\ 9[VQ8G '[PMC
MMC)S?\2Z;K>I:<(]'TWXC>&+U7#K?:;JNEW,N.05\N]N)X2#GO'D8&"#7KU%
M 'SS_P (K\2?^AR^,O\ WY\%?_(U'_"*_$G_ *'+XR_]^?!7_P C5]#44 ?/
M/_"*_$G_ *'+XR_]^?!7_P C5UOAO1O[(T:&VU+P!K_B6_#/)/JVM1Z(UW<N
M[LY:3R9DCSEL *B@  8KUFB@#P?7/"GBF36+JY\.3?$KP78W)61M*\/Q^%3:
MK($5"Z_:DED!(5<C?C/( R:H_P#"*_$G_H<OC+_WY\%?_(U?0K'%)N.1Z4 ?
M/?\ PBOQ)_Z'+XR_]^?!7_R-5C3O"_CV/4+:2_\ $?Q>U2S217ELKAO"<$<Z
M@YV,]M%',JG&"8W5L="*]]!R:6@#S9DG92/^$-\;C/<>((N/_*A7 )X1^(\:
M*@\9_&8A1@$Q>"R3^)MLG\:^B** /S27XF_M+>-O%NOZ)X'^*FIR:O'XBO\
M1M*\.:EIFB27WV>SE2*ZOKV:.R$-O!&[JFY2Y=R%16)%*GC7]IW4K07^B_'9
M]8TW5KHZ7X2>V\-:5Y_BB]4,93;1FV&RTC"2,UW(RKL1G564HS5?AW!!/>_$
MV:\T/55TOQ)XXUZ(Z?X?E9=;\=W:ZA<%=/C=3O@TR",[IY,QH6F8,RJ)/,[E
MWA64ZAJ4]T94B_L/Q%XF\.(RQH_RI%X2\*Q*P(.]3%+/$JL!"Q:02<VX*QYI
MXF^'_B?QEK>L7WQG^)-GXVTZPGL/#5WK.FZ>(+MM3CGDDDT+0D@$ NKJ5W\J
M2=XAY8#  LCF"SJ?PVM_#7BS4;_P]8S6GC,>)_#,&H0^%KU1;> H)=4M8X[&
M"6;=#?ZC.909?-4Q*-P(5!&LO>6EK?:+%:27&F:#X"O_  Q;F/49H&CNM*^%
MNG2<BUL2%*76M7"NK-*%8AI$!78Z+-D:]:_8]1\!:5>Z--I M/'/AV_T;P=8
M3.T^B6<NLV@_MGQ!(S$R:E=DF-8W9BHFD/SLLSH#/IK_ (0WXB_]#W\8/^_'
M@W_Y$H_X0WXB_P#0]_&#_OQX-_\ D2OH"B@#Y_\ ^$-^(O\ T/?Q@_[\>#?_
M )$KHM.\/3VFGVT%UX>^(VIW,42I+?7'B>*.2X< !I'6&_2-68Y)$:(H)^55
M& /7J* /!]1\'^,I-1N)M(\0_%KP]82L&33+:X\-WL4)"@';+>I/.02"Q#2L
M 6.,# %?_A#?B+_T/?Q@_P"_'@W_ .1*^@** /G_ /X0WXB_]#W\8/\ OQX-
M_P#D2A? 'BR_FMX_$.M?%#Q7HZ31S3Z+JL7A1;6[V.'5)?(ACD*[E4D*ZYQ@
MY!(/T!10!Y?X,MM!_P"$J\(:KX=T.W\/V>M^'+J^>V@MHH'8%[%HQ*(LJ642
M,.K ;FP<'GU"O*?AQ_S2O_L3)O\ W&UZM0 4444 %%%% !1110!YO'_K/ ?_
M &,E_P#^DVHU'_95[_PTE_:?V.X_LW_A$OLWVSRF\GS?MF[R]^,;MO.W.<<U
M)'_K/ ?_ &,E_P#^DVHU1_YNG_[DS_V^H ]5+ #UI-WM2D9HV^YS0 FZG4FT
M4M !1110 4444 %%%% !7C_C?P9/X)E_MW1;N2QT^T?SXY!"UP-(R09@(E(:
M2SE"@20@_(561,%04]@HH YKP5XTA\6VDB.B6NJVRQM=6B2B5 K@F.:*0 "6
M&0 E) !D @A75T7I:\8US0K;PSXUF?2Q]C;3Y=%DM'B #P1WFH/!<VX/>!E3
M(B8%5<[EVE4V^ST %%%% !1110 4444 %<1X3_Y*9X[_ .W#_P!$FNWKB/"?
M_)3/'?\ VX?^B30!V]%%% !1110 4444 %%%% '#?#7_ (_O$W_82N/_ $HF
MKN:X+X<W$46H>)0\J(?[1N.&8#_EXGKNXY4E7<CJZ^JG- #J*** "BBB@ KR
M#P[_ ,G$ZY_UQO?_ $GT6O7ZY:^^&VAWOB&;7@EY::Q*K*UW:7\\741 _(K[
M#D00@Y4@[!G/- '4T5R5G?ZCX5UBVT[6-0.IZ;>GR[/5+A8XYA<<GR)1&JH=
MP^XRJN=I4_,5+];0 5RGQ+_Y%RS_ .PUI/\ Z<;>NKKE/B7_ ,BY9_\ 8:TG
M_P!.-O0!Q?[,7_(A3_[UA_Z:;&NVMK!/#GC8BV!BL=:B>22$,?+2ZC.XLJYP
M&D1W+8')A!ZDDY'P'TFTT[X5^'KFVA$4^IV<%_=N"3YL[PH&?!X&0J\# &.!
M73>*/!NC^,[:V@UFS^V16TOGQ#S7CVOM9<Y4@_=9A^- &U17#?\ "DO!?_0'
M;_P,G_\ BZ/^%)>"_P#H#M_X&3__ != '<T5PW_"DO!?_0';_P #)_\ XNC_
M (4EX+_Z [?^!D__ ,70!W-%<-_PI+P7_P! =O\ P,G_ /BZ/^%)>"_^@.W_
M (&3_P#Q= '<$9HV\UP__"DO!?\ T!V_\#)__BZY_P 6?"/PII]SX>6WTQXE
MN=32"4"[F^=#'(2OW_51^5 'K& #2UY+XI^'^@>$-3\,7.DV'V:>75[:)G::
M23Y?,4\;V..0.1SU'<UZU0 5\O\ [4'[3EUHFKCX3_#F*XU/XEZV38Q26;QJ
MUB[1"1A'O/S3K$PE)(,<",LLI *)+]05^8WP.MK!?AGHOBDWM]?Q:]8P_P#"
M6>/XD)US5M0N55SX=T,#Y_->0[;B=#DMYGSH\>8 "_X8T/0OAYX,U*VB\97'
MV"YU=="UOQAX9MG-WJ-S)*63PMX> _>.6DW-->$[I'+.[,Y<P=1?F33)O$M_
M->S>%+K0;2+2;N]TE?-TCX;6+I&G]E:0%7%SK5PDL*/)&#M:5 ,!4BFEM+K4
M-!:"?5=8\,_#W4?#EN]IJFHZ/&D^C_#BP<'R]+TU6^2XUFYS&))-KE<X$95H
MDF9'(^GO:V$,MOX;O-%<ZOI_A_5PLMKX&T]RS/XBUQG)\_5I4+RQPS2$K)-G
M:2LTM %A=-&GZO%'IGA.U\-3^&--.JZ3H>N3K+I_@"T<RNWB#6G:1Q<:G-MD
M=(0SNJQ,3(NZ66N5\2"VT^X^#]E NI:!I=]XQT#5M.L9,R:SXKD.KV*S>(=<
M8 &*,[U2**0EM]RF0GEI'%OO:P:A$;#2M,UKQ-#JDO\ :?A_P[XA:6.X\4RK
MM#^(O$S;4:.P1U00P2B-66$!8B3%''A>+K^!O$G@#4[#69KG3M>\>^&A/XOU
MM%&H>/+V/58&8V41+>1I5LAW1^6J(S/'L)7+S@'Z04444 -;I28]J?7(>)?%
M%YIFMRVL=Y;64$<-NRE].FO))9)7F 55B=3P(<]#U/3% '6 <]/QI]<)_P )
M1JW_ #__ /EI:A_\<H_X2C5O^?\ _P#+2U#_ ..4 =W17"?\)1JW_/\ _P#E
MI:A_\<H_X2C5O^?_ /\ +2U#_P".4 8GPX_YI7_V)DW_ +C:]6KR;X8.7@^$
M[,<L?!4I)V%,G&F_PGD?0]*]9H **** "BBB@ HHHH \WC_UG@/_ +&2_P#_
M $FU&J/_ #=/_P!R9_[?58MKN*:^\'VREA<6?BF]AN(G0JT;FSOI%!! ZI(C
M ]"&!'6J_P#S=/\ ]R9_[?4 >K4444 %%%% !1110 4444 %%%% !1110!Y3
MXZ_Y''5O^Y6_]/$U>K5Y3XZ_Y''5O^Y6_P#3Q-7JU !2$XI:0C.* #<*-PSB
MF[33L<T +1110 5Q'A/_ )*9X[_[</\ T2:[>N(\)_\ )3/'?_;A_P"B30!V
M]%%% !1110 4444 %%%<[+XYL)9KB#2HKG7[F!F22/3$#HCJ<-&TS%8E<'@H
MSAAW% '->!-!TS5-3\2RWFG6EW(-0N%#SP*Y ^TS\9(KHO"%A;:=J/BB&TMX
MK6$:DA$<*!%!^R6W85SWP;U>V\06FKZI9LSVE]=27,+,NTE'FF921VX(KJ/#
MG_(8\4_]A)/_ $CMJ -ZBBB@ HHHH *\N\5?&J7PSXLN=)_X1^XNK2!WA:_C
M%Q*HD6*VEVE8;>0KE;H8)//EO[5ZC7)ZI\+/#6L>(9-<N;&8ZHZLC3Q7L\0(
M98E;Y4<+DB"$$XS\@H \X\5?&"V\5>'[W2YM&GC\]/W<QL=18PRJ0T<H'V+[
MR.%<>ZBNQ_X7KX8_YY:[_P"""]_^-56\;^#-$T/0V%C;7SZO>N+/3XTO[EB;
MAP=K$&0C:@#2,2" B,<'&*[W^P]-_P"@?:_]^5_PH XO_A>OAC_GEKO_ ((+
MW_XU6/XH^*>B^*[33=,TZWUA[N75],<>=H]U"@5+Z!W9G>,*H"JQR3VKTS^P
M]-_Z!]K_ -^5_P *Q?&.C:?%X<NW2QMD=2A#+"H(.]?:@"E\%/\ DD'@O_L#
MVO\ Z*6NUKBO@I_R2#P7_P!@>U_]%+7:T %%%% !1110 4444 %<MXX_X^_"
MO_89C_\ 14M=37#?%G5&T/2](U%8A,UG?_:!$6VAREO,V,X.,XZXH /B=_Q\
M^$_^PU;?^ABNYKRGQCJFJ3Z]H.GZI!:12P:I83H]G(SJPDDD7!W*,$>5^M>K
M4 %?F?\ "&Y:/X>:-XCGU:.'4_"W@NTL+_QK",6/@G3)8%86FG0$DW.LW2;6
M>3:=AFB7E2D4OZ85^:'PE:ZMOAIX=CCFT^PU;0]*BU'2[<@-X=\%PM&6D\0:
ML?EBFU"4F>:"%]S*#'@+F66@#O\ 1=%U'3-9\+Z3I/A?0_"&I>'-)DU71/#N
MM3;].\%V#8637-:D4#[1J<VUQ'$&^7%P3+_K9:I:*)K_ $OP3IFEVRZE9:I?
M2^(_#6@Z\6CO?$%V"TDGB?Q%)P8[.-CYT4"J"S&V7*L(XH@:+97]Q;:7IG@G
M4M:LKU3K&C^$/%EP5O?$%XK?O/$OB.21MT5FA5%BAE^9B#MA#+%'$0PPZS;V
M,DEC-XTL?$\I%Y?JRQ:I\4]111MAB7'^BZ%;_.Q9F$1B" *T;$W !2O=3T_5
MM&N8I]<O/&VD^-?$'V*26PA2*_\ BAJ<.%^S0,-ZV>AVXCV-(&*M&)<OM<M<
MX_BZ>ZU+QYH&L+=1>)=2;XD>%M(\0^*I]R:;!/#J4)31- B/2W@96>:0\N\>
M6#LQ\G?&JW@M6O\ 6/%-BT]W*-%\2>)?"<;AM4*L?*\*^%(LAQ&N-LLR8;?N
M8OO5_(YGQ?'#/XI\!V^K:5!X@U71?'6B:7!I6ASK:Z)\/87NHEM=*BFC&)[\
MN(FGE0$JL97Y$$:R@'Z4T5PG_"-Z[_S[_P#ESW?_ ,9K8\):5J^FS:@=1D7R
M)2AMX!?279CP#N)>1%/)QQR./>@#HZ\^\2_\E"L_^NFG?SOJ['Q#;7U[H&IV
M^EW*V>IRVLL=K<N,B*4H0CG@\!L'H>E>>O:26/BFRANK4Q7WVRQ=IO[3EO \
M9%V$7]XB[<$.>!SN'I0!ZE1110 4444 >4_#C_FE?_8F3?\ N-KU:O*?AQ_S
M2O\ [$R;_P!QM>K4 %%%% !1110 4444 >4_\U%_[G/_ -UZC_FZ?_N3/_;Z
MC_FHO_<Y_P#NO4?\W3_]R9_[?4 >K4444 %%%% !1110 4444 %%%% !1110
M!Y3XZ_Y''5O^Y6_]/$U>K5Y3XZ_Y''5O^Y6_]/$U>K4 %%%% !1110 4444
M%<1X3_Y*9X[_ .W#_P!$FNWKRV/P?IOB_P")/C%=2A65;8V9C_=QDC=!SR5)
M_A'&<=?4T >I45PW_"FO#/\ SYK_ -^HO_B*/^%->&?^?-?^_47_ ,10!W-%
M<-_PIKPS_P ^:_\ ?J+_ .(H_P"%->&?^?-?^_47_P 10!W-%<-_PIKPS_SY
MK_WZB_\ B*YGQ'\.]%TKQ-H5A;VL0M[]91,&MX6/RR0 $$IQP[#CUH [_P 8
MW5R+:PTVTDDMY]5NA9_:8SAH$V/)(P/9O+B=5(SAF4XP#6MIFF6NC:=;6%C
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M5!R9U[C&#5N&6Y\#:A?I)8W%UX>NIWNXI[*,RO9R2$M*CQKEV5I"SAE#8,C
MA%0$ZUAXU\/:I<Q6UGKNFW=S+S'##=QN[\$\*#D\ G\#0!M4444 %%%% 'E/
MPX_YI7_V)DW_ +C:]6KRGX<?\TK_ .Q,F_\ <;7JU !1110 4444 %%%% 'B
MGB#4K_1KRT\0Q6"W+WOC"66VM 9G9D32Y;0EO)AD<$F!VPJ-@$9(Y(RO^$C\
M0_\ "U/^$S_X1_\ Y@O]D?8OLFL?\]_-\S?_ &;^&W;[Y[5UFGZK;WVH^%[.
M,3)<Z9XLO;2ZCG@DB*2&QO9AC>HWJ8Y8V#+E3NX/!QZI0!Y2WQ?\0*I)\)@
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MT&W^-OPJMXM$TZ.WN/[5\Z)+2,))MME*[AC!P>1GI0!ZA_PFNC?\_G_D)_\
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M--/_ .??5O\ P3WG_P :H_X333_^??5O_!/>?_&J -ZBL'_A--/_ .??5O\
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MO@2Y$LD\]RZQW-FRHTLKRE0WVH;@I?&[ SC.!G T_P#A,O'?_0B7G_?^S_\
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MH(!*DJ>O520>H)'-2:OJMMH6E7FI7CF*TM(7GF<*6(102< <DX'0<F@#DO\
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M6>OW6CSW8<MI=Y]N@52,&0121C=D<@"5CVY ]*\Q_9-_Y(_/_P!C7XH_]/\
MJ%>QT %>*V?PUU5W\+WU]<^+_P"U= MFAM&MWTCRH"\2QR!05RRD+@;\G'OS
M7M5% 'G/]F^)O^@KXU_[XT3_ .-U/H6C:Z/%6GW5[=:_=6D$<P8:M_9PC4L
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MB*%7+,2S' ')))[F@#C/^$D\7_\ /A#_ ."^;_XY1_PDGB__ )\(?_!?-_\
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MKRO_ (2_QA_SW'_A&7G_ ,F4?\)?XP_Y[C_PC+S_ .3* &_#C_FE?_8F3?\
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M /@?'_C5#_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J
M+_\ PT;\+O\ H?O#_P#X'Q_XT?\ #1OPN_Z'[P__ .!\?^-4/^&3O@A_T1OX
M?_\ A+V/_P :H_X9.^"'_1&_A_\ ^$O8_P#QJ@#<TGXT^ /%5S)8Z7XHTS69
MO*,DD%G*)\(" 2P7.!E@.?6M'2M;\*Z%;-;Z:MMIUNSF0Q6EH8D+'JV%4#/
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M .A@TK_P-C_^*H_X3GPW_P!#!I7_ (&Q_P#Q54/^%::1_P _GB#_ ,*34?\
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MQY.WGVNO-_&G_):_AK_U[ZM_Z*AKTB@ HHII;!Q0 ZBF[O:E!R* %K#\8?\
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MJD,K ,/,/C/J]QK/P[M9;RR?3K^)]3AN;9B65)%TB_!V,0-Z'AE; RI&0#D
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M_P >-_\ ]A*[_P#1[UO4 %%%% !7F_[1O_)%/%7_ %[I_P"C4KTBO-_VC?\
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MX07Q#_T"?_,A:Q_\9H_X07Q#_P! G_S(6L?_ !FO5J* /*?^$%\0_P#0)_\
M,A:Q_P#&:S=3^%^HZEJWA^XU7PO;:MI]A>O<S6EUXGNM6# VT\0(AO$6,$-*
MIW9W 9 ZFO:** /#]1^#^IW=]--I6F66AZ>[9BL$9(Q$._RQ@J,G)X]?6BO<
M** /G_XL_P#'CXR_[#5[_P"HN]<_I/C[PUIEQKUK=Z'J%S<Q:_JZR2Q?"G6]
M35C_ &A<<BYAA,<O^\A(K?\ BB))_#OB34#"\5M?:QJ3V[/C,B1^'KB!FP"<
M#S(9 ,X.!G'(K?\  O@&]\0QZI<WNLZCINF+KFJ&*STG4[B-I\:E<$M*^X;
M> $B"XPV7;=A0#D?#7CGP3XW^)GAWPS;:46U)9);R>RO/ASJFCE8!;3@.TMU
M$J!=Y4 'J< <UT'Q83PUX$\9>&;IM C$,]AJ$;1Z;X0NM;8MYEH06M[.-G4
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M;]GC"O+MP97/+R$>K,68^[&M.BB@ HHHH Y3XL_\DK\9?]@6]_\ 1#UU=%%
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M_P#H6E5[G0 4444 %%%% !1110 4444 %%%% !1110!@^-/^0/;_ /82L/\
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MK_[$R;_W&UZM0 4444 %%%% !1110!\__%G_ (\?&7_8:O?_ %%WKU7X:?\
M(N7G_8:U;_TXW%>?^+-"_P"$HUO6=&\_[-_:/B::S\_9O\OS/#13=MR,XSG&
M1GUJ+X16'B;PK\4O$FB:MXRO/$>G3W6I7<=C)8VMO;6;LUC=8A\N/SL;M0F7
M][+)PJ=#DD ]PI"<#)Z4M<1\4=?M]/@T'1[ITAM=>U$65S<2RI''%;K%)/+O
M+$<.L)A^7G,P/0$T 6[?Q/J?BB64>'K2&+35P$UK4 QAGSGF")2&E3@?.613
MN!4N*/"/@R[\.ZQJVI7FHPWTM]&D>R"U,"H%GN9CUD?.3=,.W"CKFKZ^-_#2
M*%77]*"@8 %Y%Q_X]6K:7UMJ,"RVMQ%<Q.NY9(7#J1DC(([9!_(T 3;J-WM1
MM]^:-OO0!X=\1O\ D[[X)_\ 8O>*?_0M*KW.O(/B'X<2^_:0^#^M"\N;>?3[
M+7H/)B\ORKB.:*U++)N0MPT4; H5.5Y)!(/K] !1110 4444 %%%% !1110
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MP'!Q@^WV7_'G!_US7^5 $]%%% !6#X]_Y$7Q'_V#;G_T4U;U8/CW_D1?$?\
MV#;G_P!%-0 >#_\ CQO_ /L)7?\ Z/>MZL'P?_QXW_\ V$KO_P!'O6]0 444
M4 %>;_M&_P#)%/%7_7NG_HU*](KS?]HW_DBGBK_KW3_T:E 'I%%%% !1110
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MGB?5;J.-4EOKG7[N.6X8#F1EADCC4L>2(T11GA0,"@#PC_A97Q._Z&OX?_\
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M%_\ #*T-I)_9^J:Y:WHPT,TVNW\R*P.1N0SX8>H- $__  MGP/\ ]#EX?_\
M!I!_\71_PMGP/_T.7A__ ,&D'_Q=7?(\3?\ /[I/_@'+_P#':S+'X8V*65NM
M[J>NW5X(U$\\>OW\2R28^9@@GPH)R=HX&<4 3?\ "V? _P#T.7A__P &D'_Q
M='_"V? __0Y>'_\ P:0?_%T?\*TTC_G\\0?^%)J/_P ?H_X5II'_ #^>(/\
MPI-1_P#C] &+XU^*/@R[\&Z]!!XNT*::6PN$2./4H69V,;   -R2>U.\(_%+
MP9;>'K2.;Q=H44B[\H^IP@CYV[%J9K_P=N;Z\M;G0?B'XT\'O%')'*EA?P7Z
M7(8H07348;H*5V<&,(?G8'.1B+2_@_K4-_%+K/Q8\<>)+%,EM.NCIEE'(<$
MF2QLK>88)S@2 $@9!'% '0?\+9\#_P#0Y>'_ /P:0?\ Q='_  MGP/\ ]#EX
M?_\ !I!_\71_PK32/^?SQ!_X4FH__'Z/^%::1_S^>(/_  I-1_\ C] !_P +
M9\#_ /0Y>'__  :0?_%UYS\8/B)X4U.Z\'&S\3:-=B#59))C!?Q/Y:FSN%#-
MAN!N91D]R!WKT;_A6FD?\_GB#_PI-1_^/T[2M!U_0K,V5KJMM<VJ2RM"^H)/
M<3A&D9E5I&F+-M#!03V44 -_X6SX'_Z'+P__ .#2#_XNC_A;/@?_ *'+P_\
M^#2#_P"+IB^ WU2ZN[O7-4OY[F60&)-+U*\L88HPBKM$<<X!.X,Q;K\V.U/_
M .%::1_S^>(/_"DU'_X_0 ?\+9\#_P#0Y>'_ /P:0?\ Q='_  MGP/\ ]#EX
M?_\ !I!_\71_PK32/^?SQ!_X4FH__'ZJ:K\*K2]L)8M/\0^*-#O3M:'4+37+
MB>2!@00PCN6EA?I@K)&ZD$Y!H M_\+9\#_\ 0Y>'_P#P:0?_ !='_"V? _\
MT.7A_P#\&D'_ ,77*'X->+B/^2[?$#_P!\/?_*JNHB^&.DQQ(C7_ (BE95 +
MOXCU#+'U.)P,_0"@!_\ PMGP/_T.7A__ ,&D'_Q='_"V? __ $.7A_\ \&D'
M_P 71_PK32/^?SQ!_P"%)J/_ ,?H_P"%::1_S^>(/_"DU'_X_0 ?\+9\#_\
M0Y>'_P#P:0?_ !=8_BKXI>#+C3($B\7:%*POK-RJ:G"2%6YB9CPW0 $D]@#5
MV/P1K6AZK<3^'O$7D65Q#$CVFNK=ZILD1I"7C=[I2FX.H(Z?NU-5?$/@SQWX
MDAM;<?$7_A&(HYO-EN?#6AP)=2KL8"/=>&ZC5=S*Q(BW?( & )R 9_P]^)W@
MZRT&ZCN/%FAP2-JVIR!)=2A4E'OYV1L%NC*P8'N"".M=+_PMGP/_ -#EX?\
M_!I!_P#%URO_  IOQ=_T7;X@?^ /A[_Y54?\*;\7?]%V^('_ ( ^'O\ Y54
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>img183574933_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183574933_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : 1P# 2(  A$! Q$!_\0
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MEPW\(8C!).3AFJ, 7"P0PV]S??;9S-;6LY(^VX.#J%^1@B $#9'@ @* .0$
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M%^#_ -!DK0T'_D8=,_[$J+_T,5(S-9ED2YN;FZO+M+FY%M=WMJ&#71#'&G6
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FCP^$O#=NERD/A_2XUNAMG5;.,"49SAACD9YP>]; &!@444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>img184498454_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img184498454_0.jpg
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M,G@O_A)_#;31VLT\&J_9IX97WXS&T3?)\OWMW?I7*ZS^UWXX\*_#FS^(&N?
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MUXKFO^"66D^+-0^"\?B.]\8R7NA76H7^[0IK&-G^U&0%KAKLGS&)_N^]>_\
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M&OQM\"?BM\$]#U7XB_\ "9S^,;^#2M?\-:G;Z?%<V$EQY:)/ MM$CI&LC_\
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M==W^]7I'[57C:S\*_M5_LY?%/5[/4M/\&1VURD]Y-ITWFVS21MM22%4,BO\
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MN9'@B<1\M_'4/PD^.7A#XWZ.NJ^"[Z^U?2SNVW\VDWEI!+AMK>7)-"BR8/\
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M$&OJ[X2?&CP#^TK\:?$-QX:BCU/_ (5[;00V>O)YB[Y+Y9A<1!&5?E46L7_
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MGB_QC!\.?!G@F\_L_P#LFUOUTV[UIHI)8Y+FXNP5E\M?+X2)U^61=W^URO\
MP3_\2:'_ ,,A_$C2;?4[47OVS7+I;'SU\[[.+>(>;L/S;/F3YO<5ZI_P2]_Y
M,W\*?]?FH?\ I5)6[^W;\?;O]GSX/V&HZ99V,VI:QK$.EV]UJ<'G6UBS*\AN
M'3^+8L>0/I7S+^T(_A;0_P!IK]EV:'XC?\)WK2ZVUQK.M76JK.H5YK3RG$:-
MY%M&W[[:D:K_ ,"KTSX_:G:ZK_P4(_9JN+2YAN;>2POIXY(75E>-HYMK CJI
MK8\6W<'_  ]1\%+YR;_^%>R1;=_.[[1=MC_OGFN2_P""='CNR\ Z_P#%[X6>
M+KVWTGQO;>*KG57CO)%BDO$D1$9TW?? \G?_ +LN:T/V-/B#X:U']KO]IN.U
MUW3)Y=8UC3_[-6.ZCW7ZQ+=B4P\_O-G?;TK[?FFCM87EE=8X47<S-\JJHK\Y
M?^"4GPK^'_Q ^!OB*[\2^#O#OB37++Q-*L=UJVE6]S/%#]EM2@5W0L%W>97W
M;X\TVST/X2^*+.RM8-/LH-'NU2"VC6.-%\E^BKP*\"_X)?R+_P ,<>%_]F\U
M#=_X%25Q/_!+J]?P?X1^(/PHU]?L/C7PQXCGGO+.;_620R)$BRKG[Z[HS\WN
MG]ZHOA5H+ZY^WI^TAXRT6/?X7L]"31;BX0_NI=0,-J9%7_:0V\N[Z_[5:G_!
M,'Q1I&A?L</?ZAJ=K9V6EZE?RWT\TRJMLH(?,G]WY?FKPOPYX;N+#_@G5^T%
MXOEM9-,TCQ=KTFJZ39S?+BS:\@6-L'^\=P_X#7Z%_ &:.Y^ _P .98G22)_#
MFFLKI\RM_HL=?G?\"?#>J^,/^";?[0NE:$CS:F_BJ[G6*'YF>../3Y9 ![I&
M]>R? ?Q=^RQXZ^ FB:WXAM/ ^FWUGIL46M6&K^3%.EQ'&HD_=/\ ,^YE++M'
MS?6N:_:EU;2;?4/V/M;L="_X0CPK;^,(I8;"ZC6!;.S^U6K1ET_Y9YB7S-O\
M/X5ZI^T_^TU#I?Q0^&7P]\.>)=)T2W\1:E/%J7C%O)N/[+$6%:.%GW1I.V[9
MN<?)7F_@/7/ WA?_ (*2S_V;XMCU&PB\%-;76JZGK#7>^[\\.RF>60_-M_@7
MY17>?L@W47_#7G[5\)FC,KZMI;*N_P";A;L-^6:ZO_@H)\&KGXI_ FZUK0O,
M@\8>"YO[?TFXMQ^^W1?-+&N/5!N'^W&E5/V*/$VI?'HZ]\<M=LC8W&M6EIH.
MEP/_ ,LK:U7-RR$?P27CS_\ ?H5](>*M*U'6_#NH6>D:W+X=U*>/;;ZI!!'.
MULW]\)("C?\  A7DG_"E/B[_ -'$Z[_X3&C_ /R-72?#WX<^/?"NO->>)/BS
MJGC73_):/^SKS1M/M%WG&'WV\2-Q74?%.18_AGXO=SM1='NR6_[8O7R1_P $
MG;ZVL_V4=0EN+F.&*+Q#=^9([JJI^Y@ZURG[:GC,?M@^*O"OP(^%EU%XD,6J
MIJ7B'6['][9:;&BO&/,E7Y6QYCL=O\01?O5IP6,'P$_X*7:+_:<'V'PQXJ\(
M0Z!H-Y-S$DD,<*+"&Z*^ZVV_]ME_OUT'[=6A?\)U\?/V:_#FD0&Y\30^)&U5
MC#\S6UA%) \\K^B?N_\ QROMBOF[X;W]LW[<OQDMUG0W"^'-"W1;QNX\_/'_
M  -/^^Z\0_;:^ ?B+X0^/+;]I3X0Q_9-=TI_M'B/2X$_=WD/_+2<HOW@R\2_
M]]_WFKCOC%X/U?QA_P $GO #:1:R77]DPVFI7<4(W-]G1IDD;'^SOW'Z5]<?
M$7XI^%_'W[&_BCQK]JM9/#NK^$;F7[Z[=TENZ^3_ +^\^7M_O<5\1^-_#6H?
M#3_@G=^SU#XE+Z<Z^.[359$F^7[/;R_;IDW?W?D</7Z>Z+XGTGQ(;L:5J=IJ
M?V.;R+C['.LHBDVJ^UMO?:ZG'O6Q1111111111111111111117FW[0WPCL_C
MM\&_%?@BZ=(3JEILMYV_Y8W"-OA?_@,BJ:\^_8K^-]Q\5/AC_8/B59++XA^#
M7_L/Q#I]R?W_ )T7R+.?^N@7/^\'KEOVG/VV+C]GWXO:/X*73O#]Q_:=A!>1
MR:I?W<,B^9-)%R(K65=O[O\ O5T/[2G[1'PWNO@7\2-%TKXD>#YO$5UHE_I]
MO8+X@LUG^T20O$%QYORN&:OQ*_X5SJO_ #]:#_X4&G__ !ZOU"_X)G_%[P;\
M+_V?]1\.^./'OA+P]J46O7,MO:WOB2SWO;O# 0P_>_W_ #*]'U[]NZWM_P!I
M32_AAH\?AC5K#4;RPAM]4AU.ZD>2.YCCD5U\NV:%LK)\O[W%?0/QJ^+V@_ O
MX:ZSXS\13;-/T^'<L0?;)<3'_5PI_M.W%>3?L+_#76O#'PVU?QMXNC\OQO\
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MKF_\/Z##9ZE=1K%/J,TDES=O&OW4,\K/)L']W=MKM9(UEC9&^96^5J\XT/\
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MM7T1\3?BWH7PMM])34VNKC4]9N_L6EZ5IMN9KN^FVEBL:=]HY9C\J]S7)?\
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M;3=>\4:/I6FZ]XON?"R;]=;P_8K.FFY5FV.S.F]\*V4CWM[5<U+]J#X<Z/\
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M5E;:R-$JE]P8=,5R?A+]O#X2^-_&GA+PQH^J7]UJ7B4?Z&PL7\I)-NX1R/\
MPN1V_A_BVUJ^,/VR/AWX,74[N<Z[J>A:5<_8]2U_2=&N+K3K.8-M='G1=ORG
M&[9NZUZ_X7\3Z5XTT"PUW1+^#4](OX5GM;RV?='-&>C"M>BBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOS>_9AD'P)_X*-?%OP;XD_T*7Q?
M)<WND7$WW;GS+C[3$JL?O9C:3_@<>VOTAKX4_P""BGC&PDUGX%R3:A!>>";/
MQY$GB#R9%EA22)HCY4V,_,(VG^4UZG_P46\/:7X@_9!\=G4_+3[ D%]:RR?P
M7"7"!<?[V[R_^VE?-OQ,_M#5-9_X)^_V^DDVH2[7N%O$^9FVZ;]_/\5>F_\
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M+N>\O$\Q1#9VC2"-"FR3,K?+_P!,WKP3]E<>9_P2Q^,"M\^W^V<?^ L5>]?
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M-8OM!N)EVKJ.GI"T\//5/.CDC_[Z1J^</ G[ NA_#'5O$.I^&/BM\2M&U#Q
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MKR?2_P!@WP/HGC37]5T_Q#XPT[P]KUTU[JG@^SUAH-*NY6)W;U0!S'S]S?\
M^._+74?"G]CSP!\)/A;KO@#36UK4-"UVVGM=074]2DD\Y9H]CLL8VQ1OM_B1
M%-9_PI_8S\'_  S\ ZGX-NM7\0^,_#U]:2:>MAXDOO-AM[61@[Q0QQJBQY?#
M;\;L]ZXGP3_P3C\%>"YTL&\:^/-7\&K-Y_\ PAU[K/\ Q*IFW;L31(B^:O\
MDUZK\3OV9_#?Q0^*GP^\=ZAJ.K6-]X)E\VQL]/G6.WE^8, Z[<]5'W2,@8KV
M6JMY&US \:326[LK 2Q[=R^XR"*\C^$7[-=K\(/''B7Q/:^._%OB"]\23?:-
M6@UQ[&2*YE"[4D_=VL;IL7@*C*O^S6O\>/@78_M!>![CP?K?B+6M&T&[V_;(
M-&^RJUVJLCH'::"4KM9 ?DVURW@S]E6U\!_!V]^&6E?$+QHGARYC:WCDFN+&
M2YM(7W>9#%(;3Y4?>?=?X"E5/"?[%O@OPY\$;_X37VKZ[XJ\#SAA!8:W):LU
MBS2F7?#)#!&X;S&WY8M7.?##_@G_ .$/AW=:<E[XR\:^,= TN99]/\-:]JWF
MZ7#(C;DD-LB*K,I_X#_LUZMK'P1M->^-.B?$>^\2Z]/>Z)#+#IVB2?96TVW6
M6/9(ZKY'F[V_O^9N[?<^6N2U#]D+1+C]H&?XQV7C#Q9I/BN=%AFCT^6R6TFA
M"*@ADC:U)=<*OWF+?[7RKC(F_87\%?\ "WO$/CVP\0^+-$D\12--K.BZ-K+6
M=E?R,VY_-\L"3#DL6&_O4?A?]A;PAX#\.>,O#WAGQ=XTT'1/% N8KC3[;4H6
MMK:&=0LT<$4D#(FY%1/,*M*JH-KCG-S2_P!C/0M'^ LWP?M/'?C2#P9)O3RT
M?3_/6*21Y)(?,^Q_<9W+'^+_ &MO%7+K]C7P5KGP(M?A-X@U'7/$GAJQVKIM
MQJ$ENM[IVSB,PR10I]W/\:M^5<;?_P#!//PCXF\,Z7H'B[QYX^\8:=I-Q'-8
M0ZIK*LMO&BE1&BK& ,C;EOO?)\FRNF\=?L6Z)X\\5>#M=NO'_CNUN/"$GG:#
M''J-K/\ 89-R,S;[BWEDFW-&F?.>3^[]WY:[[XP?!2#XU_#F3P5K/BOQ%I^E
M742P7\NEBSBGOU&/]8SV[A?F7/[H)^5>:^*?V#_!OC#X2^%_ 6J^)_%-U;^%
M9EET+6//M8K[35"J!$CQ0(K)\J_?5F_VJ;JG[!O@O6/$GACQ)/XN\??\)5H7
MF)_PD/\ PD,C:A?1NH4QS3,I9%V;E_<>5_K']:^E8T2"-$7[J_*.]?->D_L$
M> -!^('B3Q'I^M>+++2_$4S7&J>%;/6&@TN[9F8L)$C"NR?-]POC^'[ORU6T
M/]@/P?X:^%FO_#S3?&_CNU\+ZR_[^U.I6\BQ0EM[0PJ]N4C5F^8L%W_[=:^L
M?L9Z)X@^!-M\(;WQYXSD\&P>5&L6_3_/>&-D>*!I/L?W$= P_B_VL<5?\8?L
M>^#/B%\'=#^'7B?4-:UVRT)(UTG6YIK>+4K%44(FR2*%$X08^9&W?Q9KD]3_
M ."?OA/Q7'X>;QIX[^('C6YT&;S[6XU376W)CHJ[%&SI]Y?WG^W7TQI.EQZ+
MIMM8V[W#PP(L:-=3R7$N!_>DD+.Y]V->+?%W]DOP]\6_BIH7Q"'B3Q-X2\4:
M99FP-[X9OEM'N+?<Y\N1MI/_ "T;E?\ "J<W['>AM\:-$^)L/C;QE:^(-$ME
MTW3;>.:Q:VMK$*ZBV"O:LS1XD?YG9G_V]U7)_P!D[3+CX]P_%YO'?C'_ (2F
M&/[)'%YEA]D6U^;_ $?R_LG^K^8\[M_^UFN/\8_\$]_!6M?$[4?'/AKQ7XP^
M'6JZI(TNI1>$M26TCN6;F0CY"R%^_.W_ &:]\^&OPUT'X3^$[7P]X=LVMM/A
M+.S22&2:XE;EYI7;F21CRS'FO//B)^S+;_$/XM:#\09_B%XRTC6- \W^R+?3
M9+'[)8^9'Y<Q2.6TDW;U^\7+=O:O7=:TV?5-+N;2VU&YT>>=&5+ZQ2-IH6/\
M:"5'3</]I&%>!? _]B'PU^S_ ..-0\4>%_&OC"2?57WZG8ZA/8R6M^=SL#(B
MVBL,%R1L9:T;C]D73KCXW1_%EOB%XT3Q?%!]B27?IOD);<_N/+^QXV?,?]K_
M &JR/C%^PMX-^+7Q*3XA6&O^)? /C+:JS:IX5O5M7N,+M#/\A._;QN4UW?@_
M]G71/A[\/=9\->'-=\1:5J&M-YFH^*_M:W.M7,G3S6N)XW&_9\H^3Y<_+M;Y
MJR;K]E'PO>?LYGX,2ZQK9\,%?*:\_P!$^VLOG>;RWV?R\[_X_+W?[6[FL#6O
MV'?!WBCX#V7PFUWQ)XHUSP[IT\=QI5SJ%U;_ &S3FC5U18Y$@3<NUW7$@?BL
MW5O^"?W@K7H?#%QJ7C+Q_>^(O#UTEU9^)9_$#2Z@FW&V(-(C)&@QG]VB-_M5
MO2?L=Z/)\9]&^)W_  G/C,>)='M%TVQ#3V,L$-F Z^1^\M&9UQ*_S.[2<YW[
MN:L:5^R9I>E_'N?XOKXZ\8W/BN=/LTR326)M'M?E_P!&\L6@VQ_(O*G?_M9K
M%U#]AOPK;_$S5/&7A/Q=XP^'5QK#^;JVG>%-26VMKQNI.WRR5R3V_P" [:G\
M _L/^#_A9I?BBV\)^)_&&@W7B*21KJ^M=6#NL;L_[L1RH\+85]HDDC>4?WZZ
MOX ?LV:9^SCX5G\->&_%WB74-";S&M[/5Y+.5;.1SEI(V2V1L_[+%D_V:Q_
M/[)>F?#SXP:Y\2K+QYXPO?$>NA?[52]:P:VO$7&U&C2S78/E'^KVFN9\._\
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MY(U_VG;:H^M?%'[#/C[QE\,OVB?'GPE^*,GE^(/%6WQ=:;]VU[J:,2W$:?\
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M7Y]?\%6+7[9KGP$M]\D/FZ].GG0OLE3+6HRI_O5YC\7O!X_9M_:OT2]^./\
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MV,6BI&+)_A]/+)Y?W?M#V;M<?^1C)7S7_P X4?\ /_0R5W?[;_\ RC7\%?\
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M<=^^K_Q"_8JLM;^*D/Q'\$>.]=^'7C5K=;6_U'3TCN5U%0H7=,D@VLY5>?\
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811111111111111111111111111117__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>49
<FILENAME>krro-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-26T15:23:08.8484+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://korrobio.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:krro="http://korrobio.com/20231231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity" id="DisclosureTheCompanyAndLiquidity">
        <link:definition>100080 - Disclosure - The Company and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1" id="DisclosureReverseMerger1">
        <link:definition>100100 - Disclosure - Reverse Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1" id="DisclosureInvestments1">
        <link:definition>100120 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash" id="DisclosureRestrictedCash">
        <link:definition>100130 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100140 - Disclosure - Property and Equipment , Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100150 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1" id="DisclosureCommonStock1">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>100170 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>100180 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement" id="DisclosureGenevantAgreement">
        <link:definition>100200 - Disclosure - Genevant Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100210 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan" id="Disclosure401kSavingsPlan">
        <link:definition>100220 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>100240 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureSubsquentEvents" id="DisclosureSubsquentEvents">
        <link:definition>100250 - Disclosure - Subsquent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables" id="DisclosureInvestmentsTables">
        <link:definition>100290 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables" id="DisclosureRestrictedCashTables">
        <link:definition>100300 - Disclosure - Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100310 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>100330 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables" id="DisclosurePreferredStockTables">
        <link:definition>100340 - Disclosure - Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>100350 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100370 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100380 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" id="DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - The Company and Liquidity (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails">
        <link:definition>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails" id="DisclosureReverseMergerAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Reverse Merger (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails" id="DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Schedule Of Contingent Value Right Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails" id="DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails">
        <link:definition>100460 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" id="DisclosureInvestmentsAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Investments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100480 - Disclosure - Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails" id="DisclosureRestrictedCashAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Restricted Cash (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100500 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Property and Equipment, Net (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100520 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails" id="DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails">
        <link:definition>100530 - Disclosure - Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Common Stock (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" id="DisclosurePreferredStockAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Preferred Stock (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails" id="DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails">
        <link:definition>100560 - Disclosure - Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Stock-based Compensation (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>100580 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails">
        <link:definition>100590 - Disclosure - Stock-based Compensation - Summary of Restricted Common Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails">
        <link:definition>100600 - Disclosure - Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100610 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Income taxes (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails">
        <link:definition>100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails" id="DisclosureGenevantAgreementAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Genevant Agreement (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
        <link:definition>100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails">
        <link:definition>100680 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" id="Disclosure401kSavingsPlanAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - 401(k) Savings Plan (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Related Party Transactions (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100720 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100730 - Disclosure - Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="krro-20231231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="krro-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="krro-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="krro-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="krro-20231231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="krro-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="krro-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:href="krro-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails" xlink:href="krro-20231231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="krro-20231231.xsd#DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails" xlink:href="krro-20231231.xsd#DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails" xlink:href="krro-20231231.xsd#DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosurePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails" xlink:href="krro-20231231.xsd#DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureGenevantAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:href="krro-20231231.xsd#Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="krro-20231231.xsd#DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="krro-20231231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity" xlink:href="krro-20231231.xsd#DisclosureTheCompanyAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="krro-20231231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1" xlink:href="krro-20231231.xsd#DisclosureReverseMerger1" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="krro-20231231.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1" xlink:href="krro-20231231.xsd#DisclosureInvestments1" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash" xlink:href="krro-20231231.xsd#DisclosureRestrictedCash" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="krro-20231231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="krro-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1" xlink:href="krro-20231231.xsd#DisclosureCommonStock1" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock" xlink:href="krro-20231231.xsd#DisclosurePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement" xlink:href="krro-20231231.xsd#DisclosureGenevantAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan" xlink:href="krro-20231231.xsd#Disclosure401kSavingsPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="krro-20231231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="krro-20231231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureSubsquentEvents" xlink:href="krro-20231231.xsd#DisclosureSubsquentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krro-20231231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krro-20231231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="krro-20231231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables" xlink:href="krro-20231231.xsd#DisclosureInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables" xlink:href="krro-20231231.xsd#DisclosureRestrictedCashTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="krro-20231231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="krro-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables" xlink:href="krro-20231231.xsd#DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables" xlink:href="krro-20231231.xsd#DisclosurePreferredStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="krro-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="krro-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="krro-20231231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureReverseMergerAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails" xlink:href="krro-20231231.xsd#DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="krro-20231231.xsd#DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosureRestrictedCashAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="krro-20231231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails" xlink:href="krro-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="krro-20231231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_InitialConsiderationAmount" xlink:label="krro_InitialConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PercentageOfOutstandingSharesOfPreferredStock" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInLeaseLiabilities" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLossCarryforwardsExpirationYear" xlink:label="krro_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationExpense" xlink:label="krro_ShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStock" xlink:label="krro_ConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ScheduleOfContingentValueRightLiabilityTableTextBlock" xlink:label="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NonCashLeaseExpenses" xlink:label="krro_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CommonStockIssuableUponConversion" xlink:label="krro_CommonStockIssuableUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceReverseRecapitalization" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlanMember" xlink:label="krro_StockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CumulativeChangeInOwnershipPercentage" xlink:label="krro_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProgentosTherapeuticsMember" xlink:label="krro_ProgentosTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OutstandingStockOptionsMember" xlink:label="krro_OutstandingStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_UnvestedRestrictedStockUnitsMember" xlink:label="krro_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_KorrosMember" xlink:label="krro_KorrosMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FairvalueOfContingentValueRightLiability" xlink:label="krro_FairvalueOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PriorToTheAdoptionOfAsc842Member" xlink:label="krro_PriorToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccountingStanderedSectionsEightFourTwoMember" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CvrLiabilityCurrent" xlink:label="krro_CvrLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromSaleOfAssets" xlink:label="krro_ProceedsFromSaleOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectiveIncomeTaxCreditCarryforwards" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SixZeroFirstStreetLeaseMember" xlink:label="krro_SixZeroFirstStreetLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeverancePayment" xlink:label="krro_SeverancePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1ConvertiblePreferredStockMember" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TaxCreditCarryforwardExpirationYear" xlink:label="krro_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:label="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_GenevantAgreementMember" xlink:label="krro_GenevantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlan1Member" xlink:label="krro_StockIncentivePlan1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccountsPayableAndAccruedExpenses" xlink:label="krro_AccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccreditedInvestorsMember" xlink:label="krro_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectOfAdoptionMember" xlink:label="krro_EffectOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed1PreferredStockMember" xlink:label="krro_SeriesSeed1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdditionsOfContingentValueRightLiability" xlink:label="krro_AdditionsOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DefinedContributionPlanName" xlink:label="krro_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SharesOwnershipPercentage" xlink:label="krro_SharesOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FrequencyMember" xlink:label="krro_FrequencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReverseRecapitalization" xlink:label="krro_ReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesAConvertiblePreferredStockMember" xlink:label="krro_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2ConvertiblePreferredStockMember" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancing" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AffiliateCosts" xlink:label="us-gaap_AffiliateCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDispositions" xlink:label="us-gaap_PropertyPlantAndEquipmentDispositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredTaxAssetsAmortization" xlink:label="krro_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredRentNetOfCurrentPortion" xlink:label="krro_DeferredRentNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IntellectualPropertyExpensesPolicyTextBlock" xlink:label="krro_IntellectualPropertyExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStockShares" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CummingsParkSubleaseMember" xlink:label="krro_CummingsParkSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MilestonePayment" xlink:label="krro_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncentiveAwardPlanMember" xlink:label="krro_IncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="krro_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OKSFacilityMember" xlink:label="krro_OKSFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed2PreferredStockMember" xlink:label="krro_SeriesSeed2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PeriodOfCumulativeChangeInOwnership" xlink:label="krro_PeriodOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccruedExternalResearchAndDevelopmentServicesCurrent" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FutureMilestonePayments" xlink:label="krro_FutureMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfInvestments" xlink:label="krro_PurchasesOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PreferredStockPolicyTextBlock" xlink:label="krro_PreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Denominator" xlink:label="krro_Denominator"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed3PreferredStockMember" xlink:label="krro_SeriesSeed3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncurredExpenses" xlink:label="krro_IncurredExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SubsequentToTheAdoptionOfAsc842Member" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" xlink:label="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase3ClinicalTrailMember" xlink:label="krro_Phase3ClinicalTrailMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EmployeeStockPurchasePlanMember" xlink:label="krro_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ChangeInFairValueOfContingentValueRightLiability" xlink:label="krro_ChangeInFairValueOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase2BClinicalTrial1Member" xlink:label="krro_Phase2BClinicalTrial1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReimbursementsWithInResearchAndDevelopmentExpense" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceCancelled" xlink:label="krro_WeightedAverageExercisePriceCancelled"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockOptionsMember" xlink:label="krro_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_InitialConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Consideration Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_InitialConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Consideration Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessor, Operating Lease, Payment to be Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of outstanding shares of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash in PIPE financing (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock For Cash In Pre Closing Financing, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock For Cash In Pre Closing Financing, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards, Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, beginning balance (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, beginning balance (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Share Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life (in Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Valuation Allowance Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of securities in unrealized loss position for less than twelve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock To Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion Of Preferred Stock To Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsquent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for services rendered (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill or intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Including Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Including Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities, convertible preferred stock and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Contingent Value Right Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Contingent Value Right Liability [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Contingent Value Right Liability [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Outstanding Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares Options, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares Options , Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Value, Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future issuance of share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series, Title [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CommonStockIssuableUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CommonStockIssuableUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CommonStockIssuableUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted- Average Exercise Price Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted- Average Exercise Price Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2019 Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cumulative Change In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProgentosTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Progentos Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProgentosTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Progentos Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RecapitalizationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of reverse recapitalization transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RecapitalizationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RecapitalizationCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Payment of reverse recapitalization transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RecapitalizationCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reverse recapitalization transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RecapitalizationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Rental Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Liabilities Arising From Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Arising From Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Liabilities Arising From Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash acquired in connection with the reverse recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired In Connection With The Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash acquired in connection with the reverse recapitalization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Explanation of Change in Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Explanation of Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OutstandingStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OutstandingStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OutstandingStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_MsApaAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MS APA Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_MsApaAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MS APA Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense relating to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DebtSecuritiesUnrealizedGainLoss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present Value of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present Value of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Platform Operator, Crypto-Asset [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_KorrosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Korros [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_KorrosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Korros [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FairvalueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FairvalueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FairvalueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValue Of Contingent Value Right liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FairvalueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValue Of Contingent Value Right liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other financing activities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financing activities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-2 convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock in pre-closing financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for future grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 5,755,759 shares authorized at December 31, 2023 and 2022; 8,016,516 and 271,371 shares issued at December 31, 2023 and 2022, respectively; 8,016,516 and 268,468 shares outstanding at December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PriorToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior to the Adoption of Accounting Section Eight Four Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PriorToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to the Adoption of ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PriorToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to the Adoption of ASC 842 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and office equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standered Sections 842[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standered Sections Eight Four Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Standered Sections Eight Four Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Cash Equivalents and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CvrLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CvrLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CVR Liability Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CvrLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR Liability Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, Outstanding as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, Outstanding as of December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards Expiration without Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration without limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Without Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Sale of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Options , Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SixZeroFirstStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">60 First Street Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SixZeroFirstStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Zero First Street Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SixZeroFirstStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Zero First Street Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock future issuance, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeverancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeverancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeverancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Tax Deferred Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities tax deferred expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Options, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share-Based Payment Award, Options, Cancelled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancelled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancelled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Off-Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_GenevantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genevant Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_GenevantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genevant Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_GenevantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genevant Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease remaining terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_LegacyKorroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Korro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_LegacyKorroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Korro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_LegacyKorroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Korro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Statement Affected by Adoption of ASC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlan1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlan1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlan1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2023 Stock Incentive Plan1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockIncentivePlan1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2023 Stock Incentive Plan1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service (IRS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service (IRS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccreditedInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accredited Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccreditedInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accredited Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments for property and equipment not yet received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments For Property And Equipment Not Yet Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance Payments For Property And Equipment Not Yet Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercises of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of Adoption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Adoption [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EffectOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effect of Adoption [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to Frequency shareholders in reverse recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards Expiration with Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration with limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration With Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed-1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed-1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series Seed-1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">amount of lease payments representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdditionsOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdditionsOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additions Of Contingent Value Right Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AdditionsOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additions Of Contingent Value Right Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B-1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance utilized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, OptionsExercisable at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Series convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of reverse recapitalization transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Reverse Recapitalization Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of reverse recapitalization transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SharesOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SharesOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Ownership, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SharesOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Ownership, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranfer of assets among fair value hierarchy levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized unvested stock options, weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genevant Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties Charges and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FrequencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frequency [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FrequencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frequency [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Options, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Incentive Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Option, Reverse Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReverseRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-2 convertible preferred stock, net of issuance costs (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance Of Convertible Preferred Stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Weighted-Average Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease rental payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Future Minimum Leases Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Future Minimum Leases Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series Seed Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series Seed Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B-2 Convertible Preferred Stock[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-2 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash in PIPE financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock For Cash In Pre Closing Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock For Cash In Pre Closing Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options exercisable as of Exercisable at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and discounts on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AffiliateCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliate amount related to consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AffiliateCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliate Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDispositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Dispositions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal costs settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Legal Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred taxes:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Fofeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other employee compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Common Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercises of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredRentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredRentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent, Net of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_DeferredRentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Rent, Net of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IntellectualPropertyExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IntellectualPropertyExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property Expenses Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IntellectualPropertyExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intellectual Property Expenses Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to Frequency shareholders in reverse recapitalization (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock To Common Stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion Of Preferred Stock To Common Stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CummingsParkSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cummings Park Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CummingsParkSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cummings Park Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_CummingsParkSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cummings Park Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Stock Option and Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2019 Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging growth company status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Status Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OKSFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OKS Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OKSFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OKS Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OKSFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">O K S Facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average fair value, Unvested as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average fair value, Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series Seed-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment capitalized under tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Capitalized Under Tenant Improvement Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property And Equipment Capitalized Under Tenant Improvement Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PeriodOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of Cumulative Change in Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PeriodOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of cumulative change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PeriodOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Cumulative Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities arising from lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liabilities arising from lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research and Development Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued External Research and Development Services Current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-2 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FutureMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_FutureMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PurchasesOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases Of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Temporary equity, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities, Net of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Liabilities, Net of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current taxes:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Policy Text Block ]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_PreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Stock [Policy Text Block ]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Denominator_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Denominator_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Denominator_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed-3 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed-3 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeed3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series Seed-3 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercises of outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized commercialization milestone payments to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized From Commercialization Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability revenue recognized from commercialization milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incurred expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incurred Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incurred Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent to the Adoption of ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent to the Adoption of ASC 842 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent to the Adoption of ASC 842 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination and Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements - Yet to be Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recent Accounting Pronouncements Yet to be Adopted Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recent Accounting Pronouncements Yet to be Adopted Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase3ClinicalTrailMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase3ClinicalTrailMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase3 Clinical Trail [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase3ClinicalTrailMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 3 clinical trail.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expense and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exchange Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Convertible Preferred Stock[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series Seed Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of position of securities in unrealized loss position for less than twelve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in fair value of Contingent Value Right liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfContingentValueRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of Contingent Value Right liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease area of land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number of Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Conversions of Stock [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase2BClinicalTrial1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase2b Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase2BClinicalTrial1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase2b Clinical Trial1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_Phase2BClinicalTrial1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase2b Clinical Trial1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for services rendered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Asset, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of CVR liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change In Fair Value Of Preferred Stock Tranche Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements with in Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements With in Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements with in Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Nineteen Stock Incentive Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Preferred Stock authorized, issued and outstanding Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Preferred Units [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_WeightedAverageExercisePriceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted- Average Exercise Price Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_WeightedAverageExercisePriceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted- Average Exercise Price Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="krro_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_InitialConsiderationAmount" xlink:to="krro_InitialConsiderationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PercentageOfOutstandingSharesOfPreferredStock" xlink:to="krro_PercentageOfOutstandingSharesOfPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IncreaseDecreaseInLeaseLiabilities" xlink:to="krro_IncreaseDecreaseInLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OperatingLossCarryforwardsExpirationYear" xlink:to="krro_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ShareBasedCompensationExpense" xlink:to="krro_ShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityShareSubscriptions" xlink:to="us-gaap_TemporaryEquityShareSubscriptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ConversionOfPreferredStockToCommonStock" xlink:to="krro_ConversionOfPreferredStockToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock" xlink:to="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_NonCashLeaseExpenses" xlink:to="krro_NonCashLeaseExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_CommonStockIssuableUponConversion" xlink:to="krro_CommonStockIssuableUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_WeightedAverageExercisePriceReverseRecapitalization" xlink:to="krro_WeightedAverageExercisePriceReverseRecapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_StockIncentivePlanMember" xlink:to="krro_StockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_CumulativeChangeInOwnershipPercentage" xlink:to="krro_CumulativeChangeInOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ProgentosTherapeuticsMember" xlink:to="krro_ProgentosTherapeuticsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="krro_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OutstandingStockOptionsMember" xlink:to="krro_OutstandingStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_MsApaAssetMember" xlink:to="krro_MsApaAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_UnvestedRestrictedStockUnitsMember" xlink:to="krro_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_KorrosMember" xlink:to="krro_KorrosMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_FairvalueOfContingentValueRightLiability" xlink:to="krro_FairvalueOfContingentValueRightLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PriorToTheAdoptionOfAsc842Member" xlink:to="krro_PriorToTheAdoptionOfAsc842Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AccountingStanderedSectionsEightFourTwoMember" xlink:to="krro_AccountingStanderedSectionsEightFourTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:to="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_CvrLiabilityCurrent" xlink:to="krro_CvrLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ProceedsFromSaleOfAssets" xlink:to="krro_ProceedsFromSaleOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_EffectiveIncomeTaxCreditCarryforwards" xlink:to="krro_EffectiveIncomeTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SixZeroFirstStreetLeaseMember" xlink:to="krro_SixZeroFirstStreetLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeverancePayment" xlink:to="krro_SeverancePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesB1ConvertiblePreferredStockMember" xlink:to="krro_SeriesB1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_TaxCreditCarryforwardExpirationYear" xlink:to="krro_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_GenevantAgreementMember" xlink:to="krro_GenevantAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_LegacyKorroMember" xlink:to="krro_LegacyKorroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_StockIncentivePlan1Member" xlink:to="krro_StockIncentivePlan1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AccountsPayableAndAccruedExpenses" xlink:to="krro_AccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AccreditedInvestorsMember" xlink:to="krro_AccreditedInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" xlink:to="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_EffectOfAdoptionMember" xlink:to="krro_EffectOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesSeed1PreferredStockMember" xlink:to="krro_SeriesSeed1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AdditionsOfContingentValueRightLiability" xlink:to="krro_AdditionsOfContingentValueRightLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesB1PreferredStockMember" xlink:to="krro_SeriesB1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesB2PreferredStockMember" xlink:to="krro_SeriesB2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PaymentOfReverseRecapitalizationTransactionCosts" xlink:to="krro_PaymentOfReverseRecapitalizationTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_DefinedContributionPlanName" xlink:to="krro_DefinedContributionPlanName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SharesOwnershipPercentage" xlink:to="krro_SharesOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_FrequencyMember" xlink:to="krro_FrequencyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_TwoThousandAndNineteenStockIncentivePlanMember" xlink:to="krro_TwoThousandAndNineteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ReverseRecapitalization" xlink:to="krro_ReverseRecapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" xlink:to="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesAConvertiblePreferredStockMember" xlink:to="krro_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_TwoThousandAndFourteenStockIncentivePlanMember" xlink:to="krro_TwoThousandAndFourteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesSeedPreferredStockMember" xlink:to="krro_SeriesSeedPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesB2ConvertiblePreferredStockMember" xlink:to="krro_SeriesB2ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IssuanceOfCommonStockForCashInPreClosingFinancing" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AffiliateCosts" xlink:to="us-gaap_AffiliateCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDispositions" xlink:to="us-gaap_PropertyPlantAndEquipmentDispositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_DeferredTaxAssetsAmortization" xlink:to="krro_DeferredTaxAssetsAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_DeferredRentNetOfCurrentPortion" xlink:to="krro_DeferredRentNetOfCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IntellectualPropertyExpensesPolicyTextBlock" xlink:to="krro_IntellectualPropertyExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ConversionOfPreferredStockToCommonStockShares" xlink:to="krro_ConversionOfPreferredStockToCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_CummingsParkSubleaseMember" xlink:to="krro_CummingsParkSubleaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" xlink:to="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_MilestonePayment" xlink:to="krro_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IncentiveAwardPlanMember" xlink:to="krro_IncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="krro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OKSFacilityMember" xlink:to="krro_OKSFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesSeed2PreferredStockMember" xlink:to="krro_SeriesSeed2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" xlink:to="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PeriodOfCumulativeChangeInOwnership" xlink:to="krro_PeriodOfCumulativeChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_AccruedExternalResearchAndDevelopmentServicesCurrent" xlink:to="krro_AccruedExternalResearchAndDevelopmentServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_FutureMilestonePayments" xlink:to="krro_FutureMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PurchasesOfInvestments" xlink:to="krro_PurchasesOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:to="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_PreferredStockPolicyTextBlock" xlink:to="krro_PreferredStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_Denominator" xlink:to="krro_Denominator_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesSeed3PreferredStockMember" xlink:to="krro_SeriesSeed3PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:to="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IncurredExpenses" xlink:to="krro_IncurredExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SubsequentToTheAdoptionOfAsc842Member" xlink:to="krro_SubsequentToTheAdoptionOfAsc842Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" xlink:to="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_Phase3ClinicalTrailMember" xlink:to="krro_Phase3ClinicalTrailMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_SeriesSeedConvertiblePreferredStockMember" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_EmployeeStockPurchasePlanMember" xlink:to="krro_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ChangeInFairValueOfContingentValueRightLiability" xlink:to="krro_ChangeInFairValueOfContingentValueRightLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:to="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_Phase2BClinicalTrial1Member" xlink:to="krro_Phase2BClinicalTrial1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssets" xlink:to="us-gaap_DerivativeAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:to="krro_ChangeInFairValueOfPreferredStockTrancheLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_ReimbursementsWithInResearchAndDevelopmentExpense" xlink:to="krro_ReimbursementsWithInResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_TwoThousandNineteenStockIncentivePlanMember" xlink:to="krro_TwoThousandNineteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_WeightedAverageExercisePriceCancelled" xlink:to="krro_WeightedAverageExercisePriceCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krro_StockOptionsMember" xlink:to="krro_StockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CommonStockSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesAConvertiblePreferredStockMember" xlink:label="krro_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1ConvertiblePreferredStockMember" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2ConvertiblePreferredStockMember" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancing" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStockShares" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStock" xlink:label="krro_ConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesAConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesB1ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesB2ConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancing" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ConversionOfPreferredStockToCommonStockShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ConversionOfPreferredStockToCommonStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RecapitalizationCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfInvestments" xlink:label="krro_PurchasesOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NonCashLeaseExpenses" xlink:label="krro_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInLeaseLiabilities" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationExpense" xlink:label="krro_ShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="krro_PurchasesOfInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_NonCashLeaseExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="krro_IncreaseDecreaseInLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="krro_CashAcquiredInConnectionWithTheReverseRecapitalization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ShareBasedCompensationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="krro_PaymentOfReverseRecapitalizationTransactionCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureSubsquentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PreferredStockPolicyTextBlock" xlink:label="krro_PreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IntellectualPropertyExpensesPolicyTextBlock" xlink:label="krro_IntellectualPropertyExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="krro_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" xlink:label="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="krro_PreferredStockPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="krro_IntellectualPropertyExpensesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="krro_EmergingGrowthCompanyStatusPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ScheduleOfContingentValueRightLiabilityTableTextBlock" xlink:label="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfConversionsOfStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccreditedInvestorsMember" xlink:label="krro_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProgentosTherapeuticsMember" xlink:label="krro_ProgentosTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FrequencyMember" xlink:label="krro_FrequencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SharesOwnershipPercentage" xlink:label="krro_SharesOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_InitialConsiderationAmount" xlink:label="krro_InitialConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FutureMilestonePayments" xlink:label="krro_FutureMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromSaleOfAssets" xlink:label="krro_ProceedsFromSaleOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="krro_AccreditedInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="krro_ProgentosTherapeuticsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_FrequencyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_SharesOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_InitialConsiderationAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_FutureMilestonePayments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ProceedsFromSaleOfAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectOfAdoptionMember" xlink:label="krro_EffectOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PriorToTheAdoptionOfAsc842Member" xlink:label="krro_PriorToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SubsequentToTheAdoptionOfAsc842Member" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredRentNetOfCurrentPortion" xlink:label="krro_DeferredRentNetOfCurrentPortion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="krro_EffectOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_PriorToTheAdoptionOfAsc842Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_SubsequentToTheAdoptionOfAsc842Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_DeferredRentNetOfCurrentPortion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccountingStanderedSectionsEightFourTwoMember" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PriorToTheAdoptionOfAsc842Member" xlink:label="krro_PriorToTheAdoptionOfAsc842Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_AccountingStanderedSectionsEightFourTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_PriorToTheAdoptionOfAsc842Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccountsPayableAndAccruedExpenses" xlink:label="krro_AccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeverancePayment" xlink:label="krro_SeverancePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="krro_AccountsPayableAndAccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="krro_SeverancePayment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_RecapitalizationCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FairvalueOfContingentValueRightLiability" xlink:label="krro_FairvalueOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdditionsOfContingentValueRightLiability" xlink:label="krro_AdditionsOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ChangeInFairValueOfContingentValueRightLiability" xlink:label="krro_ChangeInFairValueOfContingentValueRightLiability"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FairvalueOfContingentValueRightLiability" xlink:label="krro_FairvalueOfContingentValueRightLiability_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="krro_FairvalueOfContingentValueRightLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="krro_AdditionsOfContingentValueRightLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="krro_ChangeInFairValueOfContingentValueRightLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="krro_FairvalueOfContingentValueRightLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_InitialConsiderationAmount" xlink:label="krro_InitialConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FutureMilestonePayments" xlink:label="krro_FutureMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssets1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="srt_PlatformOperatorCryptoAssetTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ChangeInFairValueOfPreferredStockTrancheLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_InitialConsiderationAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_FutureMilestonePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDispositions" xlink:label="us-gaap_PropertyPlantAndEquipmentDispositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDispositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccruedExternalResearchAndDevelopmentServicesCurrent" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CvrLiabilityCurrent" xlink:label="krro_CvrLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="krro_AccruedExternalResearchAndDevelopmentServicesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="krro_CvrLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlanMember" xlink:label="krro_StockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlan1Member" xlink:label="krro_StockIncentivePlan1Member"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockOptionsMember" xlink:label="krro_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EmployeeStockPurchasePlanMember" xlink:label="krro_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlan1Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_StockOptionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_KorrosMember" xlink:label="krro_KorrosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_KorrosMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed1PreferredStockMember" xlink:label="krro_SeriesSeed1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed2PreferredStockMember" xlink:label="krro_SeriesSeed2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PercentageOfOutstandingSharesOfPreferredStock" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed3PreferredStockMember" xlink:label="krro_SeriesSeed3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed1PreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed2PreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="krro_PercentageOfOutstandingSharesOfPreferredStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed3PreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CommonStockIssuableUponConversion" xlink:label="krro_CommonStockIssuableUponConversion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="krro_CommonStockIssuableUponConversion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlanMember" xlink:label="krro_StockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncentiveAwardPlanMember" xlink:label="krro_IncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandAndNineteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_IncentiveAwardPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandNineteenStockIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandAndFourteenStockIncentivePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReverseRecapitalization" xlink:label="krro_ReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceReverseRecapitalization" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceCancelled" xlink:label="krro_WeightedAverageExercisePriceCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_ReverseRecapitalization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_WeightedAverageExercisePriceReverseRecapitalization" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_WeightedAverageExercisePriceCancelled" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLossCarryforwardsExpirationYear" xlink:label="krro_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TaxCreditCarryforwardExpirationYear" xlink:label="krro_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PeriodOfCumulativeChangeInOwnership" xlink:label="krro_PeriodOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CumulativeChangeInOwnershipPercentage" xlink:label="krro_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithLimitation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_OperatingLossCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_TaxCreditCarryforwardExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_PeriodOfCumulativeChangeInOwnership" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_CumulativeChangeInOwnershipPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectiveIncomeTaxCreditCarryforwards" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="krro_EffectiveIncomeTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:label="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredTaxAssetsAmortization" xlink:label="krro_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="krro_DeferredTaxAssetsAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_GenevantAgreementMember" xlink:label="krro_GenevantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase3ClinicalTrailMember" xlink:label="krro_Phase3ClinicalTrailMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase2BClinicalTrial1Member" xlink:label="krro_Phase2BClinicalTrial1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MilestonePayment" xlink:label="krro_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReimbursementsWithInResearchAndDevelopmentExpense" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="krro_GenevantAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="krro_Phase3ClinicalTrailMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="krro_Phase2BClinicalTrial1Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_MilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_ReimbursementsWithInResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SixZeroFirstStreetLeaseMember" xlink:label="krro_SixZeroFirstStreetLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="krro_SixZeroFirstStreetLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OKSFacilityMember" xlink:label="krro_OKSFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CummingsParkSubleaseMember" xlink:label="krro_CummingsParkSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SixZeroFirstStreetLeaseMember" xlink:label="krro_SixZeroFirstStreetLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_OKSFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_CummingsParkSubleaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_SixZeroFirstStreetLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DefinedContributionPlanName" xlink:label="krro_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="krro_DefinedContributionPlanName" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncurredExpenses" xlink:label="krro_IncurredExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AffiliateCosts" xlink:label="us-gaap_AffiliateCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="krro_IncurredExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AffiliateCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_UnvestedRestrictedStockUnitsMember" xlink:label="krro_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OutstandingStockOptionsMember" xlink:label="krro_OutstandingStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="krro_UnvestedRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="krro_OutstandingStockOptionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Denominator" xlink:label="krro_Denominator"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_Denominator" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="krro_Denominator" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_Denominator" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_Denominator" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="krro_Denominator" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedConvertiblePreferredStockMember" xlink:label="krro_SeriesSeedConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesAConvertiblePreferredStockMember" xlink:label="krro_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1ConvertiblePreferredStockMember" xlink:label="krro_SeriesB1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2ConvertiblePreferredStockMember" xlink:label="krro_SeriesB2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" xlink:label="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockForCashInPreClosingFinancing" xlink:label="krro_IssuanceOfCommonStockForCashInPreClosingFinancing"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStockShares" xlink:label="krro_ConversionOfPreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ConversionOfPreferredStockToCommonStock" xlink:label="krro_ConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" xlink:label="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesSeedConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesB1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_SeriesB2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockForCashInPreClosingFinancing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ConversionOfPreferredStockToCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ConversionOfPreferredStockToCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RecapitalizationCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" xlink:label="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfInvestments" xlink:label="krro_PurchasesOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:label="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NonCashLeaseExpenses" xlink:label="krro_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInLeaseLiabilities" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" xlink:label="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationExpense" xlink:label="krro_ShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="krro_PurchasesOfInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_NonCashLeaseExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="krro_IncreaseDecreaseInLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="krro_CashAcquiredInConnectionWithTheReverseRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="krro_PaymentOfReverseRecapitalizationTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccreditedInvestorsMember" xlink:label="krro_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProgentosTherapeuticsMember" xlink:label="krro_ProgentosTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FrequencyMember" xlink:label="krro_FrequencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SharesOwnershipPercentage" xlink:label="krro_SharesOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_InitialConsiderationAmount" xlink:label="krro_InitialConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FutureMilestonePayments" xlink:label="krro_FutureMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ProceedsFromSaleOfAssets" xlink:label="krro_ProceedsFromSaleOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="krro_AccreditedInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="krro_ProgentosTherapeuticsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_FrequencyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_SharesOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_InitialConsiderationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_FutureMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ProceedsFromSaleOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectOfAdoptionMember" xlink:label="krro_EffectOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PriorToTheAdoptionOfAsc842Member" xlink:label="krro_PriorToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SubsequentToTheAdoptionOfAsc842Member" xlink:label="krro_SubsequentToTheAdoptionOfAsc842Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" xlink:label="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredRentNetOfCurrentPortion" xlink:label="krro_DeferredRentNetOfCurrentPortion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="krro_EffectOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_PriorToTheAdoptionOfAsc842Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_SubsequentToTheAdoptionOfAsc842Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_DeferredRentNetOfCurrentPortion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccountingStanderedSectionsEightFourTwoMember" xlink:label="krro_AccountingStanderedSectionsEightFourTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PriorToTheAdoptionOfAsc842Member" xlink:label="krro_PriorToTheAdoptionOfAsc842Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_AccountingStanderedSectionsEightFourTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="krro_PriorToTheAdoptionOfAsc842Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MsApaAssetMember" xlink:label="krro_MsApaAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:label="krro_ChangeInFairValueOfPreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_InitialConsiderationAmount" xlink:label="krro_InitialConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_FutureMilestonePayments" xlink:label="krro_FutureMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="srt_PlatformOperatorCryptoAssetTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="krro_MsApaAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_ChangeInFairValueOfPreferredStockTrancheLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_InitialConsiderationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="krro_FutureMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDispositions" xlink:label="us-gaap_PropertyPlantAndEquipmentDispositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDispositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlanMember" xlink:label="krro_StockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlan1Member" xlink:label="krro_StockIncentivePlan1Member"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockOptionsMember" xlink:label="krro_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EmployeeStockPurchasePlanMember" xlink:label="krro_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlan1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="krro_StockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_KorrosMember" xlink:label="krro_KorrosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_KorrosMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed1PreferredStockMember" xlink:label="krro_SeriesSeed1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed2PreferredStockMember" xlink:label="krro_SeriesSeed2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PercentageOfOutstandingSharesOfPreferredStock" xlink:label="krro_PercentageOfOutstandingSharesOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeed3PreferredStockMember" xlink:label="krro_SeriesSeed3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="krro_PercentageOfOutstandingSharesOfPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeed3PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CommonStockIssuableUponConversion" xlink:label="krro_CommonStockIssuableUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="krro_CommonStockIssuableUponConversion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_StockIncentivePlanMember" xlink:label="krro_StockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncentiveAwardPlanMember" xlink:label="krro_IncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandNineteenStockIncentivePlanMember" xlink:label="krro_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="krro_TwoThousandAndFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandAndNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_StockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_IncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="krro_TwoThousandAndFourteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReverseRecapitalization" xlink:label="krro_ReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceReverseRecapitalization" xlink:label="krro_WeightedAverageExercisePriceReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_WeightedAverageExercisePriceCancelled" xlink:label="krro_WeightedAverageExercisePriceCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_ReverseRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_WeightedAverageExercisePriceReverseRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="krro_WeightedAverageExercisePriceCancelled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithLimitation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OperatingLossCarryforwardsExpirationYear" xlink:label="krro_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_TaxCreditCarryforwardExpirationYear" xlink:label="krro_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PeriodOfCumulativeChangeInOwnership" xlink:label="krro_PeriodOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CumulativeChangeInOwnershipPercentage" xlink:label="krro_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithLimitation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_PeriodOfCumulativeChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="krro_CumulativeChangeInOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_GenevantAgreementMember" xlink:label="krro_GenevantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase3ClinicalTrailMember" xlink:label="krro_Phase3ClinicalTrailMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_Phase2BClinicalTrial1Member" xlink:label="krro_Phase2BClinicalTrial1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_MilestonePayment" xlink:label="krro_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ReimbursementsWithInResearchAndDevelopmentExpense" xlink:label="krro_ReimbursementsWithInResearchAndDevelopmentExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="krro_GenevantAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="krro_Phase3ClinicalTrailMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="krro_Phase2BClinicalTrial1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="krro_ReimbursementsWithInResearchAndDevelopmentExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SixZeroFirstStreetLeaseMember" xlink:label="krro_SixZeroFirstStreetLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="krro_SixZeroFirstStreetLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OKSFacilityMember" xlink:label="krro_OKSFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CummingsParkSubleaseMember" xlink:label="krro_CummingsParkSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SixZeroFirstStreetLeaseMember" xlink:label="krro_SixZeroFirstStreetLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_OKSFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_CummingsParkSubleaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="krro_SixZeroFirstStreetLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncurredExpenses" xlink:label="krro_IncurredExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AffiliateCosts" xlink:label="us-gaap_AffiliateCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="krro_IncurredExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AffiliateCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesSeedPreferredStockMember" xlink:label="krro_SeriesSeedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_LegacyKorroMember" xlink:label="krro_LegacyKorroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_UnvestedRestrictedStockUnitsMember" xlink:label="krro_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_OutstandingStockOptionsMember" xlink:label="krro_OutstandingStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB1PreferredStockMember" xlink:label="krro_SeriesB1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_SeriesB2PreferredStockMember" xlink:label="krro_SeriesB2PreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesSeedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="krro_LegacyKorroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="krro_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="krro_OutstandingStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="krro_SeriesB2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="krro_CashAcquiredInConnectionWithTheReverseRecapitalization" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="krro_NonCashLeaseExpenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="krro_ShareBasedCompensationExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="krro_PurchasesOfInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="krro_PaymentOfReverseRecapitalizationTransactionCosts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestIncomeExpenseNet" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="krro_IncreaseDecreaseInLeaseLiabilities" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="17" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="krro_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_NonCashLeaseExpenses" xlink:label="krro_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_ShareBasedCompensationExpense" xlink:label="krro_ShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PurchasesOfInvestments" xlink:label="krro_PurchasesOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="krro_PaymentOfReverseRecapitalizationTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" xlink:label="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_IncreaseDecreaseInLeaseLiabilities" xlink:label="krro_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="krro_AccruedExternalResearchAndDevelopmentServicesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_AccruedExternalResearchAndDevelopmentServicesCurrent" xlink:label="krro_AccruedExternalResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="krro_EffectiveIncomeTaxCreditCarryforwards" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_EffectiveIncomeTaxCreditCarryforwards" xlink:label="krro_EffectiveIncomeTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="krro_DeferredTaxAssetsAmortization" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="krro-20231231.xsd#krro_DeferredTaxAssetsAmortization" xlink:label="krro_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="krro_AccruedExternalResearchAndDevelopmentServicesCurrent" name="AccruedExternalResearchAndDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares" name="ProceedsFromIssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_AccreditedInvestorsMember" name="AccreditedInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ReverseRecapitalization" name="ReverseRecapitalization" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_IntellectualPropertyExpensesPolicyTextBlock" name="IntellectualPropertyExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_SixZeroFirstStreetLeaseMember" name="SixZeroFirstStreetLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived" name="AdvancePaymentsForPropertyAndEquipmentNotYetReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_MsApaAssetMember" name="MsApaAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_SeriesB2ConvertiblePreferredStockMember" name="SeriesB2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" name="IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_TwoThousandAndNineteenStockIncentivePlanMember" name="TwoThousandAndNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_EffectiveIncomeTaxCreditCarryforwards" name="EffectiveIncomeTaxCreditCarryforwards" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_SeriesSeedConvertiblePreferredStockMember" name="SeriesSeedConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_SeriesB2PreferredStockMember" name="SeriesB2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_CommonStockIssuableUponConversion" name="CommonStockIssuableUponConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="krro_PriorToTheAdoptionOfAsc842Member" name="PriorToTheAdoptionOfAsc842Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ProgentosTherapeuticsMember" name="ProgentosTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_SeriesSeedPreferredStockMember" name="SeriesSeedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ChangeInFairValueOfPreferredStockTrancheLiability" name="ChangeInFairValueOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_AdditionsOfContingentValueRightLiability" name="AdditionsOfContingentValueRightLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_PaymentOfReverseRecapitalizationTransactionCosts" name="PaymentOfReverseRecapitalizationTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_Phase3ClinicalTrailMember" name="Phase3ClinicalTrailMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" name="ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" name="IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_SeverancePayment" name="SeverancePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_SeriesSeed1PreferredStockMember" name="SeriesSeed1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ShareBasedCompensationExpense" name="ShareBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_OutstandingStockOptionsMember" name="OutstandingStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_CashAcquiredInConnectionWithTheReverseRecapitalization" name="CashAcquiredInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_CummingsParkSubleaseMember" name="CummingsParkSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_NetOperatingLossCarryforwardsExpirationWithLimitation" name="NetOperatingLossCarryforwardsExpirationWithLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_StockOptionsMember" name="StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ChangeInFairValueOfContingentValueRightLiability" name="ChangeInFairValueOfContingentValueRightLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_Phase2BClinicalTrial1Member" name="Phase2BClinicalTrial1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_KorrosMember" name="KorrosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_DeferredRentNetOfCurrentPortion" name="DeferredRentNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" name="PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_SeriesB1PreferredStockMember" name="SeriesB1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_PreferredStockPolicyTextBlock" name="PreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_IssuanceOfCommonStockForCashInPreClosingFinancing" name="IssuanceOfCommonStockForCashInPreClosingFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_ReimbursementsWithInResearchAndDevelopmentExpense" name="ReimbursementsWithInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_SubsequentToTheAdoptionOfAsc842Member" name="SubsequentToTheAdoptionOfAsc842Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_Denominator" name="Denominator" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_DefinedContributionPlanName" name="DefinedContributionPlanName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_AccountingStanderedSectionsEightFourTwoMember" name="AccountingStanderedSectionsEightFourTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_EffectOfAdoptionMember" name="EffectOfAdoptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_StockIncentivePlan1Member" name="StockIncentivePlan1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_FairvalueOfContingentValueRightLiability" name="FairvalueOfContingentValueRightLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_IncentiveAwardPlanMember" name="IncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_NonCashLeaseExpenses" name="NonCashLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_WeightedAverageExercisePriceCancelled" name="WeightedAverageExercisePriceCancelled" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_OperatingLeaseLiabilitiesNetOfCurrentPortion" name="OperatingLeaseLiabilitiesNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_TwoThousandAndFourteenStockIncentivePlanMember" name="TwoThousandAndFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares" name="IssuanceOfCommonStockForCashInPreClosingFinancingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_FrequencyMember" name="FrequencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_OperatingLeaseLiabilitiesArisingFromLeaseModification" name="OperatingLeaseLiabilitiesArisingFromLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" name="OperatingLeaseLiabilitiesArisingFromRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_CvrLiabilityCurrent" name="CvrLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_GenevantAgreementMember" name="GenevantAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_SeriesSeed3PreferredStockMember" name="SeriesSeed3PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" name="PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_SeriesSeed2PreferredStockMember" name="SeriesSeed2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_PercentageOfOutstandingSharesOfPreferredStock" name="PercentageOfOutstandingSharesOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="krro_SharesOwnershipPercentage" name="SharesOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="krro_TwoThousandNineteenStockIncentivePlanMember" name="TwoThousandNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_AccountsPayableAndAccruedExpenses" name="AccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_ProceedsFromSaleOfAssets" name="ProceedsFromSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_StockIncentivePlanMember" name="StockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" name="RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation" name="NetOperatingLossCarryforwardsExpirationWithoutLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_PeriodOfCumulativeChangeInOwnership" name="PeriodOfCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_ConversionOfPreferredStockToCommonStockShares" name="ConversionOfPreferredStockToCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_ScheduleOfContingentValueRightLiabilityTableTextBlock" name="ScheduleOfContingentValueRightLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_ConversionOfPreferredStockToCommonStock" name="ConversionOfPreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_LegacyKorroMember" name="LegacyKorroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_OKSFacilityMember" name="OKSFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_PurchasesOfInvestments" name="PurchasesOfInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" name="DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_InitialConsiderationAmount" name="InitialConsiderationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" name="TwoThousandTwentyThreeStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_WeightedAverageExercisePriceReverseRecapitalization" name="WeightedAverageExercisePriceReverseRecapitalization" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="krro_IncurredExpenses" name="IncurredExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="krro_FutureMilestonePayments" name="FutureMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720266112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Korro Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001703647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2324450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Kendall Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 600-700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 6-401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text"> 468-1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRRO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,148,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,021,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719873376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 166,150<span></span>
</td>
<td class="nump">$ 36,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,563<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,015<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">172,728<span></span>
</td>
<td class="nump">57,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,665<span></span>
</td>
<td class="nump">9,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">27,150<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash, net of current portion</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">4,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,714<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">221,663<span></span>
</td>
<td class="nump">73,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,280<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,212<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">31,216<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">51,752<span></span>
</td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 5,755,759 shares authorized at December 31, 2023 and 2022; 8,016,516 and 271,371 shares issued at December 31, 2023 and 2022, respectively; 8,016,516 and 268,468 shares outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">352,908<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(183,005)<span></span>
</td>
<td class="num">(101,833)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">169,911<span></span>
</td>
<td class="num">(99,031)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">221,663<span></span>
</td>
<td class="nump">73,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember', window );">Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720109792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">5,755,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="nump">271,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="nump">268,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity, preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity, preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 91,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity, preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember', window );">Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,036,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity, preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227825679360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 57,250<span></span>
</td>
<td class="nump">$ 42,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,284<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">84,534<span></span>
</td>
<td class="nump">58,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(84,534)<span></span>
</td>
<td class="num">(58,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">3,389<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">3,389<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(81,145)<span></span>
</td>
<td class="num">(58,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,172)<span></span>
</td>
<td class="num">(58,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (81,172)<span></span>
</td>
<td class="num">$ (58,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (53.08)<span></span>
</td>
<td class="num">$ (227.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (53.08)<span></span>
</td>
<td class="num">$ (227.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic</a></td>
<td class="nump">1,529,321<span></span>
</td>
<td class="nump">255,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted</a></td>
<td class="nump">1,529,321<span></span>
</td>
<td class="nump">255,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227809396928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series Seed Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B-1 Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B-2 Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityShareSubscriptions', window );">Temporary equity, beginning balance (in share) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,924<span></span>
</td>
<td class="nump">$ 77,736<span></span>
</td>
<td class="nump">$ 57,703<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in share) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (42,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (43,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services rendered (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services rendered</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Vesting of restricted common stock (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,032)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in share) at Dec. 31, 2022</a></td>
<td class="nump">268,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (99,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(101,833)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityShareSubscriptions', window );">Temporary equity, beginning balance (in share) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,924<span></span>
</td>
<td class="nump">$ 77,736<span></span>
</td>
<td class="nump">$ 57,703<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services rendered (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services rendered</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options (in shares)</a></td>
<td class="nump">39,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">$ 702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Vesting of restricted common stock (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares', window );">Issuance of Series B-2 convertible preferred stock, net of issuance costs (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Issuance of Series B-2 convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares', window );">Issuance of common stock for cash in PIPE financing (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,077,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IssuanceOfCommonStockForCashInPreClosingFinancing', window );">Issuance of common stock for cash in PIPE financing</a></td>
<td class="nump">117,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">117,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ConversionOfPreferredStockToCommonStockShares', window );">Conversion of preferred stock to common stock (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(684,739)<span></span>
</td>
<td class="num">(2,029,666)<span></span>
</td>
<td class="num">(1,104,178)<span></span>
</td>
<td class="num">(1,036,656)<span></span>
</td>
<td class="nump">4,855,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">209,320<span></span>
</td>
<td class="num">$ (15,924)<span></span>
</td>
<td class="num">$ (77,736)<span></span>
</td>
<td class="num">$ (57,703)<span></span>
</td>
<td class="num">$ (57,958)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">209,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares', window );">Issuance of common stock to Frequency shareholders in reverse recapitalization (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization', window );">Issuance of common stock to Frequency shareholders in reverse recapitalization</a></td>
<td class="nump">32,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">32,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Reverse recapitalization transaction costs</a></td>
<td class="num">(12,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,172)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in share) at Dec. 31, 2023</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,016,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 169,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 352,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (183,005)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityShareSubscriptions', window );">Temporary equity, beginning balance (in share) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Stock To Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ConversionOfPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Stock To Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ConversionOfPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IssuanceOfCommonStockForCashInPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock For Cash In Pre Closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IssuanceOfCommonStockForCashInPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock For Cash In Pre Closing Financing, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Convertible Preferred Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityShareSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityShareSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720062576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (81,172)<span></span>
</td>
<td class="num">$ (58,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_NonCashLeaseExpenses', window );">Non-cash lease expense</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="nump">2,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">559<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IncreaseDecreaseInLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="num">(2,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non-current assets</a></td>
<td class="num">(1,987)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(67,283)<span></span>
</td>
<td class="num">(53,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PurchasesOfInvestments', window );">Purchases of investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(37,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">53,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,836)<span></span>
</td>
<td class="num">(5,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived', window );">Advance payments for property and equipment not yet received</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">11,164<span></span>
</td>
<td class="nump">11,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in pre-closing financing</a></td>
<td class="nump">117,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CashAcquiredInConnectionWithTheReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">36,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PaymentOfReverseRecapitalizationTransactionCosts', window );">Payment of reverse recapitalization transaction costs</a></td>
<td class="num">(12,247)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">187,761<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">131,642<span></span>
</td>
<td class="num">(42,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">41,477<span></span>
</td>
<td class="nump">84,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">173,119<span></span>
</td>
<td class="nump">41,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Investing and Financing Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance', window );">Property and equipment capitalized under tenant improvement allowance</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets', window );">Operating Lease Liabilities Arising From Right-Of-Use Assets</a></td>
<td class="nump">26,777<span></span>
</td>
<td class="nump">5,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLeaseLiabilitiesArisingFromLeaseModification', window );">Operating lease liabilities arising from lease modification</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember', window );">Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Series convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 45,458<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance Payments For Property And Equipment Not Yet Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_CashAcquiredInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_CashAcquiredInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_OperatingLeaseLiabilitiesArisingFromLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities arising from lease modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_OperatingLeaseLiabilitiesArisingFromLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities Arising From Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PaymentOfReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of reverse recapitalization transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PaymentOfReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property And Equipment Capitalized Under Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PurchasesOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases Of Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PurchasesOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720287376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. The Company and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Korro Bio, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company was incorporated in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_81265546-519d-4e10-aa08-5ad84f64dad1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2014</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a Delaware corporation. The Company's principal offices are in Cambridge, Massachusetts.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Merger with Legacy Korro</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, Frequency Merger Sub, Inc.(&#8220;Merger Sub&#8221;) a Delaware corporation, a wholly-owned subsidiary of Frequency Therapeutics, Inc. (&#8220;Frequency&#8221;), a Delaware corporation and Korro Bio, Inc (&#8220;Legacy Korro&#8221;), a Delaware corporation, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  The merger was completed on November 3, 2023 (the &#8220;Merger&#8221; or the "Transaction").  In accordance with the Merger Agreement, the Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as a wholly-owned subsidiary of the Company.  In connection with the completion of the Merger, the Company changed its name from Frequency Therapeutics, Inc. to Korro Bio, Inc.  On November 6, 2023, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;KRRO&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise indicated, references herein to the &#8220;Company,&#8221; or the &#8220;combined company&#8221;, refer to Korro Bio, Inc. on a post-merger basis, and the term &#8220;Legacy Korro&#8221; refers to the business of privately held Korro Bio, Inc., prior to completion of the merger. References to Frequency refer to Frequency Therapeutics, Inc. prior to completion of the merger.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with the execution and delivery of the Merger Agreement, Legacy Korro entered into a subscription agreement with a number of accredited investors. Immediately prior to consummation of the Merger, Legacy Korro issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42,176,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Shares of Legacy Korro common stock issued pursuant to the Pre-Closing Financing were converted into shares of the Company&#8217;s common stock based on an exchange ratio (as defined below).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Legacy Korro preferred stock was converted into a share of Legacy Korro common stock, and then exchanged in the Merger for shares of Frequency common stock using an exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.049688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Exchange Ratio&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger, the Company issued (or reserved for issuance upon exercise of options assumed in the Merger) an aggregate of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,848,776</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to Legacy Korro securityholders (before eliminating fractions), calculated as provided in the Merger Agreement, (the &#8220;Exchange&#8221;), resulting in approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,623,645</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock being issued and outstanding on a fully diluted basis immediately following the effective time of the Merger. This number includes shares of the Company&#8217;s common stock that was issued upon vesting and settlement of certain outstanding equity awards at the effective time of the Merger.  Immediately following the completion of the Merger, Frequency securityholders prior to the Merger owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of common stock on a fully diluted basis and Legacy Korro&#8217;s securityholders, including those securityholders who purchased shares in Legacy Korro&#8217;s pre-closing financing, owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares on a fully diluted basis. The Merger was intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "IRC").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon closing of the Merger, the Company assumed the Legacy Korro 2019 Stock Incentive Plan, and each outstanding and unexercised option to purchase Legacy Korro shares at such time, each of which converted into an option to purchase shares of the Company&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. In addition, upon the closing of the Merger, the Company assumed each outstanding and unexercised warrant to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legacy Korro shares at such time, each of which converted into a warrant to purchase shares of the Company&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger, the Company entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;) with Computershare Trust Company, N.A. and Computershare Inc., collectively as rights agent providing for the payment of certain contingent cash payments equal to the net amount (calculated in accordance with GAAP consistently applied) of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to Frequency&#8217;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein.  Concurrently, the Company entered into an asset purchase agreement with Progentos Therapeutics (&#8220;Progentos&#8221;), whereby Progentos acquired the rights, title and interest in certain assets related to Freqeuncy&#8217;s MS program ("MS APA").  The MS APA included initial consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment in the event of Progentos closing of an equity financing at or above a specified amount.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. For accounting purposes, Legacy Korro was considered to be acquiring the assets and liabilities of Frequency in the Merger based on the terms of the Merger Agreement and other factors, including: (i) Legacy Korro controlling the majority of outstanding voting shares; (ii) Legacy Korro controlling the Board of Directors; (iii) Legacy Korro&#8217;s executive management team became the management of the combined company; and (iv) the pre-combination assets of Frequency were primarily cash and cash equivalents and other non-operating assets. Accordingly, the Merger was treated as the equivalent of Legacy Korro issuing stock to acquire the net assets of Frequency. As a result of Legacy Korro being treated as the accounting acquirer, Legacy Korro&#8217;s assets and liabilities were recorded at their pre-combination carrying amounts. Frequency&#8217;s assets and liabilities were measured and recognized at their fair values, which approximated their carrying values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Legacy Korro after the consummation of the Merger. As a result, upon consummation the historical financial statements of Legacy Korro became the historical consolidated financial statements of the combined company.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split and Exchange Ratio</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with, and prior to the completion of, the merger, Frequency effected a one-for-fifty reverse stock split of its then outstanding common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding Legacy Korro common stock, convertible preferred stock and options prior to the effective date of the merger have been retroactively adjusted to reflect the merger </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.049688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange Ratio, which reflects the impact of the reverse stock split, for all periods presented.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company expects that its existing cash and cash equivalents as of December 31, 2023 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">166.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these consolidated financial statements. The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">183.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that the revenues or profitability will be sustained on a continuing basis. In addition, the Company&#8217;s preclinical and clinical development activities, manufacturing and commercialization of the Company&#8217;s product candidates, if approved, will require significant additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable rights to its technology and product candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227809426352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment. The Company operates only in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the fair value of the common stock prior to the effective date of the merger; the fair value of the CVR liability and the incremental borrowing rate for determining lease liabilities and right-of-use assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, (&#8220;ASC 820&#8221;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#8220;Fair Value Measurements&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#8220;Other income, net&#8221;. Unrealized gains and losses on available-for-sale securities are included in &#8220;Accumulated other comprehensive loss&#8221; as a component of stockholders&#8217; deficit until realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under finance leases, is calculated over the estimated useful lives of the assets using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 842&#8221;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity (deficit).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#8217;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#8220;ASC 718&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, non-employees and members of the Company&#8217;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and non-employees, the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, due to the absence of an active market for Legacy Korro&#8217;s common stock, Legacy Korro and its Board were required to determine the fair value of Legacy Korro&#8217;s common stock at the time of each grant of a stock-based award. Legacy Korro estimated the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#8220;OPM&#8221;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each valuation methodology includes estimates and assumptions that required the Legacy Korro&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which Legacy Korro sold convertible preferred stock to third parties in arms&#8217; length transactions, the rights and preferences of securities senior to Legacy Korro&#8217;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the grant date fair value of the Company&#8217;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-based payment, (ii) the risk-free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Due to the lack of Company-specific historical and implied volatility data, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures of all stock-based payments when such forfeitures occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#8220;Provision for income taxes&#8221; in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net income attributable to common stockholders and participating preferred shares are allocated to each share as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Net loss attributable to common stockholders is equal to the net loss for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per share is computed using the more dilutive of (a) the two-class method or (b) the treasury stock method and if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Preferred Stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#8217;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#8217;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging growth company status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company qualifies as an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-03, and ASU 2022-02 (&#8220;ASU 2016-13&#8221;). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The amendments in this standard should be applied on a modified retrospective basis to all periods presented. The Company adopted ASU 2016-13 on January 1, 2023 using the modified retrospective approach. The adoption of this standard did not have a material effect on the Company&#8217;s financial position, results of operations or disclosures.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Yet to be Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720322048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Reverse Merger</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Reverse Merger</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 1, Legacy Korro merged with Frequency on November 3, 2023. The merger was accounted for as a reverse recapitalization with Legacy Korro as the accounting acquirer. The primary pre-combination assets of Frequency were cash and cash equivalents. Under reverse recapitalization accounting, the assets and liabilities of Frequency were recorded at their fair value which approximated book value due to the short-term nature of the accounts. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the operations of Legacy Korro for accounting purposes, together with a deemed issuance of shares equivalent to the shares held by the former stockholders of Frequency, the legal acquirer, and a recapitalization of the equity of Legacy Korro, the accounting acquirer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the reverse recapitalization, the Company acquired $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash and cash equivalents. The Company also obtained prepaids and other assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and assumed accounts payable and accrued expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Frequency&#8217;s development programs had ceased prior to the merger and were deemed to be de minimis in value at the transaction date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in share-based compensation expense as a result of the acceleration of vesting of stock options, performance stock units and restricted stock units at the time of merger. This amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in personnel cost related to the severance payment to Frequency employees and this amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The Company also incurred transaction costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million and this amount is recorded in additional paid-in capital in the accompanying consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit) for the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227717662816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include commercial paper and government securities that are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MS APA asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.621%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,819</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted previously in Note 1, at the effective time of the Transaction, the Company entered into the CVR Agreement providing for the payment of certain contingent cash payments equal to the net amount of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to the Company&#8217;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the CVR is a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5a1b49f3-7a54-4e43-9407-97170c711b48;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derivative liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is accounted for at fair value, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in accrued expenses and other current liabilities and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other non-current liabilities in the consolidated balance sheet. Concurrently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into the MS APA with Progentos, whereby Progentos acquired the rights, title and interest in certain assets related to the Company&#8217;s MS program. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MS APA included initial consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment in the event of Progentos closing of an equity financing at or above a specified amount.  The Company concluded that the MS APA is a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c39e9862-e9fa-4ff5-9da0-641cc2ce94c0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derivative asset</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is accounted for at fair value, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in prepaid and other current assets and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other long-term assets in the consolidated balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the CVR liability and the MS APA are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR liability and the MS APA asset, the Company used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of significant judgment, estimates and assumptions, including the probability of technical and regulatory success, and discount rates. For the year ended December 31, 2023, the aggregate change in fair value of the CVR liability and MS APA asset was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.08</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no liabilities measured at fair value on a recurring basis as of December 31, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in valuation techniques, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r were there any transfers among the fair value hierarchy levels during the years ended December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720316432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did not have investments as of December 31, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments as of December 31, 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2022, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> securities that were in an unrealized loss position for more than twelve months. As of December 31, 2022, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716665488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company maintained current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and non-current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of De</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cember 31, 2022, the Company maintained current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and non-current restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company&#8217;s facility leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December 31, 2023 and 2022 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720372960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment , Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, as of December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.6%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:36.04%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">241</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,665</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had construction in progress of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, predominately related to laboratory equipment received but not yet installed and capitalizable costs related to the Company&#8217;s future corporate headquarters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227717780240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227807704720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the closing of the merger, the shares of Legacy Korro common stock were converted into shares of the Company's common stock based on the exchange ratio determined in the Merger Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company was authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per value per share. Prior to the merger, the holders of Legacy Korro&#8217;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth in Note 10. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends had been declared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had reserved for future issuance the following number of shares of common stock:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances of Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">813,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of outstanding warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,890</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 ESPP Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,675,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,487,208</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716663168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock shares issued or outstanding.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, immediately prior to closing of the Merger, each share of Legacy Korro's Preferred Stock issued and outstanding immediately prior to the Closing of the Merger was converted into shares of the Legacy Korro&#8217;s common stock, and then exchanged in the Merger for shares of the Company's common stock using an exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.049688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The conversion was approved by greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the then-outstanding shares of Preferred Stock, voting as a single class on an as-converted to common stock basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, Legacy Korro was authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock shares issued or outstanding. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, Legacy Korro Preferred Stock authorized, issued and outstanding consisted of the following (in thousands, except share amounts):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred <br/>Stock <br/>Authorized</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred<br/>Stock Issued<br/>and<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liquidation<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036,656</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,855,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,042,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,042,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights, Preferences and Privileges of Legacy Korro Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock as of December 31, 2022 had the following rights and preferences. In the discussion below, the Legacy Korro Series Seed Preferred Stock and the Legacy Korro Series A Preferred Stock, the Legacy Korro Series B-1 Preferred Stock and the Legacy Korro Series B-2 Preferred Stock are collectively referred to as the &#8220; Legacy Korro Preferred Stock&#8221; unless specifically noted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Legacy Korro Preferred Stock were convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the original issuance price by the conversion price in effect at the time of conversion. The original conversion price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series Seed 3 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series A Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.08</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the original conversion price of the Legacy Korro Series B-1 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the original conversion price of the Legacy Korro Series B-2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Legacy Korro preferred stock are subject to adjustments to reflect the issuance of common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warrants, or other rights to subscribe for or to purchase common stock for a consideration per share, less than the conversion price then in effect and subsequent stock dividends, stock splits, combinations, or recapitalizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock was subject to mandatory conversion upon the closing of a sale of common stock to the public at a price of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">111.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination or other similar recapitalization) in a firm-commitment underwritten public offering resulting in at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of gross proceeds to Legacy Korro. The Legacy Korro Preferred Stock was also subject to mandatory conversion upon the vote or written consent of the holders of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the then-outstanding shares of Legacy Korro Preferred Stock, voting as a single class on an as-converted to common stock basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Legacy Korro Preferred Stock, in preference to common stockholders, were entitled to receive, when, as and if declared by the Company&#8217;s Board of Directors, dividends at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% annually. Dividends on Legacy Korro Preferred Stock were non-cumulative and were payable only when and if declared by Legacy Korro&#8217;s Board of Directors. The holders of Legacy Korro Preferred Stock were entitled to participate in dividends on common stock on an as-converted basis when and if declared by Legacy Korro's Board of Directors. Since Legacy Korro&#8217;s inception, no dividends have been declared.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation Preference</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the holders of shares of Legacy Korro Preferred Stock then outstanding were entitled to be paid out of the assets of Legacy Korro available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount equal to the original issue price per share plus any dividends declared but unpaid thereon. For clarity, the original issue price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series Seed 3 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series A Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.08</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the original issue price of the Legacy Korro Series B-1 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the original issue price of the Legacy Korro Series B-2 Preferred Stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If upon any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the assets of Legacy Korro available for distribution were insufficient to pay the holders of Legacy Korro Preferred Stock the full amount to which they were entitled, the holders of shares of Legacy Korro Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redemption</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Legacy Korro Preferred Stock was contingently redeemable upon the occurrence of a deemed liquidation event, which included a merger or a sale of substantially all of the assets of Legacy Korro. As of December 31, 2022, a deemed liquidation event was not considered to be probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Legacy Korro Preferred Stock were entitled to vote based on the number of common shares that their preferred shares converted into on as-converted basis at the time of such vote. Except in specific circumstances, holders of Legacy Korro Preferred Stock shall vote as a single class with the common stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of record of the shares of the Legacy Korro Series Seed Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to Legacy Korro&#8217;s Board of Directors. The holders of record of the shares of the Legacy Korro Series A Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#8217;s Board of Directors. The holders of record of the shares of the Legacy Korro Series B Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#8217;s Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716713072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Stock Option and Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2023, the Company&#8217;s board of directors adopted the Company&#8217;s 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan was approved by the Company&#8217;s stockholders in November 2023 and became effective in November 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">connection with completion of the Merger. The 2023 Plan initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">885,028</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for the issuance of stock awards. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the number of shares of common stock available for issuance under the 2023 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2023 Plan, beginning with January 1, 2024 and ending with January 1, 2033, by the amount equal to 5% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Awards granted under the 2023 Plan expire no later than ten years from the date of grant. For stock options, the option price shall generally not be less than 100% of the fair market value on the day of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were in aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">889,922</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">255,694</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available to grant under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Legacy Korro's Board of Directors adopted the 2019 Stock Incentive Plan (as amended from time to time, the &#8220;Legacy Korro Plan&#8221;). The Legacy Korro Plan provides for the grant of stock options, stock awards and restricted stock units to employees, members of the Company&#8217;s Board of Directors and non-employee consultants and advisors. The Legacy Korro Plan initially provided for the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110,285</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The Legacy Korro Plan was subsequently amended in May 2019, June 2020, October 2020, April 2021, November 2021 and March 2023 to modify the number of shares of common stock issuable under the Legacy Korro Plan. Subsequent to the March 2023 amendment to the Legacy Korro Plan, Legacy Korro could issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">747,752</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the Legacy Korro Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the merger, each option to purchase shares of Legacy Korro common stock that was outstanding and unexercised under the Legacy Korro Plan immediately prior to the Effective Time, whether or not vested, was converted into an option to purchase shares of the Company&#8217;s common stock and became eligible to be registered on Form S-8. The Company assumed each outstanding option to purchase shares of Legacy Korro common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of the Legacy Korro Plan and the terms of the stock option agreement by which such option to purchase shares of Legacy Korro common stock is evidenced. The number of shares under the Legacy Korro Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of common stock reserved for issuance pursuant to outstanding awards under the Legacy Korro Plan as of December 31, 2023 and 2022 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,977</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">683,156</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. The number of shares available for grant under the Legacy Korro Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">159,890</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2023 and 2022, respectively. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the Legacy Korro Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2014 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 13, 2014, Frequency adopted the 2014 Stock Incentive Plan (as amended from time to time,the "2014 Plan"). All of Frequency&#8217;s employees, officers, directors, and consultants were eligible to be granted options to purchase common shares, restricted stock units and restricted stock under the terms of the 2014 Pla</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n. Frequency, reserved an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">424,853</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for issuance under the 2014 Plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock available for future grants under the 2014 Plan and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,455</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to outstanding option awards under the 2014 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Incentive Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 17, 2019, Frequency&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (the "2019 Plan"). Under the 2019 Plan, Frequency may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">154,032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2019 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the 2019 Plan.  Accordingly, as of December 31, 2023, there were no shares of common stock available for future grants under the 2019 Plan and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51,491</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to outstanding option awards under the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the IRC. Incentive stock options may not be granted at less than the fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">value of the Company&#8217;s common stock on the date of grant. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are determined by the Board of Directors. Stock options generally become exercisable as they vest. Options granted under the Legacy Korro Plan, 2014 Plan and the 2019 Plan expire no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Common Stock Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the adoption of the 2019 Plan, Legacy Korro issued shares of restricted common stock to its founders as well as to certain employees. The restrictions on the common stock generally lapse over two to four years. In the event that a recipient ceases to provide service to Legacy Korro, Legacy Korro has the right to repurchase any unvested shares of restricted common stock at their original purchase price. As a result of this repurchase right, Legacy Korro recorded the issuance of such restricted common stock as a liability in the consolidated balance sheets. Amounts are reclassified to common stock at par and additional paid-in capital as the restricted common stock vests and restrictions lapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes Legacy Korro restricted common stock activity during the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate fair value of Legacy Korro restricted common stock that vested during the years ended December 31, 2023 and 2022, based upon the fair value of the underlying restricted common stock on the day of vesting, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended December 31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.231%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.104000000000003%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.104000000000003%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes changes in stock option activity during the year ended December 31, 2023 (in thousands, except per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.940000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,953</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in reverse recapitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">835,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">368,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227714152688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes for the years ended December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153,481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">302.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">266.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under current law, the Company's federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of the Company's taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that are subject to expiration between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">280.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal NOLs that do not expire.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State NOLs expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, as of December 31, 2023, the Company had state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that expire at various dates from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which primarily pertain to NOL carryforwards, tax credit carryforwards and capitalized research and development. The Company has determined that it is more likely than not that it will not realize the benefits of its deferred tax assets, and as a result, a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been established at December 31, 2023. The increase in the valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">109.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2023 was primarily due to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the additional operating loss generated by the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the combination of deferred tax assets as a result of the Merger</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as defined under Sections 382 and 383 in the IRC. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change. As a result of ownership changes in the Company from its inception through December 31, 2023, the Company&#8217;s NOL and tax credit carryforwards allocable to the periods preceding each such ownership change could be subject to limitations under IRC Section 382, however the Company has not yet completed an IRC Section 382 study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits as of either December 31, 2023 or 2022. The Company has not conducted a study of its research and development credit carryforwards generated during any year. This study, once completed, may result in an adjustment to the Company&#8217;s research and development credit carryforwards.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credit carryforwards, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated statements of operations and comprehensive loss if an adjustment were required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal tax jurisdiction and the Connecticut and Massachusetts state tax jurisdictions. Because the Company is in a loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incurred any material interest or penalty charges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227810237632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Genevant Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Genevant Agreement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Genevant Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, Legacy Korro entered into a collaboration and license agreement (the &#8220;Genevant Agreement&#8221;) with Genevant Sciences GmbH (&#8220;Genevant&#8221;). Key financial terms under the Genevant Agreement are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment to Genevant in March 2023 upon execution of the Genevant Agreement and recorded the payment within research and development expense in the consolidated statement of operations for the year  ended December 31, 2023. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will reimburse Genevant for certain out-of-pocket and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genevant is entitled to receive payments from the Company upon the achievement of certain milestones, including potential clinical milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, potential regulatory and development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and potential commercial milestone payments up to an aggregate total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">57.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genevant is eligible to receive royalties at percentage rates in the mid-single-digits, based on future annual net sales of licensed products within the scope of the Genevant Agreement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, no milestones have been achieved and the Company has recorded payments to Genevant of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within research and development expense in the consolidated statement of operations during the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718096320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease at One Kendall Square, Cambridge, Massachusetts and occupies </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,561</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory and office space (the &#8220;OKS Facility&#8221;). On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 20, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an amendment to the Lease Agreement that extended the lease expiration date from December 31, 2023 to September 30, 2024 and provided the Company with no option to further extend the lease expiration date. The Company is also party to an operating sublease agreement at Cummings Park in Woburn, Massachusetts</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and occupies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,148</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory and office space (the &#8220;Cummings Park Sublease&#8221;) which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,453</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts (the &#8220;60 First Street Lease&#8221;). In May 2023, the Company obtained control over the space and the Company recognized the operating lease right-of-use asset and the operating lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the commencement date of the lease. The total rental payments over the 11 year lease are expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, including rent credits and other lease incentives per the terms of the lease. Specifically, the 60 First Street Lease provides the Company with a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company utilized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million tenant improvement allowance as of December 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1, 2023. The lease has remaining term approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has an option to extend the lease for an additional period of five years with the rent during the option period being the then fair market rent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments for all three leases, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expected to be received and intended to be used related to the remaining tenant improvement allowance and rent credits associated with the 60 First Street Lease, as of December 31, 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Future Minimum Leases Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,416</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present Value of Operating Lease Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted average incremental borrowing rate used to determine the operating lease liability was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities and maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statement of operations and comprehensive loss of its operating leases (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.249%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.075999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.075999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Frequency and the Frequency&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March 21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May 16, 2022, the Company&#8217;s Chief Development Officer, Dr. Carl Le Bel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company&#8217;s public disclosures between October 29, 2020 and March 22,2021. The lawsuit sought, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October 29,2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July 15, 2022. On March 29, 2023, the Company&#8217;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April 27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. On August 2, 2023, Plaintiff-Appellant submitted its opening brief to the First Circuit. The Company filed its response brief on October 27, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The First Circuit heard oral argument on January 8, 2024, and has not yet issued a decision on plaintiff&#8217;s appeal. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accruals have been recorded as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with the Company&#8217;s amended and restated certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company&#8217;s exposure and may enable the Company to recover a portion of any future amounts paid. The Company believes that the fair value of these potential indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716745760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. 401(k) Savings Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a defined-contribution savings plan under Section 401(k) of the IRC (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation, subject to statutory limitations. Beginning on April 1, 2022, the Company matches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s 401(k) contributions up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the participant&#8217;s salary, subject to employer match limitations under the IRC. As such, the Company made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of matching contributions to the 401(k) Plan during the year ended December 31, 2023 and December 31, 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718220656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of Atlas&#8217; ownership of the Legacy Korro&#8217;s Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock which was exchanged in the Merger for the Company's common stock, Atlas represents an affiliate of the Company. During the years ended December 31, 2023 and 2022, the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expense and expenses of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, related to consulting services provided by an affiliate of Atlas. As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts due to this affiliate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718846864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.968%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.257%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.257%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested Legacy Korro restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,514,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The following table sets forth the computation of the Company's basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.88%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,529,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227722549536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment. The Company operates only in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the fair value of the common stock prior to the effective date of the merger; the fair value of the CVR liability and the incremental borrowing rate for determining lease liabilities and right-of-use assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, (&#8220;ASC 820&#8221;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. </span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#8220;Fair Value Measurements&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#8220;Other income, net&#8221;. Unrealized gains and losses on available-for-sale securities are included in &#8220;Accumulated other comprehensive loss&#8221; as a component of stockholders&#8217; deficit until realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under finance leases, is calculated over the estimated useful lives of the assets using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 842&#8221;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity (deficit).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#8217;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 842&#8221;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PreferredStockPolicyTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity (deficit).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#8217;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IntellectualPropertyExpensesPolicyTextBlock', window );">Intellectual Property Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#8220;ASC 718&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, non-employees and members of the Company&#8217;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and non-employees, the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, due to the absence of an active market for Legacy Korro&#8217;s common stock, Legacy Korro and its Board were required to determine the fair value of Legacy Korro&#8217;s common stock at the time of each grant of a stock-based award. Legacy Korro estimated the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#8220;OPM&#8221;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each valuation methodology includes estimates and assumptions that required the Legacy Korro&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which Legacy Korro sold convertible preferred stock to third parties in arms&#8217; length transactions, the rights and preferences of securities senior to Legacy Korro&#8217;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the grant date fair value of the Company&#8217;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-based payment, (ii) the risk-free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Due to the lack of Company-specific historical and implied volatility data, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures of all stock-based payments when such forfeitures occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#8220;Provision for income taxes&#8221; in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net income attributable to common stockholders and participating preferred shares are allocated to each share as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Net loss attributable to common stockholders is equal to the net loss for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per share is computed using the more dilutive of (a) the two-class method or (b) the treasury stock method and if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Preferred Stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#8217;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#8217;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging growth company status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging growth company status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company qualifies as an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-03, and ASU 2022-02 (&#8220;ASU 2016-13&#8221;). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The amendments in this standard should be applied on a modified retrospective basis to all periods presented. The Company adopted ASU 2016-13 on January 1, 2023 using the modified retrospective approach. The adoption of this standard did not have a material effect on the Company&#8217;s financial position, results of operations or disclosures.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Yet to be Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements - Yet to be Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Yet to be Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IntellectualPropertyExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Expenses Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IntellectualPropertyExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock [Policy Text Block ]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements Yet to be Adopted Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227717656448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MS APA asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.621%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.936%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,819</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719896432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments as of December 31, 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716686048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December 31, 2023 and 2022 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716495808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, as of December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.6%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:36.04%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">241</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,665</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716495808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716745760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfConversionsOfStockTextBlock', window );">Schedule of Number of Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had reserved for future issuance the following number of shares of common stock:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of outstanding Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances of Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">813,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of outstanding warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,890</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future issuances under 2023 ESPP Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,675,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,487,208</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfConversionsOfStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfConversionsOfStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716495808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPreferredUnitsTextBlock', window );">Schedule of Preferred Stock authorized, issued and outstanding Table</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, Legacy Korro Preferred Stock authorized, issued and outstanding consisted of the following (in thousands, except share amounts):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred <br/>Stock <br/>Authorized</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred<br/>Stock Issued<br/>and<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liquidation<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036,656</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,855,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,042,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,042,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPreferredUnitsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPreferredUnitsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227714117184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Common Stock Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes Legacy Korro restricted common stock activity during the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended December 31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.231%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.104000000000003%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.104000000000003%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes changes in stock option activity during the year ended December 31, 2023 (in thousands, except per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.940000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,953</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in reverse recapitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">835,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">368,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718881936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes for the years ended December 31, 2023 and 2022 was comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153,481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227813000592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments for all three leases, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expected to be received and intended to be used related to the remaining tenant improvement allowance and rent credits associated with the 60 First Street Lease, as of December 31, 2023 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Future Minimum Leases Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,416</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present Value of Operating Lease Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statement of operations and comprehensive loss of its operating leases (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.249%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.075999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.075999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Lease Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716693008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.968%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.257%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.257%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series Seed Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series A Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-1 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,104,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legacy Korro Series B-2 Preferred Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested Legacy Korro restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,323,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding Legacy Korro warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,049</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,514,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The following table sets forth the computation of the Company's basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.88%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,529,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719482928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange Ratio</a></td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 166,150<span></span>
</td>
<td class="nump">$ 36,600<span></span>
</td>
<td class="nump">$ 36,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(183,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (101,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_InitialConsiderationAmount', window );">Initial Consideration Amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_FutureMilestonePayments', window );">Future Milestone Payments</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_FutureMilestonePayments', window );">Future Milestone Payments</a></td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Legacy Korro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_SharesOwnershipPercentage', window );">Ownership</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Legacy Korro [Member] | Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,176,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common Stock, Value, Subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Frequency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,623,645<span></span>
</td>
<td class="nump">7,848,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_SharesOwnershipPercentage', window );">Ownership</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange Ratio</a></td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 111.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Legacy Korro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_InitialConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_InitialConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_SharesOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Ownership, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_SharesOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_LegacyKorroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_LegacyKorroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krro_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krro_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_FrequencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_FrequencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720307232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 27,150<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">$ 1,991<span></span>
</td>
<td class="nump">$ 2,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227714138304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227713977072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill or intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">36,600<span></span>
</td>
<td class="nump">$ 166,150<span></span>
</td>
<td class="nump">$ 36,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_AccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_SeverancePayment', window );">Severance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_AccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_AccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_SeverancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_SeverancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227722561792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">$ 160,154<span></span>
</td>
<td class="nump">33,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">158,706<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">158,706<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">158,706<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720304800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Tranfer of assets among fair value hierarchy levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expense and Other Assets, Current</a></td>
<td class="nump">3,015,000<span></span>
</td>
<td class="nump">1,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 1,053,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember', window );">MS APA Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_InitialConsiderationAmount', window );">Initial Consideration Amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets, Current</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expense and Other Assets, Current</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | MS APA Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_FutureMilestonePayments', window );">Future Milestone Payments</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | MS APA Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_FutureMilestonePayments', window );">Future Milestone Payments</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | MS APA Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ChangeInFairValueOfPreferredStockTrancheLiability', window );">Change in fair value of CVR liability</a></td>
<td class="nump">$ 80,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ChangeInFairValueOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Preferred Stock Tranche Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ChangeInFairValueOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_InitialConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_InitialConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=krro_MsApaAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227806079264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 18,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 14,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719806304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Securities</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value of securities in unrealized loss position for less than twelve | $</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of position of securities in unrealized loss position for less than twelve | Securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720330480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 166,150<span></span>
</td>
<td class="nump">$ 36,600<span></span>
</td>
<td class="nump">$ 36,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">6,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 173,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227828229776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="nump">$ 3,563<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted Cash, Noncurrent</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720127808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 23,507<span></span>
</td>
<td class="nump">$ 14,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(7,842)<span></span>
</td>
<td class="num">(4,255)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 15,665<span></span>
</td>
<td class="nump">$ 9,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDispositions', window );">Property, Plant and Equipment, Dispositions</a></td>
<td class="text">Shorter of useful life or remaining lease term<span></span>
</td>
<td class="text">Shorter of useful life or remaining lease term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 11,187<span></span>
</td>
<td class="nump">$ 8,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 3,356<span></span>
</td>
<td class="nump">$ 2,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 8,242<span></span>
</td>
<td class="nump">$ 2,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDispositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting treatment for disposals of property, plant and equipment, including gains and losses related thereto.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDispositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716686784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 3,630<span></span>
</td>
<td class="nump">$ 2,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720104784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Other employee compensation and benefits</a></td>
<td class="nump">$ 7,896<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_AccruedExternalResearchAndDevelopmentServicesCurrent', window );">External research and development services</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other operating expenses</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CvrLiabilityCurrent', window );">CVR Liability, Current</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 10,212<span></span>
</td>
<td class="nump">$ 3,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_AccruedExternalResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued External Research and Development Services Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_AccruedExternalResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_CvrLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_CvrLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718009008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="nump">271,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">1,675,396<span></span>
</td>
<td class="nump">5,487,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Exercises of outstanding Shares</a></td>
<td class="nump">8,016,516<span></span>
</td>
<td class="nump">268,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_StockIncentivePlanMember', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">110,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_StockIncentivePlan1Member', window );">2023 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">255,694<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">88,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Outstanding Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Exercises of outstanding Shares</a></td>
<td class="nump">8,049<span></span>
</td>
<td class="nump">8,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=krro_StockOptionsMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Exercises of outstanding Shares</a></td>
<td class="nump">1,323,151<span></span>
</td>
<td class="nump">461,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series B-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Future issuance of share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">813,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_StockIncentivePlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_StockIncentivePlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=krro_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=krro_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227807710176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Additional Information) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">5,755,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_KorrosMember', window );">Korros [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends Declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_KorrosMember', window );">Korros [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_KorrosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_KorrosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718284960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred Stock, Convertible, Conversion Ratio</a></td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PercentageOfOutstandingSharesOfPreferredStock', window );">Percentage of outstanding shares of Preferred Stock</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred Stock, Convertible, Conversion Ratio</a></td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 111.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PercentageOfOutstandingSharesOfPreferredStock', window );">Percentage of outstanding shares of Preferred Stock</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 45.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">$ 45.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 52.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">52.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember', window );">Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">55.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">55.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 20.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">$ 20.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeed3PreferredStockMember', window );">Series Seed-3 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">26.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="nump">$ 26.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,855,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred Stock, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PercentageOfOutstandingSharesOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PercentageOfOutstandingSharesOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeed3PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeed3PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_LegacyKorroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_LegacyKorroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227806078656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,855,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_CommonStockIssuableUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_CommonStockIssuableUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_LegacyKorroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_LegacyKorroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227722685136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="nump">1,675,396<span></span>
</td>
<td class="nump">5,487,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</a></td>
<td class="text">In addition, the number of shares of common stock available for issuance under the 2023 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2023 Plan, beginning with January 1, 2024 and ending with January 1, 2033, by the amount equal to 5% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Option</a></td>
<td class="nump">1,323,151<span></span>
</td>
<td class="nump">461,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="nump">$ 23.49<span></span>
</td>
<td class="nump">$ 14.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized unvested stock options, weighted-average period</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of restricted common stock</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_TwoThousandAndNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="nump">600,977<span></span>
</td>
<td class="nump">683,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_StockIncentivePlanMember', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="nump">110,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_IncentiveAwardPlanMember', window );">2019 Incentive Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized under plan</a></td>
<td class="nump">154,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember', window );">2023 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="nump">889,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="nump">255,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Option</a></td>
<td class="nump">51,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krro_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="nump">424,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Option</a></td>
<td class="nump">36,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Legacy Korro [Member] | 2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_TwoThousandAndNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_TwoThousandAndNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krro_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krro_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_LegacyKorroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_LegacyKorroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227715591888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227716419664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Common Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2022 | shares</a></td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Repurchased | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2023 | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested as of December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested | $ / shares</a></td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Repurchased | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested as of December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227808318096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.80%<span></span>
</td>
<td class="nump">72.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718219888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Options , Beginning balance</a></td>
<td class="nump">461,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ReverseRecapitalization', window );">Number of Share Option, Reverse Recapitalization</a></td>
<td class="nump">93,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares Options , Granted</a></td>
<td class="nump">835,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares Options, Exercised</a></td>
<td class="num">(39,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares Options, Forfeited</a></td>
<td class="num">(20,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Number of shares Options, Cancelled</a></td>
<td class="num">(7,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Options, Ending balance</a></td>
<td class="nump">1,323,151<span></span>
</td>
<td class="nump">461,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2023</a></td>
<td class="nump">368,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 14.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_WeightedAverageExercisePriceReverseRecapitalization', window );">Weighted- Average Exercise Price Reverse Recapitalization</a></td>
<td class="nump">121.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">17.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">16.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Fofeited</a></td>
<td class="nump">20.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_WeightedAverageExercisePriceCancelled', window );">Weighted- Average Exercise Price Cancelled</a></td>
<td class="nump">18.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">23.49<span></span>
</td>
<td class="nump">$ 14.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, OptionsExercisable at December 31, 2022</a></td>
<td class="nump">$ 34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2022</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2021</a></td>
<td class="nump">$ 2,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2022</a></td>
<td class="nump">36,310<span></span>
</td>
<td class="nump">$ 2,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable as of Exercisable at December 31, 2022</a></td>
<td class="nump">$ 8,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancelled in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_WeightedAverageExercisePriceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price Cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_WeightedAverageExercisePriceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_WeightedAverageExercisePriceReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_WeightedAverageExercisePriceReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227806083904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net Operating Loss Carryforwards, Limitations on Use</a></td>
<td class="text">Under current law, the Company's federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of the Company's taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation', window );">Net Operating Loss Carryforwards Expiration without Limitation</a></td>
<td class="nump">$ 280,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">22,474<span></span>
</td>
<td class="nump">$ 5,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="nump">145,766<span></span>
</td>
<td class="nump">36,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in Valuation Allowance Amount</a></td>
<td class="nump">$ 109,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Explanation of Change in Valuation Allowance</a></td>
<td class="text">the additional operating loss generated by the Company and the combination of deferred tax assets as a result of the Merger<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Penalties Charges and Interest Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_PeriodOfCumulativeChangeInOwnership', window );">Period of Cumulative Change in Ownership</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLossCarryforwardsExpirationYear', window );">Net Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLossCarryforwardsExpirationYear', window );">Net Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_CumulativeChangeInOwnershipPercentage', window );">Cumulative Change In Ownership Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
<td class="nump">$ 266,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLossCarryforwardsExpirationYear', window );">Net Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Maximum [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_TaxCreditCarryforwardExpirationYear', window );">Tax Credit Carryforward, Expiration Year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_OperatingLossCarryforwardsExpirationYear', window );">Net Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Minimum [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_TaxCreditCarryforwardExpirationYear', window );">Tax Credit Carryforward, Expiration Year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
<td class="nump">$ 302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_NetOperatingLossCarryforwardsExpirationWithLimitation', window );">Net Operating Loss Carryforwards Expiration with Limitation</a></td>
<td class="nump">22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_TaxCreditCarryforwardExpirationYear', window );">Tax Credit Carryforward, Expiration Year</a></td>
<td class="text">2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member] | Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_TaxCreditCarryforwardExpirationYear', window );">Tax Credit Carryforward, Expiration Year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_NetOperatingLossCarryforwardsExpirationWithLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration with limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_NetOperatingLossCarryforwardsExpirationWithLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration without limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_PeriodOfCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_PeriodOfCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227812867952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718860560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_EffectiveIncomeTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent items</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(30.80%)<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_EffectiveIncomeTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax credit carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_EffectiveIncomeTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720408928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 80,385<span></span>
</td>
<td class="nump">$ 19,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">22,474<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">10,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,494<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Operating lease liability</a></td>
<td class="nump">9,052<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other temporary differences</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">153,481<span></span>
</td>
<td class="nump">37,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(145,766)<span></span>
</td>
<td class="num">(36,094)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">7,715<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating right-of-use asset</a></td>
<td class="num">(7,401)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Depreciation</a></td>
<td class="num">(314)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(7,715)<span></span>
</td>
<td class="num">(1,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities tax deferred expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719910624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Genevant Agreement (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">$ 57,250<span></span>
</td>
<td class="nump">$ 42,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ReimbursementsWithInResearchAndDevelopmentExpense', window );">Reimbursements with in Research and Development Expense</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember', window );">Genevant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones', window );">Revenue recognized commercialization milestone payments to receive</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember', window );">Genevant Agreement [Member] | Maximum [Member] | Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember', window );">Genevant Agreement [Member] | Maximum [Member] | Phase2b Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized from commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_ReimbursementsWithInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursements with in Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_ReimbursementsWithInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase3ClinicalTrailMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase3ClinicalTrailMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase2BClinicalTrial1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase2BClinicalTrial1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720208880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="num">$ (7,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">6,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">7,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">7,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">52,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Leases Payments</a></td>
<td class="nump">66,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">amount of lease payments representing interest</a></td>
<td class="num">(33,209)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present Value of Operating Lease Liabilities</a></td>
<td class="nump">$ 33,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720300976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease liabilities arising from lease modification</a></td>
<td class="nump">$ 5,948<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease Costs</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term Lease Costs</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total Lease Costs</a></td>
<td class="nump">$ 8,080<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227722288288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 27,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">33,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease rental payments</a></td>
<td class="nump">$ 66,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average remaining lease discount rate</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krro_OKSFacilityMember', window );">OKS Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area of land | ft&#178;</a></td>
<td class="nump">22,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Oct. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krro_CummingsParkSubleaseMember', window );">Cummings Park Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area of land | ft&#178;</a></td>
<td class="nump">18,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Jul. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krro_SixZeroFirstStreetLeaseMember', window );">60 First Street Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease remaining terms</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area of land | ft&#178;</a></td>
<td class="nump">50,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvement allowance utilized</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum lease payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krro_OKSFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krro_OKSFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krro_CummingsParkSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krro_CummingsParkSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krro_SixZeroFirstStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krro_SixZeroFirstStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227720210432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTable', window );"><strong>Defined Contribution Plan [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTable', window );"><strong>Defined Contribution Plan [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227718860560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AffiliateCosts', window );">Affiliate amount related to consulting services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incurred Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AffiliateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AffiliateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227806072864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - Legacy Korro [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,331,200<span></span>
</td>
<td class="nump">4,514,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Outstanding Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">8,049<span></span>
</td>
<td class="nump">8,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Outstanding Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,323,151<span></span>
</td>
<td class="nump">461,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">684,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krro_LegacyKorroMember', window );">Series B-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krro_LegacyKorroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krro_LegacyKorroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krro_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krro_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krro_OutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krro_OutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=krro_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140227719983328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,172)<span></span>
</td>
<td class="num">$ (58,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krro_Denominator', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic</a></td>
<td class="nump">1,529,321<span></span>
</td>
<td class="nump">255,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted</a></td>
<td class="nump">1,529,321<span></span>
</td>
<td class="nump">255,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (53.08)<span></span>
</td>
<td class="num">$ (227.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (53.08)<span></span>
</td>
<td class="num">$ (227.42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krro_Denominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krro_Denominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M DS Y]OWX/6K-^ 52'+P:<-W@N8K<3&5:F8]?KJL9KDZS()[9GG/EF> H#'
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MUM *")V(,7@%SR!$BN8*H!K.'7L+$!Q#6/X L:%%12TYK^]V4K6 R;_*!Y5
M]?PLNU/+\^G8H+36!P!O&V,2(319E1RUDT*J"[TE><<[GP4YVE-Z3=I9,VH
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MS\K+#:-*FFL#]?V:<_ETHU_]J%_U6?P'4$L#!!0    ( $V >EBLJN':4@4
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MWQ=%_?RA^=VYPP\X7O\?4$L#!!0    ( $V >E@:^2R<40@  %DE   8
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M&5/24,BMG^Q@G7 &YX/%](T@7F;AI<SV$+,HQ#O%BY]3D[U*4/#: "0V*4;
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M(]KW>-H?BF_LJS#W7"E>VZ]K2K1X,0;Z_RO.U<L/<X/]VU17_P-02P,$%
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ME.Y^5G.9/<2D^$LM_MG 0:87H8Z-Q3O2*OSV(2VZ:V8A;Q[%E-@];[/B[J0
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M5$(J3L.(-B9!<'U,F+<]">IT7ZHFW4Z\@?Y4N%YLE"-RX_?'W8JA!ST9)O;
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ML)>) KW'^\;E<<>/"@\SA1NHLB$?><",9?JA'&(MG B419R:F,]IJS.J[QW
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M9M&(4O$6I>%*@L9Z$5PF%U>YL_<&_W'<F+TQ."4KI3Z[R3_5(H@=(1186H?
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M@E3#_FC@@>K&7K<QLG&C9BD-#2ZWM'%!907HOI#2[#;6P/Z_Q_P_4$L#!!0
M   ( $V >E@FZ\.&Z (  *X&   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;*U576O;,!1]SZ^XN&5L$&I;<9JT2P+]&ANL+'1;]S#VH-C7L:@L>9+2
MM/]^5W+B9I &!GNQOLX]]]PK^WBRUN;!5H@.GFJI[#2JG&O.X]CF%=;<GN@&
M%9V4VM3<T=(L8]L8Y$4(JF7,DN0TKKE0T6P2]N9F-M$K)X7"N0&[JFMNGB]1
MZO4T2J/MQIU85LYOQ+-)PY?X%=WW9FYH%7<LA:A16:$5&"RGT45Z?IEY? #<
M"US;G3GX2A9:/_C%IV(:)5X02LR=9^ T/.(52NF)2,;O#6?4I?2!N_,M^X=0
M.]6RX!:OM/PA"E=-HW$$!99\)=V=7G_$33U#SY=K:<,3UBTV&T60KZS3]2:8
M%-1"M2-_VO1A)V"<O!+ -@$LZ&X3!977W/'9Q.@U&(\F-C\)I89H$B>4OY2O
MSM"IH#@WN\ASL\(";I[HFBU:X*J +ZY" U<K8U Y^"SX0DCA!-I)["BGCXSS
M#?]ER\]>X4\9W&KE*@LWJL#B;X*8Q':*V5;Q)3O(>(WY"0S2/K"$#0[P#;H.
M# +?X!6^.7_F"[FI/+2#2PL_+Q;6&7IG?NVKN67,]C/Z[^C<-CS':40?BD7S
MB-'LS5%ZFKP_H#?K]&:'V/_#C1WDWZ]^? +_EK>#XRY<!WB^@<L=.+>@2Z"[
MQ7I!D.W]ABB:,%BC0<AUW1AAB9;PI99D*1;>"@6NTBM+6/ONO+=+T@LDGJ!W
M4S=2/V-+0I)XZPK$OT"%I7 6CF'4'Y^=TLCZIRSKW3PY-(I+\'W@)J\"O,!'
M\K*F]B7X]HB<]*=]-AP"&V6]MB7DFH8RJ.5+ [)L1$I&O:O[NZ[TYW[7C<'9
M$-X<C5G*WO?F1I=HO?%1\A(IF*5G,$IZW[2C'?YOO3V&-.D3+TT&_70TA'UO
M8;SC(36:97!*2\U:*=?:2;?;F?%%ZT$O\-;);[E9"F5!8DFAR<EH&(%IW;%=
M.-T$1UIH1_X6IA7]4-!X )V76KOMPB?H?E&S/U!+ P04    " !-@'I8%>SK
MT6P$  !."P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R55EMSXC84
M?L^O../M;%]<L,W-), ,9+.SF38=9MG=/G3Z(.P#5F-+1)(AZ:_OD<S%)$";
MAQ#)/M]WOG/1L08;J1YUAFC@N<B%'GJ9,:OK9E,G&19,-^0*!;U92%4P0UNU
M;.J50I8Z4)$WHR#H-@O&A3<:N&=3-1K(TN1<X%2!+HN"J9<)YG(S]$)O]^ K
M7V;&/FB.!BNVQ!F:[ZNIHEUSSY+R H7F4H#"Q= ;A]>3MK5W!C\X;G1M#3:2
MN92/=G.?#KW "L(<$V,9&/U;XRWFN24B&4];3F_OT@+KZQW[9Q<[Q3)G&F]E
M_@=/33;T8@]27+ R-U_EY@MNX^E8OD3FVOW"IK(-R3@IM9'%%DP*"BZJ_^QY
MFX<:( [. *(M('*Z*T=.Y2=FV&B@Y :4M28VNW"A.C2)X\(69684O>6$,Z-;
M6124G)F1R>.@:8C1/F\F6_2D0D=GT&$$#U*83,.=2#$])FB2E+V>:*=G$EUD
M_(1) UJA#U$0M2[PM?;QM1Q?ZPS?W5/)S0O\.9YKHZ@%_CH59$71/DUAC\6U
M7K$$AQ[UO4:U1F_T\4/8#6XN"&SO!;8OL?]G 2ZB3VOK-Z#."F,#)D-(<JFY
M6()<N&V!:HG*=VN=,4+;-[_ADB4O\*M42D)2L6C'LD%%'%*L41E,@0LC:SC+
M0DY73+S\K(^!]M"D0%MK@\])QL0203$ZE71^#"IJ:T?H#!Z<+!@O%2(=?M.
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MF)^%DZ7FQIN2OSQ8&>]-SI<;!79L:0#>KPU2N+ZA!=I/4:[^!5!+ P04
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M#3^.RF10>J?I 8<U6R#91JJ@D$J @T=M<8^$WUI'L_D;C6U"N*!P622V)?8
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MUJE2G%R27D5*BT['OG@D)E#0HS,*TJQK+B,ABCAH%35F]ZBY:L;R*3>%2%;
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M FFL2CJ]3662>J]J'Y\&G29L6FW-2K<R6_76VB]%9>!IEHS=\\9B@8TJ/*_
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M#/%SG S'8[Q;8,7NR-#/<9EEMJ&\ZM4#87/!^[*=?1QZ[1&_0JL51P94"P_
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M;ED(*4P'01;C68]]1&_*!G5G-<J8BG31:%Z81#JS@4B/0]SV9$X/_8 D79K
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MS(8"].<"QOFP5H \Z7BNHVD$#SWJLU(;%VVA*Z"6O@';=M$O()$4I6G))N)
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M,3GK<,.(4>30%Z^GO2_.2V47_.<!CN=N'[Y#[YYV?X%P';YXWRX/?[Z AKY
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M7=6\9%\CO(4\O:0&*!4%E6K,EG*T$*.(SL5XG@(1""^Z77>.[[%YC\(!LG0
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M &4#<#V7TNP<6Z#[R\S^ E!+ P04    " !-@'I8C83Y*3@#  #N!@  &0
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MT$W9#6?TTP25-:#YJ91F\V(7Z'[LC/\#4$L#!!0    ( $V >EB\&!&>^ 0
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MSM%VXW3M9]=*.YJ$?EG07P\T+$#W:ZW=VX8-]']FEG\!4$L#!!0    ( $V
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M&G8'6(>JN2XT R,KUZ(7TF##=Y\YWK! 60-<7TII=@,;H+VS3?\#4$L#!!0
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M"+B>H-YO&).O'>V@^:Z*_@=02P,$%     @ 38!Z6".I+ 0H!P  R4L  !D
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M;"]W;W)K<VAE971S+W-H965T-#$N>&ULM5A=;^HX$/TK5G:UZI5ZFP\*M%U
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MN/B(DE33VYJ)D95K#W-IL-FX88&_ U V /<74IK-Q![0_6#2WU!+ P04
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M3-5'!G =H,83QN2NH^^Q]K,E_ -02P,$%     @ 38!Z6%;XZ#F3!   1Q@
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M.%O&V;JOQCVH5X"J5?0ZLR;F:[,,742+J5TQM;5,2S'B@QA2LX)K'SV[\_#
M@IX+O2.2W3CD0]N'_4R=BJFC9?J-"IS(]=^82:LV^3[.3H<+]'S7#H\Y=^-<
M)_"1%?23=BO2KI;T'V^$13%7TJ^:ZI<+HX^Q>^8H=^.0%SC> &&O(NQI"2,+
MAN6:?I1#FJE7)9@G..NCJH52;>26;W%$IL:VE,V8O?L%>M;O?2MT)+!6U7Y5
MM3_:*O!/+M)N!'3#(!Q8J4'%,?@)\S_H<H$6"MPCRMI'7SGX8558>&+*(?OL
M*:>%NG3*C036JAI:=?^T1IMT)51KM;NN%SI'.O;$#4P[V.CS4/\.2[<)_4%(
MJ=$\9]%&VI]!B?1PEVHT%EJ[^+J10WTGOTBD;G<. M="QQJ=W<1AW<6AOHU_
M;;26[Y@QG GPSQ>B;-B_O52U<!=K-!):N_C:&$"],[BBR<)NOP\L)SQ6ZD14
MFV_M":#>%.S7T=>MVHWTL]/F7ZS.2&CM:FM# ?6.XAIUO&[7LI$-77@L4#?0
M\2!$ R8(UGX Z@V!W+ (%D="-MKF/J>7K!;I8K%&0FO777L,J#<9%[WNNM[B
MV GUA*"P\4)LLZP- ]0[A@5AL9Q/"R+EJ;=:PPJ-:AK&0FMO+&O7@/2NX=JM
MI<X8E'O+;HC<4/CVP/L.U08"Z0U$*=?'<[320UVJU5AH[<(;IP _YQC@C'.
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MKS-0KQNW-P-K2%::PW7.I#JJS3!3ERG@VD$]7S F-X9.T%S/XC]02P,$%
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M6L%YYU1VO7X!3<<U=ND2R,$5<G!#Y!CW,U.K2OW.1 <VMJD?D%M\X7<RK>Z
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MBB0/BA=0-8%2TYU4>.&=V1EA/%/0@L9F0@FC51NSRU%A@_>VU4AG]CE"+S]
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MXN&-XDTJ]_GS#S<R3668O]P)OA%QUD =WTJ9_GR3/5)1/4*S^ ]02P,$%
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MOM[Z#U\5N\<I (]X,[_[T*N]$X,% $T!0*&9 K0I ->> H!8.[O'3]4[705
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MQJ!L .ZOI#2'B?U T]_C/U!+ P04    " !-@'I87*G@EST%  "3&   &0
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M<#U ?;]F3#[=Z 7*_T/,_P502P,$%     @ 38!Z6%[?] 8+"   A#D  !D
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M.0"^G^:Y?GYC)M@\>#G\$U!+ P04    " !-@'I8/!)W!ND"   @"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RMEFUOFS 0Q[^*Q:JIE;;RD,=F
M"5*3K%I?5(J:=GOMPB6@&IO9)NF^_6Q#*"1 JZIO@FWN?_Z=<^9NNF?\640
M$KTDA(J9%4F93FQ;!!$D6%RR%*AZLV$\P5)-^=86*0<<&E%";,]QAG:"8VKY
M4[.VXOZ499+$%%8<B2Q),/\W!\+V,\NU#@OW\3:2>L'VIRG>PAKD8[KB:F:7
M7L(X 2IB1A&'S<RZ=B<+UPB,Q>\8]J(R1CJ4)\:>]>0VG%F.)@("@=0NL'KL
M8 &$:$^*XV_AU"KWU,+J^.#]Q@2O@GG" A:,_(E#&<VLL85"V.",R'NV_P5%
M0 /M+V!$F%^T+VP="P69D"PIQ(H@B6G^Q"_%050$[K!%X!4"[UC0;Q'T"D'/
M!)J3F;"66&)_RMD><6VMO.F!.1NC5M'$5/^-:\G5VUCII']+ Y8 >L O(-!W
MM%9I$F8$$-N@%6>[V/Q=*EM0S?!\"1+'1%PHR>-ZB<[/+M 9BBEZB%@F, W%
MU):*3N]A!P7)/"?Q6DA<#]TQ*B.!?M(0PKH#6X55QN8=8IM[G1Z7$%RBGOL-
M>8[7:P!:O%_N=>#TRJ/N&7^]%G^+C'.@$DE]A).F \KU_6:]OM 3D>( 9I:Z
ML0+X#BS_ZQ=WZ/QH"NZ3G-5"[9>A]KN\^S<0 L>D*<9<.#!"_8W9^<[4WE7!
MNRQJ-(.29M!)LY980A-++AM6=O)&1S"G)FX+S;"D&7;2/#")B;K:E61H8AN^
MS79JTL8V*ME&G2FZA THKK C1T>?F:.?Y*P6Z[B,=?S1'!V?'.QQCG99U&BN
M2IJKC^7HU9LL718U%M=Y+0K..W(TK&5#XQ?=>9.NTZ2.5ZE9[COPTEI]BO/Z
MU([JGGQ63BY4@\W)C;(KM38!OC4MB$ !RZC,2U.Y6K8YUZ:X'ZW/=?MC:OBK
MF[QWNL-\&U.!"&R42^=RI(!XWH[D$\E24]&?F%3]@1E&JH4#K@W4^PUC\C#1
M&Y1-H?\?4$L#!!0    ( $V >E@PR3++3@,  #,*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8P+GAM;*U6P6[C-A#]%4)%BQ382I3DR$EJ&TB<770/BP9Q
MMST4/=#2R"*6(EUR9"=_7Y*2%=N5E1[J@TU2?$_OT<.9F>V5_F8J "0OM9!F
M'E2(V[LH,GD%-3.AVH*T3TJE:X9VJC>1V6I@A0?5(DHHS:*:<1DL9G[M22]F
MJD'!)3QI8IJZ9OKU 83:SX,X."P\\TV%;B%:S+9L RO K]LG;6=1SU+P&J3A
M2A(-Y3RXC^^6,74 O^-W#GMS-";.REJI;V[RN9@'U"D" 3DZ"F9_=K $(1R3
MU?%W1QKT[W3 X_&!_9,W;\VLF8&E$G_P JMY<!.0 DK6"'Q6^U^@,W3M^'(E
MC/\F^VXO#4C>&%1U![8*:B[;7_;2'<01(,XN )(.D)P#)A< :0=(O=%6F;?U
MR) M9EKMB7:[+9L;^+/Q:.N&2_<WKE#;I]SB</%9YJH&\AM[ 4-^(BL;)D4C
M@*B2/$.N9,X%9_[ [<K7<!623U" 9H*LD&&#2K^2-P[RS!#(U2,@X\+\.(O0
M2G0OBO).SD,K)[D@)T[(%R6Q,N2C+* X)8BLM]Y@<C#XD(PR/D(>DC3^0!*:
MI ."EO\=GHS(2?OS3CU?^NYYDT=N<J%,HX'\>;\VJ&U(_S5T9"WC9)C1W?,[
MLV4YS -[D0WH'02+'[Z+,_KSD-W_B>S$_*0W/QEC/YA':]X.M@U"01B2LHLH
MTT>4MF$T=!(MO4T:CM]EJ-V"ADD\BW;'%M_;=:+]NM=^/:K=A;N7#N8#D3:_
MVOMP$+X&"27'(<4M:9R>:*%3>GOR.3,P#,HN.,AZ!]FH Q=SN8:"(\F9UJ^V
M!NR9+LR0[&Q009J="1W>EB7#0J>]T.FHT">P^5F"1,(1ZD%]XP17<4CI]T/I
M9_D.T,;)OX G'FYZ#S>C3,N*R0T0+LF.B:;-H$S8HLED/AC:XW17*0UO+EAZ
M#YF$TW%/M[VGVU&J7[$"/:3]=C ,Z/F]'&>W9S\9UQG3MZ)&1[D^EB7X_L#G
MFDO9I",Y311GFL?WM/*BH_);@][XKL38%-=(; M5O]IW/O>^WI^M/[B.R)?U
M-YJVG?K"](9+0P24EI*&4YLB=-NAM!-46U_DUPIMR^"'E>WJ0+L-]GFI%!XF
M[@5]G[CX!U!+ P04    " !-@'I859O_2QP$  "Z#@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6RMEVUOVS80Q[\*H15#"\R1J ?+]FP#:8RA!;HU
MJ-OM-2.=;2*2Z)&TG?33[R@ILBU1:@;TC:V'N]/OCN3]R?E)R$>U ]#D*<\*
MM7!V6N]GKJN2'>1,W8@]%/AF(V3.--[*K:OV$EA:.N69ZWO>V,T9+YSEO'QV
M+Y=S<= 9+^!>$G7(<R:?WT,F3@N'.B\/OO#M3IL'[G*^9UM8@_ZVOY=XYS91
M4IY#H;@HB(3-PKFELSL:&X?2XF\.)W5Q34PJ#T(\FIN/Z<+Q#!%DD&@3@N'?
M$>X@RTPDY/BW#NHTWS2.E]<OT?\HD\=D'IB".Y']PU.]6S@3AZ2P88=,?Q&G
M#U G%)EXB<A4^4M.M:WGD.2@M,AK9R3(>5']LZ>Z$!<.-.QQ\&L'_[4.0>T0
ME(E69&5:*Z;9<B[%B4ACC=',15F;TANSX849QK66^):CGUY^+!*1 _G*GD"1
M$5GC-$D/&1"Q(2O8@)20FI?D5BG0BK B)9\X>^ 9UQP]WJY ,YZI=^C[;;TB
M;]^\(V\(+\C7G3@HM%9S5R.F^9B;U$CO*R2_!VD%R0T)Z&_$]_S XG[W>G?_
MVMW%XC05\IL*^66\H#=>70:-96!E&6:VI*HHH3V*68TSM6<)+!Q<;@KD$9SE
MK[_0L?>[+<6?%.PJX:!).!B*OOP+FP>V"<DT+[8D$TJ1A$GYC#WCQ*1]1*N(
M41G1=([C<N(%DVCN'B^SZEK1:33Q&JLKW+#!#0=QS>Q,<'RX_C%F%6E\ >#[
M81RV,+M641C'=LJHH8P&*>_8GFN6\>\XD<R0,9GLRM64PA%[Z1X[H[811QV6
M( RF[<)VK:CGQU,[\KA!'@\BK[5('D>F1Z8$FP0*AV*F]=HPQQV ,)RVZ]HU
M"F@/8]PPQH.,M[F0FG_OY8J[A:'!I,75->J9DI.&:C)(]?F\>@#+1[*Z8S[;
M$">=KT^]R&\A=HTF462'G#:0T^'2)8D\X-#"DQE9J'J[T#N01$.^%Q)5G:1\
M@]T/B@2LZVG:+6\4!BWVKE'L]:PFZIUERQM>]0)7D]'K=F^VZHUGX0S""6V1
M6NR"V*=]L!<:2P=A/X%2,W)DV8%5>Y<,=T\,BVJ%I1V($0VC>#QNTUH,@[%W
ML>RN<<^"1P?EI12 UU;6[PYN3-OMR6)%J1_T<)YUB@:O5^;LO"NQRC,=%+W_
MJ\\_*]IUYF?)H\.:=VXPTFQ31V(S.F"?*<?)FGQ7TD9QZ'7FO\4LNNA%U[1G
MZ:/#VK<"+$+">YLT[<K7**!M];!913'M@3N+'!U6.4LCN9A*5MRNCHULD]YB
M-C#KSXI'AR6OO3I[(./.7LMK PZ95'#NQ<'"G.K^9'++"X6RMD$?[R9&9UD=
ME*H;+?;E6>-!:#RYE)<[/%R"- ;X?B.$?KDQQY?FN+K\#U!+ P04    " !-
M@'I8VI#>2-$#   M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6S%
M6&UOVS80_BN$5@P)T$8O?DLRVX!C=VN &0V2=/M0[ ,MG2VB$JF1M)T6_?$[
M4HYLV8J2&!KRQ18IWG/W/.211_770GY3,8 F#VG"U<")M<XN75>%,:14G8D,
M.+Z9"YE2C4VY<%4F@4;6*$W<P/.Z;DH9=X9]VW<CAWVQU GC<".)6J8IE=^O
M(!'K@>,[CQVW;!%KT^$.^QE=P!WH+]F-Q)9;H$0L!:Z8X$3"?.",_,NQWS$&
M=L1?#-9JYYD8*C,AOIG&=31P/!,1)!!J T'Q;P5C2!*#A''\NP%U"I_&</?Y
M$?UW2Q[)S*B"L4C^9I&.!\ZY0R*8TV6B;\7Z$VP(V0!#D2C[2]:;L9Y#PJ72
M(MT88P0IX_D_?=@(L6/@=Y\P"#8&P;Y!^PF#UL:@98GFD5E:$ZKIL"_%FD@S
M&M',@]7&6B,;QLTTWFF);QG:Z>$?P&%%N2:CA03 ^='D9!1%S&A,$W+-\Y6"
MK5-R,@%-6:).R0?RY6Y"3MZ=DG>$<7(?BZ6B/%)]5V-,!MD--_ZO<O_!$_[]
M@$P%U[$B'WD$41G 13(%H^"1T550BSB!\(RT_/<D\()614#CEYL'->&T"H%;
M%J_U!!ZNKX3.A*1FN9*1E)0O<IU1L%+[LXY!$AU33LI&7_]$3'*M(57_5"F<
M!]"N#L#L Y<JHR$,'$QT!7(%SO#77_RN]UN5.@V!E;1J%UJUZ]"'MXA(91A;
M:2:PPDTFL])\?,!M2\%[<B\T3:HTR($[%MAL7:MAIQ=TO+Z[VB5W.*H=!)Y?
MC"I%W2FB[CP3-4MG2ZGL+"K,7QV;I'B.3!6+W%%W)SX?]^,]$K71'#E#W8)K
MMY9KQ7;Q=0KI#&3ERJP%>^W*; BLQ+M7\.Z]=1;WFM2J(;"25N>%5N?_5Q:?
M'ZQ_S.']]5_K_4AN%P6WBV>XK8 O 0N84"PX^P$1"46:@@P93=@/>U#B,9T
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MB;_+<7P^#S9<O,@"0*%71DLY= JEJFO7E7D!#,LK7D&IWRRY8%CIJ5BYLA*
M%Q;$J!MX7N(R3$HG&]AG4Y$->*TH*6$JD*P9P^+M!BC?#!W?V3UX(*M"F0=N
M-JCP"F:@GJJIT#.W95D0!J4DO$0"ED/GFW]]XWL&8%<\$]C(O3$RI<PY?S&3
MN\70\8PCH) K0X'UWQI&0*EATC[^;$F=5M, ]\<[]EM;O"YFCB6,./U)%JH8
M.CT'+6"):ZH>^.8[; N*#5_.J;2_:+-=ZSDHKZ7B; O6#A@IFW_\NMV(/4 0
M' $$6T!@?3="UN48*YP-!-\@859K-C.PI5JT-D=*\U5F2NBW1.-4-N*,$:6W
M64F$RP4:\5*1<@5E3D"B2S33QV!14T!\B6YK50M ]Z0DK&;H08,P15/\UL#/
MQZ PH?(+.D.D1(\%KZ6FE -7::-&SLVWIFX:4\$14V/(KU#H7Z# "T+T-!NC
M\[,O_].XNLZVV* M-K"\X1'>"4@)<($FH+_C!1J#S 6I[.GX-=%KT9T")G]W
M&6Z(HVYBTSK7LL(Y#!W=&Q+$&ISL\R<_\;Z>L!VVML-3[)G>A:C+4X.*+<IT
MWSJ[3(,@';CK#K&H%8L^$HN[Q!I4LB>6!-$1K;C5BC_22KJTX@.M-(S\;JVD
MU4H^TDJ[M))#K3@^4E?::J4GM1X+T FY5""Z%-,#Q3B(^KUNR5XKV3LMR4TO
MONM0>\YEVZ%=9GJ'GS6)_*3;3+\UTS]I!C->E\I$!C4.4+6+" &V/6S$Z(S0
M&P12==GJ']BZ#,/ ZW?[\KU_:>>==#9MY-$SIK7-M!\5"&SMV,U"$X+GA!*E
MTZ\SM[R#GC.^WI\7=R^0S>5VC\6*E%)OQU+CO*M4$XCFOF@FBE<VH^=<Z<2W
MPT+?L2#, OU^R;G:34SLM[=V]A=02P,$%     @ 38!Z6,:\5)'D @  XP<
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M]U!(%R2/Q:=L^RNM.C14O""+>?$7;:M[[1X*<BZRI"HL6Y!$:?F?_*B$V"N
MW1,%<%4 'Q; )PKTJP+]PP+.B0*#JL#@W!J&58&BZU;9]T(XCP@RG;!LBYBZ
M6]+4AT+]HK34*TK50'D43/X:R7)B.LN2)!(R\H(CDH9HEJ4B2I<T#2+*T>OW
M81BI@)(8?4C+82FOWJ#7'A4DBOD;] I%*?J\RG(NB_.))62C%-H*J@;<E W
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M0?Z^R#*QNU 5U*=]I_\"4$L#!!0    ( $V >EAO$_9H! ,  /(+   9
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M<-#3-7P1I]+^HGT6V__HH&@K%4\.8%U!0ECVCY\//IP _,X90'  !*\!O3.
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MZZT#U.\KQN3K@WY!=40T^1]02P,$%     @ 38!Z6/EW8!@G P  X D  !D
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M:+S@[3#%)QA(8X#?5T+HW<1LT#SJ)G\ 4$L#!!0    ( $V >ECSU98T1@,
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M5V34/7Z-]5G@V$7&IR#R)+:[=PHBD^,7&9V QOI\>70BP_HDM''<VCIL-=X
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M=_RDWG7XVI=Z[?E>XT]!/TGU<+ZW7!]_67Z?1)P7%YS3;45]^@M02P,$%
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M_Q%<O !02P$"% ,4    " !-@'I8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $V >EAUZ6TP[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( $V >EB97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 38!Z6$)<I!,$"   ]S4  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( $V >EBN$PV2_ 8  /8C   8              " @4<0  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !-@'I8K*KAVE(%  "O
M(0  &               @(%Y%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ 38!Z6*1;V4ER!   4Q$  !@              ("! 1T
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $V >EA@];)V
MU@H  ,QQ   8              " @:DA  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !-@'I8&ODLG%$(  !9)0  &
M@(&U+   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 38!Z
M6-DVK"(=$   ?"X  !@              ("!/#4  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( $V >E@,K$*A\B$  '!K   8
M      " @8]%  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !-@'I8G(%VY$<%  !/#0  &               @(&W9P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 38!Z6"*^QZB/!P  510  !D
M             ("!-&T  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !-@'I8N-GM": #  #'"   &0              @('Z=   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $V >EC5D_;U/P,
M -D'   9              " @=%X  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ 38!Z6(T1TB7. P  AP@  !D              ("!
M1WP  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !-@'I8
M)NO#AN@"  "N!@  &0              @(%,@   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( $V >E@5[.O1; 0  $X+   9
M      " @6N#  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ 38!Z6+<(9X#S"0  EB(  !D              ("!#H@  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !-@'I8<NI8=G -   $+
M&0              @($XD@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( $V >E@,(RU4_@D   $;   9              " @=^?  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 38!Z6,+H_+]?
M!   L0H  !D              ("!%*H  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !-@'I8IJ,Y*6(-  "C(0  &0
M@(&JK@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $V
M>EAXD[P350,  ( '   9              " @4.\  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ 38!Z6"0VT=D  P   0<  !D
M         ("!S[\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !-@'I8!F56I]X#  #\"   &0              @($&PP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $V >EC.X#M?OB,   .&
M   9              " @1O'  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ 38!Z6,/^@A,N P  X <  !D              ("!$.L
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !-@'I8/KDE
MFK "  #B!0  &0              @(%U[@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( $V >EA3;]LBTP(  '$&   9
M  " @5SQ  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M38!Z6(V$^2DX P  [@8  !D              ("!9O0  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !-@'I8J30=K/8"  "1!@  &0
M            @('5]P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( $V >EAGRD'N:0,  '0(   9              " @0+[  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 38!Z6(,10?(C P
M0 <  !D              ("!HOX  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !-@'I8O,K1X H%  #X#   &0              @('\
M 0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $V >EB\
M&!&>^ 0  (4,   9              " @3T' 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ 38!Z6!'9&#_T P  V @  !D
M     ("!; P! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M" !-@'I8(D2->0<$  "_"0  &0              @(&7$ $ >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( $V >EC3(?9NS04   ,C   9
M              " @=44 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M A0#%     @ 38!Z6(H5(7RS @  908  !D              ("!V1H! 'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !-@'I8;W-Y*V<"
M   8!0  &0              @('#'0$ >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;%!+ 0(4 Q0    ( $V >EC613E2GP,  &,-   9              "
M@6$@ 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 38!Z
M6".I+ 0H!P  R4L  !D              ("!-R0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !-@'I8+[,,97@$  #?%   &0
M        @(&6*P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( $V >EB<:ZOL, ,  $4,   9              " @44P 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 38!Z6%O=(+%+ @  )P4
M !D              ("!K#,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !-@'I82G)UIJH"   G"   &0              @($N-@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $V >E@[9-HK
M3P(  ,4%   9              " @0\Y 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ 38!Z6-7Y.U&I!   BQ@  !D
M ("!E3L! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !-
M@'I8R&[3AH\"  !L!@  &0              @(%U0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( $V >EA@QA67#P,  ,((   9
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M970U,BYX;6Q02P$"% ,4    " !-@'I8TB!+-<((  #^0@  &0
M    @(%.7@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M $V >E@@#[-Q' ,  +L+   9              " @4=G 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ 38!Z6,892J<L P  ;@H  !D
M             ("!FFH! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !-@'I8E\BAK-,"  #K!P  &0              @('];0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( $V >EA<J>"7/04
M ),8   9              " @0=Q 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ 38!Z6%[?] 8+"   A#D  !D              ("!
M>W8! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !-@'I8
M/!)W!ND"   @"@  &0              @(&]?@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( $V >E@PR3++3@,  #,*   9
M      " @=V! 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ 38!Z6%6;_TL<!   N@X  !D              ("!8H4! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !-@'I8VI#>2-$#   M$0
M&0              @(&UB0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( $V >E@"[@QQZ (  ,$'   9              " @;V- 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ 38!Z6,:\5)'D
M @  XP<  !D              ("!W) ! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " !-@'I8ZU$7^"<&  #Y*P  &0
M@('WDP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( $V
M>EAO$_9H! ,  /(+   9              " @56: 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ 38!Z6-3H\[31 @  +@D  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !-@'I8EXJ[',     3 @  "P
M            @ &%JP$ 7W)E;',O+G)E;'-02P$"% ,4    " !-@'I8:::]
M*$0%  "C+0  #P              @ %NK $ >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ 38!Z6)=W<N0L @  ]B@  !H              ( !W[$! 'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 38!Z6-9((R[W
M 0  *R@  !,              ( !0[0! %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     $T 30 2%0  :[8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>195</ContextCount>
  <ElementCount>355</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - The Company and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity</Role>
      <ShortName>The Company and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Reverse Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1</Role>
      <ShortName>Reverse Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Property and Equipment , Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment , Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Genevant Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement</Role>
      <ShortName>Genevant Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables</Role>
      <ShortName>Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables</Role>
      <ShortName>Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100390 - Disclosure - The Company and Liquidity (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>The Company and Liquidity (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Reverse Merger (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails</Role>
      <ShortName>Reverse Merger (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Investments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Restricted Cash (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Restricted Cash (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Property and Equipment, Net (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Common Stock (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Preferred Stock (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Preferred Stock (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails</Role>
      <ShortName>Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-based Compensation (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-based Compensation - Summary of Restricted Common Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Common Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income taxes (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income taxes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Genevant Agreement (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails</Role>
      <ShortName>Genevant Agreement (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100700 - Disclosure - 401(k) Savings Plan (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401(k) Savings Plan (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Related Party Transactions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="krro-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="krro-20231231.htm">krro-20231231.htm</File>
    <File>krro-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img83127175_0.jpg</File>
    <File>img83127175_1.jpg</File>
    <File>img83127175_10.jpg</File>
    <File>img83127175_11.jpg</File>
    <File>img83127175_12.jpg</File>
    <File>img83127175_13.jpg</File>
    <File>img83127175_14.jpg</File>
    <File>img83127175_15.jpg</File>
    <File>img83127175_16.jpg</File>
    <File>img83127175_17.jpg</File>
    <File>img83127175_18.jpg</File>
    <File>img83127175_19.jpg</File>
    <File>img83127175_2.jpg</File>
    <File>img83127175_20.jpg</File>
    <File>img83127175_21.jpg</File>
    <File>img83127175_22.jpg</File>
    <File>img83127175_23.jpg</File>
    <File>img83127175_24.jpg</File>
    <File>img83127175_25.jpg</File>
    <File>img83127175_26.jpg</File>
    <File>img83127175_27.jpg</File>
    <File>img83127175_28.jpg</File>
    <File>img83127175_29.jpg</File>
    <File>img83127175_3.jpg</File>
    <File>img83127175_30.jpg</File>
    <File>img83127175_31.jpg</File>
    <File>img83127175_32.jpg</File>
    <File>img83127175_33.jpg</File>
    <File>img83127175_4.jpg</File>
    <File>img83127175_5.jpg</File>
    <File>img83127175_6.jpg</File>
    <File>img83127175_7.jpg</File>
    <File>img83127175_8.jpg</File>
    <File>img83127175_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="691">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "krro-20231231.htm": {
   "nsprefix": "krro",
   "nsuri": "http://korrobio.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "krro-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "krro-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 306,
   "keyCustom": 49,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 30,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 4,
    "http://korrobio.com/20231231": 2
   },
   "contextCount": 195,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 564,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 691,
    "http://xbrl.sec.gov/dei/2023": 41
   },
   "report": {
    "R1": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ef01b84-410a-48aa-82c6-e6d539411e3c",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_ba766246-72fe-4458-8363-5e1fe9dfc13c",
      "name": "us-gaap:TemporaryEquityShareSubscriptions",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ba766246-72fe-4458-8363-5e1fe9dfc13c",
      "name": "us-gaap:TemporaryEquityShareSubscriptions",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity",
     "longName": "100080 - Disclosure - The Company and Liquidity",
     "shortName": "The Company and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "100090 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1",
     "longName": "100100 - Disclosure - Reverse Merger",
     "shortName": "Reverse Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1",
     "longName": "100120 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash",
     "longName": "100130 - Disclosure - Restricted Cash",
     "shortName": "Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "longName": "100140 - Disclosure - Property and Equipment , Net",
     "shortName": "Property and Equipment , Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "100150 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1",
     "longName": "100160 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock",
     "longName": "100170 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "100180 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "100190 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement",
     "longName": "100200 - Disclosure - Genevant Agreement",
     "shortName": "Genevant Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "100210 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan",
     "longName": "100220 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "100230 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "100240 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables",
     "longName": "100290 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables",
     "longName": "100300 - Disclosure - Restricted Cash (Tables)",
     "shortName": "Restricted Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "100310 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables",
     "longName": "100330 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables",
     "longName": "100340 - Disclosure - Preferred Stock (Tables)",
     "shortName": "Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfPreferredUnitsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfPreferredUnitsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "100350 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "100370 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "100380 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
     "longName": "100390 - Disclosure - The Company and Liquidity (Additional Information) (Details)",
     "shortName": "The Company and Liquidity (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_84565942-6987-4c97-b8de-234ea6a6f1a2",
      "name": "krro:SharesOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails",
     "longName": "100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Financial Statement Affected by Adoption of ASC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100410 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "krro:IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "krro:IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails",
     "longName": "100420 - Disclosure - Reverse Merger (Additional Information) (Details)",
     "shortName": "Reverse Merger (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_8d2bf99f-e0b9-478a-bb1e-365978eac30f",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8d2bf99f-e0b9-478a-bb1e-365978eac30f",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d3840a1-75bb-41e9-bdf6-5978eb8662d0",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "100450 - Disclosure - Fair Value Measurements (Additional Information) (Details)",
     "shortName": "Fair Value Measurements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
     "longName": "100460 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)",
     "shortName": "Investments - Schedule of Fair Value of Cash Equivalents and Short-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
     "longName": "100470 - Disclosure - Investments (Additional Information) (Details)",
     "shortName": "Investments (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "100480 - Disclosure - Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails",
     "longName": "100490 - Disclosure - Restricted Cash (Additional Information) (Details)",
     "shortName": "Restricted Cash (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "100500 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100510 - Disclosure - Property and Equipment, Net (Additional Information) (Details)",
     "shortName": "Property and Equipment, Net (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:ConstructionInProgressGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "100520 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
     "longName": "100530 - Disclosure - Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details)",
     "shortName": "Common Stock - Schedule of Number of Shares Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_45db7593-eb9b-4883-9384-b026cd2ff9bc",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "longName": "100540 - Disclosure - Common Stock (Additional Information) (Details)",
     "shortName": "Common Stock (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_65a239e0-5ccd-49da-844a-2f067baf9930",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
     "longName": "100550 - Disclosure - Preferred Stock (Additional Information) (Details)",
     "shortName": "Preferred Stock (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7042021a-f5f1-4b64-8355-bd3286bb3502",
      "name": "krro:PercentageOfOutstandingSharesOfPreferredStock",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
     "longName": "100560 - Disclosure - Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details)",
     "shortName": "Preferred Stock - Schedule Of Preferred Stock Authorized, Issued And Outstanding Table (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9",
      "name": "us-gaap:PreferredStockValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "100570 - Disclosure - Stock-based Compensation (Additional Information) (Details)",
     "shortName": "Stock-based Compensation (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "longName": "100580 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails",
     "longName": "100590 - Disclosure - Stock-based Compensation - Summary of Restricted Common Stock Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Restricted Common Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_7c6858e2-8133-456c-a5ca-5b7016177e3d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7c6858e2-8133-456c-a5ca-5b7016177e3d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails",
     "longName": "100600 - Disclosure - Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock Option Weighted-Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "100610 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_f61fcdc5-7781-4d89-9c78-e405590b9203",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "krro:ReverseRecapitalization",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100620 - Disclosure - Income taxes (Additional Information) (Details)",
     "shortName": "Income taxes (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "100630 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails",
     "longName": "100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails",
     "longName": "100660 - Disclosure - Genevant Agreement (Additional Information) (Details)",
     "shortName": "Genevant Agreement (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "krro:ReimbursementsWithInResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails",
     "longName": "100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
     "longName": "100680 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100690 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d4501f2-ba74-4579-94ab-e81941e63104",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
     "longName": "100700 - Disclosure - 401(k) Savings Plan (Additional Information) (Details)",
     "shortName": "401(k) Savings Plan (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_728a4108-5170-4a8f-b001-b85c0cd9973b",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_728a4108-5170-4a8f-b001-b85c0cd9973b",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "100710 - Disclosure - Related Party Transactions (Additional Information) (Details)",
     "shortName": "Related Party Transactions (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "krro:IncurredExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "krro:IncurredExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "100720 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_513af823-8be3-442f-a9fe-1a2fe1b055f9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_513af823-8be3-442f-a9fe-1a2fe1b055f9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "100730 - Disclosure - Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "krro-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_AccountingStanderedSectionsEightFourTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AccountingStanderedSectionsEightFourTwoMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standered Sections 842[Member]",
        "label": "Accounting Standered Sections Eight Four Two [Member]",
        "documentation": "Accounting Standered Sections Eight Four Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "krro_AccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable And Accrued Expenses",
        "documentation": "Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r766"
     ]
    },
    "krro_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization of premiums and discounts on investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other employee compensation and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "krro_AccruedExternalResearchAndDevelopmentServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AccruedExternalResearchAndDevelopmentServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development services",
        "label": "Accrued External Research and Development Services Current",
        "documentation": "Accrued External Research and Development Services Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "terseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r161",
      "r585"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r88",
      "r167",
      "r581",
      "r605",
      "r609"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r30",
      "r446",
      "r449",
      "r511",
      "r600",
      "r601",
      "r812",
      "r813",
      "r814",
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r766",
      "r905"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r629",
      "r823",
      "r824",
      "r825",
      "r881",
      "r906"
     ]
    },
    "krro_AdditionsOfContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AdditionsOfContingentValueRightLiability",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions Of Contingent Value Right Liability",
        "documentation": "Additions Of Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r200",
      "r201",
      "r202",
      "r203",
      "r212",
      "r243",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r298",
      "r387",
      "r388",
      "r389",
      "r417",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r431",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r553",
      "r554",
      "r555",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r350"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "krro_AdvancePaymentsForPropertyAndEquipmentNotYetReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "AdvancePaymentsForPropertyAndEquipmentNotYetReceived",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payments for property and equipment not yet received",
        "label": "Advance Payments For Property And Equipment Not Yet Received",
        "documentation": "Advance Payments For Property And Equipment Not Yet Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AffiliateCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AffiliateCosts",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliate amount related to consulting services",
        "label": "Affiliate Costs",
        "documentation": "Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r395"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease area of land",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r163",
      "r192",
      "r229",
      "r238",
      "r240",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r434",
      "r438",
      "r476",
      "r575",
      "r671",
      "r766",
      "r778",
      "r841",
      "r842",
      "r888"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r169",
      "r192",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r434",
      "r438",
      "r476",
      "r766",
      "r841",
      "r842",
      "r888"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series [Axis]",
        "documentation": "Information by title of series or issue of auction market preferred securities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r83"
     ]
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]",
        "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r83"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "verboseLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r292",
      "r574"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair market value",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r292",
      "r568",
      "r830"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_CashAcquiredInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "CashAcquiredInConnectionWithTheReverseRecapitalization",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash acquired in connection with the reverse recapitalization",
        "label": "Cash Acquired In Connection With The Reverse Recapitalization",
        "documentation": "Cash acquired in connection with the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r159",
      "r741"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r577"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "verboseLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r97",
      "r189"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash",
        "terseLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r97"
     ]
    },
    "krro_ChangeInFairValueOfContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ChangeInFairValueOfContingentValueRightLiability",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value",
        "label": "Change in fair value of Contingent Value Right liability",
        "documentation": "Change in fair value of Contingent Value Right liability"
       }
      }
     },
     "auth_ref": []
    },
    "krro_ChangeInFairValueOfPreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ChangeInFairValueOfPreferredStockTrancheLiability",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of CVR liability",
        "negatedLabel": "Change in fair value of preferred stock tranche liability",
        "terseLabel": "Change in fair value of preferred stock tranche liability",
        "label": "Change In Fair Value Of Preferred Stock Tranche Liability",
        "documentation": "Change In Fair Value Of Preferred Stock Tranche Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r164",
      "r165",
      "r166",
      "r192",
      "r216",
      "r217",
      "r219",
      "r221",
      "r227",
      "r228",
      "r276",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r320",
      "r321",
      "r325",
      "r328",
      "r335",
      "r476",
      "r618",
      "r619",
      "r620",
      "r621",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r659",
      "r680",
      "r702",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r790",
      "r820",
      "r826"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r227",
      "r320",
      "r321",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r618",
      "r619",
      "r620",
      "r621",
      "r755",
      "r790",
      "r820"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genevant Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r139",
      "r149"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper [Member]",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r75",
      "r576",
      "r658"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r300",
      "r301",
      "r738",
      "r840"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total reserved for future issuance",
        "terseLabel": "Common stock, reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Declared",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "krro_CommonStockIssuableUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "CommonStockIssuableUponConversion",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "label": "Common Stock Issuable Upon Conversion",
        "documentation": "Common Stock Issuable Upon Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r770",
      "r772",
      "r773",
      "r774",
      "r775",
      "r823",
      "r824",
      "r881",
      "r902",
      "r906"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r659"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Future issuance of share",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in share)",
        "periodStartLabel": "Beginning balance (in share)",
        "verboseLabel": "Common stock, shares outstanding",
        "terseLabel": "Exercises of outstanding Shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r659",
      "r677",
      "r906",
      "r907"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Value, Subscriptions",
        "label": "Common Stock, Value, Subscriptions",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r84"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 5,755,759 shares authorized at December 31, 2023 and 2022; 8,016,516 and 271,371 shares issued at December 31, 2023 and 2022, respectively; 8,016,516 and 268,468 shares outstanding at December 31, 2023 and 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r579",
      "r766"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Savings Plan",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r176",
      "r178",
      "r184",
      "r570",
      "r592"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Off-Balance Sheet Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r141"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r745"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized commercialization milestone payments to receive",
        "label": "Contract With Customer Liability Revenue Recognized From Commercialization Milestones",
        "documentation": "Contract with customer liability revenue recognized from commercialization milestones."
       }
      }
     },
     "auth_ref": []
    },
    "krro_ConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock",
        "label": "Conversion Of Preferred Stock To Common Stock",
        "documentation": "Conversion Of Preferred Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "krro_ConversionOfPreferredStockToCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ConversionOfPreferredStockToCommonStockShares",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock (in share)",
        "label": "Conversion Of Preferred Stock To Common Stock, Shares",
        "documentation": "Conversion Of Preferred Stock To Common Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r758",
      "r901"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r316",
      "r323",
      "r517",
      "r742",
      "r744"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "krro_CummingsParkSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "CummingsParkSubleaseMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cummings Park Sublease [Member]",
        "label": "Cummings Park Sublease [Member]",
        "documentation": "Cummings Park Sublease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cumulative Change In Ownership Percentage",
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative Change In Ownership Percentage",
        "terseLabel": "Cumulative change in ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r199",
      "r206",
      "r212",
      "r280",
      "r286",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r457",
      "r460",
      "r462",
      "r463",
      "r509"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r199",
      "r206",
      "r212",
      "r280",
      "r286",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r457",
      "r460",
      "r462",
      "r463",
      "r509"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current taxes:",
        "label": "Current taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r822",
      "r879"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r416",
      "r424",
      "r822"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r822",
      "r879"
     ]
    },
    "krro_CvrLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "CvrLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR Liability, Current",
        "label": "CVR Liability Current",
        "documentation": "CVR Liability Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of position of securities in unrealized loss position for less than twelve",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities in unrealized loss position for less than twelve",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r294",
      "r752"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r832"
     ]
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DebtSecuritiesUnrealizedGainLoss",
        "label": "Debt Securities, Unrealized Gain (Loss)",
        "totalLabel": "Debt Securities, Unrealized Gain (Loss), Total",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r878",
      "r879"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r120",
      "r147",
      "r423",
      "r424",
      "r822"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r125",
      "r410"
     ]
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent, current portion",
        "label": "Deferred Rent Credit, Current",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r807",
      "r885"
     ]
    },
    "krro_DeferredRentNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "DeferredRentNetOfCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent, net of current portion",
        "label": "Deferred Rent, Net of Current Portion",
        "documentation": "Deferred Rent, Net of Current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r878",
      "r879"
     ]
    },
    "krro_DeferredTaxAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "DeferredTaxAssetsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets Amortization",
        "documentation": "Deferred Tax Assets Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Tax Deferred Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other temporary differences",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "verboseLabel": "Valuation Allowance",
        "terseLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Deferred Expense",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating right-of-use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r877"
     ]
    },
    "krro_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities Tax Deferred Expense [Abstract]",
        "documentation": "Deferred tax liabilities tax deferred expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "krro_DefinedContributionPlanName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "DefinedContributionPlanName",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Name",
        "documentation": "Defined Contribution Plan Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "krro_Denominator": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "Denominator",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Denominator:",
        "documentation": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset",
        "totalLabel": "Derivative Asset, Total",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r475",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r665",
      "r666",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r744",
      "r770",
      "r903"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "totalLabel": "Derivative Liability, Total",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r475",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r672",
      "r674",
      "r675",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r744",
      "r903"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r904"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r352",
      "r383",
      "r384",
      "r386",
      "r760"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r786"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r214",
      "r216",
      "r219",
      "r220",
      "r221",
      "r225",
      "r463",
      "r464",
      "r571",
      "r593",
      "r747"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r216",
      "r219",
      "r220",
      "r221",
      "r225",
      "r463",
      "r464",
      "r571",
      "r593",
      "r747"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r222",
      "r223",
      "r224"
     ]
    },
    "krro_EffectOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "EffectOfAdoptionMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Adoption",
        "label": "Effect of Adoption [Member]",
        "documentation": "Effect of Adoption [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_EffectiveIncomeTaxCreditCarryforwards": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "EffectiveIncomeTaxCreditCarryforwards",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Effective Income Tax credit carryforwards",
        "documentation": "Effective Income Tax credit carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r404",
      "r425"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r880"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r880"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r880"
     ]
    },
    "krro_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging growth company status",
        "label": "Emerging Growth Company Status Policy Text Block",
        "documentation": "Emerging Growth Company Status Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits and Share-Based Compensation",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized unvested stock options, weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized stock-based compensation expense relating to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "krro_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of incorporation",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r153",
      "r180",
      "r181",
      "r182",
      "r196",
      "r197",
      "r198",
      "r201",
      "r209",
      "r211",
      "r226",
      "r280",
      "r286",
      "r336",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r462",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r511",
      "r600",
      "r601",
      "r602",
      "r629",
      "r702"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r471"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r471"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r468",
      "r524",
      "r525",
      "r526",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r472"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r339",
      "r344",
      "r468",
      "r524",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r339",
      "r344",
      "r468",
      "r525",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r468",
      "r526",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranfer of assets among fair value hierarchy levels",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r524",
      "r525",
      "r526",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r472"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r18"
     ]
    },
    "krro_FairvalueOfContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "FairvalueOfContingentValueRightLiability",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentValueRightLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "label": "FairValue Of Contingent Value Right liability",
        "documentation": "FairValue Of Contingent Value Right liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r295",
      "r296",
      "r318",
      "r333",
      "r452",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r591",
      "r752",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "krro_FrequencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "FrequencyMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frequency [Member]",
        "documentation": "Frequency [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "krro_FutureMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "FutureMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Milestone Payments",
        "documentation": "Future Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "terseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r682"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "krro_GenevantAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "GenevantAgreementMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genevant Agreement [Member]",
        "label": "Genevant Agreement [Member]",
        "documentation": "Genevant Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r103"
     ]
    },
    "krro_IncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IncentiveAwardPlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Incentive Award Plan [Member]",
        "documentation": "2019 Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision for income taxes",
        "terseLabel": "Loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r129",
      "r229",
      "r237",
      "r239",
      "r241",
      "r572",
      "r587",
      "r749"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r687"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r687"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r399",
      "r405",
      "r407",
      "r414",
      "r421",
      "r426",
      "r427",
      "r428",
      "r623"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties Charges and Interest Expense",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r148",
      "r210",
      "r211",
      "r230",
      "r403",
      "r422",
      "r596"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r401",
      "r402",
      "r407",
      "r408",
      "r413",
      "r415",
      "r617"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "krro_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Increase Decrease In Lease Liabilities",
        "documentation": "Increase decrease in lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "krro_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "terseLabel": "Increase in right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "terseLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "krro_IncurredExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IncurredExpenses",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred expenses",
        "label": "Incurred Expenses",
        "documentation": "Incurred Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "krro_InitialConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "InitialConsiderationAmount",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Consideration Amount",
        "documentation": "Initial Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill or intangible assets",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Intangible Assets, Net (Including Goodwill), Total",
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance."
       }
      }
     },
     "auth_ref": []
    },
    "krro_IntellectualPropertyExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IntellectualPropertyExpensesPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property Expenses",
        "label": "Intellectual Property Expenses Policy Text Block",
        "documentation": "Intellectual Property Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash interest expense",
        "label": "Interest Income (Expense), Net",
        "totalLabel": "Interest Income (Expense), Net, Total",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal Revenue Service (IRS) [Member]",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r613",
      "r614",
      "r615",
      "r616",
      "r712",
      "r713"
     ]
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Short-Term Investments",
        "label": "Investment [Table Text Block]",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r829"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestments1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r829"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_IssuanceOfCommonStockForCashInPreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IssuanceOfCommonStockForCashInPreClosingFinancing",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in PIPE financing",
        "label": "Issuance Of Common Stock For Cash In Pre Closing Financing",
        "documentation": "Issuance Of Common Stock For Cash In Pre Closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "krro_IssuanceOfCommonStockForCashInPreClosingFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IssuanceOfCommonStockForCashInPreClosingFinancingShares",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in PIPE financing (in share)",
        "label": "Issuance Of Common Stock For Cash In Pre Closing Financing, Shares",
        "documentation": "Issuance Of Common Stock For Cash In Pre Closing Financing, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Frequency shareholders in reverse recapitalization",
        "label": "Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization",
        "documentation": "Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "krro_IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Frequency shareholders in reverse recapitalization (in share)",
        "label": "Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization, Shares",
        "documentation": "Issuance Of Common Stock To Frequency Shareholders In Reverse Recapitalization, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "krro_KorrosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "KorrosMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Korros [Member]",
        "documentation": "Korros [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lease Costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r765"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "krro_LegacyKorroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "LegacyKorroMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy Korro [Member]",
        "label": "Legacy Korro [Member]",
        "documentation": "Legacy Korro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal cost",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease rental payments",
        "terseLabel": "Total Future Minimum Leases Payments",
        "totalLabel": "Total Future Minimum Leases Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "2024",
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "amount of lease payments representing interest",
        "terseLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease remaining terms",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum lease payments receivable",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "totalLabel": "Lessor, Operating Lease, Payment to be Received, Total",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r192",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r435",
      "r438",
      "r439",
      "r476",
      "r657",
      "r748",
      "r778",
      "r841",
      "r888",
      "r889"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock and stockholders' equity (deficit)",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)",
        "terseLabel": "Total liabilities, convertible preferred stock and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r126",
      "r583",
      "r766",
      "r821",
      "r837",
      "r882"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR Liability, Current",
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r158",
      "r192",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r435",
      "r438",
      "r439",
      "r476",
      "r766",
      "r841",
      "r888",
      "r889"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r791"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r347",
      "r551",
      "r597",
      "r649",
      "r650",
      "r710",
      "r714",
      "r717",
      "r718",
      "r727",
      "r739",
      "r740",
      "r751",
      "r755",
      "r759",
      "r767",
      "r843",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMerger1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Merger",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r121"
     ]
    },
    "krro_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone payment",
        "documentation": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r347",
      "r551",
      "r597",
      "r649",
      "r650",
      "r710",
      "r714",
      "r717",
      "r718",
      "r727",
      "r739",
      "r740",
      "r751",
      "r755",
      "r759",
      "r767",
      "r843",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "krro_MsApaAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "MsApaAssetMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MS APA Asset [Member]",
        "documentation": "MS APA Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r99",
      "r130",
      "r156",
      "r174",
      "r177",
      "r182",
      "r192",
      "r200",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r218",
      "r229",
      "r237",
      "r239",
      "r241",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r464",
      "r476",
      "r589",
      "r679",
      "r700",
      "r701",
      "r749",
      "r776",
      "r841"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_NetOperatingLossCarryforwardsExpirationWithLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "NetOperatingLossCarryforwardsExpirationWithLimitation",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss Carryforwards Expiration with Limitation",
        "documentation": "Net operating loss carryforwards expiration with limitation.",
        "label": "Net Operating Loss Carryforwards Expiration With Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "krro_NetOperatingLossCarryforwardsExpirationWithoutLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "NetOperatingLossCarryforwardsExpirationWithoutLimitation",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss Carryforwards Expiration without Limitation",
        "documentation": "Net operating loss carryforwards expiration without limitation.",
        "label": "Net Operating Loss Carryforwards Expiration Without Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r212",
      "r225",
      "r243",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r298",
      "r387",
      "r388",
      "r389",
      "r417",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r431",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r553",
      "r554",
      "r555",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r212",
      "r225",
      "r243",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r298",
      "r387",
      "r388",
      "r389",
      "r417",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r431",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r553",
      "r554",
      "r555",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "krro_NonCashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "NonCashLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Non Cash Lease Expenses",
        "documentation": "Non cash lease expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_OKSFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OKSFacilityMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OKS Facility [Member]",
        "label": "OKS Facility [Member]",
        "documentation": "O K S Facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r237",
      "r239",
      "r241",
      "r749"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities arising from lease modification",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r765"
     ]
    },
    "krro_OperatingLeaseLiabilitiesArisingFromLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OperatingLeaseLiabilitiesArisingFromLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities arising from lease modification",
        "label": "Operating lease liabilities arising from lease modification",
        "documentation": "Operating lease liabilities arising from lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "krro_OperatingLeaseLiabilitiesArisingFromRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OperatingLeaseLiabilitiesArisingFromRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities Arising From Right-Of-Use Assets",
        "label": "Operating Lease Liabilities Arising From Right-Of-Use Assets",
        "documentation": "Operating Lease Liabilities Arising From Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "krro_OperatingLeaseLiabilitiesNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OperatingLeaseLiabilitiesNetOfCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease Liabilities, Net of Current Portion",
        "documentation": "Operating Lease Liabilities, Net of Current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present Value of Operating Lease Liabilities",
        "totalLabel": "Present Value of Operating Lease Liabilities",
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r765"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r765"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss Carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "krro_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss Carryforwards, Expiration Year",
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss Carryforwards, Limitations on Use",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company and Liquidity",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r122",
      "r610",
      "r611"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r766"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r17",
      "r175",
      "r178",
      "r183",
      "r481",
      "r482",
      "r487",
      "r569",
      "r590",
      "r812",
      "r813"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on available-for-sale investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r275"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r766"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income:",
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_OutstandingStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "OutstandingStockOptionsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Stock Options [Member]",
        "label": "Outstanding Stock Options [Member]",
        "documentation": "Outstanding stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_PaymentOfReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PaymentOfReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of reverse recapitalization transaction costs",
        "label": "Payment Of Reverse Recapitalization Transaction Costs",
        "documentation": "Payment of reverse recapitalization transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal costs settled",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForTenantImprovements",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance utilized",
        "label": "Payments for Tenant Improvements",
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "krro_PercentageOfOutstandingSharesOfPreferredStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PercentageOfOutstandingSharesOfPreferredStock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of Preferred Stock",
        "label": "Percentage of outstanding shares of Preferred Stock",
        "documentation": "Percentage of outstanding shares of Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "krro_PeriodOfCumulativeChangeInOwnership": {
     "xbrltype": "durationItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PeriodOfCumulativeChangeInOwnership",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of Cumulative Change in Ownership",
        "documentation": "Period of cumulative change in ownership.",
        "label": "Period Of Cumulative Change In Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "krro_Phase2BClinicalTrial1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "Phase2BClinicalTrial1Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase2b Clinical Trial",
        "label": "Phase2b Clinical Trial1 [Member]",
        "documentation": "Phase2b Clinical Trial1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_Phase3ClinicalTrailMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "Phase3ClinicalTrailMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial",
        "label": "Phase3 Clinical Trail [Member]",
        "documentation": "Phase 3 clinical trail."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Convertible, Conversion Price",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exchange Ratio",
        "terseLabel": "Preferred Stock, Convertible, Conversion Ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Dividend Rate, Percentage",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r711",
      "r715",
      "r716",
      "r728"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation Value",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r325"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r902",
      "r906"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r320"
     ]
    },
    "krro_PreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PreferredStockPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Policy Text Block ]",
        "documentation": "Preferred Stock [Policy Text Block ]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r659"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred Stock Issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r320"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r659",
      "r677",
      "r906",
      "r907"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r578",
      "r766"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense and other assets",
        "label": "Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "krro_PriorToTheAdoptionOfAsc842Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PriorToTheAdoptionOfAsc842Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior to the Adoption of Accounting Section Eight Four Two [Member]",
        "terseLabel": "Prior to the Adoption of ASC 842",
        "documentation": "Prior to the Adoption of ASC 842 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance Initial Public Offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock in pre-closing financing",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B-2 convertible preferred stock, net of issuance costs",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "krro_ProceedsFromIssuanceOfConvertiblePreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockShares",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B-2 convertible preferred stock, net of issuance costs (in share)",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock, Shares",
        "documentation": "Proceeds From Issuance Of Convertible Preferred Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Series convertible preferred stock, net of issuance costs",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other financing activities, net",
        "terseLabel": "Other financing activities, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r817"
     ]
    },
    "krro_ProceedsFromSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ProceedsFromSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of assets",
        "label": "Proceeds from Sale of Assets",
        "documentation": "Proceeds from Sale of Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherAssets1",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of other assets",
        "label": "Proceeds from Sale of Other Assets",
        "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r174",
      "r177",
      "r187",
      "r192",
      "r200",
      "r210",
      "r211",
      "r229",
      "r237",
      "r239",
      "r241",
      "r276",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r433",
      "r436",
      "r437",
      "r464",
      "r476",
      "r572",
      "r588",
      "r628",
      "r679",
      "r700",
      "r701",
      "r749",
      "r763",
      "r764",
      "r777",
      "r814",
      "r841"
     ]
    },
    "krro_ProgentosTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ProgentosTherapeuticsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Progentos Therapeutics [Member]",
        "documentation": "Progentos Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment capitalized under tenant improvement allowance",
        "label": "Property And Equipment Capitalized Under Tenant Improvement Allowance",
        "documentation": "Property And Equipment Capitalized Under Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDispositions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDispositions",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Dispositions",
        "documentation": "Describes an entity's accounting treatment for disposals of property, plant and equipment, including gains and losses related thereto."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r160",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r573",
      "r586",
      "r766"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r142",
      "r145",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in Years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "krro_PurchasesOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PurchasesOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Purchases Of Investments",
        "documentation": "Purchases Of Investments"
       }
      }
     },
     "auth_ref": []
    },
    "krro_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses",
        "label": "Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses",
        "documentation": "Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r338",
      "r347",
      "r378",
      "r379",
      "r380",
      "r527",
      "r551",
      "r597",
      "r649",
      "r650",
      "r710",
      "r714",
      "r717",
      "r718",
      "r727",
      "r739",
      "r740",
      "r751",
      "r755",
      "r759",
      "r767",
      "r770",
      "r839",
      "r843",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r338",
      "r347",
      "r378",
      "r379",
      "r380",
      "r527",
      "r551",
      "r597",
      "r649",
      "r650",
      "r710",
      "r714",
      "r717",
      "r718",
      "r727",
      "r739",
      "r740",
      "r751",
      "r755",
      "r759",
      "r767",
      "r770",
      "r839",
      "r843",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_RecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecapitalizationCosts",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of reverse recapitalization transaction costs",
        "verboseLabel": "Transaction costs",
        "negatedTerseLabel": "Payment of reverse recapitalization transaction costs",
        "negatedLabel": "Reverse recapitalization transaction costs",
        "label": "Recapitalization Costs",
        "documentation": "Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "krro_RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements - Yet to be Adopted",
        "label": "Recent Accounting Pronouncements Yet to be Adopted Policy Text Block",
        "documentation": "Recent Accounting Pronouncements Yet to be Adopted Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "krro_ReimbursementsWithInResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ReimbursementsWithInResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursements with in Research and Development Expense",
        "label": "Reimbursements With in Research and Development Expense",
        "documentation": "Reimbursements with in Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r515",
      "r516",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r676",
      "r678",
      "r709"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r687"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r515",
      "r516",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r676",
      "r678",
      "r709",
      "r887"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516",
      "r518",
      "r624",
      "r625",
      "r626",
      "r685",
      "r686",
      "r687",
      "r706",
      "r708"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r316",
      "r323",
      "r517",
      "r743",
      "r744"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r873"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r873"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r397",
      "r896"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Credit Carryforward [Member]",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819",
      "r897",
      "r900"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r123",
      "r159",
      "r189",
      "r577"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "terseLabel": "Restricted Cash, Current",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819"
     ]
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash, net of current portion",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r736",
      "r737",
      "r806",
      "r819"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash, Noncurrent",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r806",
      "r819"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Common Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r110",
      "r582",
      "r604",
      "r609",
      "r622",
      "r660",
      "r766"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r196",
      "r197",
      "r198",
      "r201",
      "r209",
      "r211",
      "r280",
      "r286",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r447",
      "r448",
      "r451",
      "r462",
      "r600",
      "r602",
      "r629",
      "r906"
     ]
    },
    "krro_ReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ReverseRecapitalization",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Option, Reverse Recapitalization",
        "label": "Reverse recapitalization",
        "documentation": "Reverse recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r765"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Price Per Share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "krro_ScheduleOfContingentValueRightLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ScheduleOfContingentValueRightLiabilityTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Contingent Value Right Liability",
        "label": "Schedule Of Contingent Value Right Liability [Table Text Block]",
        "documentation": "Schedule Of Contingent Value Right Liability [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfConversionsOfStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfConversionsOfStockTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares Reserved for Future Issuance",
        "label": "Schedule of Conversions of Stock [Table Text Block]",
        "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Rental Payments",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Statement Affected by Adoption of ASC",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfPreferredUnitsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPreferredUnitsTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Preferred Stock authorized, issued and outstanding Table",
        "label": "Schedule of Preferred Units [Table Text Block]",
        "documentation": "Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r683",
      "r684",
      "r687"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Common Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r57",
      "r58",
      "r108",
      "r109",
      "r110",
      "r164",
      "r165",
      "r166",
      "r227",
      "r320",
      "r321",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r618",
      "r619",
      "r620",
      "r621",
      "r755",
      "r790",
      "r820"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r242",
      "r750"
     ]
    },
    "krro_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "verboseLabel": "Series A Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Agreement [Member]",
        "label": "Series A [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A Preferred Stock",
        "terseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r844"
     ]
    },
    "krro_SeriesB1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Convertible Preferred Stock [Member]",
        "documentation": "Series B-1 convertible preferred stock.",
        "label": "Series B1 Convertible Preferred Stock [Member]",
        "verboseLabel": "Series B-1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesB1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesB1PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Preferred Stock.",
        "terseLabel": "Series B-1 Preferred Stock [Member]",
        "label": "Series B-1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesB2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesB2ConvertiblePreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Convertible Preferred Stock [Member]",
        "label": "Series B-2 Convertible Preferred Stock[Member]",
        "documentation": "Series B-2 Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesB2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesB2PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Preferred Stock [Member]",
        "label": "Series B-2 Preferred Stock [Member]",
        "documentation": "Series B-2 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Agreement [Member]",
        "label": "Series B [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B-1 Preferred Stock",
        "label": "Series B1 Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r844"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r844"
     ]
    },
    "krro_SeriesSeed1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesSeed1PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed-1 Preferred Stock [Member]",
        "label": "Series Seed-1 Preferred Stock [Member]",
        "documentation": "Series Seed-1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesSeed2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesSeed2PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed-2 Preferred Stock [Member]",
        "label": "Series Seed-2 Preferred Stock [Member]",
        "documentation": "Series Seed-2 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesSeed3PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesSeed3PreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed-3 Preferred Stock [Member]",
        "label": "Series Seed-3 Preferred Stock [Member]",
        "documentation": "Series Seed-3 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesSeedConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesSeedConvertiblePreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed Convertible Preferred Stock [Member]",
        "label": "Series Seed Convertible Preferred Stock[Member]",
        "documentation": "Series Seed Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeriesSeedPreferredStockMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series Seed Preferred Stock",
        "terseLabel": "Series Seed Preferred Stock [Member]",
        "label": "Series Seed Preferred Stock [Member]",
        "documentation": "Series Seed Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_SeverancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SeverancePayment",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance payment",
        "label": "Severance payment",
        "documentation": "Severance payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock future issuance, description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value, Repurchased",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested as of December 31, 2023",
        "periodStartLabel": "Unvested as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average fair value, Unvested as of December 31, 2022",
        "periodEndLabel": "Weighted average fair value, Unvested as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized under plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares available for future grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "krro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares Options, Cancelled",
        "terseLabel": "Number of Share-Based Payment Award, Options, Cancelled in Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancelled in Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancelled in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, OptionsExercisable at December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares Options, Forfeited",
        "terseLabel": "Number of shares Options, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares Options , Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, Outstanding as of December 31, 2022",
        "periodStartLabel": "Aggregate intrinsic value, Outstanding as of December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Outstanding Option",
        "periodEndLabel": "Number of shares Options, Ending balance",
        "periodStartLabel": "Number of shares Options , Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance",
        "label": "Weighted average exercise price, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Fofeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "krro_ShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "ShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share Based Compensation expense",
        "documentation": "Share Based Compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r356",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Options exercisable as of Exercisable at December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of restricted common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "krro_SharesOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SharesOwnershipPercentage",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Shares Ownership, Percentage",
        "documentation": "Shares Ownership, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r810"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Lease Costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r765"
     ]
    },
    "krro_SixZeroFirstStreetLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SixZeroFirstStreetLeaseMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "60 First Street Lease [Member]",
        "label": "Six Zero First Street Lease [Member]",
        "documentation": "Six Zero First Street Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockScheduleOfPreferredStockAuthorizedIssuedAndOutstandingTableDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r164",
      "r165",
      "r166",
      "r192",
      "r216",
      "r217",
      "r219",
      "r221",
      "r227",
      "r228",
      "r276",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r320",
      "r321",
      "r325",
      "r328",
      "r335",
      "r476",
      "r618",
      "r619",
      "r620",
      "r621",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r659",
      "r680",
      "r702",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r790",
      "r820",
      "r826"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r153",
      "r180",
      "r181",
      "r182",
      "r196",
      "r197",
      "r198",
      "r201",
      "r209",
      "r211",
      "r226",
      "r280",
      "r286",
      "r336",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r462",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r511",
      "r600",
      "r601",
      "r602",
      "r629",
      "r702"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r226",
      "r552",
      "r613",
      "r640",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r681",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r771"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r226",
      "r552",
      "r613",
      "r640",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r681",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r771"
     ]
    },
    "krro_StockIncentivePlan1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "StockIncentivePlan1Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023 Stock Incentive Plan",
        "terseLabel": "2023 Stock Incentive Plan",
        "label": "2023 Stock Incentive Plan1 [Member]",
        "documentation": "2023 Stock Incentive Plan1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "StockIncentivePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2019 Stock Incentive Plan",
        "terseLabel": "2019 Stock Incentive Plan",
        "label": "2019 Stock Incentive Plan [Member]",
        "documentation": "2019 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services rendered (in share)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock (in share)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r110"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares Options, Exercised",
        "verboseLabel": "Exercises of stock options (in shares)",
        "terseLabel": "Number of shares Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r110",
      "r362"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services rendered",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r110"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercises of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r110"
     ]
    },
    "krro_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Stock Options [Member]",
        "documentation": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit)",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity (deficit)",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total stockholders' deficit",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r72",
      "r153",
      "r154",
      "r181",
      "r196",
      "r197",
      "r198",
      "r201",
      "r209",
      "r280",
      "r286",
      "r336",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r462",
      "r481",
      "r483",
      "r487",
      "r511",
      "r601",
      "r602",
      "r627",
      "r661",
      "r677",
      "r703",
      "r704",
      "r734",
      "r777",
      "r821",
      "r837",
      "r882",
      "r906"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStock1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock",
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r191",
      "r319",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r336",
      "r453",
      "r705",
      "r707",
      "r735"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureSubsquentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsquent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520"
     ]
    },
    "krro_SubsequentToTheAdoptionOfAsc842Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "SubsequentToTheAdoptionOfAsc842Member",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent to the Adoption of ASC 842",
        "label": "Subsequent to the Adoption of ASC 842 [Member]",
        "documentation": "Subsequent to the Adoption of ASC 842 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "krro_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Expiration Year",
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance",
        "negatedPeriodEndLabel": "Temporary equity, beginning balance",
        "terseLabel": "Temporary equity, convertible preferred stock",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r394",
      "r580"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r50"
     ]
    },
    "us-gaap_TemporaryEquityShareSubscriptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityShareSubscriptions",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Temporary equity, beginning balance (in share)",
        "periodStartLabel": "Temporary equity, beginning balance (in share)",
        "label": "Temporary Equity, Share Subscriptions",
        "documentation": "The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r886"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r318",
      "r333",
      "r452",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r591",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "krro_TwoThousandAndFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "TwoThousandAndFourteenStockIncentivePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Stock Incentive Plan",
        "label": "Two Thousand And Fourteen Stock Incentive Plan [Member]",
        "documentation": "Two thousand and fourteen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "krro_TwoThousandAndNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "TwoThousandAndNineteenStockIncentivePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Stock Incentive Plan Member",
        "label": "Two Thousand And Nineteen Stock Incentive Plan [Member]",
        "documentation": "Two Thousand And Nineteen Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krro_TwoThousandNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Stock Incentive Plan",
        "label": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "documentation": "Two Thousand Nineteen Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "krro_TwoThousandTwentyThreeStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "TwoThousandTwentyThreeStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Stock Option and Incentive Plan",
        "label": "Two Thousand Twenty Three Stock Option And Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Stock Option And Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfFinancialStatementAffectedByAdoptionOfAscDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r200",
      "r201",
      "r202",
      "r203",
      "r212",
      "r243",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r298",
      "r387",
      "r388",
      "r389",
      "r417",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r431",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r553",
      "r554",
      "r555",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureGenevantAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r898"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r406"
     ]
    },
    "krro_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock Units [Member]",
        "label": "Unvested Restricted Stock Units [Member]",
        "documentation": "Unvested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r138",
      "r140",
      "r143",
      "r144"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Valuation Allowance Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Explanation of Change in Valuation Allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Explanation of Change",
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Lease Costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r765"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureCommonStockScheduleOfNumberOfSharesReservedForFutureIssuanceDetails",
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "krro_WeightedAverageExercisePriceCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "WeightedAverageExercisePriceCancelled",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Exercise Price Cancelled",
        "documentation": "Weighted- Average Exercise Price Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "krro_WeightedAverageExercisePriceReverseRecapitalization": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korrobio.com/20231231",
     "localname": "WeightedAverageExercisePriceReverseRecapitalization",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Reverse Recapitalization",
        "label": "Weighted- Average Exercise Price Reverse Recapitalization",
        "documentation": "Weighted- Average Exercise Price Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r221"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://korrobio.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://korrobio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r221"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//321/tableOfContent"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//325/tableOfContent"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0000950170-24-036396-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-036396-xbrl.zip
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MT[)-EO>H CY1!?^3H@:?5.ZC;!L<>3;RQQ0$/,HC?_\\?*W@[VKQ4$%VM%#
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M1<HK233AN -QR>H)99<[$%M)24MUR33P>^HO/=;EB^3*'N'?)=Y@;$MW*M-
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MC:^C->+W;9RI\FQ=CRCJ3^WBE%B9R_WR+OVBF*R:+%Y;4]=00_8V264E:P/
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M2K8>=E+%:4Q7<!(A3?Q244\:-Z*7%0)\VQ["&"-/T8BG"'P1PL6Z[P5 D<E
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M:>I3M",##H(ARYW;0T@N@-F5[*?&W;?3EJN^M2!YH1_FOO@A;/KT1)WI>-T
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M_>[+<Q#6<>D[H\<SI3S%/-E3X62U2$2FK4%U(HA%/.41 ]T:4H.I^BX5D3I
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M@*DS#2%2>.JVB>UPT ]2;WJOHPH5&3)?J<_>C^98G#F.#)3CRHLH)3D(C9+
M<\^./XY<)I9;N(3<7,CP3"S)%:?/PT<*3]=7M.:LF623R+R-1%F W)H:X#S
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MFVX]_@\Y"N?(;58G'Y]B18"#/HPAXMH;&^F;MMO]_+$"#$,L<*G)"<J:L:*
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MQ>3<V'\A'O:/;_]L]O\ 4$L#!!0    ( $^ >EA/08^$+30  ,8]   1
M:6UG.#,Q,C<Q-S5?,2YJ<&?->P54U-_6Z,!0 H+$T,T@,8#20S=#2'=*24AW
M*2DA'8*@E#1(=R/=W:4TTEU2#_4?>N_]WKO?=]];Z_U8>\'LV6?W.6?O<W[<
M3MTN !Y(2TA) .#@ 0"XNQ_ [2Q %(""A(2,A(B"C(Q\[QX**CKN?70T-'1"
M;!Q,7%(B<C)2(A(2"C S+045(S4)"1T7/>-C%G9V=G):;GXH*Q\S&SOK=R9P
M]^[=0T=#)[A_GX"5DH22];_]W'X"8*$ VN!M@7!4 '@L." 6W&T;@/Q.3T2X
M'P_@CP<.'HB B(2,<@\5[8Z@X@$ '@X(A$< (B(B(-Q]^_+N>P "%B(V)8LP
M$HZB 3*5'2ZK3]0'%&J1DF:0TO ^F,W0WO<>*AX^ 2$1S4-:.GH&=@Y.+B@W
MCZB8N 1,4DI:645535U#4\O(^)F)J9GY<P=')V<75S=WOU?^ 8%!KX.C8][$
MQKV-3WB7EIZ1F96=DYM76E9>45E575/;TMK6WM'9U=TS,CHV/C$Y-3VSN+2\
MLKJV_G5C\^#PZ/CD].S\XMMWN^  0+@_GW]I%]:=7? ("$ $Y.]VP<&[?"?
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M>7KI,'XU?8HS)2?7GE^<D"S-&R_X282B!"PG%3$MAGI,\8X'G%G&'1MC]V"
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M\,+W$HO=5")[A&@IJX$"#24RH.2L2>46<#T3UM31=3K #Z4G+R9TCQN9Q*C
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M\1#)E8">S_3:CB5M>3N;GP#RZ\J*XD*=%_+77R8B[DJWNF_#:TUG.4=/+\<
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M?0MP6WZMDM*&.@-R4PW-E-M=B8OBPU/;[YK]#(TE;) $X"@KBAN:_;7;_G=
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MY!7:GN@I\='@R0?IV3D/J,3)<M63]Q9],.?HY*ZM7FV$YG"QPAV#AP@HK\_
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MNWX3M'@\IMFBE=*U=Q:]K/A4AMJNC@!\QBXS&'K/3O%R5=>A!NA.<U3L#=2
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MZX4JC8I!>GJ7XW((T@P>]E'I--'MH-[U+$S";V9+IG 0B][0EG)_,/(2+5#
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M3>T-;G.AH6-J.[C).JOY[64K__IOAN"4F^LRHPE+&OZ2C!W[!QB7Z@"GLIP
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M8V;=CPFM.TG/GUU8/4<Y'@NN:?BS^;/_]^'P!Z$8C_Y%Y8_8FK7[@Y]=RK=
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MZ70MMA.KEDOMN13#44"V5X\-C2$U0-O+?TZGR;6V>(-FXH2AM2"#=315NTW
M&S 8X77^+85+)%TH7"U,,. G>:(6P>[ZU%1B2+\= 2NK.. \ M>!!+4/=Z!8
MPN?DE%=:M&"2Y!K,V\!4"C/31:Q[I$_"1>=Q[K'O0.SW=O5)@S8BMU%DJYTF
M]AA+MF1(23#A+$IH-.^U,<GWI!*E^9PZ)R7.[8%QIDF'CMA4H@HXGE5KERO<
M$SE5YQGUJDG[IL^U_I(63*L:V7R4)UNUQ6G[B+7\\/E:M]</<DF[2[.J$J^&
M RJ<41+$NFWWG; 755CW9=BO7B-R"2)SN%CMA$L%\@4LZ2HV-H3JN_#%QA0
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MX*/7OQ<V-7&@GLOQTP,QL%YG,\<IYR\],VLXE?(THV3G55I]:?RV5?<QNL#
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M*A( [ * ;A&, 6DQ"T6$T)Z$*,"TW?EZV/^AD__KS^K,198O)_7VO&&BG$&
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MNIFH*/>Z:S0NWI4EA>TRQIG^N=6\W>FY(@@?HF*TF6/F,+"KVB#3'28G7--
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MYYJ]Q:*NHMZE_W"?LF87RHV@"_MO)Q;D9\,^1YG?A)#_;P-TEO_QA9:TEC2
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M9W'_O\P"(#T'"84NTJ?Y_P%02P,$%     @ 3X!Z6%B_"$FM+   W2T  !(
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M]MAQ(CQI.2.@SL$G5=FD%"_<:Q5;)0LO_FQ/X9YA(N=4L!9A#E1RQ\JZ]C;
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M DI?J?WX1=R$FR5E=E)-V52U0DLOP^B,N,2U<:5.D:W />HWCRASR8_9FAZ
M%NQLT,9)9KN4S!I-&,1OJY*#N.D&+WX2QV3[TCOK&>FE%RC]F++*LR:9EIXQ
M)YN]?@"66'FU]..+[3VH<ET7B_%%8A$+YO@"&5!Z$D#ZOLDF_].=W9A\"-D#
ML$>Y:T-2=E_UHR!! P7*P2BDAAJLB(!T!$>H9*FOQE*59Z_8EI_'"%O_)*8>
MUKT=W&?+KZ]#C"_2A:+VY *:;>K!>J\CZ1:2]N<*7N3#BOJWH]FZG^[JB*2Y
M[%L%1]/CC&8&OET:K14Z^^H_%-;D>MI06%F&T$\>113MBNNY=RMH)H)+/Z\R
ML=RR#;]37EO4D3W&[XXJU5;%,Y [,C>;I:/)#J_(M_.1Z-:OB.#,?V:@U^N,
M33E+%M:_C8H,%-FNJ1LVK\F)K2[JI_-7EG4RI;:@#:5CS+ME?5G7>?< C(YR
M9M]?W48!BK*0$)\8>=+3PA#LY?=G6>C=]&J:(3R$:K9G"2B(>ZJJIXO89G.G
M$'+FT.NW.D+W9)..:T8ER/A)!H_;8Z--2&-Q(=E$IIC:WH#6SHUPBR#/F2*.
M [M8T\>E7E?@K.R9:EZWS7S\]Q=$:@@$N3+?J3(?@DR.;T*5;T(RBD5BDGD\
MKVCY_V#I(SOU!3./#P-R:KK5?R4)J8]"H%PDN)Z/+X"KFQ,"Y0#XQRQD__51
MG:+"MK#=2B\7/4E<U71'^U@1$4[6\',ZVX('=MOW11"TP!TWJ:V<%&;6Q&/X
M=+=P ZVUJ:S$4',XP6KBLQ1?<C*)]LM/%>#*/V5W7>I\;JQ :3@ZL>3R3)S4
MZM'3^66Y4L,[BQ>J=]@44VR1E]$VI8L45B+\M0TBR-]B$:TCV$64KX*TDEHB
M_4?U8Y_;E 0ZB^?<V=RX!XZ\G$YL:QIBU+SQ.2*_W>FXYIWDREG6ZV:"?')]
M<N9Z=:P^@1(6B_!G8D&I7="HDB)!H8% -E,1)@*I__1*R,OS'(1NZW092?)H
M[P.@^UM#,M_Y/.J<#]>,"C(9DJ#&_6A80M)8@$*O+%Q]26J6_)P@7'W6VDM[
MVH%,WH"06!K3U5:<W8:W266EK"P?87BNUB]?A *QXE57,XQYNS/ZG-G4!VFA
M1CZF&=1^[P^,-V.;#WZ\=O&WCYKY0>W_73=Z2R5)U(?)88$M$.=P0'1K8KJ<
M9[MK.![ZX[WQQ/@%N1ME^&NWOL7V,BE[LKWXJRE_!KF:,7;M\0'Q(F$KL9I,
M=;^4%@T+TA<W8F\6[VQ?#9%>!NJG(+Q0T6QIS3J2'?54U!7JC'56)<CM&JX[
M=^;$*O @S D_U/ZNF[CX[O/NR''TNH^_FT\.N/SYXW;J8_E: .6&<T#BALC+
MR#I_!IWG;YM'Q"@O%*IC1\C/\7^?5\"1BV#*V"#50FGY@J F^/"]$K%BB!?$
M@> *I"*\WN 8C?-&H;D<6: 90@B7)"/:JS'X9?#;#I7VQ;J5!"-LMD?23!5\
MMD8UP7#,'IJG,V&%O^D0)5VN.MBXE<'%]MJ9T!;9-L98+1/SHN]>/[CQ?8;/
MCKIJ[LX,YQ%_ N>PE)D&$BH.]#F#NL$.)G6I&"[5]8O9""0*^8B=@S$D!H<J
M:;Q?,&Z3EMG>(A0]$BWN:CKM+68J]4*#A)5L7!N:6R1=#Y?0LEF:AS*OKZLY
M8/9=_LD\6:XD3VHW_+D4=<+)X9.?3A\L:X+3EZ8JK#T^3[L:YE27OJ<3A,-2
MC#Z8H-=&N$B1&:\5GA;G(H1>Z.9(?FP!R:$F1PG]!['4'XE5PQ)R>B\^,JGM
M4_:D]1QKES6HQ  ' 5E-@9QUD>Q*J9#@Z<,E"W$ER7*2$ #$IJB@$28GUG )
MI>-MELM[ !QMF?K+Q3XN3O9=]<^)$KX]>0GR<;_!O*)T!R?Q!'Z-NWZ_J.Q'
M>.24R1Q*&UM@1R%>4%@P:.F6BI2Z_%Z\+]=8\LF&?/,5YC%0_4.9YV!^OZ:>
M06+!?7X[,/WM>"?%&?QJ1F*E%?/75>!EUUW!GP=@T-K0D08AJB,O7=?MR@TE
M44,UH<E),8L\A]X6GV,<C/_Z96C4.-!)"9,KQ[1!H1@C7.PKNAAQ'JAB.S#F
MY9C.7UW4:KZIQ9,6 4=KD:"DL9P_ $SU8D]610>5S:AY?#,,A/NA.N"_CM'<
MVT(]XCN-T5LEW3X579F0\P/M0/UBCF^M;)V:\!'&[PXN"M>:*#I=F/ +]M0X
MRRW:VE3'F^/:@YM, =[(U>J7+\_57_+=,'"=E.%WJ2<PO<Z7[1;>\I(^WT+L
MC4U#%PKIQGWAI5$O<L)=T+BHTCSZ2Y0(9+?TIK)Y^4P7&:*2G6LM,=!%/X3&
M $=KSCMJG/DE"WPZRJ"NJBX+"XMZ"XYD]ZC"<DJZMS,VV^61T=EQ8>2Z%D0[
M,!+64#4 #2"8-"20I3;79Z+^T]?6C'@]SV6&M6B>B$8;M]->S'Y4-^'JX$3J
MX72,]:8&U.;3[^3>,P[<^I;G32B+!D'O:^&*M-=C4$54@7]E& 66QPQS?YQ/
MTL52B/M/0+CDHR(S((#ZF*(D#H(\D:2&"D5E&2]CZ@M?E+L UN(^!/CK9&Q>
MS?7ZOB =5&G\)GY''4K<TTCMEX),__ +#G4/8#@&:K1KZTRL&;9,;]%N[5@U
MHX1.8>-1Y%J9["H11H;4I9186%A"?'7]/K+39Z(+-=7S@G\:CC/UQ[X=*T?E
M3R8=477G"H%9>D]+5SY^"DD[:ZI38D^44\EL,7>+C<U"2J(5\X\$=E@^"O$1
MMIB;]< HNTX^BN$D/6GL? R7!8K&Z0]G[[^_\'F;<)Y238V9;>T'KI02Z>M[
M95*W1K'TA2E\54ZQ;_U$J4?&<NWMEMBSWW6>L<USF$UA(X?S>!+-=4O]&!F%
M=C_>/5WH6.;24Q.ZC5*A?+IKI.AAB^ADY1#Z7N#3Y37ND]F-M?^T+\<6[<?]
MNZH%I*A.@VR(T!1I3A"&1@.%=CHE8\.OLEB+ZMXJ+&H5K'R5EXX*O)\^#F1W
M/EU ,R+4B(U;TR/%8\W6X\ATRV#=MF37Y&(7B3QAH>-J)\<LZ,2VUOL<3>8)
MH@>E[#IN8J@VEI$MR),YZTLRTA>FV!:@6V@HBTVH*IB\";]3N(.<]05.5HQG
MJO'\F^,?O\X$[A).%R'RF(0T0ND*<4V$U,=Q7?)0@Q]%$@#YE:7EUZ_D&DKU
M/ _=FS19],7>8@E+V2#UN'7&I($,=_,]R"E%\E<0P(6)P0'"G_KI%?L%+"&U
M:^/(Z 4S7)2V"RYP0'415X9%5]-YF&A&AK E/P"PJ8K 81+M/98)C^F3,"5S
M!F]WP[.]I@8VOR(%G<D&J'OK_,R;A? 3B37U^3T=G@4Y2K"!7I 0UJV-[H#R
M+^&Q?/] :@3JP,^A2\D'@,+^8UT4DTW,0'S/6(-_$UDQ_Q,I;[N^5U<; 76?
M<A<I_>+1PW&WJ"[L&+752A)^/,>O'>'SHY;NT&_W*Q-3KG'KV:<<=#B.E:+^
M[C<]$O*.W]N[K+=DQ&YZVJ7*@P![2<4%TY?.6KA"87*M\;-R.H<BSL!MJH'M
MR S#7T0'<L8(N4F78QDF'F2EM9,\^.ST.7/X+JQ'9//;(7Q2 QQE069JN*^X
MJKLJ,RCPRT7QKTR-]Y:XO^C;Z1\QH$D1.\85]U=;'"W!0NRPG5Y5A50@X&1:
MZ7W[G=T93VE_8P##>,HVM4+&N<ISK@7S>A<[+_(<J$"F,E^;%:3V5(FOC>$!
MT&?)5SW_"F5"=[R<W[6%,OA?7*? E:1#Q32@8H\"0"16HQC0",HCV964]O":
M%Z9)5!A]M^^/\2;=NVUMKN; @)AHEV478\Y0W0R1K1N] 4;.R83>-N'&ED4N
MSY 77)EM^DO-W>F9R0X2!T[3VAVRE-JI1<DS<X9#J92VNWO$97/8;8H0($T3
ME+DJSF8V<V]/\!%X)4^8CJOWI&R.=4N%5QO)&VH[X?VI:CBP@_P?#AK$W&P'
MACKJSD(+YSAJH8B7KWM3:J!*+!T$QU#-+LVB,D'WM&/9R,NQ_*%:RTW5A*)=
MJ/$H^^%^[538P6<782TL4;GL,GT%A4@M59L&R"HCJT+\+!DI#9G>.=-W00<T
M^=;!V39TT\_"VRZ$*W#Y%6F&,,'93B?ZG)&-4Q?_/0W=B>ABFZ251)TA;;,V
M&I2M$.PA:X&HDIX047^I>LR.SU^J2P#@;/U\K9"_9=BEY<]>ORMC%ZE0TNN@
M[X1I@$J T_+["=HH'56< 5GC8X:[%6<.!D98?T^ :?S[F4B-L(A21YNH=2OJ
MT->UI0OK&5+&?O[<^M\<\P]JXRF_9@J_B15\]CY^@B$X,D 3Q6S'E>+&55V/
MJD,NNZA\_K!B39N#U+'Q<C.WJ#^*:S*A4PF3PK08GVL"]4QB5V='M4#Z/C\@
MX3HXUN@!*)+0SV,]^'W]_KSD=3%.-,FQTN.,A>M3@/"D>YZ$3&-!L7_U +RR
MNS:K9<W(RF1M+<2,?4+XM/!QL'<TX#8?+RB@MTN\"_DMB^)8WNI9<D"2#V*T
M(NBV%Q7:7R$J9+Y*/F<J!>%AFV"+2^7GA() %NAOK!Y-<@;1 _ ;-=@9-U:;
MK)T:&ZX^)L>ZCZKM,">F8?QE,%&C7VLOL\QV3,$E<BKOP_XESWG2Y'-*F[-Q
MF6K%NE0;>MD>NK3WP;&L\78I';"/#@F'B7&PJ&%)_R;FK#6.$7A;>1BRU)K[
M>44I+"YWMH_2PC+=U!*<9/2KCR&RDF&>OSAW:6E)<LC/?ET(5].1(21K+6,9
M*8$[D5> HLGT ,2\C]%OAJ$Q9Y7 T3CZ+H7YV6W&#V"VDV%!9+9A&;9A0=B/
M%@^7)>;.)"?L'[[<K2E *._,_959"NA7,R A&1 \GQU%&*0CB.1Q/(.A5F]%
ME&WU[:0AIDAFS?0T['&EV617H0N0<WFDHKR_U-&OJ:)U/5*V*T1>O_EV#L+L
MWS\,E',J4VJ':_#.R_9 RE/D,,+[Y!9-'Z4%+G  06/#*\9JP&S2S>PBJ")?
M:88%1UD0)=]VAHI^W");C+S1Y-:_"EE:(29B5^,K?P!8<]T,KIJHS-+#O/@2
M^VNNHK)<-Q;9LM"B,IM%1Z0S4,BVSLI+J#>Q;[M9-V2755Q<1_B"//F37R2)
M%X,3S:DR_%F+B!<ET#;N,-@BH=I-F;=_V)18U(!M2-7KR@+2"G=5OB#;@A37
M@A03K@E\L0E\KI?_CC"+?X5;$3G&/_$%DM':^_= 4?+:O!O&RJV.:R*F4?Q5
M)0_U,=;R\U G+"(5R366TE6R\&(RIAVX'AWQU)3)7J(PB'V4?2=L[]>UMO<1
M!V,[5:#(4YX#DDE/SX6"=$T8'$H":/G-S_N+#"M^+YQ%-R%US%M+\Z"Z_ K2
M4*^Y'ZWR<USQYN$&6Q]6.IC_R<)X#Z]M]-8MU(9$7E 5F<888_,9[@K4(RCD
M=9*T.M(RDX.$SOK+ ^^)<%Z<!@P%E%#(LH _5LI :IR7J('ER;V5"-*W3XJ4
M',%N3EP!IZR::UYOW[5PWQ9O\[Y3?4+\7!,L,(Y&0%@X'9I!ZO*)E9>H$>@$
MO[UC2VGX$UD?1\AZ(B$B3+06EVL>^[W1M)6VZZU9V4X S6?EYC!3C\AB(&+*
MG*Y/$GB&E-SYI3Z*/P<A3R1E=V'].G!:W]?>?F=KZ!?:-?]#YM9N*+\U(37Y
MW= UW-GJ1:?$R]N2(3H*V]I3Y0*T1Z(/<1<!JN<A")E'L<62'?SLGZ^GA;A1
M,4>4N[:KR1$88IIF>21A, B43V,ZZ!^:0X!:.)0^"LD?AUO9Q_\%S*/_8V/#
M/["GSH:.*(0'\C&;ND.^7<A96D/#LC+J[VNU&X^B5T.>I N.G;_&7*JL$&6;
MAH5+'Q\YS9=I;WJ96^BJ6P?5NC$Y##_-OS%[ #R+&G5KH-J"GV8)M^2WAIB)
M>J^M/H5^ @?QJ&#H).U=F:]?CW)P,@K'U<>X:Z_41=-(#KY-T:%&5,XVA[_K
M"O+SYO>'P[V*VDAV(7B.C!R,W/A\G:I\_^2UR,FP7+ZV5L+KQ&N-7:%_!$G>
M8[S]R]:7H%88!_8V72.R"HH=F!0@>W!$K ;JH]@<4R$)\LG/HX;8 H\&!(('
M07;%,TW32N^HYB1'-H39:R\T5Q05$^]0AOU5MM$DUI=F9G3QUT$ )B:=(83C
M23F.0M'JAOY0P?T&Q7')P&7-0[9G8UJW7\<> Y;$[$\@9B *M*,;P=IP_>;V
M] [R[GO/04P7W*5*F XO'A&BF&=,NBF1SU*9.&P1?SV57+H2D_X]YJMZX[YZ
M]))]TL)ZZ+G$>.V+4'I#NNN,S;R<H*?C%(_, FP+)F(4;+/^%^)G=S8Y2(E'
MXTZ&;T/YTSQN<N(#QRY+3G+XQ]1)C2['Q\W8W@^O)I?SX% ZZMKQ8"A)D"$<
MP9)EBG@T.%UDN21P24R6[D>K0X)5A/6GX"_DKONV*">(1#8W)_A*H^J14V:1
M<"A EM=-HD[FN)E:.P;EQE:[T<"EM6/)PB2;G]3 ^]?]2%^014B=%8Y!83V*
M9$GB'U:_?@+1]OQ.)-%H)'B.D/@X\>-GZQ(?'-KF$D2P^7F I@ ! 7[HGN?_
M$K?)"2)UI'Q<XM<Z/@I$@;%Z! LP+SO'DH7VW^UF:M][?+ ,W?.\D_#BQT9I
M0*++MM7RS1$%2Z$+D:.6@==:-PD<1O@P^S\ 4$L#!!0    ( $^ >EAKH\#.
MKB@  .<L   2    :6UG.#,Q,C<Q-S5?,30N:G!GU7IE5%Q-NV7C!'>78(%@
MP8,3('B@<4A#$R1X@. 60@+!&O= <(>&QMW>X*Z-2X!&&W>'X?WF?B-WS;KK
MNS,_9N8Y:_^JI\XZ>]6N4\^NJL?9QQ4 D:JBBB( !14 0'EZ (\+ 'D -B8F
M%B8&-A86UK-GV#AX9/AXN+AXU"2DA&3T-(P,]#1T=,]9>=F?,W.ST-%QO'[)
MS<<O)"3$R"XF)2H@R2LH)/#W2U">/7N&AXM'A8]/)<!$QR3PGX['OP#$V( @
MU,]H*,P 5&(4-&*4QRX X]-W8J#\(P#_%BBH:.@8F%C8SW!PGQ)JB0"H*&AH
MJ.AH&!CHZ$^M?D_M '1B#!(F?EE,4BTS+&9G,H'OL=G8+'*5O\FUQX]8!<U=
M I[A4%!24=.PO6#G>,DI)"SR6E1,7/ZM@J*2LHJJCJZ>OH'A>Y#%1TLK:QM;
M.U<W=P]/+V^?P!]!P2&A89"X^(3$I.2?*:DYN7GY!85%Q255U36U=?4-C4T=
MG5W=/;U]_0,3D_"IZ9G9N?G5-<3ZQN;6]@[R^.3T[/SB\NKZYF]>*  TE'_&
M_Y(7\1,O5'1T-'2LOWFAH'K^G4",CL'$CTDBJX5EYDS*+/ =FTPN-KOR]S,6
M0>TC<G.7<1P*5J%5MN._J?V#V;]&+.!_B]E_(_;?><T#\-!0G@8/C1@@ [B\
MX<CYAO-_'04I+ 1$32%29!GJ '$(5_+4%SVIX&R>&A$3N\+CC_&96:5(O4AA
M;YKQ7/'1)&PD1^DPK6Z\#D0Q"8V4B8Y!@+"R3+RH7P5,+"JJEF041*:EJZRE
M0 ;XGZ#N:3CC6J&%U.!,:%I.1F%6NW7OO1<BY]6*VBOJT+[2&SS3!]ZQWKQP
MOB]TRKR$RBTCEW?0%D;I2GQST52%F7A(&S94G0T20"]R()Q]_UF&8K^<: V-
MO0:<\+T%\N&F:XH]T\^MT8X>=$VNYCM&>RB6:?D&V> +7]U[X.RB6$</[IM-
M$\,.B'8B>Y$!D /G&FZ&1*$B8RASTF_6IN/RX/.YWR3(R\D1%'H6;7*LC=29
M6&(/7S^7U/+HFB7VKJ-M5WD)U7V:F@',OL$SS(+:F=K>:=: T\[-!:#<=8M@
M@$C$"H)^M[?<G7VJYA% M)S.>?.^G'?:BQ?QKI>D!XA^O@U4_=ES&UF]Y+YD
M]:?S1K@GWZUTO .K+],[3!3@.^T8C< %VW<FBW>7E?VFV.A<6*$6:*T\-&:,
M^ *\KUU]!.#*DFDO"B/8AKLT(YJQ1[#1[O<>].Q7+V"55[N@RENZ"[X_T;7R
M3I^;WRNO1/@1[@"3U8+.A:*[P\W<>( AYV:?#3Z'#-#VG?>"#H2:#_>E!)8O
M^Y+^C("7=7/QVKH,GLG<)=M_N,7*O,> CI=8.@;**I#I1G#D0 #_&J ?EI7,
MK-FZTLD^2P'-5&H29]?2TF,3U\ .-0O.^'7X\#3""Z7RZ0:G6G!5OTAOY]%'
M<T^TC*R;&75[6Y[U0V\O%&_=5>4-UT? =.GMK55ML J*&=7G2LPM7T^+_1T3
MO:\^T>E[OC\_6*OX"L%NJBO'>=D:)]9L?WV!)EB=L[2Z2+/4Q[TB;JEX,TF)
M,Y3=Y+RS V8/R<.D#7W3TXN'58TWS0[1%IEA/F6RPL#<T@D(SZAM]?<)L!:A
M7>SJYQV]&VXG>!OF( EAPSL!='QHP4:+GJZ2E(4.W:1-.W]4<OP60XC7.S-#
M7KTZHU3S,SLF^O4#R'U;1AQQD+X%=U<QTY[HYPMSWEE\2("J]$3H^B3*X1B&
M#8!E5BC/VHE,0&U@$R/G;]L^T9? ,]C$_"9M X47G>0G 6S8"]&/X.>2F2?#
M]1P],N*.@26T$H&U_01J0F_/T8H9[G>T8#NUU%)4QU0V4QJ:^C:'-@6]S(,T
M?2&<G<]O(.X^[#%D6@J OX'^34 # '/<,FZ!TZ^-Q_&3I)=YON($^@6V3T.O
M<O5L'6<4ZJTT!V@VXF&3XUC9,@,UW-PY <.F$=\H ZNC[)/<Z397*7,6#PH5
MA;)*U,&MR<FN&6UCFQD*MWKKEY,-J]056&U8 "VL'VD.O XYY[K:4U/=3F1B
MLUG6Q4@@0MM4_X->H*?-S.X4R4;X0SL+#B$AB)6-/8R5???[68G!5ZI(O?SJ
M.&56!>Y?! 2KD['S3:4XBCA9E=N8ZD:=DW;3S*)-Q<M;&;UKZG9_]B9I+YC?
M+&B_H14]?P30S-;!)16*+-=:PZT$:(2,_3DW612;HKS7&!LB^*0(T,00)S+Y
M[B:DC;9NQT[M=KW\FH:F==Y_D6^M;KQ42^R?N\Z <1+]H$-@N*\K>19=A;R3
MY[X<3QC%R-$F7!&#@CY$H4<4EX!J*QS1!]/;M0F?^T[7+J7GQ;%.=F^*'X5'
MG)Z57'HX+_<<&\OQ2>^:HA;.-XMQ=AA$M %U1O4X=",+"5,G'^BVB:??&BCB
ME0I@BZ'K0 -KX%9'F]D.YM7<%8.<N7_)7GO28>HL[( WW+5*2]C'RT:X%>G'
M[8T**[04R"M'_CF$_Q$LY%?]..F!VNTG[S?@.H.-[ZFJ!&XL:BD9*"=@3C7-
MU;BLJ8;,4Q;F)=\0$02M&)_&-?:X97UMZ>\C+N(IB=\%OYY=T,#^_;O$Q_%[
MX0Z(:+S,W.PC<;P%/VOPB(L_*<A-NX&N+7(%'U<.GM5>'848_4[-<FIMC4-H
MC 9Z_95FLEQ2WA:F7!6^J_>2-N\'*H$72[L.Z$RGF3PBZ6@S[8$-2$06O[]#
MF4#KO5"/[K><O@M*!<O^9A%"&C1T0#BR4/]5-+9J _?I=4'0KVLS>%</[%)8
M*UP6NFU@"6#2:F4BE2RR-ZOT%Q6>,_Z?7=I-5V1O,<QGY# &V=F;*!X]3B$9
M<YPH]OM,M#32MQ^[:$B-A(S7R_C&=_K*A(O+)(":AX4$:U.KRPZ7_^))5@.E
M?CU.<OXM!O2Y_1MV_(E,N4DR'/6W:I-G)0R"A!>W5N_IW\@V&M"=>(OM:QIJ
MC/4@62QC5#85\RZQ"F?(R3<+&>I+NYUIAF(5 =I\&BA;G#[3)$7IO!JER*"7
MG ^3.1]FSM?=0'CA!.G>S]/>539*/$"XL&1K%REV1@^I:H+\<!ED5-].S94Y
MU5S@E7DLF,='"7YSC<*B@U\H]4]3+!EA4T;-4:WH;$6D?0G:V\"0.+^+>P0$
MV T[\@)4,#5=E,I,D:G>44>CJ-^9B\P61&&Y#KIM]7^<N#BDS311Z.U!-?#8
M()H1$I:C@FR69V[7-X6CQ"R,+Y$R.#O0T53$WE<.B/)<77?M1YEE1-I,5F ,
M]K;].^Y#2LJQ7GIU13O[?:ZG)1^L1/2TSJ-L57(97^5J6U&;^5#^P8TP4,F[
MCNUE)65<QA1XU93YT&IEQ GR:M>MM^Q4U5\31&)OG9<9Z#6A+PP4.SO.XD>A
M'& ?X'O#+>S;ZOU3=LW9AFW.JN["SZR*YI#\2ZC1H3#*D+!?YPPY9?%@515H
M+D33V</B5'FQF*'G)RB[H3EX@E3H!#V"CL3&@:<K9Z%*\E9]?EXQVS$_-^9=
M62+U0/GRZ!:HC;*]MF+RE>/!,Q[2]"$CMN^WV4H^6V9)F\C-"UIR"5[J<&G1
MWR/V)I.JX4KU*L+/<E(0M$F,J_+(K86)%CN!1'A.75LK84Z7'"^O@$]=#=+!
MR(XF\@[S8;6MTT;:'4_:H>$1()E:CM]37ESI]Z*_I8K_ AK<4=\PZI2OGF]K
M8,*4\DJ8>;?PY1(=S^^?CP#OD$L_:*T>3K8N(,L49;X51S=?#UR7O/8(Z&?0
M\SG*Y37L?GWUZM3Z5:Z7ROXY2XE=/3/RM*0D.I:P7&JW. >R5Z@J-)7C?0X=
MJ6DLZ(#D0N6+%FT/&9*]R?/G6#Y5=6]RT#\80[;\JR3='P'R&IE/RAA_!'3K
M%U.E!Y'W/@(^>NT^!*?+/ (P<A\!D-Q;EMX/9T([CX K'L8[/0GOH)$.".(1
M\.]Z:]W'(LIO:-P> 7<4T0^<X?]OIPT;'9+.[:3NT5C>J#G6<]W^*F1L\GC8
M/.C=-7+?9."M.\:HB[JX&0T]V\UKN&:N ;]RBZLWS?5P/9QO\D?9F3_XM3J[
M.N/X9<Y_(\$Z*4RF:7CQ$<!)H]_ 7@Q_^BNSX&S<*:QY3M9RN T*4LXO>6:^
M+I! .2^[O=WU$^DQ&BQ&E2<Y,+?_JT5OS3Z::-??0?GN6]A&#Q1.Z&I,=?,P
MDLD-SAN5?]59$K^9VF*PZ;,9N>;A2\T.-USG7^'HNT 4P2#S-\O[NMW/62/V
M#R''4KB@>H=G9] >K_QDYRC_@_A'P QJO9!R+;Z(//U0V0M=L[$-,+[WYV%.
M+17@,M@WO;:";',A*OI(2E%BT-;2!I%"#5_YYAJH,Y,QAYQ.*N,MQ!&M5Y%,
MX2L4.^]V^\HX#7,/%.[LL*CC":WB4X8M\MK25*VG5CNI>1QXUQZUI'9O.PEB
M: ]]QO+9.L\D?[_SXZ7YM82*2>]$J5>!?9$;;ABW,6XB($NF>U3U!+IKU&P9
MHC?E-'V<<'C+C8.3>['H?P.OI@.#G.8F;;T? 3%F13U?SVHE)%I!3Y+O$IGN
MES!Z_^E4_IOBH<4NN(:TFW/M-?[W4>&->>FR(CO](Z"[>+@^JWC5E[G]:-7]
M+\*?8EN[C@?>.7X.U7!&VH=S=\'=%STW_[1E@*/2]+!+C!<,MVUR(#?R@S@O
MXY_14%.\>,:D31S:AT5'YPE3>Q*[_[^)_1&P5YR'9:;@_ B88Q!_!&07 A\!
MOVT> 6M%#WW',_?XXOX/N$J/ '*-9?/&62UC_PNEJ/9MV\E'P!%(YJI$YM^+
MT(GO_]FL,M\U7QY!<."[-A6'[H[H%YNRH>GMC<W5?O9V+<T]% _/Z\;G%]X?
M,Z1[\$HKEU&J+;&6+]@LQ?C=&NBL\,B )[^(D='LC_YZ?5<E/]B5N61UX)^(
MSV5,"D<^E?>Q3TO!&[KD"$>JT2=C\'6&I D-;HUV,S4LL VFU.2OP$O=$N8J
MK]VM)]!+%39'"XPHX'.^V[7NS,YY3='K2!1 Q0#,OH,.!REQ#I_Y9^_IYF6'
MJ!PD;SI^USU'90X<UL0KP8X@[5D3S\P'%VT&\3+9Y%$K[I[!&KG*"+!5)]33
M4C,Y'U"I1/MB8L?0>NQUY(^Z*WZ EZ+%TE,F!/B(2)S/2V_S@Q$ZWB1 7I(.
MR:CRJ+]\#, %)&Z#G\Y/NETU"ZG53^TMJDE!GPL:P>6-(T@?GK84?_SS!B=N
M+$R&+#H&I5K="8>M]EC8TE_NDM*"@=M<_B;)@V^W,&+ASAE_5G6%Z$(WY;)0
MY5$QL0HUX*II>B9Z%7*E2P36[7>DNB__&C6Y*FBZ*XRXU9TMJ%AK^N1<X'RS
M1V(4E @@Y&[^2= YT0Q^H?]+K=[C=L$CLVBMT8EDP7S.6CX IO95ZA&@.GOT
MJ]D&4D4"-MZ2OGL$@+:R#V:<#Z):@.W!$<V"'A .V.G@/_RN$\5;!\>:>Y T
MG@NVI<Q>1B;,7WPHX_QLZ=,/K,&?ZWA'2"66W0P%MZ]<@:-'W2<(-ITAQB,2
MPK-2E5*6:3=[O_(ZW3<69D@)QH$6Y%%<T?7K\8>0\N T,,?I?LF]EH:!44"A
M:9* *(*5T%]>OR8I8!QO\E5BP& 2^P(58[I+ITY#I:?*JM]Q(][*/BND7AKJ
MZ<S<24;:.KC/+$S-+GF^W^VBV**SB?0<Q1=I]/%)QQ\-6PUGYO)T=$[!!DZ6
M[QC2%%2[^JP1HZFSB) (F:!<T .GZ]S^/#-9C&4[]8LEP.4DFGB-&/M:.[5S
M(Q7U4V;<8<KX/+;-6D;;&Y:HV&IY*/%J]P:.<#^:]3R 6=\_S0"6X,F[EVOD
M<WP4TU<./6*,$M5P.L*))AZ9#KX\J'/Q .^F3N([<V$9C4= I%N-@;HD/8?W
M39J[*\Z49"L @(GU5'+"<G_\5_]:<6=NZ*6D/3\4,M"S(<H2.S;V;3&GP1/.
M2Z'.W'&B?PN.O,D;3O.NO/ZD=W^");TRU?!%J8367MW$AB<XV5.\*[98VHY+
M9,K%AR[MH^^4"V3+2,$%?TWJO=O@O<[>1;MU?7H9(IS=+8+M64/&-_="%:A7
M["LG;A';MB]$N-FO1FNR1_NC&A%EO/J4XO-./S.LDUL]$1Z+I]'&!B_]UWRS
M\^;^&*E9H*0NC)Y8+Q_T4L^CGC'NZS99KL E]3"VP0$(I2CUPCKC-"W3QDGN
MT+T!6&G?Y[\80I;3C2531R_8+IHY0^_FSK&S(_K3(>\L-C^Y?L.RJS9;&PQS
M,@_00A\+#PI0*TI,U#@?("*\?5-\ _E2RNM^-AU+/D4-%[P? [+O&$=NA1=$
M:>'0>J%?DN21#E$517%CFF-I&\9(Z'F=>T[5\J!NY.IP&U!J,7(359%'EVRE
M,7!LF+DVY#0>XN^^]H&J7!0[H!4-+C!7#>):YZ+!?:?4HHGM,A0>BATP*B>Y
MK6Q27[,/)S!U5DAA$GR66$O\:3P7#YSPKT>TQS*)9R96B7@,8CP5-AXWD$F8
MA-S[@Q9OF/$ 3UXD!3$MF;1Y\;LB]#.D*S@2[^^*-5AKZ@P*=GKW"]BBSS?
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MK_U$V)!D>70OKI2CS8ZOETG#I9"J[XS<?*3'@5"["J[=J]E4Z^MM\=$27TA
M\E<_)P' T<<--@\1"^BA_+$/<Z@I#EJJ-E)A@U>%S@:\L>K;,:K1TCZG^N=%
M&0/&8X8MO<!.2[=9AK>Q=8M"%MS%^^ @ <.NL1;U2[!J9D\U%$M4M- ^52NU
M4%BDW&+C1PH;:X79L#N-1JXOZ7TZ,:QT3M;F5^+",NPJ>K7L(MS6SX]^$7.
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MLFH7'A?'M8 49(OZ13['+BV^7SR,E V;74?K?008H@ ;9C[*M[UP9[O<1^)
M:MF#G59C?_BRAC6P?<!BE->>O5*4YT@Z>//-34\B>FO,X&?Q])6V5*$!_K%*
M@;F_K1RK;_//:79N',7T#W#?!^$?=3/S:9$7HB_N$4DO:6)RV<_*02%JE=\
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MX%'RPLM#R*&?944'U41&R'G#??<)H08D#<#[3P&DO]1M:<LZVO,=CY/1S54
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M%-A(,O=G=AOY:\R  #F3/<Y!/>3@W>)[#X6MF*U-5^$O)?MB3+61^"TRYJ^
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M(;^*.49'HG-@8%_E__[=]?\J$'_]\]\ 4$L#!!0    ( $^ >E@LQXF=%R8
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MSG>[F$OB%NG7[,]/@$H!7!*J:=\=#3;8O7%=5%G L]5Z-B-SO,7/Y[$F"^$
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M%WJ.3R/SE*!&F/B.)V/W1VL7HP\M*)*K*)W>%'$F1 :9HN'D&X\>,BB143X
MLC_'#(A$O*D0MXYSS$@@C+,$\S':D >:ULFKO=:CLA#MT/G81AH85]:]?_3P
M;B8=TZ,/"7PL&#D*<V+$UA1Q@G->@]JUT3CF7::<E*&\&#:2-&*G';8Z=H8X
MWB)1:;HRJ]&?>YXH];1NH,1,%XZ613V# UWED/VDN(P:.!!A YH3X@+^6F/^
MC#A6&3.-+]F-A>E\=W]<5FLHP,S;P;#KSJ>CZ8776A>I]$2QI4O9@*T2!5$?
M9VE3R,'[! ,I<G24\;#%F^WB3*_I-_'N7F8+9Q[&1I_+ZFQC0F$DK[])(K[
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MR8W>#%;TKY>FTLV\#GU_%"[C$#]B7?P=EY5\ )W-.F>NM<V-0!?!>L(H,0K
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M&VKIZ2EJM\R:UTB._>5[C.$IWE>ZQ#"ZNOHD[X DIJ"7#N3V&5&Q,6: PT;
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M>7BY?PE!P,# P,;")L'!(>&F(:?A_@\W>!N CPYL(SY$0J %$/$1D/ 1X%T
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MWOXI=S3/Y331'6)+G/(W,'<7M$)[KKNPBRQ$^P'F2J2$L!>*!SUHW%R=G^C
MN\ F+YSDJ5B(3PW:L,_$JJ?7OJ6)/G)SF-8TX[&QE0!UW2,GJ=;)?L&;C7RD
M<"\<#QS099+FZA,6N>JHP(>S+S_G![PXTI5N[-EM?"ER7Q8\6CE1$-OM<Z;
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M>MEY3PRC_]FW)2KX[/\ 4$L#!!0    ( $^ >EA<NFQ3Z2X  *,[   2
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M,/+T._C.]5<FU#L<"Q;,OE)++[[?R0FB+^9OVZS]TA@?UDW(<[Y5_2H%KS%
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M)P?WD*X]=<\H]Q@"#%?'@Q$PCTO3Z0N5S-2U\VZ.P/ATP1!@:[8? L &7"M
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M 5 A]WD/Y8\'^/N#@HJ&?@\#$PL;YS[R"U4/ 504-#14=+1[]]#1D;U>R'X
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MN1@;Z[ORV,SKQZSXZ]6)" !'IX/J! %D(X E1030,54WHK9/J\@DR DGJ@D
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M]TCK6P=/OIS)UWK1>8\I53-GXH5&UX=\;IGD44$I.[.O ]Z3*@G:X)2G?-7
M?5!QR:;*,T6>.<I*Q=XSU<<-H3_S"-$WTKD"'9O])#[+E[D/#5FTJLF_#7WS
M8R>ER3U_QH)0,<-B&^R!A8W6M^[_]"I'E$.:K(<<0X)4735,7.OFK3W=]E-E
M+\W5!GS!$R&J5?H0YZUBD[%&8BOJ.87)X\C/3_":)*D+ERZG5O'B<^;U]2XI
M)UCVH1Q2[4J8.!C27<S#A@F_YJ,"]U=998GE<"%UT")AV41>#%)3/U\?''9,
MNVLES&0+.,^E;[[%Y-1Y"E:5IU7<I&;<#D"8:4)A5+!+]?#6,4U'S#[WDFF2
M(3N99?C[T4SX()$=\Q@T9I)A@L8M_ D.L12*V[)Q%8?[1SJE&ER;'9*'M&WM
M+H(7:7B/X(3@0- I]2QXN0/L9R8/>P3AN3ZK#J3WV1>_ZY?G4KYK-$@_4K!_
M__.\ 'RU3W5W=JG^=",\:]YM3'[J18-I<XV/K)L1YKJ!^\>;((Q(3XK-6UH$
M0 C>$J]$ &T!" !GL/PR$)HLIC[.U6=[3[MJ,45)]WD+P+H2W081U,B]RT:K
M>40_$/RI/>DT=Z0P(WQ##+71^XES*TL(O] 605LJT2=I(')91P[_.B#TJ' ?
M?Y4JY)-DEF3>]F><JIA1"5,-WA5I)ID4K#.,)I$%'6]'+K?#&&(*!\V9_#9R
MG5]U?.*_@L\$E3 3=^!"L ._+%U+CV\^UL:5-7JCM2T/1 8%4 [U('[.0JJ:
MPZM-$Z?C8P<O7L<0Q?:3XS_;7*S,BAA=Y0E2]W]K&QU^)'KH@ROU@S38W=0%
M#V,Q"CBV3+Y;X^&)F)_GD\K0ZY>7%NJP>WO<NQ.>UL=) 3![U]6F=EW'^3R%
MF4\>QG[V5]74*-J;R"A,Z;O><EHIA4_42<\RN]XYFRP^];<V4T_M< T2,5*9
MP#\JD4,&D\?N.Y-Q>W$*=EKE9U+#UFIHWDP=%FH2L15^-5Y>TAWJYV,;,GTF
M#=1N,84,V=0P%9SQ5NW?[P#\G?CP22P])DH"5*84Q[517MJ[L].UG]B^[ML,
M[V+?<=2K3K$)2;2T];D_Q/CI*-7U,\:>IQEWF^5UG.)3_B!1BM[G_DXZ?GVL
MYS/'T;0IBF*+363>.)NWR$,9-1X2T;Y_!-["J/]S@S>WTS]>B.8GZ-_ZO&S9
M]0%O4?\,U2ES3^%\_J8<J\W>NU\:P.^4!\Q'M""Z8]4_8AEI7MU3\PA3N,>T
MZ^%HX)6'1H@Q%N;@^.6:JC?9>SB]8FUB'WJBT*-%;4]J^OZ^!XY)PEF4/:ET
M9,\]2-R3]2L)Z6ME ZZM?(>=F.&9%_/!ZO0T'R194K[B3VTKX7ITO'X9$=#]
M0L,5]E"*#P$(=3*CY(BK5[34M 17$F(P>R\[JVYY[0S\*[3_7Q!QK/"/'/E5
M<B]UN;MFDB )P?Y/3?#W=U8JM4T2XE2/*YTXPN2_MK >"%RK5^;F%^6,\%Y8
M4LXZ5?E6G5YQ5J8',3_#8<BD!:3YT/+2L(K-CJE[?XRRSW[?,:_V[?Z.?N#R
M.KE)7MP&MR-[&](W^LP37[^K:+Q(KR_F>Q0R]::CA@4A832FS&!+J<_US'ZQ
M,>%;:!@XV8I J?Y#I'0!>_;J08W@!5FJ+]T+M4,N%R%0$-,."ULA]^[#8?D-
M"2E:-'\5/'?BC)>B43XHF#Y8N[HI/U>H6)<7MVIP39WXI_&[EU9TDZ(9P/B:
MYSM-H.Z#\\HR4.>%V5+&F7Z^ /%((;9Q5=>R).X8W_;5@W>[&3.XWIB_S,P7
MQD";W#WMJWUW3*(8+0:P\YNW8DQ>N]EC9P6XXFC:>A"V4ALPTVP*=;*DR=G>
MZ0=BNV@+U@_%#44:B[)X7PS1'H<.W(NU^O#&00B7<?AC@C&S>^&FS:I^L0#:
ME5K9"T%I'8IUTEN0H0,0)2.";K<&3EF*)C1_K.*W^.$%QCCU&QQ\RV%\V>9(
MZ8-WI@P-G=-]PF1C(?W8$NW1'5^MA9<40,^EFDG'P@RP:]_X7GSS$PR_3+'2
M<,MDDXODON7/ =VC[1*E<6]K;:62L[\<]Q6O(("0GI :OXAU-$LBN+/<CJ@X
MP[55'%.J6IBW!Y?KO 3CJ$0$-28'!9ORFA>4/UII>D7HTN\@1K68(K5E87-X
M>HBG^3C!EE4P!B61=>VDTS'RLD5I(M-<4,C@0( \WI_(<ZQ0D(YL6=]* ]?+
MQ7T6LJ9Z9Q6]^D)5!@?N!5J^#>G\^H/-DW!_K08!?#EAXCU/_6&F'OV^3T(U
MK*63Q5F]NE1+YT55I1%?F %#GO<R *!Y8UI&TPQ8R/CX;M@<>[;L_HS^))L;
M15U$7 ZO^6Q$;3)1.QI.TRF'P>P8I\0X_L^';TK38FW+X<L1DR +/3*IA.>/
M]Z2RWSR5IL#-2/$D>)^H2P''G:)Z5QLA)-&O-<!H71C:R!@E'5([1%)\[(T#
M%7[17MBS\E3^]*9 JG"RU[:*=N2Q*[D'(Z9O\!1_OEO?>WV"G2/BNM)*J70I
MUW9X/DA(>9/^;K3# V#2,WX_R2K\6/]1CFR>Y,LGX=P[W7D!T0N$;_!U<S%#
M6GX KM<>\\G4TS3BOJC[W:!YDB%H@K'Y\,%\:2N.#PTMI8#UT'!0U3]? )N"
MC5K1@\)T_#XF$0MYFIW=,2GN=3QZV4=<&RYF;9T3XH \AEI)!+%B@,^-?GC3
M:FJ8S8IVK<X,71W*Z=&]$!2S]1VWYKN9H0"G6"D$ 6G7=C&T09I%L]SZ+QE5
M?VTB<:4W3!EL+#9H4,-/KK,N6"P"NMPBSA,'5*LK(R9!K 0XK,MV^5X*8)FH
M^RF'3VP@,'BT$!$*\$1OD74AM!F<!>C"8K^G#6$6\]_9JXZ(/$1Q#/\;#^KR
M9JWMZQQ+8MP-A>5MI6&Q.W\YZ4Q! (RG"(",W3FTY;$#^.NU_?7XJ1+Z ]92
MET8]!0Y\.?OK#?\G^CQ3W_/FPKS*[BP]&% QGH"0?/.\[WXPO/)5?9^U6YEO
MS;-K6&H[-W(K*$^T^) -(?@EERJKFS<CIZ?"+2NJRLB=.!^OKUXL(U&<'Z![
M6^?6,MOZNV?D[ST[G-X>9JEC1 SUK?,P9])6H=<(0"8E"/"^7^@ <X$_ND2R
M0#V$[8GMBG 2O JY$@9K2\L3T>DSR.7(]\*[RWH/REJD),@AOD] 2]]_[GE
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M:+D#LLX9V1(_;M"7PEA6$4!'GY:L^5PHT[Q)S3#.Y]3E FY#EHMXI).-2?2
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M(:Y#!/# %6Q9 SJ>%88<XMV!!,E$G6WL Z%KJ,*&P\&APQI/LK8H^;\K!'Z
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M%T\>2=IS_>#(+[5+^]1T!*Q=3U81J9#\A3_,_-\F%,3,_P!02P,$%     @
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M 'A'(-Q' #PV'! ;[K4+0/XV3T2X_RF _U7@X($(B$@@9)1WJ&\=:K  \'!
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MDD/E#,_8>?P=/A7G.O7Y?]#^!]G_;\ "_R\A^_\"^]]Q+0#0@&]+B W$!H@
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M^<5]*OFDAGU5/E#?U ;^*KX)J0[\H@%ATFY@,T7KT1T8O4T-"O2&.Y"@6O0
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M35;F@L\;BH<Z6KELU<TJ&V$J %!$*M2>8R8!W#P&E$!*%R4+28$"9)#SN@G
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M4?$$)1^[D:-]7;69?6][>F/%,A:L6ZNXY$6M9P<*:UT=:$Q!9^^4J7L4SK!
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M$!2/0H0SO^W?@W*[>U7V,%PB0$J_K$>7UPT. 2N_K4^);^ZBZ7=4H!S(.5
M6M]'*O.WCQ*I:HJ BK7M">%ANN.*KP+[._97]<E9U<FMNDLR>F0:/A.[TO"(
MS,B^1Z++_0_G9 G6KGO9]74U'>A;$K"5Q_;=PYD6 7 .%#HEE-,8H]BG5D$2
MY;J-1]=B.TH%[ J99SJ:N2%VV- J&Z@B+^=_O"YBXM0W&(;QE9TP'^M2A425
M*[KX.RO.M.C5(D$V_M;T1MMV57R [3A3UH5YF$R> 9F^Q<4)DC--Y7$?N0]R
MQ!;Q*Q40]/;K7O#2DZM/L.3/,AL(^""#HB8$ G9JG=7H'Y?6#+TUL^]\].K.
MD:+1KQ#@.W%HD!>6D7?3,V<1W;(.9X0IM)*.\J'2A'9#1Z1VF[S+H8T)HP*-
M)!<^FO+KI():$D)E?XU#B^!CEL*J<$\O57=ML&:_C^W(J#O>.D*DOCPTM?4=
M,DGNF\=4\.+YX)%@A1HC"[@)Y^=V6R[/YU(.@@.A.O3X$IRHCBDD]>1'#5^W
MU2<A%>(958SDFM1M:?K9_EAT    Z \HS7%<B,BCXJ[L)UH(XRP9X-@]B5XE
M>'$KWF_EEA]J"B!4#>38/U7C3)R9P/_+5NHLWL_ &T46(=SRC+D.B:VUM1N^
M7DFSO=07 X^S<%!]JB/D)51]1BG@"DL8SZ@;;.0F$4/Y )JZ=NB-M"[;($ZD
MFK!GAIE:I=AC*TC?_]1SQ?N#RMA!3,E(KQRB&O6=2-]6*&XH+E)U4OT5,$'9
M5/.%B<CEIYQW]"RT=;SF)*/R\UEU(0_!(EJ;N)+U;>V8UB@"+("I@CT; T)%
MXL@P!(,XF);'3XP<% L6WH2(W(X#K_-_7&N:^Z4G_RIT>/2%M93C&ME&(5/9
M"S_^$JXGBUT%>[%9>KROPS'(ULZ1_RV81+Q-"? X5"]HG%J?:EVVR#(022PA
M[?I$Q5B/=FPF\'+63R D-9&@W#C]J;U*'^-&@ <X&C/TV^63JW);V!75S0@]
MS&!L$_X?WT;R^O$)I;:R?<"E6A0[L9" T]P.S"K\)9MI0\+'4\&>-$1,*-9G
M6DM0K%!VPVTBHS/A7"<1(?\^B9O2-+P X<&=ZG*RQ;(_7-A%6+0VKLU3I/X5
ML$+6V[9[^)E&/#RG*W=1;Y ,R5UDI"UZZQM2R7YQ8W@N3QU?O&3_NU4G9-[U
M[T7])4AG [FZB_(L4FB:QB]VSPSHS/$]$\2,8=WLNZ?/LWRC ][DN\=R.E_[
MZIAS566HMVE(J<1#'LB5CZQ;H'HBIP;[:4#V(P:^#LH_L\EN,P4D.*$?PPOJ
M*3]RD@]-U;)!\ JUU1CC+1@PG.)I"9\L]X2(QRHD6.BZ/_[HIJ%WD@"03*B,
MBZ(8$)^#V@LDIA3R3,L;74>D+4?0F]*+O\\+M3'<\D=X?FBL@Z%L:AM%RS3R
M]AGZ$"5U0[2C>?FTNVNHBVU<1U-=%[6OT9-MK./_K@]VW\32E7?!!1ZFDB&Q
MLQE,KWW"[%]?1<VK'D959!H5;)6U%]5: _B<@3;UR'_[HM+\./4R#Q>.59 6
MK&FK\O[39O]2[<GNXR>@ M5>N6%TW+R-DEG1$HYH#JP9EG=6JV/)GQBQ4$G^
MM['+6&8_8=6F;M[J<6E1H:I+X5N28;N16EJ>%1=$3XA $B2K;XIG<#JPHT6K
M_+S6]'-?(?!D83?40DID&11]IPXM<S&R\1@:*S(:GPTA#\U$.8>HH6G>Z'6]
M FQ_?!_DPZ B%U\]+\&O^[M\@@VC^MI"',;^+,%*VTW]B3P-#/=[8S&E203Y
M8!9?('C*?4CIC_*!U)CI;/@^/O?DD\ 4M0^=BAG.P*?=7R3"W %$M<<#]_TD
M+LFW$W (6,B4"&37G?I/U&?#P_<-ZDUUX2DNNIUTV#''T5'"(<7LTO'0##3[
M4],[+Z^=JJ,Z+]AT4S!**F8.+C0K_R[HZZ1K$4WT+LOX@JD!7XJAF_%DH",\
M#/Z8-FBFA8S.UE6(2NJ=E(V)%2$%!A[8V89[LH>?ZWB+^WQ%$G\#G$Q(Y9C]
M>4C3$&'77>ICVI/_+LUY2!5*(O]"=8[BXV<I!$E1$CHFK5T*EQXXT"R7HL8Y
M1H&?X*S&>[1 JE99*2AW5X#)K]C-)N<YKI76ACR*Q-8"RU9QV]BDA"W!,S]^
M\H&81P^(L,.3W+&(<];6\]D]> W>#T1YF?TBZC3AV:OT6REP84'+P?B1WB+F
MJ-M#!*;'_]1+24F6UCB)&<IUVS#9/;V%/_:<OYP7QZS%TF_$7!%@/]P[%2FG
M:=FX$CLNQG#@'B(0,H^*(DD:T /ZPX5W&UJ=)CQ\4NZPCDW!]/FOL>.B LB7
MAUSGTQ;2+W!<8OJ'24+J>-TF3R/(#WK&H28S:G'T>J&./:\2=NMD7\U^$^;K
M:@^'\+_5_GRCE/"Y9LDR6<]M.7@:1&7QL]^9%5/KS7L<^0[[G@[HFF6SAQ(P
MN!C==+W"<#CJE<@GTUON;SB/*!5@5;I=1+;RCBPG:S58 \;HG'W -6#TZ*-X
MT+ 5/*$X/0)VE)2X*'H>.&[ FHRZI6KFSS'EHT NQ8_?1I=@+QI%UM2+3'^V
MB&>KA0W^!9WU[^N<4\%A$;:SQTZ#!)[Q-+84H1#ZS3I!LB#',K^OW17[FONV
M3*9I9N'4T"_?"'4IW#=W%MK.F,;-!=*HF9TF[G)4(&:!O(9,<&Q)Q&A#++[9
MF28$O=^:=PJF?769RW_;N" 6=SNYDCLDWVL-L*J R/F$?I+ ^RB;O^=OU-GZ
MVF,^Q#]J.<D*29/YBU@K/5AG20) \B!Q.E1P(/X13Z>0[#O/K./<ZOV4"_]Y
MEZ #M6-T738N8JN5\RSPKOC?IX].-H6+I&-ZSKPGN1%.JW.SQ#[K;:$N=]\6
M12]L-?XAS!W;\)?H 3Q9%#!G215IFN0%>AB_^VSE)SGV4>"^#SVABL+ 0T:(
M<,I0LBD@\?>VF(F1.4RBM5/OB^7[4Z(IJ+*Z'@FE8J"6E?YWUG3B4NT#0+?6
M]?3V@Y]8M\\-\4"_" 4A7/5(]U.=&Q0XT280 -93CT&34[,\'@7]A=8K:AR_
M;62Q6VW"PGXAWXN.NH'<?7 8LS03&'4ID_/)! =T&ICQ6P0H0_DE<];*=(CG
MKDN\'$P-+^<ERP;2I>WGCC@BK:_#N5_0515#;I8R6-3[0,7I/\BS-II? :H9
M,G9<V1,\0KERPUR#SK,8_&F]\;U_Y-(9:\^V@_9;22MJHHR5R>Y!.6Q+4H?0
M[CHZFN$LPI[<'&H'EM79OJF\[/C,I:S2?@_\2-<9;,$Z,^[/15-L:^2V%B+!
MSK47=VD.MO%:U]A4]"3VK&5H369&E'PG<H98DGP]C UYV1L5NU5M8=N59E@&
MO0)Z7/_LHM DQRNP87 ],\!MX4S<8?<-I/J_/V2ZAK>+6 :K3]I'I!SR=//R
MYSB3JS@00C@JC6I^?NO)0R#[09ZGYZJ-1"J.Z>T_)^H%E[!G'?N8.M'9&N)>
MP!-CJG@[]VEWIJK40/_SB4V>@$D=.@*+-_T+]\,N\$RXIL8M)V^X29+&34@M
MW5%*9MNV6K>@LBY2H^'")'R@UPPAM0J)JJE.]3#@@%XM>7LL3L8J-^Y$D2P:
M*06ASMJLL2D#=7=H'F:L." 4( 388RR8J-Z:9(*1A"241C[O"&;,9-7"OP*4
M+T.?APL&6D-4^$3.L)RN:6J<]*8VRK>7KDH45*I-3XWH\K)KV=#^Y^VF)+TE
M'*.(4B#]R9&&VA+AO*)0;7SO#J+E-&J*SWYY-HS/;ORC\6"L.2V#)";E3 R#
M0/Q&""^N*5NNS1X44%RYW\X!L6#4Z>MEKCKAF?;^QN7&8ZO_Z+&YLS@I/%6M
MI6F99Y&W.%\1R_(8LIUG#Q$ZWV,XH<L?)!K&[;JG.U#_Z^CH>4"'M+BT_;ZW
MED,[K[LF?+G=YI?1/-EPNV3PX(6DF(*42[+;:J1KDT.=;815<%FIID"")0YC
MW)KIF>05+>]Z\:8G;6<90;CK= 1;9#P]&:MC,-^"I'-NT '_3F[,/R*$\I,%
M4]WEWQST%+4RJ3B8E%MZ&$% \!6VB]2TT4QUWVFFE/1RDN,6F3HT%4N:DC(0
M [F(2S"<WQ@#&0@Z!S\R$OL)S^GJ2&W_(TRDH IF@O".BL$\]^CM;3>;B,VL
MW*,#2SXH2;72X2ITW76S2\.T%OC [#Q*DI90O&#N#\X-HT/=%7?)?L /=34A
MT^_^!8CQ<3$S@Q%_O+$V@ R]929"=@(X,1/XQORZ-:8^(668,(_7I:])PK$M
MYM\*WI#N$<DW?:RM*MM/QLM6+%YB8AUX4=E&/:'"#0,HL&+8##7+Y^HL(LP(
M<NH<RL5R#-@1>R]&CR(XPXV*3^+E;>1//ED(Q5@]+.'/NA<?,#E,9RWID@1Z
M\Q#LV236UTPQU00W3#+C0N+GL60D^MQ2@_H&OI>B\0K\942IH7Y(3:Q7P/-+
M__C;Z3'CS^!#P]P3USGEU]P%M0E"P1KV?\>SA/>Q+UY/-F,5!A9KJ."8;H_9
MLW_,:UJ_M/#JD >C+X(B4DE\-//5)^QZ5<Y6.^OD[3P\[)/GOTF_P2Y#[RHF
M"F/[JVU *$L+R7S<?_GX9UR4Y'@D7[Y:!45%*E#=@8UWB1]K<(J$/,\5$ A'
M$M3'97"H4-W<GXYH+M+%*Y)8E!TFCB.)\@&@I*BG!"QZ8\7M4$\-'R\CV^-H
M0@PAY&[GOW<4OSUS,I2TR1A]?-S,ZE"#0[ZR*1KDHI&/-)YZ6S?R(NIK84<'
MI4[*_YK;/&X&(E:9',OLU;$-$UK^LOO](<8$9XZ/MA"^Y-  I;G!3N:&^+1Z
M:8F12EDZQ;U$EG@M=1/U[QJ X[I\!Q9ACL_;>P8/<4Y0666J:JZ$.!/A4$8)
M('U08UT,SVFXS8MI+V-8EJ(IE'.6X%2B\P<2P)19(*/#(61+FF80Q:3@",T7
M;,;8*<D"L@*"5H[J4IU%5T_/:0+$Y9<>L5%?50=?#K<BS^R# VT8(XB[TI#"
M(CI[R1'CFQB,XU!?G_J]D4ED2GOQ@EU>KN:&",OXT8Z+/?%0^!P;A<6V;43S
MA/X=@1X*GL.4)$MN_2^RCTX[++,:'P(<[#,B;/[FYB1!>VE64/Q'J0)/D5_<
MYYXR/]]'E>J9WBPF[S,;/C+'M?RU^T<P(S37XP@8W5>=4':D+#T,=QZ9_R-.
M=<34CMLH$8>P%CSJW@$BN\Y1.^&TXS[1-JNOA$*HWU$98PY7!W*<L/(==K/2
M1>+O(V'R&;C+!P=HH5 A=V4\H+X3WQ@6YB.1J3RZER'89'&/TZ!N O!@_)CN
M6'\F$3XO$"W;#@U0$D-&8F7UW(1&<\K3XQKOWZR['_6L<*^A?9,18>!$E\;M
M\K8-4G+#!4]V<(C$]*H@?U6-$U13]OPCDW2#UR")@6L;OT4Z;_;\+LI:EQQ#
M6UO6=S$_[1.$O9O1#$.K8LVC_W!?PVSLJFAZ1E\8"<.#6[-HN>F-;]&>YV5:
MF[\"_AGEE?)HJH@[QX\AM_D:D_-&\X2A[18H*Y Q5.!(DRUO!-)3!R=M;M\@
M]K2#^%B0,/BG]P4%<A2:_K?6K?V?";:-;P[1'/.LISDGAS8V#8MY$-)6HK1Y
M>$0.C^)Q&DG1$J$7-;.9$&)M:W->Q#QRJ,=Y5)0AY9##BJ24+#.\O/3^ ^\/
M[^?Z7-<OUP_W_?E>U^=S?^_O?5]!@X2WL153Y=U@U0??9*BE>V$#J+_-\VJ2
M"F+^,1'7 NSSI;^#0S1R"1NG."^)LBWAZ#R\ODRK0V9MQWG=:6LL9(5;P5&F
MEHQ)_$[EP#X0WAS]]T1CVUIFGZ3PB3-Y;L,Q,6)1F@#7S[A4MFET,'DU2Q8U
M'\L_G7YZ&.2&2N\/3WBS?*'?!2F7V[N15%FX66#*O% =MJ ];EJM6;L(4=PM
M$S=/^WIVS\/['-^^BP;9,S/;U"@.^8(27:3B2.EXG:X3KV]*'+QOOKX%>/["
M0R!8]DYY&?!]?^=R$A*ITO-8K(\6>2\T%3+9H[U1(4&/ ;[G&HKMZW0R1+CD
M5<]4:YO::<W]+))W=GL>";8C0@/ .!>'W:3GKZ<5""N=Y'TWX9W*L<+"8492
M:PI0+D7E6L'Q M3O_B:NI1S'E03CMQ9Y4.V7E58&F\$5?N'[+ M?Q&*[O"<8
MQ#X^'0C*G_@N?.@5Q_4*W+8[BV7M5,=YKR9Z.8M?H:FP>G8628SH5NNM==WX
MUQ:@_@/=KH+%92(F\09+)33#?^AI[QF9[(BCB0Z:P2K,";X0=TI8; 15'S:E
M.T9$7J\VN,F3<K!+WO^+J$H2V:(;S7"MD9:MZ@6ALCKC K'P!T5BO(\=,L97
MJ3I--!9^Y3;32E$/B;IC.7O96N(S=,E!I 7BJM:C&'=?-I "R/1 N5&A8J-Z
MF[@<EM6AW;*G3>T+Y3 HHVA*.87==:)S^R1PB'8CSESF/=DEF-*\K=#99MN=
M*A\ !F"5CR98_>(YU;($BTL:.V L@5*6++2TF45%4]^\:'0S7X^]MD^#GP[$
M6CM67,W)4DIAKEL*\R%EA()^QX7FS/Q^:_9ZU*UOP:2!8?KAV+/G$3U4&X>)
MU.?1OD'@2Y*,4=-N+.U*Q;B?ORDS,JM+<T85G()U2R2;W>1SPP<P>$^]YAH6
M"79KY^ON+'?QNM,>CW5KFI/EL?+G06Q^'QT M(DK,7U0W:OH^'E2V=='%1S5
MA+RV\3B"THB6^0.'L2GX?F3.<H2^GZ2N&,MLI<ISU0U4]=\7;4P25[< P0UP
M/R(\()[C49RU#R2OOJ:#\6*EX3/ITU@HBW8TD.0-!9I8> Y3BC_ <0:"QEGS
M]1/^WD,/L8A#9T8.&3VU4+ Y:W#$!SQA4C:EJ@)"HOL3<\T)$<<DW,7%$,V%
M>R)8,DAW\=(-B\V]>#&^O@Z?'1:@NUC/M\\ZG&BO$)JDPH./$!:B39!;@*=7
M_04\@FC=QFUUA=>0OMG8O4\"HOS1')##K43O'O^D]K6^MK$Y\9Y@@KIIVZKR
M^M9U76Z84D&>)H3JKD^D4H/\["W\J'W@>.@/0X%;C(G3*P)* 9OVIKDE_7*=
ML[AH"^#X438,+PCDG>R^;5"5DIU'.J]&\CZY0P"Z (%7[_KIZ-:2WG=K>WL<
M[T_TL',#?SR\[K+07<>##Z(BEFP.]72J>"^_U Z_6R[$U-<N'U1M[X,#(CW.
M'%G2Q:.KPNV")9>Q35;.X?%P\EBD40?,SBRYE1_VX\\4<KF1> M@\>JJU>>A
MIF+4R&^BF7A"F,1O=O>*Q/,"BZ&O=7\&8LW_\T=5Y:%?V\*-N_Z*6HFK?T=S
ML;)5W (H1Y,]3W-L/EFNE&R32O*DJT+^%Z-SEG*>4:TQDY#JWP;GBFW=8I1Z
MR7Q%<FNOGO'75S'S?3XDDO.#.;/'UOX%D=0;KS:-YAN\(QI^X]%&<[.,"7+B
MC 7*^,@E2BVV5N\94I$=)\>Y7FRU9L=_&QSBU;-;"5S@(4V7XR8<9_H8TI-+
MV_;DL\9*;,7C0GWTP:7J(RWZ^YA>&KE!5X?B'B5N0]@JDF&7:CBY[BIT<G%V
M4$+E"$^$2!E?+"'A7)U2$?LY#%GP]*E2D!,83W(\"05B$%(D!T3,6C]=L&"I
M1KM'G,L,6C') ZQK 7UE]5D]'*\+.D.#-47NXS>>@/$"*"R$E;4CK0-=?LXY
M(0"0G8GPJOA)Q7GQ6MG0K)I"347R</HS!KI5R%2.$>GDUF$TDE_<:)=E2J+V
MN*3=;E^D]K5G/\KOB)Z4N5]NU(0^H.K#EP^.UI!5G(-?-+OS%8_#+ (QVRO\
MCRYEGH8O94)0QA4'6&1C,O#C-H>4(D$94F0<!F (YN&!,#,7#/)G>\&V<RIV
MJ_<XO8898;_FF1-IQ[K#RY"09+%',XU^ [0D-X3HIJ)<M.Z\LVU^W]HC+R<W
MEAWC[Z4JWZ:^JPZQ8<UZ^^XYD< YVQ%M#'E_^9;4LVLW?U1CT^P&.9]'WXC*
M9K5R$NY1^+TK8]7U4(3P=J&S]GE0T5\'(7*/#HL0(^TJH'.3H[Y<WM^;IR>^
MZ7\PE*Z37ABGU(^$CAK=9;</A*Y=J:^*6'_6!5&/\N?Z557.?,"M-VE=^82M
M'-#J+OZVW'[MG )8P[#N2\+TG,[Y.>M/B2E-[J=1N<_&XO.AG)I1)1B;+87'
M"]R!2I9%H3Q 6I:@,)0AGXK^/6 PN41OIMAU5Y$2 .V>BG1/9INUY[ACT&>D
MR\ I.7A@*,80R@@4"$"X$[(<< X/@!?@7VWCR_M993 .\__Q'-X9J9UK5@Y>
M< ;H[++S" 1C,V38G/^&$CT8+!2ZO?L<@4: 7HG@SBFC)/NMM_\!4$L#!!0
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M[JVG>.6*!O8K)$W0P+WHB\1@-!"2C:(.CH"N8Y;&#:$!.%6WNB+7]@US(S1
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M*3T:4L:F,0P0W8B#B'OF$!A\9U0H7N0EV&YX&+HX'<E_SL=R/-&YI*#3C;.
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M=5Y:LIHDNHFQGB>;_K.]Y5T,^MTCJUV >/\N1!J+U</?6Y"_P\+W?]&9_NT
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M>_2U<B2W.$SB@27'G<H,&&>IVDNCV2N^P%(>5U4D^P@;<\$HDL(T8Q:U'(&
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M ?TEE*VAVD],%9:.O_P'F(DVC1FVL+\6O.<:_BXGD5XI(BIVV1%[5%+K+3)
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MYIUI=$_'3,7 '5/'(7>HK^! NSD<P ;]/H2V/T14,BR[U0UQQL5K!->8W7#
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M/8PE?K::#R*PXW8M?%.]=_,ABC/+\53ZY).Q$-JP/ ;%,K453951!#30(';
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M5>)2OPK*F=&%1'%TH.RQU',*L]K)M>A'\]\V35SL\3IJ+:F&5S8<U/B6@CV
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M,+4"OB(].[I>KBG7I[V/4(ZI"L+(< S.3[5]1=YEY*Z _0EDKR@^J][ZV"!
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MG9*T,FC!>[S\_<!0IH(.5AV2AQ,,"O(N=2V:%C1Y&%]][Q:W*/.A,VM_"ND
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MQ^U85Q5LH"\!CSR\'$*'%1EXW=$+*_[O\Q?*%W82R&1#D53;3J>QX\<!:D&
M^QMIYW;-&Z)Q=S ^,XB8!/_"%>P;[DVAPZ[=;W(Z4IX8<F;B_F>./ /D^4!"
M.>OU9-1&PK<*%H&+?-Y5$2(N/P2SJ-9]B5R@_ZEU<EA LH>S^O#/L7(*3ANB
MC V6)*$GFVPL"^ZFHS>;+^LGJJOKFI0=W8[^OBDN!WZ8KA9_,TZ$>MI >]&$
M9XV6N*+2!44\UG0)(4QJ)SS=]W3Z9JJC;?TTK*K7FPLL [Z$^^[CCP$-[SK.
MP9;2E*C!6XWD:61SS*'K_%[]C&M%V_W^FM^#(ER"MN]ODU;LE*?8<R^N'P\F
M2(SD2SS-Y?TPDG^Q\CE!R;5"WN>IZV"RHR(]VTN4V0[D+W,VDWBIJ0,7C\DE
M)Z\7C[)0H+N?S(I 567  3*;^J20F/TH&J8)NXVTGF_<8*L\ #1>H'+;2F:&
MR/+?RX*KGI<$!'(-0YO:.6Z^:WXAW'PV_-Z2U,8]<-+O.[,X[\&6'Q,N+!;V
MI,N0:+$PS)T%=[J=-2#O'#PGK9)^JG!0+TUQ?KGT31S10QD^S:=3R*M8XY;A
M(.14'B>KE$3:VWM^N6D2&$'FWKRVE400XWOFG8W5EZ6W6L]#EGN,[APE'@!&
M$VE4E$#<YFCWG_$/*#Q=;1MW',?@6F:>ST</^!CZ>J_KKK?*O"&F]<Z#W+B'
M?5F=3$^,+4TM$$EC58PKJ#-[%^:0?P%X<H5%:")9_>&S5B5V[\" 4S)2%W,#
M\(HSTEJ:1#E71HWE=-4^Z*;:F4#/S9C#.7B[%II>Q//HHJ8 4SBR&5UI$1J[
M)A.6SOE!]1WIR!3;B0K)3F=^R_:NRV V#7G<![];7"#W9/D:7;#DVZ<O_J>W
M^?]!A X&_@E02P,$%     @ 3X!Z6'0$S7L]/@  O4P  !(   !I;6<X,S$R
M-S$W-5\R,BYJ<&?=NP585/O:-K[H%"2E1T)ID Z!01$0D986D"[I+H<0E*&D
M.Z0;44):&NE&Z49 NFOFO]S[G/-N/>?L?;[_^W[?=UW?</VN:];,FM]ZZK[O
MYUDS(+\@YX'KCV3D9  45 !  ?\ Y!0@!6!C8F)A8F!C86'AX&#CXI->P\?#
MPZ<D)B$DI:6"T-%2T=#<9.)BOLG P4A#PR+$RG&'AY^?'\(L(B[,*\;%Q\_[
M8Q,4'!P<?#Q\BFO7*'CI:>AY_Y<?R$\ $39PA6J/AL( H!*AH!&A(-L "&@G
M!LIO#^!O#Q14-'0,3"QL'%P\\(3*ZP J"AH:*CH:!@8Z.OBN#_@^@$Z$04S/
M<P^31,40B\&!E-<O\BTVX_WR9C+5H5TF/B-'?QQ<\AL4E%2W;C.SL++Q"P@*
M"8N(2CV0EI%]*/=([8FZAJ:6MHZQB:F9N86EE9.SBZN;NX=GP,O H%>O@^%1
MT3&Q<?$)B4F96=DYN7GY!87O/U145E5_K*EM:6UK[^CL^MP]/#(Z-C[QY>OD
MPN+2\LKJVK?UC;W]@\.CXY/3L_,??J$ :"A_?_Q+OXA OU#1T='0L7[XA8+J
M]N,$(G0,>AY,XGLJ6(8.) R\?MBD]R/?EC?C,/*I[I(9.0[ADC/Q+]S:^^':
M;Y[]9X[Y___R[!^._9=?DP ^&@J8/#0B  J<B"NIEP\5,S6,<JG.SHC6I2%\
MW21:ZK=WELSB2=MM^(OJ7G?*NFD=G#H]M6M7\+31;!_1>@4U&1F("?[2*&%V
M?GS)'E22I:#S_1579SD2:-FM0@(9Z$C@]'K3@NPE-Y[=.:"$!/SP$&1+,>H7
MPM&] \9(('#!!@E(XB"!77I82\2I/OG<(9".!%!O7+)WLF1];1-)_ [;K>=L
M^H8"1:!SGZH@ ;R6*80O"1*8OP]^VGV%U$OX%9]X!.)&8/45P(P$/@4B 5SH
M@KLN;! 5=HEML%O&,<(O?V7(1=<OW*W+5C' ])DJP]@OJHV@XD(<3;E!_BM#
M\ ,-"WU+[<;'J"BXK?01XG6JRZ_/$C<@?W)=CYK=W/QJ>1*9$)(!)CQ'N?W$
M09.#T"OAM5V!&!LNC5NQ)7E:T[[%QC=YQ'P)O8<^7U\U+_W3D*RXG@L<3NQ]
M_8RGT\/P@7M2/0N=A>F(;DQ]JY0QT"QJUB3X(\'>F[S0H_61)!$&FMZCG3_&
MBN670-9_]68MKBS)7OR*-?F5G"*TB\EF#=>5Y W.-RLM[QME3_7E+*\5<XNY
M3X>XD'OT\QPX#1ZNRS*A?C]4^O-=+YE+9$VX^@HI'G$$//^F:VCSMBH@M>YC
M/X\ZK)P[J$PBELF:=AJEM[#_3C+I!Y/08U)'29'$C3]+H(=^5N8&U6/ESSZH
M+;<IU7E9'3Y!>0-BA6_.^VF.-$].2=G=U>UXT\OP;-7D+K'42U=E>0SF1I9E
M7R>^(=@?DISU<_X/A';'\Y-,.[(9_;8XD<!X5SSVH\LI&<V[04KW0L?0WS5$
MJF=]J''QQF GN?YUV3C<8OFU$]\X$OCW.^['#Y>^%+2C\NAS+?U,*ODAK"0@
M,EQ4W:PZE9Z$G[CX%CP8]WK.*Y6TQ./?BG83C-B?./UNMRIWW&A=E2%W^JG-
M >"3S0=@N4[FO+NKKI*EE\B=R< C$(/JD3EW@+$D?$+MQUC-_Y>!!)%PE2+]
MEYABTW6OOW@9FH(IEFY[R*9BVQ*K^&3Y6+8L(FSP#I/[BWF_B1MXG>MROQJL
M<9)*<>8_.TC[5A;VG" WD39;39"A[C$@;Z>:C3(W6_:%N=R_75M(G'-C:V/+
M.NV=A+#.LOF]CVB(1O"B);L#;9R$;?LA%DQ>7BV\G&L 'ZS6$[)F("80^(E2
MG9B5$H.")D(GB-74WR2)DDK$^%G7AKWZJ_MLMV1F.&QPA]);MGT<I(W<I73L
MKKMKM*J^0>$O7WP*\U&D/B*K?MJG-<V2"0=^7S4&KU_0Q[>FD:0M?JV:Z6_!
MUKTHGM'=!9(L];Y@N0<L$KZZ%!&IJJVU+(W?N6=;]_5%PZM%ZU30P[$,)# (
M544"C:#/\#)",W,S-Z/>3HY>1[DC_MC:W-"SQ&WH;FT%Y!QKP^"D!;;W!-:R
M,0C[!BF S8&1;M=\I2+[ 2RB:=B"BP7TD'"T:><E$EC,_^>M"3(CS$$Z^ C2
MP1\W^)'/HGL@/;S(00+>8-F1Z=-*T_73]PXX_-,>8&UJ!( IOI)'G"HAV.I%
MX>(I4HEI2_^TA>PE5PD6PN\\_FHW_5+=/2<V^SSLNX9K9&+I;9M@JJ/;E<:[
M074"HU5[7W:BF+1QM)6+,/MG2E)XA(6!*/O?0#'6]%?^,"6WZN34$REPL!0P
MV=#W!O $*J_!3A3'U0(VV$JJ8KT\\O2MR'<I.9^W)$X3[6,*T[A  VDB"<R\
MN'\R#O+'X*HOB<8E>F3K^T2=HUWK:(=QO%&D,'$N05N@]7 1'%%,00+66A*#
MQK/ULILI2^4Y/^BU"/97X10G>)4_;<E:*&N'\#\(<> 3+=P1#U="F][3X!;C
M*5B?$+37YZSG=MTHAU0P7FV'ND;=O_B-N(O_.E/<$NDNMF9SZ$'"*5F/\A^9
M$-?,A!K?'#F\XMI4_1C$HF8DSQQW^PT1A=W]+WG?%VEZCPU.]70(K]".N"\6
MH*>%T)]B7-0>&+9$.F5YU^ZNVO/';FGU#@,TPS[P;]>O5?2\4=3AO8/2+"Z*
MULS_F_ 5_5P*$3_MNS=U=4-YI,S6QJS*U<O2.Y'N%H??E9 Q&>?:JR-:"9&^
M:8G'[QZ_J;B6NOR1B0S-7W@SZ2F8&,^=/TG,8DO+8>]NR-UH-AI>[&3'M/I0
M!_7UBQ^6=/Z9);L;+,<.8,XC_F3KA5&7W[AS6VI)\64G7IZ5R3FZ%!+XH/H+
MTB*(F!P%*NM>1]%??.4+35M.'\3UU6UEM G?DH_N.&3#.1^KQ5X-9SMO:+3;
M&9&:A/Y5 5/ZB#Y3BE$UQ;)5>67PF*JPJZM=[]&[#4(KQ;!JF7=M,GD@_6!D
M7VKN]N?9OY/C'U?E:4G.QLU& O4X:'NET]>[*1_>W,?>,6"8J+BDW6,Z&7<3
MI1T-HZ]0N57'\YDHVK_)KT.B,F;]JQY5A^;T?".3I>-ZFN@H/OR!F\)Q0O('
MS,TS&OCRYOH<F;N\XIYM&F>9%%-YE&&JQ*'Y>82*OHK;KGD;T6/IDI6P-I_$
MQ"SHZV:$BTI25::#F]@J? ?4+"7WO(M)V!42L$/<CCA5FV5%'(-L#YM" L%%
M:Q$.VBD89'-@":?M*9U4(($+Q-RE F0WKU[M:@N*0 +52(!$5LPK,/&3BAX2
MN&3=(44"7F!3TK2%!-J&0.7S:H?.CB"!G0O8'K]3YT?MA%GB/=JJ ,P"LNYI
MPBI9*J8WLC2!@N7,;)<TXTGN XHAK1&Y';7A"S:WWG>X8B<[U[45HRSL-;<K
M_+(7[">+%):F74WZ]@BZK;]LFRH\X+AQ,-V)^C[6.=(>S:E9+4HB-UYFK[VX
MFLHVG4\!GRB$8FS5=#_3PJFA;LE5$NN@_=XOFZ?OYGF##M[]NX,?J:*LD[9R
M4Y>N":G<"/-"%W24.G:?YKL7:PI4K>(K?H].ZAF[-*3+6ZAQ3HV_^YC<H8W6
M[^$D&7T7Y9*K[$J?!:PE=>\A@O/O^\G_<CE]\58UP;4V*O&CH_!RM@W7\V(<
M?)MC)TA<HU;'T<RTKX0JCV+=GD;*9/W)H*ZB&97NUW;'KF#&WFG*%&Y@/K)3
MX.V?!N=&A/T'1B4:+>Z@K8H1:^<=LAB-'-P.$L>/=G>@<^+"^K&Z:N.'UD4-
M3CKOO#[NV)$\\__&0NFJ-^4:_89,T6F#;><OT@J:KYKWVMO2N+!"\_JZBH+S
ML%B43Q4I.X4IFM%6\S-L#CRG/L*E#MT^&MVI,U ^='(&M0;EH5%3K^<F;&6!
ML::?JRX+07H"AS7D(8&Y8Q!R%O5H:LSJ$_RZ X0-8=F>H20-K3./!#O?>VCM
M/ET35K8'2CCO+F*_&]FR(=GJ?J.CTUI)@](H(G^7 !;\PF!-%?9GE2N]-"U
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MSQZ^)AEXFN(SYWG(=D (H5C>([4@_W0SXGD15_*UMN0NBDCY[NSKPI2TM53
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M=1KR%O,N@Y<0C5F(RL71WX;0C9\!6<9_>@_$0VW3E7/(F8"G'D!VD!<,7;8
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M[Q+H&;[:'$^(9W,M4I2OD6'!&2+K&D0A'G;,+4J:Z*8,*\(560,32]@=Y!'
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MXA[A>V]FZF)%N+]E++H1@X_,R$Q<2,AI0RTH=]Y:!RH)%:-+@D0/NSFGD*N
M/>#TF,='=0L^Y5L7(7]&1 8#WGY@(#CK!=T.--8.!N[@^.X*.=8PC2/%2"2H
M^[:PG&BZ$.VDI-\D:[7]PS@TRN\H<P79W9_E=@Y>/37-.!3_LY384X5(]8\&
MU2&/CV=/LR^D+W,N?=454+ D 3$A *]W]+URT[0Y$N^D1&782,\R<5V(+HF
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M/.8 K=:R*G*,MZM//*PS_E0:\?3V!$V6NXF2>V(V2C<>OL&%]!Y5Z&H0^<O
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MENUFE4730%6U-S[JT&?O6'=]9JI"CD^J1HHX%+:ELZ.?''FD>QM;TJ+7$<!
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MEC6"J%E]@RER_YE Z?\B B2:3-0MZE!(W)B\35GC-L5:@O(+5Q<PM2_OK<$
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MHH1\L.OH80W+XTV[ZF/APDLD"4/H(W4EN421XY<@EVQW<Q^#+OR7R(O!0[6
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M-PBYP'_T+:_E[U;(HM,T!<=-E<";37=9#85S:@1 ).N21S/H-VA UPS+OGX
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M@EP8D1/P= 0RU3]_M N!/SI5U^+) ;O]<C]Y.;L_0 F/U;97U':V=,O\FH1
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MM44K^T=;68-@Z6P/!\V10C@&YD3;(5VE(;7>0'O^IY)@_:X<LYQL$S5U%[G
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M.*FY E1\8<P?$*]=BJ3"7$Z &- \9G&+_U')PQ^"B;-S\[Y->B6>!%;<Y^@
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MZT?7 3]E_B!A#,+ G1 WMH3@5=[F7>44J34>\:G 0RPW=7Z/6]2=Y\@1'9=
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M%6,$Y0^-,&3Z5T.TORP9_R9H$PPT>BXI@(NV:@HS=G>^\Q]?/CQ3NY"5> I
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M,:J]TV;XQWP7ZV[#3O>/,_R0VD90.V)0=2M@*L05-Q^7GUHZIFK_R'$@U4Q
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M6-P* /R#OM=_:M_K7W" CPW$\53H=,EWRG Y\,)=- >P+;+L'T 93'G7UP%
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M6.L=F?8%/55/GLVA2<-=,6CC$^B04??S",>,/!4'-=Y(?S+I?$5;CBK]^'S
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M<U5GXT(XC"O/?%]B3X]N/.SN/E&K7H$-X:.M_27]J4BTC77B1KKH#.5J)M>
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M.;+P2-;9@*Q!FA VQ,'/7UH@MY@G>="8= :AGSW<E;W+7,17/LRP.*OF[;T
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M8?S"SL#CKIWHL)\H.%O*!&\@O?.%1T]D+_5)QK&G6)K]CK5-'T5:)[!DE(X
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M\"E&!AR]_;>Z@5/1!CG 53C'#D&2;4JT VET>[^.[\_+0V"J=;S(ZJ()G7D
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M=4*B1Y3+Y:;XN&U'FB^\C=*U)03\2,N:BK#$Y>+*VW2=S:T)1XKJ9]%V]2X
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M268-S-.LCF.K3G<'RIAV' (9[R1^)><.Z/*5>NDF,A<VWYAPH\IR8.6F$QJ
MH0A:U[I56+(O;."3FX%OJW5R7DW3:@_!S4VKV3T,:",8?^Z4RE0XIGY2F)DK
M3@4K/K6B'!C[IJ#!3:LJLR '\2@PWM'SW!1ER! PAKMM?.6?( J<3PZ1(NT5
M20V1OCZQNI+LORSPQYGLIY'CD/GMZZ?K#C8D7+=?!MXVL#H ?\A1#<\W4=<L
M+ OFJ)SUO'XO_-[.-O%3SZ3X9H HT17'&%^"D=AC32'=M&PIZ_FS5\L3$XQ2
M83?M5K#%Q%X+=B%!@T9;Y?+!2*9*D5(AJK $C0$BY#BY!"B<,>:L)! -889P
M)[J0"/GO/J@S-.3GKV9_Q2X\@TE#9:_3:N_@_M+5=;VS83E/BG;A:J^ '#T/
M[ANK0;P[]&Z6,LO:#Q*NU)>-E/IX"A>8FU-;1=KC?.,CFYA8* 2)H"T)]YKJ
M..JZY"   06:NUR2FZ&RCUVNJ$IR\X?,,C'38:WZ<]9X?PZ>6J/.#'N2R'["
M44G*MB,ZZ#YI=I16OO^EIV,  P23 .+@3/OYFGKH+]\^I&V(7+OFV7;?G WW
MVGB-*.IS9%5PV.L;%,5WX0XVWQKC(+_._)*).C V1FCBJS!-.A:M3!J93M/&
M5OZV>2[G0DUUM(&GX,1G9Q3EZ"L6W9GCHVQIULXAGE)'(1E?68:L\G*MI1U:
M#/42*9]C%%,8>(5[/)2PFF&-W835/Y@04BQE$]G'BTW$WR]D0Q-]:H 9P#V;
M-:JMJS669)**DS;,/XH13"X>S9J1+^#(+<M<%\K]Z81']\: ,'M7S7!L'8'0
M>24:Z3=E>PHE*1*/:\G^P'\ZL@4Y6.M=4.S(Q_H=2F_7/16S@H5\SG4JFHE?
M?]TILJJ]E3<;&Z\+7](XQ(+WL51Y7OL4^$&"O@CDP+Q).9_4JF_JCAZ)>[V^
M1+2*.?)!J00J?IV)^S((V 2&-1S(,DQ8,YZ33M@7W/)+;5!M7&9XNYQQSP"F
M&LIX]8X=,UYHPG!;"$@ARSA4<TJVVM6/^>75K]LX?MA!C]DRNZ^Z.='N/^H7
M%<O4A 6H5M:4OWY6)4?$3538</4&B>'NT/X@0'"M&+<D0^=1;Z[R[O,> C0.
M#.9WCU#:^/V+#0-1Y?-!CQ,BVC.\N%D=66/6KM&:,Y:'&H38SU,J$\C-N-9Z
MK'^V4BD+0=-F"4  1AN5D28H$3AO)FYVM 8_PCYI@E,F=U?JQ+?<C#PF9)?B
M*Y%D>S_?7T@-#@7M)IN-F[D$N#@]5XV<]6_QS;F"#4D2[*AXO5 C-- G:ODF
ME$6HR.>:;W>0+![%59G(&VZ]FL.?*.P>6KCL0Q<Y,V6ZR0PE%P4<U?MP]XTH
MUA,U.;T>9UUE&/?5B\T0,^4IES@J+=\'Q:P8JAXJWA$6$V969R%\37>S KJ)
M[O>N^U,C9L/'46H#]'=>'P\_.RWE&^N2A4LEM)+=<\P;>6&D'?3Y#)@)#R8)
M[],=TG# ?Y3L?RWK$B3 7P[M%_599B/.DP>6G]<S+B(G^S^63SS#-"\NMW2X
M\2#.X/5G?,G9(+.6"N<W 5D2'+?&R84VL?PD6K2P7MJ9#RP8SK]ZJ0BRD3):
M'0NL")^4$/M8'C.1^9P/A'ZC@][_2Q*J_[7_Q<'AMTM05&!RVGN@U'6U0<IT
MMYNTR "U-+B8E^UV2)=P&\ 4?( RKJ2M[BNX?4775!T[4U-6@ZNB++N%V,!]
MVX)BQG4\;B9!Z"@_]M%0S*G\A]32R!$S!YQ5)@XC=HHK*J%3'CS]O_+5OS=0
M(IXA (8+ _A79/$AS=%0 ^^!1R";(?#7FJ7 BT#_?4**<XY/NS?]MNR,[<P<
MKSZ7(I)#X]7)!BDV#V090T&O2N.A"D.)FN6VI95R_BPUJ TT\[>SOFE9Z204
M[[7336[E5&[JM%.*64*85&>'.;F-]NAK*\*4:SR9/<)XX^97)+(3Z+\,ZA7[
M#,@E7!MYQO3AJP\]!QZJ>/W;CFT-^RF*>JK"3PE' I13#RN?-^Y%0B(>J;IO
MV00>I?*GFG4;7HVJ]'.-<ZJR%#)*=[ONI5C,P8];*=0TSB+^M$G(RFO%1AN>
M,XLY1*[\Y!5&_3BSO^1;+PM#[>>-ZY\)AW!R;&:<MAAJ DUUE3O9!93>-B>I
MOK!Z!QVS=@N^AI:3<#HP9CR;L$21%O5&QA+7#4-*O"A]7(HF?'I<.HQ[X<5[
MH'G(10UYEO-]Q5H=IF4N>>'<%B9W:_$+4R2U_<P5!R)/W@:!#E'VG48H997T
M?CZ3F57)VV=RHHW@>I:38[KW*%]:;= WNDGZ:ZYA>!:R2%!2'G1DF=WJEM<2
M,U"J>^BAZV28G4^@<D5.;#_T1"T((%&2^H\':7@Z NBPT40 ^:'0E;(\T\Y!
MZ()('G14MOY \PMF&8EZ'*QD=JFB !8\KURRRQEI>3^3;(+2\H,BX:2ER/I
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M@5<CCV*1"O6:P:NE$$#R2*'H;39_2.D6_KD#%SPD/HJ94ZN(KH<4%.<46Y0
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M6XS-"IRDYF?^O;YV.GSEA=+:D=T-I540HR<WT@DCOWCIEN:,+E6GL@^8*JK
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M0 C*47E >G7NFVX=+B*@BK9]QY'*ZT%-85G5Y9IVILJJH>O:C,.:=G0?4!\
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MW2I9]!7EXM J'Y?P<N)ZA72\\9:Z_$N__TI+'ODX[!^1^7_-XY\EN_W1WS*
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M9B$QP?NBG+Q\]W]>! L?'Y^(D.CFU:LW[]^FO7W_?_J%:0!(\; :L9RPL>X
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ME!)X.]$F>MQF?ES[&"T19W#< E9?8;1%SUNW\-SHHDUQ$L1DW+KC+*.\J5Q
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M-5\R.2YJ<&?M>@=05-V6[D%R%B6GEJ"@"$C.M*ADD2 9&D0R2 ;)M( $6X*
M(" Y2$Z2FAPE*#DUP2;GG#/=K_7>.W/__]V9N?-JYM6K5W.H5=6]SSKK[/7M
M%;Z]&_0X>A:XKB2G* =@70, +,P?@)X"'@,$>'CX>+@$^/CXA(0$1"24I"3$
MQ"1T-VZ24S+1@YB9Z!D9;['S<-QBO<_&R,@I<O?^ SY!04$0AYB4*+\DCX @
M_R\C6(2$A"3$)+2DI+3\+(PL_/_I"]T,4!!@%6+98&.Q M<HL+ IL-#M  @S
M3URLWQ?PUPOK&C8.+AX^ 2$1,4:A\CIP#0L;^QH.-BXN#@[FKB_F/H!#@7N#
MA4\&[Z:Z"3ZK$R6_?U0Z =NCLA8JC<%==H&7S@&$1-0TM'3TM^]P<-Z])R@D
M+"(J)O[XB:R<O(*BTG--+6T=73U]4S-S"TLK:QL75[?7[AZ>7H%O@X)#0M_!
MHF,^QL9]BD](S,C,ROZ2DYN7_[6\HK*J&EY3V]K6_JVCLZO[^]#PR.@88GQB
M<FY^87%I>65U;7UO_^#PZ/CD].S\EU]8 #;6WZY_Z!<%QJ]K.#C8./B__,*Z
MYOY+@0('EX4/[X:,.KZ)TTU6?G\"RD=1Z64MA&P"&KM4+YT'B:C9!>=N[_UR
M[;=G_YQC ?]'GOV+8__JUR1 @HV%63QL"@ ,G)QS9KPANL=54.#-9<UC_R6"
MEHW.D_U%?N;/Q -2[P6AHOI(O'<O[16Z+F1;[B4<JW>#-.[F5I=^5CA2XEHI
MB'S/S)WP+F*?  M%NS7@CP9\L=6@K0-[D5=XX'U]$(JU9(+/)7/U.]<*^%2?
MF0\-I'6BE!^C@79U-$#\N -\2(L&NJV@IS"I&#)77SI9GY4_C8/GK#PZ48&@
M,VYR-$ A_]6D+S*3LR0)#?QQ_)*;'//$@"D:N)V.!N8YCY^*#1Z:4QVD_OD&
M&@A*7P"=DT 7*\"7LLS=(>+281F-+G\<!NU62&*>D(F\C M! Z&9$P]6Y <_
MZO1!_S2.H@X)@ZYBO(H>0 -[E-YW&%?/^6%G_7\:_P,@D69MR2 Y=6,Q-/"'
MX3_!LQG_/[#]WX?-V4=C+Z#J67ZQ%&F%\:#5;SBTJ.;%=3I\]9&C;LH,WO"Z
M"KUWJ(:6\Q>^MB.7$O.];-^H.R#B"_R</1\4A+M!(U#U*(W9L045 7L89QZM
MIDLO5<4-58&W,"&>320EF6(>5Y_?@PT'D[DNP7'=PD_[UQ>A_4(M;'NWH23#
M2MNM]IU)IQL=)]+W1O1%(0M#<Z+!C O0"[MU7RFP^")G1FWTUZ_\7D&4ZD^O
MP3C3?DOUI<@< QJ@E/>\G73\(3O^,9=AEQKI5%D?^8G*"YWT2^D VQ+\TR%B
MCQ2]K*IW&J(CY7SM28#X2/<$J;WS-,MN5=Y<0H;*(_;]99PVP6=T[-AT+9?R
MAMK<WD(1R:0Y(3Y,::?A:H;2&4-7<18X;XGO#,BG6SR3VEN_IZ(/>:XV*/DR
MA:V*0F^\NTXY:IYBZX6!1<?.)2,:J)#WT3R(_+BGS[7*9?VJ]Z@)9D\EO$']
M.DYYHU%.HG.I?#]_4J5VU8]EMS-H],0W<6AY_H7\-,\S0C30B0;$I=*<4TAE
MO98Z\IR*3\GV#:9$>=G+QJ(9#%Q#.3GI'H8!$@$Z"+Q*245H7F-\[58E<C2\
M,OOG(P/B"_;G%%VJ4:&+/A,[1[3?&.?+%L['WGO/72D6"A&,\E!IA6J3/)"3
M9RW?F#XB;H"@>->HO[Z#?J64:'YZBR/^18RHCUE*O<572>Z\9-MODZV00C^+
M&)*R-4<9(M3<8[O;E!&Z)E[G"]F,VVU+DO:PX\]O?;W;4T#*JI5M^0_O6#2.
MNNX&*S2CE@'G;/A:1*5(:#QRC9FF'D[C;/BECE)9ZJBVC<^PRD\-CS(6QVF
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MXPFK<L4OUC'K(MQOK[?PM\\R$^/9XXF/5<I+&OG6E^Z8'5PO7A0UB0H+'!_
M_^@C-& Y7%GG:7_)DJN+S"[3JR0\<G(L_GG-I[03-Q3\5*<(@37'&W(>YU^D
M:V2\08U0LXXC-;&*.TY1KC#+ZPF'KS H=N;U>>M ?_\HP/CGH*C9(,>T@15,
M&_!& ]4N$-)_',A_%BV(JEJ(TC"/PS9VO-T"OZA,S!M^)T/Y2QXP"1KHYY9'
M79:@ 2H5V88@UTB90E4*-/ WQ):A<TZGEBA/&]#)$O0T/SOW4F7 S?BK;S(O
M_@2/QKK*'M;^'9?(SR5"P?=X)Z3 !<FB<@U?4;7,R;*>)W\S__@OYN7_]!W"
M&+WI F$.E'4V IV^RSC]I 41[Y"H3/X Y^^X-NNVR%=<%:-B+Q%$J:[P#^M&
MF8_6%[WU<Y*Q:@2O QU+[-ABRT%D+7'@!P$#K<\EUJ_I&R.EJC)SOJ0#S)83
M2682O+=\71XR:^WVJ]0&?A/F.4X,KY,Q97>/-K)9<XY1WG_1 >L<K%F+]-$I
M1[SSN?]9Q8'&H#*[.L0\;OF[8I+UZZ_RW/ZXTO+<28'P$E$QJJT*0%V6$NM/
M,6J;4OJK8Q5#,0VKZ<)=:&  Z_=O*7\2K>(C8F5<[;H:3- 3F;VR*!R^'7SW
MS8WV:*QAYT!8@HL!\F>N\\ST>#^FN+V7P^R>DDNN+BFAK;*9T(%G"!2*2,7H
M^ZBKP;&!E0SU_O4GII$?AZR.M8LR= 7T6Q6KPJ)-04BJWE[CU.@-VTW,6JXO
MMEU(>TMMU:(!UJ4OZ=9^A6.?^)Y=GPNS2])*-%/[1L#*&?W :TM-0+4X_L!@
M^N?2)^XK)&:?E\_>NE=R^4X<<>79?5FP3'_NW=&TS[YA?+3"L5\2;^ME0-=S
M[QC#FWE3CS"O&<H=W1)!&8,W)M! MN5[%#&J]O,L&@@';:3+P3B+8^*W&S&!
MU75"<^6-L;9*?W8Q![J,=((BZE._-_H7>S519+W&5*)RSG_4CKD2]ZHRW;/6
MJ#^-E4[WL#3YYT1\Y]\7-&ATJG"CW8!P4V*MS)#7:UVE&:O6#!X5>*_EU"1O
MVV_2"YH)2,@1I\P1D7B;5GJ1_@5_?"F3/W6K8J^V/]7CA__RP]R?A+(R]0QK
M'72TQ8$*L!9T.,-:0P-'6R!4P%VW?^,&%_D9=/_J6>I9""9GFQX=4:H;)+5@
MIH%'$PY=5!QKVNA373)^@!B>%D(#41SZ:*!$#!SKTV8P--YGHE,Q<^:#&;%$
MQ<J56#?MGZ$!H_XK+DGC7>.CD1G\2RLT "$25)=U3>ITVXU$R<.;-J8QUAXB
M^F<(T,"B]WM4PR)*ZY#49?0TG*U4798J0>8?!>1?!9]E8;$67CVX96=OEWYC
M)OBCJL]8@*;"HIW_\/(ZY>QKY@16%?)V&A$_LL$C;I$V1,SM$8E>>.VC@2LC
M;=R6%7QXRP[D-C*YZ!*/^(>5/0O[3<8N)D4F,M*G@!91&H ',.5B?]R]&AU=
M":^<L#]<>\5^@?N!0IE5C,VW7TR.;0H1F>T6^T\R6W*FIM/NW$D;&NT?V?JE
MP=IA-]E< N1LFBYY>I51_M2I)WL%_4(E9^0VX*,##M1;FW#7W"<_$E)2.3J8
M'JN';WY6KI2%X]UH&8\E[8#JLYVVY%H/9L.LM8OCFA_1UEU[M)<Z5#_] P7>
M0@,;^6B 3W;G$OH3BM!&6=2<L1U%?EIW/0 70*=FTM>,=^N$>,]Q]*$S'074
M(#HAAH9'DQ,5!5HWE<JBV>WY'_9Z"AD-0A<E<J"('NCY]>((A6.QFH0C.TIU
MPXXO_[D(8"0V,^W9?U:2$OHF<D6[:&G8[O*GLJ-/5X\EIVB_7V4OK* 7'Y=Z
M)E/B046-)5T->X..*0^L86DM]6!Z!745N9<?'=I>R'K_>9E)((1R/:^.'9%O
MM9PGVP*IN**W=/CWPD?%.%1]').'/6G_$65/^479 S$%4/@OC/V?)#;2&F--
MBQ*Y: #1DWI.D2_DC0'APW8F&C#FAZ[*%4Q-JK[6E:%SKD^B^.;ZW>FM9]9F
MV +A,\,RG9<3T,ZKIBLWXV7.!C00>1%YOC[3,SH%N7,N 8<4C=_KRDJ*P+.J
M'7+(JDL80\(JPF2Z%BW@?M6/IV:2]9$(EZ;U^,B"J8FZF?)-\]$M&M3C6O<K
M'\S4TXE*G*RETM4ES8F=^>6%3&5_S2<9,Q\^S*;G45VF:)_DH+L\3CJG<IQ2
MSWD5IL"9/B;^0WE<VZ''E+N8(B@B"5/@3(K67ED^R(!Q:3SZQ?\V_K[VE:3^
ML3*N%.S1RV.8"1=_P'^T-_O?ZM9_!=RY"'V^WX>)?Q^X&*4_8A"#O3[)F5%#
M&L;[!S]+<NIM,7WF626F4CE#[YT%5V>7);5BN);BKQ=+E+R%[DM]P]S;A]X[
MQVOT.Y5' VP_C8]V,)BEV::4M%LS89PN_/X?;HC_S(1<QD"876D_9E=Z@@;L
MEVOI?_>-@(,M8[.832/528^)%4M+H].5+[9LJ'L[YP'01?WIC*]YRLDS"25R
M=L^J6:OO^>4N%;J14]I<6_D.8?+KEVB^:,^\WZ"PDB.4AVD8A/B3(<<AQY83
MNR['4 $_;[?Y@E/++Q@F8R*&!N*+)E?:GCL'?(ZYZ O3TJ+[3A&@/("9P);H
MK^4F_UA9<D:V_K=29/1'\,?",#I?L'0JC,_(UF:.#D"HM_?"_Q[ZK.;? ?;8
M]/_5 ,N=GJ?]_"I&+GRU!RN-D#/7;P(3 N ':&#F9605)K3Z>\ GXVDDD22'
MHYBZS@$^H*K#--\0"QA%_ME75H<1"[>?S>:*M&PCWF.(*6[HRC+H8E-'FDH_
M6MS)_BC[RO5.1OJ%><GE91L:\(7%ZD$>WR7)2<>_A9#IX<9T9-!=6^-]IA'H
MQK+J%<$H?4,1M,M='5,Q$\"';)JV1;2__WVNQ*IIGVFX:6,9?$6@1=^0@8'#
M_1E&*1X-'+(H^O^NQ\$=_T0]EJ74SL)8?,B$: 6?,<]C[GF"8WVQC<$^;!CE
M;=[SDY@SG0&A?IUYP0A,E]<V_[>(Q&^A(AU=J@S#\ZX+M9O#P68OII Y3_QX
M_3N=PJVP (D!?/ _0U2<_5@PB9F.!AQU] Q30Z&+=]$ 0(D5*\O#F8:3$0<#
ME+8JFLYPIZ!P+E@Q0AFC"ZF^"'C#/8CAK_MQF#QE0<JC&LW0P$"X>L$DXC+$
M#71^%H,&'@G)U0Z&8EAN\[WC][^T)%"-F)8\$(31XKT,<=TY/XO$:%'&@[0'
M9:FZ7IEX(%!/DFU1]9B6<4#J*[5@?';#K>3\ (-'CU #=]@R9B]BH_"+-2/_
MB-7!R1^@-#SR8U/8Q"A;J&&4@7]#L+H\QJCI<X)WEBL3-U3*ZV*W%V!X\6_&
M]EE%XM)B#AXP8H<-2W+E>$2W-3,S?PTV4#: WQ_D86OP7^)J;@TOAM]R]$+%
M3F#V6&'B(N]9QDJ$A$8JGG/W7&_]_BI[$L>.A9;9X?DRJ$MKAJT#?'A]H&D7
MSP$E!2'%4'Y:2=,IM;\.:/(*@BB-55>4\]:PRB+C^M3 >K:E^>)?RDPRIK(0
M!_'M$6SO*.CE8_MEGZCI1>+,7O,0Q/J.!EJYYE7/"=>,3PDYT !C)HK"^ 9T
MX+D2&F@6 Y\NN>EKEYD435;VI8(_TRN\_,#/+VDO7L %?&]C"\!:+E'#)T<#
M!"7OP*MWLZ&SC*F7SI&GLCZ*:$!&B@L-8+&C@878<>ZK@O4;NO=7$4YR7^L?
MYV?>H$S-T[[,_P8XHH%=V&DD*B!1!W4-\U GUS-B7AH#&<:[N:M!:B]NFO)
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M@HEU"OTVRL2L _U.N^NR^]US;\C&-8#6%$V2&[95_^#D!CWQOP!02P,$%
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M,  #!HC @&2A;!@0!@/.<LY/ NN59+\=$5RQ7:-!O2XRH:(P8#$+!OC!:\&
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MEP=S"Q*_%)B?;.V %QQ<_*&O'78O5_[(9?U27( !Q5S6%Z@ZD+D8&( ._KG
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M3[VF44-#O[!@B$OFXS=<2NXF$;<+4BOK*JIPN#:F(?85"K<%G><OO6S':V!
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MJN^9)&>GGHG/%(<.,)!A&"2?%% &VF;$I-J]NMF'\#RC8=HZ)1_Y]VS;1IR
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M5JFUR.)<!?MZEM!I'U:4;Y_Y-==QG5*;AU2:X;1)Y@>U#N=9* @>OVYZ&G^
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M7FCH+M<G$&'>N,]]\XZ4*M8K^[OT/+[8Q(\C4XJ;;S'PJNV3O'88NDW*R+?
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M-4R8YO&7EV(95X"XB7'-L?S<A/G]<UW9VD0$DL X5T*M;P3>&[/>J1:B4'$
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M5P<: %100776=7G#=(L,AQ)./PS G\=!STU$+Z$0V-FX,O41G$VWS01BR3(
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M;08"&'^IWN +,*6#L\8.0E9=5O&%FHJF"TJ+7M;R$^_^SX>0"6E$+:J)SC>
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M'I^7GSBNS$@TS(F(VJI3#C]8K;&VO_,US60X7%O&_?E<\EY;30(,;3S#J'_
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M>\Q,-_$95^Z,O1^N3"M"A:62W/=ASY;""$732]!O8&V,%1256 4!A%:.J2&
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MVEZX,#=LRV7,::O^%&;.*<?3%XM0M,=3LG#QG6^XS#()Z$(@M=6E6\SXC;'
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MEO;#-/G3<0_;=#:\^8-SLD$5.4]BX"S]'8O^K1:HNI]+!0\W-_7EH^<8K9L
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M*WR*J^E1+!'.+>_R$J%#4\YN4 )/(8\*<6\%-?6:+2(\Z0WQ^*Q<FJ;W 01
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M."\!)W"0E/;K#1WDV_\!4$L#!!0    ( $^ >EB;8?^=#3@  $%+   2
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MU>^VC%&8[7Z&F[!S$MKG QQ"\597I':/TA,L'NNAW4YCPLJ)51S/WBY@!3P
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MJ2'-MGI.\K1@Y4A0:WJ*AV'RVX/9%[<+V KS@[)5V7G"/K+G<3<\%NE5W>2
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M,V942"]:!?<;(=7'46N!'EPA:32#=-9YMM^F)/'5HHG8';]>BAV"3C4"J!%
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M?S*5Q]C_%3D:8 U;\4&IUQ/@.R23CU[M2#W=D5)6^LRD*2)YKZ0(5##!9\"
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MT=;$!!."29T.H #&<'35/H3.Z;(&#OI<IRH?X&BI%3WY3;>;>X;(YQ=]YR@
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M$_;.K#B[W:9S'I[5],3,#C,(G8&(GF7MJK!$U#WT[ N@42XW6!?TI!*;NG1
MOZD48&6FCTYJWI*/"5M>*V4";T\*GW>=*.1K;!EKN>"&7X]8>G$JXIN4<\C8
M%-&2IZ-S5NF$+2QLTQPVW8I$ZT*M)'DT3)OMVJ8U&+KR;JW/4.)&)<'GO$4F
M_MYAQ@)>0S*0P[C^N)P#>=3ZH,Y#SXRC5&H,11&P?;$^M:<WP>907(#4>0K)
M8.#9^SCC;_JHVO0V1Z9YPW1[A2Y- APQ(GZYH-&^REA(!^0&6K75TZ=T45[H
MH$P;*E>G7=?'B41.Q!JLUF5WM7U/&J=I!85%K\R 10DM#6C<0D,"%[X L>3*
M B("IC1S4#\/W)%=05Q2Q4W(81E6_*P7\^Z(-:_O-4/V8.JLOA.H@^O=IDC7
MU$DLZPQYUNY[!CIC79S2+HS(=V^LZ#73\ TG#Q;=/A^BBI[TTPWG)7GB9!#L
MRXDAC,:T509VLB@E-QBU>").25\&:[]J3\Q,A;0FP^:[#'LFA)'YKE0W[T2W
MO6!M77524,XZ+33N.F&K9 .9D$G!HPO@E6:3SI/$<H]L)2<WJ\>ND?>AA7=9
M/K:KNILE*I4:M<Q]<!9<K<YA])^>B+DK)<2R5:SB=T/V\^?=_*.],^G9SOWN
M^=>ZDXH<#/<#U4FI,=O$OS&/2E0)+)_2I7:CU8%3'Z=1L\CGO.FT9U K-[)Q
MOG?*\GF3)IS4/R5VT25L?[9I+<?^@"D[7].^;2&Z8JL5%*Q$ "L^=%= L[;+
MDCT994_C;[_7JV?JF(?2<ER_SP1)![DE:WV1W='-:W_MGEM,CG*D8H'6OVQ
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M*8#?"-6<$25<]V0,-=V-V]!0>)-$3=$7]SZ4Y5\\X& &7DC#10&_) (PRPN
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M"-M/GHY?]]4V%B38:6!TFZ:U!/9$D98%8@,SIKKRP;2C.C&GY<-8UG)AO)Y
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MN8-G_@OF]L=T4YPYE"PJ3=&9->=5N?(**+>'6\^+G/&F+"4+-^]N=VO\+OK
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M'8G6 \""O.KQWK(28(F@[+GIPI;9N<9^+<Z9>;.5'<^Q[U_Y/AQIW,S^_TT
M4$L#!!0    ( $^ >E@B>&F(US(  #Y!   1    :6UG.#,Q,C<Q-S5?-2YJ
M<&?E>G58E.OV]DN)=)=T*"4@C4@(R%"2TD,H'5(B'4,("M(I2(<T2+>(- A(
M(]W=S0 SW[#W^<Z1?;ZS]SGG=UW?/[_A>JYKAGGF>==:S[KO=:_G?>'C\#D
M7QXD!P*0D $ "?$'P"<!*>#VK5OHM]!NHZ.C8V#<QL0FQL'&PL*F("3"(Z:^
M0TM#?8>*BHZ)DYF.X3XC%16+(.O]!]Q\?'RTS ]%A7A$.'GY>*X70<+ P,#&
MPB;'P2'GH:>BY_F/7_"O ,%M8 '9'@6) 4 F0$(A0(*W K0(.]&0?GL!?WLA
M(:.@HMU"OXV!B8684(D/(".AH""CHJ"AH:(BOO5"? ^@$J 1TG-+W")2?8'.
MX$#,XQN9?IM1LK291&U@CXG7Z)4?!B8I&3G%G;OWF%E8V?CX!02%'@I+/9$&
MR<C*R3]3U]#4TM;1-38Q-3.WL+1R?.WD[.+JYN[_)B#P[;N@X*CHF-BX^ \)
MB1F96=F?<G+S\LO**RJKJFMJZ[ZUM+:U=W1V=0\.#8^,CHW_G)A?6%Q:7EE=
M6]_8/S@\.CXY/3N'7ON%!* @_=_7_],O H1?R*BH**CHUWXA(;M<3R! 1:/G
MOD4HH8K^PH&(@<?W-K%D9'II,P8CK]H>B=&K 4Q2)K[YN_O7KOWFV;_GF-]_
MY=G?'?N'7Q, -@H28O-0" !QX!3*DN&#691K)>"N\7'&<*K#SC;578X2@!Q?
MY?=ZGN\KMQ)MS-Q/:?' $A4YEZ-QY0I/"&^R^Y;/O>),Y"R*"0GQ)@^6+.V
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M=EHMV]6^C)O2&L8VISFF'=\)1K_@F\3<P5E.,G[D>-1/:\#R6RY"_BH7@^"
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M@B=]+NW9WU6?1<];<.ZL1JN\H&XI 'F^74+#]'#WUX3,6[E*P?QLX( W$QS
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ME@L97U(9Q=#A!1VW/RK!Z]BLJBXT>AZ54T(CQTET(A#O.L/9/ZC]&[/_'K&
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M0TCE:H[@%L+ $Z!?L-35+K]OL3NCO%-3A5QFX\98EC-N UJG3^LM++MO)<E
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MZUK&.1%7'41 F6LXP.EG'UJGE(N[^<C=%VMO8G&U%KVA)#O^WL_S0HP9OB&
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M1'\.([V QC'1')J5:3%6(;XT,9+L9;1<2A7 Q&[(276<ZG>QDS?&Q5<_-";
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MN>0];.,4'XNTU9$5KZ4]8&R1X5U2G$>4M?>*G!P$2PW#'0</OAFC)UKCIT^
MNH,%)_W]Z[I4_N,25_KS=RY;.29N)"?JILN:YL7*'Z06R<KE.A% 6RFC9P37
M&BF$H[/Q1^FX( H37-1!<!!$2#Z!7Y=NAX%P9J8"]XQR=T;TC9=C ?,4;O ,
M-LIY^=)]?[KY%Z(]UP%O>VW<0I\]2IUS^C.ZUO/A*9W[!1M:TCA-U(Y(#_>E
MX0)VXWVO13,R-=U]M>F"E:9] YRC#QU!&M(D/,-3. 4(=YIR'BY8D:GS;ECU
M)$J#.Z2="(QQ8W,BY,PVAB11(-2.0.+Z[JM^+U5Z:<:(+.=];JY8_4AF1TF9
MJ@W-HB.K8>_%C+R;L'&UV]>*$!8:=DVYWS5;^.A__IC NU\47GHXVSC)-4_F
MS]HDN*"2X:R,_1BTU_Q]*>9P48KV&<?!.$<7NJ!7V^ D3_YZ,!1>ASOUUE\S
M8BUULW"CSJ"K_L>/H>^]W^O4E/R.</G7Q]NL#XV+^!K"+@@@$*TZDO>FE!IF
ML:\12-5IXCQA/51U%5?WX#IR@[JN*[\?/_4_K1+/DXZ)':0_NS-.;I!&&WN0
M2.,$29"20E>TT XB]5@:\1>CJ+U<@6I1CD0N4<-V)^)O"@KN ]8^@AN)_D7E
M?&WBBJ N-\0]]B ND"JM.JT\Q9]=8<R4&DLO2U^\Q+%]\I"N+G<3;)Z]6-TI
M=Q!AA&)A:SAY(MIOK$R/#U2 D9? M!\ 7U<K1GKAG"JVN>R19X^^K@07 <B!
M*Z8)1)#SZPB490UUHWO#3RIOI/7.V1W&Z5Z/?9Z09 K _!0[2'%GWH[D,OOS
M9G_J[J"GW'FO7K=W]9.$?XKRER8)]AS!H8,E/Q88?_K&9L\UEH,;WZ).OGJ*
MG'F\_5(;9B<_3_K"&*2Z7'[]0O/,(HG-)Y[-NZBU0IR+(I"_'(/9%3KF==%U
MHF<#$/;<8#R^>>1_ BHGGX!)2[V^__-[2W4[.XU) B1N15HH :N/.7A]WTM-
MT^V8\9XR#LUV<,3\^*V8[K,5FGFL8\@+T!'X09]\_-UPQ[?5:\T3QU )ZOEV
M4DI*W\#!3Y2<<JR6S^NV-YXGV)T0+CH?V*FPVJ>/I).(S<Z.\I<&"I3?LO13
MHR^[L"GD-:5W_8?"_@VD BES:<9BAYKH$@$$B:YH,6[XQ>UY48(D%T76)Q?W
M:=SC2A@4N"N([JT3Q6Z"G=0G5 F(VB:3-U_4&EFQV@[Q@-LA3;W."&]4<!H7
M3+ABG>2"WO&-#+QT$IR0AJZ-/<^"GT.*)QQ[TATZE%@@4;E7DTXJ01.!P1%U
M;VP]]A=O8EG61^B2I8.B9=W\9]S6K(CDH65NQT4AH9/13P4]C;3^<>17V#6@
MRI.(!(GBSB(X?YHDU[6H#UK!G962OI;V25\'T+LIR3BU!E()N[H#%.E1%L(\
MW8CR9LZ((IWRPC=)F'^6@=X7Z[\R&,'N$<6,:@]H1M^0"6"8KA6!8I!7"!H@
MRLTFV8F;<\-K;:(Z-+1/ZC58*?3PN!P100VF&*>/I8DD$^R%I"E)-,>:QY(\
M,O>KM?3Z-2R@ <*O#GL6YJ<3MIX TAPV_G#' F,$NA-*F17Z\_)4#AE2QVN>
M"FWG(@%D,\M?1'4Z(AA>Q--3^QM<-:.Q8SM"FW["5Q5O3X,J-K!LA<KKO(79
M4 F.PL0B*,>=_E!E!/.M+:V&%^YZAD.ME)K?*:SMQ-(\GHH=E)UF]&$<$1)-
MJVFVUY"@0SL\2*Z83G",;^?J+ K(NZA<V-42%'_Q>Z41?LEU'Y&8F_49*NP%
M@<_[5:N> /KYT[+]=<LRTKU^Y;A6O>XP5O(?+1#FB 9-/$F2_?-&Y=L4J1?J
M6/K'_:M]V1W-88A-/]%-K&W9N<(V6R7/#&2G8[.G!JX"QR5Z0K[=/RM"\(Z^
M9-G!4G2(7>1JCKV)[[IR=^:%\E(SRWH>./RMPVQ_?T97B<"63)ATZ#DZ%Z(G
MU675>IHZ;Z3,$5W7\4[_0G<]_TX1 @H3A49&3P<.I8&LQV6:P+7.;-DQ1J4'
ML(]^P7:RVO8:0\?+%(J(U]L>XN?+>I9HH)+VP:3V-N,#^T:"E;#DP3E]99O.
M_=M&+?-@-[44[@@P@OIG&=ZK1[*9[;KQ],0I;KP9RH*4Z5Q33952.)57DKM2
MGNA7,V<_-)L%37 [PIP7V#>; CFFF!+/6OL_RB0%A@J7H])4[65X)O5J#X3R
MMNFK5]7';4\2FI,;CJG!TK5H7##?W&V*E52',:\%TH82TDNAA^3 2>PBB9=O
M+:PE:9PY:U['?-=P#6!YW6_TB:(8/@I5@GL4ZEO8V:?:V'&FWI>0T&N??&S4
MXLM2S_W[<]#8FC)<EZA#@#W/:AMC&">1X$*=C7JK# 2!;[0_35B:_R')$AB(
MFS(%**XU-O.7YD\CIL;7(<3)R0MLK#44B1*]+$] NT19-@*+"C=J%\%"=A2J
M"HFR<13?_VH6D+N DQW&@LF6>A8<7"$J5="#%+G%7]T_9;H=,HC>JDA*@N@4
MS'1:'E4IJIV28^G@:PP=XICXAFO\PU !1S0&=0P96T:HJY\9_B7*1SE+<V]0
M<UYB#N^USJH\WU*8!N^'QN7E=62/$^V[J*H"2SKZ0GTI:P:;HFU^ :KG!.KR
M2 TFE!4)/ZRC?K[ ^^-+YB>M3W QO6M^7/TH%'!3.6?\P1[E?9!G#2$ZE>&\
M#_G=P(TV7XU/*:M[+O,9<!^D(2/2KL\HDG<@3%A6';*%,JA9?Q.BS^C%NT29
M:E+\S^?"*]'^G\)$=NTJ3!L#UC4$Y^"OCB@@['%^>M2@XYB("'A@L]Q)G.SC
MFP(K?:Z:AC^BWUT"BK9EI_A%:_=_RH%#,W$D_M<!?!9_&?SPA$[)RC(VICWF
M$?B(*OPF14'.5LWH=Y7#5A0-9E0ASH<!P@R.K?GSNOK43KI4>;>(8J^7US\N
MJ/-,(>E4,Z)RB/).3DC9_=!$T!M:"C?KB$?XAEHH^/"!>VG<WH[Q5:!?O[WP
M1DWK;S;MP<7^5)H\KY$&NS_4EN98WZC4V/P4/H:.<!W+'5MY,I?ARWTDX8>V
MH#-G?P_X+]]Y_R<T11/?O'<ONQC,2QII:$A.-Q(_4Q'&<90H3P]SB ]O9K17
MU:U>R"JV:':M,[SB>#W+%$S->5SL+;F/Y?$RI!W?BLAZ>C?.NQJ[73ZF^N6%
MW51;?EBC^C=^GI+@0(-0:M95K96]/]_M./(;OOEB%JH]UO&5UQ4O%.I\>'>.
M1(FH6AT],3\]3U1_'4M2_BG,?5PM 0%G<#[EY@E8G\%?3%.4K)7-_VJF8Y$$
M+W6IO"\F,J_+Q15?&[LSTZ6 D8*]D](1!GM]4%<W^O8+].CE(U^RV,]K%8^D
M%W)L&1NQX=1SS7;P-]**!!"$,0T]\>6@1I_D"\EC7TE]J/DZ-8[6*X@-U:B6
MLUD(%W7H4'&1-L%*J;D\EDKUMMV;G0?J[J6YYC7+*_S!Y*Z$H!GJ4_H^SX+
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M@_N6:(Q+4>S+P=T4O8&P2\.B?8>2+CNRUSZ35@*I1(P\+4BZMJQ;\%&-_4(
M@D%WQ89(F?[Q^:.FGK!T/-&?OFK9#/NE+W&H2JC+K\@#>.+U OD%IYCC!&=
M%EGJ:I\ 83B%YSS)@- ]\O#+GJ?G3[N\!@_1W7@/?TF@T>#60E.(M8G&*<IO
M^DPS?*MR-G/Z8I'.DA[SFMND(\:>'R52TDR:";&"]5W\@.;-FZY)RP QZ7/0
MO:KT#V,+)5%K@<]CP[(>K[:(UV+GVP#K&WU*,RP:Q@9N>7OR:Q.<[XS( HZ.
M3O$SEZ1"9<4LY7L$-J (/ (B,V,_8/\#P$(K"?)#48'XS_$=&>O-$$WW!$%\
M:W1YS8R2/^I)#'?0]".[874&4?BY(T<^MGALC-Q>E#!H5*>81I+*I,1EOS+:
MI&%FE< AC_DHRP85JPAN%8.LWU,S$H3\[(N(&\!]'W#8)7%8TAI(*D@ 5P1\
MT^EE,K4,P.&*^40T('@U*B=E=M#<UQZ<J^@E6D6K+JZ54!_\&1_9%UOQ$]HN
M,[R-JLH7N6G;E^5N'O99CH5YW]?, >RZH=WY=-!LJY)=XAOD1'M0?>P;Y@]^
M19%=4,8--UN$B!A/P)'#^F6KFV/T9TP\G5ZUVLI0,B(S#5:2-8\O%FRLIN_2
MO<RG;&QL#LOB5N=(U@-YZ@5G6"-24^&.+>"M_M5WXINB;MYB/Q9N/>.UI35>
M#S+Q;[_FBI"K#9 !T_8[Z:6IS]B6'3K?GG#ZO>H,DMX4A8.NIB!\KSE3GVG@
MG^"!=N>3X"2Y1M0LVZG(,^LCHVY]BFH-RV&*Y MAKVU*61I=O?IU1(/$C/W.
MGX3]"?"*<^2!_C[1$]6^3+T[U-8*4JS[X<2#GRH3V<$BWB&X9E8Z5+3G(+<U
MY&);0<Y]: :4L![34XV,3Z7!OCHZN4-5Y-/TB(:!>H=E[A+JY,\=S3I8<>0/
ML_NO/O!?]WDFU$&E>%W'.5KC#'-6PWH.RYB1W)S&*1[LL5Q"2RWQA[@Y+G.$
MI?656^W]3.(/X:C?E0B$U#K'S=Q.M H@2YACMM O--D,-!!\]GO>4;XVJ(1X
MN%$;1J;(*U\%1-"%FDD;:1'M(#FD1FPYEP?WI*0N]0<C76S0@B+6;C]"SYN4
M(_Y,J,I-7_8W5\4)P358+!RY1L1(;WT:EAQ0OB&;J*EIF#ZBKZN+D,$T1F]B
M6C[W8!(;Q>Y4E")0B_CWXZ:_XWD^D_$,#H?D,'Q?0W<QAS2_]]R.%L\ !;WD
M@; %8M4E?&&A.966&!23(8#[>3.B/4?;%/V^*@2D&=M<&OL[-^%=E)$0\*[
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M&B/Q_JQH(Z_(SA*K( :(58H?\\EIPM+L&?Z_U8V[:\=-%S3O99& $4SZ4\*
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M::*IAPN6$!9KY<1(2ES9\4SOPYB9R;;:AM7)9<MW>6( @X.TYR;[30-T0-%
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M <^/25"PL;%Q;^!2W+Q)P7.;^C;/_^<#40\08J%@H[X H3  J(0H($(41#-
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MX97L!7YKCE%4E@T'!7A_'QR)GWK?I)^NMZJ]GP4G&1T$X#56)-?F37I#M!$
M."EB4F K.7+VHN[<IZ91,)J$C46+QJ\^FU_SIJ_]#0:AZ#'_PFQ[",Z]Z>2A
M5 %+F7K37;.V+RHP]FS!K3"9Z>.[K'H780DT5Z:K79_!(YV8[%N^LJ7R'$.&
M4U+HL!.C^?0(&1*65<K3=>V ](0R+KL\S<5"FARZ.X_&)--8);XXC0HXZ4X7
M1KN9U53'78+&@\_7C=3C5TLG717;.;D/NG%YO/>115L^!\/3!*4WA5U?+"QV
M\-C9.%J5\2\00'#=K'-JCCHT'EXWGW^J.TQ2,K*N#&MZ@RPR@1_"_C/SJ23I
M#MG9,Y4G7LP(I87W>$R(4VH,0P-T$MD+;M@0-S!TD<0X%0E3!U'AT_=CA/R3
M U==PW&F-N(_Q#INZO!WSJ&0>-;7MV7!H'3'W B@"APM!B.]@^D1-YJB7.-I
MPUX0?Q5FHK@7W9N4+>5VL3S2V"K/+?9BRB(IOL1'(N5NG8.# ],ND33K^P\;
M+V4 [Y#W<B($7%ZCM23*Z5]VZ5.",R5%2D9B>^#/6&WG;9='+;\EJ!'N(@E[
M;<Z?(I45)S]:[> 9_3-,4H[,P"=E5;6>?" 1'7='P_8" MQ)S&DF"Z';$/06
MEV%-*FJ7&>P*3]B4C;E*Z6.][J^A#7J2A9V+'/4-HD"+VX,_0"I2;H(W,2L>
M;-@>M6\(?>D-YZA.UZ#X_"$P0OR.BD5 0S(V"\Q;?NQ)V.C%K*'5PK<AS9*=
M-!M%"DJBK"/&K"U;?L'2ZFDB? (#%>$-])[&<=XD3CD5.>A1[Q2!UTJ9IM&Q
M&[=KK#3D#-.0(UDC LWTN%U"G3>']9EICG#D"W35DM$\SJV%"G)N&1HG=5F<
M3F]_?$EV*O5ATY%\2ZM=\[ >+.[ V_'SQ==3U[,JQK7";8RU'^UM8S_:N*RM
M,P3):&M,*TNS4[.*C43,-Q!]5RALUWO=;:2P/>$+7&@7.TE>'%]HECXS:SED
M:E$+!$W$0%E)_HBV2=34# V;K!WNM#1GDW"'5%?6@S;%B485$$#[+/.UQWUX
MB$TI1GZFD0HU@7$#4Y'L2BJ37XR*VK:6#EQF';S9 #FR4,4H_2,F_!?!LJGI
M[J"J2G%3E5.;NM *4!/ ^"(MZQPQQ'0S>UP@]NZ"";!8(00.YAL5= N2#@ET
M2F<5#6./BD, SS:,S=8='&L00,4T1!+"MJD:EKSDQM<1-"!8MZGX,O@I6\^7
M6$@O LAJSX<WF1<:R.2IHI1\LC]>'4U!<24OJ\ 2#_PN++A$;7$^\JXZO&A<
M28QW.>6Y^GAKX81,CG.K_#%SI&UJY\8-6VHE@5RF&$M_G@-^X%HE.<=-3>&=
M2-'5%VN!''<U/Z'31;X[R]6=_5V478V79<1->*]]?=G<'TS4P"[P[J>\72"8
M?>*WHYKZ9(/'W0U>XN&C<+MB9J-CE::"HJ$-/)@R]@7?V=8ND9@7_'4-7+"L
M4V(5XO7\2= M24O&#2?P8QTVG7S(IL,9LX5;RK-K6P0 C!A_V+ YRM2Q$8Q3
MDR9I_N$NIUM]KQ! :>EYJ01DF2P4E3GZ<UX%HTA(2%8?Y09O&)OM+GY&[&M.
M>MNNR-$3IZ46=AF8W%.F+,$-E7DCI6>;LP><&\B:[3[<SPIURV1#XWI Y8L4
M_ OX5/8@L_\OZ\_'E\'72<LJJ7ZL,]9NM]YB' RR[G$?PIQX/WF'VU0 (, 4
MQWY0;+VM<%UFA4833C+I(,$4T^Q@Z\!(YNWQ,5Q=E5CW5N(GETW6F-$9UGNS
M(#-CT]6<Q<AOT]6.]6NG"*!HV&?UJ\EH?)3D!_L\2P^7[2'=.#=B=M.Y<-[9
M1-\ZG#&UD*CAXPP<3%&5[(STZ>DVTLX\I%%N!_Y1R#VSG3 Y&7WKG.DYH_()
MF"UWXY)8;_LB2']!8"L#!99<PM$@3S8(#&DDTN72&M1H1^\OGWO>3,28F7;N
M53(I+#:X3]J=R]=<G:>ZXJDO"?:8YATLW_PY'2-] OR5:-JS*4BR<J>!#$NF
M4K=U7FB-LRT*F9@TG6OJ\Z<R8)N]N KC6&(.-NY*4KN SCZ!.6L.:F/-6(VY
M%NB\H\ZL0G*^S6(V.;9S&Y+^7YT[3&UEWN%K1_+[&3AQ.BR<WC\/!<TT8"82
MS<!#F^F>EI>]4/T13+E+H[JL/332U?ZQ>B%NG10"&,TG7,  X6<J4UW'JK.E
M&',X\UW '_7A+;*;'%WU+!PCT:X:U IBRKRG3,1WV3OC7\0\9C^N$FU'4P&_
MZJL(KW>\&+GA;;T#^]":M_)X93YJV40=W/@EP[U$YWC]FB%[?FA4Q6$3LAYI
M8-"3;?SUP_+R[56S 9VB\.7S^$U"\7H0X$)JW-O[4-"GXI60T%-1W8OXJESH
M:*B8%FS%-<?Y(4<@28F:$2;7/ZQF[.S#\6S_DYO;GGU4;TM+=^R!@[I!:$B1
M&9<PIQ CQ:YQ" 9  FB_K$4 ##N9", X$IDN,$K8_[7L-T, &G27:><:Z^^1
M;4SX]<!5]M%?^NOOR8N9AY&C[&\T)]\E=  'HP:Q!P.>'0<C8XE) INM+*#*
MU&QKKC</$G0;F$]-$0#,6KQ/$&_J*\W;;6BU.+IEP57H 63,'[GKUGR;#I-S
MJB7DGM$1P$"H^*UA-8DU*Q#368(L6H!')=U6^9GF_0(KSI;X97E1Y5$$@'.X
M#AZMNVP['WYS,@]X6#[=D5J\T/A*,W;2^F[%,\CU0&X"CVH7<I&]7K"F5K94
MJ>KK5GZF<W-UDN*1R;,H*[O9S8=P+9)0E,>RQ+E>L7U'J?5>;!Y1\A$C9%MD
MY@"5020$9Z2 N0@!A%\Z7&S4=>ODJ?^B]65!P<H:M]'GEL\-?4AB?R]_1X;Y
M%5.;I"SC?DZF9&$?-MLEMB[^JOZE-3^T9R# W6I$.U[[<4^P7&%@ $=1,5[(
MN<7%R%Q=M&*)&M0QDV(K[W&.@D%UJ%:+&)1=D7+JGR7-O'W/M^!<&QY(HU2:
M;B6J;4SDI !AF@"UPZ1_&VQ&A?EN=?3M"#G3^I @FLW>&MFTICR/_=L57S^:
M6;[QS;E?XK.ZTDLI)LWNQS-3NO:BB::&L(EH.XP/*W<-J"=!:=Z$4XPZ'%].
M=GDR>'NF2./LAN1L3Q,L,CIB,@LV44,KQ6)S]#P8%-WJ=!_S\[QE(#P/2*-)
M"1<$ J_8\_.NO>'2TRKPVCL(H/\F8/3N6@%2Q7K4#AEN@Z_!M?!2N^.?3.:2
M/@EL9\QZJ 3H,:$@D[[$R:3*^44P'(YS[BNBL8#ZKMI@F,+4DBJ(_MHSDX[(
MYI%I^VLO.P2P.:!-JK,W^&30Q62?RCAXJ/%@^#UZ-U,B0(23^,T  ;R.U=P6
MU/B>11^>R?=,:9^_YJ(T4JPTBZ>TV33@13.!KN,HU&6CY'Q0,F?];FW"\PM[
M*!O5QT2LQV_1HKXR+H53@C^B1KGI$.FX/1K6?E0U];[$]FZTUQ?M[TG.4?Z.
MI[6A^F7?XCU?.V0:B:<3?U.*HXLBULOIM^\Z>%J4(IA;UT-NE0H=;OZGC_ZN
ML,?LW\QSM(W1F9W0U\KO3JHJ-SB[0686=?!^,ZJC7JA5F3M^P_;MV;OGG-LE
M:Z$!A@6?)I>T/M:DE%<$K]"_QUP6I[D;X$D*#T7O%@[1A_)#!LW%<Y:(!$%?
MA%^2]!&MGPIG!L.V\I8/5J+%T?AY0*A=B8[OL:ZL?40S#*PN[I&5Y<QC'>+'
M=7?K'CA7)]E[XPPGX]%)[_46/\N?F)X282F<1)L)_QSP=(!L"A!_+N9!N<7^
MM)4JRT>'JZJ:_-YS#;1'Q'0U#@JS>=%(GOFF<K%G<DTQC)*/Q&ORT0.4)75(
M/N0T_/#+4#H"T$< NW2K2CD_8(+J??\, 90A:2#WJL6KQ5,T]@HR"1G3@IO7
MFD<A![ ":DIN;)6:G+X8X'S),<XW>OGI.!CRG0@@%-!-33Y<8H2+IE^-7=D\
MN?.!*$-^RUL5=>"O20IEI<?,!2X:IO4UB-VDA%&:8?VQI3A%#(;2I<Q*1R_^
MS43V0=NVU=C&XBL%67_ILN$AM4>1(Z;A/I%Y&>ZYQZK.E<$OA*$G./_:4NB3
M)A5 VJNS$<!8>MT%2O*-K_^36G-NJL E=)*.&Q# $;%&TW^4%%E\X'-T8\@8
M)A(A2H!/7-+&V!KK\# "T*Z30/8M!+E>.E=!S\&;*_>O<;44RC,@[4^;X-^0
MU7]_"[U8S+YVAG/Z&K&Q?C0Q(PMZ+&,D^@M0V\4^ HB)00"G&]4JM)#V3&?X
M%>2"H( 1ED=#T1MEQSZ;??BQES.?6M."DH^*/7U[Y#/3S(-1&"UYQ%SW_96[
M#+O^X @^UOV3&O!R1MWU.4P?6N7!3%DIIIUT"IG[Y.KL+FS#[:S$<3[FO;F3
M&#AO0K91559+^GFHV<S27+(MH!X&KPFO-SG@ET  AK/G.C =6F'"0$5I ZGI
M#G;-_""GK)V=TW-D_6'X[.M/5;;V\WZ;-Y&"PV:-_N*7]Q' $]5QSEQW"_2&
M85.->S:7TC#'B*1=;;&1V=AH.-V*PY;.?0'A\KZK4"@KAF3(I\25F#*N7SXV
M.$0 M/J&AC;\*Y,J_E:-"\Z<\6-W>O$:,XQ>[H+C-HU?&1OM\UUQWRVVL\OM
MN/EYKWR6IKMLO[-(9L8\^G8MSA)M2[ ^<!0JS$OVT9J*J/MK:J2&F2#HS-OW
MH59\2BJ),,8G<R*LGCR#1Z_)6@="%NOR39)1BY#E__E_E/_:I;_/:,DW;?"E
MI#%3DO$9HGX4L360S_R?F2_&$( ' A"V4_U1FQ&/0]JNRZ]=35;81]D[MNH6
MX9/PJH)#TDV2.'3+C8LC89$(IJ\=S''8Z-RM[/H5==20MI&DR]"K%GI.2*/#
M,P0@5@Q/6I38#\SOOQ2>?'S+Y#UQ".Z^H>83$'Q?MR#UTZU"DM%"A<A[ZLMR
MC)S@QL]^FY!Y_F)CL2XPM2O=HNS5W1/(X29X'<[73E["E,3F<+D%"12?5/SL
M%[B%W8',B$\C\J3SI.]%/-I_\YUU-LPCGVW9!Q]I9!W(\3"$;2/[+RN$.,I>
M= X254SB!3T?/02 #>),PEU4('N>DLPF;[<?XZ#:(!!(6\EGX^E:./<6O:5(
M_G9A;(_W6S<Y#"I*%#EF>][VE:K.OK&Z)2,D6#8'3:Z!?O3O=<.9EZG)R!^6
M2#V1T4>' "3X1/[9M0<@$?I>:_7Z!>0:K1^SXRT\_Z7_9R658]LCDHTM;IR?
ML*7Y>]RI@];J?@^D L/]U2NH.WBW#0&DX!P([W8AL\VU2N0"_FD&G/3\:RJ4
MO6(O+/8G#$2<W8#+M(,W$Q  VW'GOC/^0H'4MB#D>N"BKN,'%I@KG*IFF\'X
M9Q"M**6Z&-?*4*TXICM!6.U+VNA]S7TW#)4';UKHO*;VB9 *I(N/GQ-C0P =
M4M^0E*F*#"G42L%=SMOB$9U:LN) [F=:JUSVJ^WSVT/971Q&W^3A;J)AX#?Z
M. Z7RM5Y0$\532&>Q792;('^0-E9P;RB!QFO+X2;KHVC\AZ$GKVIKL0!_ZI&
M8(D-F\GS4TUH9;B&7G^3H(_BOL.A3.D^85(C D"KN^NKEKK)[P6/)LLP[1T=
MC,$Q4DC$Q@S889>LZ N$'*@\0-)/QH]RS7"D+<QU;>=+J#W#!*P3[%2+ HO7
M]=2RDTU97N0^^@KES#C>\LIHN_)6A,_#M0QDD2[B"+]^H7*-IA-;'E:ZJA[J
M3$9! '$J^>YC!S.0H":<>L08*IEU$)L\I^&!\VV</3]I)83,-_ $3]L;]J[X
M4/0E](!WL8_  BZ&=&0=NW$AZ"/'@MMEMU]2YY<R6A>[GN%)]+C!5O[L6>6E
M#VK2INY_V!G=!HY)2E11-$O?WE\8M#=Y_%K)NY@@Q11CL=5S,:QB-T1K@@7D
MOS<]!EVJ&X*4I-4 WS,_%;>28A\$Z;VAP'NR/0P:+,]+/% A[7:@#R*[Q+$C
M5#"DFQ'(@?Y[4R/L?AO=_O$S^"*$VRC#\:4@LB;-!9]2G4/E\-2A+/^8 %2Z
M![[R-$)F([6KW!R83CT"V%]V1P!&L@>PG'14*&OB<\CA $08\"4UBN$W?SFX
M*!H0HJE TL>0D#D!M/6*KJ%NDZ*9/WA^G9(P_HE0W;,P*G3SO!^T]JL*YG];
M-GSW,RJ/^WY*?E=U9RK#YYST",#+9-XD 9D5JL.QUGV0/06C)=UQ#P*(]EKV
MI/.K6WH> *^L.R@P+"#G@K,=B0T%(X!INMRK]VK2I(W>P;T(@!2RE#(+&6.!
M'*$8/G&#_/355=;2\A0Y=Y;L !T.DH82K9&^5$0 :;=J9@[A8!AX,Q?":QRQ
M5P"77TF"']5=<.?V[((7+Q;A5>6'? .Q5\YBD#=P' BX_PV>%6.\@%I5U:V"
M;9)S[1X?E:[+S+!$XN]5/@<CF7NPMPC NUMJL'9G#"XRAPP/VZO<!GR%TVJ3
MLT.D @4'>;P<:8>BQM1G.3YUZC8LJ35I&Y(_W@[[E?RW9:O?A^4V^[O]MBM?
M)-]7S':KBSLA ?B/ZVD*7B& Q<Y=>%7XLI&6TS>D_\/9ZRXVP-&N6O2RX"OO
M#O@Z7&LIZ6V!01)<%-D+NB!I]$#!"CM&4,%_[(Z*X]=/FMT<\3."\&&GP#"?
MXEZ;SR3U,8_>ZK *.:^70)/DD;32$GOM9K*JN;$2A0!NO[M_L577ZR>J#&7)
M_J/&#12R3_?._JC6\^CR?K%*T?B33SQT1Z:]I$9A.T[R#\6I69F@B:M&B8<-
MZGU\(0?RCD]8K3F&N,,HG3O:,2EW&V IR8'I/ _48AG1H2&+0WR*1B@^0MD
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M#32P!KNAL<_\AE0$3)J?]M#H3LTIL;0]LET1,P\.E:!0^1"IN!C0QI!@M^A
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M2:7]V+?O9 [7582GC?R \FC4;%V)4)Y*-(>(=P)TC/@9V^!6X>N9[,P)^91
MJ.=2F/5)53).O<_K,(^'18Z?"%M90-4_RB68UWT,:V[#]5,VYL.MIY[F43WT
MG[>V-%\U4+Z'2U;=^G6=]2O)FL!*M/R8*A/#)2FDJB>Q&3 IF,V2C%%BM16R
MEM?N?IOQCC)WQ'H#XW[F'[YK\O]#VLV@,W>@6)$L8X&/5)-]@<P!\9MRBV\(
M;[&AMKQ1"XGJ &LH_\T'48CQ_P%02P,$%     @ 3X!Z6$]!CX0M-   QCT
M !$   !I;6<X,S$R-S$W-5\Y+FIP9\U[!534W];HP% "@L30S2 Q@-)#-T-(
M=TI)2'<I*2$=@J"4-$AW(]W=I33275(/]1]Z[_W>N]]WWUOK_5A[P>S99_<Y
M9^]S?MQ.W2X 'DA+2$D X. ! +B['\#M+$ 4@(*$A(R$B(*,C'SO'@HJ.NY]
M=#0T=$)L'$Q<4B)R,E(B$A(*,#,M!14C-0D)'1<]XV,6=G9V<EIN?B@K'S,;
M.^MW)G#W[MU#1T,GN'^?@)62A)+UO_W<?@)@H0#:X&V!<%0 >"PX(!;<;1N
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M%C"R8[SOD^V;64Z)K\PPO(S77DB9O\>U?/"1HU]FZ5X+3U54E64.V/\U*T]
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M% ]<*<[^,-X<X:_P/'[:2H1>J'NLRQ]_*%6EYR5M<T752'8+2"5+N05X;]V
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MUDAS/CX?]=>[K7=+Q4?SL^+G6B_P)PIJT5YA4YX*3N1/H,];XO[QAL__S5(
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MZC&F)5]<C>4*%<V0!Y3Z"ZM"FU-DXT,_Q]I]=0],X MC9TG0ML,J 225HB_
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M:Z8S2"S LASTC+PXWLUT+J;<DV':FYWC[Q^8XYN^C#(J+?)R_X::-[L1A^?
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M;7-A V&V,(#" >%J$*4D#0*VA89,6SO4G=F>[MTG]#,ZSS(N,Y+S ":T3$'
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M^0VDY&Y/ ^H.26"=R['W]NV?>[\G^Z_>O]O_D+S_<__@S[VW'Y(/[Q* XA\
M;R=,)._V$Y;^X'Y,WKU./OS;JV0%I2\0^MZ+#_@U4T*N2[+=1%XM=JGG?/@7
M!=2&@KRS/'UCC%?5R>S()Z%L@#J3$Z_KQ$^<=]< O^O>=XG8T"FW2J>,2(9U
M+*WC@ "I)87. /?1O%!R;;CO?72MOFI=X:?DQC,'GY QO.4(;R-.GQ"<.?&3
M&PO-&TZ8%I:KS EB/$A':00E!64YL1GWGGO&*=/?.N$7\[K& (2XA?\%\[CI
MG,]-]V%H\*6WK4<?W>172M>''^O.W?"%\8J"YJ3$8T,_R4*.)8X<4<XY(3Q\
M4^3KXHLEG;R&3YI!D  >E%RG66]F,'WW$OO=_G"X86L W*T!L&;+=;TF0*X!
MZO-"$L- ZLB4"E($P8F@/F/HQ9$^6YL/IX;AQ/J*@S #Y'V; 0-P85RV(!_V
M]]X>O(F(?ZW&0/)Z*>EP.>]TD=8GX"]=)ICQRE*]?[7_YMW+Y/7^NS^2"__[
M\.[.K:&+_OM^+:1;'Z!@EG+98* )6$F@WB;S"%:O<8Q?][;+#"2I.+6Y)B(+
M&&B+L?K,>:(+3DW*C%3FFX%@&]+T&N;R-DYE&,M,*2-"T8QO/>2;Y"&_>'[+
M5_%;,D+*!&<TS4EAE2*RD()HPR3Q3@HO>1!&N/4PPKX_+)L9 (P9II>LE1FN
MG?QE&QG#"Y-?RVHG>3.QNVNS@09UI'U;J^.'5U^TG<5]3*J0U(O]2W23-%-O
M,8K0)>4D*6=-8H]T#4/_<2L_!AA(\RW@])MF>J7ENDH2>CZKGJ_/E#VUU?'9
MWV3<IO0*ZW;ERRNLV[B77V'>GM^]:XR<=M_O^LCK-)]<$G4@TV"UI,18RXD4
MRA,C>4$RSHN<IXH&7ZQ'IV"V<PV&:@QNCZ&Q72O"%Y7SYXW7!J_ ?"-\SEJ\
MLI?[6D?ZL\88WW78K\/9VB(%?&P *80L>"*IQ 2U+"<^#Y8R)KGW;#U;^T%_
M>=.%JK<EJ-<&HB_;,YD3+KB4*?V*7;N"X_.'9/A\<(#D4I@1^3:IZJ3"VGG)
MWU>*$@#NN,8WL3GS+%=E59QN?:@GY?_$OW]<IT38G#7YX<WN_N[!;O)J/!U5
M)Y@<\IUL]FG1E;RM=B_<X8W!"VNS7"^Q0G5(J1,%43S%,!>7$57HV#O!6L\S
MXX-:CUK9<PXK)'7__%Y./+M#,G@W\<EO?N+T:)0<_&-^/2"XJX&</D^]!+8Y
MD:=8'(%Z%HB4UA-ME"24B]0)9U@J^%UM K_#3?AU7H[0U$PR2DE.K]/N#[D%
MN0!XG!86EC/6RL6BY[[P!,M4\"P-TIOTKK9 W.$6',SA[B1V5'J@U?_)U$]_
MN7X#"@E2R.2>I [Q;<YR4CBKB="Y*70N=7!RK1OP GY]5W^H/M^E-?)"CTU=
MNL,A2Q_TN!>:%D#KWF.H>D:, !%$-672R4PY_<TA2Z=6/L+.=_5[, <!FJW#
M(7G9]/_8^][,0)U3:31H"50*!*02F(&:4>)B7TSCG;#?'&YU:K/>5V"[C_Z[
MG$;#_NZVBG(FU-;\NT\3H-MA=#%/:^#$<JI'B?_B;:Q( !\#BO;-8S60@.03
MI/DKS8?-/C&^[?G$\D#I7_Y2<)8_;Y*9'_GI437I3X]W$B"HT3RB/P#?&D22
M\\^2'^XDN-!Y;75J/!$>V[X%RT@A@R12%TK'<'WVS;'Z"!?V8")K$H/?O@D9
MRP<?3'IA*L\W;W<H%&.AP )0V(2QR!R6^[,D%ZF7*M4NY-\,%6.5SO=(T'<0
M0G#K:$29%80I=0,]N3T!'$X$P3>? 1:[Z6VSQA?E+KI39%][ETSG=3/'X^19
ME< 5T5'&^ _F1X0"F"RQ9V?/'OB0]#ZW?T//1D5QQ=DHN^J[])8WRO0F!Z[%
M_>#OTZ*&(H]TPN9B[%EL#/;\4,Y&,?(#<,U18K&4W^U ^*5+E/PEQ/^H>)#%
MNG!YOJ(0S+<OP.;32*U1AU]S;K,Y\VG#\G^XK;FYI?3OEM+?=F%P41CZ+_8(
MRV,F %G@L?#)$M=\I9OHKM74W:3!<[CU*Z)36^AXB2'%4ZX#*S!(R.5$6D^)
M*:PB- TV4,.L2K_YW*E#H">,FZC6OIY0K@I;K_!!E?VTDP#$2HZQ#'7ROP&$
M499,L4CCT?U$ K6K?)<[>F]R9-@42Z41S 9'M YXJ%588G(NB,3:\MX63$O_
MK13;:=96(:V/7'_;WW^W)<4-(,5;F.:7@C2PI:]V@5U-[45*4^TPDI-)+'=>
M$)/Q@E EJ.%%EFKZS8ZN7CZ_ZA1K3!$X%[^):O>VH9N7Z_7&Z7_<@0_S!AO3
MDN4+/2UG>I1@Y2$_&X:?_YN=1?G].(L.3SF++J3R;W.2WGX>;ZN)WRP'W^WG
M^F;B,-3-)^8DL4?>?DK&6$:K;+=F)7.D;!*=?/:C$?DTJ3[#,+UN8)T<?-',
M\;Q&-XGSH9RTB27[\Y%/)$W[35ZA#=COW>2_X)=OYM'ST[XR3?N&&<L/L NG
M,DLO%O37/_P2):"\R85)'>%.<LP38T3G:4Y2[JPV.0CX=06'_0VHXS<DCH..
M-MY$TG@8PGY;W95F^(9M'A3%9QMVBG$_0FY2S1)L5%2B[@*5%3.:ZUA3H;E8
MEPD,"6\3]Y<:;3?9BKA[$W$4NY%*4:"D$M@%1!(%,H[D3!:^R+D6=DW!E_]1
MC>:3F:YC<GA]V]) &R3:;D5MR37R)4J%<H*1]L_D;BK$/U]Q?OQ=B9S/1SZF
MRIR6.\^2']B/R1$@*)0V+L&@\U[DK,HBX[L+X*%7B)\5K-5;92B2\.M8-\3-
ML;-:O!3F;'T,LF$\B;7/FN0'>![8;TDSMT=)<U1A<G#2MN& >_3LK-#\K)OS
M$C/>W,WA1P"'$Y?\P-LY&K "X7OS=Y@!7A\OA9MP%-US8E.Q.(@X2-W,$D43
MIT^:W3L3(B(#GJ=%3BP7.9$A\\0XHTA:I)(6WJ7VVXWE5HATY>C:0CWH*9KI
MV:W+C'TCG:XJJ8%*DS/"Y*%TU]MJJ-I\*UZO%J]1ZH# &9>S&8@H/P+!4U<3
M=!B.3A)_[.N3Y UZ\K2-@:LO]4PGKUO<=TKX+I^Q"@173=U]?S@?M9EC!^1#
M\@/ZB?+G7/#=A2U<QHH+4ZRX<->2N!WO0L#ZYL>[$Y^*:2QX7(#0Y([(W%'
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MJYLV4C':?CJLJ_G$D8Y(VWX&WQ;B>29(9UPZ-_*72)=U=0JX[Y#IKZJ:/8#
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M_#%=Q.>U4>MM\B7<V5\:NG0(E'6-]]&"[#PZ[3G(23(!QE[X;%H"[0Y'0"C
MX#J_X&4NORV!/BX"?;62TG)&0]XRIBH*;-QE=/TDD_G8UYC:O.J96?@^6Q=-
MZ[><3S"[=DN76[KL!.<BF7MY<%OK,CJ)I@AIDZ:J)A&?:12:?=Z16QR9@1!M
M.P%B0$57?*7-*3I$9#@J6XI>!%C#5W7G(UP-H^C&<0A$/[O@=5N*W5+LJJIO
M%3!06 R(P @<0-ISWSJ3^P/>1H\ZJEOJ["X\OE?3HZTLW%)63UEM$0G?U4_!
M>MNMR;BP8L)\XF)FW9N 1A#JX/DDXL-S8O/SD9_$9V%^[6??YV8@J+1]? Q,
M&2U.H%6P^#SFSDZBOQ^C8\H*;9O_\2M5IZY/>($[.Z"Z&G#3)J2 Q0L&_:6G
MT%MR?USDCBX6%)^)1^H&"@NE'[5:??_MWN)3M&@TEB.<8VYKV;3Y2K%,$5#W
MY[;Z4)-X=#[B]3"ZTHU.XND4L@>(W),$J!;-_,G55-P1Z%)>MQ5AFKFUOFG"
M?(1/Z+-IVY3JQ0/PS_-A/<"GLP7CC=&%= *O;N"OZ,;ZW!Z\P\?+T/,%^XQ&
MVE0Q'ZLY$[VFS[\)G]/KHOC 3AWAB7Q )U"]F^PMQ A6>&KCDT]MP*E N@X.
MX8$E=L:+Y<=TY/1C6()3!JYVQ_"//L34,M1P*]O7.VY;O\N*R^5(U^,;!:=L
MQ<+C$@NG>!\/#"9 4Z,E;9ZT=-AEG)_XV2)C$JCJ6/?UQ]"%<C0?QV3U9<+'
MO/&M;U=/@9#!N(4A 1/.]*>H0'MB7V7L_OTKM10[M1NMVLD9=#?RVK7!6.@O
MC)JY#_W;4OB6PCN<=SO%M$RDO6'R\,5:[&+P>), Z:1J,UKJ6,GME Z(6#(&
MF[@J1GU4.V>#Q'LM>$H'; WK+5NT;+$W.;F(Y#XO8K C-0==1ABVR@$8OM3_
MOLHV51T1#%)F:_#HUG>)IE%;R!#/@3L&B4;YD@E0F91;ZWQ+GHOR\@N9&:,&
M.JG99:=$@[G-G[DRX:6OM8"TV)XG7RQH=\ZE$YXWIR^]N8?NW4DSEK3N*@AO
M:7E+R[WI?=&!-A)9->D""<J^$%I+KT!08&(#Z8W\Q>$$;:'CE0<@&3I@ ,#B
MHU'UN<^:Z>I5QZ.F21N.WM:#Q0NZAX:N0MNYY[7A \NTKK90Q*)1["G$LW"+
M :QJ@WM*C"4&%H[1%:>>C2_4G4\VFLP8D3 :;1EFRS!M)\3JN LOZK Z%N/#
M8R)7V7F7.#+I0M279;+AGX7GXY-OR?T?\W*9&[9:RC_&EV%P.KJZ9@NS,MJD
M\QHS>_ J-%5;$W6&]?3Z(H+G>& 1UA3T<54OR_#@=[V-"L/&\*:C%BR%E7J(
M6[K?TGT?X.F_>#MO*UTC;<9L7==U\.W3&?L^H:?(,!Z3M34%5Q+>@>:J"-E7
MK,=H H?1/%J5&&4V;OM]XRG(N)QU&NB<K(]"&QTYQ_HFDGJ;1+!-(OBJ)()M
M%L'=4L[CJYO=MNU\B*X72>E^?H(ZEGWL77+#6)(V^GLW^?5;8M+7/*9S1U(W
MWJCL8=(XUCS_=\?8V]M_'M"6))?MQ5>EV3S0]JSEO$ GIJRFZ#.'%\QC?[Z%
M[= V?DK&92S[O'J4M7-%%10=#]#M2#?1(,:S8#PD&V.]:F2 97AG?R"W_W9O
M!\P&,"<6I4<Q7*XW(&#=CI):=V'*1T  HY/86DV/8HY&V7AXXI*O[G\MMV34
M10G$\(4$,VQ"-2HKW+U%&8&RJP?;Q?0LTC.<1\S>@G&@PTG?WLI4[F11/'^B
M9V"MCD[%<,"C;+RXZM->='3@8[@2GN#.:@W6*I((-A4;M7'%\6[0"R>KU =V
M0C-#\Q7&^Q*)L?/)^B]3/5D49FGCEB\F:<P7&8$U$^O9KD16M>/I _-G># 6
MK98^@N%(MY-=B=3 T@@36_O()9B(@^9,V55**L?Q?!A39Q#X^7H,TQ_!TG>!
M^<F?31M"DL#Z'U:3N1WY:@8F.VFYKC^ACE-<Y@F8NH_;7LX)JS?!CO8IUECK
MH=:'_77H@ZY+/\.L-ZR_CS4?6H&!4_9(\=[UBX)N"*='7<(4D-,<6TVTQ7\Q
M$8<<59];1X)O\'2[;(YB[..B3!D,Y A!<$R9FG9+<&:&B:OGA\UN\F_59W_<
MY0LEC2UC8 WLEL<($S0%9]BD;AK3P&(Z!*QTV=F22*]71=XD\Z9?@%5*7 DC
M*)M67DWK+O"M;C>NZR"QF_Q1U;X5H8OY=49M'WFPN@8QH=^'6( 9+CF<ERYZ
M,DXY_?%Q:-^N>O=[3TT7AHQ4=6K$,?"@/^"=5"M'71B7CV1IL(G@,A(5I3_\
MLI6R#^5:QX.75B&.8(CP%MBM*'CQB+%I6R7BUN+>]67&VX VC-J":UVL%@-;
MW,LO;!S7GOJL%,%H(I^/NC"77KGN7*.%=Y._]D)QONAQLE)CO!7 *\P:W]T6
M':R3@[?_@9>/8V&+65LFHWMSRQJ1%@,VM.X.#5S9YCO"A5$UM*.RZ MM54';
M+&5B>Y\HSKGI<_C*&C-**MNJ)%=]QN9L7H\1"]DC/XZ,T,N<76Q'J9-8"&34
MJCC0$3B._?:??J33(]B+V<FT&[/SX]CTK>L&"]H.I[EPD^J8ED6J0);#Q-."
M0PTT<.K3]A $)W"F[TM[7O)WC*B-HBL^__0JMJ7:ORSVL=6X\R@$02;'?.;E
M BU6[)2"C(^%B_8[S=CU8EF-_NT/1?JTY_EDC(<XK?IH0X^Q2D>OD$=1(73A
MCJ=?O!4O#Q$DT425%J4 QH>[KNY_+RA<'=FMA7,]6S9+F+)S/G 3Z[TL67>,
MC1BQ9,QJ+.@J\"O1@8L!XPO$$U7AU&,EJ:C/8@>G)FE[)48.C-6G8KE&M!:6
M=D#RMZ-RY+M<W9<K2F\E/*^*U7IB5@X*RW'9EB,Z;WSTJ3]1\BVE88SRP#HY
M+;P\4YJ@2]=88+KE-/H\[;Z+:@ADAM)\UF>PXUB;LU&UW2%HY.1.W+5(=3$U
MQ#[+:H#=P!H0QJ-9";?A\HU 3N,*+J7R2-M/^""/'OBRS7?O\!JN:AP7+,"H
M:^F "B<R^BD %^6V[T%RN>A".>M,QG9S^M%?:KTM]%J]$!O3:MK)IT7=A.62
M+MN5=G363-L<60"UHZZ);$2+(P#)DZYJPW+_86!G4?PJ?-IIT]R!QE= TU8V
M/<34_]#C<=]4I(TN'P' KULY 4\8E9^ O/T4"+R:5JZC!ABEG[@*T=&\65B*
M>!JYT#LK1N%2O:TV?SVS^\GY&.+.*)T>G8")AU+-MM$Y-J;Z]YVS.J2 (3QU
MUQXVHA[XL-SI:I-@48AX"AS9[52#-2!0%'YE,XZD&C5[[-P.,_R?$PPO0]9V
M(#)@LNAB3%X"E '+HXD-[Z(H[V8'+]U[N;??]L#;OT R+LNMV(I4T\Y4P)B-
MY6+V]S0G#3I9CTO=QC@LS$&/Q7I]#.X_:Z*=DO2]K1Y%7K=*,<$""*GNDS%P
M$..^YU+_ZEY@V2N"G3I339_JC0Y7XP(@SD-K;2>): ] VDEWC&V/< $!H]6Q
MJV$,2YV5&-_=&M9MP;)5(QHQ)XZK;T \P2H4TQF"\F@.H\1;'7"4I$NK?A$X
MOI"9V%(G"I_)<EOP)7V.Q)FSSRC@8)J TMKHEQ;_=C-$DNI:-&*F2<2S6S'V
M@ F>V,=Y;)!?L6A1V97!6X5%K2$S7:87H\4S+T?NG-NA][OL)._.\-E[P!\5
M"HI7W:7PDEX"O'O_:G]OB$3PO9U$WM\99#D&<5S;GY_ +X5@/&=Y^I'N_GUZ
M^ 3EPX6?GPH-206=?GG>G1QSFL$?3YXN9G2?4_F:G5I;Y;EM2,<VI./VY,2V
M 1WW'-#Q57!A,V<]D/G>4T @0I)H(!W6;=\"++\V/>^06@7O+;Q>(/080GL&
M!BW0_<YY:-\9%LNLA]/WMC@,APD(BTSG]11KU?7^D8O+)B^BVGV;_Q:3QGMK
MYLK<"FWKJCWV7"25MNZ79K?%:[%Z=FNGMB6\^MCW3_XD.E>JB5_T_NY>/U^X
M.6+^=CQF7#'35I'DN<G'Y\0SO7@4JYNRZ8=__D#WS&R>#0=;;B.+-RBR.*Z0
M\[;SWCUK#Z7P66N@C)?GY4ETTJY*E(>CVYW^1+KU[<!"^$D36[ZL)"0N$GE;
MS\:0JL""[#TN9W7U@)P/AC4&"'2-<!92;EQA@XQQY;!1A<;$3Q#<7= %EKW1
MZ.[%NC95_6E1@7,9-*#=<=GT$>GQ !+/05#$C^:VK9&!$KB$W8JI>'A9']%P
M5F%UM8);Z1SK#5^LW_I>&NTI:-^$H_=WQBSN[A F5KEO:_BWVJ 5^?^7O7=M
M;MO8MD7_"FK7SJFXBM32VW9R[ZE2K#CQCA\JVRLY-U]N@20D81D$&#PD,[_^
MS#$?W0T0E&S%"6D)57OM6!()-!K=L^=CS#':' -]_"%#(\9@+F]E=KS=K=JD
MP91MY*0I@HRH<>D(8 H*'HN"/2!7VN<B@.9;VTY2K%S<\@D L)8Y71X.66<6
M=#=;#;3JZFRY2Z[X5NRWHF WYMJ%=O.F6E8LD\G2KFK(,Y>F!WP!*68IB]&3
M?$HF?-CNPW:_M<CVF='1)G<^HQ%RQEP"F,.G]30Q)/)"\4? ,8=9=%3W)2 3
MW(%8!Q>;"4&Z4H/QT\=]1R=?1OAK]0R>))R*;\JJ ;QOV&K#5KMQ_3Y?DU+8
MY(YB> Z-IDJ1-\")FE:TG,<.B^-Q(6&EBI,$7/_,+UG9BQS=&1R#=-((0BTH
M=-*^;0RF+%#?WF+N35ON@O>];KRU6VU[^VG^HE ,BL(]TR-0@21Z1ANG0*E\
M%OU,P<CXG*'"--EON@Z(@8$5)R"OBG[W[.<W;T_O:MJOX,.0<Z7S1/%L4@:/
M?;2SNW]T5_3KJ\UMCKL62F^9CN.=QW<-=/^!P'_MO66%B)JEP&< <,V9#!:T
MLN,*NO2K+F^[Q^,J$52$(LS6@R,Z?0><P4RS+!8H8KN0_? @!0". $T(]A1%
M (<Y7<&]T)QSO('00#+)KEMC4A9D]W/)A:RFGB,><;NAWK"5'.N$X!10\%=*
MLYZP[ G@TX ,T?4$WAU7;4@TO5MN."DJ!QEU[4'"\G:2+2[C\5YT0BN+HLT%
M+3FR6;98!,YT\OYTM&H51]$O;]^^&>_M[3J,#JNS&#1IJY)G,[1^7&TR=\8(
M;_:?&64;X5@HHGB:SKCBP"14J43* ()!6R?1;A_L[%)>G$:QJ(DP/V52H=_3
MX4)EN94.ZMUUT&,P R5 KWO)R3)Q+$*"_7/M8]]6)S^/HI.7[T;169SFCQ@:
MWT-@R.]_#1Y?31@VC<&+I]+S4#:+VAY[K/\5 %\\U>:&!7/AND]%\<4%%##4
M[TE8UH(1; JS3R*$&;A/GBB<D1-]G$)DM)Y#N8;IB1"T.N64809F(4]):C!=
M]%N:3Z8FEOR!4BE,&87M:6"0)"R;BZ#K4C*'$L:@*10OB^(EK :/^M;<A4/A
MTH49LVNX?R$F787O"A&3X9GI==;H<*BFM&2$E,FQ!K< N<&C\^(4;:;P8H)[
M]LUEVPAKNO\'T8_:%ZGI)]F@P7:3$Z9S5.%7_3V*2(*/'=2U%Z;J6A8_H=4R
M[$M96=A?55OQD$08D@BR,MZRC\6))^]F64O=)NOO)XQ#-B[M./H)N^_$-07"
MF^ &ZTP5+9FR,HHG25ERZY!S//#)V!VNZF**:TE&02J@+73^NRYF6DC]$Y#(
MBVH%AP\KAQ-W,L4<==1E,P][G.A)TW-TXVH/+>K%-!TSVE9C;I-<GX08MNJP
M515X(-ZD]I.O=2@WNVG5$\;>+29PVZ5[5'J S2^SEMF4^2V%'GR5OX!;/#B^
M1 F<&\!\UZ?S>/W6UC9;;OR8QGF(5THK]RFU;:V+]??B]]'>6EG-PC]I#!EB
MP$X,.%BSP9K=AM3D2*T=<V[2=+UWFL"NU;7H&:(O54Q<L,IR6-+DJ;%\8*/#
M<+XOFN="X9IXGF&9$M$'X3A'X.TX^#(N.6.F*4Z)A0/^$<?%<GNMX_X'F>\Y
M^;M@,R$\N:KSO!)H FH_JSDBI1EQ, ]^0[[/K@H1)*O9T9&R7^&43I689]IP
M.NR\%><Z'B,@@J\O"WJQX^(Z1RVX1=9@::CZNM E&G[87P\L,&7"LJA\"&]E
M^#ETR P=,I_QI/M#A\S64)Y^E<:_7F/\OR-[+,>FH&G3:IH5E<^*XR]<*&#V
M /NHGL[AAZ:0KB[FT-8J,@ >#&1P(GT>+9//Y<\:U#=IKLQPBLPNNB)*L>;/
M.[H;4A$!5PC^"O49<'I0O(,TY!9E'._MEMEP;^[>FM[<O9[>W./]0]^;N_?T
M*^G-_6K>U!V-VM^&[]C;(+[C73/YCS)",D>^\+ZB3.*I&,_3S*#(<5-?%J6A
M1%$^!/5),MM"^W7_XR.DSPK$L$KN!FF0@/E#$18J*B+MAN&AUJ*<X<_B7X:B
MH"M>TPE9]2JB[43O%+(C;%7N2ZG<XCPMJ[I-3ND$9E<YM\X5U<&!U2A(\JWK
M7?1L+%(>D" PJ"1,BQD8[1BNK^ 4K3^V*8(X[N]-:$Z!BUY)#21:$D"@2+]F
MA*329>$[>").= ;5<G4KQIZ%*) 9[3163I(\H5?,$R+7=I2 L? @*L0BB;(&
M[6SVU\E2N6*4"3:>)7\T/)9YT0BK64X1+CT:S;,]U8Y,>EI)R$OQ*>A*/0,<
MNJ" WG")%'!))L(6F81\DS(8H3S%H*V8HJ2#L6,=TS'$"O*) Y"/CLD0/B.Y
M&4?J2%$[BDGSO][]^/;LQ>N3/25)]$DA8%,K8+GQ+ <[ARC?9)@C) 9HAAHP
M2RF.Q8/0LBS)DI WJ$)[6#:[YK:/TZ1:@+=%@-^TS  5I]<G',3,,\:4JK6V
MDFBZR0!L($.L5!=G*9-N-+ODIC87W(\F!I4A64O#/3"1IV-VXU7_D9^,_O#?
M>_1L$_=L-((<0G%5C$:S8.QN:_8N<ZZ6::<P=Z4A/P4./"N2"Q^R/$8SGR2\
MD1Q),(;LMC'WX8471^*-RW[(? BQN&!'5)RKX/[')D?%/ABQ8_.U_ DS.[/D
M"Z?Y,8E2INBHE([ZNV$B[ME1A=1*Y:5['71QR,F(7#0QBI-)B_$R$#X=CKL-
M/'IXR+3IQU8XQV"Q&@!/_DSTLX"19REZ0?(X+T0(/A-2MI>OST;*4.] [\IT
M%L^PV>F?)2?FZI*6(\Z.;-DM<]$FK8O2:32K$Q4877=<7-)Y5!?3);=I_; 4
MEMFI432'U7VMI,/^]5D]X2Q/YQX:LV+B\)W??2E>E$L=9ZVHE[((V-'N-P8F
M=430.K!$#QYA<%L]1D8A[J]S$K2.KR#E?MZ4G ^=Q7/:CBT"[[1:>0L8D3%E
M"RTP&>F,8>]TW9&B#^DUAORC'BX7G+?<*2M#ZP*6/?]CE3)O%O-].I9NF1%_
M)5U2-URP2\#M;["F9V\P*IOQH8W<N(5P9B\51QN6*Q_96(6NXN3/.?:<^5 9
M2#"&ZNTF925GPJ)C2"87;YA3B27-E.X=(]W!/'58NQU?3.>8\+R7[%T%IYI*
MI?)QN'I<#("#8<EVEFS OKW0,,B7[NLXI>$H/:]B>J7D"U1OB.'CP)1C"8G.
M\2D)MCSR;UA\P^+#XFO%P,*=%5 Z6_+3^(/)>DE2*L@> ;+>R][0-GD6#,P:
M]=#/,[!;#XMQ6(RWM8<[.FN--2C D33O1Z''7NVF;H&L6>D _5-NK;MTB>49
M!XB1<31[T2/P2219)L"PI*V1Y'%'BAM#F1@"\/DT6=268W=!PLUT>UR)MJB_
M$]C[Q+PE/;I-KX.1>%A&HI7&!75+ L"V,,VOLBIL$\YY"XCBOOU?%_7WB%V<
MED,K8'FT3=/U"?KCPX9_2!N^U<3,&SZD2^ T;UY0U,[E&SKOI2C%0?FKW[50
MLBC3.1+E8>YY6&?#.J-;OO!5#5?N\.3%;A520+X_O_C7![:=L2XKS@%)K>(L
M_3TDWE1R+>DIJA(*CIPZ4ZN*>;3;O")GM>[DB$ ,P.4ZI.,3I@ "TR>YQWA<
M;ER:D:L\K.%A#;<K@XZ:D;$>'Q=<AE^IQ=DRHR@)GL%CR6JN+D.TH:;EM)L\
MV@8W@;VJ37:/[42?D+\8F@:&IH'/>-*#H6G@GVD:& [(AW5 GN3N:,2A%O Q
MA<>=@XRD^64Z2<UC2[*8'IB^Z5C*K^&6T<3$3#967Y9%0V')=9)\B'*T:S#W
M@CN4\>D9MV@D0BAY7?!GJU$GH1:P14+#+IT.#MZP?H5NR.M+5DU9%A>]+-NB
MA )A1F1>T:,)).Q_8AQI4<7">STPJD@TOJ\8JQJDV1QEH6??[O+M!1DW90J9
M\E7R@LX:'W@S(4%11J]_/EM9\VU$IC:K3AQE4@N38O0,G] <O"5'UQ>5:WLP
MVDA"N-B676>6.I\)$BBQ8MHA1^%A2)U%*BC!DLFXEAI5@^^Z*5L(6%K*1:EJ
M%H:U,R%LO8V$]-#3H+LO+0FM-#QTHLBGF=A/"6I'T:213FE<DO6;N9 O\M8B
MYHT#9G4[ 3(MR8/8>O:$H#ABY"*P ')[J+UVREK2^F?4)3 9\7GBMY-HSP9[
MZ2PL\P13$J8_T->07Q2:.UZ@IT"3)-)>Z+?P:M^,0A&J! !F,BP9%XWV=_</
M=:0Y(^&GZ2*6A EYMND\"D1@XEE!\[CV.D=K&5'7;XN])YLIUUV+"SXILMF7
MV"I0-7Z?Q/._$@=_X2$];##E-2#%64SFX%+V[_[NWA->YOR7:3$621WN['@-
M LD\^B$IZ8H7ER"!_9\DSL?/Z<B=%K3GGA?EG$YG^G51738QW1ZM$)<X*>F*
M)_FLI#'1I[-D*0K7I@P GU,@W2 SI7VJ%$"N;9?/:[9"\02T*=BOM)NZ]QE%
M9Y<[ISLC>!/X]*NXA(/[@]?^?NF^SV?\JQ]>XJE_*Z!+_G,!B/DKZ!1-+YLJ
MJ2'N=EKN^.O# ]M[_'TE8D1J-BL:5#Y#DP30?%,@[\2HMIP/]WBQ4P&?>7;O
M 4V\H0V TR[S>NT0U>$E2><>O1WK/$H6;1G#+A$J^XFMHZB?.#/@<*Y&HADM
M&"0<K2'!LY&<5'+F<+\ -S,96"&\DL!,T*/3833A\_-C,FW87Y;6GNHR7<BS
M*:V>:Y.!ZSS]0'MN6FA743%?P&]QXV00JD)6)FD!J0']$//X>AC$6[K\2;J,
M2[<AZ=2N6/:'+_*,G('SZ$<WM#=P)=!0T'D'?O"F'>+&8TU*^[OD_"C?^ Q
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M>N\<C#[1BXXOW@ J^^<-\4*(6ZB6.5V)^0%6N$B"GCXVB^+'/(LK749]Z4R
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M.L[.QUEZGN#3J&30W'+#JC^4!:$@^O:XCAR2+5IJNN(U9V7S=M^T04.F0B0
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M@0M4TDI/@1Z"8E:E'C6#1I80ZFU@\,&E]W?W#W6D.6-&INE"R09HXZ=S_U@
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MT.Z:<94%VY&RBMHD$YT]N7KN.#8U#S#0DX1'@]6BC/">XT)NT4)EM^@>1A'
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M'5O*&_7>WCB[5:<!1^*YJGI^G<1O]]^.!9*0P6X6HR-$G2W*2Z=%+9G*9TH
M>MHC^PQONJZ3^:)601G<05),TV+!/8QM"F9X;^SY*S,-R&"FHL3M6& "P9D.
M]4QK"&VM&V%2R=(/,)(34%_&6<-^"(YL3C^-C02>3O19,B[.SUNHAKK3?,EC
M:C5>ZF$\$K?!S/P*H_.:B=);L-).4K;.@T!39QOMX/W?(9[Y.GQC@>?6>J?6
M@]C>-V& '5Q$>R#]+F&AX91)EHOH0UY,/XQ![/I9?<9R4?%N+>%:!2B"->M6
MD 1APH3.WTH8VIRP:NN[.]#TSN(IL[>V]5HM+&+NVSYO1L]^#6T<1SX"<'6;
M ]KSSD2BGM+^7IS.*VE)KH7SD&>$N]>X C(I9LNHFL;GYP#>!V*NS<+8<$W1
M=5:PCP;VWEEZ,1>J)J/ZMK2NR0W@UCU/MQ,];XV/PHJ"74%RVXI,0[*^E\$W
M*U'HD8"A"&58E!F72723 '9/<4E<U6 (K^""1G.*/:<-)YG8@**W-%AB-*8Y
MC8KE3=$11S/"W:9BU'X?!VN))KN(1/1[_:49:C)!=<"/VJB7@XI"D!'OY5+F
M(MFTD:(%@J?\MB6[1=9PP)$,.)([XDB.!QS)/XPC^2R/Y?:1;*/+\INO\<Z]
M#$#5\CW8;CL)W[#\Y3G988'I@,B*:RR9K;2W ^AWVT&_7Z3+Y.9D,8=G@3ZI
M\S!8Q1S>TQJLS8 J'Q;8Z@(SX1!=:.N5OY#0+"5<T.SG!%3@].LV$>.PRH95
MA@X%.EW3&<15*$Q2S9D5Q14FT <GRK!HAD7S?2C.RJ(":)@JFIS+A VHH[QD
M&)921:=>J-WS&<K<#[FT\:8IHQ/+.)'YAEP-0(0\?T'=XSM($=$FE@SU,\F"
MK*A6_BJLZ<AAO'U],E0^MC9(8B28!VZ[NJBK<K31)%+S:&E^A:IY2'&5P"MT
M=)%%IO9#XFDH86)%9"_-_;*9TV(966K-51!H^'!)4FBQSH!Z8+H^ACUP6A@>
MKH@;,@4^F/8U!5S!G L@Q=WY)WI?XQ-73]F)WJD\I&@,ND<3#30> "T!Y$23
MZ-N31^P>H;:LOWGQR(L^=P9^'C<9C)(?/\,L/6G8:E)[%8"\13F^![0S8 T9
M9"0R/!/5ZNZ@&CE=["MSK-:PN#27]YKK'06RMT="]H:J!@ 'G"O6Q2(;1X6*
M^MZ_I/NE@*=L=QZ6KC"G*=RJJN9*'P;6 _)K%LAUFR*> ZZW!!EXT3)6H]7#
M[!06:"@B-;>B*AHHBE9=G4Z6</6QQ:Q,-?^O]'.TK2^92B?EPR*JF.>1)H,?
M1:2+^Q6M6\*IC("JV_#S8?-L./?6DN_%TG=:V('FKY/E''$Y*:")%$ R7?D\
M*4MO\4,)8EIS,9;6D)L;XI,[QR=W=#+7-U@45RS"#6'6E(80=*M),PP;L X8
M4C$B+ITG\CF =@20BTXD\]T&I<I_2[R_%\MAP&@-Y]J%"(_0;-,3UD49K_H\
M@A#V5\J96VY%!IQ9YJJHJ<(9BV^#CJC2*FM#&6B^CT'NI I&X"2E!<GKP#DP
M5+DRW]EIQZYBF*3%ZK9J.J,& 3:>\BJPWU:JXCO"<4]K1H#,OKO+]'I94==9
M3$V<T%?.TXR.Y2%/,MBA6^Q0C_E1' IR),RYGRFVNP]Q4&W2T/RP]#L2^&+=
MDUW/FC\S+=.%2E>#);F8+NNDW?+I6A9AA))^[G9#U73]ZEC,AF6WG:_/AJM:
M<S%G'%HP8*-XMV;,$.TOW,P<$+"?; W6G\%P/9B$P23<G$L%SEW@2@'"RM!5
M04PEDAV=A,XFS4%O9PMWK?%&JCT06V)!#%^9TUW'3F6H[+"RI1"UT <3>B:V
ME_,$86I:S6UB_%09XC"M@GD*H&HSZ6CJ<LICXHHY#1#/;5(L'".)#,+3W>:5
MDP-606)R4$Z;4CR*5?T1,E>N09.5DZL4 1>Y+-)'I1*VD)A%5L[0<YS[I5^,
M)]R,'O8OK=@MLYOL_:"^W+]X^('Y=I8-6[2ZCLV(S^1A(,512#N(B7&H'=;D
MV&#1!HO6;P[^36X*';;P<.HRG30.'UPV@3(#\Q5(&OIC.J<;V@K<I"7[=PY$
MOMHM362DB?8K,Q84!90 7#WB0$AW!0S(+ 4XM1H%B"5+8"LE=ZOI,":#UC-;
M04N!TDSXR]'O7_]\)L01GC "&<D4=. (Q7A09C0"$W%;:AO73ICU$&]G)"X/
M[EG2?6(V%#(H&%XG8]645RD9$A<9P9!C>I!'Y)<L&C7!K VV8[ =_1OP1R>Z
M-$MXY2_5W8DY'J=P_>7KLTUF%K5)FA/SZ3E%(,SM$$_(+XE%JLTVDF/09W<D
M["L,>IJ""$E%&T0 QD[C /K3B_AQ-0F:EDI3%DF'?\&U$15^4B5"&[O(C=9Y
MX36VJQYO@5N5TLNBX,;+0!VK9;C2O&W@F?__%90'0,ITP'$?0YNY4T$J=S$Y
M&-);S+/T$PT7^>?H'1<8:# _S2<_,V.S_6E$3\CB!XB&G?:!='"JV:3YB/CU
MC[2:(Q,SG;(C63@X'CF%9+O8:,_X2S5YE3G<)[:<2 3RX13.G!GTG>BL3!RN
MK_+\#VR.<3'WK>"J02%&6SYFR#XEXUFR2+@*X=J[94(D\ QZ%*:7R1R3+DYV
M/*,[(,&'Z%6.!=20%TU9->S0!1T-P> =W:8]HCP^EV;=*_CVIU_?C_<>"5>8
M/LO.UX?5^-((!9O#SV_$W>KRT:=/P#NF,%]:(GC1LPU89 8R)LB7B[-32^=.
MF'EVJS$OYDH^\Z#+=&P<_(RAULIMI_,%F3N.RX*IYNE5U[2<RZ%$#HYR^ZEC
M6G!YV<7*;!]$&H:,3#GGZ)*NX,J JWE)X<K006D+6<?=[?%L^=9C^C\&#RXX
M8;Y-/%4T'');BPVZ$K93.O@3OQ-:YIK[AT-;[F9_BVKJ0]/9T'1VQZ:SQT/3
MV38WG7V5!^J/='*E%!-\PMF%>5#W.UOZ;NH@3 AJP&N;+VXI4SELE^9WPL-\
M"\_&#2;B8M'Y$/R:\@!((B!X(R73 N5<TD\ZQ&7,HJ'L9:BGIL9D!O]H)_HI
MO6**,<@R"R.:OCG@\<99>L[I>L[[9T5^@2K&)6(E3@RBK2OM%#%]QBU--!57
M-4P<A+!?+H%A(NI-RBO6,)%4&C^/=\OHISI5#RIP]1 @>AJ/XB,%W_72< >A
MSZWN Z: AD0N'B /?6[#*$A,,D'.-.&T!.+T+7(IOA9S]45T1#Y]B[[ %JW+
MN_JO?ZOJB2>GL"*9)(,VF;=#14VV5J8 ^4BT,KF]&/'2C?FPZX35OG*<'4*R
ML77V^NZ+X4O,K[SF:LD _Y&82(7P8]Z,$U(^QK5.&"OYL<6:Y A;?U=BVAWP
MP"NNS9*1TW@AP"Y-N,'4O3G[\>T)2%]J1,,>!>:C:0]U774" MYQ?K_& ^Y@
M<RM+>E@ [6A67OUP<FQ8\O#0) ^O$[%:1H 39&=<29^=FG6\\L+Q)!T\7;(S
MO&LVZHY>R:.[N%1@?/1D6']^^<QT$'WF'+^D_5E.#.PFFQU,DYP7)\<)GMT?
M32SP3?;4^N /$P8RS%(AN"1;8(BL[=N@F\PV25T +&"M+)V#T^814U:GG-85
M ]?"ZT&WX.>?#5>C+\ZU<#E;O86[_[Y%\IL6('JR3H#H29^&\N&!%R#:WS\:
M!(B^,@&BM?DZL>!F_;ELZ&5-1E+9/I=V.C;]Y%ZGKT[^C_RP]^]_-2]AK%\\
M?SWRG4/D<C4(W@^?C"_)I:O(TE>UOQ2,^E4:1_$<#)9%/JZ2/Q[$9.]'9V:9
MO4V6.2>K/2ORHAS1CTDR;A8UNGII9E^^/KMU9O73?WU.M]II^O13VOE0 1]U
MZ[CLRO (TH-=;W. PT94R_?=@;#Y+W!\W6; GZXSX$_[#/C^<6# #P[O:,#O
MV0(YVJ&O7]#P4CC7M@0 NSIX^OV4-:+.Q]KXZG(*DRHIV5:2Y^3[]=GQ"K;U
MPPUB^K9<)>W&%?F6%H ;O)"C\C!&X5;E%(E-BA,48./C(GIET>NB[\5<0X[%
M7LXMCC 8NY*J$O&)O=U=Z:W#72L5HD!:@R.P8&0ZJHLXI<=B/J8+(4PQO'=T
M(AP[T-C@8^X"5*^)<)"ZL6EBA'/!!BYO3P'S-^!N.T-A=BC,?AE'[\E0F!T*
MLU^:0"HH;5FQ,<RPSE-CF[!#X3OP/HOQ%6B9*9>R=B/ROY]2Y(I#7HR(F9TA
MYI$MK1K'K<KG:0()H>M$/A&OLFN\?O?3^"S]7:Y&YAM=TO:[%1(.K18GVD2^
MFO(.7,:Q9\$Y072%;G4YE>0<JZ*]8]$N>VQYOE"8R4J@90]^J([VH_G%OSY<
M*&F)7+;KT3)A5\CBT99S.=HUS2;N=JP4'(8#EYNI9[3S.;88:V9(:Y[\=*U9
MDW< ?'#0 Q64T(W^),TOTTEJHTFRN*KQ:;=:.,=9T5$DFE"U$J*@W!OE( 1B
M,:D92\Q);T-]7?"?JU'@:6CKD[6+ZQKL'J/;9H7NNO^V+:FTO[LF)K$_M&*2
M@R=A3/)T?XA)X. >D\FP^E5G5VM@XDI7WD3I7T*K2+NL@U3Q>5YLHXUG!Q[,
MIMA;MRGV^@+UX_U@4QP>#YL"F^+Q3O0N/,TZ[?K?=D^WYM6CUJGVN/]$NZ',
M,=L[.#QX,@CN;A:"<O;7D77_,*#GKU4(_SD\CW?-DU5T91<WLVG$3T5;7^2"
M0C#=XC(NY_%4VK$,.^<U8SS,QUH/R2&FWT7/CA[_\/)?QUT?5BE:R)JK]&>C
MN?G3<B?ZG^3\/'J?3#_06''8[CW^OHJR>((7!9( <LO?U3O1RZ))*^C^HI<+
M,_UN>ED4?!B_0G$[93DQNIY>RGH0%VB=2YD B<*,I*RM0Q>/M72R-!R@A,/O
M9PJ4 O'M\4H Z&DS+FY1_7?(> T9KSMFO)X.&:\AX_6E.7(JZ+?5-W1,>L2B
MUX)TB,450"K<A;A<JCR<_(+/)60MHE]^&.\^?GK(8*K;C^E1/R8HQ()I'8;^
M>WSP#<X8<HNC<T:8FQ:/,C-W$U N=CR0Y!-&NQ.]EIZ)5Z&T6[L0 SAF'NT]
M<2+A[0)),(1N&J<-$1/)3/KS9;J@\[V^QA'?]XC=Q%?(@AC]&Z)\,C:[A?#@
MKEX(23>;_FO&FDZ949"[SL6UX*YW+^&XY6T@&VZ17"IO,Z\VU,T6(E+-?BC^
M<,&]'.BRN+8F"_K[OBPWIJ$*BGNQ[*DQ?TPNS]A"Y!7A\2WPFOA6G"*DK930
M)^(/20P3+WZ=J+]VKB($+<EL$*@:N%6V0J3#)0-E31\=]J)\.9*33^PKNYDW
M?"-N9*O3NN&O/=YG:L>ZJ#WS2(?I9"#V&18?!OJ2*6 61;:<)^6JSAELY%JY
M8+'JQGI"MAD'_?Z3$5TNS1TK3I>\4PA>A'K&,=YH,8@<G;A415ECZ$S6JAD]
M(*\4:0'?\>B9#?EPQ=$)IC&OD. .4L'=J^K/WGA?LJ3XPO[XD'\8,?TA@W:2
M;+D3_2R-/\R^6OF6R-;-#\?'^EU<B>MV4SKNLW#5*%N-<R]Q4G?<62&:LQX?
MJR/&TVDS#Y@T6Q\*/83.Z;[.4_?4:[1"T6N!EL^);[<PVB9KM9BU19'"IE!!
M$O:UA4J#!O_<E"R*6; .PVI?J_M^JTEM3:BQ16F:![39WG1?ADM.6@X2*N"8
M ++_?3UJ;!>+,J5'L[ZZ=J(R;Y-.7267Z925L>>+,N6/9.DBG56":]"5QB40
M%4CG.[YY?7;R_OW;-W=<)'3K&L^G\UTUBZ0,IN]H9W?_Z.ZIA,>'WV]N\>ZP
M")=J''%?]32>";^K@$84>.U? 2MLQ& >@Z;&-!$:7/S2$-F398<]?D5^3^A@
M^S@FU43.)PQ]8!MI=B*(]M<1D;6HOOK(*3TSV*KC.%HG%CC8E@TU ,8KEGXI
M*8?Y GQP6*/]V0K^XE4*_%!GU7S+)P]? -4*_.Z1,"6OKC+'&<=,A$(<QY_%
MO_8?"?.?2VRU2BGL;""12C[#-$FOM.@B::-]GS8*4BO<LY! >T)E.$ DG:R8
MOJH-HQ)<;@ *)J>R,]" ^D.>&\<Y/3JR/8D''M-=*9;@KQT??=-V=AA_K-/.
MKM+^4Q]ZF0!B>U9WHC.FD;2'YBU;*'4TN)B1^0(1O0O/QN*I69LRW>7X^!N^
MNG^@)T?^-_NCUI".],.K0QDQ=)I+9L[!9OH_X04;![Q@YVC*^?J=B:\SB[YI
M<,K^.G#*_JW@E/TG SB%K<].](SW7EHINK$_+>WR*_2G-N\K;-F**;4D]ZMG
M!VQ([F:PMRD1?8?>WOM"-?JZEPWP0<)2-V?4_[EDC/00,;%GJPO*"DY?E@S4
MDB/T $D#.0Y3]"*WR96GX-"L<JGD13[^Z>694%%)/,$CX-S&/\\L:DT$EN 0
M2#ZF*DMJG= J$0J)3%R@O\:U>=/B/-XY/GZ\-1['5P.'W2:SRY+:F5.111KT
M80>7@09H-ZG8V7LK:2F1MFU!YEBD>EJF$R3X8?*\B6$(FK<SJF,HK\(8 3$*
M8VWOE/M#IG(Q1EX D+LC6ZKHC&9300TC1-^><&: L T0MCL21NP.$+9_&,)V
MSVS^[:BQG>B'9!K#I*^#"9MAG16)J+4J;=0JK1B;?V0IVTBNGN*>PU!W[7H@
MF30M9B):=*&.W:K-=U5!?Q4[9[2DUW?"N22>H8"Z2'!U%7;^GTGYK_^]N8-D
MZY)%!^N210<]R:+#HR=!LFCWZ9 L0K+HZ4[THTGT(7"Y,KJ1F#Q/U)!9G&NZ
MS N_U+$WLF8J?E+ 6:/);.4Q?KB.[6]A2:+M1_:72KK% DNANQEOFQXGU=;;
MRQWM[UH/-R,;#(-@MV:F1KWI/H-C/04YA<WZ$LE4'1QR!0(^\A5C#_8.OK'J
M[F4*Z3>V8L@'<EF(QO/RO7*/C$3=NE)9[S5%O9'4GEOW%[@EW<9/"B+XN'0)
M2"VHJ*E%*M*7&DR@5WK1A:]%#.\Z0;U/*W:VLIHCEO0,B2]C)O^5JDZG["HD
MXQW5J]5E,&0 -G>,'*X[1@[[:@ZM8^3XKM2#6VW8/OL8V=]=5W,(PFSGN'W9
M2L+#.U_>](#5:&(AF5D6%R*%Q;G(7WX8[QT^/>34K0H4IVW<UYKI-H6V'>E0
M".OG6C@/Z4&DI"P8R9#]RM,#CH\\E&_O<+QG/Y[7BGMQ'.I\J2Y4L(OZ6W/N
M[7W"B;?G\S+K3[X6C_'A;N<8W#_^IH7LPU %6^CY0G""MYO '3U(]X@R8?@T
MRQH]3AAY$&P<%;[WI.%E454:(>@<M5$:XH$]]#-E2'0-B:X[)KKVAD37?4AT
MW>;Y':WS_([Z/+^G(>GTD7I^&UB=7VD::*M]K<]W>?=\YH3.YYM#=3ZEVSP/
MR.LA.F5(8&GMI \2@;%E1=\[:H]_!OB&QAF]JY-%]5<V\=\^S >,>PYY?M8)
M78-"-[\H-/=)=^<4%#8]._^M7O$+1%_@93E/,_T"LZD( 0RZE;BW>'?_D).K
MN73[N+C(@@ 5O5KM&U+-;8K>TFFZT$"/3KYT[C]-SLJL:.KU]S[:1LCM]D'Q
M[KCO;FK?.8O+#VE>%9[*YU1!36<4T)?Q_+OH+2VOE)L-S^+ZLA".G5_C,J5W
MO@DS,AB-OK2_U!K97@B0KEB4:5*SIGF7:D.DP68SD"+QCLR2!H1,XQ)2.&1.
M$OH[+0LL@WU6RGGY]NTO^SM>- EV9NW2$6V=TY%I9W#>@6R6,CSI]E_(^E*R
M E%#H[$AHQ34, TWTZMP5F"LM#9Q(UN85[HP1U&5TAS&I2'CF A7;SJ8FTVX
MKVL7S#_ *3'X'I_B>YQBC\:*,OTX$J3K>3Q%P4TP^A<L$WSEL:^\?>E;#)R8
M<0(5M$ CM &R:4&^$-W)Q2(&KQL]]C3*DZ:$2B73EU1U21M;RW4,\BUC<#!
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M% [ MBOAQPR-FE?%"M^&,&>H:IA7& Y"[S!D8[5!<&@R44617YB,\3ZG0%:
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M&%TG\8><+@*M6'KW2]Z0S%B5U2:;-Z,X]5*HO.;Q?XI2PST,RS''@ 2+\[I
MIJ:E*E[':0:/75FBZDLE?CS'J$!/10^%%(TIV<$UH-^"D<6$K:-J3D$Y^*P0
M6(&G##0M=E=ALH&-FB1+\ GM[<IUO7#?)&%],PH%*M&4$$I*-I/JWZABT?/3
M$T<]\^.KDU&D\Q[H1C)%T;E*F97)K2*$%6C>LAF]U(1IEL@-8CE$(Q6K$!\O
MA3<H9;HQ?)2F/)Y.DX4G'?.\7U#JC<'-E@?,9/M'S +6>B']A%_O3770>YNJ
M/\B6GZ[0TB'$2!QSE..\25(A@ 5/D&HZVAN,(0C)&H7G3.::%=="%,4Z'H&
MJ>/KM*D:S/_ P#$<!+=[ZQV)MAX.X<1[:#EJ2_\B7V[<\>5,A6T:ER5KBS:
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MTI4P:IL\K\VW ?1HEO'[:4& YDF,S0!BZ\3K/-H:YS=;<4M_Y85SUHF<27,
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MQ9EB]EZ%5&ZQ*?(MO+%&L^WTR6+5/L,O[CW^Y(LE=0!VE.7J..KR=M;%BB?
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M]#:2^IQ9A'WNCO5,)W&';<M9V_8[<?T8++ON0^^ RS*&9--X(MA$5#?%)<"
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MA\3!EFFW ESOQO7^UNM&P/;X23O!Q-$#U4P3U%>*"\%%>4U-+O_78P_R^V5
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M"M^VC D+JD?*TEU/5OG!1'C#I,="M?CISWK#F)['^E#A.'4;/Z@*IX?),X2
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M?1/5FB^]'E3D[H4,]CI=O(CN1/+^><_3?@(>0K9DX^*H6^#\7%PTC&.FAX+
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M%'U,B='-0 :-1>^,POWJ,K^4D'E*>8LG(6=)NX0EAQV(TH1ZB 6S9?5XDY_
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M'WFVC655)!4]H\3#D>3<,"-B#-UJW,YADUC%8+ S'=B;[S[<WJ6!/Y:;? N
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MY4M$7N\@Y ;RB/EG=8XY$Y& ZCR*([,;@JV_GL;E95J.&:D&1MU_Y#,IWMI
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M3?2[T.*+@HBC[[)*]%^*=Y7>I:;>!I,2L/]#Y1ILIA.A !62]B'UL<T-'O#
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MX8^.E&]BR322O=(<2:VR".YY"D:T+ U-_S$42GCN'A\DA56Q[=:XOF3T;YN
MT%TN03NI)+(]A+.-G#U=CP.+$'YL\FJ0_#=>IE=.2+,I?R'R#X<Z]"!FB^ZI
MJ1^ZST[\!GHL4V#%RFTP/P=DPY;(-A/1YHWG)(+C_&C)Q1ED2H"IF1X-%5&[
MN6.[;-EYD,Z$G%N*3F3 N91U5WP&A+Y!:%#PR I]E<1#WWIT[V!L0QSIHFV
MI@^U8<Y/I^$^!LP6$!4:APX(=])$S/TI/D8@_M&>Q-/%2YG(=W>L^PREFZ%T
MOQ-*]WB&TLU0NC\B0=X5M7[4+/4S!GG&'>.)C ^*-.N&1,0:[\/D5;$*T5?D
MNEK)#$HA39DRV)&0<NB9^]\W!?D)#)BNN3_%Z.SN8FSV!28)?ZKA0<%_79S7
M],'#XB6S\K&9?^ZM\]M$B,S[.GWWAU[DG'S[#T 5.$CPG(D I3 RD,>C:ZI&
M( 4^2WLT$89A,<7U]C 1R00" GQ3?7BN[X<61T,![/L&M<Q!/2^A9QB.(,2
MF+KQ,WFL3CH]FR<,(!P4A-41!\2->R(-6)E? .0SSG"EC!1<?#OLE6.)F_IM
M6,#K=S+;D!&BQBELYP1#Q"D2"0,M--T%P"E7%=]94"O\#M9\TD:$JHO.3G$S
MC?K;F$B1LLPU+J#IO#Q9?7"FC20B>;D&A$HREX,0T$H_6C3"*H0DR'40KPJ
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MB$B9>B@5"[N&*A\FUG!,.Z>%BDDUGKQ/KRK'R(18&IAQJ3U&4Y81J3#LI7F
MQ("=^]=LJ%V_O[6(^ HVQCU)V?)W__W\BZO'?Z/,DFY]SVJ%=,S*""6X!7I;
M;GH&OE; N5)&W)RX9EV(YN>P4F$BF'V]KD+1:AJ,AK)0^M>*1WBZ#XR59/F'
M;MV3^5?T,S)C^"'%PZA$+@BE)%EVEQ0;O6RN&_IS!ZO#R5#I="B=L\"<BP2H
MO(=%T.^PK;BQWW\6=S.F\$)=R=D=#U).:>#"$4\Z7^P&.P&%8<+0M53Z-.#8
MA@U840?3M*M<];NL8]BAW7XK15+07':TKPHFO*Q]\*S"GPH_7+'\;FS)LR>!
MOFNK% 2+;<E0'RZH97#P"+"+O%[&IJ"#[A@S#4RE"+F;N\#0<\X9JVH9U3UJ
MP!=H)UU!3;8^30U8)#WU,UK(UXN7O"4#]Z%(EZ23E+#Q2WE0\IST^7*M\.I5
MN7ZU*M:O>"B^Z*4<6=!S87Y%\K+,9E^4>R6BHR=3=SS[P,55G-*QC"6J3ZEF
M9>,KJ&/*F$\&Q^(#;H,0^+&(:)!R+J,A+.7VG\_W=.ZTL;+)<P%!1!XHL<0M
M!0I65J/G=ULV:9Y8P?Q=?'29>G"&,/5W)P4RCHU$PUX1,LGD#Q9%N?'FZ=?A
M099,IKFF?:V2XGU;[F6((AUL4^QI>Z4?6)6%_UUV-TU[$Y+J*\5=/$1H S#
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M R#,/B?'_5O^<D&QUPSQG2&^;PGQ_7"&^/[.$-\_?@S]$O3/3*2!R"AFXEF
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MB#O,+T4053=-LTDQLOP5QR'/6$3>2)^390DCZ!*95!(G^(9%(EN%SQ>9O[Y
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M6%HWS=)]4\8?H!=#'^F#TTW,AF:8@ZF]8;8HX9!IXKS4KS<C-=,?_4+O!P
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M'(SNA2X=$O B?$_GI*?W\?7B[\V=4''D9S]412W1A(C>#W3$53_<56/ZFEN
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M#(]E90(^7UE+O5PC4=LQXA;0G;HC!;D<@>>[F>U"$E#%B&F;MB*K&G@%(,>
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M*SW_T-)KRBR3FQ ,]=A38'HT% *2MAQX\IUXV!#HDBRX&',#+)Y[79M,7M;
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M]Z]/DQV-S=*66*(WW A2/7AN^XSH-:^E.-6&\S34?&R8W5V)4DY9Z1AA.24
MH8S)1N#N3%)IX*?'M])"3QE$6GU ^,M'U4#ON>2(H5<(?;,-&,XR'AFZ^)O
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M5WM5C&'IZ@R&HBJX$>$1X$/2XPPTR.O:7HP *!4*?KUXYC]B9^$+%<;^Z:[
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M/FXI+XJ<G X< %PCUP(@T/L-VV_B142@KO@)D")%^JBQ5]'!(F[OV][:P(J
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M]ZD.3</-(<S<T\>;S6S%LQ4+^_HN."218443Z=OV;3 6/GA9,4==>R.J235
MR9$L[C-:#NS^#47?]4JGE@E\"$JG&_5./9?MRKY#@0[:H#N6H*IO0!@XX(3$
MF+M.I@#U""9,EI*TU:C(Z2-?M\DP<OUISU"R8G/+0,9-#'66$2++-0.AZ&-N
MHC.WG'@ )1S;T)[%_=V$=!IYD/^?O6]M<MNXTOXKK*W:JJ0*,[$4)T[656^5
M(CN.*G&DDN7U9Y!HDHA(@,%E1MQ?__:Y]NE&@S.2+V(L?-EU-"0(-$Z?/I?G
M/ ^<87N?.0& CWK@T\LN^WG9S_XGP4Q1$^@&]L-9*T\2_ O2":$,YPET/B7
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M/__-\U<J8YD.U,@Y&*&&#!G/;":8CO-0:!SRS0M@DB*4'*#\@'4($S]3\XZ
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M%*5DD5H4% BM$)8_/NX"C1^9FQ"4TMG3=CMO=D2JZ\]S@Z/%-2&UPC5$.AC
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M99%]NW.-X(-<>)G^9:SK-FOLUD;49<"M^X.$@W2J##8]O;PP**FXX[%GB*9
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M"8=-J#V(?T!@(@WX0VWC,-:4 XR--V0H]T"J<KMZT!WKG2*@$/AO^D-[3RP
M4&II'/PJ-/4A9P9;K;IQUP=7*((15B&"/D*4*_0:*$/Y'8$,Z$/>M,/%,VLG
M3WH_+U$=!*8GB)#O;[^[M5<%UL)^/PZK"DAI>NA#0&F)C /* )S!VU1$;X0@
M.'T@KT(#VI/2ZG;L#MC,V'3\JF"%E9V+6:G:4_A[>.-7E%A\RD'+#SDR2,T.
MI_2/C$TP>S5RTJ>NOBLWS, $#3%M&)$.>$14B26HH/+>K@^!0U/NP*3725'C
MF,H!+['!E<<&6'MAC'CI#:+S1]6_1ZA2D_'TB! @0JUL&SC?,\:#G(:8)%"V
M+4LBYVI8(I?*SEB.F2#B D;1F'>6ZHV\J_!,6:-7>V\9OFAN!0_43,V:&K/(
MGB5MABFOW^6=]< =PNZF!2@@("EL3YS9Y@:GQ5X*:])FN^G&SY .1LLN]TO[
M?OJ5%+@7J172ES"8FWP1T;-' E#*3</G;U=?9TF*S;N4QDW,04N+!^<[?@7L
MM6Y&X4T#V *P5-ZN5B^Y[<!Q;?(6L4<1]RCQK'1-B?$L($U\E(F8TN153I[D
MS>5WALB'IM]2]J1P4H@H."S35\BHA-I[@W)0<CBX_:]'X/?S/N!K_\3ML=ZL
MGODW@4G;UU\_H]7G1_R[_V+5'O%OW_^]@%4E^PK\E-]0]V?U%?S>J_ \K]4F
MZ<K?K[[YZM7KP,/W_=\?^U7X)'X58R._!.V.0+=:Y=:+U\"?Z5>'&UT<OL#?
M*%PR';8(>=NPZ?B-!"X->"'=Z@5 FI^L<$0K5#U^/N_Y^*/D+^P!,4MX^N4W
M(>0+2\=_>V5,+D)3?;PH#!?TR9>WJ^=)\XO>@>#J.58//8CW=(0U)C3UKM7V
M+42^-XQ'(^9,RBZ8Q9 C'-LI/8W893L=D,DK&,_10>98]T>,^%V#_C3T\@I.
M>&1(H24$"R!L"A[0RC5L%%>?H68LY Z15&Q*:8C.7%CU+1]W-HFP",X V<F
M9WA5,W";)8R_BJ@2#@PF:FVXR.( 38 !@+?2QM_H+DKH8 K<FPYAZ@9W\,_H
MT&:]P3U[4>@<!< )_%42=K95+]*)BM$*,#9F3^VQQL&-_P8IX?V)ACSP9)B
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M" %#&SLHUP2$OG^:H6T//>UALD,D5I>@Q/*YRSY0H]1O"^#GZ!S@^6MB^(7
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M#_B&JD+1F*RZ#!_&2=,S:X.Y=WX_=&L\44L6+'SDV^!10H$M$P4UZ(>2\%A
MNII>+4C9^H#@>$!T*0K;^B5@) A 8'H>>*-*NN BXPUR/:?;,E:RC)5\X%C)
MY\M8R3)6\F,LB)Q_<OJC F<[)/2K+ M'AZ4_%@=73<]+G[6,//XI )T<V+]"
M_C6:XX_/IC<S5&7XLU8E-],;94UQT%$E;CAF2@LCB6OAGE(N5SNP6'7E?>Z^
M"5P4W:8J6<Q1JS'TLJI1;0;R/+^JP$4#G0@:QJ6\F3F4WN/,+$S3EA/+1QZV
M:T?<-OXPH6/>!^@*Y[S&?._7'_@3U)=1H6+? L4,4[+QA$1CZOI(U56"7$EN
MEINFD?,,@!Q2>\,$F9=Q$$IOL\FJD7<2IG'G%6NI!!D12.NLNH^AYV3&T7QX
MG#%.F*<F81I&M2KG9S'9'%%TG9OR#O028NT:N2-I<CK] ;JV0,;@LRS$^Q*&
M&ASAX\GC'IL&_+RD<F^8Z"5D*BQ*G&./$[ZIW*U3:'_Q3K_YQZMBCL#MP>\^
M?Y5(6K\OF]PL:]PO30\7W\@EGCA&]G/!!0_?G/(IUU[-OB(*&WPD&<^L1)IR
M)J6J8 (,R :0P1$>%1U^T'R6IQ\>8S'$5JJ<@Y":<:G'D@#$=T+B5C&!9&Y0
M0AP1!Q-5Z_\VY7V418F9'_D-6WVQO+@X;V<LW5IA = X[@=+:YKA1SZU_3 Q
M/R(@=IE:!S!N!%7"&[SC%GX/7B#TJ8K5<_[.&UHI_VE2XH,;X!N!,&'KG1G2
M6X8"/1)QX%A?*"YOR4VR5UN=QC4 $\1BZ[N:768'Y0S8X_Z%\$RE#LS1G,,%
ME=R+RKA%OH@LOHJ*)=<88GRZ)>7IAN1HDLF'::Y&)FW<? D/CZ"8,GSVL+9$
M*2+?41$RI_>FSCR,"EK 6S&SR9GZX3)Z=YV1[0^<*X(G/[O!FE(U9TCH.>WK
M]R;C@J$D\VSD"1%I$\J9,U2&08_C TU?])T_T-KU&0RIN7D 9))LX8H.GTY8
M)0T.:$L%<I:4M.1]0O,G*Y$A2>,YNW2G,9%^M-MT)6&"3JZ%5Q@G*40^#/#'
MZ4E7-)[54Y%YX6W'!Z\/!PS\@!>RWVLEMX0)2DB-MZN[(%7@GQEU$V>]$1<J
M H_\0\LLG5T>E6\XCL2@!6,4^*&P-H]X[S8EP65,;H_"K&!22G6]UMH*Q9T=
M3"E3KNY_UL<7&_Y?^(TU+D/48Y-&1:"S=1R-!QXF2 U#;GGR%X5-\MKYY&+C
MA+ZK5.KXY)T+4QY);(J4"$6&E@Z"AF)BIDV0%2[)C&#!A4=0ZTF!> Z?8UNC
MI>M]]0EC'M1K=!$A BEW%"S+K&G;8%**$CF7[9&"=K^E.NAJ$!VGI2IC5\9O
MCBI#Q/:+!U179"FOHG_MQWJ0.-RL/_P,+ EW/%1'GJF"\1%0W&4S4&9/]* #
M&CZHX70*.A1YV&0CYUPB%[" ,ZT(:6<@$-L:IH8P>NM?T.;@ +.QJ4F!O#PA
MU4-?Q*]4+E1%E+&!*E1N#V-J^Q97*HL<*0T=@2T-V<C\J=;B7;2#3\/FQ'-8
MRG3ZPG^>.&(I?_VX^?RUG3"G['I[MB=P]P!OG'4L6?K*^%H@6LXNAS-@_VMC
M3YO7_$AK>7/IG"6=;CA$@),WSZ%[N_J.W4*?AA)=I#@V@A8)_"Y6O@P_3&RT
M<27 %DU41QZW\.:;;U]-!7Z1;G#70CVCQ=%Z?^%:N]G"6>,#"-@(. 'O@*I7
MD^3U>8XJ& H0T A*ZQ?FXRHMH'DYY9FTS4/8UNN"H8>S+RM7(<'P(2H\$L)?
MHA$J95KA>2(?-$-5\"]!+1W[_)&PVFS_0-@MX0<ZJV4AQ=8X7##GD.+H@KOS
M=MO"5A%S1(!7./>W^A4J\O961L[_<</#$N*WLPZ/_E%^$29NW&%;Q.=;B(_C
M!D]Y*I-2"W=%"B(Z"%(OC6'SIOIUDR(NE3\YST_AX[2VR52S_9(*.^0SFANB
M]0GB=2FOI18@PN,_ZA (<2G9-5,]8=W7VYI>WP0=X=^/Y6$[4ETE $:DJ 5K
MIR 2C2YK_U\.(Q?=,/R37'6BNG/C=D3<+ KB0@;%'VX;L;?-'J3?C(Z2(SKB
MH)VEXX$4H]1D__ROL&+GV@$ZA>^L]YM]0+'-*"A3X;P":;\HTC0<Y^IB6@.E
M; /0%"A72/\<6;OTX\DX8E/2U!E06D&1#B<:8NTZ3&%@,0]A]@%Z@NPL1?9/
M'OM2%(A.GIYX"V<*5*TU:,Z3Z*DAH'N+N+N0EGJSYZ+Z6Q^OQT0MYZ@,&66;
M^;Q&#\KZWZ,C;I(@Z,A'E??,.ZSP61<J&9'V495;Y5RP\&&(W.(>*Z4<Z$#]
MK^WK=3W0N87OIR"T+0C%*'U,]DG1/TR\ =7>5UN_X:D4;RC*Q3T@DXRTA84@
MGP%4ENW65IGQ/J(%P/3)%J^%P-8[N@W@9LG<IE^T)QPN7>XQ'GYWEE+9OG5"
M**7G':?QY @#]4NBB L$^4CSPNT*(+V)[AVTCP9T![R]Q(>;*3;\MCU8Q4?I
MN4W&@_Z<"?HX1#%Q!M%&CG5%?H::4.+(DBE1N%6\=::49TV$].9IFXOCBPO1
M!@PG-)>9[5(;WFM"GE+>C#7V]5CMW#5I6"X@L 4$]H$@L#\L(+!?& 3VR>3E
MV"U-SAT3\Q]:,!8?I*>,;(%^E \8/(C\8>XSUQXJXEBDOD-B43P]?H>EM*!"
M;-D[3\X'-%1ZC&9:X#0.Y3+I?3H^)YIXC$=GP.%PW6*_-Z>,]$ C(2>,P*%$
M&PY<"@YNTN  H]HVGW;0O5&A^F%XSTSZQ&=ARF0[&U!:*K^HQ>S>N<U(.B[P
MU4O%"*:/79^Q2X__@7(,M(9V(7S:7[4A@K_88KZB@_E3;A0S?"/%61(\9,/0
MECN0%T+9LG-?>XN3LI-]]Z?RC'$[A[$B%05I00@H8>O?O*TW;]?EYFWA(_)R
MI/)<Z<T"NX#^[^NN7KO.#F*8NX&9=XM.HQJ8]1H^*6YU(' *AR@8+*$NIXCA
M<")''PB _;_"'!,]<@77J_N]PQ@;YQ*1HHZF UW9P;S"TK&^UD/O;Q]JUQ"8
M^[/(GS%'R,6[]N"DT !8-N^*FRHHQOE;[KWIG>R9D_'.5I9*7'M4LN.#QU"?
M<B.8<%<RDQISP@M;;?P >&3( #6U]^Q&67=M61W.=K,FN_/Q^W&E"F( .?=;
MBQ<JJA(IOBBZ>[J2=4?#OFO'W=Y6%6$QBI4_6 ZR)Z&&L<;C#,XR0)YK,>PQ
M:_G:%D%( =NN@ZL0J$FM:< 0/O3\!X";:3NRY['I<@W\-D,]'/S?<,@_!*$_
MWTYXO%MXC8/@KV'U*0Q\K27+8O4/@ 73<@NN;47 MH]WCN,:/ODR:I<PL"[[
M6LP[1?UCPEM@E$E604X==NE5AB>_?O?\'517:8_1&S10S@M:=TGCZ.0V4'NR
MO3,C?RT53^."L-W A )!<V+NYTI2VYB<([8$>>E>":P,_#ZM_PRZABYL.N^N
M.:UJ!:0[_9G@Q*P$V&*S'^/1OV;5$\R; S8]EAW(G] !<*/\\6S#QE4]=-C@
M=^OF#N4^;(*-<JRWJV]JGY;1^>O3S&K82\,L'TI+6Q!JO;AUK&AUWJU")PI^
M'NPQ8*)7 88>">WF?S9\#T[:!)7.73*,)T0S-UWB$V[@C9G-LNOYP")BVH_8
M$P-K[N#905&/P%7^\2/V+8.>PDM6&/*M 6^ ![U@%C%B,LLR"914$6>,6K\F
M@S*YBCGJIIAO\SG-8Q@WSG490.A &T0'&$3+Q]Q@XG584E&ZIM_B7%]'X2#]
MCQJ0;$<?&O<M7D&":"?:D=)31=<[)BW:L.198I.?#*=>7#]0_=?O+-_L72@+
MPONQF@K^57O7A9UH,'I-R@C^(%JAR$N$^% >B]1,JTA2,6_U6(]R9)2GL=OL
M<3*#.ND%]?VP,C<2((Y3!Z+APS@0<$32%@TA_=??4P/L_1]%J(5HOQ'T!EM[
M4FJ(2B#H6/REOQZ!%="_K.\;^+%O':*?9.[% FV_O_W[[>HO_/5G?KL\_>S)
M9]"Y-F2".FF#ET^[[?8(0>=!9#!F?R];YV,\^BL)#(]EY5*K"B-%ETQ% 7 T
M/>1]*B [#J!K?[OZMNT<&&5A:_LL^*4_1,I=<IG!:,(C  ,*\/[H#9U?K!XD
M&O5Z.<C?GGSQ92\3Z/ZG]S5NG[V3"6Z>^-R"M /N#\MJ4TA?@<HP>:W[+<->
M*W]>5E#BN[1" D.(<&<F_%8/H/N52#A5QWW35ESLC^X:_YF@8C0T:P(\\2D7
M;\N4[B^/$4[V<U3(!#ZS@E\__ 7*62@U6598UP3&-I2/#Y$$^0!FZ+UF%_ )
M5N\G)1NH"KX*P*V7\93>-UU[/^S??_T^DK_\V9<OU^LK!YK/IPP!76K Q('0
M@V'8PHH@\C+YG=,S2U$1$VTT&,+Z?=/QD+N!MA@"["B5@0EP&9R83K$OO87K
M/*!_(%/:^Q6&DU48R%;CB9NLO6MJ@CY; \*_D!'Y8]/PN2&L'!.L UE69$P4
M@ KVD>K,W5V]<4EN>L1S1*<KI_>@\.-8Q81%%$DDS8S"4<4]Q\= ,'CJU1\R
MW'\_8J@XG@DRDU^6.\\.0S&0SPRI".F\3Q&ZL::EWT.I+H-XA6#ZWE$0O]'>
M>GA*_^OXY@*1ICV?(_D\^W/L3L+/T!KS( OZ!L-;&JWQH>0U4:2O_TG4/"W!
MAQ2I0@B\^><O__?%5S=/_@Q9D#N":4FU&Y3A*JOS@&$"W)P,YK$7C'4>\-E.
M6+R\:!&LE52H>6\GH^T&W]',X#J,GTS "I&CQ+%%V'=AP[$$LMA#97<&0A84
MLQM>A0R7\-KQ)@Z?A$=I?'A\(,#RA>'$ FYKH(%)>&%&M5'K(EBB1N!&9:Z7
M1K$2-S-V6>;W%(<;[E[X(%0!6$91!QBJ*@&6,\#BH(W7;:7L3<EC3X?T0MS<
M"QF%QKH*]C2%1<8&ZTA@C52X%EP4;0]]L_:U,F\P4V7>SRDJ6M3L9+"H%5ZK
M[/X6_"TM(VOEY,:/HLF$;X-;O9[P=T&5+JC2#T25_G%!E2[4@C_&@F+==PS9
MYOJ>>%;<[]LC,>)B:0?=<,X]8V"P0S'F""FB !0SH@9GGNNPL0)<[0C*.O!1
M"^!5@*O4P"A@*"#T!!.ZWJH-',4,AU054E?201Z'QTJ@2/.'W+NE(A% :FA8
M,XU "II#I?!'10YXTI N'H;K1E(Z\F<.'M7P;S"92*69,\8]3*NDJ%2X1UI&
M?Y1OX4%E#$W%D[ HIPC8]$$U6TC2@0AOQ"<X';X4=JVP.=CM'':6)% +SV^"
MN4R"S=%6, 6;#\4QF+EA,Z"&\?H!X_9@1;B(@9<@X4"+.<U</TQEIY.N9&C<
M3?"W)<DOOS"C1!CH!AROT^X^/JW4-Y$]G1CZMQQBQY2<3-2LK-ULL&&6DS(A
M"I4PG,E=_A1JQV>!52<3A_+.@MX )V9H:*PE/3?Q;R(K)-(<Y YP\Q<PT(8:
MOU11Y/(CI7CU'>P S26\Q?KKCI.NL')^&B\0$9SGD=L7JSG&@(BD@.GAQ+XA
MQ+2SK!:(#1.1=SQW)]"]"V0EERH]$L-R\+V45J^BD/6#I9>1A#^B!#(I+_R/
M YCX>>)")FXB&@4VV.&^E&,KH'NBV6QBX/4/Q!("(>,O F,+:[:$5)"//?2;
M0D*[PSIP#)OV%@T#UTE+?BDV7FGH]0P+9E^Y#;6)?O^D6#W][.GON<93K9Y\
M]F0%*?8-Q@Y&1"D 2'[_.01D*Y!/6KW:WWYUZXT8.G]2N&GH,(^O\.7JB\^3
M,(AH@BHJ(LV4A.!_/_W"?%%,4FN00H=*-<ZH&14HMO"(S0E+D45+@10B'NET
MHU.N3U@TP[\C'0/6N>0@$J4^@1K#!;]U/ICIHEICPL$0:B13$FVL\6S\-LJ!
M7"(>(HY(2[@N*@8!E53D6:RWV&[+FK'<&7=QNWK3\JI.JHGL9'3G.VKBVIII
M.*.DX8\P)HT2H:Y;A"?A=Q7"\_[<@TI;8;UE&$L6QJ;P>[8T2B!Q0S"6.:5O
M5U^-2B<NE:KP\T89@]^ ?,84HF;"7NL@2[6'0$-B5](NX71"2R5%#](I(D84
M86K M1'$2((X0X34^ZY):-MCQ$UQ(??8L3WMLVWF:0$G%-B;C*B(T-TU?O/2
ML-_L1M[71*=P,,,2YO'T=R\])]S"P954#31T8@A8U-)E!>?ID+XNW,$2/MD;
MT]<O#"(FY> 7P4["=C;HYJ$&:6XU"L_PM?P,A^."@_GPDZ_$5PEV&%<@5%50
MF(!E)Y[&KA^1W,Q?7LKSVF3*T H<Z3Q0\C-VT'B^;#IHNI7>/520-#3$5.A-
M!(X&)(8R!6Y#K#;#JDHA('P6)T\0J1ZHL*-(,:$T*8<]U.,PS_$I1-#'R]XW
MWR#!ZY7["1[$[D&?SC-"V)\O=/Q8M[IINU.+B1(W)1***'\?[;V_X!$35@=4
M5&%[\<K!W^K3@0^]K%<W]9WW<+-U/_O+P4_]M-[W#?PH$6<+WN;>E6^;L#+8
M,-EVI2!???2^@Z"F@YH$/+8Y3X\^YBG?PE,3"S_>DEJ &6?@AIHAOPFS5=B@
M\PDW';KR]S@^Z1R@*=7X:5R[/+:8]1^Y#VB*/V\4MO53NO;<V6WJ!_[F_D6,
MB!;@&-% <7BG%' S ]W)&5+WID+PT(&=1K'Z]'3@JFPC439R?'@DQ>>RT>M,
ML!_"\:YZCX'FYLY!A*3R!O*R#,5/LAMFJ@O21XN*=V'1F4@-#4KBM4B$C(JT
M=H&F<^<SDXW)4&-2*;0U0MOFG;Z*-MSX[(NXQF/X$RR83+!H+ZRL^2N6-?_/
MK"=<70CU"T+CL/,^(<)@P8L9[7K2U;!C;1=9-XK)YLXR=UPF35N0<O\Q(?R+
M&$A2,%_?O]J.Y580N=6T=PQ&IG>N<'%#9WY7'D;4:Q[[49A4"%93B82/$\P+
MQ&98\*Q!9+3GNHEEK &(1_IOI.6#T&>'N!F_E'N(O16_A\%*?A_P+B&H>NA1
MF: N^O6<K D5>Y"FE+LJ8S-T-=$BNR;S%' R4F0/E&T09O@\ -LO/(57!H9(
MTA ESMM02V)!4*32HV6%#T)Y.YH.P4BR/-40)&V(?E+%RN(WAL4JGYAO6/4'
MAV^00I4Z+10:]!=B V'SPWOD;B>]!-L1HK0.84OS;LG60'V$5#EXZ+Z@_X9I
M_<[117&%(YIJ;\_,)OC@KZ##@IO"WYMYK^!+X[>JM9B91I)BRRRN+#*N+:IL
M#?NV8E;T1U%/L@(#?P]9O*'_SGEF[43X2ZT%@&$;COHAX-S-7SC<6_)287C+
M=5QDC):_X#\SD;"=E<4,H:9Y)B2J%'BMY<KD=U#2]"8E**&%GGZ;33;]MK[!
MV]5SGJZ9+W '&0B>Q:5(-\9#1-_HL/1T/ TRDCG0U*R9U)HU'+*:?WD?UU>U
M$-ML+2 T^U69P%%BKNL)G1<<VX)C^T <VQ<+CFW!L?T8"_*._O=_6'U_^]WM
M\]L5//\77ZZ>?O'DQ6^>_%;8DU??E5NW^EO9^9=^N_I;>^^PYS+KH&4<,^NH
MD^OQ,0!9#NC3!%P8!GB$%T=Y.8B^CD0Y)@.$"L&9\AJM?N-N=[?^_,45^ H:
MB\_"E_#!_OG5L_PS_)8%<[8H'H*E:$#7$5]!S(P,>P/JO@[!7],S+"J,<0R0
M"V[@KDN$(Z2XJNLYI#ZA'.T'A=VW +#$!%Y9[7O@N!@%'B6I.>=$P<:$G 2(
MYHMT4H#XKX4+GK^,A%T.]XR98<(+5!KO"V"*V#E\N 6Z%KCKQL8U*)D@(CSR
MT6&/:%(=N#<!)6F'77A4I=\V-T\H&I\'96[+-%:A"CX 7Z?1HZ9HS_2%TGH'
M8Q-$E2N2\>&A!>XOA1$>)H?OG=Y-1#^B_WC/*]!V0HM>!=D,>$:AE$/^5-G.
M?BVP2BR=4T#MB68GQ\HA1PH*0.$V/X"'5>6WB:7+()N(=+R.E5G8Y[%S3:9<
MN!80E##P.3AS+J<_SQQP_/@AB9_4Y!?7]!&9BY,F"-'H(!HU; $N&TS?9!L8
M$TH:,KQ08>24_/4_GZU<1?((FH>_?/7UZV<1$_VV[/>,Z97)(>R?Z3WTTI84
M48JZYSX2HIUXRN\&<;]'Q/7DG]BOJ?=A#N8J6>=7+NZP(1SV)$ 87%]W)'.1
M\=-XK,]1$D/SCMI4.;K]FC2UHQ#G=O5B4*H3U3BQ=)>B^*,#6W17Q!(;7@B(
M8S?26JR4*V&#"C?8=G^P<&PR\S7&,U#_JZ%KWJX.B+YO+YJ)_[WCW!O($$-G
M5[<)IP1KP%GJC&,Y(%OUH:R/5#:@N;0'KK1V*!K)Y0N"LE4MW,CBEC[&H[_$
M=G"-DP02LF )-HD3$$3B#S\^:C5\,!2E1E!08@F_YY"CU1;&J#I% 46HP1E
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M?Z7)@/9RHY*&XZJFW4%\S51JV18]P=00C"*GK&VV[3&7\]#NW^>R/<PWE:2
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M):DD?^Y(J[<EC+#A'TDCM"=5[KFBA<B^N+/.SFE>&.$T,8N"F$LVCN,=R%_
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MR]B4/<9(6+ _4.N=#D,TWY4A!SH!,G: K2TIP9%N/:_T18F-7&8M#91P$:+
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MUFBQ SNT<;/,XK T!$BVU1M@*H,(6ZU:C)HCTJ%#NIW)\L:8]XAM-9=G8_#
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MQ39Z]8Q#0%44K#4?ST:VP&\7^.T'PF\?+?#;!7[[,184HD3>IFN:9F-48X,
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M3PH6%-8>CN##]6IWZM(QD.0:GPV)D2+>@P/AK+,JJ B'2;U!IM&X&E5G>UR
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M:T3R<VD;X8]V1!;N%"]"DM^2Z83U41FI1JR:JSAYCZ4<PI?N8'<H5B2YC4]
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M"^QU@;U^(.SU\P7VNG#;?E3>8WWPZ2C8+;HV #G9>]9FVY2]@7?TV)U?.JK
M8W$=[KOGICG$X5G5(U_Y$_KE(PY/L1%&-(]8#V(EL<S3&":,&&4/'W9[VDOX
MQ,_J[0XS(P9Y4KWDJKBH&TC3<)248K\HM-;-Y$XK%8]^@G?B?FJS#6RX/YE8
MZHCJ%8].DV^/J%B!5/IOZ7EA#J7/ZQXGMM_AA')HC2XAS1+2_.%#FL=+2',T
M(<T=6= GWC9>/WWS??+RY0?L]C<^]5OO]C]]=AS/@K;USTZQG'!$&[L**+U!
MZEFDBNM"U8_%%%C9*/78Y+>A2@OWTOG6Y$L,'YOD==^L+XD)L]ZH*E*HU'U
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MU)\L!?4_?D%]X$(?_Q0&T-J?PG3R3ZSM71Q3$_GQ*05C1^1I^;GY$O/SH-N
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M/UA;R?B_4<"XH0B7B&O^[GDSP*N</(.C4 542]K+!GBG2AZP0GJVH9!/##3
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MV_F^S*M9B>T_[<3>=P],['6 =IR ]LF6\[01DR:X@JW.L?:M:NN"5@RB>MS
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M?4SNLA+>XRE1W7AWXMYJE[="V\__:D;FBX"_ ,+]FWTX>E;A-Y9PC9JT""N
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MAQ,9-(O[4@R_= ,5]3+:16,6!/P<_GH(]V7E:F$=T6!KJG'KWA,2VP?=V^9
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MZT>_6!P-]B6O\EK/?-7^_O6*V<SV;5%TE:; 4+6-O>(+]"IBFS[>]!F[2I+
MG_UOXY>/:@T;)JZA%O#(P=@KZ7#Y1AX<K-[2^ H^2@[M(=H& U:.:'C,[)*^
M=KGKT25P7OC)GU]$+S9O\U$3'8_Y^I=4A'4GAXK*"CWE:52RS83'8SC GFCK
M&%!I<>KC?IAS:WUE&T7S93X"_:F85* B53]<-#XQAT^+,PM!=W9@M"TA.1ZY
M4!YACD>>)[#[&=S\E#G->S*^GV$S_(8=R-#?,:G'=G1S%:;Y46Y0XE-GW1V<
M&/8Q!/'D!QR^C'!Z\H.ZR.G?^H,:N./D(]JNX^3'<W(8#"(>GO^MK^3DQ^M
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MB?4.'4X"'5;%NQ^##DE\E:R&AZ&IJGJX]'?^;#;WDU6<[HNF.LZ#.\E7J#D
M11V]#9]^7195M0 7N,8/</IOAT6%#_UYUISK.QY>A=W?=Y&P?D33K5G/GM4V
M/?O57 MU[_UW49;%?U3>1]"98)T_$C;7!*WN:X0G:9N'6;SYCO$K/GWM])W-
M(*GF5?/-?O'%?S/E-;:C:SI)8[--94=:X$^P^31VW\3F5V5ENTS77;V:=M<
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M_/JO]S]^Q _JM(UF9.:X]A-]$:,QVO 8*S3E6*#5]\VTZ276*III'.T]-I[
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M[&7^PW8J5:-*>>M A(4/@DBM!^;P1NMGJI7(:5%+$R/]CG;0J(&&:J)NVB)
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M?!&!?& I$8F4)&$8+90\5:*?3*2:'3O1RYX[>/L#1G<8AC]C.G> =287>1&
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MNHA\X#F5$47]U$1^EIID*6K6V[;>3\;5&$PBL(:>M[=1L0WS[9\;ZXU8J^\
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M5%+_B ,,:]+DC<G K(^)3"-T%D4920,1$P7&(TUXS*-XR7FK(Y:(#%0V+D6
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MX&4,HTF8)211DA(><4-2GT8D\#5GBH>92.+%L592Q%'$>$1BEAG">0B_#J*
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M<$0FX2T[UL(1KOK,,$?!#@ 7 !< %Z? ,$?!#@ 7 !< %Z? ,$?!#@ 7 !<
M%Z? ,$?!#@ 7 !< %Z? ,$?!#@ 7 !< %Z? ,$?!#@ 7 !< %Z? ,$?!#@ 7
M !< %U!R?8Q9&$-[7P!+ $L 2["M "X +@ N[L\P4$(.Z GH">@)Z EP 7 !
M< %P<50,<Q3L '!Q\G#QN,6H=\"+*Y2Y80=_7&W>]MT?N=158V>4]@%A+15B
ME1/(:,R1=88*P:RQDEPM==5!"R)X2!>%@!A/W[:**R0UUM$)BKVT5TM=_PB+
M36WKW6M:F[3KZ:=O%+=R-<;5(U:X'B<,[_+"363_"? 8\!CP^%3P6-(0M/,6
M59KG_@."(U5YC[05GD9!8Q#B$*T' (^/"8]AQO6WA/5+NQMV/O4W;NVO9FIF
M+HS,8O1;<.'<AGI4D?&(8DKA-+G'W3V@E\W-"@5+Q@-3#%6&2,0T%LE8=Q(I
M(T-,B&U4J*XJE&@C=T96*-J0% H3!-G .3+6!\XJIA3>4R@?P_G%O#;UY>__
M6DX6EQ_.3!T^+&WCZLE%7LZNDFGRGYMM[8*_H5.$8F-9Z6&WL0&[_51H>S=C
MX#\ S;ZS,U>0E:H(R?VX7#9U#3)448154#IHRH.PCX!FKTQ=7TYFGUZ>)R-L
M\7*QJ"=VN3!V&C[.WR4DFRT.U*:+\+&F#$ .0 YH.S1LB]9Z277R^CG7N?5@
M1%I6&=NL-PP;3DB\BFU61RRMQXA&5R'F2((U[&VR[A1S/EJ:UO/4EAH=8ZK'
M0@B ,8"Q4Z MV&J/@F?!QB")),@(2CL\4S*W=8^"*.J=HN$1\.S);#4IDT,*
M( <@![0='+8EFTPQ:RHD:$*GY%-:9"K!D"*6!6N$)8)=Q;;@H\3>"<03]"4\
MM!PI2@0*V/N@H^;&ZJ>VU<B88#8F4@&, 8R= FW!5GL4/!-$4$TB3HB4Q^F(
MJDIV5_I))DO-55HK9_DCX-F3V6H\V6JX I #D /:#@W;F&#:>9%@S3F'F'')
MG531(ATI$]%$$?=3'(E.#S>>(2M40,P2@XQF%5):!LMU#*+"3QY7H]68$0D@
M!B!V"K0%2^U1T$P%&JQP#&'LD]45C4::<()$#++2%4U6V]YLH@.@V=.=@-(Q
MQQA ;O5MZ/L"F7K]Y&Q ]BMVJA(\V7@..:LH8E)&I(WV2!*&#4Z.N2=[=JI2
M3/J8W&\A=<AC<)-MF] <Z6 MHPG68]CSP5_-S\_GLP^+N?NSV*C-V^6B69B9
M3_#^4!-5J'&E(4D/3%2@[='1]HCJFD^&U- @I@^</RQ4 \?[<2JEE4S&F:"H
M<I0C1GR%K*0:$:VXE]@Y8ZZIS(M8>1%0,M-,,NE,<L$I84AP7U7!,:REOVJ>
M%</L;#Y-7E_3^MYO9FZZS-;9NWF=%[3K??\QG^6'UO/I-%WR)F]_: [EC=.Q
MPA!Q!. ["=H.%?A.NN#9":R52 XO5]JAY+-*I&1P2# 6*\LQKMA>UG-E./$\
MN<:QRM_QUB&EC$6$)2]8<:4H-\\-JW>LE.X3MD)#"@!9 -EC!-D8J C9#O6"
M8Y2 52,=E4+!5#3B]&.(>[9K9)6G1D0D0TX)4H0@S6."VR!,Q(9;*JK3 %F"
MR5A5O<K^ :@%J 6H/4JHK3!6HB((4Q\18TPGE]\HY".5Q%$EW#50*TATWG$D
MI4I0ZU6"9R<3/#/,N<964WPB4*OU&%<$D/9^77W:YD7#Z.ISTTZ^:9IEZ>(S
MCZ,/H9ZD9?R*:!:8\F:)ET?I'C'4=<@;D81@/)J%1;Y\LOJJFS>+!O((3D;&
MAA64@W.XP9 :Q+B_M 4Q'@RI08S[2UL0X\&0&L2XO[0%,1X,J4&,^TM;$./!
MD!K$N+^T!3$>#*E!C*'B[=ZY?SHZKX-#U@N#F# <:4\8,L)AJ94RCN]U" S&
M>J8T19)@@IC%!AD3=2YH#DP;7XDH5V>E?];U_.=W]=R%X)O7]?Q\=;CT-K[:
MG">]6QTG;97$/; .3I%J3*%9/: :T': J!9]Y(8H)!6WB$4JD++!(&J=X!6U
M2FOS$%1;98!\)[ =J"*$\3'CT"X0^C- 7D7/.?O4=#8XG8,A-8AQ?VD+8@P\
M##P,I.[SBP$/ ZF/B-1@3O67MB#&@R$UB'%_:0MB/!A2@QCWE[8@QM]%ZN^N
MH'4QXNB@@G950>M*K]]1J9/-YWJC)M2?)RZMK XS'^K@X3BGQ_(#4 FD/@%2
M@QCWE[8@QH,A-8AQ?VD+8CP84H,8]Y>V(,:#(36(<7]I"V(\&%*#&/>7MB#&
M@R$UB'%_:0MB/!A2@QCWE[8@QE $"460 &)0W'[;D&K)+3'&H1"=0XQ7#BE<
M,>1#\,Q190AQ>^.Z?.598 8Q2P5BD06DN>.(<H>=M3YB'ZX=;Y S68+_;5GG
MH0:AGLQ]VYVC_?SUO/[09;,\=&RUIE#0?JIJ&]"LO[0%DPQ&5L/(:D UL-&^
MQT:K&"-6<H:D4PJQ2E)DI0NH$D)Y99SVPE^UT904 0NO$%<N?4=3B4RE(_(N
MV7CI,QP)NZ.-]G<S78;;3;3[MQ\28*@!I %MCXVV8*@-AM0@QOVE+8CQ8$@-
M8@P.QGT=#..I]$PY1&..ZDI,D TQ_<1\9(X$ZJ+>[W!:,8V51='RW.N9F.1@
M>(]\%;42)K(8+3@8S\[V,+/V'E+R^]=0NTF3GCZ/H[;6=GZ1>0>&T/995DY9
M_8.E-QA2@QCWE[8@QH,A-8AQ?VD+8CP84H,8]Y>V(,:#(36(<7]I"V(\&%*#
M&/>7MB#&@R$UB'%_:0MB/!A2@QCWE[8@QE!="]6U &*06'5+8A4F*FJM'>*X
M4HCQ8) RF"'GHZZ$#L:1^.C5M>6/;]O\E55FBW]@A:VLQI5FPTZM.F7M#:#6
M7]J"909%ME!D"Z@&IMKWF&K><(R-LSF+/9EJSGMD@PE(LF"(#(P&SAZ[R/;;
MEMK]\^ EAIXH &Q VZ.C+9AK@R$UB'%_:0MB/!A2@QB#FW%?-X-&P:N*<"0<
MTXAQ(I#F*B)J) [2"BE=>.Q26W SCJG@%D;<_O#??P_-(O%H+K>MTX_UQ"V"
MWQEV"T>(/9:94S8&P.X;#*E!C/M+6Q#CP9 :Q+B_M 4Q'@RI08S[2UL0X\&0
M&L2XO[0%,1X,J4&,^TM;$./!D!K$N+^T!3$>#*E!C/M+6Q!C*+R%PEL ,4BS
MNFVB@;,5EC@@:P)%3#.'3*@4$L$Y76''N=Z;:'#PPMOWZU26<MG++Z;. PYB
M2*_WT )<.M9#S[0Z924.V-9?VH*!!O6W4'\+J-8OV@*J#8;4(,;]I2V(\6!(
M#6+<7]J"& ^&U"#&_:4MB#$,,WWLVLH2>T;6-&U%Y468-:9$RL/7_'. ,Z(>
M2PR (Y#Z!$@-8MQ?VH(8#X;4(,;]I2V(\6!(#6+<7]J"& ^&U"#&_:4MB/%@
M2 UBW%_:@A@/AM0@QOVE+8CQ8$@-8MQ?VH(80V4E5%8"B &( :E/@=0@QOVE
M+8@Q%!%"$2&@VI/3]J3;/A G/25!(\E91(Q)@@PQ(?V$C0U8"2/WVC[<9XCG
M2__/9;,X3TMI/LY?>C_):S#3=V;BW\Q>F8O)PDQ+#XB2=OMJ*^OV??C7<M*D
M%_T0ZL\3%]I^$>^#FW^:E;N4"3T'&L9#QY7DT"0"D!!H>VRT!?MN,*0&,>XO
M;4&,!T-J$&/P2^[KEXC@M39$(R%5\D:P8LCJP!'66!EK?1"B.L343_!+3D5:
M8$SH/80K-UHT,Q?RG-#MX:"9VT;.-&>CR6ST[LV[WT=Q,DL73F:?X)RNQT)T
MRN8$6(Z#(36(<7]I"V(\&%*#&/>7MB#&@R$UB'%_:0MB/!A2@QCWE[8@QH,A
M-8AQ?VD+8CP84H,8]Y>V(,:#(36(<7]I"V(,U:U0W0H@!HE:M\T-E=BX2AKD
M0RX@T=8B[:U -DA-L-1&5WN)6M\S-_3/NI[_O$IC>1M?E226TJ']];Q^99JS
M-[-W=7@UG3>3V:?7JR26#]UXT =.#,52CI5@PTZ\.F45#L@&R'9?9'/>"><5
M03'D%%2E(K+4)Z!35?K_4581VZ='MD,EE *F0?4S0/Q06!T@_OHJ VD3R#.2
MT%TDX]4+C+1T$?&@K39&1>G"0ZJ?GQ7B"9%CRC$ /2 ;T/;8: NQQ<&0&L2X
MO[0%,1X,J4&,P<^XKY]A!6-8<HJDY1HQ6EFDDN.!E-/!4,>UE'M^QO=4,Q^!
MGS'P@!(,VKV'L+R:S](K-%E.YG&4+H^AKD-^YURBO)COE"S#"6N/Q>>DE<<=
M).#*OM^P/S^NMN8)59..3 B73SEB\(A5WB++#$5>TF"4,E%Y=E4U.5QAYC!!
MF$>*&(L6:4,%,H)SRAVEG/D=U;01]+?QW4K,BW[Z.-]25G<]M6T2*9)B^H9>
M$HJ-9:7[I)=VJ7\3H7\"TQO0$]#S2= S@1]F1B$?9868L@QI*F,"1J*])U)Q
MIIX*/>]NSM\-/PD?:]JKW!> 3X!/@,\C@D^1;#1LI$6XD@$QR3G2(5A4*6,9
ML5H2A??B(A7SE:0.62,(8IIHI(@42&H3A(L48\N?W_BD8TSU6 @!^ GX>5)$
M!OP\'?RDSBE>B8"DRLZ[T,EY-SR@: 5EG/OH]\W/Q\+/0YN?4B;O'> 3X/.T
MB SP>3KPJ86-Q(2 *BDD8H$39#&7R&'*=$C6)S;Q*GQR+C0Q3J!DWVG$"*Z0
M\@HC0Z+PF%MFLLGZW.8G&1/,QD0JP$_ SY,B,N#GZ>"GE(Q)*B62%>,)/YU%
M2A*)HB"14,4I"7ON^V/AYZ'-3Y[,3UP!? )\GA21 3Y/!SZ#"-C;9'E6L3*(
M^02DUJB +.-1F5!AI<U^5IA-/KVF*!FGR7NWV"!CHD9&L\"T\96(\AC,3UR)
ML>#@O@-^GA:1 3]/!S]-,"%!H4#.<HR8<@QIG+UY&YF6VH?@]D^/'@D_'\'\
MU!R\=^@L!)V%3H?%!Z8\'AG>60)WPW1$"9@M8KS22"E6);RF@G#FK3</[RQT
M8//X5DQG8\7YF.)>P?K1\3P8P_VE[4GC664$5S;9I[A$2SGA2-,H$8X\J,H%
MIK!\*CP[4.G7P$=20A<A /8AL3H ^[7 SBGCBH6(A$PV*@O2(".D1U&[2LH@
M*TO]@[L(/2VP4ZS'%0%X!SP#VAX=;:'IR&!(#6+<7]J"& ^&U"#&X%W<.VP4
M)+6,<"09H<E3$ )9+2CB3FM)%7'QFAJY[^T=] S>!1UX9]+O[ACD8L31#;MC
MT*K'5>X7M-T<*#<+>EV'?RW#S%V.RM',V7SJ$TN/)K-1'3)SA_2O,Q>315K9
MOTUF.#A:A1@F6!FP!2 4P!&P!2 4P!&P!2 4P!&P!2 4P!&P!2 4P!&P!2 4
MP!&P!2 4P!%'L050 #?44YH^GH+"R?_-)_^8."\)P<BR4 K@+-*8&232IU(&
M;*7<Z^YXF '4'^?KP]0/6V>I;V;OVY/4]U<.4@]2'B<K-69<#CLK )0=T':(
M6$>TX(&[B#SE'#$A$]:IZ!+T53((3;@+_#BP[E!3TP#GP,<!V!\*JP/L7]^!
MUQ#B-4XVK>8)PEV5(%Q(C 1ANB+"$HGI@TOGC@GV*SJ6>."9KP!V0-MCI"T4
MY R&U"#&_:4MB/%@2 UB#*['?5T/3R.K2!1(!1L1LX0@8Y1"E5'4.>R],.[!
M=75'YWH,/.STW45WL?QOV$5W[V\HGQLM:C-K.J%R\V;1P%%MCV7GE T%L D'
M0VH0X_[2%L1X,*0&,>XO;4&,!T-J$./^TA;$>#"D!C'N+VU!C =#:A#C_M(6
MQ'@PI 8Q[B]M08P'0VH0X_[2%L08"IRAP!E #$ ,2'T*I 8Q[B]M08RA-!5*
M4P'5GIRVCYL??@=8N[+O-^S/CZNMV;[[(V>?,^ZPK11!2DJ,F' 4*<T4<DYI
M12D6HB(/*7Q=-NB3,1<_7\TE?Y73= _5PH".*>M5OY9=,M]$T9\ )@$F3X6V
M8/P-AM0@QOVE+8CQ8$@-8@Q.RW$Z+01+HJV1*#@G$/-,(QV%14X+124C+OWS
MD))9<%J>V&F!&93WD(VWB[-0Y^F3Z<JS,&LFG\-H,DN_!SC(.QFA.3JU ]8C
MD!JL1Z MB#&0&L2XU[0%,1X,J4&,^TM;$./!D!K$N+^T!3$>#*E!C/M+6Q#C
MP9 :Q+B_M 4Q'@RI08S[2UL08RA_A?)7 #$ ,2#U*9 :Q+B_M 4QAO)7*'\%
M5.L7;0'5!D-J$.,>%X0\<LF&QEQ0JBURPEO$E.7(8A&0T X;$5CE9;Q:LD&E
M)SA(A[S)0YE5Y,@(YI!P)"A#'7<5O5JR49+B7VWGQ+\I*?%_F3?-'V'Q-GXT
M7P]4P<'[5+QQ=-P.2 :T!8,$2 UB?+2T/6F#Q'(?8S 2,:\Y8M1[9&6T*"HG
ML6$V<!H.44,*!@G,5#WB(M+$@J-I8D4X_+JG9'3'I*NE7G-.>@JR<T]2?_OE
MC\).."*3\)8=:^$(5WUFF*-@!X +@ N BU-@F*-@!X +@ N BU-@F*-@!X +
M@ N BU-@F*-@!X +@ N BU-@F*-@!X +@ N BU-@F*-@!X +@ N BU-@F*-@
M!X +@ N "RBY/L8LC*&]+X E@"6 )=A6 !< %P 7]V<8*"$'] 3T!/0$] 2X
M +@ N "X."J&.0IV +@X>;B <:F_W%3J2HS @5.#,%<58MHH9)5GB%C"0["8
M1:NOEKI*545L;84<U;GW1N61$I(BQ8D7RAHJ(K]:ZOI'6&QJ6^]>T]JD74\_
M?:.X59$QD?3Q*ER/$X8?,%,5\!CP&/#X&/'8.>Q#K#*VNHS'P2#MI4 N**]"
M97FTU2%:#P >'Q,>PXSK;PGKEW8W['SJ;]S:7\W4S%P8F<7HM^#"N0WUJ"+C
M$<6T@M/D'G?W@%XV-RN49(^S8"A'EC"<% K72'E=H<AL3':_\T;CJPI%*.JP
M8P))+ETR\$- RB6%8I2C*AKCA ]7%<K'<'XQKTU]^?N_EI/%Y8<S4X</2]NX
M>G*1E[.K9)K\YV9;N^!=G1(G7X-'_P[U?"NJ,N0.-F"R VV'B%\V1$NPE"@&
MS!"SHD+6NP1(E<7<*I^;<3T"?KTR=7TYF7UZ>9[,KL7+Q:*>V.7"V&GX.'^7
ML&NVN%]C+L UP#6@+>#:/SS1T9I*(TQ#3+AF(K*5UXA89I065>7H7M-C%75P
ME.5NA($B%@U!2E<4V2"L$)0'I3S89;WB<<"O_M+VI/$K"&Q$I0@2@2O$I$RH
M1!U'1!GI*L598.X1\ OLLG[P/N!:?VE[TKBF"+?8<HZ2FR@1,YXA)9,7*:+E
MC.:1%)3L'8B+D"!/&)3<49R;1N?O:($XB16NF*^$9F"7]8K' ;_Z2]N3QB\K
M(Y:2.^0JDFRLA$O)QO(6:6Z5TM)1HM0CX!?89?W@?<"U_M+VM'&-5MQ%'U!5
M<8\8H1H9;BM$?24QUDQZLC>3PU0.>T4(<K%BB(5TN5:*(ZT%(S&!FV$:[+)>
M\3C@5W]I>]+XI9UP0B0$DM'9Y%=2A2S5'DEK@Y),!4_L(^ 7V&70J^6XLLV&
M]KZ]XFQ ]:O9*91CQS#BQIF$T$(FA+82*5+IRAJ,)1%74=T2:?*46B2-DLE#
M3Y=;G?X3C27!.9'0W5Q%]5?S\_/Y[,-B[OXL%FGS=KEH%F;F$[1_GT&ZGZP]
MQD2,.1& WV"7G@)M[Y9G_Q\ 9=_K8 ?.J1>Y\H0C5EF*E&<&5=&8$%RD?-_!
MO@^4%1 [FT^3A=2T-NJ;F9LN,Y*]F]=Y0;M6ZA_S67YH/9].TR5O\O:'YIY6
MZS[X >A!$QS0 2?'ZJ #'D4'4,NI\8HCHP3-00J<S%FL$*F8%QXGHS;C^:X.
M<!7!KM(&128M8C2PI -TA;!W)*D![#5W1ZT#*D['&H,F .@#VAX=;8^H&0^0
M&L08+)A!=V>(%6.""8],%3Q*/WADB;?(:1>HBD03NG>(4]FJP@P[)"N6;"I!
M)=*B8JAB(AHA*N7LWB'.4]M'=VOK0%0UQICWR5""'CH M;V%VD<&0^%-]+*R
M2)'<=D91A0S+_<,8]IPKS"N_UZJ&>,8QB119(QEB7&JDF;$H**(9"2+YDGN9
MAD?E+!*AQYJ0/F'@]\O]JEU-^C=O>?GQ,;G[SJ>V6\^FZ=FW/NZN;_W8+[<!
MB'N;264MMSV^O33?^>?)(CW6W?CZ'\_"R#@W/T]KR7DCH]E\D6YEZO1Q$OQT
MV:?:3$<7IEZ,YG&T. M-R#)>\AO,(OA1G,S,S$W21<TB?7">[MN\>,+]O ^S
M?&O_OHM9_.3S^O6FX2ORDSH4D/@Y$75Y/OO%3YJ+J;G\.?_UEPOC,Y)M-;.:
MM,_K^C^U'_QSV2PF\7+UZ/)5%&;^%SO_FM\AW>'G=5>LKX^M;9Z"96_:\M?H
M.KO_:9Y-R&X?J43I0O&S==.N"_,IM VYD(EICWXVTR_FLOGEA_^ZRAHKNA="
M7$_T9Z'MLV+M9DN/EWVW.Y$=@*?^=U[7\]&OD_EXE,R:%P]A[@.O;/0,2K"8
MELXT9_^(T_F7XZ#0JVWM]F&ETXZ(4$W6Q*_2IHU>ITUKCFAES\%"SZ$8?C0E
MO;9)!E(RB>;+QLQ\\]/S*:JGW/=G-\Z+#[)V9MJ%YD7];):+^:I7:%Y+5J1I
MZ?ERE.RO^;)+8_ZE?13!^ 7^S]47$J&FYJ()/S<A&;M)Z%=[T&;UEGO_<+5G
MY^=),[&3:7)1?UY]_Y=KNG&6QPGQ0NOJ/SO3X)H+R M!;_OS;7^C+Y2J\.9_
MMUY\5&NXI16JNK85:MOQ]896J-<RXC[S7EW4][CFZBCPZR[]44??"E(<SVL?
M,D"YSF\2/]S^HO?M[GTZ'/!_@ZF;T>\SGRR9[1:Y]V.,^[=A/@GF 20")'HD
M)**#1Z*[].0>).J % Q+"BA(P??IWN*X?N=$A&M7]4UE>_-$A$=UG@_)8&\O
M0O)=\SG.2[>8?)XL)J'Y^9"P\_1AA,=&G>,XNW\R;3*PUP4N[B59>_6ZWZ_\
M;O4\#ST.Z+F5WTT;^D=8C*;SIOD6!SVX&<')H,5A<H^>D-[#R<U[ )]?F_A\
M\.R^RJLH554ASZU%S.+<0E!RQ'4@5AMFK-[K;'"?073OZGE:SBE.H3M::3ED
MNC(@X''0%!#PR1'0,,QXI )A;B)B%0Y(*4Z0\R%BQ3@U80\!&5&!66T1,08C
M)IE%%NN(:$)-P[R)Z>]/AX!<C7$%" @QI8<(QTN?DT]+&N]H,1_5(?W)3:9A
M-.OL[?QI_CFG;8V63? Y"V:^#CP9"#R!RPZO"US<2[+VZG4A\'2_P--\AHKR
MFP;3A%'X>A%F30 G[(3,RJ/KM'"TOM?UOA*G/!KO"5)1J.0KL8@T40I1@[WR
MH5).[DUI_9YHT9]U/?\YR5G.<O]+EK+?6R'[#I?I]AY 8T%PKQRE9V[8"^!T
M@J3L*3@QH[VD4B$1&4<L(0TRC%:($Z*,T901O =.WQ/(>6QP(N-*/WEWWB/C
MZ ,';X9BFI;>"<B:')7)1=V)+4V1##!2AR UH =VNEL*)[2O$I)+IA'#22-H
M[#BBQ#M''-66[HVL_6XCM;1G_S4+W*LM>>LTPH$4 AU7ZLE;D/2#M0&E>D/*
MGJ(4=B%0;#C"E<Z#M:-(*,4CJBHF*\99\J0?=.SX9"A%QH0-W:>&B.J])..W
MD"YQ$S!5AR,IH 1VII +1PT/%:HX<8AI)Y%E$B<K5*E*.X,9W>NM=Y_LNVU!
M.UPHM1HZ[ ,N#9V4/<4ES'UEO'(H<B'; 1&V<A@%H[0TW!-GY"%RXAX!E^B8
M/WW?SB-C9HBB/NR ?](UDP6;=!#B MB_<\;/C5,T6*2BCXA%SI'"N?US\,8G
MO1""/TA%R*IC\YN9FY^OSM+^"*<[J+@?7 T U1M2]A2@7"1!!4H1QT+G)"2)
M#',"$4ZY%LF;YE0=PCA].$#=<=X&>?*A9$?&WQ ^O7<EM#G/LQ'^W890YW&4
MOG0^69XW(S/S(S]I7-NP- O/['/H"CQ 7?1:G(:J+IZF7C!20O)T*$1\'@Y5
M*8(,<2IK(\%)8,Z)!Z47K-3/2^?J4,:>;(GXV_C;2J9?SOR[3MC?;$3[4 .3
M^Q7:A8)JP$7 Q<?%11&HC58()(A+&.=I1(9:C)31W"D3*&=[0_/N8Y8_*RX2
M]N1S\8X5&"'(?"_AR0T LCF>IP/-&S-MC?9<1[VX+$9[^-=R<K$]>@*TT0D(
M$FBC!Q9O!*=98 91DTQK9D*%C*HT,ICDC#BB]&'Z$/V/F<RR"+Z=_58$<-)J
MCY=-$Q8-.71H1_1+6T 0&O *\*HM,K!:"HH]BC0FR]5IC92J&')6ADB$E=J;
M0UB[A\(K."M[P@#T4'H&O3HSLT^AN=((J+!F,66G$U/&)$%3(&BG,N37!2[N
M)5E[];J/'LXI[S&9^;20]H[WB>]TFU/F_I6;;-\57YVI>(0J\UT=+LS$KS(+
M6STY7YR%>N26=9TNZA0H>%.]MCC!F]JM@U&*"V60"BYY1H(&I&W@B%)K,5>>
MNQ /DW/HZMRYX[?0_OMFULGC;R&&)'V^R_)Y.?-OLTRV;M;!^[5R/7!_"X!L
MZ*0\>2![FD-5Q:6D.&!$%=>(2>N1<B%AGC>*>!,IE_XPN8Z/"XRWE^ST*__Q
M2<]4OS,1$HSP?)^7KDN+O#"7>4PXJ*@3$B]040]3*96OJ$VHCKC"(=G-7"%5
M!8]HE-Q24>DJ[IU<',;67HG=NU;J#E:(3G"_LA7!G@:P K J8*65-T&JB)RH
M%&(V 8_6KD(44^R)YL17CV3_/@Y8D;'D0\\)@4CS4QFY]3)L(LV@-WHM5: W
M=M()(V:**X8J@Y/>,)8C0Y1&5LB(M:TJ9@]4Q'Z-WLAB]Y=-ZL/!5 >58.<"
M7@V;E">/5T]5I%AY@V5$@8F<GH@)TI1J)!QF@7)%C>*/9C??&__N=GQ6]>OT
M#,+%QVY)OUWG-K:3G[;2&D%)G9"D@9)Z8.2X"EBI0! +AB-6N8B4-09ISW0E
M7-(M=J_QRG<WUM_7*&76RF/8TQ4;>J- @*JAD_+DH>II[.E *FRH"HA@3A%3
M4B&C34"RTCQ0ZZRT>PEJW]VM_Y#0=S=3FHZ)AN0+B$L_J35=DIUGN=<J)#P?
M1,QL8K=0KY?Z@E\L1LU\.O&C%8'ZK,&^_?:@X^[65]$J*5D(J*IDA1A).DY9
MR9#@)F+BO39T+V9TF)AY@82UEWW0W$(RUDH^GH:[A?G:4 NN3DP+ N0"Y +D
M/A'D8E=IAGV%$EAZQ!AQ2'&I<ZS>2$D=I?(@702>%G)I!8![I$%\>@BW@YZB
MVY&;Y9;A#LL\)'>W8T'BT<\0S@>%" KQN14B%]H8K0VJF,K#)XA%BE8.11F]
ML"9I/!T.X8,D-,ACW-_5\\\3'_ROEW]+J)"TXEHAKB'AX"W!Y)@J4)#@D0
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M\%2.SC19F=6OY_7*H-ZVI?^8+_YO2,]H39)#U]_(1[2OCQ1ZH3O L=OLZ^X
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MM)F)-FFN/NDF6K25_Z7O:7JU26LMYI>]YK;)\[N6VEWRZ-8-/G>5*%DUM\.
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MEWEO?;K-^ ^8A+-9TWH45G\</Q1GZRI&K"%B7=3:3MPLI89E-4=/;.X(]&Y
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M!,:.AV/OX-9C..D:-^_J++3]R#X&VYQZCN?#!K]MC6L.%'YJN8#<;/9'^^F
M%VEQ!E8G*GTDX1VS6]^3DC<-8TYW.FQ?(" W$+=],M1B[H_SIF%W"[K&44H(
MY\A8[A$'H$6.XH08Q=PI89W6]BKHZD!=,B:AB)U!7&F+G",1,2F,TM%ZAM-V
MJSTP5]_G9N.ORYK\$I<_=46!?YW-0K95OQJMIN/F(7__[[^_^_ZK$2!NGB"
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M(1E^S$8S1P<  @<>#'&(I1S/LDPA0RT'T'?>$V.\M^H@W?9::I/OXC3"N'(
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M&Q=)>& 0J[']"F!U25\D@$4N#*-$(*89 3 B#&#)640PL2HY2[&W5P%,ZD0
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M20"$.FV-<(ZSN%4F>P^8^:S"M!5%*XI6%'V>*/KU+8O@OC"J'&(TBH,1JUA
MG)F0$38A@K4@5(4@F'U,5#Y 5'G+O'V9INW-HI3?5'2NZ%S1^99HRG.#\M+Z
M)'"P<7&D2'-F$6.8.RY%U(S>!YK><_ ZQP/V]_M[SJ#YA!)]Z2'BV_0IQK=_
MGRWMI.JMRH-<>9 /TAB?YQ;&B2*I2.8TMN 22&&1]HHG1Z-C=,LE2)(D'[Q
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MA9Z366<%C=ZPB'R@@$I88N0$<0BG()4Q27"\%;(Z*)(=TJSCNAIU%;?JDKX
MW%)&!Q-,1"JF@+C6 6D,9DSR&.",1JGB5K'#0<V8@^+6?1>Z/1DAK\>D=VM6
M,3N_6,$>KP[H,W= A2)21L.1)Y2 V18%<AA'%!VEUM%(@]HZ48@FGTT*@0(G
M '_!,S#U;+;=>%+2<2DM?@ '-,@4J;4.!6+ =_;<(1O B[9)"L!R3IG8LCB)
MEEZ:%&&LE"/.P?;44C@4D[+$A,@L5L?I@++J@%9#KAIR^PTY&@6XF82@Z)U!
M7%@/FUQ2I+3!S$KFN=YV0 ^)9(<TY&@]5:BX59?T)>"6Y8)0&3 R+&K$J?>9
MO4$CJF6PV J&@[Y7,^:@N$5JG_.[.*#U-+3+TXUV$<]FDS :GV>:YH;XN"J)
M9^F$TN0]9TJ@A%5 / F*K&7@DR:,K8G$ 3+>=P><B]EBG.%JL<?;]-9HG\">
M%-A0!.8B03HRAK3%!O.HHO);8^1$1^Z,0\1:C+@"#]5ADQ"%=[(\V 2?WW:,
M!]IG[\YF\QSGF:71JJEGF^1ZMME\-(_G=CS-9.F3O!='<-5Y]4&K+5=MN?VV
MG)"2">,XPDZ #PJ8@+1W$BDL4J1!DNBV6N<)K1U@F4?$@_O)F01@(01^<LEY
MJQ4C^.8@<4A;CITP(:LU5Y&K+NGS1RZ> M%,9=L$9_.&)/ H T6&)A42)8;$
M+=XM3RUUW'(4.!8(G%"*M$H*X: ""=8YZA\I>G9B:OSL3GYH/0CM#T*GB^5\
MU6Z5Z0A\T??SN*B>Z%/W1(]G&I[GVE>*H4HQM+.$T5.*N?.(T9SQGK.H=%0"
M:9J,$8XX2;<HAL 2B51QC9*/'!PCEY")"B-%I% "4Z/I5G?Q!RK_H9Q6RJ&*
MD!4A*T(>"B%3 FA,R2)&4LZD!Z?,:"R14#0XP;G$9LL5(R1([:)'+N8T+N48
MLA'<M\@9$21&RYQ^)%<,\TI3>83'AI64+=_G]]G23K)3M[/[^ON\$:HNJYY>
M7?MG'R>KX>"A#6(2CBE:AURF?^7<&&02^%Y61>Q<%,)M$\'>ACCO86P0=B)P
M+8RIT%67] 5 5Z"<\!048B*7A1@*(&:=1@[K!,Z4E]IL]26X#7W=P_3(XB>$
MUJ.LN_A&]2BK3ZE<+%Z-K/>K\]6D=# /$;[DQS;+5-47U<VI:U_#M35<NU=N
MOKXE?]Z7V2]P&^TC<X@P\+JX2F"ZV)20Y(%I0D/ GA["]7J]5@3?#_0 _#R)
M^0<P:5Z?SV"I_U7^OM?<.9"EHT[T"SU*NUEWR1L1BU20KB!=0?H!0-HZSJ.A
M%!#69L#U.C<QU<@[)0U3406^U<3T-D[FD8$T/Z%"5)#^<I"NQWI'=*PWC;6;
M3?5VZ]H?"*/I*<T@'6:KS'K]B*;4X[1IO\ED/'FK:K<5I(/7EGD)7BJ80ESY
MA$RB 043L2/.:N^WFD<=])3PEW@HRX:($RD?U+2Y(BE/+U6IXF7%RXJ77X*7
MWA,M!4 E &/!/H\<-0JY1'$2V3\D6WAYT*/)P^&E.='RGHN#GQE<#EU ^-G"
M:^QHG!#&'XX$'P?/IO#LSS[NQA-RA,>E5T9RF_=\O<C],X8<]:/,[%O\SDQH
M>C):GL51[JEJIY>C,YL97W>7%>;[_-NN"-87C/(>S#PN3#"YT[%.B$NLD%$4
M@YFG/*&4:Q^V&VW>PLP;UEK^E&-994H^GTXA-U!+7%>O<[K_B.'AQ68$5T_R
M-&<Y.;I5E\0&ZZ1!T6H!QKW((4[+D91*)N\P\=O\'K=15O>_ZO04'^&JG\"F
MCV$&E]EEG%R.YK%)REC.1I,=)+7PN8_C#W"!6RU'T]ER=!F7 !V+I9U,X*]9
MAKR]&,.OXW]EY0)+LU@NAK<=@-#__7]I2M2WBU%:%<HA/YM?Y$?&T5FTX7]6
M-C<%6IP^XBQ]H=:X7D<=H^(8QO1'\=-%G"YBEN6R5+E_\&(4IP%6;[]N&7VT
MB^,##RIQ%#(WRK+*(IXIC9R@'&&;E%1<)A:V&N'<IJ/7< (/A!;L=+]=6W7$
MYC(3Q1EW&"/,/%@&7$MP:$#+:^Q""C"E-FQ1+-^F*=H]+#,]W1_M>4RE ,KO
M(L)P/H!..!;\W>FE@"OS9_CO+<1P3X<]1UPRDA.DG8B(1[ ZG#($2>PQ!JO#
M$'$0S'CM_6PU72[>VLNL)^'7^2J&G\?6C2?CY3@NP&/^%0!X/OC3]^.%G\P6
MH"K?K.9SF*+?80S?36;^CZ]&$>3O(A^]P6UNYHT2_3C*ZF-SVNAFDW (&=&G
MHW;R1C\TNFM18*I,WJB=J-%@%N\BS@<>^X9\[Q;CZRR*/6)L8X@L$8F$(#I3
M^G&DF0I(1HJY9EH8ME4Z<QLQ?N?/8EA-XJ]I6X)_SX)])Q&53]&<ZJ0Q#J5Q
M5J31M](X64_2R%[CMH\^QF(:GU_,QXML8H.Y/)M,9A\7HZ_!9U^>S58+N';Q
MS:LCP>EG&S?JPF8E:K8K2\&NEK,N8)C',YZ^S\//EZ.)O9RMEO"(3S%\VSQ.
MXU/\I^YZ6*B)O5C$5XMX8;,/U$U#"0HWM_YJ5_+&A_%B7(3I\E5WCWT%!>6I
M4IX:P_[T[5?__IF+R*FDUUURW>?T5&N&U_]<^X6C'],U^3/ZR]-G=LKNMKSO
M&N"7G&OI>\U^N(WRO)G%MR=X?SRO?N@S/9C*_&EQ(S[[LK?-(GTZDC#4B+<7
MBMLG\CT9P:FH5%'I@5")OGA4RJ9Y1:,;IJ;4'?$R=@2M.Z(6C-]7%OT/YQ>3
MV65L0B!QNFB.J7)TQ,5IA&MK;ZRGV'SA<=+^GFE*GS 1,ZDX<BPS2.9FC8Z&
M@(2C-"7M,.';[&VWJ];-H<UN2W[7;L VR'ZX&EQ3&3\JA!W]DE8(.V2_66E3
MBM@A$S,!D7, 1]%I)*S*[;B=L]8=J);U_B&,GDC**X3=P?RM%)2=^?L)MOC4
M3G)*1K1S?U9,WQ _Q,FL2<E;Q/F'L8_5#'XY>ZJJC@TR!^*M,-*B2+1$G B!
MK+8&:>&C(@K#G]5=K-\_YO-9KS?:[?A;NQM?3\/WZ[WXKMV*A]4FY/[['3QW
MR:]@]NR6])F"&94$VZ@"PDID8$H<62,H"CXICA,32IB[V,&/#6945<.XQH4/
ML'V:_,Y<8FJ7F1^Z2[>KFN/%[*"J.39:-CI.DE0RI^\*Q!/&R(!=C+P'0UA2
M;NAV&<1M@L!EXVUG^QY637!>6^57W*I+^@)P2T9CK-0>G/;<*C]Q,&PRZ8=.
MDH48 (,X.T3D]T%PBU:*CQKW/0CE\S]^Z\M$+D^ZRI&J)%[,_JE*8B,L@KFU
M)'B4F-:(2Q<!\'-;"&R42SP99>[4_:.$1=Y\Z*LM+P^K%IBI =R*5'5)7P!2
M66.M<\2AW($;D"H*9$UR""MI)?;44X[O', ]&%*5>D3TKSB?Y576E-!O*U#5
M\.S=-\?;^2S%Q0+DQTY&*=:X;&6.J,P1MT_PM4P;P?-98$[P33RW<^ .6:NM
MH]XY&[9B)'=(\!UNWA_CP6,DI'*Q5X.YXF/%Q\.=?041J P!)6\DXC$(Y'+W
M&Y<43U+QZ.6=C.X'Q4>UOU%DA<?*:7,$G#;VBUH<5<U66_?7UOT'*9(AB@G8
M?,C0*'*=GP$W0 ;$ M5!6R^INE.F\Q4U=V^GI 2?4/*@/)M/OG%_!<L*EA4L
MOP@LC<5*>H [FQSB3( [$*A'2D9IF6?PGX/PG-PW6+(3HBHGU#V1G.QM*GP4
MJ#EX]B&[6!ZVU6PT/"698*>$%,$H\0G9P#V27&%O/5-.;ADEMVHUNYSY/\YF
M$Y#41>826E[^,EO&=4_DI]AI]L#]A,UIIE8X!P@LDW6LG8Z/=SWNV/EW62@3
MLCSFBH19*K_"7GD?YPW[SN+,SF-I^/MS?&_]Y>C_F<WGL]S:)B_:(B]:U^]W
MFJ$:?.SQ=#D;?&] G_&_%YM?=#;W!YY-RS7QDS^ST_=QE,LC9J!O0*_#N,L-
MRP5_*\,:O7X_CS&7^YQ^X0H]3:Z+/21)F]Q(F<S"KI9GLSD\JY"6C!>+51SM
MVD]?,*;#%[XFHP M+<)@XH"U(C6RQEEDC$Z..DQ8VHIZ1I' ^@$GD'L"WR$:
M+O>.(L],RAW" XM;R-M@2H&4=T407_>3LV'C-%(Z-&Y^^N7':Q-F\0EN_G],
M3 CK#3?<8B?'1W[!M(F.&X]HHEG[4HZLAW]1:F4,2@?CMCC@[R@#;^W\U_F[
M92;T^8>=K.+;."]BL6GOPH\QE*L6OZ;7Q6"PW^<&U?-%>W5K#>.AP%QG#.-3
MC,DQ"<H%H,B'/ OEIR(VIZ.W\W&FSYEMX7]KOEQ5 #T1TK8B6*S</Z-?YIOE
M(.O_K !!TS@3,%V6.Q9?:G$RNIA]S#?.U\#[)?CJU*\UQN"Y^=>WY8HYW*4L
MZ&@1EWG:EV=9.62K:D3PZ>@_UU_:&!>\X@C>?KR<-. XF\;1A_REP0S\-!W9
M$,;+PB9R=L,;M>12(S!/QR%. [S6.)57^G@6IUE*0'K6KWZ51>J[F9V' N]C
MN--R-E^<CO;B_;'M8R]@&POL4?(J )8KC@QXJ@ASP/)H R/;:6-26,I,Q$AX
M#]\QP2+-N04HP%(YFXQA^#/[^/MNFKL-_'T[P5^ZD=?;%V]L7[2(/F_A?*JR
MB-.O_C*='=/6[<6LD"&Z.!"Q8^&\@<D"0VZR"G&3'V02/Z%0I!SF,/?]7YU/
MOPWCQ<7$7K[*GWY[D;??]/W@E&_</+,]&&O^\,_58CE.E]WCRU<13,FW;O8I
MOT=F,.B# Y_N.P)PMV:E=YOV']'C+3G)S:(&H8PV!I&C%V?]@>:%?1^;LTID
M$TS3*SOY:"\7F9]@*!K=NI>%V+WHC[*VC\OXN@[V[-Q.=XZ!$!F\X8#$-BJ)
MN-,)?F(V]Z$)^=Q%22,/2[?SICB(.04!4+G ^=W(H)Z3-_<9RMO<16N>^2LS
MOV%+.YF=.PO64KFXX=;)[CLHKGQ3>,!N9Z#R[3PQOAWS:'P[4EW+;4/D7;EM
MV"D3US[G*,?Q0 P6-V*LV)]I?ZB&XP?.R+D#-\6.03WE1NN'9M YANEYFHPZ
MQS!S3X]AI^+32\*GNS.'',/T/"UNG6.8L0?EVGF.+UQWT"-R\1S#C%5NGF/1
M[>L@5 Z.@+^]6-II#C]NIC>\B_/,=/PNQG#UZ*FFN[Z8@OK:)F)XWL<5$YHY
MCR26'G%O(W**$12(]]IC1DC8ZO/K(_4Q7\ZBE8AKSY'E7"*2;*1*)6+T5G9J
MO]\&Z1N_KC?J-?D;N':+J.GY%:\J7OUW4"%9&SC2D@C$A2/(&6$1M58(#7\D
M:BO/2"6GE;46*249XL%AY&AD"$<;>0C.$*;O%:^VTH>DYB>*W7/[@2<CX;5%
MXP-:OZ^KZ5M5254E.6654>>\24@+G)LUB(@L.-0H$1^5U%0:N:5*+"9.>ZU1
MD-@TJD0KGA/EI'>)$BQ)JJ;O4Q+NBE?/;DF?*UYQ%[FS 9$@,.+<:.0\<4A9
M'V*@5."PQ:X+2!8241QY+P&E+*.YG[E$27A-G".2Z*WDKOLU?>D)IN9$RDJM
M6T._#V[\?H=(-7^K.JGJ!-2)8S%H[2A2BH IJYU$SF*-J)0J1,:LMUN]''F4
M)!@P>JVR%+Y#X3L"_B5][FYF-0U45?/W*0EWQ:MGMZ3/%*^X#4*"4XZ<Q( ]
MUF9F=JD0..]*"H$9Q73+7=>,6"L)XC+!=X0A\!T!_]+!1*QT]M<?UOPE)P3S
M$Z)TA:T:^WUX\Y=6\[>JDZI.<J$SP4H90Y$-."%N4D2.<(Z<TEHZ[87@6]$4
M$PDW40M$ G>(*T*1ELPC[XR67@HC<K)$-7^?CG!7O'IV2_I,\<H*3YT1'FF>
M6P)*JI'C%H-EB1V-6,I MVAU63!&&"^0TX$C'G)IKS4!):.D2SH&2A[8_*64
MG7!2N2EK[/< &^7'S;KI[7YFU>RM:J2JD<U#Q&!BM!(CR:0 $Q:#Q>N=1(K8
M*'W".GE["+-WJU?;3[EUW75]VJJY6\W=BE,5IW[\;^>$B 30R6H!.,4M12YR
MA01AWIM@P7S=ZII]&W/W(#BU9>9JPDYHS>^M,=Y#;)!_Q,6R[>,+8KB<CWWN
MQSML 52UQ(O92U5+; 1%5-(,)X:4=0JT!.@+32Q'5$E/I'2"B:V>[]@P++%S
M2%!J04L(#UH"OB@4ETI9Y9VXOO-PM6:/0*@K3CV[)7VF.)6T<H++A*)P8)ER
M[Y#+I08J41PDQM;YK2I;ES@S1BD4K3&("Y&SK@1'S!,%H*>QIUM5:_=CS=(3
M@^^9)>O)R'4-V=YI>_SP*<[]>-'$:H?I"DTG[ME%%JW*U/AR]E/5$T,](1D1
MB7N.5% 8\<P:IJ6T"'-..1'6\1U)"8E9@C5%U@0&NH4H9'%2.?[A OS?6[O5
MC6%+3QPRP8U1=D+$?G:$*N 5LX[DE2MF'2 O5R16>HYKKP&SO";(D:@1(!D3
MEBG'MLO2<(S.)H_AI3P@E<$264$%2AGD..$\</N F,4E.2&TIN36<.T!3=RK
M%NY'.Y_;Z;+JB1>SD:J>&.H)2E(P##"?A%R*[))%SNN HF?*,QJTB5N9!Y08
MH2*+H%8RT3CU##F./:+8Q^2EI_$&+'&'TQ/Z!/-ZJ%?QJB[I"\"KY*B25(-Y
MFD@&("*1<SD-06*;DE8)O.PM+AT?M&5@!ALF ..P\T@'^+:, &_)"D;,]9E2
M%:^.QZJM@=M]N;8P27$^HIB8EKSQIVG>_9DW\>W$3JO:>#$[JZJ-H=H0WC.7
M3^R$<EEM:(^L5Q(Q;JET5E@6MKJ*<1&<$H:AZ(Q#7&L&"D1SY#"5/M"4"GEN
M34DX?J&N./7LEO29XE3@PE,-.&4PHXA'G)OB$@<^.78\4A8BVZ**%#2"X0N(
M4=+_.4O9&N8)J9Q2Q16G++=@>(B4!"+,B3;[J=I?EF37B.W]V+:45=NVZHRJ
M,_IT6ZL-3<&CJ"78MB&WX$G$HL UEU(I(_16"-=%CUE4"AF7,.))4- XE"'F
MJ)=8!VGP5L?<>TIC$^)$&EYU1@6KNJ3/'ZRX<C11CY&W'HQ5$0&LE-9(DV ,
MY91CB;?.FZS#H?08(Q; *GJ!M(\*.:<<E\8SJGEUQ)^ ;5OCMC>P;7]X]_9M
M-6@/LIVNYWA\,AONEHO^12R7STG/:.-4\LPBRD&[<.TIT@!(2+%HJ14Q4KE5
M@\93"H1I@5C",;,8@7E,343$"&<Q]4J[AZI4UB?BOHL[;D+H^=RW1\7$BHDO
M!Q,!P0BS,B%K<^X$4QPY 4A'L/):.QTUW^K5&[RG3G"'C*4$<2<E8*(3*!+G
MD_586/9,NLP\*SQ\L-AS&?T8K-=I>]?;&.SME.37;VXRO&L[FT=MS_\^6]I)
M[@,1YQ]BR'(\2ILF?E5<A]V?])3F#1IF*S>)+U1U[9Z#9ZJ\(@N6Z^014TXB
M;AQ%QJMLU2>P[EG$(L6KRHL$+C#)YZ$6=!T7RB##K4-1$\-)E(S@SP6.WMB+
M,>SK1H?]UF[N'V?SQGO_J=W9=Z[,DTJ<,'//S$N?E9RGI]\J;%;8K+!Y ]A4
MTAH?E$:)<(:X)0%I0@Q2/ J-O34A;-G\29+D@Q=(J=S4.&B3H5:CR+$0!CM#
M\>=JEQ\$-L4)U^J$XGLN#WQFL#ET"^!G"Z_QEVX"?UF=Q_G8P^]A_&'/7^&K
MQP&@@V=3>/9G'W?3F<HO5UY]X\V[<ZOD"/.Y(14U.<DJ>.1P@MT!3K!GFD9%
MPE;=@67<8.U0<L(B+G/G0Q8""BP9+6WB*5U#\_@[W.R["?SPU2@NO+W(#M=\
M%6\F;_JZB3FX>U2>]K%Q,=UL$JYZ;K=9)H)/][6)/H+1C88[[09K(A]G3>[V
MDJ]+7YCOHX_G+LY'C)R4DZJ3T?(LC@#X84"7HX]V,;*KY=EL#L\*H^6LN+YQ
MM+K(/^]:LB\8V>%Y1HS@-K=QPBH%\ Q -VJ#%6*1>F]@-_M<PGAW;V)7W_[7
M_2S=U77 )S =^?][E>##"\NH>8\L,1?]MFWZ"-GER(XN['STP4Y6I1+[WXY-
M+KBG6DA!D' 28%[) &N<RV%3=-%QI[$\B)>Y*1=O[?S7^;NE7<;PCSPU;^.\
MB,J&?/P=?LS7PU6+7]/KHISL][/)Q,X7[=6@(O($XJ$0L6N$")]BO+\KS"/(
MS\?Q\NSH\"(12K6,,==%8\0QU\@PJQ )%%O)&2-N*R_[4'AQV\I#M(@^KW>.
MWB[B=&]I#(<;*".1$50A_O^S]Z9-CAQ'FO!?2>.*.Z09HA3WT:V568O'&-<T
M(HVDM#:?7HNS"Q(*J$$"W5WZ]:]')H "*H$Z@4("%=R=%@K(,\+]\=L]4HN,
MQ!YYI0(VW#O;G3BZKU=[1F"@\U;CR1;J[0\YWP7!!3PVPC%4D^EZ-XJ+MZ!-
M_#*?9@MPEM6"K$" J7W5B(O\QW_%Z4=0,3Y\G,9X!<</JN'550Q# +W1#:SE
M$!8,SO.C2;UHOGQ[UJ"*UE^V"WQWZ,A_U'>5R.4.P,IO- 39>K]&T=EVST;M
M\<VXO]S^>3B&@V\%8#YN_2F:.)9Z7V^TB1XTCP"'CJOXQ5_:\<?F0NLWR?&$
MS:LNM*[_V+Q4-6^>T-Y>J9I:8(!\5M\0E;+(0?G2B&I"<M4*0RX"CGB*30K>
M19HZL*,P!\43S*@D4A.,Y$@S(9 +#-#9.2:ZE2Z;L--.9IP-P?"]'=+X:UZC
M#1"";W:(4_FP..5&ZMUNB==GN(OJ=Z 8?SN3LE'5KZ^GDQRK<C<5,!N\+Q Z
MD$SOZ"1Q:4S,PTURIU8>'0@J1\&F3MKSQ 3GM"-YGT(G_P*^? <*5W;ZV8_Q
MY[0F;A?R-VW2T :E7,_7%"]$UTF%/D J<K?+__6)Y.LELF0@0AL]0%? <P=!
M!]6G2=,"/Y-3E9%G!&0VLC4</,X@9&MT"XT9M=>ARMEZ6+\)@;?=?*:#S:E8
MIV4_$^LU\RGF=NV@ $:ID5-8(.6(\%)J#WQYERNE% ( /R(9M$.<!T!\RB42
MTEN<$G9:=&I.BOU\6O8SV)+16$>14,$@;HC*5:DLU\P3;X*P1G;:L[R<+HK]
MW'?[F1D7M24&:2(D['$"NB#,(FM4M'D8?/#D4'AQ8/M96J&9# '90$W.JHO(
M>+"D&15"8RM9,)V*EGV]6K&?-^WGA^C^H5C15]N#/S&IF)R-0+.8(9ZRK4)-
M1C6,02T57MG.%C\G^/.;OXQA/HIK&F=&K7I7&*BYY7 ,"_%A]MCG_/](CY6@
MNS;ZK4(TV&6OPRU D<P:YD*!30#ID\_YIV\:*WHRK^'0>I!MXIAS.AO_@+V:
MS,>S^MMW*PWT;KSS5C$-PT_/P-"6EA8[9-<SF1ZY2\LX;1.FW98J":LS64:H
M\X[!.V>=-Q^.1O8&5JG-HGW?;@C!(*N^7I[@L^2[KN.[.H)* 4)QJ3PW>0GM
MM;_:ED+Z:5@/W7 TG-V\6UYC5^U6<ULF+HS^^OU7?[SG&/+"W\T%YP>^Q8._
MDPOYXF>XH/3%*X$Y7OOOX*_]P._Z\)O_\)*H)UWA@=QI_?34Z:V@NIUG'EW:
MJ/N9"5T])OWFP8KGY4,=\+UOD[P.F:T'*YE__3]?$?W5_6__I*J4HZW/<](L
M=BU?1QEX/ND\IG:C#\NW1_(J*%50:N\H10M(W8U6KBR2/[GI'__<FB7-QULW
M9,&M9Z9P%PXK'';+86L,UOJUFB_ =F_^=\V+5_BM\%OAM^?RVW=V.KW)[K&&
MK9IX26&HPE"%H9[+4'\=_L]\&!H/;V&IPE*%I?8@HYI,H5N%L/G45 [F4,C?
MKQ>_W:;P%78KS?M>RWFT$;'\+4Z'\!R_Q1AVE:F5VO5[7OH\VF&6'J\;Q761
M"QP4159)FXNH(C):6^2H$\I(G3 6G8;47)#HHT06.P;G*(V,$ HQ;$RB*0]%
M>*!6=L_)@5+S@6)E3M<9$'B!L;>PR_NO!64BSP>4" N6:X1I0II8AJ+6Q,2@
M 2$Z%2K[@K&]=!'=_EI.J^!CRD_G->*&&J2C54ARR8T!%8^P3NKVOEYK?T,4
M=\-SP>M3Y^2"UV]AE_>.UXX0+[$#3+,YKY)CL%,MXRCD:7W!2(+# =3.QMNW
M66CPV_>K4@*VCFGHH5H"(@:&EE$H9T#<;Q#"-OEYU[O^X2RW>__U=2PI2A4@
M&,TCJRUQH*2!IA9PC*#V2,E=IX[JY5BV%LEH?XAC'_<*<') B"@ 5_R 94O/
M'\2BLU@$21%A2B".14(VUT%1XH5U+$JG7Z20-:7[:XTGEP&B'!^Z#0T5/^ I
M]I5_.Z&C#R5N5.1%D1<@+XP(D=L\V$]ZB3@Q EG#/4K):VE5S W*NF6VU/!$
M*$I$YCE/C""'+4%,AZ ]"Y8(_:IQ(SK U SD/<U="HF?#(D7('L+N[S_GE7&
MF4 "0=XHF7M6Y=@WX4A%BT,R4NFTI5GT?H#L@)&C0'CR1C)DO!7YM1(RRBJ$
MG2.6Q\2$.-AK[2]R=!] %\0^=5XNB/T6=GGOB"TLI<92CJC6N2=';LC#?$*$
M"NQ-4#8QO7]HVZ=K5:F!8D7I/ /B+A#V%G9Y[Q 6..921(<"BQ[@2 1D"7;(
M*\X4<XPINJ5)U4LA[. A(T,&XIX&C87BBPNP)Z]<0&P/(2-B6!0&(T&X0=P*
M!<9F_F2X20H0"1OS$A![E9!1<0&6>J,#!XW^@D@)&Q69461&'G&IC5.82*1X
MEA2$>60]2 (,QKN-@3J/.[E2($P,\3Z"I% 1Y(Q7R!$?$"."L*"D4GF>SVOV
M(A\0S =$'7B>92'Q8L&77>XID$F6C! X(I:L0CPD@[2P A%)+%>.*IXZ0PGW
M!60'#!N1:+UP%!0[$27B+NOT$@L4X?F$84DJT_&M[NNU]A<VN@^@"V*?.B\7
MQ'X+N[QWQ+9*4R>,0<'9A'C2&#FI8V[J+@V5W//@]P]M^W2O"C50F!4(.WWB
M+A#V%G9Y_Q!FF3':<B2I 0BSH'DZ)22BAC!C@Z!,'T#I/'C82.A[YWH5BB\N
MP)Z\<@&Q/<2^&0TT1XQ$4KE51R1(I\A14C(%C+VQ[$4NP%<)&Q478*DU.GC8
MB):PT;YEQL/M.4^&Y9ZYZ4]J4'I.<H<HKYAA&I1G21'WGB*7E$="8:J%((KJ
M3D9\LCR&$!+R,DC$@S!(4Z41"\9R;"0.^H$AYGL//6$F!U(<.%WA,8U6SYU1
M^L$&!3"/30=O%C"C%Y3FX+PW1K2-F@S7 N&H-2!F8I;:0P'F 4-<W/*4.)/(
M.Y$['5"-;.0)"2&5,YXH8^2A7FN/E5&4#3A1KQS@*G*AR(4B%]ZX7$C81.6L
M0 'G:=G*!) +1"$5!4L4^Q1CI_3_Y0"ZU]96]/!U"@4J"U06J'SC4"FLUS1R
MA9*,!''*-=),FESL93AEUK-$]@^5AV\-6/"S!/4*6!:PW&\/?RZH3<8@YD1$
MG$N+<DX#XL:F&%CRC-.7@.7KU)/MM,L+-NXS=/B,BK/FZ8?C  _57O4YL<3%
MDN37;R^R?M7%:O8ZU/C[9&9'14[MEP7I!<T\&";S///N;4JJ[6MPIK**>!*,
MD0KIR 7BT@6DN67($VUB4!H'WZF3(,0[ARU%-!*-N'(@JZ3 <"*W@3CMJ3.O
M&DSD RW$@!ZZ8>Z]9')Z\JKX0@IL%MA\)FP*JZAR )LVSWX15""MHD8):^])
MRMUP.C48^X+- X84K0DJD"B0PBXA3@)&-NF(O"/$Y787P77&=.WKM?874N0#
MS.F.3.PB'XI\>,/RX3CS<MZTH)#&*.H042DBSCA!EBN,L##<,2%HDIUQ%"]'
MU/V.SV$#+0]<K5>@LT!G@<X"G1OI&23DF6,:64-,'AR;QY%AA007FD67(K&=
MWI(OA\[#QQR5/OP\LH*GQ9W;)_ L?HG7P4SM)946)V0] "=W@2)C21Z&YG5B
MUDIL.ZTLGX*9KQ)ZO,]^+QCYF/ C?,Z[TOH[\@6&X[E=K& 8?GK4*Q$-?[]N
MJ*^YV^<V7.HFHW W"GG?T[2'YEN]&\[@*?Q.SODU7[\>5+?BO:[L.,#?PT_#
M4?P(?TY2M5')N*-\L9>O5ZT3R"/V61YGFQ_WVCN#OY?QWAVJ;+.)WT<?KUR<
M5HP,*HHIK2YMJ&9P<IJ,1I//P_''J@'FE@*N;RGBHOIIW!P8AK6?UQG5*A?A
ME$'S[;8ZU]]B#-WG&(>=)W2&\.V^]I;6J_=>>DO-;04P#,@_&D7 TD]Q=%.M
M?I]-\GKE:_WO_Z4IQ>_O7=OF&/(>,'X4Z[JJKP&W4X97N.1X,HOAXB7\\3*Z
M>"KQ'POD]LWTM[+W\&M?H&CC)7^P_K)JE)R'Q$;U.38L.&[T$9#/@\K.&K:;
M7#<Z')R?_[H$V0"8!1^G<9*:@^SXIIK! S5,GZ:3J_8O8-S\OX/FZ\_#V>5D
MWE[PVMY<P>/E*]H0AOGJ=I1O70_ATHTJ4+F;K7<;CN&J]1Q>"A2SC)UPC33/
MS'UMAZ&Y$ZADR-8U<'_6,MJ7;_#6-YHAK/\"@H<UJ'V@7,/:P2+ #4'Y&.8(
M3_O6 +W#_%S#K$4"Z@( #^'?Q8/Y%4TOOA^.JY@2P-=RV9HU:&Z[//*B^GW]
MPIU++%9X)WQO1]F=AW=!]C.\]1^V\> 3*&WO5@'S'M.(?>[L21 7GB/ML$-6
M1XF%(SZI3J<2'ZF/6'K$HI6(:SC'<BX12392I1(QFMWO2?GNEM!OX>F7O V;
MGA3XF,^PLUC_G#Y<P?)Z^SW(*3NMF\C@RL^"UXT(^E#^(KX@NYW6KP\3@TV2
M?S)ELM,@-8FY!0O4($4I&)/8,F1DG@_#@_$* QV93DT5BRXW-!3(N-R"5I,\
MN3!JI)0)T6'#I>DWJ<D+LKN/P4F16D<E[2>5>9*G]5*#G',BNSD\<MX3% QS
MD6B-O>NX.2S.O@RM49#8(!X<1EKQ )^D=XD2+$GJ,Y5Q<8%W=VDZ*2K;9LWT
MDLZH8,)&JQ'Q,H<@B$<&)Q"".<5'V>"<['0.D)*$E)A OJ%-'@72-B:4B+("
MXTABM'VF,T$O1)\$Y\K.?2:IG8B.EC@H9T%S1(4#?0LKBHS2"E'+C&,!2T8[
M77T(H9@ZKE#,X,=58LB% )>@1OGD'7$$]YK4Q(79'0A[?5*[J(YW[]]61M0&
M&5^O:+=>.7'JN?MGMH*RVR;\<U[/LJE7YS_AX%'S"W##RJBZ8Y<->N*=@5V/
M7_QH'N*?_P1FX8H'1_$+"L-I;(CA'3S8_&K\/@SKZY&]>9=_?7^=3=KQQ[6R
MH6%[ST6E3?M%7IAANEG>OCD5Q7%X[R9?\GO %=ZM0@!?#NWGOPTRO?ZR_XB.
MM^6$BHV 18X^M$&*/UVN*J2N[<?8%C\AFV"9WMG19WM3O__JCQNDL=SW9B.V
M;_I1]O;1<>"U>]-GKN>6&% 3T/GC.CN=JZNM=9/5@R/"]&<[G=IQ#A]-IM4D
M.\V6 83&:^9J/QVZ'%Z8Y@/@N^OYU%_:.F[ZQO+O]HX_[AJNU;C2!E7C6)]=
MVO%V1QA\.5[WAH&"E&\=_V>>?7[M'1I/&\ =/&G[!0#H,#\W/(<#-6JQDO <
M +7VNO'D_KO]]I3\]P_R41_I^,'H5=90UZ0\7"O8V61ZLTX*\^O)@CQ&DSJ[
M5+.OMZI!"^MX8K.;.#N%YVXT](T[^59QAK]&T=:S_FG$Q+/@:+;0$V-@IF..
MK"<"1<>)I$08J3OY7P$SDGADR$LXG#NPU1S'+C=F#IY@0W5NZ;.I$?\&2_9S
M:A:^T7Q_B=.%3GMX#9@0<F%VYSD<@0%7*%1]LZYG7E]/)T S\/IK.F?&H$Q8
M\=,RUG '?#:P9P-Z;N&S'L(#VBX,?9NO;JLTG%ZA3,W#]I;S,0#FY^EP!@^\
MI.@)X."TB>7&>CZ:Y4_YW-Y2-A"VB,Q+)$D RLZ^3DN30()0XGDD.+*.^RII
M*B(U&HDH@24BM\@ZI9"0'!,IHA"Y)NBNK3?Q,8;ZQ^GDZJ>%.? 3$/+0CGYI
M5N[GQ<(],K7Q(6I6XJ)7M Q'CQ9QM8_3"8C4Z\6"9))>!^ V;/0@),,J3!Z/
MRY\FL^RTJ);$FJ7]@D]NXV[U!@;WC5 %X=8%;Y%B376P$,@P31 QR:@@+=:A
M4[WP% ANTLD ;[-U!#; SVFM"&Q1%98V'18;E JZU2WN9NI\//#>,R?Y]0GU
MZR5-9,4.36[78"VT>A]Q#C*MY<,SC599&1AEM< "Q<-6PMO8&BW"SFVVQX9V
MX&P]/"F=[TQR-KY?:N@E9>,(^O<:_-[/6L/Q6E[87>997&70IG; U8>S4<MB
MH,[$X2>PY3X#3P\:S@0S;9@R1H&ZTZ9#9)[_;G(%"W"3LZJ(>E]7?YG8:6B2
MUQHGV"1??67,M<K[-*MA<$3?Q(5BR?G<^$A9Z1'7(B#+HT,J&F7S3&2?.AJ[
M 77>$!I1E [$19().<,Y8MA1&P7EQI'[?=A+/OH55N56ENQ+4/0IY/8UT-!X
MGA/M+JH5>F2(?SCK**?L^/G5?&1S\E^;+Y2_O[8W30[/9#RZ:4AU&YFN7_X>
M.FVUJ$<R5I=CKFW.TAY>9^(&I@OK+[@AL+;(M$:&/>KY_V/[D_\VS-R]]47S
M+XWC:0"KN/98EQ86TD6XY?)>18B^NKQ:*]=:2^@N$O65R>^GNXZ \0WHI*,Y
M0#%81V $#<>W?XYN]RR+MKJ&7]H_/@];M7=^G<\),5X! Z\=?GN#=4X=W+6G
M'J<UMV[4=6V[ TDNMDF/.:URH:+GO,=9]]KVDQV.&B3-KEUXJ=ETZ)JWRM<9
MPAGK^@)<& Z+S3(M4S7AH4>C?,<K&^+29;?V4ALQO 8 KR:PH%7\'Y (R^,W
M4BJ7^92W+IWKT;QN;GJ+8K<X.<_.E>9UVUS0\47U([Q+_GDXNQGLOO[;3*J4
M&%,<;3-W-]NY(B%M#45*@,U,DQ;>=G)#GI-4>4SW9-^2*-=C),\FQQ/)I.3&
M*.>H0S@U8YZX1H9:GSN"$NZ"2)AT>O$\)Y/RJ/35L\S)E]+7B:1/,D&)44!0
MB;%<\1D(R@-Y$>8X">:$];YCISTG??*8I-6W=,F7DM;)Y$P"[41NO$1"<< M
M#;:\"XDB[ 4@%O'*I$YKM.?D3!Z3N'J7(WFKXG6R)1]-7R>B=P67F#:!(N=4
MIA5FD(T"R$T %%D)I"?8/A(ECTI?/4N,O*6O4W)QG&1NR$^IC2 >P8)^NFG;
M&,S#<3U/:>B'^<*-'^_FKNWZD!G>%!@N#5JX!"RNO\P_W&S:Y,^U]%O;N@7(
MJ<V]$6Z:#('&$EY[GTT;_YX7;X("D^O)=&GAY]/@2:[;XNK%JS0Y7+/J\V0^
M"FVVP^=A'5NO0NMVA>LLSEK>>_%&EW&TC!!<M031E&1N/D2J[&K9ZC57;A-U
M'LXN5]=>5G0N+K[P_(*E#_?/2W]*7'TFCLM?8XA7C5NY."O[F'[7=DWY"&<T
MG1(RDC;<M4KOF'@_G[9!P2;S:1?6#A9H-APWV;D!#@4UX6-L$D1O$_9R N?,
MCG-N#MPP\_6]#L>+ZL/V#A>#>QZE>;'Q9+9*/+WU<DXG+K]> 8)79[E_M*D;
M;5>:@@7]307HA@>:#"]G:_AK 0JW+1.6[OI6XC9Z !PPG*Y7]+2_W48QF]8+
MDZVAS3L=#QIIGF]_4?WP)8<GLR1?=F*I_'#JYU<93GRL!X]^OU9+:EZJFTC4
MZ!-M-GHG_>&44.,DC8([5#J-?M)&L-<TQH?<WKMRQIJJD;KM")2=!^W6QVO;
M9)D\+8ML2QY,; O2/D] ZF7>Z.1>/B6AX*DOOJ7#TA'?^NY3'O+-_W*R;]X3
M+%DX7_XV;WPZMY5K&[6*M_=\"%96WJS%!9?.+!N,=90C3[(S*RB<VX-KY!7&
MFAC)I.A4_4;+N,':H>3RV&))++(L!!18,EK:Q%-R=YU9WP_K7"8RG\:?4TXX
MB^.ZT0M_C2/8]?#=I)ZU_JJ_9&GV2QN2KG^'F_YEU&3=QMK;:[C@;#J/CRNG
M.['^@3L+&,E%RT"H%?3KJW>$/H GKJP=O/LAF$!LH<[\W#;5RACWTSAG!6;'
MS"\C>XQM*UKWW72AX\'\WR:?6I,YT\I@:PZN6XJEL!1+E0V3ZT8.;CG\,417
M?;/67[$Y(7^[Z*7X;2OO5U^WU2:YYNK3[D3AC80B4/\WWJMY A<]2(%%F6A^
MD+M']436EE8 ;Z,5@"RM $HK@/T0T_"8$@0^C5M0:MTB8!A=C^)Z!.F_&@_O
M750?MK67C4.YCM.,[7V+KM-$"6%1(T9R<H_$V2"1! D=?(PVAA@ZJ4&12T'S
M> X?\NQJXR2R42O$DZ%!Y*(/UXFNK_60_ZXM^VWK_7Y=+,R/D^F/\QG8*\NZ
MU1?VE-=:###M54+0PHC/L<6[_7H6O7X^@Q92;V]*](0'V&%Z8FN"%=P@G <7
M<B(U[)JRB!AOK52*>]-I"OH<T_/6K%PWG3[D-AH?8S8S_W+3L3P_Y#?_/N9F
M&HT^=2PE==D[=W#'N;NKX^U&P'BUH4W)>G.%-05OV"9[VSF JITMVF</QQY$
MWYH_.0VG]:P*]B;?*^9.PSF;9!SLM+J)\$^83Y?==.&I4?-=[K>[Q*'5#0=P
M,T#Q<9/FGC'K_]KQ/*<2M&$CWNB+<9$&W_F=@9Z\T$+O9IV+5?'J>B;]MJ7:
MIL/>K>M9"V<M3[G.E73-13=?'5:X\8+G7BEPPN*Y[-V.PX]3[U=>IX[;YVCP
M4#5,4%<?<[\9>)=M5!2_7 ^;XJXJNW&FBY8Q<=RL4+UH%)V;V"\*!IMKM6G]
MBR5?=M19ZT+=IHJUP8"/<1RGR\[NF5YO.],0C%=;G^QP6H&>\*\XJS[E64E+
M^EU0;GO?%R^F>:FQ\?K;N#U*VYJ=L'.+!)K*?OPXC1_S+O5.(:#<8>X9* 0"
M1#JW.0W=4!22DL$J*K3KB FMF?."<11URF4.1B"7!(5_" X\4LN).+1"\-/?
M?GQ0)3 #0VD/58*[<F6E+6Z(E8S8O:.6Z(AT'H/NYW-R)FB.SF&)F*+Y_Z7H
M0J>SR7.HY=E*Q=\:P?1S6DR@7PILH*[_S!CU8J*B0@RDX3TDJEOE!*1V \C;
M1,K%<=V/AUJ$KJW<7\/X%7SDQ"S<E6?L&']5'\ZKTN4!QYH>T)9:&A29^KJ#
MCK:6Y6\XW7=2;?5-=I8#PN?DNBVS4=;\[IOI+QW_>^?GG!>7"V5OK?06.%<F
M^DI_7K?8&\D,D#L#17JVZMR;!4L3#(]7UZ/)3<R9.<L0^0[K:-N*+,:O+"_2
MI/+-1SESL/W1AD_#>I5!T'VC6Q_4XMW"5@_$_#H_:M_4"T=%H,YBE"C\PS6W
MR'&94.Z8%H ^,,&=V@\N@E/",!2=<7".9KF'%4<.4^D#3<DX?VSO%"%X0'6O
M*CZVJZ*[J&K1L'+1@C1GEBSX$6R;_[)+IO^_\W&C:N!!]3.0\R(*!7]] )MS
ME#^#>;0>H"(-2?^7G8*=WZ@HN>G:) S3S>,<,L/%>,HU3:?S[!?5;[>]4Q>Y
M*FMW;%[D:NVWS@4&FU_Y)MN_K;KJ)Q<QIC5W$?C .. (%C32'AL4HW4JT:2M
M)'>YR%&I?*02J=S?AX/=A&QF*LVQ]? +=[;#1?M2TN>SR\D4EBJ\D,L45P,E
M3L'@NX]<>Q*S+1K8R6E@=\-6F;[:4H1!ZUM>. #7NU;O*+#:;"_<%#GEB9MK
M'N ,W #W7^+4#^L-]^46G>3J*H;<6[;12H9MX^Q\Z ^KS(7?&U7N\V5L>L;"
M$=D?^0ETK%P4MJC76,^BAJO>^S8/.J/7\R=@ZX8+P]GE,J^/0[COM/72@RIP
M5?V&="L9%Y?,11OS7(+1+NO:LCQSB;.+T.<,T$8_6^U>=G37C?Z[U@U\]7Y+
MK^]M0++Z\'$:&^C]=FOR:+,;RPKB]N++C-,U=;>RRZMD!WM;W=*XXI_[<G45
MFW8T/H9V&3N"_3[J66O(ND& "UU\]0JW:3#K"W/K3&_(>#%?XU:1\7G%F])#
MD"TIYG+?MFGZ\A7O1AEN0SLAM"FQ:QF[*T_>'EPO!5Y[!*];J?9Q?EP@I/QI
M%P'?1_K;IQRWR5_-N..,C'U3/SEU(2@PPVSDH$K:/%3+&@V?@J.)6\,(O:M^
M*J\DP48@GW*PFGJ/+%,1:6TB:+,V\6Z7R-<VXB3& Z-4#]7+/D8*HE)1 S;
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M">1HGM[!B "#P'$DB8^<"U#\S;Z34-=$WIVZY+UUIB\94,5<*/A;\+?_^,L
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M=Y*=\BS<* IXN)#97^$.%H9%C<4R>M5S@,LH*8$F[(-&U+-(*B7@:<+/J&0
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M_<0]8+V=%N%^WC56W>X"[>U _EZ]H7C8P]RZ.;P%WZ#SHO7ZK-@I%PX=L ,
M1J]8>L[6I2RRTT>-YMSI(,8/_4'.]B;D8^RM7-P]<@B2@["OY?_S]W 3? _8
M]0'6HOASY?@V"+[G-2U8=@HO)AFYX]XF)3LM.%_"PU+Y1U(ME*,PQ *3#'\
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M\'>6GS'1.E8\>Y_FYY]X521A\\M)#A/@:\I7$*,9]23[??YUKGS*BU.@NV/
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M%7K9!>,#-/UG?4IQ"3S/J#G/F0*J^ZEH*][H<.36QF;$H'&7,#\K9*?U<I6
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MO_NO)-V(][:K_J^/7UZ2OXC.:91F<:@0:;/A)^VX[]434/Z' Z^:DT!2A^&
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M0&*[,N3P'E?/S;*9N0J6UF\I^YF?+(&R_\ 2W\@'^CDNOK"OK[*;V<YMB&
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M)-D_68Z FQ-'/Z(>L;K*7TO6B&M!3@E+Q]=5$')Y#<(J^<FCUZWTGX/\EQ_
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MS[/B2U6*N:E,\Z3_F*JDV:=(1RAKJ#CST,7JL5+VH-NVVA1Z)>NW%MLEOJ5
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M^58*(3*0J8U*@+NO)%JW^VI+3<@+07$_H'T-91"F4-+&D)7931F0,"]/QK'
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M!T$D,N&T6=A^#,5_$A#Q2P9R"P;D2%I :;\'UX:N#%DI:8MR%P99!"$^!G\
MP<*<D:)4<;N0N8#%;Q9!%)^FX^+W(#Y#1T;PBPAEX&:47Z#Q3?2[@P<[N M>
MCWYFJ&:[T8D?D\!S'P-[OP?^Z0>E/(1@[V4(L@#4R44P7P@_4F!,(52#Q;(5
MYS/#DH*M]%UD(&3[[JLM?O@+(6Z_K?^QSB16@9W =%J -0!L@A3^1817\)QB
MN<_BBL,#OP5A&+38>:R9!\P'1QD6,<R?,H9^#<P&-N=_!J&,,S\MG\@U)!(!
M/T8 $N%:>A[-DXY8I"SYGH-QPSXGCC.3?J =.GPH%',PD91=E9+;-7>X[T@
MA%(YP.D>P,]EDR7S 3+YG*Z:4TD-^&UE:XX3A!B-\9:P),%F'+:7F5@XLU.@
M:A@T<KP@2F ^M7[8SL(H0@Y:,I\3MI)O'S=1G!;&Y;$2>#"'FX2X+<2->G *
M6XMG(!F9#UPF4BXK#;T^F (!F&V!]!4^ Q8D(7L7\% 9BD 2/N(.]7,*=XVX
MUO%RQ[\-NEU#DPK\$ED"#6'4,0#"$OJ!,*Y"/E<XPA\W8 BI(8Y#[H U/0^
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M_2W[_>GOG58*UP) ]?B==GMUP.?:6AG_WV>"\7F0^''$0K$(PEBX^$<H(GB
MQ?CSU54HKG@LV%7(X3L7_YQR&;)K[B6"!5/U6!0'S@\6+&(9^(S?\-"-] LP
M8!RP( F9'_BG8K[P@J40S)6A<.(@C)B;A-*_8E,9@7Q@2\%#9K?MKL6<8+Y(
M\'T)(SI.$+K<=P2[D?&,?3R_?,?.+R_8]V A'3;LC"P6<EA("*L!*,:%C2VX
MU&L(86M 3/\+0TZ6ZI'J);48NTR<6?6&8<$!O ? X3\$+ T&QL7!3(S[2R:
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MN;BK;+DV-<J/67E?<>]@G<O2GZ#IP!%L]Y$[IA^:%-D$T)^[.H:-PN)*@-@
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M"18-E/N?:'Q6XW(6L!FL:R*$OZ6P/GM^>U^6*'%F>GF(, 72% K;!TTKQ-4
MZ5[6Z"SK]*)*@76S@/N07J=O2*]$2J.=*,GD45<14O&G,AVIWAO5_4$"7YPB
MS53U_-"=6#2:P]4V+:I2&\31G5UOGI04MW 2HKX2-KJ4O+ L!1[@>I!*NA8\
MG2-K5Q)QK]B[!D3NLL7.$:A3TU8E%%>!HIQ2^Y-5TC&D +:R0?2]N^=P\^*]
M&NFH9<PXF.H@L=I*1C"4>*WC56)(./SJ"M"FQ$36(J38U< "WG&\! NE024!
MYDP'@%+G U4SA2T(RF\NN%2-E;"K2,HMU7T-4)09=H@T/V0LH%K]9"U.%-J
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MSYZ=]EO=[O#5VP5W7>E?G>(JSX H!O!=?4RVE94\!"3_AWT3,%X$GR(V$;X
M@TYRCP4W/MAP,[D &X]Y(HI8/(.U=5YEJ2W/OU:V@CE77J<+<&6T\/CR;.J)
MVR)&!C#5GTD4R^DR'4@]<QK%/(S?*NB?PFKGT=F$1\*3OEC#4[X<)(#^JY="
MG)D]W:KT<;6G:L=;MOC3WT_R-KT%B.DQ.^WVZH@O0X<7X"[("&@0R.U$OF;C
MGFVUAWT6S3A0)WX;)"&X]O-Y@"L+G!]L)CR739;L//; _?@7C).$@GT$_XW]
MWT_Z1D2+!2$[_]=']06Z+B<2QNX,AY;=&=Y_[#\6BR",$U_&2SW/I_(\?\ 7
MK95WSJ,H</ 6ZRA;%9/(38)= ;N%P&L+P!/\A0O1:U5+W3[,YXMMH]RY@N_P
MXES,)^B[W?D"S.7@D;2#/I^W9'/^0S#I7XLH5K=ON\*1D00$,H#?1,RX-UT?
M-,?+YXL6RUH".(5N +@C;I:UTZH03,47?@O",&#O9* "@,.W(-$"'KKX4^;!
MMM@'[LQR6%MW0\O:#1]SOH3= S0$7C\5!P5Q"D #@:K098@N(S"UB!9['[8R
M,(A;E,@1O 2<Z7A<SC=*YL*(^'UA2 N&<<0BQH7@4R"S$%?PS@S O  /WI<\
M7 (>P3P#3.)#H9"^Q>04]KO<0L=%-OBT"TW_H1[;"L2U,1]&X)5+VY78J]:P
M/^%OGZ",^5T9H'*@G*XUO.\%I >@YX'TKH7DH]*[WN^^]*[(A$O0@5<,S#Y<
M4HX$&*/;;K/OPIGYH!"OENSR/PFLPV*C>,8^>D$06NR"SR>A=*_@VR_GK&UW
MNN-6;K2 \C7_W=%X:9/I8C?,=.F T6);X^Y@%^,"A_Z Y+@(951BM\ZP8%?\
M_N%<?8$,VK' +=EI;'C)\''$['9G7)"%%0)5SX%4CG]]U3]4K*/T"RYH@X!>
M>38=&/[ZY:N2'H6=:>FEN<_G5T9*Y[\QCN9#H)CV'8]^B#@&X59LR0SLUGK?
M0OX#@>*S"_CN"A[QXUG@@WQH(7^&PG> +_\1PG-?@AF?<Y?]VF)?^(_9_P;)
M',;XX-Z@L? =OT3A$%GLT@%.8N];[!+V*CS/@DTE'OLW]W[ /G'_WR0 _7]@
M/BW2LB6MBO+B=O:R6E8AJRZ\S =_D%#6[V\EC@I:4BB$[\U7L.'?8%2?_5MX
MT4P/5A"C."W0N>_(!8P^22+@5_4+GB#D$++6R2S?G568#O?])<PPHRAL$S]9
MK#/N]]@OH1!^A(NX F2!2@<$)R 3V*#=MAA6<?@RF0-YO&=VISWNWG\/)1*P
MU/HRBOT"2#24B=\7" \_%D@*/R)%W;$E>]3OJ]VS7R7L_UO 71A*^%Z X/N!
MW.#):1""V@-OJFWW[[\=7$G*.MG2#'/<!?!VC_5!,YY?"S\1B(!<3>)K_Q/@
M$G__'WBPW>[LHB658M , 2;7&<CV9.Z_+>G.-%J3ZK]67VJQ;8[Y]!>5&D?X
M[MM)<(NJ $8XFP2A*T(8Z/:IPW=Y?/3Y-5>GWRV% %.HS[+ST07(8WWT><JG
ML,XS[MWP9?3VIS>KZ$EAKX!1#?@7@>^+QA?)W+N?N==MF+F'D:K.J&V-1KU=
MC+*/$E05NE"7 IU*]A5\JFG@R2 Z0_T?Y\Y%]HNE0U:]MF7WN_>:XTO< G49
M^O#$91SBU9_?0P#^67$5H831?@F#&Q#.%\$<8*D#6VI6W-MX:'7LT2//NV'"
MZ]?,[K>M<<>^UWPKH\&_V&#; ^OG:Q!X.NH'0ZNF.4^\D]\&:C,MACD31L&"
M!A97 9H<$?B@H8P1Y&C1KAIFPE4&584!5_DH+O3+-VT5.2*,N?1Q2@F$&263
M2+K@[:JIT-H$C>X9Q8R? ]3@N'E8-3P#ZYW(*_!\&3@(_PAF?@0[5O9K>J^Z
MI;8"UHL,@34RP_]B)L5T_:)U7(=9&Y@+>> %7TF'UTP'5J/O> DJCHHU6 I.
MVDH1;@!HY>C1JWB 96QC!$@(SX1!<C5C,>('?H/)#'&_8]=!C,.GJ,[PGT$O
M3 ] \+'>^%6Z5//B(KA9V=+WM7V8U!<%:T2]@F^V C7G+/!<A,., Z"4S@?T
M2A\0S$L/&"<@G9U?A4@)L&\@+!@4I!KX 3C)]@W>H$TX49M0\S#N.*!S.5IR
M-Q)H-E;^UI]!B'2,3]T)-" 3-09RU]+*80XZ/BQ':2I7E!*-R1X*_%(\YX[=
M6\4 WCH=E;G&,K#"YS[ET;J42\\=%1;J@%%L(8,!A\X!"2CAP\!3X1^-3@4G
M6/H"934\6"* @AUMOD>6L7M@DR?S.:)?B0R+O0M O/@F(@1^!46$]C(1>@TS
M$?J]@=6U=SK(^I+$"3ABZJ3$<*)2.%8YO/SA&F65*UK97^AY@7;ZHL(GFET*
M\?-"P)J[US)">1D41OD63$ ^7&BQF[ZT1;3?,2OR^4?IHSI,PN0:Y!!/XS-?
M9_"/UBP7P:F>HL"@Z1S*T\11E:-N5-#=,[=@+".-0$PM@A 4'G,X8!=%''#Y
M'>]K1UP! 5> OGRV X;R*9-*OOL&1D-*"R*IP&.4Q+61.BOQE1S66V:X,_8=
M)2#YS<B;8MUZ^YNCW679583)UMT#RO[9NL1@AO]#TR02Z#5@*T*L+B/,>F%?
MPP"^B*0*<?QV^N]/[++;ML'W[_?[['?V#0 57BC55PZ_J(>^2/ LDQ\"OH47
M^UV[8Y.DW$M2]ALF*>WAP!IU.[M(RJ]@4,=#.W6:@/+D-7)[+DRB/,J\\K V
M@>U!WQK9.X7IT_>+X:W5L?/?6B"QIE-@-N JCK97%CFM7-R&AZU4#L]3.9C'
MBU<WC]M9\QK4OG8Y1ML TA:#OPNR^5>0?[",PLHW_6X6'@6>*"QZ$U#V6SQ\
MT@;QIN'O,72+J>I['\\++H*9\-4N42B:3]4;JP;#8^UKP^CWVE9Z<K"1U+9L
M(=M^IIXV9XGM0E1?DS!*T(M#O\<OFB;S3!D7K?X"?ZTJ[/0$8O,C<_")T2^.
M2B:0[Y8]NU4K?\LV"B=TQIL)!?KW]\5T09.WLL$O^$+&\.2YMM$ +Y]\I[S%
M]4<VITAL LMC4>;&\>]%FSE]57/7IIT_]B[6QG\0AVTFQ:W[>"0F*^J@52NO
M2F=44#4@P7D3I+^D3(;K3E14+=(_F<.FRYC/87#XZ^([:P_&;;+8]K/8!@VS
MV/J]MM49[.3;?O5XS/VD: 7E1I3YK<7^K_27$IA$IN+ +7A_V1!(O.B/106'
M;*LWE@=>LZ2A?,XU5DFGP90?]H%U0Q=/,5-GQ<:SXDN ^A?@F !(_YR->[W=
MCC")]#>2_K !I/\.H.\J#8519Y]=.C/A)J"O.MU?V)\H&.'[J?0TA5V H'=%
M0=2GY+[Z@[7^:&:#??ZJ7SG_-7_JEZ_Y4)A-DWY_F9/YZE3Y3Y6/_Z+"G=E<
MGR]ZU8\5)K[$F5/E]9OP?0%6U"\AF)A2&\ZEQ$EE8U7L6VVK>@^67HB:0\^F
MPE+FN6\"\Q&1][_J4E-KS8Y;31-,7_V2>+$\O8PQ/'2U9!_^D^C=?>$11B94
M].US[&)&)$BB)9YW?(H\6$9D3DR6&@)?\E5??/CRL>C>;7K?DW.)IG=IG(M/
MGRNAK3;^[=T_"\2 P.?LO?#X#1HCZ7">Y!.ISJ-* W][]VMKG;2,8%VD!XQI
MTI62?1=?]+2PIA9B9X-5MCIH"Y&XQ1:%D5H&G>8A/_!/S7CI_(5QUZ& [U_>
M,0<,KPU*0X;IPU^!#*2;FKY; IL7*4T#S40K)P)9( U#I;"0E"S7#@.$L06W
M4BLN[3)(X!D@.HR6<E^9>CHZ9J&281AN W.0+WW!WGG72% F7-9%%?1%<LP=
M^O@9/G>ZI'[V4S^C!JB?U<2#;L>VVOV=#LLO@G >A.AW_^(%$R"T7P7WXIF#
M4J0@]ZQ4!Y2^R^IF[,[0ZG1V.D//)TQ#<X49\](9/9OYW-JZS&+>J/DU9=>M
MDP&OFH1U;6N:)\S7D0A!!O"-4J6H%-3!1KITHVB4>BLNO")0\57/$J73K 4]
MU'G,AIE0",P2T"3H'I;'J0@-%@!3VN@*F*H6F7NQFP:Q[MJF,@<BRN5[H5R^
M'N7R42[?4ZE4,/2D-C+/9M(%:^K^2K8!&G:W&-PN![&8:'+7,6R>>UV,/RC#
M<:.@13F+(7QE'&/""5B*%Q[FW;MYFEK?1@6BDZVS]!,>12#@$Q@.3(BVW>D,
M:E'*3=;J_:W5<<.L56R,8^]VV I>=!*QK\G$DT[NFV>'/>KGUH:G\L!":NV9
MYSX4?C).7:1_L]"8PIS)5=M/I?(5T]T>5%ACEHO,_@L\?LW9!&N>=9EFB <!
MGU R^!S-(/ATV;IHG9MJ\O6?5Q=?WIC9R*I5^*@;J5IS039=;EE\R5A<M6"+
MI;U;]UTU\'X[C&<\KASVSE%2<.CHV<K>U9?91E7\1!&ZSG/<A/\BC+;N>>4\
M[PFVO^U$;QT2_P;E)C!M+86"^2*#P )55)P&J/+]&SBM;/:7/)WV,7:FA]MA
M&Y>Q=&8J4'/N@F #^14"/,0/T,1!<5-&36>/JVUFV;2%A%;<:/96MLD46H^P
MP72H'3:'H;'S.4_ 'OFW!%68.#_*!)K[D?A55H2XLM-L%Z7O'V,OY0%WV-'J
MT8V6BKB2-?F(MM*PWV:?Q2T,#A915IG6;6^N3+/M]4DJ!=1=S%PB]B+Z5>V?
MP0:N\5^P.[$T%7R]GL6^)0@#YG'UTU__8G>[;V'5GT_MP: #_R:W@#50IU?K
M*RW#$P8'0S&!L=Z+21)%2X]SL M[ RS6&]E8]7@^QQB$R^>6&NMW@>:J"EUO
M@O5&J%9!DFR^?9KXM!MF]'5'UG"\M2Q*9>E[2R3.8!&K/AI*#F#83MR*T)$1
MMB!#:6O*&>#U\D]XZ"-]-F@SER]U,KZ8A GZ7/88X^AVC^AN/[IK8O>HGC7H
M[%0MAU+M&Y^S<[GD(-/"4%P'CJ*L-/->BU'S*6\A-;"MX6AKKNIS47=%4;?.
MT#;)/":K\4N+O4O"'R":O[;^@+^#6]:U!Q@7 '\$%1*JOU]9N]MI]XEE]F.9
MIG4M4:=)?:O3V2JN,^(?#JUNKQ:T3V2Z#YDVL=K:MJT.&)R[D"E0]&BX->A$
M9-H$,FU:Q9^^QXSHKNETU[3Z*12/@P[(O*T-P@KB<6B-N^,:T.D&,JW;2?)#
M<;2]ZW3-NDG?Z$/^2>"Y]]F[?A2G.L/Z!NELON(TS^T[3^)9$,+XKHXH15@:
MY CV3U6]KXYU5#^/A? C%53#W&P_VJ5_=Z_5[W:WM>H>W(7,.C;K_J[ZB7A>
M<(,LJ?JSLT487$L7#X-];&2@X<05I[T7CH[H=CN*T[K;:IVJ^%\QNXG#2L .
M($IW5L GQ2T('ER'T(ARBHA:(*):+TSSS\K0&AOI10MZH:IK/$_BX*W)D<&U
M8,H,+!T?/P7U$22@>.2M<-]FJJ4%RL6\@%G4?!&)LT@L.&8LIS!0%Q[HL7]:
MO=2HD*N1OE]U6Y%6CW:K;;\R.4 5OW<>^ENW-1P\]-V6_=!71ZU.[REVL^VW
M06NT&P2W7$ UNO_]4Y74O8[F^]Q),:J9 MK$@*@&V 7F[P?A\JY[.NZ\H21=
M[1,"I#HQ<#,0S S_A2T<)Z'\+RL"<7H:B5!.'_%6O&K(9.E\:=[E(L;C0>FR
M%'EU@-UCDM/O27KN63!._C8)W_Q=M]_ZI%7?/Q>@V-37'[2!JUHF_9'$X#+X
MJH65^O$/;2E;[-\\Q!2NR/2)A65$#Z/5+1C1$J+=K05.GN VI8>2Z//+MR>^
MP9)X54/NW^H9X9Z> T3XE2CSX]=0=Z[5C%C@S)0IU0_$F,28Q)C/H42_">S!
MH?*IKKGTE(LT514_ZH*)73U^=O+A-FT361A=^NRC#"/L[(?U(W?>-$I,_*!;
M<!T P=1Y5"^D>;?@?M@4Y&!\@2$876-<2/&,V-W9];C!TUYK,!H7_P\(\*X(
MTJ UA(=TOX/ /PN%Q[$4;>/J"U> /=A-.I!K.G<6X?78^AXDV[&Z]LBR[7&=
M"-$F0CS.[1X/W_W<&;1ZHSHQ79>8[CBW>SQ,U^WUK,Z@5JJN1USW$'=CZZ%'
MQ3'6#K>2'Y*[X0?Q1I?CX&YP?P+17^=KVQ]O9XW [A[\H>Z)L G9S4$VL?(A
M8Y=8^8B03:Q\R-@E5G[1 Y5C\7"^!S'W#HYY2#22:-SM,(;077MT'QDSEZE[
MX^G&P:%Y'ZXNGO0T$>?$T8?,T4>&W<<[/CH.9*>>"_R+F7FKM<'%(J9>JV^/
M7KW=5"Z,U72/5S",Q7O#%RL8[K6&?;LS' UZ8[L[[ WMAU4/-Z!X^).Z>UM$
MYI[RM*Y0G3.=J2]5T2"F8%KF8V=<^/A97'%GR7X+PC H/]53'[,KG]4P'RZ_
M?FTIJHON*$HGPMN#\)K0>R8CO,PK2JM0L<I490DG6&QCK@O/:FV"0D9_D);9
M9'>Y#=IM:SP<LAL18DO_*)GKF\]A7E\WFL]O/O\BPBL1[M(A@8AQ#V)L0H<9
M+*J^,54EC.NJDISJ%JJB!%MI<<])/'5SYF3E'J@B6>K":4.<1%]/3%]-: US
M7EV+CS<YQ1@#55<?]_O6(&^6J"08_('7?>C>"#*ME%@4+E M:6C=@#4?DHU&
M5K]M/W1(K:T_YLT&,J%IP5C,E:[*1+E23>JQHR]>2>5&IC] A;&060593[T*
M\V&2P&">5^*HTL"J];Y.A$$(2S\1NC4LN\+K_LQ57_H6]*Q! ?@C<^!%U2DO
MA]>,8P$8$_ :WC?KZTX*D51ZAZMU!#>ZUZF"KI\ 8*7OA )X"_6*NL<JJWHQ
M<.:E.I<,QD6PI O0Z^:N"XLVRFZJREE<KAHD_X/[V"?%HOM47N8^E3[=I_+L
M]ZF0-LRTX5'<N*)6BC):6>9&XC&M(GL62EF4O?,@ 2TC_H,2V"@I3T21%KS8
M]JK_*FU]6M0<:\*YJL>-D;QR#MX"7H(,)AULT!%JA(+61JVE^F8I%;0N]R/F
M"E0T,M=!(-NS)O)!UE<]5P"P.W5;H(,*)4HF?YJN/-Q%K*K6^T;-8 =7?:V,
M635@3L:6^0#HQ?L-75QB@"V[F3/C_I524FJ_^M)I^;\JCU1WC,TALJGC5T&I
M*RV?-?_9[OIKG9_J^#P6D#4. [TX%7AOI04+ ]WHX5\@19W_)*# %.R2".WN
M0-V+AG>EJ;[SF 4;324\@;0">-9X2S4LH@*W8&50N$'[7:-$F>TG&C:P$!\G
M24W\UUF88@-,LI7CO*IQL').BXXI+]G]N *\9L?3UR>D-P8I8.*6G.QFXA4W
M W?,;_4\^M+/M*^:,1/66C:56[OM;'L4C2&T]%[4&%(+N,L84HR2641WB W#
M?F494;:'*T2!95H[[RQ+'B1'+"-(-DJ2-:S>3[)HP_U[%3HR\[\* >#B/K,(
M,NLSX^O^66X@=(J[U"$B<V&BIC.@OS"8KZ)[C_:!G=&^7>"8=/_[)S0R_E^G
M^[P=]S;&UF QK--ML0L1QAR ^TUX?)^+OAYY?2HP,I,+TWU#Z)#*=] P$7=,
M2 ]_>9_>_/X)B'4AL*V?(Q[04>Z%&OT]0Q_%$'L@O&,7@:_.H)!]OH9B*D+4
MHI>*+<W-PO[5"Q# [EMAF[!Z^!T=/_GL=[ &E" $808B+5,5^%%?$<-#T!,Z
M9E2RNR+ B%+'5Z"SK_">5KQKK6NU1WVKWRTV:,>+P3*"661$8A0,J'<, H'$
MSBV1*?O9;@WT N"OX8@M,/PR,Q9<8<ZK,(C07@L<(5PUV\]XMV"; 2"\3-BO
MMJV,DCD@!& 795.K=XL;5.FDP[=;E@[:,#029&%NUC[1:]0^0P2&S;50"F6"
M5DVR<-7#H.%@)$\I.V6&&6V%.UOS$(R"TM&OUV=UN#21^FG6M9_F8- :#X9;
MFUMV'MP7L]OJ]K>._>+S4HO+QVIQB0X.7@[KQP?6X)):;STVK5RF>EYUMRN9
M".J;5'VJ#YF)J']"#4=]L^Z9&4<<=^0<IXM7%#L9X]7P%MC.ZJ^3GZD;'15/
M/5GQU'GL\8C]"SY@&\6/ ![V?S]9ZIILMD.OMWMD]M;E!)*2M"E)NVNU!SW+
M'G8)W<2Y-=@N<>ZNN!Y9=K]MM=N=XT(W-;]Z$+7@G!^0S!<AGHV?1U'@X)%J
MQ#K#U,BYNX\HB<H:;9=$Y:ZXMJWQL&/U.@-"-W%N#;9+G+N[D0.OX/^."]T4
MPGD0M7SU>,S])&*??$QQ5*E6GS]?L!V:-9-\K-%V23[NW@)GJ,(W1U9E3YQ[
M[*AL/.?VK*$*W]C'A6X*WSR(6OX_.<<\OW^V+EOL5\&]>.;P])3J4W9*=7=W
M?!*6-=HN"<O=S9Q.!\R<T9'%NHESCQV5C>?<+@5P*("S,[5\26(L@E1FC<FP
M_!XF46QA*>!$S+@WQ8*&#U@W)UU1-(7^RN>+M^RSG IVZ4@L;(KT."=]LHH.
MF]F.5;8.K9X]LOJ](Y.MQ+G'CLK&<Z[=)K.(HC\[D\LG_SJ)V-=DXDE'W^@.
MEE$:]!F0>7/83'.L0K)O]3%KI]TG=!/GUF"[Q+D[AVO[9-Y0U&?WM)U ^O'0
M9N]D$ MGQKZ&\AJ[8.19/&CL8![/D&R=P^:@8Y689.L0Y]9IN\2Y9.M0*.<)
M;!WLV_6-S]FY7/*0?0I#<1TXJBV3.NAB)R,R<0Z;<8Y54(YM:]0?$JZ);6NP
M76+;G8^JJ,B< CD[TLK'+]]TG&9,1LQA,\BQ2L.Q98_ZUF!(<1KBW#ILESAW
M=SN&XC04I]F97"YDS%WAL2^)%\O32[P41%PML^0;]H5'P 0ZP_AS[&*+P#89
M/8?-2L<J.D?=OC7L')G<)+X]=E0VGF]MR^Z-K?%X=%SHIN#-@ZCE@Q]KTX9/
MI]*3ZDX7=17<11#. W4G\7D4B1A,'Y]?Z6OX/G\%NX=Z(Q\X0QVK_"2[A_BV
M/MLEOB6[9R>[!_[%A!+U9RUX<F7NK=/MNFO<7.$*[DT7FK</Z#IS-?N][RLO
M7%U1WRO+]=T;$^&+J70D][PE"V[P:EXP/(6^75I?1UZ\B.F_HO0*7&8N7?3=
MM3&BM2'P+L+B+<2E,5KL'X+[IQ_!W/WK7^QNYVT@(_81#&#A<;S.ES.\1,P7
M(=[PJ%>-LW(V%^G%P#C^),!KJ>&#:VY<C5KY18/E*W6)B'<A8KL!1/S[A_-Z
MD/"Y)]D[,9MP>$.N42TNDVCV&6BVVP":S3KFUH)P?^6^SV?L B^.7:/;;*DX
MU0T*W@(!5UYQ2Q3]R!3=:P!%FTZ)]Z?GC72I"&[&46*Z(@)D"8'MB(CDGH/D
M^@T@N2?H6@6OAMD+5CVD,]'Q'G0\:  =;VLS0A38= H<-H "=ZX$KP$YDEGP
M@L0\:@ QYV5^X,K$,\&N\! U4/[*'66 %KZ"U.?,I)@R<2N<));70&!3H%CT
MAX#V[G+?,T=ITR K3+(6%9 Q4>ZC4^ZX 92;UG'40,KN0FT*P)H^9>"? 8R2
MN?^V1(,+[N+8A3O I=Z^20S17U1B3OCNVTEPBR"%$<ZRR\1OG_I4:+\KU_>C
M@$Z_?%=>"O59EE&SX%=")\N<\BFL\XQ[-WP9O?WIS2IZ4M@K8%0#_D7@^Y#S
M*_NQSJ](;-[S%*O= +EY[Z3QA@A8HLO-=-F$X]4'IO8]!77>DS@WT.8.:J$S
MN@M8CYY9J6:[T7IM$GCN?5"G'\6ISG#[TMGL(\-T%UX0(; ^2I_[#OR5PJF6
M*V8K>1L9]A3(I>\B6R$'=E^M+J" T,'+X',_SBOY5\J> R:2X 6"HW693"(G
ME LT6MGY52@TXTF?_2,!9K';=E=S*?AJ,8>OI8J"H&<'[\,<43*?8W0$?<M*
MJFBQKTD8)<C?\ 8^5CVGI7[+A^?X@_O_MW>MSVT;2?[[_14H)]FS:BF* /B4
MDJV297NCC6/K)">Y?$H-@:&(! 08/"3Q_OKK[AF   F^)) "R=FJK$42F$=/
M]V_Z-3WXSC@.K"& MQ8.60 SGC49+7\T\CTAK#6,TC%M'(!QB0]^:]0[76T,
M&QZ]7-,&8/NR>VC['D=]'_AA"$_[%O1%+7^KZYVZJ0&!71A>7;OC#]S#'_*C
M@U;@"R>8HEFH/0)A,UBC#8&9>4"M;@)9-<(L[(Y2J*!%UW_4 !E#'#PL!?[D
MQ8F!O 914@H"%$ZT,+:&Z=B 6MB<)5=-SK-P(;6WU)7&1G[LP6"&#,QXSX]@
M@$"A>&P3I,-Z!1RV)TLTS)\L#*1RHCLY$[+C G["AW[FP3T/3LY? B O$Y&%
MZ% 1E;_4E#7!5DF*GQ@H#NJ<Q9%_(6T?' N:0C!T?/P4U ?8(:'Y)VY?I*I%
M'90+^0(LE,O&(3\/^9BATIG0@#(K1=MO9H]$/#BATP?YB2;GR?M%9QVHNW:[
MWFN#?B2,NX(']+K>7O;SLM_,NME:VO:K][OD1$EW\R.TA0PW3_E-,E&[KWND
M9$Z-6*B[,)R3 ZU'JW)S5^8F)V/=(CF*/3!EYIT#<?&7']X8;Y9//'6+)/ZK
M<:2%ONO86K(R52!-F;QREVRNW_>#LYPB15]<T69&?][AAO8\?EI"5B'##;,2
MA-W"60<E8$<N8%]]T'M)@&ZDCBH^H/Y.?[W]=N7)/B55ZL#I<X_IB/3Y7^%#
MG%QE_+_I5<;J4.F!GU8ZUL-I>J=3,W15!U7);16FJ^1V_<I_O1[]=US+K<J'
M/8M;L,\/R.;CP DY1M=\2WBJ]4ZBXAA*Q3ELV3E6J%0JCI+;ZDQ7R:U2<93[
MIGP5)RWV;BH]YK %Y%CQT&BW:EVCK19;R6T%IJOD=FW[HZD4&>6KV;C4^]6'
MGS]F3YI2BGZFYH5"R8.4FF-%2:7=*+FMSG25W"KM1KEIMJ#=I&73IIJ-<-NT
ME&)SV )SK #9K77;JFB[DMHJ3%=)[;IKW5*7\RF/S9J\(FM\_E*_JV>+*5(*
M\76:0MQ6"LYA2\^Q0J79JC6;IEIK);85F*X2V[4=-\IOH_PV:W/+%HI*:YD:
ML I;#U+8CA9;5<JQDMO*3%?)K4HY5GZ?\G6BQ1<4:)F*X HB#U)FCA4B]:9>
MZW2::K&5W%9@NDINUP]#-U1(2[E[UDW3D3??3$^*BXMN,O=%*'P\2($Y5GQ4
M^<=*;JLS726W*O]8^6RVH-A\>-[=$]D+7Q2 'J1 '2N *L5'R6UUIJOD5BD^
MZRD^\"]>1T%_5D(H9_I>VMVZL\;)J9O/UKKY; \N/A,EIBMQR]Y_./-./X*^
M^X]O#%._\)U0^P@:,'<9WO7+-+P:P\.;?4$?IE'/WL9;?,FONK[O14QL[ $3
M?_YP60T6OG0=[1T?]AF\X<QQ+0Y3\>P.>-;< Y[=LQND%;<MY+;F'G!;4L%'
M<=N^<UMK#[@MK:A0"7;[D7D>&VI7>-7CW)Z<#A6[>D2E,K,Y9\?VCV^ZAMZY
M"-5N739'M_> H^5YVLWY>2%?$L,-&6J#-@]AL3C'<RN*Y7;!<IT]8+GTW%(E
M0%2QVPO8K;L'[+8X<[RN.'#O.;"W!QR8)/B]<_R(6T/M)G >\!KT3,%1ROC#
M*\BGL7+DG 6I@;4=,6[AGJTV_BK*029GHKJ"\,R$D&TP^X8@O8 WUXB%Z=U5
MQ"H]'X=ZRUX#6\+2?8F&8#I>W@><BPK)M&Y?@&AT!?,0NN%!F)"I @/69B)[
MZ5(1?1W/1AE"<3._F^TNLWKMUUF\EVH\&GSP %<=P%]:J$(0EK4%WN'3%*3N
MNUR#@0QX$'!;"L_ \9AG@434<HUH%,>'IV"#\N'_<"<#%)=M:Q2 A\WJP8]0
MF% "Z2N4M($3A)$&W<0AR!?^9/FG\"?7V)2]<#;,\?#E@-\[810PFDW2L.,-
M #/RW\G.Q,=IG^%<I[#1CGQXTB>FCH;P%KQ.A+* #M"O)AEZ%EOFR$/#7_&.
M1?>5)^K>UR$/N?@@7LA.&V@*JTK &(_A'1B@9KE^B/."9O'CSSRXYT%-XT\6
M'T<:D(&^+J"2=H^0BDUYV$TA#RQ8N>F8ZB^1Z2V)\,&C[34LV,AS8,,2ZSG%
MW0HC;$;O(-U$J'8P_',88#SR+G+JVYC9N,]F;@IW1%<RL59\4:CT<,^^Z/M/
M.'QHX3R]<OQIVTDU+[N8_674UEOY$A>)"C),,Y+'H#*)9.-3-H!QGC/WD4W"
MBS=GL\N3T)Z(44SX5Z'O<])_C++2?PJTNL-7%7[C8+$]\/QNGMV/<&\76#0A
M%3FUUVCGXT_<BB/G 8U5 "N.9IS8WUA64W07[+@!_SN&]K1XIJ.(FH#/SH-C
MQ\P-:9=+MEG^-.9>"--[ZWB6&Y.VSH"H@<<GZ38VX#P\J6E_QO:]-+!!D>%B
MU&!A1*ZP+F!4,8X1I";T/=8'XP :C6F#[T^T, 9S?0S3 @R&GIDWT9C0JF \
MX\"W.+=)-<J,9/H,- "/P7M(.-I7J8(3LRSL%/=S?#CDP8.#=9IHEX[87]R;
M[=H7322EGY" +)(_ICLY6"X1AGO"-=(PD-RH-(S8DS.*1T#2B*CANOYCJB^\
MYRY[Q*)2\(_2 EYA@[W-JG2W0B\32_,1)8=[H,U=)_K;?R=/I+K"\1I 4_+D
M<0UD#1ZR0>I!A8!OR43@*#CTR I-N*9)5?MZ]LE9RB,>:/^) 4R,AMX3A@5G
M(,]2X0=1G YQQJ( .V3HP*,"47BA=3'KNY@VEC4U, J,PXV :CD[)?M&"A]K
M ?OJJ0N;(Z2.QRP@;P]B/@?Z)_T7F2KT=3B&(21V#O9@-"Z2A]$VA>6+ _(@
MT8_ZA3;D+@$UO#!**#=]*B&B]E8_H3;#(>!9N(1D3AC&U!4"-_R=L\/(2@X)
M_0<+FEIH1]?PTF^!]RO&0&R&#\X-#-J2PZ(ATL R@X)U.X/?8>D""V\>E_M+
MX6IG:,0LVH03,J:K1CHD?6-+;_2:O(_\\]9<;[+)O&C7HNT>)!-G*10%&Y?>
MZ<=31T;"))%?DYLKV,&8 ,%11TB^"S@8&I9@2']0RZZ]S4,+FB2!I^_A-7[O
MD\O/93'I%?J)F(1Q(K@^Q[ +USXSJW$<P")Y4;+/9M=$*#=%,O#HQ\#-W*/5
MQ=<2D2<!PE=]6#C7%;J!'(38$/#IN^F:7@*%'H=<3)"-QRX8DMAHKE?"/2*1
M@V2!V2,7\,$ K;8'7M=^29M>8]6GE$!]#[AH@NK$5%D+0)L@]PQ. L>?'4N8
MU:"$-T/J8YPT.=)D/%A#6'N'N1HJ4$")U/E!/&LY8]%#QK<2"G:D]<]\FQ\C
MD? 120<O \M90B<4GJG1"%@4AYB; 36(+BNQH$X@EV-=E 2=UD_0*=0LL')A
M0PLFJ0Z<&/XX!M(S[3B >:-[**SOCT*TWC8N'L66S]'E[EB+-W8_&&EWIWJ1
M^!RONG,]P*T>X9:V^BQR^/23"](4:<W&=PF*%V^J9(\!XR(R)N) ED9&GR)T
M0+#.K< ,-$_[-(2"DA/XF4XCQ*ELY.4M[G_P?@B6$1HY%D&4&#A@JI!SW#/N
M09SNQ=X$6RV^.@Y 5ZEI'B<M K$2OTTPJ)8@[!/:;=JW>J/>T(#2+DSA)(M@
M@(=^'Q:5NH'IB)$++,R(^N(7!)F0#",?J! ]^GFX2]0=^)-+.($_0/2%1CK'
MVW7M>I!;5[E2<^YQ!WF"AI!NG3PW:MSE1YQY@C6\'/;5I$WHL7ML./U):*RT
MABFE"4#)=4#\1+Y]Z-5U1H[0.KT83= PLUW"SWT^;14&2O@MH%["JR"?&$;P
M%X\R?F])]>,%OQOG_GZ"I084^BU!OZQAY8_]4#!>*L%K*:6+=*H:"$'_3XEQ
M4W<4QF&$$C,#O0L0CV2G3TXW)W(%RWL^ !N?Q>=4!XA2;4%*\X*FI4Z;?9^P
M8]X"D-2Q9_'CP7<?R$^V;6A0R%"V6F0J8,@#0RV'#,*@G8I\GX/00TNI&"XT
MI;( 4F!+2SCQ9K6BJ8$%'Y(UF@.)7>AC"]HGZF3T*%*?$C$;BXQ)B2BI=&<U
MRF_UI-!AJG.E]EX?_?&)3R$UQE:J3'.FX8R:!3A9^-[4)89VXIPL2.>];L"#
M7D2.=<>WCQ@R/B3KA+O+C-5YO)#Q)0 +A 7P2BT-5<WLA(L=!',^D#Y/(ES$
MJ7,ND6RD:?IJ9K=#ELVQL6!V^/%9#J8D-I<.8,0FJ5J!(\N^@P$S-\G=^3N&
ME4F=$NB1J2%8>&ERCXQIX4?Q*WEM\!<@5Q\&*V.!A<Y(Z<VI27]\WO-3V :;
M\P EMIY$MXE$G+IV:=L.CAH3_[(K-&32M6_G8X]I0UEW$?9BLQ&[Y]*AA"OC
M FBZ4U]EQM,U%TN$EP*'DG@&@3_"=S 35?J6L2V@71#S[(X1X(KP>]J69G]#
M HS@4X"^L $#^)/I4L*K.<<VZ:N48>Q+ALWVD7Z'WCE\>JZ'+"?WY6A6](8=
M>-P"0QY=6_#>B/W%I2]./B)]F] , CL, C86$5&53O 'QW=9-#/:Z9=R?TF7
MCYP +(@FPOY/=SJ7/88KM/<CW@R^RJPSZ=Y>K46J5)_MIOIT5:J/2O4IF:OF
M EDRZ@3[%N;@R" G9X'K".,\"9I2^(_L#M"_!Q@3GL!3V0!A)D-U?G>_OOF2
M1-/F[!(*BF=V6C+8R 00%ELH0UV99%D+Z89!,%18H$,G2BVPK%)T&X,"H3>;
MB84U8]'1[B+V[= !,C**FXYH)UAL!]IQD*3X1$-0'7+&!$W.CZ.\];+YIE(R
M<^VT?-;NIU>YU)Q<YO?*0.#QFEJ+#Q,PS \,7IREL]E"4,K.9_]!),X9#4,O
M3-LIS*&?2?40,>#-ND_29@CN$JNC2ODRA1-_<>K,.N0LRIQ9.9HM)-$4]KD@
MCR:WC,6)-)NR9W%6S<)S)IG$FK=S\YU=DOGY/K( &;*6IJTF5FYB7Z<*0=K/
MR7YF\*QF[$-+YMF4\W+/3UTFN\WP2=PR\VD]^1\*!ECLO:NE;V9S?"@]G%8=
MQNV% R09>T+IGM)]/OUG@7]=#++0BX4OKIBB]E:>\,HYJOJ8[.00R&37Y>19
MF\Z.LY JK:>H)*2M)B%I(_:G3QO'\T)>>75QPRRD5J/*64BM7!92;J)K)B(M
M?4?E(E4H%ZG2HKWE5*0]I<K"<TGI_V:@;^:\^,HDI-4:Z.'E(RTP_%1*4J5%
M8;L927M*E'7PH2@1*0<3S\M%*G9)O"P=*56:])7IXG,Z4YG*VR8I2TMTK0V2
MF5K39*9U%"I"&#8#;;,OKDY70GUL5E#"\O*5*BTZ6XQ0[SMI5J+*;L)YA0AS
M??.E=CSA/%(2!(F3%\3CI]G'IP[:&0IB,3Q 71O:^3MV;)G']9"MK%-YEBTY
M>'8#C5])"GU,RDMI!2&UO2%023)=4+@+N:F07C7M<;9L1R$>S ?&BF*7A4?7
M#7.^>)@X'8YR#N)I#1EZ1^2N6CC,NG8SXSY?T?TCSW@[L_Z.C0-<TQ$NU8:(
M+L4_H=-Z,$UA(VUBC#L1!OD3_Z^ M"FR4%>XN(X7^U@JGH5. 9@U]9;PV:XU
MK30PQTX(*:?6(Q;X* K\I(I/2@-9#J"PG%A!/''#$ GU4D3Z9=P!VTA_W0DM
M'?[\;/,3HMU%[ \KII6K'"FYJ3K%3U3BW783[WHJ\6['B7<'MI=/=T5&(..,
M0/?#2K<N'DAT_!2J%E1U)"W2DF'^C!\MS5P@HSL?SJ=G":] ]AW8T):'X;'N
MEH0YY__2W.I4;T;5=$ZSSX79L\'DU;MYKM1"&@S-'H+ L::]P/Y*E3T]X7VD
MLKS"@'YA%#FY*>CJP\\?LZ6WM4^13=4T,P6\\G[&?N#_A3;4E$BBKR!_^D.<
M!TAG* AO^6&T.I0;AR=)YD7*0*KDUFN8)K[K6"APR#&7XW'@/S"R2V^EP_>&
M#A=\Q>0 4>6MRA4YCRC\_*6XSEW 'QS^*&_4I.5$OV5F]032Y2H;UM*:5Z*B
M_=0WBL4L N&[D] D2PYG'90B+\4)ID7.H46RF%@:-J C*G6\""#9$-#)*+V2
M26 C<_J&ROI)@,RUD>JM(OD&)C1TQB*%"BU#X8O%MS)SUK"F'^;!N!1L@687
M% G,[E<.0ID7 E1GDJC(LS-M>)J4D^U->D&3MWFZ$(1\"[J./8R\%Z0-3!]Y
M'/HT$VP\F>TT)RPW7]'?[/=U[6,<($C71'I5[L07MIR-A\%"<V':95LFYIE9
MUL+E2QWI6UF[?,$C),P(=/I%\\9F[WW?AJ'!\(]MF]$<^X<W>!O$'WJS&GO.
M-0Q&TYL$!QZFE51H1W&U2W&R$UT7'Q/5YDZ6+%WHP3S\_>8W/CV^*Y1CK)V:
MG'\5QSP_!!Y(X3_8:'RA_0Y$O-<^?;I)T_T8J)NILP71$50/F]!!EMPG+T1Z
M3I)2"3-IN+)H[$P@6KCR1=[\>VZ);'93KPEO'K8Q^ZTAO%#3\4?"!16/@.Y
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M'$$V]D&0Y\56"Q.$%Y=1]CE>H$?F$EJT%EY>CW([$::00PY-M/;Q8CTG$!<
MX.?,;>32MG8\JIJ?5%S.1C?6JR\JVX'6N;RC/O(5&V^7C<T]8.,/0FD)SQ?P
MPL%:$'M<M;7WS,JHO485*Y_.IID:AU^W3PI=UI[=Z_E\INN5RZDZ:*R?9KS-
MZK@[*]=YA.S_GJ>!UAV<HWL>..U?NK91U_^Y(0N^TB2W+UL[G!C3AF 7 H=&
MT3@\/SM[?'RLA]RJW_L/9Y>!-70>>'C&[7L6G(%ZSL[T3L-L-SMGL+ZZWC-U
MHV68>K<#_YW9[19\TP8#W]#KPVB4UKL]A09/H>N 6=$Y%YO'8L9!22BB, W>
MYI8O<I/.Z18LH88OBI,G-WV):+C+Z%X8>2<C?G7+_>">>?*>L9HF#!!Q-1K=
M,JHWQ=T$-;2?Z9:>D9_>[27RI/ >L8]TM;AG39+&[^)^3;OVK'IZYPS'VUKH
MRH$1I7']Y?F/'G8E[BU]Y_CRA;<Y*SYKMJ/;1&Z]&DC+],:=9"#IE2U7>/,#
M3'O&2] ]_0G3J]!0\_+S.YG:4DRA61E'F>IZ=65>@=E",--[1MOL=#MG=J?7
M;C5; &9F-<#LEI,[Q-:ND+R8YA!1D/<ZA0MTKJR''N:+T>.+%?EX34L'\4/O
M*?PH'3^,ZHJ9PH\ERI#1:71[H RUFCW3[%8'/V9@XQ+T(IMT([SRNU+8\ME_
M$'= M95RLB5P,:LK@PI<-@(7X\C Q5#@4G5P:597!A6X+ :7AM$R>[WFF=TV
M>EUSJKCLPE$S$G=""I^,A(MW$Y<]ACO3.N[X.!+(@.X>H$9#04/)T-!43I%7
MA(:_@L 'W:#YQ\[$.A,HP0W_+KV&7,E5J7*E-^KZ-]5EP(.7K!=I]+U>KX,:
M?:]CZDW8=?5&-?P%LW$)NN;R#J]RU[X(D<;=&G["R,8#I_!*+;D'>D1'TQY9
M 'MZ$H21>5O4\YJ[.C+VDFW]-GM4?9JHG#FI?G8I-_CT7FFCH?3^;8&0H4!H
M3T&HVVFV]!P(&;M2$@IQYL-H[/H3SB7@W,0P$18*D%D?.Y;Y"A1V5 L[3(4=
M>XH=LRY)O=&MJ *C]R2>;%UKZ2HO9>41IZD0YV 01Z^FS?39]TY35>8]'5'W
M RS<,N9>*%0/6:YE?7LH-8@2U*A)V%"8L7W,:"G,V$?,T'N&V>MUVF=VQ^CI
MG0IY6::9HU]!S6!C'@.1PZG&TERDL80:$T&3O/;B2]?,:SI=M+>F:9X:IMEN
M&2=% 9:V2AK;%D"U%4#M*4"UX)].%J"JD=FQ"J!Z&6BZ)-.)?#2E6U0O]N6L
M B41]56HM U4ZBA4.A14TLT]@:5R7,BZJ7!G?W&GJW!G'W&GV,53#7UHUL5S
MQSW'#P RN!63$G3%PF%&)WKG>W&X*>@8RL?S>J#14Z"QKZ#1T>$KNZFW6\U&
MA9P\0A4AW2 ]DIP_;)S*M=Z8.7#<Y]$CUF&:Q1U*E64C[=*9L*"FW0SK[]<]
M.YQU\,R$GJ;C4 >#MY>KUU (<S (4PVM9!G"I#+=W0!:?H7>.#;&@D?F/L--
MHX#E%8!%90'O*[#,)^#I.TO3+QT\[H;<A<=^8^Y?&T6=5*[O'F&-2O8](*S9
M6;9O^5@3<72Z^*[+H\AYCH]%@4WUP49E!Q\0V)B5 IO>!F#SU;=M[6K(QF/N
M;F 4O3R(I+!F=UBC\H+W%6OF@T;M2GAG/LI$&+S\8N2)$B@H[=/ZE'BYZY<!
M_, #\@<_KR@DYG^M\K^HP-'VD$-E!Q\.<G3V"#F2DP4O@XY.:= !_^)5 ^JB
MOAU<U)>OJ*(NZMO:17WJL@VE$6RL$;2KNV\JA6"90F"TFVWSS&ZV]*8A% *C
MLRNWQ=>A$]A:84VT:P\&CSN]=!]HMRB&848?F-< %KA7]0V"NGG5X.ZTF;HD
M,GFL7659; U'.M45-X4CFQD6%<F?EX;%)]_ZZ_27<09 UD8%4[D:7@\0NM65
M&P4(FP%"LQ* < 5_@>6""/ K<V,^KUG,:!&B2*JY/EXT%5Z\'E[TJBM6"B\V
M-$1VEACVB>.!N4SH=(T0Z>7MA].?+RFJ276,ZEJK5],^?;I*S)#+^#X.HR31
MO9$M98!!SY\94$8S-C91]%D311DHNZS\V*BN&!X\OLC"SGKC#Z.Q*VBX@X<]
M.W_1PS;APM1)> TEN^7+KBK*7@G9W=FVGO$O;E5TDSOBDFPE);OERZZZ)6Z_
M]/I6N]GJ@=K;T(U>IW,V"/C?IR(I\H].JQIU4S'7P(OB@"YI(F"H:7PPP*C]
M T\NQV5>S(*)N/[1:*0X\>/5S=E/UY__K75:VH]L @TA(!!<%%?L*"F)\M*#
M\;BS)57U1K:FJK0LVNIREZVAD;I6;K_02'H9#+UG-,S6F6T:W6:G5Z&3\W=Q
MWYU5381R0==7"XO>F%-7EE4'$O42[X"(_K_AT8+R0:6425S_"F[AZS 4(&T!
MD-15='L)2(7U?ZH"2-,[K184\Q!BW=PT/J*NS=T#0&E55^X4H&P&*-6HW)$[
M_C4;<RT%5]2-N7N *RI1]&!PI2(54G]C 8KZ7 )'XKHQ-HZQZG,97ZHLX8X@
MPM#5U;FO'Z4Q]-W=G?L)MFJZ-!<,#L=V6.#P4$E5R5)E*JFJ@%29NY.J*]\+
MY2F)#X$'$O8/-AI?:+^#:-QKGS[=* DK6<+4E>^O*6'?A/ MPUC>+H3KQG\$
M%1!$ZQ)&%GA<W&KFQC*S#Q7'=#P:GDO56!0Q:P@_XX4@D:_4QI+%S]P;M?$%
MD]2J.\.9G<[<H?YXA9-.ZP6 4-X$((S.F+F96O6RY A>CA'&3*0"W<8N3%,W
MV:G>?,M.*%JFMVSY2=S:@Z)\!XT$3@1J*31H#9D'\GQIT=8*QG&3\GHO;7^,
M1F6V_3MQ_%\S&P8^2TVQH,\\'IY^>7(!-60K1J.ATOW*!X0]R1@Z%D#86>7%
M)8#PT?$8_ E_*4 X-D PZCIJLZT*:[/'!PM&1?4$%/UU84/O:K_4[^I7]53
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MC=D]%_K;*1O .,^9^\@FX<6;,WCP^[.^;T_^]5_?GPVCD?NO_P=02P,$%
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MOC7] C\ZQ'(T;5?1IE ;GO&^<RUV[H=/Q[_=6<]LT:(;SRJ\0/D_-^Q0T;[
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M'!?:#<TG35P/-Z+AO4Y^&:W6*W;%6ER+]C%R**1/<-4^4Y#U&M=$%_W)KL#
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M8<'V;9GN0]T$]P.&E[==HL&G<-@ZKJWH 2.3=M'1HV5M^<I1ZFP^7KS&$)7
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M_GOXS&GX[-J5AJ:.1"8E^(GY=9%A18\Q'RWVV ,L"+>JL >('2-O!];KGX+
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M%/]EU&0$.)"8YGL;2M?8>\2GJ;ZQBXU&CD]/ "6;B]J4MIY>+$A[OUPG$I,
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MS5>?L=$GIT;OD%/#KD"-74,]^QHZ1EU_%QL:/K)9,1'A)7Z";;/\O/FIJ?5
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M:P-%VO0<WKF2,^VRUXA=O%V]*PU$QK-RRVRU ),10EH91%!E^&Y/8'YB36-
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MY<V2'])Y3#QW\1IE( $7@^K"(,P<DO620;$%0@0H37K*7GZVAO##TM!<3=
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MZ9BP\<FH HB&C8O8\?@1&W06)L^T-/7J '](WW[IC!@<S% ;'UZ>A21AS"A
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M3$P'!:'/7J<D"= </NUF#(8302=3OGF1 F8?,<)',!W$HY13X(8\DENB!7G
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M2U5OP&\22IJ$_6UC"/];-UNY9['@.T]&$ YF&&-P=6R')4X^6^%O-$Z-_DD
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M2H7O_>"-F!F[>[R[]CGW?"B]QEJK6PI)/1/>^V&"JD))W&&193[47?/7'R3
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M^6I3?'R5P-?I^PH^OW*+[P]OC;' &Z_"EK6(@;T2OKMB'U[Q+Z^$3P]OPK'
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M#$BE)R5P)8S-L.0WXVC,\&UZU56HZV"X9,2 %E:E:BSDO%/AA.^S_!8 @8C
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M!>3R11X<0<:CG[G?I<B56?YP5T1B-BIL5F[U%P8>$1^[R:@L_]=.WAP-WMS
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MF.U"\B4$I9;&G@Y5Z0;K2,PZW)2F3Y]=V23H'QOFD;;X$R $D$/\/9]2VAW
MO7.(98;L?4FWC[M-C1GK/>A].>^"QJ:,/W^R1 94%UPG5/T)PALWW-]NQ8G7
M?K0ZU2)&-HH(*><SYX$-F=/X*B&?Z<7^S I<\.H,(F5=QT+!",%S!^^>SX'O
M%/\"(1\15(?-A:6,_I9#6-^J5ZD 9U-C*&:/Y!"$<777JMJA6+>3/<5Y6-&:
MJNI[?FV!Y0@LL3\''AT&MBV@F\C6>H3/XF'O2S.=+ZVS:G+H I:K3T]&XG@
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M;48/P1<JJ8N#4+-"-/9 L7(I]&\%\%=2N%KZG#7MC()4MJ] /4I#'$H>:)W
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M2AOUFTS7&L7JUW(4H!I6&<VP$D>>1GI$\D0BT'QENV"([Z!@(!5WL$F9P&,
MW*\0E*=VF.C:V]_>GZ+UP6$+I-C1U08HUH#EIX'P4%EA2PU03+D"KVF,PXF(
MZW('NTYMU/= 051F6U7M)/%W%!-6V_$0/8S*+[K*VZW9\U_I@(*D+)TJQ:F1
MWU*? ^:_(ARH.V+UFZNWV.<@_B>)P8/WZ@/&EJ@H2#V 8WP8B27QD;RZ(!S\
M&,Z<W(!8;H-DXFEL?OH?>/+]*)^]I"&*[5W&ABL0X'ZB6CC8KN0ZGKX/"L)X
M@M<=MU[D.=#:EWY#%Q1DB2D4ZK=8O162R<=T*O0AX(10L2<2,I+H&X$^&!7N
MMZ9>*(A[2@X'C]F%J BFFL^-%WR]]7=!N.<O'5ULGUE7%&165T.GT<I:VG_[
M?$FO3!GRO>(UU-P%Q=KD,:)BG)M*PU4VQD'*J? E/"!6L"@QIS8 F*8J3ZXR
M#0!*T_;C.%A="R?.P?X>@I 'FM%=_Y+$S*<7F+O ^AD9!9,RW>;>OW*C0PJ-
M>[_C;R]I_KR^A_54C]2/6Q=XM1]1\+]P0ZOK!I6C(]NXMD\;$P5CGHE/GT2W
M^T,8O'.OE-0X7VN%8O*LCB'9,@^Y^"S- IBE4#6-G5"0ILAI:#:"Y$U1D/'E
MZ2>Z8T*?77&OA!Z%:GTNM0)HVA<%H?Q^RE-?U6\K:4,4),!KR >=Q>>7*F1&
M>@ZS 176'X73IKFC]1N+3BF&-Q$_+D%X&1X/<<#NTQHLKDE[^R^1?P3T?U5O
M#O%'^U,%H+]WR(9L0!6MD6':$<4)4E=N4@(O-W1!0=9Z^S])FEWQ'&0:#2FA
M:ST'8'A@(*I;LKTX?HD@QJ.(!89<%!Z;I4MJ'N [*!B8PUQ>'#_1.SH)F0YU
M$[(J!)NCZHEMT V)'3L-+.9UX5D4@Q,G)9J:VJ)8)U$U%&-3X16>%YPM]EB3
M=FDP! JR:^"-^OI@FN8HR)&7-9=4I3/J@((DN4?\3@N$K^^"@JPLLB>/85;4
MQ#5ICX(@\?2+E:QST!%UT>\3AT!!-C=*->.5H+J458R6%H R[H2"M),-T-RL
M?+]+Y;I@UF*0W;T:NQN^A8*10CBB(&K S@*W>$&C5EHU=D9!JK"'E:#PU38H
M)FZ2ZI[%V=?"2^OQV%*;3;^?0,&V-.4@HD<2CAW]:YB0;;G(2;5B>X&*DRKQ
M6OMXOU^P;\-X"-T@? Z>W\AZ&QPR=\SFKW_YJ$QBUG= L0^8U8[>R9"%<4F?
MWW1_YPMRA)P,/R%Z\U^[$5 0?9.$O@OIB'0+WKC?X$\:0[2Z-0IBR@KAG4NU
M_2T3./P'0@=02G33OB@(K4L07=$I56/K)I-T'C=4U#D> (1?TW=G!<=%U\XZ
M 6E97UFLI? 3BBV36P8+$Z+6"ELTL\YE;BV[_L82HYCWG]?2D5O5ZNWL7YA%
M5N,39#<1#I/.G:U@O+\)DO#Y:Z"X/5OU1K'9:N:),NBMD46CW 4%62W(P4U&
MAA'5'-JA:HN"$*VY4ILAU-0-!7E"&'7T$'CNYJA=*DUS^Q+P(:$,AYE!Q7".
MZ"B".>:)W_D;R=^F>HNR,$SW(5&L,CR&-Q"#+;<?::SU9CWMK_WE>Z@#+U6U
M0;$Z^792BY-*$Q33OMT?'#=D*+<ACYITO/O=7>"_WKGO9,OM,08RY91Q4#"@
MQW*8MQ#,0Q7*S6 E(I4?LW]VH=*+,C"C*&H%%H\@B>_<O1O+,2].'0C%;LHR
M+S($<X.3T] %!5G,YO@Y\(/RHT]SY>A[H" *PH[3) P&VZO#JU>U14&(Z&'[
MY,1II"<KQLBC*9A3V_.H_L.618!^;7+8M1P.!3MRZ9%I;SHOJ[(Q"E*4F.8Z
MDAH[(;'3_!QX5.EVPN.-ZY%0$?I4:81B5:#$+PLHBZ_?FX 95&WM7]BEH'XF
MWA2@<:J&*-8"_*MNG(NE+-YU4W*,:9$SV@R @F2AJ*X>15?:$ 4)_99*_RE4
MV*@'^ P*]O&%;>/:T?= 050]=?%S$!/#DC3&G>W+W7IDQ&5(MFY<>N?4A+!1
M+_O$/;G?_IN$P8T;1O%3'!(2,S.CJLR$KC6*37E%#B'9N+67JNQW%!,^6>0)
M^!N]BE)A7!0,4E29E)I-Y4U1D"'&!)E5*42EPU33?\M)B@+>"+MTRX W',19
M48RXEX%1L*AML3+4%<KRO)PTJMD7M9 T4V=[[S_"2H40Z^EOJ<H:9G^E4L75
MQ^[W^@$4+.->.D6F<I8G<T4)WL4DA%B7&ZH=J-U]+0="P@('P$LC _>SHBD"
MC0@PFB&$->5T70FJ-$!BG:FG8U=_P\!;5E'X@S+50Z5WFO5#<0:85O72K'B]
M*-ZP/S/PF^P-FXM)*8#*4-]"P<A40O# V\3QGDFX5V,.J%O;W_;2QU_A&0,1
M7MOR!GU0K%+5&Z;3>51M[:^0/(^E#LPMH^ZD 5"LG5"2 7R83:GKRM;VUZ^K
MX? 2[G//*V1A_0KJ^PLH=H <SU.)Y*!ICH*<2V@"5P!,Z]&-?N,B%/XD=R4H
MFZ,@Y^0]IWUY=1_5_GG_B?CD';REKR$A\B N73L4JRM[YCT2T%BROX$.8_I
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MFI<O9"U<JC\=/*(,2NPT( J64$4>4K(W:44D]7TI;8B"A,*I*3<#MW&+FHR
M@FC-SN.7N4$H7MLQ4! N2[O@F=3-6I[8&BTQ>M! ?0\D1"EL(DJ7J;X'"J)2
M-TPI4;=-B1-]1Q0D9CI:6HU%/V-=ZM!) Z%@0>>*BA),CM&K.K:<@W7MF]E
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M)OVP$"@)(&LR4LC;HR#HB<XJ!J^3(E!=UPX% 0T["]L&NM[M"%P*)-\9X)@
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M<L/]CFY0]K*X?^%1C+?^]3>Z+?Q7<A.$_!HC=S#U.]=Y<3TW/BI(/7V\X4Z
M3#VI+0&4B-QLPB1_<36=EE-'17'QMP%:;.Z' TP/(LBHMN61DBOC.9")XMRJ
M8"S3!_D4BKWPR8G3@L[,]'!D--*->^EX'MWGS.R@OD3Z&'$@%/&VT.$3N&Q
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MCH1<$)_LW-B,!E6G4XF!TC??9X>(S9(5P\F/ #W-5 8\TAU-Y12$+%Y!%=6
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M8[/,1K;H/;Z+B%,\XZC87@"4MZ4T%& 14:(#K<<),0:]!G[^C;/;)Z]P22V
MX4/$-_0*Q;&4%1DJPJ)7I(>E+,:0D16#X#5,$ZG&RII( D3.V L83HC>^S,$
MN )6*T3_%\M)T2Y#@"&<CT7_D3;9VV_>29Q(%ZIEK$ZV5C,WE^!<J]:A/MEJ
MG=_R/=XW0CA1QM]>LS;/9JL>PXKR)3H#:UI_KIC)J@$P'9>S4&,'6F6+=@9O
M''_!3@K1RA;L;"NP>FU5(Y.R93F;!] M#H1QY>LS$K#B/%=GH'"TS%\Y@OG
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M?L<&]:3,H%%,<L\FM* PV+Z+;D67B"0\:Y/J@;^*T)%+!((Z4I7OZU5@TS#
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MG(&V:QLB3+O&($*41YIB7Y,4-Y3/<*;0WO^G(+>%DE2:T/ (&5[Y8YUM_><
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M="3Q%)Z#;D G!D$9GF>":=.#(G[#<S1<1!NBP _/$^;T24,_2,1SE%A@(8(
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M?1!3S)XS59BDFJR:?ZB-+%,PNH)'E;!]-,R^!CFZ7Z^1T (V\B;\1/8)HI*
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M\VHLHSR69^KV7,QU+IU.]IQKFYB+:AP3R56<$[Z]MN<;4,]P9 /:JD]?Q/#
M+")BTWYWD ]OCJS*B^$J/H [U!,[4-&,#.<U!)!_G8$G__CEE4:<<RFR_>NH
MV_H<?(^VQ5:XL>;OXV.,0_/-W]P_A+ <<[:$=Z4+3#')=;Z]3H:]:]X/HS1
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MT#+]Y]H+<Z$"NV!]1 G1(V.RM\5J2UZJ+*=/X1[I *8W=TX9F%,&1L2O[K,
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M.YG4VYOBNM[-YDX/)/>5I4M:/T<H4Z(_O7TGCE2@)\(@E]]0O$>?"4/;R+E
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M<KJ_QV05[:,5N>*TI!K;$]W>)MHMTWO"!?*#,)3<=(51P;N+, K)4L+(O-8
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MP0*I8SO6AZH]U3+'US'O=OF[QBQ !\"WT6H> 7<RK!2.<[TT[BN+\G.M--Z
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M.#9S:IIM3[ )?P;'",L*TQD1A[?!__G_4$L#!!0    ( %" >EAY@G"&01\
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M)/! Z+%PR$-F";#MI,LN! \$ZPQ\(1"&,)NC[I[! I5R"?$ _#_\F2-@@2<
M&LR\Y[/TX=$$SN XZM7I%W[AOC5D57I=A;V=OJX$+Q/% 6<T\_R4'/L:^4'$
M%161,#2?4KRE#OX6))2'D4>2_N"-1I[K3-@WV' 727X3P019\ZA>KI08C@3/
M@R'/^'CL>P]R!%L#CU>JI4JSP7R8!N\Y@@5_1'AJ^D*$B)H+M"]7(*2DRQWV
M5:\Y1]3LSI[_7B0==)(PQ[/4B0_9Q_AOS7+Y?:M<QK]=N8+]"\X\=QQV0X0N
ML3,^ZOG2'L"/7W@0<&L8!2(,@X)1/UY%O*P\P3/8+!Z<49)J5N1P'\ZQ+0++
MESV@/6V.9AL#R#N6(>BN/^$3 #6C@ %Y;384OH '[V4X]"(0?*(/S$%P.QCB
M[@SYG:#7C 1'K@G4(_#-ON>S( ))IMXV,UJBUM$!MIX;S&B\&-C2,EJURE05
MDDZ>@:HK]"^MYPAF/@I.>D!2TJ(+H*5P *5E5*N-9J5:;K;+C>-VO3F/!!0R
M6;'P'W[ZN":T8-+^YP\]TX3C9^)9-+T^_4P:PI2!&5A#84>.L,W0VR$0N05V
MN(7YH,Y/6 ,=#<E\4+.)A[$$'@:&^V_N@B2<L%J%H$%].RYZ*4RT/O8_P/[G
M@_UGF_"F99J.!N4F_ M,B@C.!$T%)]\T@ZCWN[!",\S92%#S*3$]GQAV*O6&
MSZ&ODG0CL#"@0E" X9#UA./=E_!A0O$I3@\]4-& 10?,@S_Z\ GJSQ)[*]\Q
M;EG"$3Y@)/H""0'EY4)+(988B]*C[WNC!4&!@W\2EACU8!3]QUK!8-.\IY=U
MITO^!$O.#\/BSKZ5L"=@#=Q)6Q"P44="/=0^#92U@5L1(UV:!YZ(0 (SX1[W
MYPV*<JG6;F8:%*6E5DJE?@0C)O!Y+7Q=J>\]N*8E% -9!T/<&#B=N1,E#F-V
MMIK*)B/S,.2(590H!.2RP,4SQZ=2SYU6J>.3OWF\%8"K[QV &V?#MTKB5)_"
MMU;CS?S@3^/#KQF-@N&U'WZZO/JMQ&Y_Z5YW/U]==W=]&DNH1$A/V4+K6XTH
M0,^)@8><<BTL] T -H&QP:)'/27=./8V]1*0NQ/$@"_Z\ ?7$LIC.8K"B#NH
M/Y4+;@XK:9=;\AH5]4,MJW#1P/,4#KOC3D2J<F:Z:@P?\(T<A_1<$/7[TI(P
M@0FN93IG?#]&:RW4JF!?#="GF@7UX@?1X8O"ON\Y@.*"DTVB+)679FH]H[]B
M+ZRMIM&J';>:K>-6Z[C=;M;*C0V<&)5-#*4'4SDP3),'L1<#(9$9XSY3N;F?
M@!Y$91O4N6*RDPADLT]3V=S? 5/?M70S6">(Y=D,>$RT/SL#J(VRBO *FAH4
M<HF]F&2^O5,R)OX;[D%Q,/%'M#SRH&V,8Q $C_D "+S@R;+!B-5VB@1C KX'
M%G2H\F5\ 0?<@@_1MZP5#DI9S*'<"ACMG[S-1D9UHUY_/AC4?%(@M/GY><T<
M=,(^"M@4BC9B I-\1WRP*)&(17P1C%-^IX4P'R.'0>*N6$OD90VPY,LXBH)H
M8.3A)XC4R$E%W)U^<-'K9,1"(^=4RP.(>@D@JKHAB,K"3"( 6"5=$[/X$?&8
MQ011V4RY>UAU[K*84DL%DG)C@J#1\FUK$):8:CJY P96!ELI;;SI#\D5'G^C
MM&+PK=PPU1>"-EI&JU5[-K11;U6S90YQ)*!$>2?\B:EBM,O8TRHF1W[2L]\]
M#]X6UC6_@K%SLU)4ODI/!=1L%5GC(5HI%=:+ C@# 4@<#@BJ#P9>[+02#\**
M2,J1<TLD*8)DZF2XO W6?; $>J("Y;^Z!SI@  _050#X;!H93&?$G!#XTP),
MS11#@/":%4)3O4#ZR2'@P9$,D@4G+C:=5[B.^#U5&#(1N*ED']=C7@^X6/D*
M$?QAU0*(:H".29I/]CBG,3I-UCJ-H(7\&SXZ]@)X,$BY(9=,.=E.6*;EP/[!
MU 3&YV 9:F?CW$ZB8_ H!;"&6Z]U$/R/,3-K3PHVGRS?=^H!5F?E+4^XS[.L
M:"R%O>KPC7V)1L]*.VD1THQG$E938=L@ZJD ,H\SC)?;$@2 ;3"T+%)@0+EH
MY,Z9$S)=:]J6;C:*!H$U4X0Z].,QT)MSU/,%_W9$PO"$._=\$BQ6M>J:U]C3
MC66MBX6N/>\!-P[].CW8!^'#:<$*V<(;?0O#/9;9,C#D6BQ7-RIK"I<LHR]?
MMHO+X6Y].79 YP%8@?<)T*46& ;GKF44J6!+33+'C (4)%;D^U05H 71*OTW
M8_$4*TGC1DNSG,L&W_;>)8</<!HZ[<$ZI5P<\D4_Z,0<)7F+1<)XWOF66*SC
M%>0ZM2W>?"1Y3^ C,>$%!7WU&7<(3/L"1S"F,!,>Z$M,IR/UB!C0WTS7*H::
M(6,:P_90,DTGMA$ W#_\MZ%'\KNU<@>WY*Q;LK:A6S)Q>9CFU'%F>NY,G+>8
M3I"\<O*,F/4W<#$6.JB;<XYCP6*Z^R=K<PCIUAOU%4[6AY1T27YL@DQIP7^>
M*\QO*B7X50: -3U.=IY!NU#\^+WD[ XK5RNU=L'P:F&*'DD*S6:\;T318J4J
MYY>AO$6X?A\3<0XQ^V<'Q_4-P7%<)V," W-,?LQ"R\4$Q]=QB4\'IHYXZH"6
MG[@)3E$(_ CXK%/+\T#1+R57X9DS(U>!Z%52J%IOFJUVS0S^V#1W:*]!]%(F
MW#VJAITHP4ZPX ^#]4,CTX\Y#UF)\RJU>JE6KJ_\XHS W H@5?>.'7/#1RNP
MT#:=-/,$0HT-@5"2#U5,L/,4*8E/(H\.[3&0-=O:F-B)/W_7$>>ZT6BVZ^5J
MHUEOMEN;L2$O;*.Z]2N74AA=UU;""PH#$/*NMR8-7QAJ+,"EW,FSQ&9)%<ZF
MC!:5>+@;LV7O9'$>SO_C2MX9/X5AK;PXZ83=8MH"7@BA\U<QK3#+V-BPSZ1V
MV6SEFZ:%-1< SNJ5 3_OFIA]Q\,. /UL8VUY%T]6+U<*E%E6G&:<TZRH!4BQ
MZC@N[U(4'\?JSH\CK"/7XSB+QU;T:F+50AW&8A2/I4\DUCE@2H'*Q0+L,"W8
M*F:/I9V[[+=Q,.V?%;L+Y+2&=W=:&EJMFHUF!7V[9O\U8JK"F"LGK%HMP5;$
M/MJM(M1[QQ^/]_(<'#S:P=/;L%WPZA8[6(\*>K_@[J#<Q49^O0G3EP*DXJ[Q
MS0SPL<2Z05N\9B)]MX'CH5/[(<"U:8"KN6& RQM39S\0M>)A+-SBAKJNXHEB
MLV*::.ZBY!#T2EVL\.+@4 7LH.8Q@*$6((!&K5';Y/J$=0->Q);\9>"A(H?'
MX@5,6R+<#-'51K:6AQWG#X$SU49RMG$$4>D0-#OD^JT?-:L9C78M VLI)#(K
MY@(\9LHG1,QHFF:E:=9;KS+7;R$>D[>H.F$U./.M-XD[:.>F5&'V9E8;YK\Q
ME:917[HQQ&BJWX$93'DLKDM+9=?6D=%>ZYYFZCS<U;P+KTY8W0 1NM[NS@I6
MTVR9K</N9NUNKM>=G# PH^IOECG8U\@WK![R#;=W1_<]GXPO?N=)FX-9@YQD
M>U$O3+4MW2$6^:R[_B;SP0-+\Z$;)=+-01\MO4JS'?!T61?VW)N@+GL<G[!%
MM\RZM4[+O"CKM>&*FV/%1]@X;BSTQUK9G.LU-\XZ-"-[>IINYMQ6S<@.#NY%
M4=[:M,\+WCN*N08%]6M3/WP,^.\\V>40;=J1^[I97M*0^<6ZKSV=B)EN]QZ;
M)H@V3!PMSVO <L\4->;1EPL@*DK05R(5'GD;!0_B&S-GKQJ'GWPO&BAGY_>N
M_=RN-_M!(!3;GGH2@;"I0;7T$HAT[[4\!4(QLG6WZQDQ(U% D*2D2'QMS,KF
MYGA!<J1ZH?Y8*3<,>!2LN\5T=,_[3K]4^MI$<-]@5RX3'&\$=%WL\ [_8/_^
M &],7ONF,'Q1B?'B1,>63+UC(P_EWH1?-[J='@(X$K2/:W0:31J_2]?R4:'8
MV)I_%#FA'#NDJ;8>0L(^VU(50/0$WH/)@@A.S..(B].IO:'HGK)(]065 4X1
M"RS4D=93R'&B6RG7YDM1KH?F3D]G$1]O:!$'PHI\&4Y,6XR]0(:9#5"+:2S?
MZ*FS3VKJ^Z6?B]O3*6^ZIC,\OA:G$^JZ%P/D+W9W7-*SC3-QKZ.(\PRS^[9+
M/S;+6)H#UFICFZJ<YOXY\O*X62?O<O]IT_ZDI?\0#G  UM#\423SK5:NE,K'
M-3@<C-3N5):B"DM=#$ 2<S[6%]\1AX X&1E>RUU]11==+S">++V7:\X6U>^;
M>1V\*RX/N1 A7@(&+SOS 6&'^A+YV.0(YFQ3NOXTOE!BX;OJ'H2A<,A228:#
MH5,<P^@BK21N"H;IPGOF3>(<#F&^1X[.4/VXCFZ 8C5 [DRWK2C Y=U&MUJ\
MF)+(@UGW=&9=>]-6==S_IE*\@JA'2;.A1[8<FAJ!"8(0[+QBFG5?U=1W;\W=
M*$K%CA^B%%D45GR=(Y4M;#BQYS& *5Q3*>^:6#,&F6IO(A>O)=:'D!&C!FS@
M PA0%8\:$-!%1$2(;2XLGL,7=,T0^?UP6$J)4GU"%+RAFT'U15])'8M.T<6I
M17@E%2XH\7;ZXH\(S$N:.#K2OP 9AH"6]$%E9T.01WCML>>_8V6CG:R;J*W\
MWP# 8#'9O5Q6>;X-MFFQS;)9XK@_UAOEV*%/DZ2?1OB-0QG;X6*F9]!CE?)&
MBJP,^@M6S@=BI28KIB*[43,_*+)'*[+:<5Z*+,Y1B36:/G6Q*M(]J%QMC*Z*
M"P7,\2RZ<X^4R.Q['*^'=6F4O.JA28W:8(D*2$7; LN7/6&70+-(4J%HL?;[
M\@%^Q&"NUG]I$Y>'R<]34][R@E!IZ^3E:,@SI!QJ8(<L85!TD['0MS>3NDJ9
MZH](T%U#D%8JQD&0KB=(*QL)T@J(3SAQ*$BIP]*2>^X**DC5S*D!TGX%>0A[
MNJX6;YGN-<2;R'-T^35WK>^D0JP$NS%^G;GB.DV][$OB5[31*U?*N() .]A0
M6LPV*6S4LE&M'@A9ENB1N2@8:821<P#,H;0BA_L.5NUJ<5>H]G,?\^L0@T82
M;&QQFAGFR8_3^\;B+"8MU_"$S?,6G%0P;'1<$)]W/6W_(9?@#;>1/_;0#:Z9
M:@3FG>N%]$YDRPG[A?_)?=N+ O8%3CQ.+4F02I/!R&!+_"&&%SW0.UPAKSD7
M?&;2R0S/<O1Y3_,VTQ_="\T]4T,V%A/B =6W$@5OY;LE&2\ &?3$OSN-!#+\
M>%PJUZI&HYQD=ND&IQ*&F2$#DC+#@,XH$_K>Z E]N85"RA'V0%]]S >^$/K:
MXK</[P#-^ *.68!"*91W="X25 3H+#T9@#C>:(S;K-].^"?Y[2N*)7QWUJ;@
M@B=SZYU?JTK"G0Y/JT2B."*@*;NLPF!K_2 ^LXS;=U32!4])^.>M ISZ-SR>
M/03TCA@//5=:..$[R9D8<>F\FU[8C(L %.!B<@'BN"![$1*O><;3B+S!I_.<
MHR!\M8>#VUAS!@/AR3'8JC(T5TAB,TT=-YNN:5Y9/DDDFA>%*^:GHCSZ3ZD[
MK5/O=[U#85G>15"'PK*GI^EFD<?Z^DU*BA8#GVI4%!HC_DVI:Y ,7/H!RD6E
MZ.4(I3!AT.6"?$:(C]#&YEK'!WR$_NUP 5H$'FA/M*?I!;I=&@'^(.J!L>:&
M,'M L_%+IKX7U.<@8P1(+IO9D1^GJ5(2V*RNIR\NU?'&HK)-Z,"=4"@##*!
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MX%O__ %^J!S7&JUZNU8SR\;OX\$/>&E?]@<S-6_-<F7\<*JQ1;5<'C^D%G5
MBP>TN%?,]YVZ"X (]6>LL=@SE!"CQH^O'#56GLL'OF?G80XUWMQ>77=^[K+.
M=7<#NV*?I,9C\[ K3U*8DZVT*\N4=B5#:3?:M932KC0RE/;KW*(7N*3VDT0B
MLP]===FAJV8<NEKK>'KH:OMXYC8&: <4_'R(+5,KU^*7+@E6-O<G-M_> NA_
M>-_S[,E/?_WP?AB.G)_^'U!+ P04    " !0@'I8XEBRW^80  "K@0  $
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M3=2C*532=*SSGHJ<'1S"@*A*0'&%^! ^_#M/<Z['S,6X]FK32@AF]MAI^:F
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M]?:FTJ-2Z7&\&ZAH_/8/Q[LCF\1O_P]02P,$%     @ 4(!Z6(I[H_7\ @
MS!<   \   !K<G)O+65X,C%?,2YH=&WM6&UOTS 0_LZO,)O@$VG320.4A$J\
M#(G7(;8/?'7B2W/@Q,%VEF:_GG/2=&4M;"IT':.5VC3Q^<[WW-WC^*+,YG)\
MCT49<$%7%EFT$L9'7[R#T6 4#;M;$AC.)*)8B889VTAXMI=S/<$B8+RRZC[F
MI=*6%S8LN1!83 +VM)R&>ZU:@6?]I-FH9U49^(-#+,(<"R\#G&0V&-%MK*:>
MP7.G(59:@/;H">F)REY%J@KK1" 8^:4-NV5T"L-V+.4YRB8XQ1P,^P@U^ZQR
M7O2"L;)6Y21K86H]+G%2!-J9=T;<_-Y.G:$%SY0\@:#4X-6:E^&"\0,R_EM[
M9*Q&8;,@1>LE) F%,_)P?_38#Z.AFSN.AB5]": 6J!OW,5%2Z6#?;S_AKSVN
MNP#%2HKPTMK6@>!HFF&,EG5I-@=BTQ D9!WT+<'@I(H-"N0:P6P=@ZMR?5TG
MEW*]91D>2^@MSXK<F78U3VMUHY[DC:HL:9N""#O-(]\?^ _"V02*FN2E@<!
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ME9F*"OD_A0 ''.L5,G:[.+O/5U#=1B2;11(OHYR*6Y]8>A#  ;BQ@%L4L>"
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MN=  \.P^GU0"O^:#=B['2HP91NZ2#LN/6>DRFF!9+M24P=/)2/GX@2[1"M#
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M LX<)BL5HW(4>>.-J+6P/_P9/099M9;RK=."J0"?DC7OI^IO BUZY!VMP,0
MX\)OBC80^Q)'8K*8 'MFL%DW!T"[  >!6 TX%=%0WD0<XYGU!@Z,EV5);)GA
MV,UV/@9=N WKK%2=N^CD'-T)L/E3PO7]L4[XO*) ,+A;(D+0W38W8O/:>OAV
M!EN+P$_"^PH#MXY,_'OXAB.KX8.RSJM"6DMK'1Q3>!FSSQ0:]VX6NJ9WHK_'
M!YF[4YF;[9',O<@R=$: X#"\T9.Y[T!M8Z;XU&6*)^Q -[NDF\4^T<TM,F;
MUN2%JDOKM,P:<_ P(Q#>^"=N-FN ]4V9K2C"U<K?+@F3CQX)RB%U=CL9T[DX
MPQ7@F0)NZZ+L4K(OW0K4>#SY7CJT115;@\<-9O%LKJ[Q(+#T:ZX >1JFP0*P
MSQW./[Z-'W9')R?/CF=1D+Y%\U*'Q2N^$..Y%OQR3,<YY?F*K\TG%<(=9,^0
M[+F21LYE#M[8="E3<,,^71I]_;+(1Y_)*!77B1!I1]#0YVWFW-F#E"J?"]&5
M,<ZD[DB9)4\;'[<53/1FY S,279Y?U:[7$#J 3!4P; I?XG3UC@835 %]JIS
M"M ()7N/7P,.*B[3"7O%\\2'%E%Z?G(><ZNH;79@J":ATFB]@GRUR@+(X !I
ML51Y2GE56^MRY$W8KD2_%29IR%4P]?PW#U7!80KX2V*4'PXCVJ03O)BZP%(1
M7$F69.VZJ;9@M7'8FFWQ-A\L& R5!2H)[W8)4AWAM\$YP^'>$3VLKO $FAJ9
MK;A?<=.085LCTLUJ%UR6%OYGJ4IJ!*BA QP;2+'YD$AV:,>^EN<*/"$WJ#L?
M'$@G##U0?-/7IACXWD$B_)] [G*NY3]'!BR',;A',KL]&_X0E0Q;3E::D-AJ
MSU=PC2(#B.<*3@4Y?RG*&X2'E>%HN_P"9U@#G\%,W"(!X!3(0LU;/+$UO%+Q
MM:/]A<;T@I^>_'E,#)J#L[=3HWVY3T:[Y^X!XWR@,(W]_/.K"3OX?#LE'[D'
MY'->1N6-O?C40)0VQ >7*L2V.G5>)0WR^JNM3<!(I_F$:%>4@KW-Q$'5UUA[
MVT>24]E&1$,TSP/ME"N&9(^Z(5R0R6AGN@%W5OEAAXTW&X4%HWAV"T.S_N.I
M0PL8>3(EX0^&"6B0"O1!UB@3%<*A[4/4Z6"RN6BO"S >8;D(G8;3-J4O?!L8
M2A7"0!8 0BXTE;6N&0'70()@@I#1"[*Q>+3TO#9 P0;+B"4 #.0NJ1P7EL_J
MTB7$C]S*L&D.J(7Y4Z!)::POS<>AM#OAUR;KO@$/*<Y3"@;_*U?A7/!+W$.S
M!F*[>36BU>9-(X$[N-[P/E5+=S*M4=#60T(T@>6+Z 105'8.V)%<8SUQ-T\+
MTZ^C,A@Q.%6'?^C7=0#7T\P=03W(\EW*\M_V0)8'0;[%Y.S6U.!?]*GSI[$F
M-TZ&D5<A#+8[I9N<ADB2>'& HIX*W.$-5^D;)'VGX0;%7RO.&I?,..8? DR3
M7 5VSL%[1,%6NB(V<B2)59JWC@"2O,80WHCX1%QS+#W#3':IRO%_G9^_CQ;W
MK_E2_M@9)+=M@S=X,)]VS'*7>\1RV^R" 3.J$W?RGGLZ:F,C1-WAMU$;Q7)J
M(FBYC$I,.PJ(V 44/?F+@XXI!4^HZ ,Y242,-'+Q#>)J\DI=B"3K163Z3FRH
MFW-*%\O\[7KL0C2#V[S[;JCG-;!Q"*7EH,%=7&/D6555I!!'%*,#ML5=NB?8
M )@./4 SQ43<#@8GX%KZ! 7&HLTA(;9;[L[W@+O/V9!*;715G[%#D#CP#8!R
M)5W<U+>U#2F\OA&8UB)$[#"XIW$T*"TJGI;<5VC%+Y NQA_:V77#I;IM0XH*
M7TW; I?S5<QHKLHV-.O$&P*80/VC2,)B!J&UEQS-)L?;-AD$4[,EO\4[ODZV
M+@^%'P!6G5L7+&XFQ!; !ECI8\ $Y4JX-F"$W=DEY.SX,IQ0R*X9LA @Z9:1
M!\&P6\%0[(%@"&*AWT+2E0BC&]F:K1UOH*ISB0RJ7'07^-SUC% R ./\;=TF
M@((,BSI2=;KBS+)-A85!H;CK#BUY6U(EVK6!-,!@/T>-5H,OCH<!^!]9 ;E8
M<+32>0U*6U/G*UV8XDP:TX'D+JMO<F[_.@UR3R>/+JX3486$SJ'I-.IWC^,M
M(D=>PV0*8.G.?>MQ!P?=[.!;Z&6C:GWU=.,?>Y6F ^J;DD195)HGUL4OG4L)
M:R-O%%CP>",X"EMQ;67 RU8M7+"QU>G 8DOR.9N3Q;"A]7W]7D/U4W<C<ID+
M82,!0JP'GC!N6E#VV4DDV"X(%'0 UK$= +8V1OT<*R.KPUOYB%XQ1AK2O@(S
MMXES[UN<.4RXI'TG9T]M8!YA45+TZ^FWW9,B(6*^/UDG=+_+:^[9*_\%2H:^
M63D7=Y@6/!7=X@=PV$51=63>W<K5@UKOR;%<7F)[:<)K@QY^5&IC^?7X]QJP
MD4ER$&SP+H Q2#-E7.:>UXUB[5#G?<3==6U3W>%VG(>P*;Z?//J57P,]N!IZ
M/M1[_Q5CXYYV@_,_ 13AZ\E&FZR 4=]RQE"?S9WE'-B->EANX[;@!6^K@76K
M+;0R)FC.9OB1G(C)J%L(=Z.ZK:U*0=^7WP 7'XY"_P5%'$1:QTDEH FT/S#:
M[5.8/J'FJE',X[84RX7"-Q7:':[2> "N?C9Y] L8D:XW?]!-V!_4?!;7P%ON
MCF8;^YU"X!1QQB@X&'8)ZK+ ?H7#8$;.-6$-.>%6_L8\.^FYD2\31(_$V=1B
M.(1-H>\M[L'T;G>AG!S_92),SX_/XC_/OM&;4)S#YT*XLIB#9FKBR@DWMU2B
M1)%G=/1FGQ:Q/!#3MW;#AA'BTI&2M_)]H\X"BX_!C7"7T_GDGR\Q'6'!"GCW
M!B27$18,"%^&S3&LX>[(%5',#_>I_.4P?OI.,M EXV:?&#T_T.*W=OU%@CFL
M//>6I18FP50W%N2I@O0@JFF,/EGN/O>):WA2E_[G V%]8<+:ASLQ>$I;<'05
M.S!4(%27%/),>L$/)[M OHU5EAWTY Y):!]NJ^C*)J (5'R4%4=-:5R0"]W=
MK+98^T)E-I3!'Y1((,">P#P'JMH=5>U#/WY;'>7=R@I=4.LO$8LBHCE?(=U1
M&3;??%?8-^NPOU46Y7:C^9TGK,5"D3TZ<,-'_YY!RGNC=#<4<QXLNE=SV&;3
M&>=;^VX/W:E^J?;= NP4[?-!LG!MY#4<+D!9T.X*5XN'T0)I.ST$L[9FSO7!
MDHQQJDWDM%^W56HIC?8U= /C0',LEO.C*TD=$"&@*#!B'W;;#P7Z"" E(';]
M911?;X3M^80]\KG.-YA-@\5<.&=_,'+?P%J;[6U"P3*@PA>+ Y& JM1-S)NN
MZC$4;=_8<MHK)NV*Q@D;"NA9?DEKJ^8NH- 8U!&MLG-0;J%%+=.XH ZO<L2@
M8!C:2VQWRE$[5>6R[1NGJUI]QQ#O5.2UI30A)^8OLAJNMVE"B;#M7JIB &^^
M/*#CX&]O8FVOL\7T?N>K >;4[X,%#LH FBN1N P>GRO,')0*;Z)=.&DV0 BM
MS*% I_?RJ #7M=(C,Y)]U0KB7DECE%?9N@LOIK(Z!R38@*&FL,DG);Y 8_,A
M+7';SG^8!)EYWFG\VA^$[$!FAAXXH>,4FA=PLZ@S8*E6X@K3"DTAGZL#C+XC
M0ER#<#+87N:K[BSQ45."MZGH;MN-UZER@9E1M"2F-#06!_@+&/">2%&F'3X^
M!REI-]PY.2S&G>'F^MU6V!I'FL!O1)*$R^G^#<_R_>[!K".+4*YJ,:AR%BA5
M2$R'2Q)N5&#3TG=0/00SRAX'<P=D0C'J)LK"^N(K9U)=NK;+$06Z>-+J([HX
M [19G*?RZJH1:3!98Q1F%!)S-=W1WLOT,\)'1^*U<01J V?TO <REN"!PAPX
M J]1$O]M*,WM%8;>ZQUE7+G:U."!B^M+3$HP9HWAVO615#!/I275RFZ@DZ]'
M]A^JS7:*[K-#M=F?1U[$@1-&PJ]K0!/3(F];[4I';FBOD -J./N&C$9I=%/2
M46W;C<DB,5?U="C:V/F(S7T6P0/F=>&AL.PA;+T7F[\4*=00D7KXV-X8]08.
MN"A1*_REK,)^Q LXQCE77GVY4*!>=TN^R4A9:.$\19Q@Q/QM $HO>"G_X-ZQ
MBVV<;AG;MK;+_A>XH2V%YQ47DLGN@9$Q<I=JT\POG"MCT /6(!Q<N3G"XGK*
MJ*O-F9G!YKO+Y;T>ZALF43]2=5"\.Z7II_=0O"^?8)_0CW][^82^DOG_ 5!+
M 0(4 Q0    ( $^ >E@^FU0!0%0  $E?   1              "  0    !I
M;6<X,S$R-S$W-5\P+FIP9U!+ 0(4 Q0    ( $^ >EA/08^$+30  ,8]   1
M              "  6]4  !I;6<X,S$R-S$W-5\Q+FIP9U!+ 0(4 Q0    (
M $^ >EC4RS.;=A8  !H8   2              "  <N(  !I;6<X,S$R-S$W
M-5\Q,"YJ<&=02P$"% ,4    " !/@'I8T02Z#V90  !Q9   $@
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M,3(W,3<U7S$U+FIP9U!+ 0(4 Q0    ( $^ >E@LQXF=%R8  *(O   2
M          "  22V 0!I;6<X,S$R-S$W-5\Q-BYJ<&=02P$"% ,4    " !/
M@'I8 B@0)%PJ   <-   $@              @ %KW $ :6UG.#,Q,C<Q-S5?
M,3<N:G!G4$L! A0#%     @ 3X!Z6%RZ;%/I+@  HSL  !(
M ( !]P8" &EM9S@S,3(W,3<U7S$X+FIP9U!+ 0(4 Q0    ( $^ >EB8<+D8
M@3@  !="   2              "  1 V @!I;6<X,S$R-S$W-5\Q.2YJ<&=0
M2P$"% ,4    " !/@'I8LVG0X\A(  "]2P  $0              @ '!;@(
M:6UG.#,Q,C<Q-S5?,BYJ<&=02P$"% ,4    " !/@'I8(<ARS[TJ  #Z/@
M$@              @ &XMP( :6UG.#,Q,C<Q-S5?,C N:G!G4$L! A0#%
M  @ 3X!Z6-C#M^0.3@  &5H  !(              ( !I>(" &EM9S@S,3(W
M,3<U7S(Q+FIP9U!+ 0(4 Q0    ( $^ >EAT!,U[/3X  +U,   2
M      "  >,P P!I;6<X,S$R-S$W-5\R,BYJ<&=02P$"% ,4    " !/@'I8
M:KHB"G%)  !!5   $@              @ %0;P, :6UG.#,Q,C<Q-S5?,C,N
M:G!G4$L! A0#%     @ 3X!Z6/SJBW8'<P  C7\  !(              ( !
M\;@# &EM9S@S,3(W,3<U7S(T+FIP9U!+ 0(4 Q0    ( $^ >EC;C<LX 34
M +)#   2              "  2@L! !I;6<X,S$R-S$W-5\R-2YJ<&=02P$"
M% ,4    " !/@'I8&1U49DD[   13P  $@              @ %9800 :6UG
M.#,Q,C<Q-S5?,C8N:G!G4$L! A0#%     @ 3X!Z6/4WP^8E)P  ^#<  !(
M             ( !TIP$ &EM9S@S,3(W,3<U7S(W+FIP9U!+ 0(4 Q0    (
M $^ >E@'UHOT(SH  .Q*   2              "  2?$! !I;6<X,S$R-S$W
M-5\R."YJ<&=02P$"% ,4    " !/@'I8&]GI@4XJ  #A-@  $@
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M,C<Q-S5?,S(N:G!G4$L! A0#%     @ 3X!Z6,M0PDBR-   KD8  !(
M         ( !B",& &EM9S@S,3(W,3<U7S,S+FIP9U!+ 0(4 Q0    ( $^
M>EA"/;R3WD<  /):   1              "  6I8!@!I;6<X,S$R-S$W-5\T
M+FIP9U!+ 0(4 Q0    ( $^ >E@B>&F(US(  #Y!   1              "
M 7>@!@!I;6<X,S$R-S$W-5\U+FIP9U!+ 0(4 Q0    ( $^ >EC,8G.MA30
M .XX   1              "  7W3!@!I;6<X,S$R-S$W-5\V+FIP9U!+ 0(4
M Q0    ( $^ >EC=G5Q0P"0  &8I   1              "  3$(!P!I;6<X
M,S$R-S$W-5\W+FIP9U!+ 0(4 Q0    ( $^ >EA51$LH'S4  %=$   1
M          "  2 M!P!I;6<X,S$R-S$W-5\X+FIP9U!+ 0(4 Q0    ( $^
M>EA/08^$+30  ,8]   1              "  6YB!P!I;6<X,S$R-S$W-5\Y
M+FIP9U!+ 0(4 Q0    ( $^ >EC*936D^A8% %.\-P 1              "
M <J6!P!K<G)O+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( %" >EB P%4_<TX!
M "$*%0 1              "  ?.M# !K<G)O+3(P,C,Q,C,Q+GAS9%!+ 0(4
M Q0    ( %" >EAY@G"&01\  /$^ 0 0              "  97\#0!K<G)O
M+65X,3!?,C N:'1M4$L! A0#%     @ 4(!Z6.)8LM_F$   JX$  !
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;,2YH=&U02P4&     "T +0 :"P  !G$.

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>krro-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krro="http://korrobio.com/20231231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krro-20231231.xsd" xlink:type="simple"/>
    <context id="C_3b33040c-7342-4627-9634-346fa6638cb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f43d2a6f-7e41-4811-95fc-4e6af0a5b263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8bd7505c-82d1-468a-a930-ab481a0db383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e34d372c-ba61-4919-8176-79ae6cf200b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_597278ba-5ca6-4b61-aca3-d85a7999b364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:CummingsParkSubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9aa93606-02db-46a9-9b63-7b4d0578cd82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_27d10e7c-da56-48f5-a64c-6c1e8a2c5c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4ffd1385-3f0e-45b7-929e-195ba02c78b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7d015c4-04ba-473c-982c-ee84943ae574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f43b4902-d2c6-4c47-bc7b-f3057b2dc2af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_952c1d35-4cc4-4d37-8f7f-0c70663501bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:OKSFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dcc2b54b-9a21-4b66-92b5-e1bcfac05a39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bf439977-ea99-4550-a754-3c1783080c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4e61d9b0-a7a2-4826-b526-6cf674a82d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_074064b9-afc6-45bc-a7ef-5e7a10262640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55691ac6-0299-4103-8d80-a1f6d05b4a80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fac002bd-d841-4cb9-87ff-6726c92a87a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f821a1fb-8b0a-44e8-b18a-e92e693bb9d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_06426193-e63d-4cf5-a2db-19dbf1197a90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e46527cb-cdd6-49b6-ae87-4f92d5ccf0b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_21957e3e-4ce5-42c3-b40c-20cefc6c2eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae8c2fd3-de68-4508-b076-43b5d6c93aad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_68f1cdf4-0429-4263-8211-79aaef7f7fd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_93f80774-1bcb-4131-b2c9-93def7a01c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9019f292-8abd-4d72-a541-b2e15e70e9e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:FrequencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3e74070-621c-4737-963d-07ce423a28f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ab8f59ed-af83-49c1-80a2-d1a10ec53e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3870cdb7-60a5-4355-8d59-703d871350ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fefcff45-a321-42bf-a7e9-1a416bde8bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9fd09c06-35f8-4ac3-827b-5890bfa49ef1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_46cc1979-5c24-47f7-bf95-9aa5c051807b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a623cd32-caa5-4962-8d16-001ea4eb82ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_86dca00a-98c3-49ec-b174-5d61f32beb4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_661dff35-cbb5-44e5-8aef-f17a500e1eea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d2ac73cf-1c8b-4a06-aca0-5f30e10f6acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ba766246-72fe-4458-8363-5e1fe9dfc13c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_98b4de31-fa14-4fd9-bd5a-480f77633a40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_093060bb-522a-4d5c-aa04-574677a7cb5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e12df146-e11d-4351-90cd-40afa0abdd05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_11f11e50-ea6c-40c6-950d-f8060c5107d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_efa34611-a425-44a2-86e5-16976c9be1dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_513af823-8be3-442f-a9fe-1a2fe1b055f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_397c2e74-ff43-4295-9f70-85a5ca23db1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">krro:Phase2BClinicalTrial1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ce4b9b25-ec19-4975-80b3-be6c42826a43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_876e06d8-58c8-4927-a39f-dc45358c0f14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_09fab13f-bf4d-4e13-b1df-cb7d113cce21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:CummingsParkSubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d16b2e0-26d9-46e2-9676-3b3691cb6871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a1efc944-079f-4e9e-8fcb-7284de744653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_14d8c666-1849-407f-b8ab-d3b227ede1d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a01b8c88-d609-4db0-874d-4d6cbf21061f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_919f3e26-6567-4206-aa08-0ae94fcbc65a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bed67611-bf29-4fae-9416-b0c86cc2e8d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_783f0bb3-c296-483d-8672-851d68ba26f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7af3db31-6c33-4c0d-98ce-e0c17f536ee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a982d847-1fa7-4a2f-a886-60eca2f91051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_45db7593-eb9b-4883-9384-b026cd2ff9bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0fcf0a27-21b0-415b-8c89-231bbee07b61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73266731-93a7-48aa-8ed8-61bc2b4c90d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f10a3be4-4ec6-4c00-b69c-d83c843296d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_abf5d9da-538d-418d-b41f-9269c757a637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f61fcdc5-7781-4d89-9c78-e405590b9203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ae566dce-3b97-4369-8930-694f01849c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_36fd05f2-24c6-4d41-93ec-f56ca9af1f89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:OutstandingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_072ef9d5-51f5-493b-a877-923f3cd50ab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_002cf6f3-a14a-42d9-8339-4c9a7464ddc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_16286e85-fcb2-4aeb-8a74-8b8cb490439b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ecda1a05-7107-41dc-a5fc-7124dc194f84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9f3a1082-a9d3-4417-a0f7-4d1bdd1bcaa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fbf5ca73-fbe0-4461-be55-abde5434880e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5aa971ad-c939-4c21-a327-57534a1ce091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1d4501f2-ba74-4579-94ab-e81941e63104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:KorrosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b649a5e7-5c6c-446c-9fb4-344b0a1da0a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:OutstandingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_41f08d6e-847a-47a4-b214-65d33ec4097d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f825e298-5e6d-4e4a-ab77-5640165e55ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2ab0d269-b1a0-4ec5-8ce7-bb7b469c3284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bc4d7e4b-8b44-4d70-bfd8-4175df616bb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7797a79c-4109-4291-85d7-9f1f44b8f9ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9a2b3b81-fe26-47a3-b213-a4e83175b18c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ecd8a380-935d-40bc-8d1e-6ed89fa53199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_682c0c46-757c-48ee-8cdd-a8c28faac6de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7042021a-f5f1-4b64-8355-bd3286bb3502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2c63df81-1292-4b21-8598-c514db4b083e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0304c01-05f2-44fb-9a26-a65525c2254d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b451ece6-a0b3-4778-9557-3099f2fc289b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b267ce26-7f99-4922-a593-840ac7ce4bac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_744282a9-e212-4b62-bd6d-0bd21501afbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_745d62aa-8d61-427a-9115-a346c910fcb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ea294f12-f168-4831-b0a1-38dd8c3da158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c10f8f23-79a1-42bb-8447-ddc5b11bb910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="C_f8f40235-5f27-48ad-ad53-52935a2bb13b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_728a4108-5170-4a8f-b001-b85c0cd9973b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_23c62caa-1ebb-4380-b45d-f24627644a23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8847dfc8-679e-433b-8e63-9ebb42630fe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7fb87aaa-7763-4db0-b2e3-0eae4ddb9138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a831aa61-46f2-4591-9e51-98d9e0781061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_72eb9539-da9d-42ea-ade5-45879867b4dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_588ba34c-1cc3-4361-8113-4bfbca87310e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_81b7cadd-72c3-48d7-91c7-d8614a9176e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbd86c0c-db69-4c76-b0b5-17ba9213ddff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cd46bccb-a691-424a-a33d-f99566514d8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8cfbcf8e-1721-4cf1-9208-7dd35da5b429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_45c261a8-1fa5-407f-ace7-946cf709a7e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">krro:Phase3ClinicalTrailMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krro:GenevantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ab8215de-6795-4f27-b53e-55d3375d2af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_8eca1fa2-2518-420d-8403-4912df0dca2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c310c39a-f47b-42e4-b993-0dc1ab10d95c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ba47ceb2-3907-4c75-93da-352aebf2bc11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_84565942-6987-4c97-b8de-234ea6a6f1a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b6e3c39b-8096-4f8f-97f0-daa59596a1a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:OKSFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a91b6de8-ece5-41ce-aead-f4c5480a52b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f7339a6-1078-443f-9a49-06210ba9d73d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be8ba35b-0380-4fb4-a4e6-89fb909ebcce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_df66f09e-7513-4224-913e-a00329ea7267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3253f6cb-13ac-491b-a7c7-9edb74475ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_186c69fe-8d24-44a5-865b-ef7a19de3a07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krro:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="C_85bbe7f5-08dc-4646-8679-f35a1d5e2c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_28de2dc3-2ca9-4bb6-8723-f572b9234796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52ef87ed-863c-43f2-b64f-793064742302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fab291c7-d953-4b7e-86e4-50c5ceed14ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11d68bec-be21-47b3-aed2-e43151eea3b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e96165e-bcee-45de-b858-7909fc620d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_65a239e0-5ccd-49da-844a-2f067baf9930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:KorrosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bbbfcc39-8343-47e0-a50c-2b474af31554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3a51d59d-f39c-4dbc-88ab-1479e858825a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_22794dbf-a4f9-4f21-8513-02ae3c6a8843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5a9015d7-d3e2-497e-ae73-4ee485589e02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7c6858e2-8133-456c-a5ca-5b7016177e3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e149e85-1d4b-4712-863c-cb986c6595d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_306fb8af-4fc4-4970-872c-b483d03fb9e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_096221e9-4b77-4f75-a7ca-adeffcec02e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9eb4912e-e6b4-4f6f-b944-30b2ae5249b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5e3928f9-e795-46c2-8b3b-47cb73bcf901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_19000ad4-b68e-4b1a-a943-897eb59fe630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4c0a17b-b744-4c53-8416-6686a4fc0acf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36085e8f-16ab-4161-877d-07990acb5c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d6c273ee-ecf6-4069-ae3d-4c61b89c6153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_883bc534-e8f6-4895-bf52-bf10d4e2a415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c288594a-72d1-4f6b-8b50-f8d38cf9d937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bd07e99c-bb55-45ba-8e28-c3c05197c876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c761095-cfe8-42cc-a37e-889e388af4b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:TwoThousandAndNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22e502a6-3646-4014-b58b-4798f5344e84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="C_2d3840a1-75bb-41e9-bdf6-5978eb8662d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4331d39a-acce-4178-b456-7b04be2b6063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76ec386a-8db0-4d94-8796-51f3034d3694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_24975ddf-6b2d-4418-a7fd-437c84c577ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesB2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3eb2b595-9ba7-481a-b2e8-779deb094693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeed3PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6a634502-8868-4319-974b-a0bdac21d6bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:FrequencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="C_0eebafc0-fac7-4906-a525-f415a4144d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">krro:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa7dd013-7306-42b5-8ed5-d73bf12a2654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_36660a78-b341-4333-95b7-20b31fa422ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7ef01b84-410a-48aa-82c6-e6d539411e3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">krro:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1497c1b1-c02c-4386-9a0b-01290e5e3553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8dd132b6-7063-44e3-af52-d367d2ce82ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_55c76954-1de4-47a3-95e3-7300d73d84fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_86de2748-fce4-4bbf-9e70-716575029823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ef3d01f-e4f1-47e1-8d30-5ca772b0c60e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8544c9be-728b-4911-819c-b239ec0b27ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a190f767-c341-455b-9ad4-483737f0d73f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="C_bec03e77-9bf0-4f52-9023-3b2c608d690f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krro:StockIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_745aa97d-b654-4fe3-a288-63cea2f6c854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">krro:MsApaAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c2a2b4a4-d405-4a52-87f7-0d7d1dabb2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1ffa510-b12a-4e8a-ae92-845d73bdc92d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab007b59-97df-45a4-a462-77226307ef64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1de4389e-f2f0-4d25-b59d-6d52f9adce3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">krro:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krro:LegacyKorroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8f5dc272-fb80-43d7-a5fe-feed1975a355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krro:SixZeroFirstStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_Rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Securities">
        <measure>krro:Securities</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_c5a7063d-575f-47e9-882b-df9c31119919">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_05629f41-d8ed-40c8-ba46-c41c32dc44d1">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_2398e112-547a-4b2f-8db5-cddcd0e4e2d4">0001703647</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      id="F_df40f193-0acd-4da6-a9cd-f7e3b8583f44"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      id="F_b3f0be16-92d6-4d75-b406-665cb27d9874"
      unitRef="U_USD"
      xsi:nil="true"/>
    <krro:PurchasesOfInvestments
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_3c03b9d3-a541-4644-82ad-919fd697092d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <krro:AdvancePaymentsForPropertyAndEquipmentNotYetReceived
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_7f34c903-b265-46b4-91f2-c9b15429742b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_81265546-519d-4e10-aa08-5ad84f64dad1">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      id="F_5a1b49f3-7a54-4e43-9407-97170c711b48">http://fasb.org/us-gaap/2023#Liabilities</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      id="F_c39e9862-e9fa-4ff5-9da0-641cc2ce94c0">http://fasb.org/us-gaap/2023#Assets</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_634fd6d0-ad20-46a4-8d5b-0841462aa503">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_8183349e-ae67-46c6-8488-1322a4e5ecd0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a52c9a51-41ab-4cd2-ad0c-8a6146078943">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_08c296d3-be88-4b30-8017-c62ee2e1201a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_be903220-e9da-41f7-bdfd-9ddd33e22087">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_7a22a284-b1dd-4503-8f32-30e6114624e6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a4920c7a-36f5-4a77-91de-a820b51b49b7">001-39062</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_51321057-8c99-4843-ab14-ed43e42f3b3d">Korro Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_645fca40-bcc2-439e-b428-622872590fe8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_8520bb99-f6fe-4042-8767-e7fc01142ee1">47-2324450</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_5af50d38-9257-46d6-98ae-417cce26bef9">One Kendall Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_6d375288-0e1f-44ce-ab94-0235d3db1532">Building 600-700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_7325958c-fb41-4319-9e8e-c854265f4eb5">Suite 6-401</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_84d38b7e-5dfe-4717-8dca-3a7b8a74afd4">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_49b78a08-c8ee-46a6-b3ce-0a014d469da3">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a704ba1f-b153-4eb2-8a10-d8d38cbed3ca">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_deaca5be-3ece-4fc1-84f4-4a89a22a4e10">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_f8911f8a-4eef-486d-9bfc-735e495adf74"> 468-1999</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_252af18e-b4d7-4ce0-b8c9-05fcf0b1c952">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_04b31cfd-aaf6-408c-b723-4a288ec81a4e">KRRO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_08505ad2-4314-4e88-b628-0930b2865a04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_9eb73b5d-2d42-4841-a757-52dcab761a32">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_0ef3d438-4613-4d24-9a75-7148e872a3c5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_36f4f087-c237-4f6e-bdb9-585408ed5c04">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_91a83348-bd2d-47d0-9a20-8c813f4feff4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_6a571421-76b5-48f0-bb0e-489ecf346308">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_ce3dc34f-8429-4091-8230-54c8fbae806f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_7c00ff15-feb2-416a-a2fc-77b2af24a0b3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_6132a8d9-f781-4ca8-adab-0f4c006c016c">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e36d64d6-4130-4f54-8ef7-f785353b5ae0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_417f9a85-7d52-4352-a081-cbda2da5e0f0">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_95be36e2-3fde-4303-ad4b-eeabac660773">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_9fd09c06-35f8-4ac3-827b-5890bfa49ef1"
      decimals="0"
      id="F_a6e62bf9-3d57-43e7-b38d-d1bdc37a62ea"
      unitRef="U_USD">12148224</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_22e502a6-3646-4014-b58b-4798f5344e84"
      decimals="INF"
      id="F_936f5b53-0fe4-4aed-8f2c-ff10edff69bb"
      unitRef="U_shares">8021946</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_5e38fc3d-fb62-4ae0-8e40-4c680eb1d075">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_38f727e8-d714-4cfb-acda-5e56503a9354">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_eec1bcf2-b1b4-4911-9aa9-228b1d8b0e83">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9b2061bf-69e9-4718-a0bc-39831222fd12"
      unitRef="U_USD">166150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_1301a00e-1932-4d83-afb4-35ad5504d109"
      unitRef="U_USD">36333000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_86da18d6-c7fb-4a62-a02c-1048aa8729c3"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_7bcebbaf-0598-47e2-8d14-a106773730ba"
      unitRef="U_USD">18915000</us-gaap:ShortTermInvestments>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_d1a521a8-bcf5-44bb-a846-9603c4c0487a"
      unitRef="U_USD">3563000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_053dc648-9f99-40b4-9a37-c1b09cd87076"
      unitRef="U_USD">603000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_623dfcbd-ce23-4dda-b627-755ced327778"
      unitRef="U_USD">3015000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_88b31d2d-939b-469d-b49e-1119955b9253"
      unitRef="U_USD">1232000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_80008493-5810-4345-8b86-e94084a0f7a1"
      unitRef="U_USD">172728000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_c6ed4dcf-675f-4a84-b40c-81e81ac96f65"
      unitRef="U_USD">57083000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_7d4a89b7-3901-4b60-85d9-3f5fa995c938"
      unitRef="U_USD">15665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_dd6803c6-8c85-4f91-b699-d8a65eacb611"
      unitRef="U_USD">9866000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_141e2533-2df8-44d6-8e98-fec111ec5314"
      unitRef="U_USD">27150000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f8becb9f-d449-4982-8ac6-1e2ee2e5bd01"
      unitRef="U_USD">2024000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_7a9b115a-5d6c-4257-9a94-b6e576d3a3fe"
      unitRef="U_USD">3406000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_2bf080b3-0e6f-4f67-9546-ad8d7d5a2f37"
      unitRef="U_USD">4541000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_927ba28a-813b-4e35-8acf-1e00fa6730ee"
      unitRef="U_USD">2714000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_d0364bcb-51f6-4718-a20b-d3837769afaf"
      unitRef="U_USD">228000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9f59cf58-4df3-4bda-b44a-86228a477352"
      unitRef="U_USD">221663000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_407d6070-8734-49b1-afed-cdb040b116ec"
      unitRef="U_USD">73742000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_7bc36799-e9fb-47ef-a474-05a0d6c88440"
      unitRef="U_USD">7280000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_119a50af-efb0-4d02-8a8d-bf68934807cb"
      unitRef="U_USD">2605000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_5f552e8d-20a6-4d29-a8bb-828217b49ca2"
      unitRef="U_USD">10212000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_b3c3b598-22e5-44e4-aa84-e52f5a6908d3"
      unitRef="U_USD">3175000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_eb7994d3-31d7-4eae-861f-b45a2087e8b7"
      unitRef="U_USD">1991000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_29f435c5-2f20-48df-929e-963446c1b31c"
      unitRef="U_USD">2921000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9076f0c6-9bd3-4fde-806f-c42edf6f31f6"
      unitRef="U_USD">19483000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_fef0387d-aff3-4819-b2c5-347b4c3b7ed9"
      unitRef="U_USD">8701000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_716710c6-350a-41fd-b33c-1304e5e53150"
      unitRef="U_USD">31216000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_c409e4b8-16d3-49f9-80c4-a9cb2407c04c"
      unitRef="U_USD">209000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_231b5b78-6533-4f03-aa5e-5955a0b78574"
      unitRef="U_USD">1053000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_67f347dc-583c-4c32-a9c3-fdb4483cb7b1"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_e940de89-0e07-41e9-8c4b-f70f14e42dfc"
      unitRef="U_USD">51752000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_25c8c80c-e0ae-48ba-90a4-983217aa9590"
      unitRef="U_USD">8910000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="3"
      id="F_fa81c196-979a-4a9a-91b1-535f422fb0a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="3"
      id="F_a5bb69d7-13e7-4b45-846d-a722e7c3a55c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="0"
      id="F_602442a7-69ac-4b22-bf9c-f15c3762482c"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="0"
      id="F_207cbb85-f4ba-449f-abed-fdc696f81f9a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="0"
      id="F_d00a6ed4-3b3b-4a60-84cf-c109e60f9e81"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="0"
      id="F_ba850d27-84e1-40be-bc47-5399f529aa3a"
      unitRef="U_shares">684739</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="0"
      id="F_0da7704f-77ff-41e6-a106-f0e5e0be84f3"
      unitRef="U_shares">684739</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="0"
      id="F_9da22deb-3bd4-4555-80d2-4bf1a0f5dc1e"
      unitRef="U_shares">684739</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="-3"
      id="F_1645bd9f-87f9-445d-bb69-6e4211603574"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="-3"
      id="F_877453d9-b3a0-482f-9b0a-ba366051e9b2"
      unitRef="U_USD">16115000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7ef01b84-410a-48aa-82c6-e6d539411e3c"
      decimals="-3"
      id="F_0c621fba-d8c4-4ec5-8f1f-1eb132a96dfc"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_f08095e6-e7ee-4fee-be89-841ee0d7b36d"
      decimals="-3"
      id="F_94789e3e-2c28-47c5-9deb-cb964304c69b"
      unitRef="U_USD">15924000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="3"
      id="F_2ed1014a-ba7a-4e21-b4b4-165d15b839b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="3"
      id="F_f65ba488-90fe-4623-98e4-80ce764b6a3d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="0"
      id="F_ec9c4c4a-1eff-44cc-899e-742f8f6364cb"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="0"
      id="F_c3805195-d28c-4ddb-a583-dd8bb165b29e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="0"
      id="F_7116dcd0-e008-47b9-aa8d-1c3efd878edd"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="0"
      id="F_f9559690-d650-4e3a-84ed-e10af2326782"
      unitRef="U_shares">2029666</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="0"
      id="F_37185a1b-639f-43fa-b95a-cd9f31d8a2e1"
      unitRef="U_shares">2029666</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="0"
      id="F_f4ca0744-bd39-4cc6-8b12-893bc35ebae2"
      unitRef="U_shares">2029666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="-3"
      id="F_28a69fa5-7f4f-4fa8-819b-19d1be9a20ac"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="-3"
      id="F_f5bcdc91-aee9-47eb-98de-883d00b5c2f3"
      unitRef="U_USD">91500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="-3"
      id="F_ff8ef5a5-2bd4-42a9-97af-e82ddc725864"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="-3"
      id="F_028acb62-05eb-4547-aa38-c7dd6dab8c95"
      unitRef="U_USD">77736000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="3"
      id="F_0253c473-77e7-4a78-8342-dbd8cf4413c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="3"
      id="F_fdd04145-9881-47eb-b7c8-0a2978052b0c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="0"
      id="F_b1f45b7d-68f2-485d-919e-7f23ee0566f4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="0"
      id="F_926bfb7e-5d2a-476e-a520-b3061d691ed7"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="0"
      id="F_bf2abccf-eb82-441f-909a-855950179965"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="0"
      id="F_6a0fcdc6-c93a-43d4-99d8-4a90831a696f"
      unitRef="U_shares">1104178</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="0"
      id="F_9b7153ea-246f-46c3-be59-a5411898cfec"
      unitRef="U_shares">1104178</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="0"
      id="F_239aa23c-939b-4c89-83b5-56c091cb6c00"
      unitRef="U_shares">1104178</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="-3"
      id="F_afa507de-7042-45d4-942f-52c24412cfed"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="-3"
      id="F_eed24f44-e011-4230-a307-dd22de103b04"
      unitRef="U_USD">58000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="-3"
      id="F_51e7d991-751a-41b8-a018-085158415bc3"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_661bdbd3-9530-47f6-a0f4-2829f3b1351c"
      decimals="-3"
      id="F_a928748b-957f-4a9c-a0cb-dcb452e0b68c"
      unitRef="U_USD">57703000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="3"
      id="F_1fbfc390-1d46-4298-92b2-3bee478dce14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="3"
      id="F_7eef9427-b96b-4c6f-93a7-cd2418474675"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="0"
      id="F_b6343578-a2c5-475d-95d9-6b63ba746816"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="0"
      id="F_ac20ea40-d242-4a15-8857-8111d6519f71"
      unitRef="U_shares">1036656</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="0"
      id="F_93e4689b-211a-42df-b675-3f1f8dbf3338"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="0"
      id="F_c18d0ba7-363b-40cb-818c-4d31a75b6dfa"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="0"
      id="F_f5056490-d3c0-433e-8741-2876a211bab4"
      unitRef="U_shares">223417</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="0"
      id="F_92b86e73-99c8-4893-be7d-5a697a4a0763"
      unitRef="U_shares">223417</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="-3"
      id="F_0a30e0a3-425f-4645-ad23-1ead47fba548"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="-3"
      id="F_b4852263-a6aa-4538-92d0-6b8f90428079"
      unitRef="U_USD">12500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="-3"
      id="F_5708460d-55e7-47a4-8a27-160c20762db8"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_d628afef-4ba3-4d6e-ba9d-49ca6814831d"
      decimals="-3"
      id="F_cf9b969a-8a78-4203-bc3a-563308b058ff"
      unitRef="U_USD">12500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="3"
      id="F_0dd932b9-d98c-4917-904c-c3b37b588664"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="3"
      id="F_c2c11d37-3b78-48f5-9272-5486c24df5ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_3604f747-010e-466d-86de-ec6d6fca9df8"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_b1dead66-168b-479d-964b-697aa58a5e55"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_7a2f977a-f392-480e-a28b-03d1ba64d8dd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_e2a78281-8a0b-4dfd-b408-7885052a78c6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_42c3c929-286b-41ef-bf2d-8579d8e87cbb"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_6bfdcd5f-eab7-4a73-ac8d-ea5633d6dbc9"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_2d841b0a-f257-40e8-bb8b-16b328071876"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_5abcb9fe-507f-49dc-bd6c-bf141d303ec8"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="3"
      id="F_9ce2f0a8-ea55-496d-85f6-0f09b6fc672e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="3"
      id="F_d83b5ac5-4ffb-4498-940a-4906e6b2ebeb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_d63c296b-e194-4314-8e51-acb3e4b8dc43"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_c453bbb1-784d-4ba4-a2d5-11a62fbd8803"
      unitRef="U_shares">5755759</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_2c26c9ff-f4dd-49e5-9583-a54a3f66fb9e"
      unitRef="U_shares">8016516</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_7a5b57b9-e5bf-411c-8421-c40b2d4b4ef1"
      unitRef="U_shares">271371</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_9ef7762b-8430-49de-be7e-38ac03c2ee5d"
      unitRef="U_shares">8016516</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_95b8b8e3-5d3d-4142-a00d-2201e82f15c4"
      unitRef="U_shares">268468</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_c41932d9-4ecd-4031-8d6d-5ec6a2c2d5eb"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f896e7ed-c7c2-4ad5-810e-796c14eaeea7"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_437d9b8f-34c1-45a7-8466-3d22192949f4"
      unitRef="U_USD">352908000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_8873938e-2981-4c5c-b5a5-b668c8c3a99f"
      unitRef="U_USD">2807000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_bc1c3d5b-69e1-4a54-a32a-0fc9586392e1"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_1744a23f-1aa0-48e3-93fb-acf16d174caf"
      unitRef="U_USD">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_4d8bb770-61f0-4509-ad72-41b98ae505a1"
      unitRef="U_USD">-183005000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_26db4087-53e6-46dc-bcd1-66cd99c10734"
      unitRef="U_USD">-101833000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_080e2c76-19bb-4aeb-b5ac-065c9b94becd"
      unitRef="U_USD">169911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_d9a30140-5cae-45c4-9956-1ee123c8359f"
      unitRef="U_USD">-99031000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_18bd1d7f-3b51-426c-bc66-248c46c5a232"
      unitRef="U_USD">221663000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_fc8d8fe7-d9fb-483e-8d29-8f56a0437429"
      unitRef="U_USD">73742000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_5e5edb7e-3b36-4716-843d-ef86f95e3dac"
      unitRef="U_USD">57250000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_629a2356-f1b3-4645-92b6-3a5de06e4c51"
      unitRef="U_USD">42201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_53c08b35-5db5-4846-9de5-33c35273471a"
      unitRef="U_USD">27284000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_60b39879-52b8-4bdc-855a-58b461c77f1c"
      unitRef="U_USD">16797000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_6522a20e-84e3-4903-ab50-40a48a5365bb"
      unitRef="U_USD">84534000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_500fe696-a885-46f1-bb4f-521db8dee5e6"
      unitRef="U_USD">58998000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_70d88743-48fe-46cb-9a9a-e07e11f83ec9"
      unitRef="U_USD">-84534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_9e05c6e0-a8b4-459f-90b0-761a81326339"
      unitRef="U_USD">-58998000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_8f45b240-ad3a-45b3-bbf0-3b6dc63954fd"
      unitRef="U_USD">3389000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_05b4d3d3-b0aa-4059-93ef-95bbf35e0307"
      unitRef="U_USD">976000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_3ed636dd-1c16-4fb1-bad1-ea979e946965"
      unitRef="U_USD">3389000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_410af4cf-fd91-423a-8ed1-169055e2f84b"
      unitRef="U_USD">976000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_e70a84d5-6cdd-4a3d-90d3-bff1d517585d"
      unitRef="U_USD">-81145000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_ae9396f5-5ebc-44a2-b40d-db71b554c508"
      unitRef="U_USD">-58022000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_1f0033d7-b51f-4552-83dc-2d1fd80a0e1b"
      unitRef="U_USD">27000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_4c00a228-38eb-4951-823d-bb788f31a835"
      unitRef="U_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_f92e3556-dddc-4a14-b113-e03ab4bbcc7b"
      unitRef="U_USD">-81172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_da7c1058-2b2d-4dc0-8666-7dc139f7b4a7"
      unitRef="U_USD">-58032000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_5da394ea-7da7-4628-991c-d99c2413588d"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_0adeca04-40ae-440c-8606-e295681dc0e0"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_0bfe9b68-ac56-4d0f-8ab4-139fb16e25aa"
      unitRef="U_USD">-81172000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_34d1450c-b7da-415c-9850-1504eb76820a"
      unitRef="U_USD">-58030000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_f5d857b4-5345-4a3a-bec9-7344a5aaa133"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-53.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_c5ea7c88-8128-4a38-bcc5-f91214429215"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-53.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_a212b035-0ecb-4aee-873f-1035b898c26c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-227.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_f7a8f6e5-00f3-4662-9c74-47ceed834d4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-227.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_6697c27d-699a-4b36-adc8-2b125612edc1"
      unitRef="U_shares">1529321</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_186a4006-1496-4cc7-9bc3-f04867db64b9"
      unitRef="U_shares">1529321</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="0"
      id="F_47d4b1a1-b5d2-471a-b420-b0af14dee7f0"
      unitRef="U_shares">255175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="0"
      id="F_70cd0c18-b608-450f-a331-04769b68f24c"
      unitRef="U_shares">255175</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_ba766246-72fe-4458-8363-5e1fe9dfc13c"
      decimals="0"
      id="F_ee2185f8-8cb1-464e-9016-30d42c45fa87"
      unitRef="U_shares">684739</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ba766246-72fe-4458-8363-5e1fe9dfc13c"
      decimals="-3"
      id="F_f703f3b7-c4d9-4a23-b11b-8411e7211ee5"
      unitRef="U_USD">15924000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_744282a9-e212-4b62-bd6d-0bd21501afbc"
      decimals="0"
      id="F_99ffa825-44e8-43d8-ba31-a07895fb0a2f"
      unitRef="U_shares">2029666</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_744282a9-e212-4b62-bd6d-0bd21501afbc"
      decimals="-3"
      id="F_1261356b-e2a2-4a06-9203-91cae6ad12b7"
      unitRef="U_USD">77736000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71"
      decimals="0"
      id="F_aac2a2e1-0d5e-40f2-a2a6-71505c0004bd"
      unitRef="U_shares">1104178</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_16b4404b-d2a4-49c5-9809-24a1f2e93b71"
      decimals="-3"
      id="F_4c2aeb25-71b3-443c-846b-8bbc5cf1004a"
      unitRef="U_USD">57703000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_cd46bccb-a691-424a-a33d-f99566514d8c"
      decimals="0"
      id="F_16a1a01c-5e8d-45df-b855-208c19794c46"
      unitRef="U_shares">223417</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_cd46bccb-a691-424a-a33d-f99566514d8c"
      decimals="-3"
      id="F_83e63268-d3f7-44b0-abc8-b4d04a74d5a3"
      unitRef="U_USD">12500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_df66f09e-7513-4224-913e-a00329ea7267"
      decimals="0"
      id="F_06930ee1-f920-4879-b9db-8cd9f7534377"
      unitRef="U_shares">237803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd07e99c-bb55-45ba-8e28-c3c05197c876"
      decimals="-3"
      id="F_2b4a8d93-cb8e-44eb-b891-6bee396691b1"
      unitRef="U_USD">1600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_074064b9-afc6-45bc-a7ef-5e7a10262640"
      decimals="-3"
      id="F_4d84f1d8-319a-4f6e-85b3-509b4dad6638"
      unitRef="U_USD">-7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_85bbe7f5-08dc-4646-8679-f35a1d5e2c54"
      decimals="-3"
      id="F_45de1917-c50f-4366-b05b-87a38d54e5c4"
      unitRef="U_USD">-43801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47"
      decimals="-3"
      id="F_93e8d0e3-b3d1-4063-a972-6ac0072350c0"
      unitRef="U_USD">-42208000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee"
      decimals="0"
      id="F_f51f4137-c548-46a7-9e1a-d773cbb4d23c"
      unitRef="U_shares">497</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139"
      decimals="-3"
      id="F_1591c274-e6d8-4494-9bb8-bec45e73a7f0"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_b1c73c30-f85a-4b08-9716-c2776070705f"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee"
      decimals="0"
      id="F_8ad5b6bd-5da4-42a8-b53f-d3e401075f32"
      unitRef="U_shares">8722</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139"
      decimals="-3"
      id="F_40f54840-ed66-44b0-80c2-ac675e4d82cf"
      unitRef="U_USD">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_d192e343-b58e-4c66-9800-1f441e4b9cf6"
      unitRef="U_USD">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_3870cdb7-60a5-4355-8d59-703d871350ee"
      decimals="0"
      id="F_c0a6e713-1fce-45eb-874f-c260f0710c9e"
      unitRef="U_shares">21377</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139"
      decimals="-3"
      id="F_20d83a97-78f0-44c4-b375-9b019dad8dc0"
      unitRef="U_USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_eb74ccba-1250-47a2-bac5-920bee440b10"
      unitRef="U_USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a094b4dd-52bb-4c3e-91d1-df850f2f6139"
      decimals="-3"
      id="F_fb292612-a0af-441d-b7ec-ca283e60fd52"
      unitRef="U_USD">1129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_4fb7bd98-4a98-4677-ac83-857e63ed9aa8"
      unitRef="U_USD">1129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_36660a78-b341-4333-95b7-20b31fa422ac"
      decimals="-3"
      id="F_ad79b0c0-fd52-46fd-b1a3-18e3dd24ec10"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_2d7cee34-4d1d-4c7e-8877-bfa46fb943f9"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_9e96165e-bcee-45de-b858-7909fc620d7b"
      decimals="-3"
      id="F_90ca89de-0978-43c6-a905-bca2664bab71"
      unitRef="U_USD">-58032000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_72ee9cdb-3954-4d65-83dd-9b6d2f62fe66"
      unitRef="U_USD">-58032000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_fbf5ca73-fbe0-4461-be55-abde5434880e"
      decimals="0"
      id="F_0745e484-3a17-4906-b8c7-8a7efdeca8e3"
      unitRef="U_shares">684739</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_fbf5ca73-fbe0-4461-be55-abde5434880e"
      decimals="-3"
      id="F_2e738311-887c-474a-a282-08e89e925e6b"
      unitRef="U_USD">15924000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace"
      decimals="0"
      id="F_fbbd7294-4559-4d1f-9732-08bda40a511f"
      unitRef="U_shares">2029666</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b9f07bd0-2fc3-4c15-a0db-8a84cdfb2ace"
      decimals="-3"
      id="F_ebfe7171-a622-4d1f-9873-18f6182dc82e"
      unitRef="U_USD">77736000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9"
      decimals="0"
      id="F_08b84ba3-62db-446b-a364-81b4eba6b164"
      unitRef="U_shares">1104178</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_edf70dc6-5dc8-4db5-8216-e0dde9f95ab9"
      decimals="-3"
      id="F_616291f0-8241-4633-a041-7618c3998cb5"
      unitRef="U_USD">57703000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_19000ad4-b68e-4b1a-a943-897eb59fe630"
      decimals="0"
      id="F_4649cd61-4ccc-4acb-88fb-9f246faf6f71"
      unitRef="U_shares">223417</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_19000ad4-b68e-4b1a-a943-897eb59fe630"
      decimals="-3"
      id="F_8e2eb6c4-00d8-4fa9-9151-6fe739320419"
      unitRef="U_USD">12500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8847dfc8-679e-433b-8e63-9ebb42630fe9"
      decimals="0"
      id="F_4865223c-cb82-477f-9a9d-7140a0824d11"
      unitRef="U_shares">268399</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_41f08d6e-847a-47a4-b214-65d33ec4097d"
      decimals="-3"
      id="F_98723c62-3c25-41d3-b729-1985d70ccaa6"
      unitRef="U_USD">2807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3a51d59d-f39c-4dbc-88ab-1479e858825a"
      decimals="-3"
      id="F_c6098682-589c-4267-87ec-644f3b50034f"
      unitRef="U_USD">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f43d2a6f-7e41-4811-95fc-4e6af0a5b263"
      decimals="-3"
      id="F_fe26ed6e-d650-4f39-9f88-ea32f09f8ef6"
      unitRef="U_USD">-101833000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f3008631-02df-4449-b2a8-df271c286cf6"
      unitRef="U_USD">-99031000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <krro:ProceedsFromIssuanceOfConvertiblePreferredStockShares
      contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7"
      decimals="0"
      id="F_c9fcd9ec-bd6a-46a5-9d14-a6c07988ac5e"
      unitRef="U_shares">813239</krro:ProceedsFromIssuanceOfConvertiblePreferredStockShares>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7"
      decimals="-3"
      id="F_cfdf5a18-785b-4f26-8bea-2bc6532b899a"
      unitRef="U_USD">45458000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_475b1aac-efcc-453c-8034-deed4c28a11c"
      unitRef="U_shares">292</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_3441b754-7c88-4372-b7ce-3668d8ac9d6d"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_ad27d48c-2f4a-4701-befa-44df4c1e2cf9"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_018f999c-5038-45ea-8a04-cdf9369eac1f"
      unitRef="U_shares">73394</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_da500acb-a3d8-4cdd-beae-74ea17e42e54"
      unitRef="U_USD">702000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_2f653315-6c49-4516-958f-2a70e7b677ce"
      unitRef="U_USD">702000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_acb3070e-bae2-494c-ae38-6ecc930c5599"
      unitRef="U_shares">2902</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_1c7d21e9-754f-4471-a1ae-440abe086a79"
      unitRef="U_USD">2375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_6ed99a19-678e-4084-b9e5-0908abbde663"
      unitRef="U_USD">2375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <krro:IssuanceOfCommonStockForCashInPreClosingFinancingShares
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_a70ac37a-de4f-49bb-9db6-be791079a933"
      unitRef="U_shares">2077864</krro:IssuanceOfCommonStockForCashInPreClosingFinancingShares>
    <krro:IssuanceOfCommonStockForCashInPreClosingFinancing
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="-3"
      id="F_cdc6cd81-fe8e-488f-b2da-d83d83f73f0b"
      unitRef="U_USD">2000</krro:IssuanceOfCommonStockForCashInPreClosingFinancing>
    <krro:IssuanceOfCommonStockForCashInPreClosingFinancing
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_67bdc641-486f-4d60-97cf-5e9b9aa8f7ce"
      unitRef="U_USD">117250000</krro:IssuanceOfCommonStockForCashInPreClosingFinancing>
    <krro:IssuanceOfCommonStockForCashInPreClosingFinancing
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_b6440752-7b59-423b-8dc6-8c9ea2c5977e"
      unitRef="U_USD">117252000</krro:IssuanceOfCommonStockForCashInPreClosingFinancing>
    <krro:ConversionOfPreferredStockToCommonStockShares
      contextRef="C_c0304c01-05f2-44fb-9a26-a65525c2254d"
      decimals="0"
      id="F_9f466c81-ffed-43db-b4a2-d72ea88af8d4"
      unitRef="U_shares">-684739</krro:ConversionOfPreferredStockToCommonStockShares>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_c0304c01-05f2-44fb-9a26-a65525c2254d"
      decimals="-3"
      id="F_944f04a8-df73-48b4-927f-0519dd178548"
      unitRef="U_USD">-15924000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStockShares
      contextRef="C_e34d372c-ba61-4919-8176-79ae6cf200b5"
      decimals="0"
      id="F_66840a7b-037e-4755-9eeb-38ab41b97180"
      unitRef="U_shares">-2029666</krro:ConversionOfPreferredStockToCommonStockShares>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_e34d372c-ba61-4919-8176-79ae6cf200b5"
      decimals="-3"
      id="F_2cc8536e-78ed-469b-ba5e-fb62455dfd48"
      unitRef="U_USD">-77736000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStockShares
      contextRef="C_55691ac6-0299-4103-8d80-a1f6d05b4a80"
      decimals="0"
      id="F_96bf1aee-3767-4e51-b057-c0249e9710af"
      unitRef="U_shares">-1104178</krro:ConversionOfPreferredStockToCommonStockShares>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_55691ac6-0299-4103-8d80-a1f6d05b4a80"
      decimals="-3"
      id="F_77447277-7345-4ecb-8717-f61f128521e0"
      unitRef="U_USD">-57703000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStockShares
      contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7"
      decimals="0"
      id="F_e6e0db67-3f3a-4d77-ba8e-b45f8ae3089a"
      unitRef="U_shares">-1036656</krro:ConversionOfPreferredStockToCommonStockShares>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_eabd4892-7101-4b0a-aaf9-a94e49ad36f7"
      decimals="-3"
      id="F_aeae8926-cb50-48c4-90ee-3bf4979deec0"
      unitRef="U_USD">-57958000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStockShares
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_4e89a49f-e49b-4539-8843-aa26154dbda3"
      unitRef="U_shares">4855208</krro:ConversionOfPreferredStockToCommonStockShares>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="-3"
      id="F_3a658bee-0345-4515-92f7-0f5e83ce4807"
      unitRef="U_USD">5000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_524584ef-6739-4e7a-a67d-f9c377e73b2d"
      unitRef="U_USD">209315000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:ConversionOfPreferredStockToCommonStock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_3e72b415-7412-4966-b962-5c997281cf80"
      unitRef="U_USD">209320000</krro:ConversionOfPreferredStockToCommonStock>
    <krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="0"
      id="F_01cd7110-b4eb-453b-904a-6d7177e0b778"
      unitRef="U_shares">738457</krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalizationShares>
    <krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization
      contextRef="C_3d3d4e4a-4b26-4f4e-95c5-25c0cbbdf0de"
      decimals="-3"
      id="F_1965e5cf-d255-467b-98fc-b437e6915ce5"
      unitRef="U_USD">1000</krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization>
    <krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_9a11d90a-6956-4c3e-9670-6149316b1702"
      unitRef="U_USD">32700000</krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization>
    <krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_d2f431f6-8ebf-4b11-aa88-3a82cc0dd6ac"
      unitRef="U_USD">32701000</krro:IssuanceOfCommonStockToFrequencyShareholdersInReverseRecapitalization>
    <us-gaap:RecapitalizationCosts
      contextRef="C_876e06d8-58c8-4927-a39f-dc45358c0f14"
      decimals="-3"
      id="F_45c0b381-8770-46c2-8948-cc8982206631"
      unitRef="U_USD">12247000</us-gaap:RecapitalizationCosts>
    <us-gaap:RecapitalizationCosts
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_10719ba7-ecc6-4d49-9f6b-c9682741c682"
      unitRef="U_USD">12247000</us-gaap:RecapitalizationCosts>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_27d10e7c-da56-48f5-a64c-6c1e8a2c5c32"
      decimals="-3"
      id="F_9056229b-c6db-48b5-b06e-69c0a6e43d7f"
      unitRef="U_USD">5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_b5dffea7-4d95-42dd-b7fb-f8c70a4be52e"
      unitRef="U_USD">5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_783f0bb3-c296-483d-8672-851d68ba26f5"
      decimals="-3"
      id="F_1a60e52a-0583-49a8-b8d4-1b15eeb04fb9"
      unitRef="U_USD">-81172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_cc0def33-c2c3-49ea-9d76-ce8d8e3b5fb3"
      unitRef="U_USD">-81172000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_682c0c46-757c-48ee-8cdd-a8c28faac6de"
      decimals="0"
      id="F_8ba4ea25-b140-4959-8d93-f4bf52acda90"
      unitRef="U_shares">0</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_682c0c46-757c-48ee-8cdd-a8c28faac6de"
      decimals="-3"
      id="F_befb1077-fe04-4b63-bdce-83b05b8dbe52"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d"
      decimals="0"
      id="F_d19fba39-02ef-4baf-b3d9-1b4a89633c2f"
      unitRef="U_shares">0</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_8f9ec24d-b7e2-4fa1-8932-be6b6625e88d"
      decimals="-3"
      id="F_e60a6381-6e58-477d-b2c5-18a7c3854e4c"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_76ec386a-8db0-4d94-8796-51f3034d3694"
      decimals="0"
      id="F_815b0b55-aac7-4ad4-877c-6fb54269c021"
      unitRef="U_shares">0</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_76ec386a-8db0-4d94-8796-51f3034d3694"
      decimals="-3"
      id="F_b7f0775c-c312-4c38-89db-95b8897c2188"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49"
      decimals="0"
      id="F_b235cfde-335d-4129-a5b3-2d3700947d1e"
      unitRef="U_shares">0</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a3c0d811-cf34-4eb3-9885-99641f1f3a49"
      decimals="-3"
      id="F_9c6c66b3-7fcb-4a28-b29d-7bbe8748ed1b"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a"
      decimals="0"
      id="F_be250c40-5aca-4e67-98b7-81393ba00716"
      unitRef="U_shares">8016516</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b17ac1e8-7a87-4cb7-b9b7-fab1ecc6996a"
      decimals="-3"
      id="F_b2e552d6-c2c5-43b2-8d4a-3faaeecf251e"
      unitRef="U_USD">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c310c39a-f47b-42e4-b993-0dc1ab10d95c"
      decimals="-3"
      id="F_2b52ad85-a862-4a20-9808-134d6d01396a"
      unitRef="U_USD">352908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3b33040c-7342-4627-9634-346fa6638cb9"
      decimals="-3"
      id="F_f344646d-a3ed-46dd-b1db-c9ce28f1912b"
      unitRef="U_USD">-183005000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_6dafd73b-815a-4828-a4a8-b40d558053d3"
      unitRef="U_USD">169911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_3d8f7833-d5bb-4b0b-9575-59e1b9a4ab96"
      unitRef="U_USD">-81172000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_a4045f26-05af-430e-8851-cdef08452ae6"
      unitRef="U_USD">-58032000</us-gaap:ProfitLoss>
    <krro:NonCashLeaseExpenses
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_525fadd1-8f68-434f-9188-2a0d8de38c72"
      unitRef="U_USD">3610000</krro:NonCashLeaseExpenses>
    <krro:NonCashLeaseExpenses
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_4a9d7278-6f45-4461-a423-5118aa924102"
      unitRef="U_USD">1396000</krro:NonCashLeaseExpenses>
    <krro:ShareBasedCompensationExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_26c69d3b-b749-4078-90c5-21dcc1c29b2c"
      unitRef="U_USD">2381000</krro:ShareBasedCompensationExpense>
    <krro:ShareBasedCompensationExpense
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_0cee20a5-0398-47f6-905f-33473454c726"
      unitRef="U_USD">1140000</krro:ShareBasedCompensationExpense>
    <us-gaap:Depreciation
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_86c2a5e3-351c-49c7-b470-fb8839ca0423"
      unitRef="U_USD">3630000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_05d3ad8c-f567-4a20-b3c0-ea897a5d1ca7"
      unitRef="U_USD">2511000</us-gaap:Depreciation>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_55ac82eb-8fdf-4f55-803b-8edad5d3eed6"
      unitRef="U_USD">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_cf1e8e22-5069-4347-a4c6-1525965e3528"
      unitRef="U_USD">-118000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_f2114646-1ded-4381-a1c8-506651e4cc6c"
      unitRef="U_USD">80000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_6e2bfb66-61ca-4d2f-a2b0-8a95c8ae254b"
      unitRef="U_USD">145000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4ec94e4a-2a46-4ae3-a839-a01334718996"
      unitRef="U_USD">-65000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_2b97620d-f2f0-4c99-8834-cb7ef16b79da"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_8688568a-8ec0-462e-9be5-22bb058d5cef"
      unitRef="U_USD">-559000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_857720e0-2859-47bd-8ceb-fda81daf257d"
      unitRef="U_USD">28000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_3d32befe-580e-4658-83ed-2f75b26393fa"
      unitRef="U_USD">3100000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_98dae78f-c638-4b1a-99c3-2020d1951d3d"
      unitRef="U_USD">1755000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4f048584-3a08-4ab5-a189-b67f09b334b6"
      unitRef="U_USD">1270000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_f23da07f-e460-4c01-9229-6c04e2582a85"
      unitRef="U_USD">-39000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <krro:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_33e088e1-4ea5-43cf-8baa-9d4936c6c0b8"
      unitRef="U_USD">1341000</krro:IncreaseDecreaseInLeaseLiabilities>
    <krro:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_e130a28e-1052-4878-a9ae-7395e2bcb7bf"
      unitRef="U_USD">-2198000</krro:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_cb8774ee-3373-4178-8b74-65af01dd9a25"
      unitRef="U_USD">1987000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_0c3940d3-986d-441c-8579-922a772c227a"
      unitRef="U_USD">123000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_569aa99a-348f-4f1b-823c-f7fd6baaa09e"
      unitRef="U_USD">-67283000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_6c370a68-745f-4340-969a-4c888cd7f54b"
      unitRef="U_USD">-53645000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <krro:PurchasesOfInvestments
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_8e4ac8b7-177b-4194-a124-9d450a74488e"
      unitRef="U_USD">37213000</krro:PurchasesOfInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_910779c0-301b-44c8-ab7a-a9e5bca880d9"
      unitRef="U_USD">19000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_77f9d1aa-6525-4889-b938-100f98be6150"
      unitRef="U_USD">53485000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4df4529e-3a99-40cc-bfe3-d0bf66154512"
      unitRef="U_USD">7836000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_c2aebfd7-2139-4f2d-886a-104bbb606e75"
      unitRef="U_USD">5136000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <krro:AdvancePaymentsForPropertyAndEquipmentNotYetReceived
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_c1c0a072-e0f9-4daf-bde5-df82ee95eb3e"
      unitRef="U_USD">-76000</krro:AdvancePaymentsForPropertyAndEquipmentNotYetReceived>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_80e69d6a-611e-4d13-a047-2dcb0e17f7b2"
      unitRef="U_USD">11164000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_647fee4a-33e8-4b3a-aff1-be38aff1c741"
      unitRef="U_USD">11060000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_16286e85-fcb2-4aeb-8a74-8b8cb490439b"
      decimals="-3"
      id="F_7bce5dff-227b-4907-8ca8-d4b43e78a3c2"
      unitRef="U_USD">45458000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_f8f40235-5f27-48ad-ad53-52935a2bb13b"
      decimals="-3"
      id="F_03f1f635-a10a-433d-bdc2-305ea8d59f69"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4d6bbd2a-9080-4574-b921-3d814ba89dbc"
      unitRef="U_USD">702000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_a087c28c-d7d9-458d-a7d9-c1ef71bdc4f4"
      unitRef="U_USD">62000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_9bfd4025-a1b7-47c6-95a6-dd76bef28fb4"
      unitRef="U_USD">117250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_5e55ab47-22a0-4504-b287-63365fad8bef"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <krro:CashAcquiredInConnectionWithTheReverseRecapitalization
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_10c300e7-94a5-4cb1-bc6d-fafd87a22b29"
      unitRef="U_USD">-36600000</krro:CashAcquiredInConnectionWithTheReverseRecapitalization>
    <krro:CashAcquiredInConnectionWithTheReverseRecapitalization
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_ad3c4c00-de73-4e64-a88b-1340fea63701"
      unitRef="U_USD">0</krro:CashAcquiredInConnectionWithTheReverseRecapitalization>
    <krro:PaymentOfReverseRecapitalizationTransactionCosts
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_d80f4cbb-ae2e-4c29-ae55-4f7eec165405"
      unitRef="U_USD">12247000</krro:PaymentOfReverseRecapitalizationTransactionCosts>
    <krro:PaymentOfReverseRecapitalizationTransactionCosts
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_0ac1896a-0ae5-4211-a6c1-c42ea0f4ded6"
      unitRef="U_USD">0</krro:PaymentOfReverseRecapitalizationTransactionCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_e65ed290-7fc4-456f-b99b-a5db75615c96"
      unitRef="U_USD">-2000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_b5912cfa-19c7-47cd-bbcc-57b45a21eb96"
      unitRef="U_USD">-44000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_dbe1fed2-ebce-4954-b4a1-9df007bad5f2"
      unitRef="U_USD">187761000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_20e48a34-2f57-459a-8200-902f61caf445"
      unitRef="U_USD">18000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_18cfa912-6c60-4782-ba42-64afced94f91"
      unitRef="U_USD">131642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_ac8ef301-d02a-4b01-ab8f-e190c22e8d44"
      unitRef="U_USD">-42567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_a8853513-efa8-4885-9ad7-15f0971a17e9"
      unitRef="U_USD">41477000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e4d50b42-e002-4e04-bf4c-f72b0bcf0a47"
      decimals="-3"
      id="F_895a975c-b2f2-45a1-9953-9fe7bfca744b"
      unitRef="U_USD">84044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_b3a5d085-6f77-4c07-a715-6506c4182831"
      unitRef="U_USD">173119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_12362f84-071e-4a62-a228-c551aa8e60b7"
      unitRef="U_USD">41477000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_a0007a18-7b9d-40e7-a47e-73725625ec71"
      unitRef="U_USD">2271000</krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance>
    <krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_5b3e69f4-d1c7-4878-a2fd-3770901da65a"
      unitRef="U_USD">0</krro:PropertyAndEquipmentCapitalizedUnderTenantImprovementAllowance>
    <krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_64d208e0-1c55-4f9d-87b2-2c1d85a4521e"
      unitRef="U_USD">1983000</krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
    <krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_a581a107-9ce6-4c20-af8d-b20c7e7e1413"
      unitRef="U_USD">402000</krro:PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
    <krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_959a92d2-d3fa-4d94-b211-c003f6987567"
      unitRef="U_USD">26777000</krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets>
    <krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_3aaa2e54-e29d-4475-9139-617cee48a45f"
      unitRef="U_USD">5629000</krro:OperatingLeaseLiabilitiesArisingFromRightOfUseAssets>
    <krro:OperatingLeaseLiabilitiesArisingFromLeaseModification
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_d4620346-e37a-4b24-a6c2-1357feff07cf"
      unitRef="U_USD">1959000</krro:OperatingLeaseLiabilitiesArisingFromLeaseModification>
    <krro:OperatingLeaseLiabilitiesArisingFromLeaseModification
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_31c799eb-f203-44f6-a9ef-0076c985d8f2"
      unitRef="U_USD">0</krro:OperatingLeaseLiabilitiesArisingFromLeaseModification>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_8f3e20a1-d8e5-43ed-a1d5-225d5e862d34"
      unitRef="U_USD">27000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_7e2a673a-6568-4192-bb4d-c54a2ee719ef"
      unitRef="U_USD">11000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_0d4e0e3a-27b5-4839-878c-37e82ae0098f"
      unitRef="U_USD">2978000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_950c43a0-e65b-43c8-9399-4ca889c2c1d2"
      unitRef="U_USD">2335000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_f01e0d21-261f-40f5-9003-53d4846c06e2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. The Company and Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Korro Bio, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company was incorporated in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_81265546-519d-4e10-aa08-5ad84f64dad1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 2014&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as a Delaware corporation. The Company's principal offices are in Cambridge, Massachusetts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Merger with Legacy Korro&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 14, 2023, Frequency Merger Sub, Inc.(&#x201c;Merger Sub&#x201d;) a Delaware corporation, a wholly-owned subsidiary of Frequency Therapeutics, Inc. (&#x201c;Frequency&#x201d;), a Delaware corporation and Korro Bio, Inc (&#x201c;Legacy Korro&#x201d;), a Delaware corporation, entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;).  The merger was completed on November 3, 2023 (the &#x201c;Merger&#x201d; or the "Transaction").  In accordance with the Merger Agreement, the Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as a wholly-owned subsidiary of the Company.  In connection with the completion of the Merger, the Company changed its name from Frequency Therapeutics, Inc. to Korro Bio, Inc.  On November 6, 2023, the combined company&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;KRRO&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Except as otherwise indicated, references herein to the &#x201c;Company,&#x201d; or the &#x201c;combined company&#x201d;, refer to Korro Bio, Inc. on a post-merger basis, and the term &#x201c;Legacy Korro&#x201d; refers to the business of privately held Korro Bio, Inc., prior to completion of the merger. References to Frequency refer to Frequency Therapeutics, Inc. prior to completion of the merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concurrently with the execution and delivery of the Merger Agreement, Legacy Korro entered into a subscription agreement with a number of accredited investors. Immediately prior to consummation of the Merger, Legacy Korro issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,176,255&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Shares of Legacy Korro common stock issued pursuant to the Pre-Closing Financing were converted into shares of the Company&#x2019;s common stock based on an exchange ratio (as defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Legacy Korro preferred stock was converted into a share of Legacy Korro common stock, and then exchanged in the Merger for shares of Frequency common stock using an exchange ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.049688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Exchange Ratio&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the effective time of the Merger, the Company issued (or reserved for issuance upon exercise of options assumed in the Merger) an aggregate of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,848,776&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock to Legacy Korro securityholders (before eliminating fractions), calculated as provided in the Merger Agreement, (the &#x201c;Exchange&#x201d;), resulting in approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,623,645&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock being issued and outstanding on a fully diluted basis immediately following the effective time of the Merger. This number includes shares of the Company&#x2019;s common stock that was issued upon vesting and settlement of certain outstanding equity awards at the effective time of the Merger.  Immediately following the completion of the Merger, Frequency securityholders prior to the Merger owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares of common stock on a fully diluted basis and Legacy Korro&#x2019;s securityholders, including those securityholders who purchased shares in Legacy Korro&#x2019;s pre-closing financing, owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares on a fully diluted basis. The Merger was intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "IRC").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon closing of the Merger, the Company assumed the Legacy Korro 2019 Stock Incentive Plan, and each outstanding and unexercised option to purchase Legacy Korro shares at such time, each of which converted into an option to purchase shares of the Company&#x2019;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. In addition, upon the closing of the Merger, the Company assumed each outstanding and unexercised warrant to purchase&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Legacy Korro shares at such time, each of which converted into a warrant to purchase shares of the Company&#x2019;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the effective time of the Merger, the Company entered into a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;) with Computershare Trust Company, N.A. and Computershare Inc., collectively as rights agent providing for the payment of certain contingent cash payments equal to the net amount (calculated in accordance with GAAP consistently applied) of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to Frequency&#x2019;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein.  Concurrently, the Company entered into an asset purchase agreement with Progentos Therapeutics (&#x201c;Progentos&#x201d;), whereby Progentos acquired the rights, title and interest in certain assets related to Freqeuncy&#x2019;s MS program ("MS APA").  The MS APA included initial consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment in the event of Progentos closing of an equity financing at or above a specified amount.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. For accounting purposes, Legacy Korro was considered to be acquiring the assets and liabilities of Frequency in the Merger based on the terms of the Merger Agreement and other factors, including: (i) Legacy Korro controlling the majority of outstanding voting shares; (ii) Legacy Korro controlling the Board of Directors; (iii) Legacy Korro&#x2019;s executive management team became the management of the combined company; and (iv) the pre-combination assets of Frequency were primarily cash and cash equivalents and other non-operating assets. Accordingly, the Merger was treated as the equivalent of Legacy Korro issuing stock to acquire the net assets of Frequency. As a result of Legacy Korro being treated as the accounting acquirer, Legacy Korro&#x2019;s assets and liabilities were recorded at their pre-combination carrying amounts. Frequency&#x2019;s assets and liabilities were measured and recognized at their fair values, which approximated their carrying values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Legacy Korro after the consummation of the Merger. As a result, upon consummation the historical financial statements of Legacy Korro became the historical consolidated financial statements of the combined company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split and Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with, and prior to the completion of, the merger, Frequency effected a one-for-fifty reverse stock split of its then outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding Legacy Korro common stock, convertible preferred stock and options prior to the effective date of the merger have been retroactively adjusted to reflect the merger &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.049688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Exchange Ratio, which reflects the impact of the reverse stock split, for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company expects that its existing cash and cash equivalents as of December 31, 2023 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these consolidated financial statements. The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2023, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;183.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that the revenues or profitability will be sustained on a continuing basis. In addition, the Company&#x2019;s preclinical and clinical development activities, manufacturing and commercialization of the Company&#x2019;s product candidates, if approved, will require significant additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable rights to its technology and product candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d"
      decimals="0"
      id="F_dce1ce74-13b8-4e62-8891-ae9bbb6b4dee"
      unitRef="U_shares">42176255</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d"
      decimals="2"
      id="F_6de63771-9567-49b4-80ff-128b1e362114"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.78</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="C_8889cc3f-cb2b-41fc-a7eb-057e5056f07d"
      decimals="-5"
      id="F_14cbdb18-0c5a-49df-b2ad-a2a1e78ceb55"
      unitRef="U_USD">117300000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_86dca00a-98c3-49ec-b174-5d61f32beb4f"
      decimals="6"
      id="F_bdbd8535-c351-42d1-a728-2109a14eec13"
      unitRef="U_Rate">0.049688</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6a634502-8868-4319-974b-a0bdac21d6bd"
      decimals="0"
      id="F_d7e2dbbb-1f83-4f98-883e-ca4b2dca5c87"
      unitRef="U_shares">7848776</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9019f292-8abd-4d72-a541-b2e15e70e9e2"
      decimals="0"
      id="F_13675383-eb60-446b-919d-3d0c327932a0"
      unitRef="U_shares">8623645</us-gaap:CommonStockSharesIssued>
    <krro:SharesOwnershipPercentage
      contextRef="C_9019f292-8abd-4d72-a541-b2e15e70e9e2"
      decimals="2"
      id="F_e7dfc9f0-5bc2-4115-b0a8-b2af419a1753"
      unitRef="U_pure">0.09</krro:SharesOwnershipPercentage>
    <krro:SharesOwnershipPercentage
      contextRef="C_84565942-6987-4c97-b8de-234ea6a6f1a2"
      decimals="2"
      id="F_5e4792d3-588f-4814-81fe-2b02c32f59cb"
      unitRef="U_pure">0.91</krro:SharesOwnershipPercentage>
    <krro:InitialConsiderationAmount
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_aa50c0c3-4b12-4f58-9b10-77dc3fe5cb25"
      unitRef="U_USD">500000</krro:InitialConsiderationAmount>
    <krro:FutureMilestonePayments
      contextRef="C_8bd7505c-82d1-468a-a930-ab481a0db383"
      decimals="-5"
      id="F_eff0dd75-beac-4fa5-b820-7665050b1720"
      unitRef="U_USD">17500000</krro:FutureMilestonePayments>
    <krro:FutureMilestonePayments
      contextRef="C_98b4de31-fa14-4fd9-bd5a-480f77633a40"
      decimals="-5"
      id="F_07a8c67f-8e86-4fba-8465-84e26ac27002"
      unitRef="U_USD">700000</krro:FutureMilestonePayments>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="6"
      id="F_0e649222-d194-4969-bd02-75207f73d101"
      unitRef="U_Rate">0.049688</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_9c5f2685-6d14-48a8-84dc-a63abc71adb8"
      unitRef="U_USD">166100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_7e2b9208-8442-429b-afe4-d5eb5b70d588"
      unitRef="U_USD">-183000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a0d51b51-67b4-40a3-bbe9-97b3dc0a8fba">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s chief executive officer, views the Company&#x2019;s operations and manages its business as a single operating segment. The Company operates only in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the fair value of the common stock prior to the effective date of the merger; the fair value of the CVR liability and the incremental borrowing rate for determining lease liabilities and right-of-use assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, (&#x201c;ASC 820&#x201d;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#x201c;Fair Value Measurements&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December 31, 2023 or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#x201c;Other income, net&#x201d;. Unrealized gains and losses on available-for-sale securities are included in &#x201c;Accumulated other comprehensive loss&#x201d; as a component of stockholders&#x2019; deficit until realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under finance leases, is calculated over the estimated useful lives of the assets using the straight-line method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#x2019;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intellectual Property Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based payments in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, non-employees and members of the Company&#x2019;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and non-employees, the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, due to the absence of an active market for Legacy Korro&#x2019;s common stock, Legacy Korro and its Board were required to determine the fair value of Legacy Korro&#x2019;s common stock at the time of each grant of a stock-based award. Legacy Korro estimated the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#x201c;OPM&#x201d;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each valuation methodology includes estimates and assumptions that required the Legacy Korro&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which Legacy Korro sold convertible preferred stock to third parties in arms&#x2019; length transactions, the rights and preferences of securities senior to Legacy Korro&#x2019;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the grant date fair value of the Company&#x2019;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-based payment, (ii) the risk-free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Due to the lack of Company-specific historical and implied volatility data, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures of all stock-based payments when such forfeitures occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are recorded in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#x201c;Provision for income taxes&#x201d; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net income attributable to common stockholders and participating preferred shares are allocated to each share as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Net loss attributable to common stockholders is equal to the net loss for the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;net loss per share is computed using the more dilutive of (a) the two-class method or (b) the treasury stock method and if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and Preferred Stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#x2019;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#x2019;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#x2019;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging growth company status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company qualifies as an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-03, and ASU 2022-02 (&#x201c;ASU 2016-13&#x201d;). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The amendments in this standard should be applied on a modified retrospective basis to all periods presented. The Company adopted ASU 2016-13 on January 1, 2023 using the modified retrospective approach. The adoption of this standard did not have a material effect on the Company&#x2019;s financial position, results of operations or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&#x2014;Yet to be Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_9fca7404-f94e-43ab-a2ca-dcedc1d76f43">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_0aa78488-50be-40b1-8d2a-fcb5b0924151">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s chief executive officer, views the Company&#x2019;s operations and manages its business as a single operating segment. The Company operates only in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_5b2d2111-2aee-40cb-b1e0-2e83bf308ab6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the fair value of the common stock prior to the effective date of the merger; the fair value of the CVR liability and the incremental borrowing rate for determining lease liabilities and right-of-use assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_3164e490-fa78-493e-95c4-bc2ea54a77bc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, (&#x201c;ASC 820&#x201d;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_265cbe9d-c50a-4d7b-9b14-90cd71101878">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#x201c;Fair Value Measurements&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_1193f5d3-c2f7-4209-9999-4a0375f4ca5f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December 31, 2023 or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#x201c;Other income, net&#x201d;. Unrealized gains and losses on available-for-sale securities are included in &#x201c;Accumulated other comprehensive loss&#x201d; as a component of stockholders&#x2019; deficit until realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_1a7fc957-e326-445a-91b1-9622de312632">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under finance leases, is calculated over the estimated useful lives of the assets using the straight-line method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_d026db1a-6648-4d29-85ce-bc77199aed65">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#x2019;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_71b70656-ac6b-4b3c-b2e2-996cc121ce24">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;), the Company determines whether an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize a right-of-use asset or lease liability. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as noncurrent assets, current liabilities and noncurrent liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to terminate a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will exercise such options, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <krro:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_f117b832-182f-4a47-8d30-3e079af1ab5d"
      unitRef="U_USD">0</krro:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <krro:PreferredStockPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_8d8d4be4-546f-4799-8f7e-f95c36e81a61">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, Legacy Korro classified its convertible preferred stock as temporary equity due to terms that allowed for redemption of the shares upon the occurrence of a contingent event that was not solely within the Legacy Korro&#x2019;s control. Legacy Korro did not accrete the carrying values of the preferred stock to the redemption values since the contingent event was not considered probable.&lt;/span&gt;&lt;/p&gt;</krro:PreferredStockPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_b0b19603-fd8f-4a24-bb89-bde4668d93d4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <krro:IntellectualPropertyExpensesPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_b304e861-c497-45ac-be7a-aa6136a6cdbd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intellectual Property Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</krro:IntellectualPropertyExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_d914083c-0b90-4c18-a2ce-43d3677d68de">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based payments in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, non-employees and members of the Company&#x2019;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and non-employees, the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, due to the absence of an active market for Legacy Korro&#x2019;s common stock, Legacy Korro and its Board were required to determine the fair value of Legacy Korro&#x2019;s common stock at the time of each grant of a stock-based award. Legacy Korro estimated the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#x201c;OPM&#x201d;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each valuation methodology includes estimates and assumptions that required the Legacy Korro&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which Legacy Korro sold convertible preferred stock to third parties in arms&#x2019; length transactions, the rights and preferences of securities senior to Legacy Korro&#x2019;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the grant date fair value of the Company&#x2019;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-based payment, (ii) the risk-free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Due to the lack of Company-specific historical and implied volatility data, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures of all stock-based payments when such forfeitures occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_aef4e9d2-91ce-4961-a1e9-a6671ab1b3d0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are recorded in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#x201c;Provision for income taxes&#x201d; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_c78a6c16-33dc-4fc1-a0d3-670fb4bb80d2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net income attributable to common stockholders and participating preferred shares are allocated to each share as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Net loss attributable to common stockholders is equal to the net loss for the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;net loss per share is computed using the more dilutive of (a) the two-class method or (b) the treasury stock method and if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and Preferred Stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a6380407-6a7d-483b-9ad1-b3ba80c3b192">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#x2019;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#x2019;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#x2019;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <krro:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_845994c9-5ee0-4065-9bf8-b7949ff61f78">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging growth company status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company qualifies as an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/span&gt;&lt;/p&gt;</krro:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_c96c3b1b-893e-489a-a5a9-5227cf26c7b1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-03, and ASU 2022-02 (&#x201c;ASU 2016-13&#x201d;). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The amendments in this standard should be applied on a modified retrospective basis to all periods presented. The Company adopted ASU 2016-13 on January 1, 2023 using the modified retrospective approach. The adoption of this standard did not have a material effect on the Company&#x2019;s financial position, results of operations or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&#x2014;Yet to be Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <krro:RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_b8459fcc-2405-42a8-8092-3f466b1042df">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&#x2014;Yet to be Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements&lt;/span&gt;</krro:RecentAccountingPronouncementsYetToBeAdoptedPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_cf25396f-1702-455d-a649-95ee15b3ceb3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Reverse Merger&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As described in Note 1, Legacy Korro merged with Frequency on November 3, 2023. The merger was accounted for as a reverse recapitalization with Legacy Korro as the accounting acquirer. The primary pre-combination assets of Frequency were cash and cash equivalents. Under reverse recapitalization accounting, the assets and liabilities of Frequency were recorded at their fair value which approximated book value due to the short-term nature of the accounts. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the operations of Legacy Korro for accounting purposes, together with a deemed issuance of shares equivalent to the shares held by the former stockholders of Frequency, the legal acquirer, and a recapitalization of the equity of Legacy Korro, the accounting acquirer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the reverse recapitalization, the Company acquired $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash and cash equivalents. The Company also obtained prepaids and other assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and assumed accounts payable and accrued expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Frequency&#x2019;s development programs had ceased prior to the merger and were deemed to be de minimis in value at the transaction date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in share-based compensation expense as a result of the acceleration of vesting of stock options, performance stock units and restricted stock units at the time of merger. This amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in personnel cost related to the severance payment to Frequency employees and this amount was recorded in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. The Company also incurred transaction costs of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million and this amount is recorded in additional paid-in capital in the accompanying consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit) for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f"
      decimals="-3"
      id="F_9b221144-9a4c-4e15-b20f-3204b75ab88a"
      unitRef="U_USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f"
      decimals="-5"
      id="F_029eb2cd-2dc7-4a1a-a59a-aff6fd4b00fd"
      unitRef="U_USD">36600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="C_8d2bf99f-e0b9-478a-bb1e-365978eac30f"
      decimals="-5"
      id="F_149e1e54-24e9-4ec0-be57-d26ca5637424"
      unitRef="U_USD">1900000</us-gaap:PrepaidExpenseAndOtherAssets>
    <krro:AccountsPayableAndAccruedExpenses
      contextRef="C_c10f8f23-79a1-42bb-8447-ddc5b11bb910"
      decimals="-5"
      id="F_93b839b3-04e4-4f5e-8e4b-a8f707e81179"
      unitRef="U_USD">5400000</krro:AccountsPayableAndAccruedExpenses>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_50d4d91b-3f5a-4a37-92a4-36bcc199cca7"
      unitRef="U_USD">300000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krro:SeverancePayment
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_fe414e5f-5b6c-427e-aee1-54b49bcd13da"
      unitRef="U_USD">2500000</krro:SeverancePayment>
    <us-gaap:RecapitalizationCosts
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_4e4d2363-9180-4333-a392-92398135dc18"
      unitRef="U_USD">12200000</us-gaap:RecapitalizationCosts>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_916e07c6-1fdc-499c-8838-78f8658a5360">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include commercial paper and government securities that are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;MS APA asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As noted previously in Note 1, at the effective time of the Transaction, the Company entered into the CVR Agreement providing for the payment of certain contingent cash payments equal to the net amount of proceeds actually received by the Company or its subsidiaries after the end of each fiscal quarter following the first anniversary of the closing of the Transaction related to the disposition of assets related to the Company&#x2019;s former multiple sclerosis programs, with the time periods and subject to deductions as provided therein. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company concluded that the CVR is a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5a1b49f3-7a54-4e43-9407-97170c711b48;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is accounted for at fair value, which was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in accrued expenses and other current liabilities and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in other non-current liabilities in the consolidated balance sheet. Concurrently&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into the MS APA with Progentos, whereby Progentos acquired the rights, title and interest in certain assets related to the Company&#x2019;s MS program. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The MS APA included initial consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds that were settled through net cash at the merger closing and will be entitled to future milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment in the event of Progentos closing of an equity financing at or above a specified amount.  The Company concluded that the MS APA is a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c39e9862-e9fa-4ff5-9da0-641cc2ce94c0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;derivative asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is accounted for at fair value, which was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in prepaid and other current assets and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in other long-term assets in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the CVR liability and the MS APA are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR liability and the MS APA asset, the Company used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of significant judgment, estimates and assumptions, including the probability of technical and regulatory success, and discount rates. For the year ended December 31, 2023, the aggregate change in fair value of the CVR liability and MS APA asset was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no liabilities measured at fair value on a recurring basis as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no changes in valuation techniques, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;r were there any transfers among the fair value hierarchy levels during the years ended December 31, 2023 or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_1e7cf111-46ed-4e0d-bfe0-9ea8fda577dc">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;MS APA asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.936%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_72eb9539-da9d-42ea-ade5-45879867b4dd"
      decimals="-3"
      id="F_c8923679-8b22-4682-8b79-6e9598f81118"
      unitRef="U_USD">158706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8eca1fa2-2518-420d-8403-4912df0dca2b"
      decimals="-3"
      id="F_dea35144-52da-45a4-8185-e2b3f98a0649"
      unitRef="U_USD">158706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ae566dce-3b97-4369-8930-694f01849c54"
      decimals="-3"
      id="F_fa0f26e8-84ab-46d0-bac7-54323876e807"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a7d015c4-04ba-473c-982c-ee84943ae574"
      decimals="-3"
      id="F_f6d996d4-d499-4e41-bb49-afa50d0ba7b2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_002cf6f3-a14a-42d9-8339-4c9a7464ddc4"
      decimals="-3"
      id="F_65f16c9f-1683-48df-9c86-abf2084575b0"
      unitRef="U_USD">1448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ce4b9b25-ec19-4975-80b3-be6c42826a43"
      decimals="-3"
      id="F_40ed9312-2fc5-4b6f-9e2c-7ceca1007ea9"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c288594a-72d1-4f6b-8b50-f8d38cf9d937"
      decimals="-3"
      id="F_c837db7d-f174-413f-bca1-5947d2e925b6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_745aa97d-b654-4fe3-a288-63cea2f6c854"
      decimals="-3"
      id="F_305385fe-f851-49aa-95e8-d6078a9f04af"
      unitRef="U_USD">1448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2d3840a1-75bb-41e9-bdf6-5978eb8662d0"
      decimals="-3"
      id="F_da475345-1203-47ee-b65f-c49494acb3fd"
      unitRef="U_USD">160154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d6c273ee-ecf6-4069-ae3d-4c61b89c6153"
      decimals="-3"
      id="F_2ebf8ebb-fdc5-42c0-a9b5-222bb68b428d"
      unitRef="U_USD">158706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aa7dd013-7306-42b5-8ed5-d73bf12a2654"
      decimals="-3"
      id="F_c9a6b0a4-7550-4f39-a020-27c81ff3ac0d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7af3db31-6c33-4c0d-98ce-e0c17f536ee6"
      decimals="-3"
      id="F_aebf3eeb-34ee-49fd-8e89-d25426f7da06"
      unitRef="U_USD">1448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7797a79c-4109-4291-85d7-9f1f44b8f9ab"
      decimals="-3"
      id="F_64554640-48f5-4147-82ba-6af6b76e7d12"
      unitRef="U_USD">14904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3d16b2e0-26d9-46e2-9676-3b3691cb6871"
      decimals="-3"
      id="F_c2b75aea-1aab-4c29-873f-6dd88d828970"
      unitRef="U_USD">14904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d3e74070-621c-4737-963d-07ce423a28f8"
      decimals="-3"
      id="F_4f7a4146-07bc-4c9d-910a-77a69f84cbaf"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_46cc1979-5c24-47f7-bf95-9aa5c051807b"
      decimals="-3"
      id="F_06af4979-8dc1-41f6-a8b3-0d17ae87c45c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d2ac73cf-1c8b-4a06-aca0-5f30e10f6acc"
      decimals="-3"
      id="F_276fbe2c-bdf2-4ce6-a91e-4a15ed55db89"
      unitRef="U_USD">14935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_efa34611-a425-44a2-86e5-16976c9be1dc"
      decimals="-3"
      id="F_34db245d-4247-4cdf-bc8e-a139fb5a8793"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_68f1cdf4-0429-4263-8211-79aaef7f7fd4"
      decimals="-3"
      id="F_e4593215-3831-4413-a4ba-101a7fba20ca"
      unitRef="U_USD">14935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1497c1b1-c02c-4386-9a0b-01290e5e3553"
      decimals="-3"
      id="F_04114192-4a5e-4a99-ab19-190f788c0de1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e12df146-e11d-4351-90cd-40afa0abdd05"
      decimals="-3"
      id="F_39024415-d7a9-4dd2-a053-b49a8634c0c8"
      unitRef="U_USD">3980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_28de2dc3-2ca9-4bb6-8723-f572b9234796"
      decimals="-3"
      id="F_e65e95bc-4a34-4243-a412-33ef02931b62"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bc4d7e4b-8b44-4d70-bfd8-4175df616bb0"
      decimals="-3"
      id="F_d15abc08-bec6-4b92-b641-b275c1afadf2"
      unitRef="U_USD">3980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ae8c2fd3-de68-4508-b076-43b5d6c93aad"
      decimals="-3"
      id="F_5838003b-2327-486f-8f93-6457f60acc5b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_73266731-93a7-48aa-8ed8-61bc2b4c90d7"
      decimals="-3"
      id="F_70d856a7-90d1-4b9a-ba10-6dbfcd837180"
      unitRef="U_USD">33819000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_22794dbf-a4f9-4f21-8513-02ae3c6a8843"
      decimals="-3"
      id="F_0dcc5709-6650-486a-a060-7adf6b0cb78d"
      unitRef="U_USD">14904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bbbfcc39-8343-47e0-a50c-2b474af31554"
      decimals="-3"
      id="F_dc42bcde-f675-4871-a352-73dabab28554"
      unitRef="U_USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f821a1fb-8b0a-44e8-b18a-e92e693bb9d0"
      decimals="-3"
      id="F_d00b215c-b501-47c5-bb39-4c085e5de828"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_1aef2565-5874-4831-a5fc-081e9726c44e"
      unitRef="U_USD">1400000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_b2815e8e-9e70-42ce-84a5-9392c1046c2c"
      unitRef="U_USD">400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_1f0fcccd-3604-4a2a-a1b0-1eec36726223"
      unitRef="U_USD">1000000</us-gaap:OtherLiabilitiesNoncurrent>
    <krro:InitialConsiderationAmount
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_89cf140d-4dce-42e9-b9b0-5d7e9ffa04cb"
      unitRef="U_USD">500000</krro:InitialConsiderationAmount>
    <krro:FutureMilestonePayments
      contextRef="C_8bd7505c-82d1-468a-a930-ab481a0db383"
      decimals="-5"
      id="F_1b415ffd-4a9d-4763-bbde-419515c93f6d"
      unitRef="U_USD">17500000</krro:FutureMilestonePayments>
    <krro:FutureMilestonePayments
      contextRef="C_98b4de31-fa14-4fd9-bd5a-480f77633a40"
      decimals="-5"
      id="F_bb2bf865-eab2-43ca-aac3-76b73d429abe"
      unitRef="U_USD">700000</krro:FutureMilestonePayments>
    <us-gaap:DerivativeAssets
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_d3ff4cf0-8e50-48cd-92c3-2e7c82284e36"
      unitRef="U_USD">1400000</us-gaap:DerivativeAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_fb62d813-1a3b-444a-84bf-7a0c3f03ea70"
      unitRef="U_USD">400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_14d8c666-1849-407f-b8ab-d3b227ede1d8"
      decimals="-5"
      id="F_372d591a-bed5-4bd2-9874-42e7a6e05d84"
      unitRef="U_USD">1000000</us-gaap:OtherAssetsCurrent>
    <krro:ChangeInFairValueOfPreferredStockTrancheLiability
      contextRef="C_096221e9-4b77-4f75-a7ca-adeffcec02e8"
      decimals="-4"
      id="F_879f9104-5d0c-4182-9f14-dd5f18ed2c75"
      unitRef="U_USD">80000.00</krro:ChangeInFairValueOfPreferredStockTrancheLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_7d2006d2-2521-4c89-a888-650a3fee14fe"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="0"
      id="F_dec654db-a54d-421d-a406-46ff99881669"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:InvestmentTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_c8ef9364-f1c6-4a4f-9e77-6f5471894221">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did not have investments as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments as of December 31, 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of December 31, 2022, the Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; securities that were in an unrealized loss position for more than twelve months. As of December 31, 2022, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_312bfc85-8a3c-4543-87a2-ef642ce1891f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments as of December 31, 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe"
      decimals="-3"
      id="F_d0b1e1f0-f327-4e31-9c35-1b0372ac3fe1"
      unitRef="U_USD">14935000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe"
      decimals="-3"
      id="F_a6428b37-f693-4037-bddc-1eea2f18ac25"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe"
      decimals="-3"
      id="F_f7261f1f-9c78-4142-9829-5e7acb16f639"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e5e938ff-92da-4d84-86f6-b08f57fa06fe"
      decimals="-3"
      id="F_0dfd7116-38a1-40c9-b2bd-8059370d593c"
      unitRef="U_USD">14935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f"
      decimals="-3"
      id="F_2ca680d8-6cc5-4cd0-8940-651a27972df0"
      unitRef="U_USD">3985000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f"
      decimals="-3"
      id="F_8c2c1546-615e-450d-af58-6b8a95bb43ee"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f"
      decimals="-3"
      id="F_fdee9745-473d-439d-9adf-1085127dd53a"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a190f767-c341-455b-9ad4-483737f0d73f"
      decimals="-3"
      id="F_4e9ff4db-ad4e-40e2-843a-3304b465e832"
      unitRef="U_USD">3980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_b47a0cf2-671a-44ad-965a-8c74fb2eb32a"
      unitRef="U_USD">18920000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f45805b6-3981-49b5-92d1-0229b3344c6c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_19e924fb-2aba-4aa1-be94-e1f5efd34a50"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_23d7e627-dc7c-482c-b6f1-046eaaa2016c"
      unitRef="U_USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-5"
      id="F_6758845b-0e55-4409-a32c-d4b201931c72"
      unitRef="U_USD">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_7b4b40b8-5f70-4d33-8477-307751185fa2"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_41092256-ca22-4d71-a378-a7ccf2cfc253">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company maintained current restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and non-current restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of De&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;cember 31, 2022, the Company maintained current restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and non-current restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company&#x2019;s facility leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December 31, 2023 and 2022 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_56e13fb5-33dd-4005-991d-ab878d95e8f8"
      unitRef="U_USD">3600000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_1c357400-17e0-4394-aa7e-a258637d2849"
      unitRef="U_USD">3400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-5"
      id="F_353ab1a5-9c4d-47a8-9d7b-5d23dd1cb424"
      unitRef="U_USD">600000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-5"
      id="F_348aaaac-9986-4e96-bb23-b354911780bf"
      unitRef="U_USD">4500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e9fb56b4-5a15-4b84-b461-b0e33ddcbea5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December 31, 2023 and 2022 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_177811ee-6134-4941-94b4-e045ca1e1359"
      unitRef="U_USD">166150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_48699b83-a3ae-4a33-b2a1-cb155a871321"
      unitRef="U_USD">36333000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_fa7b2b7b-430e-4495-abc8-71e9f8162a99"
      unitRef="U_USD">6969000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_c0e6bdd6-abdb-4b13-a67b-f3b1d01518fa"
      unitRef="U_USD">5144000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_c74329b3-bbee-451d-b500-080c9a48d897"
      unitRef="U_USD">173119000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_a30cdb28-828c-4516-bc17-017c9944be1d"
      unitRef="U_USD">41477000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_0fe9155a-990d-41c5-88da-0b16f22e901e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, as of December 31, 2023 and 2022 was comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:36.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had construction in progress of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, predominately related to laboratory equipment received but not yet installed and capitalizable costs related to the Company&#x2019;s future corporate headquarters.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e18d8e93-f8dd-47e6-bf21-e1fe24b8d717">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, as of December 31, 2023 and 2022 was comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:36.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_5a9015d7-d3e2-497e-ae73-4ee485589e02"
      id="F_979da3b5-4d87-4a12-a2be-164f380aa155">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_072ef9d5-51f5-493b-a877-923f3cd50ab2"
      id="F_4354be5d-b53d-47f3-8b1c-8be16c6a9264">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5a9015d7-d3e2-497e-ae73-4ee485589e02"
      decimals="-3"
      id="F_3b4d6a89-e2db-4cdd-86fe-d56e173d008f"
      unitRef="U_USD">11187000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_072ef9d5-51f5-493b-a877-923f3cd50ab2"
      decimals="-3"
      id="F_747811b7-90db-441e-98b2-205724ccfd3c"
      unitRef="U_USD">8441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5"
      id="F_9f2a7523-4f3c-49ad-93cc-5c430f01e129">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a982d847-1fa7-4a2f-a886-60eca2f91051"
      id="F_f9ac0491-9ebe-429d-bb33-1609edc2f63e">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb4941a5-3a3a-4648-8d1d-f0bbfb9508d5"
      decimals="-3"
      id="F_a52ec93e-cd2a-4060-b51b-0fd6799f5404"
      unitRef="U_USD">481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a982d847-1fa7-4a2f-a886-60eca2f91051"
      decimals="-3"
      id="F_798d9d9e-7efd-488d-8033-fc0c932e67e7"
      unitRef="U_USD">477000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0"
      id="F_57166e94-c121-40e5-b00e-eb22ab2e2d7f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_186c69fe-8d24-44a5-865b-ef7a19de3a07"
      id="F_d6fe2aab-d19c-4c4b-ad3c-af65efd42354">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e9be5d55-d417-4dc3-b5a8-8d4f76b466a0"
      decimals="-3"
      id="F_2e599f11-ecb9-45ac-8d62-78903a63c484"
      unitRef="U_USD">241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_186c69fe-8d24-44a5-865b-ef7a19de3a07"
      decimals="-3"
      id="F_a45126d0-93e8-42cc-94b8-286da0a530d8"
      unitRef="U_USD">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentDispositions
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_2fcc4375-f07d-4f52-aa34-cf00a9e1b3e8">Shorter of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentDispositions>
    <us-gaap:PropertyPlantAndEquipmentDispositions
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      id="F_ca98cf62-5092-4171-8e33-8a0904e7e7c8">Shorter of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentDispositions>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_588ba34c-1cc3-4361-8113-4bfbca87310e"
      decimals="-3"
      id="F_566359b4-0b59-4e7c-8cb6-705fe2d61ebd"
      unitRef="U_USD">3356000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c2a2b4a4-d405-4a52-87f7-0d7d1dabb2c0"
      decimals="-3"
      id="F_4fd1837f-2902-411f-86d2-92f7df2191e1"
      unitRef="U_USD">2941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_86de2748-fce4-4bbf-9e70-716575029823"
      decimals="-3"
      id="F_3c2204bc-323c-4847-8e75-82f995b1b62a"
      unitRef="U_USD">8242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_11d68bec-be21-47b3-aed2-e43151eea3b8"
      decimals="-3"
      id="F_ff323ffa-31fa-407f-9806-572db5446091"
      unitRef="U_USD">2049000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9f0efeab-b67b-4499-9fe4-a7e0bbe55bfa"
      unitRef="U_USD">23507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_d2414fd7-359c-492b-bab8-b08f407c689e"
      unitRef="U_USD">14121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_0008ce3b-1399-47f8-baff-64d3812dd0c2"
      unitRef="U_USD">7842000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_ab44e922-e8a4-45c8-98b8-cb76937e7d4c"
      unitRef="U_USD">4255000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_8dc8a3c6-4722-47cf-9f2d-d9e0b1ba8ccf"
      unitRef="U_USD">15665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_cc186522-8cc4-457c-b297-bf20f5f61f1f"
      unitRef="U_USD">9866000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_8d459d97-4a8f-4607-9720-d97c12248cd4"
      unitRef="U_USD">8200000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-5"
      id="F_61adab69-ea85-4758-98a4-6676fcb01c3e"
      unitRef="U_USD">2000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:Depreciation
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_260e5692-4a7a-43cc-b524-0af76746f3dd"
      unitRef="U_USD">3600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-5"
      id="F_17434b00-03cf-4486-b2ab-80bdfddecad5"
      unitRef="U_USD">2500000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_b1bf9641-8b5e-4e85-b791-60c00667915d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;External research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_aede3f16-5518-49a4-837d-6e204838593a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;External research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_59e03674-b317-407f-b2dd-5b22ff8b0148"
      unitRef="U_USD">7896000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f6affe0b-9ec3-4bb9-9eb8-5a7b1b6bbaab"
      unitRef="U_USD">2624000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <krro:AccruedExternalResearchAndDevelopmentServicesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_31ca596a-e186-4155-a8a9-85ce7170e187"
      unitRef="U_USD">1255000</krro:AccruedExternalResearchAndDevelopmentServicesCurrent>
    <krro:AccruedExternalResearchAndDevelopmentServicesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_2610ae7d-0754-45f4-a952-dcf740f35759"
      unitRef="U_USD">274000</krro:AccruedExternalResearchAndDevelopmentServicesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_0b41f676-fb55-4f00-9a59-cc85c62492d5"
      unitRef="U_USD">447000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_6e99a68c-a89c-4f4d-beab-8f63ded63143"
      unitRef="U_USD">207000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <krro:CvrLiabilityCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_204aa1dc-f388-46be-9c69-e097bf4f9794"
      unitRef="U_USD">395000</krro:CvrLiabilityCurrent>
    <krro:CvrLiabilityCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_a9aabb1b-937e-46e5-a9fb-076a60c2c240"
      unitRef="U_USD">0</krro:CvrLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_5a389544-a917-4f44-834b-aa8ab2cbbad3"
      unitRef="U_USD">219000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_0d5d26dd-fc96-4ed5-bf16-bf74f674ec60"
      unitRef="U_USD">70000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_f1735acc-92e5-4079-836d-3d28d8ac6277"
      unitRef="U_USD">10212000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f9a076c9-9afb-4356-bd2c-76e6a3c36e6f"
      unitRef="U_USD">3175000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e94ff6f9-9dfe-40cf-ad4c-6470cac37b67">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the closing of the merger, the shares of Legacy Korro common stock were converted into shares of the Company's common stock based on the exchange ratio determined in the Merger Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company was authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per value per share. Prior to the merger, the holders of Legacy Korro&#x2019;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth in Note 10. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company&#x2019;s Board of Directors. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends had been declared.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had reserved for future issuance the following number of shares of common stock:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances of Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;813,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vesting of restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercises of outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise of outstanding warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2019 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2023 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2023 ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,675,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,487,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb"
      decimals="INF"
      id="F_3f9786aa-09af-4d68-a9ba-998fb2b013f0"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e5f6a379-4c1f-418a-9cb2-c39f837dd3eb"
      decimals="3"
      id="F_389eb49c-2f2e-4024-ac24-22a6ed78d9bc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_65a239e0-5ccd-49da-844a-2f067baf9930"
      decimals="0"
      id="F_c5eb450c-fc7d-4d74-976e-048fbead3140"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ScheduleOfConversionsOfStockTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_16dc94e0-ae76-4b8f-ae3a-a8adba747696">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had reserved for future issuance the following number of shares of common stock:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of outstanding Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances of Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;813,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vesting of restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercises of outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise of outstanding warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2019 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2023 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Future issuances under 2023 ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,675,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,487,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfConversionsOfStockTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983"
      decimals="0"
      id="F_473583bc-606c-4cae-b731-d1cc8c0311d9"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7fb87aaa-7763-4db0-b2e3-0eae4ddb9138"
      decimals="0"
      id="F_d7dfaad4-8615-45b1-b95a-2aa55886117c"
      unitRef="U_shares">684739</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="0"
      id="F_332bbc9f-8506-4e5e-af0f-f1ce7682696c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ce7df174-cc6d-4a32-8f66-f5c81bb1618b"
      decimals="0"
      id="F_34be4bad-1d50-4498-bc1b-7acded2250d8"
      unitRef="U_shares">2029666</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4e61d9b0-a7a2-4826-b526-6cf674a82d27"
      decimals="0"
      id="F_b3ed88b2-7719-48b6-ba08-2667de33aca3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a831aa61-46f2-4591-9e51-98d9e0781061"
      decimals="0"
      id="F_4ad56269-b602-4aa9-9e67-506765503202"
      unitRef="U_shares">1104178</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9e149e85-1d4b-4712-863c-cb986c6595d9"
      decimals="0"
      id="F_c1077992-ad0f-49fe-b144-b7886b8c5548"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211"
      decimals="0"
      id="F_a5c2b95c-8481-4628-b4a0-de0b2e066d25"
      unitRef="U_shares">223417</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9e149e85-1d4b-4712-863c-cb986c6595d9"
      decimals="0"
      id="F_3d9eea60-6365-4704-bcb6-71ae6cf08fca"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3d9959c5-b8d4-4d1a-aa9d-f976bf8ed211"
      decimals="0"
      id="F_bb55e104-a855-44a2-be47-513cc9dabf8f"
      unitRef="U_shares">813239</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_093060bb-522a-4d5c-aa04-574677a7cb5b"
      decimals="0"
      id="F_a7f830f3-7ab7-4404-81a4-276c166b5357"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bf439977-ea99-4550-a754-3c1783080c28"
      decimals="0"
      id="F_f87b546f-e5b4-44cb-bf0f-7f20d600abc9"
      unitRef="U_shares">2902</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9f3a1082-a9d3-4417-a0f7-4d1bdd1bcaa3"
      decimals="0"
      id="F_6315f4c4-7d70-46c9-866a-0442415ab448"
      unitRef="U_shares">1323151</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0eebafc0-fac7-4906-a525-f415a4144d4a"
      decimals="0"
      id="F_45f394e0-8c80-4c81-b1e8-15f35a37b3d8"
      unitRef="U_shares">461128</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_21957e3e-4ce5-42c3-b40c-20cefc6c2eeb"
      decimals="0"
      id="F_21fd93c0-1d6d-4bfa-bc8d-ec37c32d89ea"
      unitRef="U_shares">8049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ecd8a380-935d-40bc-8d1e-6ed89fa53199"
      decimals="0"
      id="F_fb276287-4f1e-4c16-bba2-b60aff87fa0f"
      unitRef="U_shares">8049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_45db7593-eb9b-4883-9384-b026cd2ff9bc"
      decimals="0"
      id="F_5cc3ba99-57be-4c8c-ac76-34a26ba5a3dc"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_52ef87ed-863c-43f2-b64f-793064742302"
      decimals="0"
      id="F_d45c2899-9032-4e00-b21b-bc0b4e23de36"
      unitRef="U_shares">159890</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bec03e77-9bf0-4f52-9023-3b2c608d690f"
      decimals="0"
      id="F_aa892fdc-e86e-4da9-9f1a-d4846677958a"
      unitRef="U_shares">255694</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2ab0d269-b1a0-4ec5-8ce7-bb7b469c3284"
      decimals="0"
      id="F_47b2f2c0-cacc-45e9-9788-81d992424060"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4ffd1385-3f0e-45b7-929e-195ba02c78b1"
      decimals="0"
      id="F_89b7fc3a-2488-48c2-8bac-73ea2a5ee267"
      unitRef="U_shares">88502</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_dcc2b54b-9a21-4b66-92b5-e1bcfac05a39"
      decimals="0"
      id="F_2c713a6f-aa1e-4374-b50e-107c88b8e842"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_e3da48fc-37b6-49b2-9c72-8bf48c3e05fe"
      unitRef="U_shares">1675396</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_76a9cd78-f143-4a1d-8119-74e580ca9dd2"
      unitRef="U_shares">5487208</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_4fb13c04-529c-43dc-b0f1-4facc382e71d">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company was authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock at a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; preferred stock shares issued or outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the terms of the Merger Agreement, immediately prior to closing of the Merger, each share of Legacy Korro's Preferred Stock issued and outstanding immediately prior to the Closing of the Merger was converted into shares of the Legacy Korro&#x2019;s common stock, and then exchanged in the Merger for shares of the Company's common stock using an exchange ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.049688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The conversion was approved by greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the then-outstanding shares of Preferred Stock, voting as a single class on an as-converted to common stock basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, Legacy Korro was authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock at a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; preferred stock shares issued or outstanding. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, Legacy Korro Preferred Stock authorized, issued and outstanding consisted of the following (in thousands, except share amounts):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred &lt;br/&gt;Stock &lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred&lt;br/&gt;Stock Issued&lt;br/&gt;and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liquidation&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,855,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,042,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,042,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Rights, Preferences and Privileges of Legacy Korro Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Legacy Korro Preferred Stock as of December 31, 2022 had the following rights and preferences. In the discussion below, the Legacy Korro Series Seed Preferred Stock and the Legacy Korro Series A Preferred Stock, the Legacy Korro Series B-1 Preferred Stock and the Legacy Korro Series B-2 Preferred Stock are collectively referred to as the &#x201c; Legacy Korro Preferred Stock&#x201d; unless specifically noted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Conversion&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each share of Legacy Korro Preferred Stock were convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the original issuance price by the conversion price in effect at the time of conversion. The original conversion price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the original conversion price of the Legacy Korro Series Seed 3 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the original conversion price of the Legacy Korro Series A Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the original conversion price of the Legacy Korro Series B-1 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the original conversion price of the Legacy Korro Series B-2 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shares of Legacy Korro preferred stock are subject to adjustments to reflect the issuance of common stock,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;options, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;warrants, or other rights to subscribe for or to purchase common stock for a consideration per share, less than the conversion price then in effect and subsequent stock dividends, stock splits, combinations, or recapitalizations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Legacy Korro Preferred Stock was subject to mandatory conversion upon the closing of a sale of common stock to the public at a price of at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination or other similar recapitalization) in a firm-commitment underwritten public offering resulting in at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of gross proceeds to Legacy Korro. The Legacy Korro Preferred Stock was also subject to mandatory conversion upon the vote or written consent of the holders of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the then-outstanding shares of Legacy Korro Preferred Stock, voting as a single class on an as-converted to common stock basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holders of Legacy Korro Preferred Stock, in preference to common stockholders, were entitled to receive, when, as and if declared by the Company&#x2019;s Board of Directors, dividends at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% annually. Dividends on Legacy Korro Preferred Stock were non-cumulative and were payable only when and if declared by Legacy Korro&#x2019;s Board of Directors. The holders of Legacy Korro Preferred Stock were entitled to participate in dividends on common stock on an as-converted basis when and if declared by Legacy Korro's Board of Directors. Since Legacy Korro&#x2019;s inception, no dividends have been declared.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidation Preference&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event of any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the holders of shares of Legacy Korro Preferred Stock then outstanding were entitled to be paid out of the assets of Legacy Korro available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount equal to the original issue price per share plus any dividends declared but unpaid thereon. For clarity, the original issue price of the Legacy Korro Series Seed 1 Preferred Stock and Legacy Korro Series Seed 2 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, the original issue price of the Legacy Korro Series Seed 3 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, the original issue price of the Legacy Korro Series A Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, the original issue price of the Legacy Korro Series B-1 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and the original issue price of the Legacy Korro Series B-2 Preferred Stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If upon any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of Legacy Korro, the assets of Legacy Korro available for distribution were insufficient to pay the holders of Legacy Korro Preferred Stock the full amount to which they were entitled, the holders of shares of Legacy Korro Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Redemption&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Legacy Korro Preferred Stock was contingently redeemable upon the occurrence of a deemed liquidation event, which included a merger or a sale of substantially all of the assets of Legacy Korro. As of December 31, 2022, a deemed liquidation event was not considered to be probable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Voting Rights&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holders of Legacy Korro Preferred Stock were entitled to vote based on the number of common shares that their preferred shares converted into on as-converted basis at the time of such vote. Except in specific circumstances, holders of Legacy Korro Preferred Stock shall vote as a single class with the common stockholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holders of record of the shares of the Legacy Korro Series Seed Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to Legacy Korro&#x2019;s Board of Directors. The holders of record of the shares of the Legacy Korro Series A Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#x2019;s Board of Directors. The holders of record of the shares of the Legacy Korro Series B Preferred Stock, voting exclusively and as a separate class on an as-converted to common stock basis, were entitled to elect two members to the Legacy Korro&#x2019;s Board of Directors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_c954a977-07fd-4543-8907-3e2cc92e7ceb"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="3"
      id="F_4c285651-5b6c-476d-948d-efebeb4b806e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_f12286ee-ec30-4048-93a7-1d20a64331b6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_54dec796-9527-4e2a-960c-c77d094cbaa3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_7042021a-f5f1-4b64-8355-bd3286bb3502"
      decimals="6"
      id="F_23e407f8-2811-43f3-be79-c209fdcbe2f3"
      unitRef="U_Rate">0.049688</us-gaap:PreferredStockConvertibleConversionRatio>
    <krro:PercentageOfOutstandingSharesOfPreferredStock
      contextRef="C_7042021a-f5f1-4b64-8355-bd3286bb3502"
      decimals="2"
      id="F_f4699e12-846f-4eb6-9b2b-ff8c4f354426"
      unitRef="U_pure">0.66</krro:PercentageOfOutstandingSharesOfPreferredStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f"
      decimals="0"
      id="F_1ac83cfe-5224-4e68-b705-7b15c668c544"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f"
      decimals="3"
      id="F_001e9ab2-57d9-4917-8633-b021c9d5a96f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f"
      decimals="0"
      id="F_39be8a19-8156-44f7-813a-a97ea1aa6dc1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_66557f8e-6d8b-44d3-b246-56ca0ff0b85f"
      decimals="0"
      id="F_6a5836dd-ad29-437e-9c27-325580a63d90"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ScheduleOfPreferredUnitsTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_ef7efbae-8103-4ff3-b293-b0008465c7a0">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, Legacy Korro Preferred Stock authorized, issued and outstanding consisted of the following (in thousands, except share amounts):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred &lt;br/&gt;Stock &lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred&lt;br/&gt;Stock Issued&lt;br/&gt;and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liquidation&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,855,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,042,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,042,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfPreferredUnitsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="0"
      id="F_ce450d72-a76a-476e-988a-b2b57968f005"
      unitRef="U_shares">684739</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="0"
      id="F_435d89f6-053d-452f-81a3-e8819ed86843"
      unitRef="U_shares">684739</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="0"
      id="F_b87dcef3-47c8-4929-8ea7-6464990fc134"
      unitRef="U_shares">684739</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="-3"
      id="F_b11c60b8-4a03-440d-ba34-d6cd2d9610d5"
      unitRef="U_USD">15924000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="-3"
      id="F_13f7227d-b25d-4a1b-8e29-d0ee739664bf"
      unitRef="U_USD">16115000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <krro:CommonStockIssuableUponConversion
      contextRef="C_b451ece6-a0b3-4778-9557-3099f2fc289b"
      decimals="0"
      id="F_eba05d62-1375-405f-a61a-21c5ab3e6b85"
      unitRef="U_shares">684739</krro:CommonStockIssuableUponConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="0"
      id="F_95de4ae7-b6c6-4195-a94c-ffc86a7e9527"
      unitRef="U_shares">2029666</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="0"
      id="F_f9b9d1d1-c976-4eba-b214-7ea0df9678fd"
      unitRef="U_shares">2029666</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="0"
      id="F_d14fc963-9ca5-4ebf-97a7-0bb1a4ef355d"
      unitRef="U_shares">2029666</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="-3"
      id="F_5a229a24-2883-4fd3-b3cf-1250c9d7af38"
      unitRef="U_USD">77736000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="-3"
      id="F_d40465eb-d3ec-485d-a10b-c74373b33720"
      unitRef="U_USD">91500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <krro:CommonStockIssuableUponConversion
      contextRef="C_ea294f12-f168-4831-b0a1-38dd8c3da158"
      decimals="0"
      id="F_e193e590-5149-4a57-9c49-4949f7c3d099"
      unitRef="U_shares">2029666</krro:CommonStockIssuableUponConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="0"
      id="F_789b7016-7449-413c-ac68-0125aed2bc0f"
      unitRef="U_shares">1104178</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="0"
      id="F_63f9550e-3fa7-4df9-85a5-161a47b274fb"
      unitRef="U_shares">1104178</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="0"
      id="F_1eac5b2d-c5e6-4b57-9605-e3d7593f6798"
      unitRef="U_shares">1104178</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="-3"
      id="F_a782b599-dbaf-4f80-b68e-4ff69264c4dc"
      unitRef="U_USD">57703000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="-3"
      id="F_aa3998a4-629f-4aa7-b756-29139ad5238b"
      unitRef="U_USD">58000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <krro:CommonStockIssuableUponConversion
      contextRef="C_9f791cce-b07e-4ac7-b1cd-31513d7677b6"
      decimals="0"
      id="F_d32d2149-5f7d-45e1-8fe4-f76fd00c9a3f"
      unitRef="U_shares">1104178</krro:CommonStockIssuableUponConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="0"
      id="F_17c73938-6262-4cc2-bf7c-57028551728d"
      unitRef="U_shares">1036656</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="0"
      id="F_ec522c68-c995-4a03-9485-0e88285f3a2a"
      unitRef="U_shares">223417</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="0"
      id="F_4a4ff436-cb55-4028-ae4f-5567b9c17996"
      unitRef="U_shares">223417</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="-3"
      id="F_f09e7ba5-d05a-479d-9417-7e53f20cfee7"
      unitRef="U_USD">12500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="-3"
      id="F_5ac82e47-f6e1-4248-8369-a109423ac3f1"
      unitRef="U_USD">12500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <krro:CommonStockIssuableUponConversion
      contextRef="C_fa4edddf-c6d6-4d59-8278-3d9a40960d82"
      decimals="0"
      id="F_4452af99-3b5e-446a-ad52-49afed3fc342"
      unitRef="U_shares">223417</krro:CommonStockIssuableUponConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="0"
      id="F_1c1d9967-8e45-46bd-84a3-c189ed780dc8"
      unitRef="U_shares">4855239</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="0"
      id="F_15a727b7-8ab8-4525-87e8-f08cc1fd3ecc"
      unitRef="U_shares">4042000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="0"
      id="F_a9d7d1e5-70bf-41d0-af8e-cb11b4f12db4"
      unitRef="U_shares">4042000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="-3"
      id="F_1569972b-17fe-4341-a470-0594b3552f65"
      unitRef="U_USD">163863000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="-3"
      id="F_f1d96648-a919-47cb-8e07-54583ebfe1a0"
      unitRef="U_USD">178115000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <krro:CommonStockIssuableUponConversion
      contextRef="C_11cbb0a2-2e18-47b9-8650-844ad1b8c2b9"
      decimals="0"
      id="F_8c626a0f-ac48-4bd2-9a12-13c8f3aa60a9"
      unitRef="U_shares">4042000</krro:CommonStockIssuableUponConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983"
      decimals="2"
      id="F_3cc02e0c-85a1-45c4-8b0b-a8e605b1cf7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.13</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_3eb2b595-9ba7-481a-b2e8-779deb094693"
      decimals="2"
      id="F_604a26a9-7228-40a3-96eb-d4d9c7048c97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.16</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="2"
      id="F_c1b6c629-bbb5-4bdc-bcc1-d93be1880cb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45.08</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="2"
      id="F_2535aea8-1c69-471c-90f6-11fd37adbb6a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">52.53</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="2"
      id="F_f485ad84-25b6-4072-9787-2a39b3d0632d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">55.95</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7"
      decimals="2"
      id="F_1c3db24d-4f33-4d04-ac15-eb4162159680"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">111.9</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_f825e298-5e6d-4e4a-ab77-5640165e55ed"
      decimals="-2"
      id="F_c3d5e3c6-61d3-42e8-a2f5-5121c4e10e39"
      unitRef="U_USD">75000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <krro:PercentageOfOutstandingSharesOfPreferredStock
      contextRef="C_d031f4e3-c604-4bf6-b40b-8fedc10928e7"
      decimals="2"
      id="F_514abdca-7345-4655-9381-19f97d6a08d5"
      unitRef="U_pure">0.66</krro:PercentageOfOutstandingSharesOfPreferredStock>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_9eb4912e-e6b4-4f6f-b944-30b2ae5249b1"
      decimals="2"
      id="F_73fbcf99-7a6c-485d-a4eb-7e97ad2bccf0"
      unitRef="U_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_ce2ce06c-3ea6-48c4-a446-1fae277f1983"
      decimals="2"
      id="F_60020eae-4ff4-4b5f-8a92-754ab2f85caa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.13</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_3eb2b595-9ba7-481a-b2e8-779deb094693"
      decimals="2"
      id="F_4997bb2b-0f62-4c48-92ac-3d914bd5f014"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.16</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a01b8c88-d609-4db0-874d-4d6cbf21061f"
      decimals="2"
      id="F_35219748-f338-47d1-a399-040f53b5acc0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45.08</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_661dff35-cbb5-44e5-8aef-f17a500e1eea"
      decimals="2"
      id="F_cc0e49c6-5742-4844-bdf2-0c50141c79fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">52.53</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_11202b47-ecc1-47f3-bdd4-2297cfcb1b10"
      decimals="2"
      id="F_dbf389d2-bb75-4439-ae56-554d6a649c53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">55.95</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_dad9ab24-c175-4d70-a478-c7008196365d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Stock Option and Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 2023, the Company&#x2019;s board of directors adopted the Company&#x2019;s 2023 Stock Option and Incentive Plan (the &#x201c;2023 Plan&#x201d;). The 2023 Plan was approved by the Company&#x2019;s stockholders in November 2023 and became effective in November 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;connection with completion of the Merger. The 2023 Plan initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;885,028&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares for the issuance of stock awards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the number of shares of common stock available for issuance under the 2023 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2023 Plan, beginning with January 1, 2024 and ending with January 1, 2033, by the amount equal to 5% of the outstanding number of shares of the Company&#x2019;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  Awards granted under the 2023 Plan expire no later than ten years from the date of grant. For stock options, the option price shall generally not be less than 100% of the fair market value on the day of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there were in aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;889,922&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock reserved for issuance and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,694&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available to grant under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2019, the Legacy Korro's Board of Directors adopted the 2019 Stock Incentive Plan (as amended from time to time, the &#x201c;Legacy Korro Plan&#x201d;). The Legacy Korro Plan provides for the grant of stock options, stock awards and restricted stock units to employees, members of the Company&#x2019;s Board of Directors and non-employee consultants and advisors. The Legacy Korro Plan initially provided for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110,285&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The Legacy Korro Plan was subsequently amended in May 2019, June 2020, October 2020, April 2021, November 2021 and March 2023 to modify the number of shares of common stock issuable under the Legacy Korro Plan. Subsequent to the March 2023 amendment to the Legacy Korro Plan, Legacy Korro could issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;747,752&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock under the Legacy Korro Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the merger, each option to purchase shares of Legacy Korro common stock that was outstanding and unexercised under the Legacy Korro Plan immediately prior to the Effective Time, whether or not vested, was converted into an option to purchase shares of the Company&#x2019;s common stock and became eligible to be registered on Form S-8. The Company assumed each outstanding option to purchase shares of Legacy Korro common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of the Legacy Korro Plan and the terms of the stock option agreement by which such option to purchase shares of Legacy Korro common stock is evidenced. The number of shares under the Legacy Korro Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance pursuant to outstanding awards under the Legacy Korro Plan as of December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,977&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;683,156&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively. The number of shares available for grant under the Legacy Korro Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,890&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; at December 31, 2023 and 2022, respectively. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the Legacy Korro Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 13, 2014, Frequency adopted the 2014 Stock Incentive Plan (as amended from time to time,the "2014 Plan"). All of Frequency&#x2019;s employees, officers, directors, and consultants were eligible to be granted options to purchase common shares, restricted stock units and restricted stock under the terms of the 2014 Pla&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;n. Frequency, reserved an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;424,853&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for issuance under the 2014 Plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. As of December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock available for future grants under the 2014 Plan and there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,455&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares subject to outstanding option awards under the 2014 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 17, 2019, Frequency&#x2019;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (the "2019 Plan"). Under the 2019 Plan, Frequency may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#x2019;s subsidiaries. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,032&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2019 Plan subject to outstanding awards as of the effective date of the 2023 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2023 Plan. Upon completion of the Merger and effectiveness of the 2023 Plan, the Company ceased granting awards under the 2019 Plan.  Accordingly, as of December 31, 2023, there were no shares of common stock available for future grants under the 2019 Plan and there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,491&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares subject to outstanding option awards under the 2019 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the IRC. Incentive stock options may not be granted at less than the fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;market &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;value of the Company&#x2019;s common stock on the date of grant. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and are determined by the Board of Directors. Stock options generally become exercisable as they vest. Options granted under the Legacy Korro Plan, 2014 Plan and the 2019 Plan expire no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Common Stock Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the adoption of the 2019 Plan, Legacy Korro issued shares of restricted common stock to its founders as well as to certain employees. The restrictions on the common stock generally lapse over two to four years. In the event that a recipient ceases to provide service to Legacy Korro, Legacy Korro has the right to repurchase any unvested shares of restricted common stock at their original purchase price. As a result of this repurchase right, Legacy Korro recorded the issuance of such restricted common stock as a liability in the consolidated balance sheets. Amounts are reclassified to common stock at par and additional paid-in capital as the restricted common stock vests and restrictions lapse.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes Legacy Korro restricted common stock activity during the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate fair value of Legacy Korro restricted common stock that vested during the years ended December 31, 2023 and 2022, based upon the fair value of the underlying restricted common stock on the day of vesting, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the years ended December 31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.231%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.104000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.104000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes changes in stock option activity during the year ended December 31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.940000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed in reverse recapitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;835,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;368,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which the Company expects to recognize over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e46527cb-cdd6-49b6-ae87-4f92d5ccf0b0"
      decimals="0"
      id="F_2f2113e8-314d-4600-a461-58dceeaeded0"
      unitRef="U_shares">885028</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_0a9da549-07e8-4168-ae7a-19caa6774c9f">In addition, the number of shares of common stock available for issuance under the 2023 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2023 Plan, beginning with January 1, 2024 and ending with January 1, 2033, by the amount equal to 5% of the outstanding number of shares of the Company&#x2019;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_883bc534-e8f6-4895-bf52-bf10d4e2a415"
      decimals="INF"
      id="F_224b04c3-3157-44a8-9292-df76da7258bf"
      unitRef="U_shares">889922</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_883bc534-e8f6-4895-bf52-bf10d4e2a415"
      decimals="INF"
      id="F_2eb16bc0-4fc5-4461-bb06-3727272febd9"
      unitRef="U_shares">255694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_45db7593-eb9b-4883-9384-b026cd2ff9bc"
      decimals="0"
      id="F_b25d2ba0-f2a0-484a-b46f-10e3d0190103"
      unitRef="U_shares">110285</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_b267ce26-7f99-4922-a593-840ac7ce4bac"
      decimals="0"
      id="F_33884be3-99bb-43d8-8c09-eeab7f2f8a61"
      unitRef="U_shares">747752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7c761095-cfe8-42cc-a37e-889e388af4b1"
      decimals="0"
      id="F_42bdd783-ae49-4a1c-9a98-4adb2f4a9312"
      unitRef="U_shares">600977</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fac002bd-d841-4cb9-87ff-6726c92a87a9"
      decimals="0"
      id="F_e77e8160-4ab6-472e-adc9-500eecf2eb83"
      unitRef="U_shares">683156</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f43b4902-d2c6-4c47-bc7b-f3057b2dc2af"
      decimals="0"
      id="F_03d2dc5b-644c-4497-85f8-bd86b5417646"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_ba47ceb2-3907-4c75-93da-352aebf2bc11"
      decimals="0"
      id="F_f6212e06-0947-4f6d-ac21-45f19bea7ec4"
      unitRef="U_shares">159890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e"
      decimals="0"
      id="F_04eaf671-d9d4-4f23-a5f2-f1f97a732f12"
      unitRef="U_shares">424853</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e"
      decimals="0"
      id="F_d615fcf8-3911-4592-9962-ad92d4e895bb"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2c63df81-1292-4b21-8598-c514db4b083e"
      decimals="0"
      id="F_9d9d95ba-29f7-40a8-9e7b-df0e2519989e"
      unitRef="U_shares">36455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0fcf0a27-21b0-415b-8c89-231bbee07b61"
      decimals="0"
      id="F_12cf8631-5426-4741-9ab8-c2265f5aa64e"
      unitRef="U_shares">154032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_abf5d9da-538d-418d-b41f-9269c757a637"
      decimals="0"
      id="F_76f5c15e-553b-4b6f-a8a4-825d1ef5cde6"
      unitRef="U_shares">51491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_c5fe850e-1270-4481-9615-6983726e227c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_28416616-771e-4781-9539-2026f993e1ea">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_9ef1ef88-cbc2-4f54-ab00-77643d3b331b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5aa971ad-c939-4c21-a327-57534a1ce091"
      decimals="-3"
      id="F_943c0d76-2c3e-4260-9732-f7d9070e8618"
      unitRef="U_USD">759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4331d39a-acce-4178-b456-7b04be2b6063"
      decimals="-3"
      id="F_bca714ca-d00a-4e4e-bb84-3391d5416a19"
      unitRef="U_USD">243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dbd86c0c-db69-4c76-b0b5-17ba9213ddff"
      decimals="-3"
      id="F_7284427e-f701-448a-964c-93c4df4c8eec"
      unitRef="U_USD">1622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ab8f59ed-af83-49c1-80a2-d1a10ec53e1d"
      decimals="-3"
      id="F_4b6e5c0b-d3e6-46b7-8cf3-aa436a807f85"
      unitRef="U_USD">897000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_2578dffe-fb62-4f38-a8b5-1bd00877bf4d"
      unitRef="U_USD">2381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_61211b65-aac4-4138-8a22-552578f16dce"
      unitRef="U_USD">1140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_fd139dbd-b6dd-43e1-bba1-b77cd1bd274f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes Legacy Korro restricted common stock activity during the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7c6858e2-8133-456c-a5ca-5b7016177e3d"
      decimals="0"
      id="F_2225cc16-6b86-4d7c-884a-92f5a770e61c"
      unitRef="U_shares">2902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7c6858e2-8133-456c-a5ca-5b7016177e3d"
      decimals="2"
      id="F_dbb64bc2-6bb9-474f-91e2-d06a8754a072"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="0"
      id="F_0f77660c-9c0f-44c7-8ac7-13f00784125f"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="0"
      id="F_2fc7a818-9e17-4eb0-8232-d20107715211"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="0"
      id="F_16cf03c9-756c-4322-becb-5923b0ed70bc"
      unitRef="U_shares">2902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="2"
      id="F_33faad5b-380b-470f-91be-bdc37c60a60a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="0"
      id="F_518b3b93-803a-477d-b99c-eb200cea3c1b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="0"
      id="F_eefb9d27-b3fa-4987-9593-ac98c9947f81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6f7339a6-1078-443f-9a49-06210ba9d73d"
      decimals="0"
      id="F_0e7cd552-b403-4066-ba8d-d651a8729e5c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6f7339a6-1078-443f-9a49-06210ba9d73d"
      decimals="0"
      id="F_b5e7c24c-d5d6-473a-9bfa-f5c953826f39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_745d62aa-8d61-427a-9115-a346c910fcb3"
      decimals="-5"
      id="F_7ed4b263-2d75-497d-ac6b-a1db3636ab12"
      unitRef="U_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_9a2b3b81-fe26-47a3-b213-a4e83175b18c"
      decimals="-5"
      id="F_a236fd35-2da6-4ebd-8a77-1e61844c2678"
      unitRef="U_USD">500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e5ff5b72-42f0-4f33-8bbf-80a53448f1f2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the years ended December 31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.231%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.104000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.104000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_50f53b42-6b9b-4159-8f99-628c848adf0c"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_5d2c2287-6d35-4bbb-8b55-90e4e3205d1c"
      unitRef="U_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_9854f968-31fc-4155-a0bb-1b000fe7edc5"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_4dd38928-999c-4754-921b-b649155b9499"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_036cf9bc-a70f-4c9e-9ad2-c00305edc46a">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      id="F_f5cc2e85-a70b-4262-9f69-62b4b9032cd3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_988919e5-b07f-471e-8ed5-4792d5afd653"
      unitRef="U_pure">0.728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_34cb1df3-f8e4-4f4a-a203-0a5fc9b50fa8"
      unitRef="U_pure">0.729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_2dd27c4e-2ea8-41b8-941e-4e926435d006"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_7eabfe6f-e281-4246-99d0-499f52ddd85f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_fb503998-7051-4b45-8c0f-9ad37c712723">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes changes in stock option activity during the year ended December 31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.940000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed in reverse recapitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;835,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;368,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="0"
      id="F_02f8ebc3-bb95-4a2a-a9f5-25dfa1e23513"
      unitRef="U_shares">461100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="2"
      id="F_b01213ae-bf89-4684-9c89-88c5f18e0b95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      id="F_118bb1ea-2323-4874-999d-51509b6f50a2">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_534dfb9e-db05-40a6-8619-3fe08b9f3fb9"
      unitRef="U_USD">2953000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <krro:ReverseRecapitalization
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_7a427aef-b716-4e80-8602-9095004b4a4c"
      unitRef="U_shares">93153</krro:ReverseRecapitalization>
    <krro:WeightedAverageExercisePriceReverseRecapitalization
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_78c077f5-c94b-42c1-9c6c-26073cc5ccbe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">121.91</krro:WeightedAverageExercisePriceReverseRecapitalization>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_4d2eb555-190a-48b5-90d4-5417dcb01bd6"
      unitRef="U_shares">835839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_55612b0a-3ff8-45c3-a94c-67822dc4ed45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_a288e0c3-a5e4-4d64-aca7-f51420291c18"
      unitRef="U_shares">39395</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_ef487d70-9aa1-47e5-96cc-7b2646220169"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_33ec6bd4-b385-4ca8-bb2a-8969c8dce164"
      unitRef="U_shares">20091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_0496fcf5-5208-45ff-93f4-8b77996657d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <krro:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_c5e6e0b1-91b4-4dab-b3cf-2ef0943cb217"
      unitRef="U_shares">7455</krro:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <krro:WeightedAverageExercisePriceCancelled
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_7489bdb9-f8b7-4798-b9ea-982719575fcc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.85</krro:WeightedAverageExercisePriceCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_4d0998e6-d4a0-4a94-a992-b4de09dbcae2"
      unitRef="U_shares">1323151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="2"
      id="F_d31c149d-0699-40fd-adce-d8f92cdac470"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_8bab1acf-09fc-42c2-9f09-79711c912a73">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9d648d31-0356-4a56-8d24-d9c70a2a0d37"
      unitRef="U_USD">36310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="0"
      id="F_a58bf96c-a40a-40f9-84a0-8e097dcc22fd"
      unitRef="U_shares">368036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="2"
      id="F_1b6abab4-9b10-4f7b-ad69-57f0f427119d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a0b44212-569e-453a-ae60-9cb1642b4ab9">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_90d265cc-8549-44aa-af01-4cff0be107a2"
      unitRef="U_USD">8457000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_45dd7527-e8d6-4d43-9fe2-21406542673d"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-5"
      id="F_b17ca62a-e5a2-44db-a528-e8e6b8197e20"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_57cb11c2-1779-4363-92be-64993694df72"
      unitRef="U_USD">10100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_389ac3bf-d91f-4b2b-bdaf-ab6ce82d64c1">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_84cf7904-4d58-41f3-a6cb-d9a13f641845">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision for income taxes for the years ended December 31, 2023 and 2022 was comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;153,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;266.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under current law, the Company's federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of the Company's taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has federal NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that are subject to expiration between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;280.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal NOLs that do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;State NOLs expire at various dates from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that expire at various dates from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In addition, as of December 31, 2023, the Company had state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that expire at various dates from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which primarily pertain to NOL carryforwards, tax credit carryforwards and capitalized research and development. The Company has determined that it is more likely than not that it will not realize the benefits of its deferred tax assets, and as a result, a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million has been established at December 31, 2023. The increase in the valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2023 was primarily due to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the additional operating loss generated by the Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and the combination of deferred tax assets as a result of the Merger&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% as defined under Sections 382 and 383 in the IRC. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#x2019;s value immediately prior to the ownership change. As a result of ownership changes in the Company from its inception through December 31, 2023, the Company&#x2019;s NOL and tax credit carryforwards allocable to the periods preceding each such ownership change could be subject to limitations under IRC Section 382, however the Company has not yet completed an IRC Section 382 study.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized tax benefits as of either December 31, 2023 or 2022. The Company has not conducted a study of its research and development credit carryforwards generated during any year. This study, once completed, may result in an adjustment to the Company&#x2019;s research and development credit carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;However, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credit carryforwards, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated statements of operations and comprehensive loss if an adjustment were required.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company files income tax returns in the United States federal tax jurisdiction and the Connecticut and Massachusetts state tax jurisdictions. Because the Company is in a loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incurred any material interest or penalty charges.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_12d52701-5147-45ca-88a7-71ad7cc4de4a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision for income taxes for the years ended December 31, 2023 and 2022 was comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4f5a3739-5b0a-4ec7-8348-712e0d9cea49"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_f00fb8da-ba04-43fc-8ef9-d9d827bb37bb"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_0295dce7-cd7f-4ffa-b127-1b4824bfd6c8"
      unitRef="U_USD">27000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_9cb3889e-2563-428c-92a1-1d061730c96e"
      unitRef="U_USD">10000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_67594fa4-44e1-4f72-ad01-f8bf4b098269"
      unitRef="U_USD">27000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_111334e7-8bdb-4da8-b9c8-b97e9404efae"
      unitRef="U_USD">10000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_5d0f2b5a-1b0b-4c24-99cd-fcd6b34b84b2"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_1ffddc20-0fa6-4890-b617-69ac53e704fb"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_ae0cf5f4-ef7c-446b-a21d-bd9cac3dd9a1"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_8bd1aeee-7654-4a70-a7a6-2b12b5b5dc8d"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_8b0bec86-4a5b-49a1-be86-10e69f152676"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_d75cbd83-81f3-4dda-a4d0-0bae6a3313ca"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4902abc1-98d8-4a66-8121-83c12ff9c054"
      unitRef="U_USD">27000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_81f7aa65-6752-4f8a-ba22-2cc5ba3abbd8"
      unitRef="U_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_8890fae6-0511-4f1d-aa33-7ec95ccf2379">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_1d37ad14-5044-43bf-9cec-db6ab600e9e5"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_7adf8496-9b09-40ed-9fa1-b41c8b255a65"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_99704c75-2a7f-4ed4-8677-d12d190842cc"
      unitRef="U_pure">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_fb06c163-7fb0-4735-9168-f906b335284e"
      unitRef="U_pure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <krro:EffectiveIncomeTaxCreditCarryforwards
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_f418a060-bc7a-4fd6-8553-19e24359b61a"
      unitRef="U_pure">0.036</krro:EffectiveIncomeTaxCreditCarryforwards>
    <krro:EffectiveIncomeTaxCreditCarryforwards
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_37dd7008-bab7-41f4-bc28-932bc1751b51"
      unitRef="U_pure">0.062</krro:EffectiveIncomeTaxCreditCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_561c0233-0c2f-4058-85e6-088889384c78"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_dd339b2a-b0f6-425f-9316-5e59f566d467"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_e3158521-15f5-4bac-a8d7-92181d6552f8"
      unitRef="U_pure">-0.308</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_759c7053-2aa1-4ee7-a6d4-2f51f81f60cc"
      unitRef="U_pure">-0.327</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="3"
      id="F_9b146e17-938f-4de8-989c-c344514b8f02"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="3"
      id="F_a093eb09-da9c-4b40-8952-942d7889d22f"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_12f079b5-66bd-4d72-97e8-5c557059e6c1"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_0cbd09f3-ec2c-4185-a999-8510e25fb453"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_2be0aad4-dcb0-4feb-8b65-fdd1cedf7554">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2023 and 2022 were comprised as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;153,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_96e5e8c4-bdae-4b79-b4ec-1c5b429af8ac"
      unitRef="U_USD">80385000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_dc65d1ab-37f1-43c2-8dc8-8d694874ef76"
      unitRef="U_USD">19580000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_780692bf-51b1-47e9-bb0a-3fabb0a0ddd2"
      unitRef="U_USD">22474000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_a63ad551-cbed-4b03-ae7d-f0e4288fced4"
      unitRef="U_USD">5477000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_ffddb3e4-de5c-463e-9135-ae3e11f60c9d"
      unitRef="U_USD">34395000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_7aa50f75-da68-40bc-8a06-1e2c1ff6b71c"
      unitRef="U_USD">10279000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_f45680f8-4597-4ff6-91f9-be2ad3d65591"
      unitRef="U_USD">4494000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_33bcb766-34dd-4ab7-939e-e0076b091486"
      unitRef="U_USD">319000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <krro:DeferredTaxAssetsAmortization
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_1e22ac67-aed6-4974-97d5-f354c66b9c36"
      unitRef="U_USD">1138000</krro:DeferredTaxAssetsAmortization>
    <krro:DeferredTaxAssetsAmortization
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_2e9659da-41a4-4978-8e06-a4596256e1c8"
      unitRef="U_USD">0</krro:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_07307f28-20bc-40a3-80fc-b60f6da80c65"
      unitRef="U_USD">9052000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f6eeed9b-73e8-46a0-ba25-ce09b647e729"
      unitRef="U_USD">855000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_57364533-2ba0-4224-b402-cb49cc73c797"
      unitRef="U_USD">1543000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_967fef86-7c61-48cd-b066-0dacc138b415"
      unitRef="U_USD">707000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_3465b89f-d3ad-4b82-9134-88c2fd56f98d"
      unitRef="U_USD">153481000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_19166d7b-b5a1-4742-b613-7179b5a2351d"
      unitRef="U_USD">37217000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_ddcf029a-02a3-4668-9b5e-faf577c10dcc"
      unitRef="U_USD">145766000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_6c3037f7-c95b-47c2-a3b4-a3e184925e0b"
      unitRef="U_USD">36094000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9c62a495-dd41-48d0-9c7e-a9fbd3de32de"
      unitRef="U_USD">7715000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_f7a6071d-3ca9-4d3c-abe0-3acf1d8a3183"
      unitRef="U_USD">1123000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_befc4c31-bfa0-452e-a9f2-2993f552ef5d"
      unitRef="U_USD">7401000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_d9acf938-06cf-44fa-8256-f3b1f70a8f09"
      unitRef="U_USD">552000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_8f2cf8b5-b2f8-4315-a9b4-61ce4455019c"
      unitRef="U_USD">314000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_3a74a521-dcfa-4b6d-b045-5677fed82102"
      unitRef="U_USD">571000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_0ace855a-81ef-4d69-83f6-dd6762bda562"
      unitRef="U_USD">7715000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_48dcb79b-2d7c-43f7-bab4-e843867ceaf9"
      unitRef="U_USD">1123000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_8279b2c8-b4b6-4565-81ba-75af827535e3"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_68a387c6-c100-4f0b-8e22-b5f6ca52b29f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5"
      decimals="-5"
      id="F_278c298a-a691-429e-a05e-8f2e786395a4"
      unitRef="U_USD">302500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8544c9be-728b-4911-819c-b239ec0b27ad"
      decimals="-5"
      id="F_fd51676f-4d69-43e5-806a-b88a220cd813"
      unitRef="U_USD">266300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_91162885-47c4-4921-a206-ae5af37914db">Under current law, the Company's federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of the Company's taxable income annually for tax years beginning after December 31, 2018. Federal NOLs generated in taxable years ending on or prior to December 31, 2017, however, have a 20-year carryforward period, but are not subject to the 80% limitation</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <krro:NetOperatingLossCarryforwardsExpirationWithLimitation
      contextRef="C_941fe9a3-ecee-4f95-bad6-d4b410ef6fc5"
      decimals="-5"
      id="F_11d9cd90-7e21-4f58-8080-8947cc3c125f"
      unitRef="U_USD">22400000</krro:NetOperatingLossCarryforwardsExpirationWithLimitation>
    <krro:OperatingLossCarryforwardsExpirationYear
      contextRef="C_ab007b59-97df-45a4-a462-77226307ef64"
      id="F_51d5631f-70b7-4311-b13f-996322d131a7">2036</krro:OperatingLossCarryforwardsExpirationYear>
    <krro:OperatingLossCarryforwardsExpirationYear
      contextRef="C_306fb8af-4fc4-4970-872c-b483d03fb9e4"
      id="F_fcb171f5-4122-4a09-86f8-57816568657d">2037</krro:OperatingLossCarryforwardsExpirationYear>
    <krro:NetOperatingLossCarryforwardsExpirationWithoutLimitation
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_c4d06699-950d-4785-b297-4d2e7ccbc95b"
      unitRef="U_USD">280100000</krro:NetOperatingLossCarryforwardsExpirationWithoutLimitation>
    <krro:OperatingLossCarryforwardsExpirationYear
      contextRef="C_9aa93606-02db-46a9-9b63-7b4d0578cd82"
      id="F_69ffecad-5fa0-458b-8a9c-6def065d7608">2035</krro:OperatingLossCarryforwardsExpirationYear>
    <krro:OperatingLossCarryforwardsExpirationYear
      contextRef="C_93f80774-1bcb-4131-b2c9-93def7a01c20"
      id="F_3a590398-64bb-4127-a1fa-5739f26191b4">2043</krro:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_a1efc944-079f-4e9e-8fcb-7284de744653"
      decimals="-5"
      id="F_95618fd9-18fb-4a74-b9da-95a48e836468"
      unitRef="U_USD">15600000</us-gaap:TaxCreditCarryforwardAmount>
    <krro:TaxCreditCarryforwardExpirationYear
      contextRef="C_5e3928f9-e795-46c2-8b3b-47cb73bcf901"
      id="F_df9f9a3f-b2dd-4604-b2b8-79b896c8961b">2036</krro:TaxCreditCarryforwardExpirationYear>
    <krro:TaxCreditCarryforwardExpirationYear
      contextRef="C_ecda1a05-7107-41dc-a5fc-7124dc194f84"
      id="F_7c887c31-2ccd-4ce8-92a8-12f1f3bf794b">2043</krro:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_11f11e50-ea6c-40c6-950d-f8060c5107d8"
      decimals="-5"
      id="F_145951bd-df5b-4aaf-9e74-096297b907b3"
      unitRef="U_USD">8700000</us-gaap:TaxCreditCarryforwardAmount>
    <krro:TaxCreditCarryforwardExpirationYear
      contextRef="C_a623cd32-caa5-4962-8d16-001ea4eb82ed"
      id="F_eb75c5d6-7727-4f20-b937-eed97b4c2f49">2032</krro:TaxCreditCarryforwardExpirationYear>
    <krro:TaxCreditCarryforwardExpirationYear
      contextRef="C_3ef3d01f-e4f1-47e1-8d30-5ca772b0c60e"
      id="F_d22755b4-62f0-439e-840b-6b27d8cd84f0">2038</krro:TaxCreditCarryforwardExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_982cd7a6-4d3f-4508-a806-b3958c6cf7b0"
      unitRef="U_USD">145800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_ed23e78e-db44-4292-8633-16a232e8ff4f"
      unitRef="U_USD">109700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_76e0ac53-1ed1-445b-b88f-267d3461948f">the additional operating loss generated by the Company and the combination of deferred tax assets as a result of the Merger</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <krro:PeriodOfCumulativeChangeInOwnership
      contextRef="C_f4c0a17b-b744-4c53-8416-6686a4fc0acf"
      id="F_7a898a5e-6925-41bc-8865-6bf97b828322">P3Y</krro:PeriodOfCumulativeChangeInOwnership>
    <krro:CumulativeChangeInOwnershipPercentage
      contextRef="C_919f3e26-6567-4206-aa08-0ae94fcbc65a"
      decimals="2"
      id="F_cc7a81c6-7181-4c78-9a07-237e89afcce9"
      unitRef="U_pure">0.50</krro:CumulativeChangeInOwnershipPercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_e3c09149-a1e0-4c13-997a-0a9af2053cb6"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f61fcdc5-7781-4d89-9c78-e405590b9203"
      decimals="-3"
      id="F_276fa272-3e5b-414e-8fd5-08ea5eb6c202"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_7eb96b1b-d2f2-4334-b933-c76785edf22a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_a4512ba6-2c8f-4294-85a8-5c9993e0fddb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Genevant Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2023, Legacy Korro entered into a collaboration and license agreement (the &#x201c;Genevant Agreement&#x201d;) with Genevant Sciences GmbH (&#x201c;Genevant&#x201d;). Key financial terms under the Genevant Agreement are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment to Genevant in March 2023 upon execution of the Genevant Agreement and recorded the payment within research and development expense in the consolidated statement of operations for the year  ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will reimburse Genevant for certain out-of-pocket and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Genevant is entitled to receive payments from the Company upon the achievement of certain milestones, including potential clinical milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, potential regulatory and development milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and potential commercial milestone payments up to an aggregate total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Genevant is eligible to receive royalties at percentage rates in the mid-single-digits, based on future annual net sales of licensed products within the scope of the Genevant Agreement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, no milestones have been achieved and the Company has recorded payments to Genevant of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within research and development expense in the consolidated statement of operations during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_23c62caa-1ebb-4380-b45d-f24627644a23"
      decimals="-5"
      id="F_af83c3ec-5e8f-4bd8-a5db-c99101ca13bd"
      unitRef="U_USD">2500000</us-gaap:ResearchAndDevelopmentExpense>
    <krro:MilestonePayment
      contextRef="C_45c261a8-1fa5-407f-ace7-946cf709a7e3"
      decimals="-5"
      id="F_dd952e99-269e-4e4f-a514-5ccb86fbab54"
      unitRef="U_USD">13500000</krro:MilestonePayment>
    <krro:MilestonePayment
      contextRef="C_397c2e74-ff43-4295-9f70-85a5ca23db1c"
      decimals="-5"
      id="F_f342e26b-bc65-4602-a555-efe89247e65d"
      unitRef="U_USD">27000000</krro:MilestonePayment>
    <krro:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones
      contextRef="C_23c62caa-1ebb-4380-b45d-f24627644a23"
      decimals="-5"
      id="F_9350ca4f-1acd-4ad4-94f7-00e7372c0e4a"
      unitRef="U_USD">57000000</krro:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones>
    <krro:ReimbursementsWithInResearchAndDevelopmentExpense
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-5"
      id="F_1b115613-5737-49a0-9a57-565b7f36f8e0"
      unitRef="U_USD">1200000</krro:ReimbursementsWithInResearchAndDevelopmentExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_402b31d9-8ded-401c-91a6-b8a1b34acf75">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is party to an operating lease at One Kendall Square, Cambridge, Massachusetts and occupies &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,561&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of laboratory and office space (the &#x201c;OKS Facility&#x201d;). On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 20, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into an amendment to the Lease Agreement that extended the lease expiration date from December 31, 2023 to September 30, 2024 and provided the Company with no option to further extend the lease expiration date. The Company is also party to an operating sublease agreement at Cummings Park in Woburn, Massachusetts&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and occupies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,148&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of laboratory and office space (the &#x201c;Cummings Park Sublease&#x201d;) which expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;July 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is party to an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,453&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts (the &#x201c;60 First Street Lease&#x201d;). In May 2023, the Company obtained control over the space and the Company recognized the operating lease right-of-use asset and the operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the commencement date of the lease. The total rental payments over the 11 year lease are expected to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, including rent credits and other lease incentives per the terms of the lease. Specifically, the 60 First Street Lease provides the Company with a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company utilized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million tenant improvement allowance as of December 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1, 2023. The lease has remaining term approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company has an option to extend the lease for an additional period of five years with the rent during the option period being the then fair market rent.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments for all three leases, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expected to be received and intended to be used related to the remaining tenant improvement allowance and rent credits associated with the 60 First Street Lease, as of December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Future Minimum Leases Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present Value of Operating Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the weighted average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and the weighted average incremental borrowing rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities and maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statement of operations and comprehensive loss of its operating leases (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.249%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.075999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.075999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#x2019;s accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Frequency and the Frequency&#x2019;s Chief Executive Officer, President, and Director, David Lucchino. On March 21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May 16, 2022, the Company&#x2019;s Chief Development Officer, Dr. Carl Le Bel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#x2019;s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company&#x2019;s public disclosures between October 29, 2020 and March 22,2021. The lawsuit sought, among other things, damages in connection with the Company&#x2019;s allegedly artificially inflated stock price between October 29,2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#x2019; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July 15, 2022. On March 29, 2023, the Company&#x2019;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April 27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. On August 2, 2023, Plaintiff-Appellant submitted its opening brief to the First Circuit. The Company filed its response brief on October 27, 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The First Circuit heard oral argument on January 8, 2024, and has not yet issued a decision on plaintiff&#x2019;s appeal. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accruals have been recorded as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company&#x2019;s request in such capacity, as permitted under Delaware law and in accordance with the Company&#x2019;s amended and restated certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company&#x2019;s exposure and may enable the Company to recover a portion of any future amounts paid. The Company believes that the fair value of these potential indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_b6e3c39b-8096-4f8f-97f0-daa59596a1a7"
      decimals="0"
      id="F_62db0d61-427c-4f81-9cf0-a920c3484683"
      unitRef="U_sqft">22561</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_952c1d35-4cc4-4d37-8f7f-0c70663501bf"
      id="F_f7592afb-281c-4198-b5ce-cedb53c55dd0">2023-10-20</us-gaap:LeaseExpirationDate1>
    <us-gaap:AreaOfLand
      contextRef="C_597278ba-5ca6-4b61-aca3-d85a7999b364"
      decimals="0"
      id="F_991ae706-bca9-4f06-9558-99df47f7b430"
      unitRef="U_sqft">18148</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_09fab13f-bf4d-4e13-b1df-cb7d113cce21"
      id="F_0ec0b283-814b-4c2c-ae9f-199e4f29a434">2024-07-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:AreaOfLand
      contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355"
      decimals="0"
      id="F_994efda5-5844-4920-a95b-afa9086a8ad9"
      unitRef="U_sqft">50453</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90"
      decimals="-5"
      id="F_fdaf539c-d2db-4082-b10e-bbe70b09952b"
      unitRef="U_USD">26800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90"
      decimals="-5"
      id="F_cb4969d5-203f-4b01-86a1-997167e39100"
      unitRef="U_USD">26800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90"
      decimals="-5"
      id="F_9aab2aee-6204-404b-81ef-b4ee271a150d"
      unitRef="U_USD">62100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:TenantImprovements
      contextRef="C_06426193-e63d-4cf5-a2db-19dbf1197a90"
      decimals="-5"
      id="F_6d62cee1-5a6d-4181-a513-37fceb4e233d"
      unitRef="U_USD">13100000</us-gaap:TenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_55c76954-1de4-47a3-95e3-7300d73d84fc"
      decimals="-5"
      id="F_cce5c2aa-5b00-4b63-98a4-06f2cf1f4fb4"
      unitRef="U_USD">2300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:TenantImprovements
      contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355"
      decimals="-5"
      id="F_41d80baf-b005-426a-a5c9-102890a9f724"
      unitRef="U_USD">13100000</us-gaap:TenantImprovements>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_8f5dc272-fb80-43d7-a5fe-feed1975a355"
      id="F_e819857b-96bc-4f8b-9b64-3473747f9972">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_337c85f9-ee6e-4edb-b9e9-b0641a29a65c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments for all three leases, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expected to be received and intended to be used related to the remaining tenant improvement allowance and rent credits associated with the 60 First Street Lease, as of December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Future Minimum Leases Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present Value of Operating Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="C_ab8215de-6795-4f27-b53e-55d3375d2af5"
      decimals="-5"
      id="F_d0bcbd05-fc99-4955-8c4f-7eee1fa71204"
      unitRef="U_USD">10800000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_ef540a62-cee8-46e8-b82e-43e87f2457d4"
      unitRef="U_USD">7227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_5598323c-05f0-448a-81f4-5ac6a482b577"
      unitRef="U_USD">6247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_4f599c0c-e242-4581-b961-1cf73bd4a0d4"
      unitRef="U_USD">7341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_f57492f5-e86d-4ade-8bcb-3c673462ff2e"
      unitRef="U_USD">7557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_22f14f52-074e-41c9-b101-c70e5d8334f2"
      unitRef="U_USD">52498000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_e747d2b2-db97-46eb-8db9-586e03ba9d3f"
      unitRef="U_USD">66416000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_9f9071d3-6d19-4284-8af8-dac8032c6937"
      unitRef="U_USD">33209000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-3"
      id="F_a11183d7-60b9-4de7-94f0-ba40a0bc38d1"
      unitRef="U_USD">33207000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      id="F_58607e68-3040-4891-b61a-263769c412ba">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="3"
      id="F_3f6f5d4e-67be-4756-aa35-96eedf349590"
      unitRef="U_pure">0.112</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_30a653cf-d428-4043-9294-f01e84ed822b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statement of operations and comprehensive loss of its operating leases (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.249%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.075999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.075999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_4ec25fcb-7190-4e55-82d3-2ebe579feefa"
      unitRef="U_USD">5948000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_29a7bd3b-467b-4c4f-a213-941e4bb6e230"
      unitRef="U_USD">1675000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_df78b6c3-2b92-4901-b187-f050a00252ed"
      unitRef="U_USD">1211000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_5afd2098-bf4f-4c6d-bee1-1f5bf675fb6b"
      unitRef="U_USD">732000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_6193903f-df5d-4fa6-aa2b-059f92ce9a96"
      unitRef="U_USD">921000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_78c981d4-6ccb-4a35-86e3-3bc0106bfd7e"
      unitRef="U_USD">626000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_95eee584-4a8f-4d26-95d0-1bc29cdc965f"
      unitRef="U_USD">8080000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_19d9ce22-a0b3-4d03-8fd9-168b8a88b3b3"
      unitRef="U_USD">3033000</us-gaap:LeaseCost>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_1d4501f2-ba74-4579-94ab-e81941e63104"
      decimals="-6"
      id="F_9d86fc1f-4b54-4d1e-84a5-5b6bf7a010ad"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_6f2aa78b-25dc-452e-b37c-38c9b1762400">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. 401(k) Savings Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a defined-contribution savings plan under Section 401(k) of the IRC (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation, subject to statutory limitations. Beginning on April 1, 2022, the Company matches &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of an employee&#x2019;s 401(k) contributions up to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the participant&#x2019;s salary, subject to employer match limitations under the IRC. As such, the Company made $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of matching contributions to the 401(k) Plan during the year ended December 31, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_f10a3be4-4ec6-4c00-b69c-d83c843296d7"
      decimals="2"
      id="F_84dd07f0-b10c-4dfb-8bf8-4b65581736fe"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_728a4108-5170-4a8f-b001-b85c0cd9973b"
      decimals="2"
      id="F_d0f54ddb-673d-41f7-a0be-174c7593972a"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-5"
      id="F_05c637bb-6914-4458-be5b-7703a698e392"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-5"
      id="F_8f5e3fbc-43a9-4d48-bb80-3a4c8843e698"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_e14228e7-b0ec-4ff1-bce8-184c1d9d05d4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;16. Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of Atlas&#x2019; ownership of the Legacy Korro&#x2019;s Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock which was exchanged in the Merger for the Company's common stock, Atlas represents an affiliate of the Company. During the years ended December 31, 2023 and 2022, the Company incurred &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; expense and expenses of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, related to consulting services provided by an affiliate of Atlas. As of December 31, 2023 and 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts due to this affiliate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <krro:IncurredExpenses
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-6"
      id="F_67be121a-1156-4a4b-8f40-fa8900fc95d8"
      unitRef="U_USD">0</krro:IncurredExpenses>
    <krro:IncurredExpenses
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-6"
      id="F_08cfe937-3529-462d-9d67-9630952cfcad"
      unitRef="U_USD">0</krro:IncurredExpenses>
    <krro:IncurredExpenses
      contextRef="C_306fb8af-4fc4-4970-872c-b483d03fb9e4"
      decimals="-5"
      id="F_ad25d863-d42f-4dae-a612-284f5c53c029"
      unitRef="U_USD">100000</krro:IncurredExpenses>
    <us-gaap:AffiliateCosts
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_05c88c9c-ad3a-4aa5-be06-b5b1943a29ad"
      unitRef="U_USD">0</us-gaap:AffiliateCosts>
    <us-gaap:AffiliateCosts
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_d880b54e-e504-4e1d-906d-0f48fcac6a8a"
      unitRef="U_USD">0</us-gaap:AffiliateCosts>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_925fad4e-bac2-4f4b-b29f-92dd25a01b4d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17. Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.968%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.257%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.257%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested Legacy Korro restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding Legacy Korro stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding Legacy Korro warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,331,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,514,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The following table sets forth the computation of the Company's basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,529,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_fb0a9dad-8e3f-407c-8fca-7108ae5f5145">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.968%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.257%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.257%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series Seed Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,029,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-1 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,104,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legacy Korro Series B-2 Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested Legacy Korro restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding Legacy Korro stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,323,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding Legacy Korro warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,331,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,514,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fefcff45-a321-42bf-a7e9-1a416bde8bee"
      decimals="0"
      id="F_ca56d908-4a31-44ec-9f40-e2c66e476390"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3253f6cb-13ac-491b-a7c7-9edb74475ade"
      decimals="0"
      id="F_43937e14-0b70-4e6e-88cd-d71145b795f4"
      unitRef="U_shares">684739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8cfbcf8e-1721-4cf1-9208-7dd35da5b429"
      decimals="0"
      id="F_4bbc58ab-989b-497b-87f8-9e22cfa57115"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e1ffa510-b12a-4e8a-ae92-845d73bdc92d"
      decimals="0"
      id="F_cf805268-4dbf-4e00-88bb-e4121113dc8f"
      unitRef="U_shares">2029666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be8ba35b-0380-4fb4-a4e6-89fb909ebcce"
      decimals="0"
      id="F_31a58040-4827-4ed5-8b00-9e2476c6af2a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_81b7cadd-72c3-48d7-91c7-d8614a9176e6"
      decimals="0"
      id="F_f6278e31-3ccd-4c87-a31f-ab083ad4682a"
      unitRef="U_shares">1104178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_36085e8f-16ab-4161-877d-07990acb5c48"
      decimals="0"
      id="F_1aace4e5-39e9-4977-98a1-095ed299327b"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_24975ddf-6b2d-4418-a7fd-437c84c577ac"
      decimals="0"
      id="F_72e5065f-6e15-405d-a55d-f77f46b2427f"
      unitRef="U_shares">223417</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8dd132b6-7063-44e3-af52-d367d2ce82ee"
      decimals="0"
      id="F_0339427c-6cd1-454a-b998-6a57efe22f2a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1de4389e-f2f0-4d25-b59d-6d52f9adce3f"
      decimals="0"
      id="F_2d179d95-5d88-4b81-9517-f9c6ee94948f"
      unitRef="U_shares">2902</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_36fd05f2-24c6-4d41-93ec-f56ca9af1f89"
      decimals="0"
      id="F_14993045-2207-4893-ae6b-d8da644ba41f"
      unitRef="U_shares">1323151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b649a5e7-5c6c-446c-9fb4-344b0a1da0a9"
      decimals="0"
      id="F_9ae631f6-aa43-457b-83ee-32bbec4750ce"
      unitRef="U_shares">461100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a91b6de8-ece5-41ce-aead-f4c5480a52b6"
      decimals="0"
      id="F_d999c915-29ad-40a3-b91e-48c86d96cb5c"
      unitRef="U_shares">8049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fab291c7-d953-4b7e-86e4-50c5ceed14ec"
      decimals="0"
      id="F_9630f50c-7020-411a-bca2-9c8ffed1b490"
      unitRef="U_shares">8049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_513af823-8be3-442f-a9fe-1a2fe1b055f9"
      decimals="0"
      id="F_2b9a0f0f-708d-42fc-b870-4a64e10a5b3f"
      unitRef="U_shares">1331200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bed67611-bf29-4fae-9416-b0c86cc2e8d6"
      decimals="0"
      id="F_97ccff7d-adc0-46c9-ae0c-dca7b3d9930f"
      unitRef="U_shares">4514051</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      id="F_99334947-02b1-445d-9994-ff16c6349dab">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The following table sets forth the computation of the Company's basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,529,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="-3"
      id="F_8f2ebe3e-db56-437d-9d13-fea95335474f"
      unitRef="U_USD">-81172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="-3"
      id="F_c134da88-94f8-4b94-b07b-acb11b76c9f7"
      unitRef="U_USD">-58032000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_8f4d9e14-3d2c-4a56-a09a-fa33bdea8097"
      unitRef="U_shares">1529321</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="0"
      id="F_412936e7-d044-4d26-a02b-1c36ed5b4845"
      unitRef="U_shares">1529321</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="0"
      id="F_f8bfcef8-03ed-4ac4-be64-f4662b0e1d64"
      unitRef="U_shares">255175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="0"
      id="F_a7aaa5af-35d0-4d9a-ac51-9f34555ba44c"
      unitRef="U_shares">255175</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_cabd71c5-1e8a-48e5-b33d-a08a36826ef3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-53.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ea34908b-fb5a-461a-a3dd-d3f986af4ffb"
      decimals="2"
      id="F_4659c477-0fe6-467e-af72-6fd066a009c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-53.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_d752ec48-53d3-4199-9ed0-b3f6c2e4eeb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-227.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_418e4b9b-1aa0-474b-b09f-29e1a4daf18e"
      decimals="2"
      id="F_6e63ea17-f123-44df-a676-b8c5aee19efe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-227.42</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
